6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
36_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
1_CD
Accounting_GER
policies_NN
The_DT
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
applicable_JJ
accounting_GER
standards_NN
and_CC
under_IN
United_NN
Kingdom_NN
Generally_RB
Accepted_JJ
Accounting_GER
Principles_NN
UK_NN
GAAP_NN
._.
The_DT
particular_JJ
accounting_GER
policies_NN
adopted_VBN [WZPAST]
by_PIN
the_DT
Directors_NN
,_,
are_VPRT [PASS]
described_VBN
below_PLACE
._.
The_DT
accounting_GER
policies_NN
,_,
applied_VBD
consistently_RB
throughout_PIN
the_DT
year_NN
and_CC
the_DT
preceding_JJ
year_NN
,_,
are_VPRT [PASS]
described_VBN
below_PLACE
._.
Certain_JJ
balances_NN
reported_VBN [PUBV] [WZPAST]
in_PIN
2003_CD
have_VPRT [PEAS]
been_VBN [PASS]
reclassified_VBN
to_TO
conform_VB
to_PIN
the_DT
2004_CD
presentation_NOMZ
including_VBG [WZPRES]
restricted_VBN
cash_NN
from_PIN
cash_NN
at_PIN
bank_NN
and_CC
in_PIN
hand_NN
to_TO
restricted_VBN
cash_NN
and_CC
the_DT
inclusion_NN
of_PIN
equity_NOMZ
method_NN
investments_NOMZ
._.
a_DT
Accounting_GER
convention_NOMZ
The_DT
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
under_IN
the_DT
historical_JJ
cost_NN
convention_NOMZ
._.
b_NN
Basis_NN
of_PIN
consolidation_NOMZ
The_DT
consolidated_JJ
financial_JJ
statements_NOMZ
incorporate_VPRT
the_DT
financial_JJ
statements_NOMZ
of_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
and_CC
all_QUAN
its_PIT
subsidiary_NN
undertakings_GER
drawn_VBN
up_RP
to_PIN
31_CD
December_NN
each_QUAN
year_NN
._.
c_NN
Acquisitions_NOMZ
and_PHC
disposals_NN
On_PIN
the_DT
acquisition_NOMZ
of_PIN
a_DT
business_NOMZ
,_,
including_VBG [PRESP]
an_DT
interest_NN
in_PIN
an_DT
associated_VBN
undertaking_GER
,_,
fair_JJ
values_NN
are_VPRT [PASS]
attributed_VBN
to_PIN
the_DT
Groups_NN
share_NN
of_PIN
net_JJ
separable_JJ
assets_NN
._.
Where_RB
the_DT
cost_NN
of_PIN
the_DT
acquisition_NOMZ
exceeds_VPRT
the_DT
fair_JJ
values_NN
attributable_JJ
to_PIN
such_JJ
net_JJ
assets_NN
,_,
the_DT
difference_NN
is_VPRT [PASS]
treated_VBN
as_IN
purchased_VBN
goodwill_NN
and_CC
capitalized_VBN
in_PIN
the_DT
balance_NN
sheet_NN
in_PIN
the_DT
year_NN
of_PIN
acquisition_NOMZ
._.
The_DT
profit_NN
or_CC
loss_NN
on_PIN
the_DT
disposal_NN
of_PIN
a_DT
previously_TIME
acquired_VBN
business_NOMZ
includes_VPRT
the_DT
attributable_JJ
amount_NN
of_PIN
any_QUAN
purchased_VBN
goodwill_NN
relating_VBG [WZPRES]
to_PIN
that_DEMO
business_NOMZ
not_XX0
previously_TIME
charged_VBN
through_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
The_DT
results_NN
and_PHC
cash_NN
flows_NN
relating_VBG [WZPRES]
to_PIN
a_DT
business_NOMZ
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
and_CC
the_DT
consolidated_JJ
cash_NN
flow_NN
statement_NOMZ
from_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
up_IN
to_PIN
the_DT
date_NN
of_PIN
disposal_NN
._.
d_LS
Intangible_JJ
assets_NN
goodwill_NN
For_PIN
the_DT
acquisition_NOMZ
of_PIN
a_DT
business_NOMZ
,_,
including_VBG [PRESP]
an_DT
interest_NN
in_PIN
an_DT
associated_VBN
undertaking_GER
,_,
purchased_VBD
goodwill_NN
is_VPRT [PASS]
capitalized_VBN
in_PIN
the_DT
year_NN
in_PIN
which_WDT [PIRE]
it_PIT
arises_VPRT
and_PHC
amortised_VBN
over_IN
its_PIT
estimated_VBN [PRIV]
useful_JJ
economic_JJ
life_NN
up_IN
to_PIN
a_DT
maximum_NN
of_PIN
20_CD
years_NN
._.
The_DT
Directors_NN
regard_VPRT
20_CD
years_NN
as_IN
a_DT
reasonable_JJ
maximum_NN
for_PIN
the_DT
estimated_VBN [PRIV]
useful_JJ
economic_JJ
life_NN
of_PIN
goodwill_NN
since_OSUB
it_PIT
is_VPRT [BEMA]
difficult_PRED
to_TO
make_VB
projections_NOMZ
exceeding_VBG [WZPRES]
this_DEMO
period_NN
._.
Provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
any_QUAN
impairment_NOMZ
._.
The_DT
asset_NN
is_VPRT [PASS]
deemed_VBN [PRIV]
to_TO
be_VB [PASS]
impaired_VBN
to_PIN
the_DT
extent_NN
that_TOBJ
the_DT
carrying_VBG
amount_NN
exceeds_VPRT
the_DT
recoverable_JJ
amount_NN
._.
The_DT
impairment_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
Goodwill_NN
is_VPRT [PASS]
denominated_VBN
in_PIN
the_DT
currency_NN
in_PIN
which_WDT [PIRE]
the_DT
acquisition_NOMZ
is_VPRT [PASS]
made_VBN
._.
Capitalised_VBN
purchased_VBN
goodwill_NN
in_PIN
respect_NN
of_PIN
subsidiaries_NN
is_VPRT [PASS]
included_VBN
within_PIN
intangible_JJ
assets_NN
._.
Capitalised_NN
purchased_VBD
goodwill_NN
relating_VBG [WZPRES]
to_PIN
associates_NN
is_VPRT [PASS]
included_VBN
within_PIN
the_DT
carrying_VBG
value_NN
of_PIN
the_DT
associate_NN
._.
Goodwill_NN
arising_VBG [WZPRES]
on_PIN
the_DT
acquisition_NOMZ
of_PIN
a_DT
business_NOMZ
,_,
prior_RB
to_PIN
the_DT
implementation_NOMZ
of_PIN
FRS_NN
10_CD
,_,
which_WDT [SERE]
was_VBD [BEMA]
written-off_PIN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
reserve_NN
as_IN
a_DT
matter_NN
of_PIN
accounting_GER
policy_NN
,_,
remains_VPRT
eliminated_VBN
in_PIN
that_DEMO
reserve_NN
and_CC
will_PRMD
be_VB [PASS]
charged_VBN
or_CC
credited_VBN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
as_IN
appropriate_JJ
on_PIN
the_DT
subsequent_JJ
disposal_NN
of_PIN
the_DT
business_NOMZ
to_PIN
which_WDT [PIRE]
it_PIT
relates_VPRT
._.
e_LS
Intangible_JJ
assets_NN
intellectual_JJ
property_NN
Intellectual_NN
property_NN
,_,
including_VBG
trademarks_NN
,_,
for_PIN
products_NN
with_PIN
an_DT
immediate_JJ
defined_VBN
revenue_NN
stream_NN
and_CC
acquired_VBN
for_PIN
valuable_JJ
consideration_NOMZ
,_,
is_VPRT [PASS]
capitalized_VBN
and_PHC
amortised_VBN
in_PIN
equal_JJ
annual_JJ
instalments_NOMZ
over_IN
the_DT
estimated_VBN [PRIV]
useful_JJ
life_NN
of_PIN
the_DT
product_NN
generally_RB
not_XX0
exceeding_VBG
20_CD
years_NN
._.
Where_RB
a_DT
product_NN
exceeds_VPRT
20_CD
years_NN
the_DT
Group_NN
believes_VPRT [PRIV]
that_THVC
the_DT
product_NN
is_VPRT [BEMA]
well-established_PRED
in_PIN
its_PIT
market_NN
._.
The_DT
Company_NN
anticipates_VPRT [PRIV]
these_DEMO
products_NN
to_TO
be_VB [PASS]
sold_VBN
for_PIN
the_DT
forseeable_JJ
future_NN
because_CAUS
of_PIN
the_DT
market_NN
positioning_GER
of_PIN
the_DT
product_NN
and_CC
the_DT
likelihood_NN
of_PIN
a_DT
competitor_NN
entering_VBG [WZPRES]
the_DT
relevant_JJ
market_NN
._.
Intellectual_NN
property_NN
acquired_VBD
for_PIN
valuable_JJ
consideration_NOMZ
but_CC
with_PIN
no_DT
defined_VBN
revenue_NN
stream_NN
is_VPRT [BEMA]
written-off_PIN
on_PIN
acquisition_NOMZ
._.
f_LS
Tangible_JJ
assets_NN
Depreciation_NOMZ
is_VPRT [PASS]
not_XX0
provided_VBN
on_PIN
freehold_JJ
land_NN
._.
All_QUAN
other_JJ
tangible_JJ
fixed_JJ
assets_NN
are_VPRT [PASS]
shown_VBN [PRIV]
at_PIN
cost_NN
less_JJ
accumulated_VBN
depreciation_NOMZ
and_CC
any_QUAN
provision_NN
for_PIN
impairment_NOMZ
._.
Depreciation_NOMZ
is_VPRT [PASS]
provided_VBN
on_PIN
a_DT
straight_JJ
line_NN
basis_NN
at_PIN
rates_NN
calculated_VBN [PRIV] [WZPAST]
to_PIN
write-off_PIN
the_DT
cost_NN
less_JJ
estimated_VBN [PRIV]
residual_JJ
value_NN
of_PIN
each_QUAN
asset_NN
over_IN
its_PIT
estimated_VBN [PRIV]
useful_JJ
life_NN
at_PIN
the_DT
following_JJ
annual_JJ
rates_NN
:_:
Freehold_NN
buildings_GER
2-5_CD
%_NN
per_PIN
annum_NN
Office_NN
furniture_NN
and_PHC
fittings_GER
10-25_CD
%_NN
per_PIN
annum_NN
Equipment_NOMZ
and_CC
other_JJ
10-25_CD
%_NN
per_PIN
annum_NN
36_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
37_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
1_CD
Accounting_GER
policies_NN
continued_VBD
g_NN
Investments_NOMZ
Except_PIN
as_IN
stated_VBN [PUBV]
below_PLACE
,_,
investments_NOMZ
held_VBD [PRIV]
as_IN
fixed_JJ
assets_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
cost_NN
less_JJ
provision_NN
for_PIN
any_QUAN
impairment_NOMZ
._.
In_PIN
the_DT
consolidated_JJ
accounts_NN
,_,
shares_NN
in_PIN
joint_JJ
ventures_NN
are_VPRT [PASS]
accounted_VBN
for_PIN
using_VBG
the_DT
equity_NOMZ
method_NN
._.
The_DT
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
includes_VPRT
the_DT
Groups_NN
share_NN
of_PIN
pre-tax_JJ
profits_NN
and_CC
attributable_JJ
taxation_NOMZ
._.
In_PIN
the_DT
consolidated_JJ
balance_NN
sheet_NN
,_,
the_DT
investment_NOMZ
in_PIN
joint_JJ
ventures_NN
is_VPRT [PASS]
shown_VBN [PRIV]
as_IN
the_DT
Groups_NN
share_NN
of_PIN
the_DT
net_JJ
assets_NN
of_PIN
the_DT
joint_JJ
ventures_NN
._.
Current_JJ
asset_NN
investments_NOMZ
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
net_JJ
realisable_JJ
value_NN
._.
h_NN
Stocks_NN
Stocks_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
net_JJ
realisable_JJ
value_NN
._.
Cost_NN
incurred_VBN [WZPAST]
in_PIN
bringing_VBG
each_QUAN
product_NN
to_PIN
its_PIT
present_JJ
location_NOMZ
and_PHC
condition_NOMZ
is_VPRT [PASS]
based_VBN
on_PIN
purchase_NN
costs_NN
calculated_VBN [PRIV] [WZPAST]
on_PIN
a_DT
first-in_PIN [STPR]
,_,
first-out_PIN
basis_NN
,_,
including_VBG
transport_NN
._.
Net_JJ
realisable_JJ
value_NN
is_VPRT [PASS]
based_VBN
on_PIN
estimated_VBN [PRIV]
normal_JJ
selling_GER
price_NN
less_RB
further_JJ
costs_NN
expected_VBN [PRIV]
to_TO
be_VB [PASS]
incurred_VBN
to_PIN
completion_NOMZ
and_PHC
disposal_NN
._.
Provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
obsolete_JJ
,_,
slow_JJ
moving_VBG [SUAV]
or_CC
defective_JJ
items_NN
where_RB
appropriate_JJ
._.
i_FPP1
Deferred_JJ
taxation_NOMZ
Current_JJ
tax_NN
,_,
including_VBG
UK_NN
corporation_NOMZ
tax_NN
and_CC
foreign_JJ
tax_NN
,_,
is_VPRT [PASS]
provided_VBN
at_PIN
amounts_NN
expected_VBN [PRIV]
to_TO
be_VB [PASS]
paid_VBN
or_CC
recovered_VBN
using_VBG
the_DT
tax_NN
rates_NN
and_PHC
laws_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [PASS]
enacted_VBN
or_CC
substantively_RB
enacted_VBN
by_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Deferred_JJ
tax_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
respect_NN
of_PIN
all_QUAN
timing_NN
differences_NN
that_TSUB
have_VPRT [PEAS]
originated_VBN
but_CC
not_XX0
reversed_VBD
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
where_RB
transactions_NOMZ
or_CC
events_NN
that_TSUB
result_VPRT
in_PIN
an_DT
obligation_NOMZ
to_TO
pay_VB
more_EMPH
tax_NN
in_PIN
the_DT
future_NN
or_CC
a_DT
right_NN
to_TO
pay_VB
less_JJ
tax_NN
in_PIN
the_DT
future_NN
have_VB [PEAS]
occurred_VBN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Timing_NN
differences_NN
are_VPRT
differences_NN
between_PIN
the_DT
Groups_NN
taxable_JJ
profits_NN
and_CC
its_PIT
results_NN
as_IN
stated_VBN [PUBV]
in_PIN
the_DT
financial_JJ
statements_NOMZ
that_TSUB
arise_VPRT
from_PIN
the_DT
inclusion_NN
of_PIN
gains_NN
and_PHC
losses_NN
in_PIN
tax_NN
assessments_NOMZ
in_PIN
periods_NN
different_JJ
from_PIN
those_DEMO
in_PIN
which_WDT [PIRE]
they_TPP3
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
financial_JJ
statements_NOMZ
._.
A_DT
net_JJ
deferred_VBN
tax_NN
asset_NN
is_VPRT [PASS]
regarded_VBN
as_IN
recoverable_JJ
and_ANDC
therefore_CONJ
recognized_VBN [PRIV]
only_DWNT
when_RB
,_,
on_PIN
the_DT
basis_NN
of_PIN
all_QUAN
available_JJ
evidence_NN
,_,
it_PIT
can_POMD
be_VB [PASS]
regarded_VBN
as_IN
more_EMPH
likely_JJ
than_PIN
not_XX0
that_DEMO
there_EX
will_PRMD
be_VB
suitable_JJ
taxable_JJ
profits_NN
from_PIN
which_WDT [PIRE]
the_DT
future_JJ
reversal_NN
of_PIN
the_DT
underlying_VBG
timing_NN
differences_NN
can_POMD
be_VB [PASS]
deducted_VBN
._.
Deferred_JJ
tax_NN
is_VPRT [PASS]
not_XX0
provided_VBN
on_PIN
timing_NN
differences_NN
arising_VBG [WZPRES]
on_PIN
unremitted_JJ
earnings_GER
of_PIN
subsidiaries_NN
and_PHC
associates_NN
where_RB
there_EX
is_VPRT
no_SYNE
commitment_NOMZ
to_TO
remit_VB
these_DEMO
earnings_GER
._.
Deferred_JJ
tax_NN
is_VPRT [PASS]
measured_VBN
at_PIN
the_DT
rates_NN
that_TSUB
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
apply_VB
in_PIN
the_DT
periods_NN
in_PIN
which_WDT [PIRE]
the_DT
timing_NN
differences_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
reverse_VB
,_,
based_VBN [PASTP]
on_PIN
tax_NN
rates_NN
and_PHC
laws_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [PASS]
enacted_VBN
or_CC
substantively_RB
enacted_VBN
by_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
The_DT
deferred_JJ
tax_NN
balances_NN
are_VPRT [PASS]
not_XX0
discounted_VBN
._.
j_NN
Turnover_NN
The_DT
Group_NN
recognizes_VPRT [PRIV]
turnover_NN
when_RB
:_:
there_EX
is_VPRT
persuasive_JJ
evidence_NN
of_PIN
an_DT
arrangement_NOMZ
:_:
delivery_NN
of_PIN
products_NN
has_VPRT [PEAS]
occurred_VBN
or_CC
services_NN
have_VPRT [PEAS]
been_VBN [PASS]
rendered_VBN
:_:
the_DT
sellers_NN
price_NN
to_PIN
the_DT
buyer_NN
is_VPRT [PASS]
fixed_VBN
or_CC
determinable_JJ
:_:
and_ANDC
collectibility_NOMZ
is_VPRT [SPAU] [PASS]
reasonably_RB
assured_VBN
._.
Revenues_NN
are_VPRT [PASS]
stated_VBN [PUBV]
net_NN
of_PIN
VAT_NN
and_CC
similar_JJ
taxes_NN
,_,
trade_NN
discounts_NN
and_CC
intra-Group_JJ
transactions_NOMZ
._.
The_DT
principal_JJ
components_NN
of_PIN
the_DT
Groups_NN
turnover_NN
and_CC
their_TPP3
respective_JJ
accounting_GER
treatments_NOMZ
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
:_:
Revenue_NN
from_PIN
the_DT
sales_NN
of_PIN
products_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
upon_PIN
shipment_NOMZ
to_PIN
customers_NN
or_CC
at_PIN
the_DT
time_NN
of_PIN
delivery_NN
depending_VBG [WZPRES]
on_PIN
the_DT
terms_NN
of_PIN
sale_NN
._.
Provisions_NN
for_PIN
certain_JJ
rebates_NN
,_,
product_NN
returns_NN
and_PHC
discounts_NN
to_PIN
customers_NN
are_VPRT [PASS]
provided_VBN
for_PIN
as_IN
reductions_NOMZ
to_PIN
net_JJ
turnover_NN
in_PIN
the_DT
same_JJ
period_NN
as_IN
the_DT
related_JJ
sales_NN
are_VPRT [PASS]
recorded_VBN
:_:
Licensing_GER
and_PHC
development_NOMZ
fees_NN
represent_VPRT
revenues_NN
derived_VBN [WZPAST]
from_PIN
licence_NN
agreements_NOMZ
and_CC
from_PIN
collaborative_JJ
research_NN
and_PHC
development_NOMZ
arrangements_NOMZ
:_:
37_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
38_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
1_CD
Accounting_GER
policies_NN
continued_VBD
Initial_JJ
licence_NN
fees_NN
are_VPRT [PASS]
not_XX0
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
separable_PRED
from_PIN
the_DT
associated_VBN
research_NN
and_PHC
development_NOMZ
activities_NOMZ
,_,
even_RB
where_RB
such_JJ
fees_NN
are_VPRT [BEMA]
non-refundable_PRED
and_CC
not_XX0
creditable_JJ
against_PIN
research_NN
and_PHC
development_NOMZ
services_NN
to_TO
be_VB [PASS]
rendered_VBN
._.
Initial_JJ
licence_NN
fees_NN
are_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
over_IN
the_DT
period_NN
of_PIN
the_DT
licence_NN
term_NN
or_CC
the_DT
period_NN
of_PIN
the_DT
associated_VBN
research_NN
and_PHC
development_NOMZ
agreement_NOMZ
._.
In_PIN
circumstances_NN
where_RB
initial_JJ
licence_NN
fees_NN
are_VPRT [BEMA]
not_XX0
for_PIN
a_DT
defined_VBN
period_NN
,_,
revenues_NN
are_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
over_IN
the_DT
period_NN
to_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
relevant_JJ
patent_NN
to_PIN
which_WDT [PIRE]
the_DT
licence_NN
relates_VPRT
:_:
During_PIN
the_DT
term_NN
of_PIN
certain_JJ
research_NN
and_PHC
development_NOMZ
agreements_NOMZ
,_,
the_DT
Group_NN
receives_VPRT
non-refundable_JJ
milestones_NN
as_IN
certain_JJ
technical_JJ
targets_NN
are_VPRT [PASS]
achieved_VBN
._.
Revenue_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
achievement_NOMZ
of_PIN
milestones_NN
:_:
and_ANDC
The_DT
Group_NN
also_RB
receives_VPRT
non-refundable_JJ
clinical_JJ
milestones_NN
when_RB
certain_JJ
targets_NN
are_VPRT [PASS]
achieved_VBN
during_PIN
the_DT
clinical_JJ
phases_NN
of_PIN
development_NOMZ
,_,
such_JJ
as_IN
the_DT
submission_NN
of_PIN
clinical_JJ
data_NN
to_PIN
a_DT
regulatory_JJ
authority_NOMZ
._.
These_DEMO
clinical_JJ
milestones_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
receivable_NN
._.
If_COND
milestone_NN
payments_NOMZ
are_VPRT [BEMA]
creditable_PRED
against_PIN
future_JJ
royalty_NN
payments_NOMZ
,_,
the_DT
milestones_NN
are_VPRT [PASS]
deferred_VBN
and_PHC
released_VBN
over_IN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
the_DT
royalties_NN
are_VPRT [PASS]
anticipated_VBN [PRIV]
to_TO
be_VB [PASS]
paid_VBN
._.
No_SYNE
revenue_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
for_PIN
consideration_NOMZ
,_,
the_DT
value_NN
or_CC
receipt_NN
of_PIN
which_WDT [PIRE]
is_VPRT [BEMA]
dependent_PRED
on_PIN
future_JJ
events_NN
,_,
future_JJ
performance_NN
,_,
or_CC
refund_NN
obligations_NOMZ
._.
k_NN
Research_NN
and_PHC
development_NOMZ
Research_NN
and_PHC
development_NOMZ
expenditure_NN
includes_VPRT
funded_VBN
and_CC
unfunded_JJ
expenditure_NN
and_CC
is_VPRT [BEMA]
written-off_PIN
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
it_PIT
is_VPRT [PASS]
incurred_VBN
._.
l_NN
Pensions_NN
The_DT
Group_NN
contributes_VPRT
to_PIN
personal_JJ
defined_VBN
contribution_NOMZ
pension_NN
plans_NN
of_PIN
employees_NN
._.
Contributions_NOMZ
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
as_IN
they_TPP3
become_VPRT
payable_JJ
._.
Differences_NN
between_PIN
contributions_NOMZ
payable_JJ
and_CC
contributions_NOMZ
actually_RB
paid_VBN
are_VPRT [PASS]
shown_VBN [PRIV]
as_IN
either_DT
accruals_NN
or_CC
prepayments_NOMZ
in_PIN
the_DT
balance_NN
sheet_NN
._.
m_NN
Foreign_NN
currency_NN
Transactions_NOMZ
in_PIN
foreign_JJ
currencies_NN
are_VPRT [PASS]
recorded_VBN
at_PIN
the_DT
rate_NN
of_PIN
exchange_NN
at_PIN
the_DT
date_NN
of_PIN
the_DT
transaction_NOMZ
._.
Monetary_NN
assets_NN
and_PHC
liabilities_NOMZ
denominated_VBN [WZPAST]
in_PIN
foreign_JJ
currencies_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
are_VPRT [PASS]
reported_VBN [PUBV]
at_PIN
the_DT
rates_NN
of_PIN
exchange_NN
prevailing_VBG [WZPRES]
at_PIN
that_DEMO
date_NN
._.
The_DT
results_NN
of_PIN
overseas_PLACE
operations_NOMZ
are_VPRT [PASS]
translated_VBN
at_PIN
the_DT
average_JJ
rates_NN
of_PIN
exchange_NN
during_PIN
the_DT
period_NN
and_CC
their_TPP3
balance_NN
sheets_NN
at_PIN
the_DT
rates_NN
ruling_VBG [SUAV] [WZPRES]
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Exchange_NN
differences_NN
arising_VBG [WZPRES]
on_PIN
translation_NOMZ
of_PIN
the_DT
opening_GER
net_JJ
assets_NN
and_CC
on_PIN
foreign_JJ
currency_NN
borrowings_GER
,_,
to_PIN
the_DT
extent_NN
that_TOBJ
they_TPP3
hedge_VPRT
the_DT
Groups_NN
investments_NOMZ
in_PIN
such_JJ
operations_NOMZ
,_,
are_VPRT [PASS]
reported_VBN [PUBV]
in_PIN
the_DT
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
._.
All_QUAN
other_JJ
exchange_NN
differences_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
n_JJ
Leases_NN
Assets_NN
acquired_VBD
under_IN
finance_NN
leases_NN
are_VPRT [PASS]
capitalized_VBN
at_PIN
their_TPP3
fair_JJ
value_NN
on_PIN
the_DT
inception_NOMZ
of_PIN
the_DT
leases_NN
and_CC
depreciated_VBN
over_IN
the_DT
shorter_JJ
of_PIN
the_DT
period_NN
of_PIN
the_DT
lease_NN
and_CC
the_DT
useful_JJ
economic_JJ
lives_NN
of_PIN
the_DT
assets_NN
._.
The_DT
finance_NN
charges_NN
are_VPRT [PASS]
allocated_VBN
over_IN
the_DT
period_NN
of_PIN
the_DT
lease_NN
in_PIN
proportion_NOMZ
to_PIN
the_DT
capital_NN
amount_NN
outstanding_JJ
and_CC
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
Operating_VBG
lease_NN
rentals_NN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
in_PIN
equal_JJ
amounts_NN
over_IN
the_DT
lease_NN
term_NN
._.
o_NN
Finance_NN
costs_VPRT
Finance_NN
costs_NN
of_PIN
debt_NN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
over_IN
the_DT
term_NN
of_PIN
the_DT
debt_NN
at_PIN
a_DT
constant_JJ
rate_NN
on_PIN
the_DT
carrying_VBG
amount_NN
._.
p_NN
Debt_NN
Debt_NN
is_VPRT [SPAU] [PASS]
initially_TIME
stated_VBN [PUBV]
at_PIN
the_DT
amount_NN
of_PIN
the_DT
net_JJ
proceeds_NN
after_IN
deduction_NOMZ
of_PIN
issue_NN
costs_NN
._.
The_DT
carrying_VBG
amount_NN
is_VPRT [BYPA]
increased_VBN
by_PIN
the_DT
finance_NN
cost_NN
in_PIN
respect_NN
of_PIN
the_DT
accounting_GER
period_NN
and_CC
reduced_VBN
by_PIN
payments_NOMZ
made_VBN [WZPAST]
in_PIN
the_DT
period_NN
._.
Convertible_JJ
debt_NN
is_VPRT [PASS]
treated_VBN
as_IN
a_DT
liability_NOMZ
as_OSUB
long_NULL
as_NULL
there_EX
is_VPRT
no_SYNE
genuine_JJ
commercial_JJ
possibility_NOMZ
that_TOBJ
the_DT
option_NOMZ
to_TO
issue_VB
ordinary_JJ
shares_NN
or_CC
American_JJ
Depositary_NN
Shares_NN
will_PRMD
be_VB [PASS]
exercised_VBN
._.
q_NN
Government_NOMZ
grants_NN
Government_NOMZ
grants_NN
in_PIN
respect_NN
of_PIN
funded_JJ
research_NN
and_PHC
development_NOMZ
expenditure_NN
are_VPRT [PASS]
credited_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
as_IN
the_DT
related_JJ
expenditure_NN
is_VPRT [PASS]
incurred_VBN
._.
38_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
39_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
1_CD
Accounting_GER
policies_NN
continued_VBD
r_NN
Derivative_JJ
financial_JJ
instruments_NOMZ
The_DT
Group_NN
uses_VPRT
derivative_JJ
financial_JJ
instruments_NOMZ
to_TO
reduce_VB
exposure_NN
to_PIN
foreign_JJ
exchange_NN
risk_NN
and_PHC
interest_NN
rate_NN
movements_NOMZ
._.
The_DT
Group_NN
does_VPRT
not_XX0
hold_VB [PRIV]
or_CC
issue_VB
derivative_JJ
financial_JJ
instruments_NOMZ
for_PIN
speculative_JJ
purposes_NN
._.
For_PIN
a_DT
forward_RB
foreign_JJ
exchange_NN
contract_NN
to_TO
be_VB [PASS]
treated_VBN
as_IN
a_DT
hedge_NN
the_DT
instrument_NOMZ
must_NEMD
be_VB [PASS]
related_VBN
to_PIN
actual_JJ
foreign_JJ
currency_NN
assets_NN
or_CC
liabilities_NOMZ
or_CC
to_PIN
a_DT
probable_JJ
commitment_NOMZ
._.
It_PIT
must_NEMD
involve_VB
the_DT
same_JJ
currency_NN
or_CC
similar_JJ
currencies_NN
as_IN
the_DT
hedged_VBN
item_NN
and_CC
must_NEMD [SPAU]
also_RB
reduce_VB
the_DT
risk_NN
of_PIN
foreign_JJ
currency_NN
exchange_NN
movements_NOMZ
on_PIN
the_DT
Groups_NN
operations_NOMZ
._.
Gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
on_PIN
these_DEMO
contracts_NN
are_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
,_,
or_CC
as_IN
adjustments_NOMZ
to_PIN
the_DT
carrying_VBG
amount_NN
of_PIN
fixed_JJ
assets_NN
,_,
only_DWNT
when_RB
the_DT
hedged_VBN
transaction_NOMZ
has_VPRT [PEAS]
itself_PIT
been_VBN [PASS]
reflected_VBN [PRIV]
in_PIN
the_DT
Groups_NN
accounts_NN
._.
For_PIN
an_DT
interest_NN
rate_NN
swap_NN
to_TO
be_VB [PASS]
treated_VBN
as_IN
a_DT
hedge_NN
the_DT
instrument_NOMZ
must_NEMD
be_VB [PASS]
related_VBN
to_PIN
actual_JJ
assets_NN
or_CC
liabilities_NOMZ
or_CC
a_DT
probable_JJ
commitment_NOMZ
and_CC
must_NEMD
change_VB
the_DT
nature_NN
of_PIN
the_DT
interest_NN
rate_NN
by_PIN
converting_VBG
a_DT
fixed_JJ
rate_NN
to_PIN
a_DT
variable_JJ
rate_NN
or_CC
vice_NN
versa_RB
._.
Interest_NN
differentials_NN
under_IN
these_DEMO
swaps_NN
are_VPRT [BYPA]
recognized_VBN [PRIV]
by_PIN
adjusting_VBG
net_JJ
interest_NN
payable_JJ
over_IN
the_DT
periods_NN
of_PIN
the_DT
contracts_NN
._.
If_COND
an_DT
instrument_NOMZ
ceases_VPRT
to_TO
be_VB [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
hedge_NN
,_,
for_CONJ
example_NULL
because_CAUS
the_DT
underlying_VBG
hedged_JJ
position_NOMZ
is_VPRT [PASS]
eliminated_VBN
,_,
the_DT
instrument_NOMZ
is_VPRT [PASS]
marked_VBN
to_PIN
market_NN
and_CC
any_QUAN
resulting_JJ
profit_NN
or_CC
loss_NN
recognized_VBN [PRIV] [WZPAST]
at_PIN
that_DEMO
time_NN
._.
s_PRP
Associates_NN
In_PIN
the_DT
Group_NN
financial_JJ
statements_NOMZ
investments_NOMZ
in_PIN
associates_NN
are_VPRT [PASS]
accounted_VBN
for_PIN
using_VBG
the_DT
equity_NOMZ
method_NN
._.
The_DT
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
includes_VPRT
the_DT
Groups_NN
share_NN
of_PIN
associates_NN
profits_NN
less_RB
losses_NN
while_OSUB
the_DT
Groups_NN
share_NN
of_PIN
the_DT
net_JJ
assets_NN
of_PIN
the_DT
associates_NN
is_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
consolidated_JJ
balance_NN
sheet_NN
._.
Goodwill_NN
arising_VBG [WZPRES]
on_PIN
the_DT
acquisition_NOMZ
of_PIN
associates_NN
is_VPRT [PASS]
accounted_VBN
for_PIN
in_PIN
accordance_NN
with_PIN
the_DT
policy_NN
set_VBN [WZPAST]
out_PIN
above_PLACE
._.
Any_QUAN
unamortised_JJ
goodwill_NN
is_VPRT [PASS]
included_VBN
in_PIN
the_DT
carrying_VBG
value_NN
of_PIN
the_DT
investments_NOMZ
in_PIN
associates_NN
._.
t_VB
Employee_NN
share_NN
schemes_NN
In_PIN
accordance_NN
with_PIN
UITF_NN
Abstract_NN
17_CD
Employee_NN
share_NN
schemes_NN
,_,
the_DT
cost_NN
of_PIN
awards_NN
to_PIN
employees_NN
that_TSUB
take_VPRT
the_DT
form_NN
of_PIN
shares_NN
or_CC
rights_NN
to_PIN
shares_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
a_DT
charge_NN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
The_DT
amount_NN
recognized_VBN [PRIV]
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
difference_NN
between_PIN
the_DT
market_NN
value_NN
at_PIN
date_NN
of_PIN
grant_NN
of_PIN
the_DT
underlying_JJ
share_NN
and_CC
any_QUAN
exercise_NN
price_NN
,_,
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
over_IN
the_DT
period_NN
the_DT
shares_NN
are_VPRT [PASS]
vested_VBN
,_,
with_PIN
a_DT
corresponding_JJ
credit_NN
to_PIN
reserves_NN
._.
u_NN
Related_NN
party_NN
transactions_NOMZ
In_PIN
accordance_NN
with_PIN
the_DT
exemptions_NOMZ
in_PIN
FRS_NN
8_CD
related_JJ
party_NN
disclosures_NN
,_,
transactions_NOMZ
between_PIN
Group_NN
companies_NN
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
disclosed_VBN [PUBV]
since_OSUB
Group_NN
accounts_NN
are_VPRT [BEMA]
prepared_PRED
and_CC
include_VPRT
the_DT
results_NN
of_PIN
all_QUAN
subsidiary_NN
undertakings_GER
._.
v_FW
Significant_JJ
accounting_GER
estimates_NN
Sales_NN
deductions_NOMZ
primarily_RB
consist_VPRT
of_PIN
statutory_JJ
rebates_NN
to_PIN
state_NN
Medicaid_NN
and_CC
other_JJ
Government_NOMZ
agencies_NN
,_,
contractual_JJ
rebates_NN
with_PIN
health-maintenance_NN
organizations_NOMZ
HMOs_NN
,_,
product_NN
returns_NN
,_,
trade_NN
discounts_NN
and_PHC
allowances_NN
for_PIN
the_DT
coupon_NN
sampling_VBG [WZPRES]
program_NN
._.
Statutory_JJ
rebates_NN
to_PIN
state_NN
Medicaid_NN
agencies_NN
and_CC
contractual_JJ
rebates_NN
with_PIN
HMOs_NN
are_VPRT [PASS]
based_VBN
on_PIN
price_NN
differentials_NN
between_PIN
a_DT
base_NN
price_NN
and_CC
the_DT
selling_GER
price_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
the_DT
rebates_NN
increase_NN
as_IN
a_DT
percentage_NN
of_PIN
the_DT
selling_GER
price_NN
over_IN
the_DT
life_NN
of_PIN
the_DT
product_NN
._.
Provision_NN
for_PIN
rebates_NN
are_VPRT [PASS]
recorded_VBN
as_IN
reductions_NOMZ
to_PIN
turnover_NN
in_PIN
the_DT
same_JJ
period_NN
as_IN
the_DT
related_JJ
sales_NN
with_PIN
estimates_NN
of_PIN
future_JJ
utilisation_NOMZ
derived_VBN [WZPAST]
from_PIN
historical_JJ
trends_NN
._.
c_NN
Turnover_NN
and_PHC
profit_NN
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
Licensing_GER
and_PHC
Product_NN
sales_NN
development_NOMZ
Royalties_NN
Other_JJ
revenues_NN
Total_JJ
Year_NN
to_PIN
31_CD
December_NN
2004 000 000 000_CD
000_CD
000_CD
Turnover_NN
619,969_CD
7,391_CD
123,405_CD
3,766_CD
754,531_CD
Cost_NN
of_PIN
product_NN
sales_NN
84,477_CD
84,477_CD
Distribution_NOMZ
costs_NN
181,463_CD
181,463_CD
Funded_VBN
research_NN
and_PHC
development_NOMZ
costs_NN
14_CD
14_CD
354,029_CD
7,377_CD
123,405_CD
3,766_CD
488,577_CD
Unfunded_JJ
research_NN
and_PHC
development_NOMZ
costs_NN
112,520_CD
Depreciation_NOMZ
,_,
amortisation_NOMZ
and_PHC
impairment_NOMZ
199,963_CD
Expenses_NN
not_XX0
allocated_VBN
general_JJ
overheads_NN
110,399_CD
Operating_GER
profit_NN
65,695_CD
Share_NN
of_PIN
associates_NN
operating_VBG [WZPRES]
profit_NN
37_CD
Profit_NN
on_PIN
disposal_NN
of_PIN
fixed_JJ
asset_NN
investment_NOMZ
8,264_CD
Loss_NN
on_PIN
sale_NN
of_PIN
discontinued_VBN
operations_NOMZ
23,191_CD
Finance_NN
income_NN
,_,
net_JJ
6,630_CD
Profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
57,435_CD
Licensing_GER
and_PHC
Product_NN
sales_NN
development_NOMZ
Royalties_NN
Other_JJ
revenues_NN
Total_JJ
Year_NN
to_PIN
31_CD
December_NN
2003 000 000 000_CD
000_CD
000_CD
Turnover_NN
635,545_CD
2,232_CD
122,110_CD
1,181_CD
761,068_CD
Cost_NN
of_PIN
product_NN
sales_NN
102,384_CD
102,384_CD
Distribution_NOMZ
costs_NN
156,070_CD
156,070_CD
Funded_VBN
research_NN
and_PHC
development_NOMZ
costs_NN
3,273_CD
3,273_CD
377,091_CD
1,041_CD
122,110_CD
1,181_CD
499,341_CD
Unfunded_JJ
research_NN
and_PHC
development_NOMZ
costs_NN
128,381_CD
Depreciation_NOMZ
,_,
amortisation_NOMZ
and_PHC
impairment_NOMZ
582,889_CD
Expenses_NN
not_XX0
allocated_VBN
general_JJ
overheads_NN
88,006_CD
Operating_GER
loss_NN
299,935_CD
Share_NN
of_PIN
joint_JJ
ventures_NN
operating_VBG [WZPRES]
loss_NN
2,806_CD
Profit_NN
on_PIN
disposal_NN
of_PIN
fixed_JJ
asset_NN
investment_NOMZ
698_CD
Finance_NN
income_NN
,_,
net_JJ
3,702_CD
Loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
298,341_CD
40_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
41_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
2_CD
Turnover_NN
and_PHC
segment_NOMZ
information_NOMZ
continued_VBD
d_SYM
Analysis_NN
of_PIN
net_JJ
operating_GER
expenses_NN
2004 2003 000 000_CD
Distribution_NOMZ
costs_NN
181,463_CD
156,070_CD
Research_NN
and_PHC
development_NOMZ
112,534_CD
131,654_CD
Administrative_JJ
expenses_NN
310,362_CD
670,895_CD
604,359_CD
958,619_CD
3_CD
Operating_GER
profit_NN
loss_NN
Operating_GER
profit_NN
loss_NN
is_VPRT [PASS]
stated_VBN [PUBV]
after_IN
charging_VBG
crediting_VBG
:_:
2004 2003 000 000_CD
Depreciation_NOMZ
and_PHC
amounts_NN
written_VBN [PUBV] [WZPAST]
off_PIN
tangible_JJ
fixed_JJ
assets_NN
owned_VBN
12,409_CD
18,772_CD
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
contracts_NN
107_CD
597_CD
Amortisation_NOMZ
and_CC
amounts_VPRT
written_VBN [PUBV]
off_PIN
intellectual_JJ
property_NN
29,164_CD
30,405_CD
Amortisation_NOMZ
and_CC
amounts_VPRT
written_VBN [PUBV]
off_PIN
goodwill_NN
158,283_CD
533,115_CD
Research_NN
and_PHC
development_NOMZ
112,534_CD
131,654_CD
Reorganisation_NOMZ
costs_NN
26,529_CD
14,597_CD
Government_NOMZ
grants_NN
14_CD
2,169_CD
Operating_GER
lease_NN
rentals_NN
plant_NN
and_PHC
machinery_NN
3,580_CD
3,591_CD
other_JJ
3,541_CD
3,868_CD
Auditors_NN
remuneration_NOMZ
for_PIN
audit_NN
services_NN
1_CD
Group_NN
1,715_CD
630_CD
1_CD
Company_NN
60_CD
20_CD
Auditors_NN
remuneration_NOMZ
for_PIN
non-audit_JJ
services_NN
2_CD
Group_NN
audit_NN
related_VBN
1,172_CD
1,015_CD
3_CD
Group_NN
tax_NN
2,583_CD
1,145_CD
4_CD
Group_NN
other_JJ
100_CD
177_CD
4_CD
Company_NN
other_JJ
75_CD
1_CD
Audit_NN
fees_NN
consisted_VBD
of_PIN
audit_NN
work_NN
only_DWNT
the_DT
Companys_NN
auditors_NN
can_POMD [SPAU]
reasonably_RB
be_VB [PASS]
expected_VBN [PRIV]
to_TO
perform_VB
,_,
such_JJ
as_IN
statutory_JJ
audits_NN
and_CC
in_PIN
2004_CD
included_VBD
the_DT
audit_NN
in_PIN
relation_NOMZ
to_PIN
internal_JJ
control_NN
over_IN
US_FPP1
GAAP_NN
Form_NN
10-K_JJ
financial_JJ
reporting_GER
._.
2_CD
Audit_NN
related_JJ
fees_NN
consist_VPRT
of_PIN
work_NN
generally_RB
only_DWNT
the_DT
Companys_NN
auditors_NN
can_POMD [SPAU]
reasonably_RB
be_VB [PASS]
expected_VBN [PRIV]
to_TO
perform_VB
,_,
such_JJ
as_IN
procedures_NN
relating_VBG [WZPRES]
to_PIN
regulatory_JJ
filings_GER
._.
3_CD
Tax_NN
fees_NN
consisted_VBD
principally_RB
of_PIN
assistance_NN
with_PIN
matters_NN
related_VBN [WZPAST]
to_PIN
compliance_NN
,_,
planning_GER
and_PHC
advice_NN
in_PIN
various_JJ
tax_NN
jurisdictions_NOMZ
._.
4_CD
All_QUAN
other_JJ
fees_NN
relate_VPRT
to_PIN
assistance_NN
in_PIN
CSR_NN
and_CC
executive_JJ
remuneration_NOMZ
._.
41_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
42_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
4_CD
Directors_NN
remuneration_NOMZ
,_,
interests_NN
and_PHC
transactions_NOMZ
Aggregate_JJ
remuneration_NOMZ
The_DT
total_JJ
amounts_NN
for_PIN
Directors_NN
remuneration_NOMZ
and_CC
other_JJ
benefits_NN
were_VBD
as_IN
follows_VPRT
:_:
2004 2003 000 000_CD
Emoluments_NOMZ
2,592_CD
2,256_CD
Money_NN
purchase_NN
pension_NN
contributions_NOMZ
278_CD
4,676_CD
Gains_NN
on_PIN
exercise_NN
of_PIN
share_NN
options_NOMZ
118_CD
114_CD
Amounts_NN
receivable_JJ
under_IN
long-term_JJ
incentive_NN
schemes_NN
86_CD
276_CD
Compensation_NOMZ
for_PIN
loss_NN
of_PIN
office_NN
1,335_CD
3,074_CD
8,657_CD
No_SYNE
fees_NN
were_VBD [BEMA]
payable_PRED
to_PIN
third_JJ
parties_NN
in_PIN
respect_NN
of_PIN
Directors_NN
services_NN
for_PIN
either_DT
year_NN
._.
The_DT
number_NN
of_PIN
Directors_NN
who_WP [WHSUB]
were_VBD
members_NN
of_PIN
a_DT
Company_NN
pension_NN
scheme_NN
was_VBD
as_IN
follows_VPRT
:_:
2004_CD
2003_CD
Number_NN
Number_NN
Money_NN
purchase_NN
schemes_NN
3_CD
4_CD
Contributions_NOMZ
paid_VBN [WZPAST]
by_PIN
the_DT
Group_NN
in_PIN
respect_NN
of_PIN
these_DEMO
Directors_NN
can_POMD
be_VB [PASS]
found_VBN [PRIV]
in_PIN
the_DT
Directors_NN
remuneration_NOMZ
report_NN
._.
The_DT
above_PLACE
amounts_NN
for_PIN
remuneration_NOMZ
include_VPRT
the_DT
following_VBG
in_PIN
respect_NN
of_PIN
the_DT
highest_JJ
paid_VBN
Director_NN
:_:
2004 2003 000 000_CD
Aggregate_NN
emoluments_NOMZ
1,419_CD
311_CD
Gains_NN
on_PIN
exercise_NN
of_PIN
share_NN
options_NOMZ
21_CD
Amounts_NN
receivable_JJ
under_IN
long-term_JJ
incentive_NN
schemes_NN
183_CD
Compensation_NOMZ
for_PIN
loss_NN
of_PIN
office_NN
1,335_CD
1,419_CD
1,850_CD
Further_JJ
disclosures_NN
relating_VBG [WZPRES]
to_PIN
Directors_NN
remuneration_NOMZ
and_PHC
interests_NN
in_PIN
transactions_NOMZ
can_POMD
be_VB [PASS]
found_VBN [PRIV]
in_PIN
the_DT
Directors_NN
remuneration_NOMZ
report_NN
._.
5_CD
Staff_NN
costs_NN
Particulars_NN
of_PIN
employee_NN
costs_NN
including_VBG [WZPRES]
executive_JJ
Directors_NN
remuneration_NOMZ
are_VPRT [PASS]
shown_VBN [PRIV]
below_PLACE
:_:
2004 2003 000 000_CD
Wages_NN
and_PHC
salaries_NN
97,754_CD
85,026_CD
Social_NN
security_NOMZ
costs_NN
8,366_CD
8,527_CD
Pension_NN
contributions_NOMZ
4,914_CD
9,824_CD
111,034_CD
103,377_CD
The_DT
increase_NN
in_PIN
wages_NN
and_PHC
salaries_NN
was_VBD
,_,
in_PIN
part_NN
,_,
driven_VBN [PASTP]
by_PIN
employee_NN
retention_NOMZ
and_PHC
relocation_NOMZ
payments_NOMZ
that_TSUB
were_VBD [PASS]
paid_VBN
during_PIN
the_DT
year_NN
as_IN
part_NN
of_PIN
the_DT
US_FPP1
reorganisation_NOMZ
._.
The_DT
average_JJ
monthly_JJ
number_NN
of_PIN
people_NN
employed_VBN [WZPAST]
by_PIN
the_DT
Group_NN
during_PIN
the_DT
year_NN
was_VBD
as_IN
follows_VPRT
:_:
2004_CD
2003_CD
Number_NN
Number_NN
Manufacturing_GER
and_PHC
distribution_NOMZ
358_CD
374_CD
Sales_NN
and_PHC
marketing_GER
837_CD
797_CD
General_NN
and_CC
administrative_JJ
265_CD
327_CD
Research_NN
and_PHC
development_NOMZ
432_CD
407_CD
1,892_CD
1,905_CD
42_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
43_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
6_CD
Finance_NN
income_NN
,_,
net_JJ
2004 2003 000 000_CD
Investment_NOMZ
income_NN
2,607_CD
2,804_CD
Interest_NN
receivable_NN
11,917_CD
10,361_CD
Interest_NN
payable_JJ
and_PHC
similar_JJ
charges_NN
7,856_CD
9,404_CD
Finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
contracts_NN
38_CD
59_CD
7,894_CD
9,463_CD
Finance_NN
charges_NN
,_,
net_JJ
Investment_NOMZ
income_NN
2,607_CD
2,804_CD
Interest_NN
receivable_NN
11,917_CD
10,361_CD
Interest_NN
payable_JJ
and_PHC
similar_JJ
charges_NN
7,894_CD
9,463_CD
6,630_CD
3,702_CD
In_PIN
August_NN
2004_CD
202.6_CD
million_CD
of_PIN
the_DT
convertible_JJ
debt_NN
was_VBD [PASS]
redeemed_VBN
at_PIN
cost_NN
by_PIN
the_DT
note_NN
holders_NN
and_ANDC
as_CONJ
a_NULL
result_NULL
costs_NN
of_PIN
3.8_CD
million_CD
were_VBD [PASS]
expensed_VBN
in_PIN
the_DT
year_NN
._.
These_DEMO
costs_NN
were_VBD
being_VBG [PASS]
amortised_VBN
through_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
over_IN
the_DT
life_NN
of_PIN
the_DT
loan_NN
notes_NN
._.
These_DEMO
costs_NN
have_VPRT [PEAS]
been_VBN [SPAU] [BYPA]
partly_DWNT
offset_VBN
by_PIN
a_DT
reduction_NOMZ
in_PIN
interest_NN
payable_JJ
for_PIN
the_DT
period_NN
from_PIN
redemption_NOMZ
of_PIN
the_DT
loan_NN
notes_VPRT [PRIV]
up_RP
to_PIN
31_CD
December_NN
2004_CD
._.
Interest_NN
payable_JJ
and_PHC
similar_JJ
charges_NN
includes_VPRT
net_JJ
exchange_NN
gains_NN
on_PIN
foreign_JJ
currency_NN
borrowings_GER
less_RB
deposits_NN
of_PIN
1.1_CD
million_CD
2003_CD
:_:
3.9_CD
million_CD
._.
7_CD
Tax_NN
on_PIN
profit_NN
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
The_DT
tax_NN
charge_NN
comprises_VPRT
:_:
2004 2003 000 000_CD
Current_JJ
tax_NN
UK_NN
corporation_NOMZ
tax_NN
925_CD
Foreign_NN
corporation_NOMZ
tax_NN
82,673_CD
76,830_CD
Adjustment_NOMZ
to_PIN
prior_JJ
year_NN
tax_NN
charge_NN
Foreign_JJ
corporation_NOMZ
tax_NN
2,119_CD
512_CD
Total_JJ
current_JJ
tax_NN
81,479_CD
77,342_CD
Deferred_JJ
tax_NN
Origination_NOMZ
and_PHC
reversal_NN
of_PIN
timing_NN
differences_NN
:_:
Current_JJ
year_NN
3,341_CD
17,040_CD
Adjustment_NOMZ
to_PIN
prior_JJ
year_NN
7,272_CD
4,712_CD
Total_JJ
deferred_JJ
tax_NN
10,613_CD
12,328_CD
Total_JJ
tax_NN
on_PIN
profit_NN
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
70,866_CD
65,014_CD
43_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
44_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
7_CD
Tax_NN
on_PIN
profit_NN
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
continued_VBD
The_DT
differences_NN
between_PIN
the_DT
total_JJ
current_JJ
tax_NN
shown_VBN [PRIV]
above_PLACE
and_CC
the_DT
amount_NN
calculated_VBN [PRIV] [WZPAST]
by_PIN
applying_VBG
the_DT
standard_JJ
rate_NN
of_PIN
UK_NN
corporation_NOMZ
tax_NN
to_PIN
the_DT
profit_NN
before_IN
tax_NN
is_VPRT
as_IN
follows_VPRT
:_:
2004 2003 000 000_CD
Group_NN
profit_NN
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
tax_NN
57,435_CD
298,341_CD
Tax_NN
on_PIN
profit_NN
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
at_PIN
standard_JJ
UK_NN
corporation_NOMZ
tax_NN
rate_NN
of_PIN
30_CD
%_NN
2003_CD
:_:
30_CD
%_NN
17,230_CD
89,502_CD
Effects_NN
of_PIN
:_:
Expenses_NN
not_XX0
deductible_JJ
for_PIN
tax_NN
purposes_NN
7,318_CD
12,063_CD
Non_NN
deductible_JJ
goodwill_NN
47,813_CD
161,195_CD
Additional_JJ
tax_NN
benefits_NN
non_VPRT
taxable_JJ
income_NN
1,662_CD
891_CD
Movement_NOMZ
of_PIN
tax_NN
losses_NN
4,080_CD
1,385_CD
Capital_NN
taxes_NN
and_PHC
withholding_GER
taxes_NN
150_CD
1,548_CD
Different_JJ
tax_NN
rates_NN
on_PIN
overseas_PLACE
earnings_GER
5,358_CD
26,008_CD
Deferred_JJ
tax_NN
liability_NOMZ
non_NN
permanent_JJ
timing_NN
differences_NN
10,613_CD
12,328_CD
Effect_NN
of_PIN
discontinued_VBN
operations_NOMZ
10,686_CD
Adjustments_NOMZ
to_PIN
tax_NN
charge_NN
in_PIN
respect_NN
of_PIN
previous_JJ
periods_NN
9,391_CD
5,224_CD
Group_NN
current_JJ
tax_NN
charge_NN
for_PIN
period_NN
81,479_CD
77,342_CD
The_DT
Group_NN
earns_VPRT
a_DT
significant_JJ
proportion_NOMZ
of_PIN
its_PIT
profits_NN
in_PIN
the_DT
US_FPP1
._.
The_DT
US_FPP1
statutory_JJ
federal_JJ
tax_NN
rate_NN
is_VPRT [BEMA]
higher_PRED
than_PIN
that_DEMO
of_PIN
the_DT
UK_NN
with_PIN
profits_NN
being_VBG [WZPRES] [PASS]
taxed_VBN
at_PIN
35_CD
%_NN
._.
Other_JJ
jurisdictions_NOMZ
have_VPRT
lower_JJ
effective_JJ
tax_NN
rates_NN
._.
In_PIN
the_DT
future_NN
,_,
changes_NN
in_PIN
US_FPP1
tax_NN
law_NN
may_POMD
affect_VB
the_DT
Group_NN
tax_NN
charge_NN
._.
No_SYNE
tax_NN
deduction_NOMZ
is_VPRT [BEMA]
available_PRED
on_PIN
the_DT
impairment_NOMZ
of_PIN
goodwill_NN
that_TSUB
was_VBD [PASS]
created_VBN
on_PIN
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
Pharma_NN
Inc._NN
._.
As_IN
of_PIN
31_CD
December_NN
2004_CD
the_DT
Company_NN
has_VPRT [PEAS]
not_XX0
made_VBN
a_DT
UK_NN
tax_NN
provision_NN
on_PIN
approximately_RB
729.2_CD
million_CD
of_PIN
unremitted_JJ
earnings_GER
of_PIN
its_PIT
international_JJ
subsidiaries_NN
._.
The_DT
Company_NN
does_VPRT
not_XX0
provide_VB
for_PIN
income_NN
taxes_NN
on_PIN
the_DT
unremitted_JJ
earnings_GER
of_PIN
subsidiaries_NN
located_VBN
outside_PLACE
the_DT
UK_NN
,_,
where_RB
such_JJ
earnings_GER
have_VPRT [PEAS]
been_VBN [PASS]
retained_VBN
indefinitely_RB
for_PIN
reinvestment_NOMZ
,_,
or_CC
where_RB
it_PIT
is_VPRT
managements_NOMZ
intention_NOMZ
that_TOBJ
the_DT
earnings_GER
will_PRMD
be_VB [PASS]
remitted_VBN
in_PIN
a_DT
tax_NN
free_JJ
liquidation_NOMZ
,_,
or_CC
as_IN
dividends_NN
with_PIN
taxes_NN
substantially_RB
offset_VBN
by_PIN
foreign_JJ
tax_NN
credits_NN
._.
It_PIT
is_VPRT [BEMA]
not_XX0
practical_PRED
to_TO
determine_VB [SUAV] [PRIV]
the_DT
amount_NN
of_PIN
unrecognised_JJ
deferred_JJ
tax_NN
liabilities_NOMZ
for_PIN
temporary_JJ
differences_NN
related_VBN [WZPAST]
to_PIN
these_DEMO
investments_NOMZ
._.
8_CD
Loss_NN
attributable_JJ
to_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
The_DT
loss_NN
for_PIN
the_DT
financial_JJ
year_NN
dealt_VBD
with_PIN
in_PIN
the_DT
accounts_NN
of_PIN
the_DT
Company_NN
was_VBD [BEMA]
17,492,000_CD
2003_CD
:_:
profit_NN
of_PIN
194,246,000_CD
._.
As_IN
provided_VBN
by_PIN
Section_NOMZ
230_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
,_,
no_SYNE
profit_NN
and_PHC
loss_NN
account_NN
is_VPRT [PASS]
presented_VBN
in_PIN
respect_NN
of_PIN
the_DT
Company_NN
._.
9_CD
Dividends_NN
paid_VBD
and_PHC
proposed_VBD [SUAV]
2004 2003 000 000_CD
Equity_NOMZ
shares_NN
:_:
First_NN
interim_JJ
paid_VBN
of_PIN
1_CD
penny_NN
per_PIN
share_NN
2003_CD
:_:
nil_NN
4,967_CD
Second_JJ
interim_JJ
proposed_VBN [SUAV]
of_PIN
2_CD
pence_NN
per_PIN
share_NN
2003_CD
:_:
nil_NN
9,952_CD
14,919_CD
44_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
45_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
10_CD
Loss_NN
per_PIN
share_NN
Basic_JJ
EPS_NN
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
net_JJ
profit_NN
or_CC
loss_NN
attributable_JJ
to_PIN
ordinary_JJ
shareholders_NN
divided_VBN [WZPAST]
by_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
ordinary_JJ
shares_NN
outstanding_JJ
during_PIN
the_DT
year_NN
._.
Diluted_JJ
EPS_NN
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
net_JJ
profit_NN
or_CC
loss_NN
attributable_JJ
to_PIN
ordinary_JJ
shareholders_NN
divided_VBN [WZPAST]
by_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
ordinary_JJ
shares_NN
outstanding_JJ
during_PIN
the_DT
year_NN
and_CC
adjusted_VBN
for_PIN
the_DT
effect_NN
of_PIN
all_QUAN
dilutive_JJ
potential_JJ
ordinary_JJ
shares_NN
that_TSUB
were_VBD [BEMA]
outstanding_PRED
during_PIN
the_DT
year_NN
._.
Share_NN
options_NOMZ
to_TO
purchase_VB
approximately_RB
16.6_CD
million_CD
ordinary_JJ
shares_NN
for_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2004_CD
were_VBD [BEMA]
not_XX0
dilutive_PRED
and_CC
were_VBD [SPAU] [PASS]
therefore_CONJ
excluded_VBN
from_PIN
the_DT
computation_NOMZ
of_PIN
diluted_JJ
loss_NN
per_PIN
share_NN
2003_CD
:_:
17.0_CD
million_CD
._.
Warrants_NN
to_TO
purchase_VB
approximately_RB
1.3_CD
million_CD
ordinary_JJ
shares_NN
for_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2003_CD
were_VBD [BEMA]
not_XX0
dilutive_PRED
and_CC
were_VBD [SPAU] [PASS]
therefore_CONJ
excluded_VBN
from_PIN
the_DT
computation_NOMZ
of_PIN
diluted_JJ
loss_NN
per_PIN
share_NN
._.
The_DT
$_$
370_CD
million_CD
convertible_JJ
loan_NN
note_NN
is_VPRT [PASS]
excluded_VBN
from_PIN
the_DT
calculation_NOMZ
of_PIN
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
for_PIN
fully_AMP
diluted_VBN
loss_NN
per_PIN
share_NN
for_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2004_CD
and_CC
2003_CD
as_IN
it_PIT
was_VBD [BEMA]
not_XX0
dilutive_PRED
._.
Basic_JJ
and_PHC
diluted_JJ
2004 2003 000 000_CD
Loss_NN
for_PIN
the_DT
financial_JJ
year_NN
13,431_CD
363,355_CD
Number_NN
of_PIN
shares_NN
2004_CD
2003_CD
Weighted_VBN
average_JJ
number_NN
of_PIN
shares_NN
:_:
For_PIN
Basic_JJ
and_PHC
diluted_JJ
EPS_NN
496,306,604_CD
498,212,826_CD
11_CD
UITF_NN
38_CD
Accounting_GER
for_PIN
ESOP_NN
Trusts_NN
The_DT
Employee_NN
Share_NN
Ownership_NN
Plan_NN
ESOP_NN
reserve_NN
arises_VPRT
in_PIN
connection_NOMZ
with_PIN
the_DT
ESOP_NN
trust_NN
,_,
a_DT
discretionary_JJ
trust_NN
established_VBN [PRIV]
to_TO
facilitate_VB
the_DT
operation_NOMZ
of_PIN
the_DT
Groups_NN
long-term_JJ
incentive_NN
scheme_NN
for_PIN
senior_JJ
management_NOMZ
._.
The_DT
amount_NN
of_PIN
the_DT
reserve_NN
represents_VPRT
the_DT
deduction_NOMZ
in_PIN
arriving_VBG
at_PIN
shareholders_NN
funds_NN
for_PIN
the_DT
consideration_NOMZ
paid_VBN [WZPAST]
for_PIN
the_DT
Companys_NN
shares_NN
purchased_VBN [WZPAST]
by_PIN
the_DT
trust_NN
which_WDT [WHSUB]
had_VBD [PEAS]
not_XX0
vested_VBN
unconditionally_RB
to_PIN
employees_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
The_DT
Deferred_NN
Bonus_NN
Plan_NN
the_DT
Plan_NN
provides_VPRT
for_PIN
participants_NN
to_TO
use_VB
up_RP
to_PIN
50_CD
%_NN
of_PIN
their_TPP3
annual_JJ
bonus_NN
to_TO
buy_VB
shares_NN
in_PIN
the_DT
Company_NN
._.
The_DT
Company_NN
will_PRMD
match_VB
any_QUAN
shares_NN
bought_VBD
,_,
but_CC
the_DT
matched_VBN
shares_NN
will_PRMD
vest_NN
,_,
for_PIN
executive_NN
Directors_NN
,_,
only_DWNT
if_COND
the_DT
Companys_NN
EPS_NN
grows_VPRT
by_PIN
more_EMPH
than_PIN
15_CD
%_NN
in_PIN
excess_NN
of_PIN
RPI_NN
over_IN
a_DT
three-year_JJ
period_NN
9_CD
%_NN
in_PIN
excess_NN
of_PIN
RPI_NN
for_PIN
other_JJ
eligible_JJ
employees_NN
._.
Recent_JJ
fiscal_JJ
changes_NN
in_PIN
the_DT
US_FPP1
have_VPRT [PEAS]
made_VBN
the_DT
Plan_NN
less_RB
attractive_JJ
to_PIN
participants_NN
and_CC
the_DT
Remuneration_NOMZ
Committee_NN
has_VPRT [PEAS]
determined_VBN [SUAV] [PRIV]
that_THVC
it_PIT
will_PRMD
discontinue_VB
the_DT
Plan_NN
after_IN
bonus_NN
awards_NN
for_PIN
the_DT
2004_CD
financial_JJ
year_NN
._.
The_DT
number_NN
and_PHC
market_NN
value_NN
of_PIN
the_DT
ordinary_JJ
shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
ESOP_NN
trust_NN
at_PIN
31_CD
December_NN
2004_CD
was_VBD
:_:
2004 2004 2003 2003_CD
Number_NN
Market_NN
value_NN
Number_NN
Market_NN
value_NN
000 000 000 000_CD
Shares_NN
allocated_VBN
but_CC
not_XX0
vested_JJ
50_CD
128_CD
Unallocated_JJ
shares_NN
29_CD
52_CD
137_CD
45_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
46_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
12_CD
Intangible_JJ
assets_NN
intellectual_JJ
property_NN
Group_NN
Company_NN
000_CD
000_CD
Cost_NN
As_IN
at_PIN
1_CD
January_NN
2004_CD
275,210_CD
23,668_CD
Additions_NOMZ
26,765_CD
84_CD
Disposals_NN
5,181_CD
700_CD
Foreign_JJ
exchange_NN
12,944_CD
As_IN
at_PIN
31_CD
December_NN
2004_CD
283,850_CD
23,052_CD
Amortisation_NOMZ
As_IN
at_PIN
1_CD
January_NN
2004_CD
103,662_CD
4,338_CD
Charge_NN
for_PIN
the_DT
year_NN
20,709_CD
1,962_CD
Impairment_NOMZ
8,455_CD
70_CD
Disposals_NN
3,695_CD
Foreign_JJ
exchange_NN
5,314_CD
As_IN
at_PIN
31_CD
December_NN
2004_CD
123,817_CD
6,230_CD
Net_JJ
book_NN
value_NN
As_IN
at_PIN
31_CD
December_NN
2003_CD
171,548_CD
19,330_CD
As_IN
at_PIN
31_CD
December_NN
2004_CD
160,033_CD
16,822_CD
During_PIN
the_DT
year_NN
,_,
the_DT
Group_NN
purchased_VBD
:_:
the_DT
exclusive_JJ
rights_NN
to_PIN
REMINYL_NN
in_PIN
the_DT
United_NN
Kingdom_NN
and_PHC
Ireland_NN
for_PIN
$_$
30_CD
million_CD
16.3_CD
million_CD
,_,
of_PIN
which_WDT [PIRE]
$_$
19.0_CD
million_CD
10.5_CD
million_CD
is_VPRT [PASS]
deferred_VBN
consideration_NOMZ
at_PIN
31_CD
December_NN
2004_CD
:_:
and_ANDC
the_DT
rights_NN
to_PIN
the_DT
global_JJ
patents_NN
for_PIN
FOSRENOL_NN
from_PIN
AnorMED_NN
Inc_NN
for_PIN
a_DT
consideration_NOMZ
of_PIN
up_RB
to_TO
$_$
31_CD
million_CD
,_,
dependent_JJ
upon_PIN
achievement_NOMZ
of_PIN
certain_JJ
milestones_NN
._.
As_IN
at_PIN
31_CD
December_NN
2004_CD
,_,
two_CD
of_PIN
these_DEMO
milestones_NN
had_VBD [PEAS]
been_VBN [PASS]
achieved_VBN
resulting_VBG
in_PIN
the_DT
capitalization_NOMZ
of_PIN
$_$
19.0_CD
million_CD
10.5_CD
million_CD
._.
13_CD
Intangible_JJ
assets_NN
goodwill_NN
Group_NN
Company_NN
000_CD
000_CD
Cost_NN
As_IN
at_PIN
1_CD
January_NN
2004_CD
2,773,269_CD
Disposal_NN
2,741_CD
Foreign_JJ
exchange_NN
1,047_CD
As_IN
at_PIN
31_CD
December_NN
2004_CD
2,769,481_CD
Amortisation_NOMZ
As_IN
at_PIN
1_CD
January_NN
2004_CD
1,407,686_CD
Charge_NN
for_PIN
the_DT
year_NN
77,098_CD
Impairment_NOMZ
81,185_CD
Disposals_NN
410_CD
Foreign_JJ
exchange_NN
134_CD
As_IN
at_PIN
31_CD
December_NN
2004_CD
1,565,425_CD
Net_JJ
book_NN
value_NN
As_IN
at_PIN
31_CD
December_NN
2003_CD
1,365,583_CD
As_IN
at_PIN
31_CD
December_NN
2004_CD
1,204,056_CD
At_PIN
31_CD
December_NN
2004_CD
,_,
an_DT
impairment_NOMZ
charge_NN
was_VBD [PASS]
booked_VBN
in_PIN
relation_NOMZ
to_PIN
goodwill_NN
that_TSUB
was_VBD [PASS]
created_VBN
on_PIN
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
Pharma_NN
Inc._NN
._.
A_DT
discounted_JJ
cash_NN
flow_NN
model_NN
was_VBD [PASS]
used_VBN
to_TO
estimate_VB [PRIV]
the_DT
recoverable_JJ
value_NN
of_PIN
the_DT
business_NOMZ
and_CC
the_DT
impairment_NOMZ
is_VPRT [PASS]
included_VBN
within_PIN
net_JJ
operating_GER
expenses_NN
in_PIN
the_DT
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
._.
A_DT
range_NN
of_PIN
discount_NN
rates_NN
between_PIN
7.5-10_CD
%_NN
was_VBD [PASS]
applied_VBN
to_PIN
probabilityadjusted_JJ
forecasts_NN
._.
The_DT
net_JJ
book_NN
value_NN
of_PIN
the_DT
Groups_NN
assets_NN
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
agreements_NOMZ
is_VPRT [PASS]
shown_VBN [PRIV]
below_PLACE
:_:
2004 2003 000 000_CD
Buildings_GER
3,277_CD
Equipment_NOMZ
and_CC
other_JJ
35_CD
3,312_CD
All_QUAN
finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
arrangements_NOMZ
were_VBD [BEMA]
short_JJ
leases_NN
with_PIN
a_DT
life_NN
of_PIN
less_JJ
than_PIN
50_CD
years_NN
._.
b_NN
Company_NN
Office_NN
furniture_NN
Equipment_NOMZ
and_PHC
fittings_GER
and_CC
other_JJ
Total_JJ
000 000 000_CD
Cost_NN
As_IN
at_PIN
1_CD
January_NN
2004_CD
97_CD
13,012_CD
13,109_CD
Additions_NOMZ
9,378_CD
9,378_CD
Disposals_NN
94 284 378_CD
As_IN
at_PIN
31_CD
December_NN
2004_CD
3_CD
22,106_CD
22,109_CD
Depreciation_NOMZ
As_IN
at_PIN
1_CD
January_NN
2004_CD
97_CD
5,088_CD
5,185_CD
Charge_NN
2,589_CD
2,589_CD
Disposals_NN
94 279 373_CD
As_IN
at_PIN
31_CD
December_NN
2004_CD
3_CD
7,398_CD
7,401_CD
Net_JJ
book_NN
value_NN
As_IN
at_PIN
31_CD
December_NN
2003_CD
7,924_CD
7,924_CD
As_IN
at_PIN
31_CD
December_NN
2004_CD
14,708_CD
14,708_CD
The_DT
net_JJ
book_NN
value_NN
of_PIN
the_DT
Companys_NN
equipment_NOMZ
includes_VPRT
nil_NN
2003_CD
:_:
35,000_CD
in_PIN
respect_NN
of_PIN
assets_NN
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
agreements_NOMZ
._.
47_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
48_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
15_CD
Fixed_VBN
asset_NN
investments_NOMZ
Group_NN
Company_NN
2004 2003 2004 2003_CD
000 000 000 000_CD
Subsidiary_NN
undertakings_GER
3,419,605_CD
3,419,192_CD
Associates_NN
12,849_CD
Other_JJ
investments_NOMZ
39,872_CD
33,269_CD
559_CD
559_CD
52,721_CD
33,269_CD
3,420,164_CD
3,419,751_CD
Principal_NN
Group_NN
investments_NOMZ
The_DT
parent_NN
Company_NN
and_CC
the_DT
Group_NN
have_VPRT
investments_NOMZ
in_PIN
the_DT
following_JJ
subsidiary_NN
undertakings_GER
which_WDT [WHSUB]
principally_RB
affected_VBD
the_DT
results_NN
or_CC
net_JJ
assets_NN
of_PIN
the_DT
Group_NN
._.
To_TO
avoid_VB
a_DT
statement_NOMZ
of_PIN
excessive_JJ
length_NN
,_,
details_NN
of_PIN
investments_NOMZ
which_WDT [WHSUB]
are_VPRT [BEMA]
not_XX0
significant_PRED
have_VPRT [PEAS]
been_VBN [PASS]
omitted_VBN
._.
Country_NN
of_PIN
incorporation_NOMZ
or_CC
principal_NN
business_NOMZ
address_NN
Principal_NN
activity_NOMZ
Holding_VBG [PRIV] [WZPRES]
%_NN
Subsidiary_NN
undertakings_GER
Shire_NN
LLC_NN
US_FPP1
Licensing_GER
,_,
development_NOMZ
,_,
production_NOMZ
100_CD
%_NN
and_PHC
distribution_NOMZ
of_PIN
pharmaceuticals_NN
Shire_NN
US_FPP1
Inc._NN
._.
US_FPP1
Marketing_GER
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
Pharmaceuticals_NN
Limited_NN
UK_NN
Marketing_GER
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
Pharmaceutical_NN
Contracts_NN
Limited_NN
UK_NN
Marketing_GER
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
France_NN
SA_NN
France_NN
Marketing_GER
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
Deutschland_NN
GmbH_NN
&_CC
Co_NN
K_NN
G_NN
Germany_NN
Marketing_GER
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
Italia_NN
SpA_NN
Italy_NN
Marketing_GER
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
Pharmaceuticals_NN
Iberica_NN
SL_NN
Spain_NN
Marketing_GER
and_PHC
distribution_NOMZ
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
Pharmaceuticals_NN
Ireland_NN
Limited_NN
Ireland_NN
Marketing_GER
and_PHC
distribution_NOMZ
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
BioChem_NN
Inc._NN
._.
Canada_NN
Marketing_GER
,_,
research_NN
and_PHC
development_NOMZ
100_CD
%_NN
of_PIN
pharmaceuticals_NN
,_,
including_VBG [PRESP]
on_PIN
behalf_NN
of_PIN
other_JJ
Group_NN
companies_NN
Shire_NN
International_NN
Licensing_GER
BV_NN
Netherlands_NN
Licensing_GER
and_PHC
development_NOMZ
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
Pharmaceutical_NN
Development_NOMZ
Limited_NN
UK_NN
Development_NOMZ
of_PIN
pharmaceuticals_NN
,_,
including_VBG [PRESP]
100_CD
%_NN
on_PIN
behalf_NN
of_PIN
other_JJ
Group_NN
companies_NN
Shire_NN
Pharmaceuticals_NN
Development_NOMZ
US_FPP1
Inc._NN
._.
US_FPP1
Development_NOMZ
of_PIN
pharmaceuticals_NN
,_,
including_VBG [PRESP]
100_CD
%_NN
on_PIN
behalf_NN
of_PIN
other_JJ
Group_NN
companies_NN
Shire_NN
Laboratories_NN
Inc._NN
._.
US_FPP1
Development_NOMZ
and_PHC
licensing_GER
of_PIN
pharmaceuticals_NN
,_,
100_CD
%_NN
including_VBG [WZPRES]
on_PIN
behalf_NN
of_PIN
other_JJ
Group_NN
companies_NN
Shire_NN
Finance_NN
Limited_NN
Cayman_NN
Islands_NN
Issuer_NN
of_PIN
convertible_JJ
notes_NN
100_CD
%_NN
Shire_NN
US_FPP1
Manufacturing_GER
Inc._NN
._.
US_FPP1
Manufacturer_NN
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Held_VBN [PRIV] [WZPAST]
directly_RB
by_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc._NN
._.
All_QUAN
subsidiary_NN
undertakings_GER
have_VPRT [PEAS]
been_VBN [PASS]
included_VBN
in_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
48_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
49_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
15_CD
Fixed_VBN
asset_NN
investments_NOMZ
continued_VBD
Subsidiary_NN
undertakings_GER
Amounts_NN
Shares_NN
in_PIN
due_JJ
from_PIN
subsidiary_NN
subsidiary_NN
undertakings_GER
undertakings_GER
Total_JJ
000 000 000_CD
Company_NN
Cost_NN
At_PIN
1_CD
January_NN
2004_CD
3,208,042_CD
211,150_CD
3,419,192_CD
Additions_NOMZ
25,337_CD
25,337_CD
Disposals_NN
17,181_CD
17,181_CD
Foreign_JJ
exchange_NN
7,743_CD
7,743_CD
At_PIN
31_CD
December_NN
2004_CD
3,216,198_CD
203,407_CD
3,419,605_CD
In_PIN
October_NN
2004_CD
the_DT
Company_NN
subscribed_VBN [WZPAST]
for_PIN
shares_NN
in_PIN
a_DT
directly_RB
held_VBN [PRIV]
subsidiary_NN
and_CC
satisfied_VBD
the_DT
subscription_NOMZ
with_PIN
the_DT
shares_NN
of_PIN
another_DT
directly_RB
held_VBN [PRIV]
subsidiary_NN
,_,
valued_VBN [PASTP]
at_PIN
cost_NN
._.
In_CONJ
addition_NULL
,_,
in_PIN
August_NN
2004_CD
,_,
the_DT
Company_NN
provided_VBD
additional_JJ
investment_NOMZ
to_PIN
another_DT
directly_RB
owned_VBN
subsidiary_NN
._.
Associates_NN
Group_NN
Company_NN
000_CD
000_CD
Cost_NN
At_PIN
1_CD
January_NN
2004_CD
Reclassification_NOMZ
from_PIN
other_JJ
investments_NOMZ
20,699_CD
At_PIN
31_CD
December_NN
2004_CD
20,699_CD
Provisions_NN
for_PIN
impairment_NOMZ
At_PIN
1_CD
January_NN
2004_CD
Reclassification_NOMZ
from_PIN
other_JJ
investments_NOMZ
7,850_CD
At_PIN
31_CD
December_NN
2004_CD
7,850_CD
Net_JJ
book_NN
value_NN
At_PIN
31_CD
December_NN
2003_CD
At_PIN
31_CD
December_NN
2004_CD
12,849_CD
In_PIN
the_DT
fourth_JJ
quarter_NN
of_PIN
2004_CD
,_,
the_DT
Company_NN
reviewed_VBD
the_DT
nature_NN
of_PIN
certain_JJ
investments_NOMZ
previously_TIME
accounted_VBD
for_PIN
as_IN
other_JJ
investments_NOMZ
and_CC
determined_VBD [SUAV] [PRIV]
that_THVC
they_TPP3
should_NEMD
be_VB [PASS]
accounted_VBN
for_PIN
as_IN
associates_NN
._.
Accordingly_RB
,_,
from_PIN
1_CD
October_NN
2004_CD
these_DEMO
investments_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
as_IN
associates_NN
._.
Between_PIN
1_CD
January_NN
and_CC
30_CD
September_NN
2004_CD
these_DEMO
investments_NOMZ
were_VBD [BYPA]
impaired_VBN
by_PIN
2.2_CD
million_CD
in_PIN
net_JJ
operating_GER
expenses_NN
2003_CD
:_:
5.7_CD
million_CD
._.
The_DT
following_VBG
information_NOMZ
is_VPRT [PASS]
given_VBN
in_PIN
respect_NN
of_PIN
the_DT
Groups_NN
share_NN
of_PIN
all_QUAN
associates_NN
._.
2004_CD
000_CD
Turnover_NN
43_CD
Fixed_VBN
assets_NN
Current_JJ
assets_NN
19,302_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
within_PIN
one_CD
year_NN
23_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
49_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
50_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
15_CD
Fixed_VBN
asset_NN
investments_NOMZ
continued_VBD
Included_VBN
above_PLACE
is_VPRT [BEMA]
the_DT
Groups_NN
share_NN
of_PIN
GeneChem_NN
Technologies_NN
Venture_NN
Fund_NN
which_WDT [WHSUB]
is_VPRT [PASS]
detailed_VBN
individually_RB
below_PLACE
._.
2004_CD
000_CD
Turnover_NN
22_CD
Loss_NN
before_IN
tax_NN
530_CD
Taxation_NOMZ
Loss_NN
after_IN
tax_NN
530_CD
Fixed_VBN
assets_NN
Current_JJ
assets_NN
5,425_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
within_PIN
one_CD
year_NN
5_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
Other_JJ
investments_NOMZ
Group_NN
Company_NN
000_CD
000_CD
Cost_NN
At_PIN
1_CD
January_NN
2004_CD
48,569_CD
559_CD
Additions_NOMZ
39,771_CD
Disposals_NN
7,445_CD
Foreign_JJ
exchange_NN
1,151_CD
Reclassification_NOMZ
to_PIN
associates_NN
20,699_CD
At_PIN
31_CD
December_NN
2004_CD
59,045_CD
559_CD
Provisions_NN
for_PIN
impairment_NOMZ
At_PIN
1_CD
January_NN
2004_CD
15,300_CD
Impairment_NOMZ
11,723_CD
Reclassification_NOMZ
to_PIN
associates_NN
7,850_CD
At_PIN
31_CD
December_NN
2004_CD
19,173_CD
Net_JJ
book_NN
value_NN
At_PIN
31_CD
December_NN
2003_CD
33,269_CD
559_CD
At_PIN
31_CD
December_NN
2004_CD
39,872_CD
559_CD
Investments_NOMZ
in_PIN
private_JJ
companies_NN
At_PIN
31_CD
December_NN
2004_CD
the_DT
Group_NN
held_VBD [PRIV]
1.3_CD
million_CD
2003_CD
:_:
23.3_CD
million_CD
of_PIN
investments_NOMZ
in_PIN
private_JJ
companies_NN
._.
In_PIN
April_NN
2004_CD
Shire_NN
announced_VBD [PUBV]
that_THVC
it_PIT
had_VBD [PEAS]
contributed_VBN
cash_NN
,_,
equipment_NOMZ
and_CC
intellectual_JJ
property_NN
to_PIN
the_DT
start-up_NN
of_PIN
a_DT
new_JJ
Canadian-based_JJ
pharmaceutical_JJ
research_NN
and_PHC
development_NOMZ
organization_NOMZ
,_,
ViroChem_NN
Pharma_NN
Inc._NN
in_PIN
return_NN
for_PIN
a_DT
14_CD
%_NN
equity_NOMZ
interest_NN
._.
The_DT
transaction_NOMZ
followed_VBD
the_DT
closure_NN
of_PIN
the_DT
Lead_JJ
Optimisation_NOMZ
business_NOMZ
in_PIN
August_NN
2003_CD
and_CC
the_DT
decision_NN
to_PIN
exit_NN
the_DT
vaccines_NN
business_NOMZ
._.
In_CONJ
addition_NULL
,_,
Shire_NN
contributed_VBD
2.8_CD
million_CD
to_PIN
various_JJ
partnerships_NN
during_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
._.
Distributions_NOMZ
from_PIN
these_DEMO
partnerships_NN
totalled_VBD
0.7_CD
million_CD
2003_CD
:_:
nil_NN
._.
During_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2004_CD
,_,
the_DT
Company_NN
recorded_VBD
an_DT
impairment_NOMZ
of_PIN
8.6_CD
million_CD
due_JJ
to_PIN
a_DT
decrease_NN
in_PIN
the_DT
market_NN
value_NN
of_PIN
its_PIT
investment_NOMZ
in_PIN
private_JJ
companies_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
Company_NN
recorded_VBD
an_DT
impairment_NOMZ
of_PIN
2.2_CD
million_CD
2003_CD
:_:
5.7_CD
million_CD
against_PIN
the_DT
investment_NOMZ
in_PIN
the_DT
GeneChem_NN
Funds_NN
following_VBG [WZPRES]
reviews_NN
of_PIN
the_DT
Funds_NN
investment_NOMZ
portfolios_NN
that_TSUB
identified_VBD
permanent_JJ
declines_NN
in_PIN
the_DT
value_NN
of_PIN
certain_JJ
private_JJ
and_CC
publicly_RB
quoted_VBN
securities_NOMZ
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
Funds_NN
._.
At_PIN
31_CD
December_NN
2003_CD
,_,
Shire_NN
held_VBD [PRIV]
an_DT
investment_NOMZ
in_PIN
a_DT
private_JJ
company_NN
that_TSUB
was_VBD
entering_VBG
the_DT
later_TIME
stages_NN
of_PIN
an_DT
Initial_JJ
Public_NN
Offering_GER
IPO_NN
._.
At_PIN
31_CD
December_NN
2003_CD
the_DT
anticipated_JJ
flotation_NOMZ
price_NN
was_VBD [PASS]
used_VBN
to_TO
value_VB
the_DT
investment_NOMZ
._.
In_PIN
March_NN
2004_CD
,_,
this_DEMO
private_JJ
company_NN
gained_VBD
its_PIT
listing_GER
,_,
but_CC
the_DT
initial_JJ
listing_GER
price_NN
was_VBD
below_PLACE
the_DT
anticipated_JJ
flotation_NOMZ
price_NN
used_VBN [WZPAST]
at_PIN
31_CD
December_NN
2003_CD
._.
The_DT
Company_NN
recorded_VBD
an_DT
impairment_NOMZ
of_PIN
2.3_CD
million_CD
included_VBN
in_PIN
the_DT
8.6_CD
million_CD
above_PLACE
to_TO
decrease_VB
the_DT
value_NN
of_PIN
the_DT
investment_NOMZ
to_PIN
the_DT
initial_JJ
IPO_NN
price_NN
,_,
because_CAUS
it_PIT
believed_VBD [PRIV]
the_DT
decline_NN
in_PIN
price_NN
was_VBD [BEMA]
permanent_PRED
._.
The_DT
total_JJ
value_NN
of_PIN
the_DT
Groups_NN
investments_NOMZ
in_PIN
private_JJ
companies_NN
that_TSUB
underwent_VBD
an_DT
IPO_NN
during_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2004_CD
was_VBD [BEMA]
5.4_CD
million_CD
2003_CD
:_:
nil_NN
._.
50_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
51_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
15_CD
Fixed_VBN
asset_NN
investments_NOMZ
continued_VBD
Investments_NOMZ
in_PIN
public_JJ
companies_NN
At_PIN
31_CD
December_NN
2004_CD
the_DT
Group_NN
held_VBD [PRIV]
38.6_CD
million_CD
2003_CD
:_:
8.9_CD
million_CD
of_PIN
investments_NOMZ
in_PIN
public_JJ
companies_NN
._.
During_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
,_,
the_DT
Group_NN
received_VBD
31.3_CD
million_CD
$_$
60.0_CD
million_CD
in_PIN
the_DT
form_NN
of_PIN
subscription_NOMZ
receipts_NN
upon_PIN
the_DT
completion_NOMZ
of_PIN
the_DT
disposal_NN
of_PIN
its_PIT
vaccines_NN
business_NOMZ
to_PIN
ID_NN
Biomedical_NN
Corporation_NOMZ
IDB_NN
,_,
a_DT
Canadian_JJ
biotechnology_NN
company_NN
._.
See_VB [PRIV]
Note_VB [PRIV]
16_CD
for_PIN
further_JJ
information_NOMZ
._.
During_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2004_CD
,_,
the_DT
Company_NN
sold_VBD
an_DT
investment_NOMZ
and_CC
realized_VBD [PRIV]
a_DT
gain_NN
on_PIN
the_DT
sale_NN
of_PIN
8.3_CD
million_CD
2003_CD
:_:
nil_NN
._.
The_DT
Company_NN
recorded_VBD
an_DT
impairment_NOMZ
of_PIN
0.9_CD
million_CD
2003_CD
:_:
$_$
nil_CD
to_PIN
its_PIT
investment_NOMZ
in_PIN
a_DT
public_JJ
company_NN
._.
The_DT
company_NN
concerned_VBN
announced_VBD [PUBV]
the_DT
resignation_NOMZ
of_PIN
a_DT
key_JJ
member_NN
of_PIN
senior_JJ
management_NOMZ
and_PHC
Shire_NN
believes_VPRT [PRIV]
that_THVC
the_DT
decline_NN
in_PIN
the_DT
investee_NN
companys_VPRT
share_NN
price_NN
following_VBG [WZPRES]
the_DT
announcement_NOMZ
indicates_VPRT [PRIV]
long-term_JJ
impairment_NOMZ
._.
16_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
a_DT
Acquisitions_NOMZ
The_NN
Group_NN
made_VBD
no_SYNE
acquisitions_NOMZ
during_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
._.
b_NN
Disposals_NN
Vaccines_NN
business_NOMZ
On_PIN
9_CD
September_NN
2004_CD
the_DT
Company_NN
completed_VBD
its_PIT
disposal_NN
of_PIN
the_DT
vaccines_NN
business_NOMZ
to_PIN
ID_NN
Biomedical_NN
Corporation_NOMZ
IDB_NN
,_,
a_DT
Canadian_JJ
biotechnology_NN
company_NN
._.
The_DT
total_JJ
consideration_NOMZ
for_PIN
the_DT
sale_NN
was_VBD
$_$
120_CD
million_CD
65.1_CD
million_CD
comprising_VBG
$_$
30_CD
million_CD
15.6_CD
million_CD
of_PIN
cash_NN
received_VBN [WZPAST]
at_PIN
completion_NOMZ
,_,
$_$
30_CD
million_CD
15.6_CD
million_CD
of_PIN
cash_NN
held_VBN [PRIV] [WZPAST]
in_PIN
escrow_NN
and_CC
due_JJ
on_PIN
the_DT
first_JJ
anniversary_NN
of_PIN
closing_GER
and_CC
$_$
60_CD
million_CD
31.3_CD
million_CD
received_VBN
at_PIN
completion_NOMZ
in_PIN
the_DT
form_NN
of_PIN
4,931,864_CD
subscription_NOMZ
receipts_NN
of_PIN
IDB_NN
._.
Each_QUAN
subscription_NOMZ
receipt_NN
entitles_VPRT
Shire_NN
to_TO
acquire_VB
,_,
at_PIN
any_QUAN
time_NN
during_PIN
the_DT
period_NN
from_PIN
10_CD
January_NN
2005_CD
to_PIN
9_CD
July_NN
2006_CD
,_,
for_PIN
no_SYNE
additional_JJ
consideration_NOMZ
,_,
one_CD
fully_AMP
paid_VBN
common_JJ
share_NN
of_PIN
IDB_NN
._.
Prior_RB
to_PIN
10_CD
January_NN
2005_CD
,_,
if_COND
IDB_NN
were_VBD
to_TO
raise_VB
up_RP
to_TO
$_$
60_CD
million_CD
from_PIN
equity_NOMZ
related_VBN
issuances_NN
then_RB
they_TPP3
were_VBD [PASS]
required_VBN [SUAV]
to_TO
repurchase_VB
the_DT
subscription_NOMZ
receipts_NN
from_PIN
Shire_NN
for_PIN
$_$
60_CD
million_CD
in_PIN
cash_NN
._.
On_PIN
21_CD
December_NN
2004_CD
,_,
IDB_NN
gave_VBD
notification_NOMZ
that_TOBJ
it_PIT
intended_VBD [SUAV]
to_TO
complete_VB
a_DT
convertible_JJ
debt_NN
issuance_NN
on_PIN
7_CD
January_NN
2005_CD
and_CC
subsequently_TIME
repurchased_VBD
the_DT
subscription_NOMZ
receipts_NN
from_PIN
Shire_NN
on_PIN
7_CD
January_NN
2005_CD
._.
In_CONJ
addition_NULL
to_PIN
the_DT
$_$
120_CD
million_CD
consideration_NOMZ
,_,
IDB_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
reimburse_VB
Shire_NN
in_PIN
full_JJ
for_PIN
the_DT
net_JJ
cost_NN
of_PIN
operating_VBG
the_DT
vaccines_NN
business_NOMZ
from_PIN
30_CD
June_NN
2004_CD
._.
As_IN
part_NN
of_PIN
the_DT
transaction_NOMZ
,_,
Shire_NN
entered_VBD
into_PIN
an_DT
agreement_NOMZ
to_TO
provide_VB
IDB_NN
with_PIN
a_DT
loan_NN
facility_NOMZ
of_PIN
up_RB
to_TO
$_$
100_CD
million_CD
52.1_CD
million_CD
,_,
which_WDT [SERE]
can_POMD
be_VB [PASS]
drawn_VBN
down_RB
over_IN
the_DT
four_CD
years_NN
following_VBG [WZPRES]
completion_NOMZ
._.
It_PIT
is_VPRT [PASS]
expected_VBN [PRIV]
that_THVC
IDB_NN
will_PRMD
draw_VB
down_RP
the_DT
entire_JJ
$_$
100_CD
million_CD
loan_NN
._.
This_DEMO
facility_NOMZ
can_POMD
be_VB [BYPA]
used_VBN
by_PIN
IDB_NN
to_TO
fund_VB
the_DT
development_NOMZ
of_PIN
injectable_JJ
flu_NN
and_PHC
pipeline_NN
products_NN
within_PIN
the_DT
vaccines_NN
business_NOMZ
acquired_VBD
from_PIN
Shire_NN
._.
Drawings_GER
under_IN
the_DT
loan_NN
facility_NOMZ
will_PRMD
be_VB [PASS]
segregated_VBN
into_PIN
two_CD
components_NN
:_:
drawings_GER
for_PIN
injectable_JJ
flu_NN
development_NOMZ
with_PIN
a_DT
minimum_JJ
drawing_GER
of_PIN
$_$
30_CD
million_CD
15.6_CD
million_CD
._.
Such_JJ
drawings_GER
under_IN
the_DT
loan_NN
facility_NOMZ
will_PRMD
be_VB [BEMA]
repayable_PRED
out_PIN
of_PIN
income_NN
generated_VBN [WZPAST]
by_PIN
IDB_NN
on_PIN
future_JJ
non-Canadian_JJ
injectable_JJ
flu_NN
products_NN
,_,
subject_JJ
to_PIN
minimum_JJ
annual_JJ
repayments_NOMZ
in_PIN
respect_NN
of_PIN
the_DT
$_$
30_CD
million_CD
minimum_JJ
drawing_GER
,_,
to_TO
be_VB [PASS]
made_VBN
between_PIN
2007_CD
and_CC
2017_CD
:_:
and_ANDC
drawings_GER
for_PIN
pipeline_NN
development_NOMZ
of_PIN
up_RB
to_TO
$_$
70_CD
million_CD
36.5_CD
million_CD
._.
Such_JJ
drawings_GER
under_IN
the_DT
loan_NN
facility_NOMZ
will_PRMD
be_VB [BEMA]
repayable_PRED
out_PIN
of_PIN
income_NN
generated_VBN [WZPAST]
by_PIN
IDB_NN
on_PIN
future_JJ
pipeline_NN
products_NN
developed_VBD
using_VBG
these_DEMO
drawings_GER
and_CC
will_PRMD
have_VB
no_DT
fixed_VBN
repayment_NOMZ
schedule_NN
._.
The_DT
combined_VBN
drawings_GER
of_PIN
the_DT
two_CD
components_NN
of_PIN
the_DT
loan_NN
facility_NOMZ
can_POMD
not_XX0
exceed_VB
$_$
100_CD
million_CD
._.
As_IN
at_PIN
31_CD
December_NN
2004_CD
,_,
IDB_NN
had_VBD [PEAS]
drawn_VBN
down_RB
$_$
56.8_CD
million_CD
29.6_CD
million_CD
,_,
$_$
30.0_CD
million_CD
15.6_CD
million_CD
for_PIN
injectable_JJ
flu_NN
development_NOMZ
and_CC
$_$
26.8_CD
million_CD
14.0_CD
million_CD
for_PIN
pipeline_NN
development_NOMZ
._.
The_DT
transaction_NOMZ
gave_VBD
rise_NN
to_PIN
an_DT
overall_JJ
loss_NN
on_PIN
sale_NN
of_PIN
the_DT
vaccines_NN
business_NOMZ
of_PIN
23.2_CD
million_CD
,_,
which_WDT [SERE]
was_VBD [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
second_JJ
quarter_NN
of_PIN
2004_CD
._.
This_DEMP
comprises_VPRT
a_DT
profit_NN
on_PIN
disposal_NN
of_PIN
net_JJ
assets_NN
of_PIN
13.3_CD
million_CD
together_RB
with_PIN
a_DT
provision_NN
for_PIN
a_DT
loss_NN
of_PIN
$_$
70_CD
million_CD
36.5_CD
million_CD
out_PIN
of_PIN
the_DT
$_$
100_CD
million_CD
52.1_CD
million_CD
loan_NN
facility_NOMZ
available_JJ
to_PIN
IDB_NN
._.
This_DEMO
provision_NN
is_VPRT [PASS]
made_VBN
on_PIN
the_DT
basis_NN
that_DEMO
loan_NN
repayments_NOMZ
based_VBN [WZPAST]
only_DWNT
on_PIN
the_DT
future_JJ
sales_NN
of_PIN
pipeline_NN
products_NN
in_PIN
development_NOMZ
provide_VPRT
no_SYNE
certainty_NN
of_PIN
recovery_NN
._.
51_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
52_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
16_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
continued_VBD
The_DT
following_JJ
table_NN
summarises_VPRT
the_DT
major_JJ
categories_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
attributed_VBD
to_PIN
the_DT
vaccines_NN
business_NOMZ
at_PIN
the_DT
date_NN
of_PIN
disposal_NN
._.
2004_CD
000_CD
Goodwill_NN
2,331_CD
Tangible_JJ
fixed_JJ
assets_NN
38,960_CD
Stocks_NN
3,376_CD
Accounts_NN
receivable_JJ
5,315_CD
Prepaid_JJ
expenses_NN
and_CC
other_JJ
debtors_NN
205_CD
Cash_NN
1,078_CD
Debtors_NN
:_:
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
229_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
within_PIN
one_CD
year_NN
7,416_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
392_CD
Loan_NN
provision_NN
36,460_CD
Other_JJ
provisions_NN
4,423_CD
Acquisition_NOMZ
costs_NN
3,684_CD
Loss_NN
on_PIN
sale_NN
23,191_CD
65,062_CD
Satisfied_VBN
by_PIN
:_:
Cash_NN
consideration_NOMZ
18,184_CD
Deferred_JJ
consideration_NOMZ
15,626_CD
Subscription_NOMZ
receipts_NN
31,252_CD
65,062_CD
Cash_NN
consideration_NOMZ
comprised_VBD
15.6_CD
million_CD
upon_PIN
completion_NOMZ
and_CC
2.6_CD
million_CD
in_PIN
relation_NOMZ
to_PIN
the_DT
working_VBG
capital_NN
of_PIN
the_DT
vaccines_NN
business_NOMZ
._.
Qualia_NN
The_NN
Group_NN
completed_VBD
its_PIT
divestment_NOMZ
of_PIN
its_PIT
investment_NOMZ
in_PIN
the_DT
joint_JJ
venture_NN
,_,
Qualia_NN
Computing_GER
Inc._NN
on_PIN
31_CD
December_NN
2003_CD
._.
This_DEMP
was_VBD [PASS]
sold_VBN
to_PIN
iCAD_NN
Inc._NN
for_PIN
a_DT
total_JJ
consideration_NOMZ
of_PIN
3.1_CD
million_CD
$_$
5.5_CD
million_CD
._.
The_DT
following_JJ
table_NN
summarises_VPRT
the_DT
major_JJ
categories_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
attributed_VBD
to_PIN
the_DT
joint_JJ
venture_NN
at_PIN
the_DT
date_NN
of_PIN
disposal_NN
._.
9_CD
associates_NN
and_CC
joint_JJ
ventures_NN
the_DT
following_JJ
information_NOMZ
regarding_VBG [WZPRES]
the_DT
Groups_NN
share_NN
in_PIN
Qualia_NN
is_VPRT [PASS]
disclosed_VBN [PUBV]
,_,
prior_RB
to_PIN
its_PIT
disposal_NN
in_PIN
December_NN
2003_CD
:_:
2003_CD
000_CD
Qualia_NN
Turnover_NN
3,594_CD
Loss_NN
before_IN
tax_NN
2,806_CD
Taxation_NOMZ
Loss_NN
after_IN
tax_NN
2,806_CD
Fixed_VBN
assets_NN
Current_JJ
assets_NN
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
within_PIN
one_CD
year_NN
18_CD
Stocks_NN
Group_NN
Company_NN
2004 2003 2004 2003_CD
000 000 000 000_CD
Raw_NN
materials_NN
and_PHC
consumables_NN
3,672_CD
3,797_CD
Work_NN
in_PIN
progress_NN
6,163_CD
5,644_CD
Finished_VBN
goods_NN
and_PHC
goods_NN
for_PIN
resale_NN
11,640_CD
15,841_CD
21,475_CD
25,282_CD
There_EX
is_VPRT
no_SYNE
material_NN
difference_NN
between_PIN
the_DT
balance_NN
sheet_NN
value_NN
of_PIN
stocks_NN
and_CC
their_TPP3
replacement_NOMZ
cost_NN
._.
19_CD
Deferred_JJ
tax_NN
Group_NN
Company_NN
000_CD
000_CD
Asset_NN
At_PIN
1_CD
January_NN
2004_CD
35,267_CD
Credited_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
10,613_CD
Exchange_NN
adjustment_NOMZ
1,760_CD
At_PIN
31_CD
December_NN
2004_CD
44,120_CD
Included_VBN
in_PIN
the_DT
above_PLACE
balance_NN
at_PIN
31_CD
December_NN
2004_CD
is_VPRT [BEMA]
an_DT
asset_NN
of_PIN
4,023,000_CD
2003_CD
:_:
liability_NOMZ
of_PIN
782,000_CD
which_WDT
is_VPRT [BEMA]
receivable_PRED
after_IN
more_EMPH
than_PIN
one_CD
year_NN
._.
2004 2003 000 000_CD
Group_NN
Accelerated_VBD
capital_NN
allowances_NN
12,222_CD
17,902_CD
Other_JJ
timing_NN
differences_NN
21,909_CD
9,226_CD
Tax_NN
losses_NN
available_JJ
34,433_CD
44,725_CD
Undiscounted_JJ
deferred_JJ
tax_NN
asset_NN
44,120_CD
36,049_CD
Accelerated_VBN
capital_NN
allowances_NN
782_CD
Total_JJ
undiscounted_JJ
deferred_JJ
tax_NN
asset_NN
44,120_CD
35,267_CD
As_IN
at_PIN
31_CD
December_NN
2004_CD
,_,
based_VBN [PASTP]
upon_PIN
the_DT
level_NN
of_PIN
historical_JJ
taxable_JJ
income_NN
and_PHC
projections_NOMZ
for_PIN
future_JJ
taxable_JJ
income_NN
,_,
management_NOMZ
believes_VPRT [PRIV] [THATD]
it_PIT
is_VPRT [BEMA]
more_EMPH
likely_PRED
than_PIN
not_XX0
that_DEMO
the_DT
Group_NN
will_PRMD
realize_VB [PRIV]
the_DT
benefits_NN
of_PIN
the_DT
recognized_VBN [PRIV]
deferred_VBN
tax_NN
assets_NN
._.
However_CONJ
,_,
the_DT
amount_NN
of_PIN
the_DT
deferred_JJ
tax_NN
asset_NN
considered_VBN [PRIV]
realisable_JJ
could_POMD
be_VB [PASS]
adjusted_VBN
in_PIN
the_DT
future_NN
if_COND
estimates_NN
of_PIN
taxable_JJ
income_NN
are_VPRT [PASS]
revised_VBN
._.
53_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
54_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
19_CD
Deferred_JJ
tax_NN
continued_VBD
Unrecognised_JJ
deferred_VBN
tax_NN
Group_NN
Company_NN
2004 2003 2004 2003_CD
000 000 000 000_CD
Accelerated_VBN
capital_NN
allowances_NN
1,257_CD
Other_JJ
timing_NN
differences_NN
12,761_CD
7_CD
Tax_NN
losses_NN
available_JJ
66,886_CD
93,948_CD
6,124_CD
10,346_CD
79,647_CD
93,948_CD
7,381_CD
10,353_CD
As_IN
at_PIN
31_CD
December_NN
2004_CD
,_,
based_VBN [PASTP]
upon_PIN
the_DT
level_NN
of_PIN
historical_JJ
taxable_JJ
income_NN
and_PHC
projections_NOMZ
for_PIN
future_JJ
taxable_JJ
income_NN
,_,
management_NOMZ
believes_VPRT [PRIV] [THATD]
it_PIT
is_VPRT [BEMA]
more_EMPH
likely_PRED
than_PIN
not_XX0
that_DEMO
the_DT
Group_NN
will_PRMD
not_XX0
realize_VB [PRIV]
the_DT
benefits_NN
of_PIN
the_DT
unprovided_JJ
deferred_JJ
tax_NN
assets_NN
._.
However_CONJ
,_,
the_DT
amount_NN
of_PIN
the_DT
deferred_JJ
tax_NN
asset_NN
considered_VBN [PRIV]
unrealisable_JJ
could_POMD
be_VB [PASS]
adjusted_VBN
in_PIN
the_DT
future_NN
if_COND
estimates_NN
of_PIN
taxable_JJ
income_NN
are_VPRT [PASS]
revised_VBN
._.
20_CD
Debtors_NN
Group_NN
Company_NN
2004 2003 2004 2003_CD
000 000 000 000_CD
Due_JJ
within_PIN
one_CD
year_NN
:_:
Trade_NN
debtors_NN
116,843_CD
120,841_CD
1_CD
43_CD
Amounts_NN
due_JJ
from_PIN
Group_NN
undertakings_GER
116,463_CD
97,048_CD
Other_JJ
debtors_NN
6,609_CD
9,172_CD
1,851_CD
1,472_CD
Cash_NN
held_VBN [PRIV] [WZPAST]
in_PIN
Escrow_NN
Note_NN
16_CD
15,626_CD
Prepayments_NOMZ
and_CC
accrued_VBN
income_NN
17,082_CD
11,033_CD
2,095_CD
1,792_CD
SERP_NN
929_CD
157,089_CD
141,046_CD
120,410_CD
100,355_CD
Due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
:_:
Loan_NN
to_PIN
IDB_NN
15,626_CD
Accrued_VBN
interest_NN
on_PIN
IDB_NN
loan_NN
205_CD
Other_JJ
debtors_NN
418_CD
2,497_CD
SERP_NN
4,010_CD
6,727_CD
20,259_CD
9,224_CD
Further_JJ
details_NN
of_PIN
the_DT
Supplemental_NN
Executive_NN
Retirement_NOMZ
Plan_NN
SERP_NN
asset_NN
are_VPRT [PASS]
provided_VBN
in_PIN
Note_NN
29_CD
._.
The_DT
amount_NN
shown_VBN [PRIV]
above_PLACE
is_VPRT [BEMA]
the_DT
gross_JJ
asset_NN
represented_VBN [WZPAST]
by_PIN
non-current_JJ
marketable_JJ
securities_NOMZ
._.
A_DT
related_JJ
liability_NOMZ
is_VPRT [PASS]
included_VBN
within_PIN
Notes_NN
22_CD
and_CC
23_CD
._.
21_CD
Current_JJ
asset_NN
investments_NOMZ
Group_NN
Company_NN
2004 2003 2004 2003_CD
000 000 000 000_CD
Institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
78,056_CD
102,373_CD
Commercial_JJ
paper_NN
91,143_CD
67,522_CD
169,199_CD
169,895_CD
There_EX
were_VBD
no_SYNE
material_NN
differences_NN
between_PIN
book_NN
value_NN
and_PHC
market_NN
value_NN
of_PIN
the_DT
current_JJ
asset_NN
investments_NOMZ
as_IN
at_PIN
31_CD
December_NN
2004_CD
or_CC
as_RB
at_PIN
31_CD
December_NN
2003_CD
._.
54_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
55_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
22_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
within_PIN
one_CD
year_NN
Group_NN
Company_NN
2004 2003 2004 2003_CD
000 000 000 000_CD
Other_JJ
creditors_NN
Bank_NN
loans_NN
431_CD
Obligations_NOMZ
under_IN
finance_NN
leases_NN
158_CD
35_CD
Trade_NN
creditors_NN
18,518_CD
11,895_CD
3,406_CD
308_CD
Amounts_NN
due_JJ
to_PIN
Group_NN
undertakings_GER
307,094_CD
241,661_CD
Corporation_NOMZ
tax_NN
24,354_CD
10,395_CD
Other_JJ
taxation_NOMZ
and_CC
social_JJ
security_NOMZ
2,723_CD
2,683_CD
766_CD
1,162_CD
Other_JJ
creditors_NN
33,865_CD
7,662_CD
2,188_CD
168_CD
Accruals_NN
and_CC
deferred_VBN
income_NN
147,042_CD
106,945_CD
9,431_CD
7,706_CD
SERP_NN
992_CD
1,553_CD
Proposed_VBN [SUAV]
dividends_NN
9,952_CD
9,698_CD
237,446_CD
141,722_CD
332,583_CD
251,040_CD
Obligations_NOMZ
under_IN
finance_NN
leases_NN
were_VBD [PASS]
secured_VBN
on_PIN
the_DT
assets_NN
to_PIN
which_WDT [PIRE]
they_TPP3
relate_VPRT
._.
See_VB [PRIV]
Note_VB [PRIV]
29_CD
for_PIN
details_NN
relating_VBG [WZPRES]
to_PIN
the_DT
SERP_NN
._.
23_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
Group_NN
Company_NN
2004 2003 2004 2003_CD
Notes_NN
000 000 000 000_CD
Convertible_JJ
debt_NN
i_FPP1
2_CD
%_NN
guaranteed_VBN [PUBV]
convertible_JJ
loan_NN
notes_NN
2011_CD
60_CD
202,659_CD
Other_JJ
creditors_NN
Bank_NN
loans_NN
424_CD
Obligations_NOMZ
under_IN
finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
contracts_NN
3,238_CD
Amounts_NN
due_JJ
to_PIN
other_JJ
Group_NN
undertakings_GER
206,459_CD
Other_JJ
creditors_NN
13,819_CD
2,353_CD
Deferred_JJ
tax_NN
liability_NOMZ
782_CD
Accruals_NN
and_CC
deferred_VBN
income_NN
4,726_CD
7,503_CD
SERP_NN
1,870_CD
3,439_CD
20,415_CD
17,739_CD
206,459_CD
20,475_CD
220,398_CD
206,459_CD
See_VB [PRIV]
Note_VB [PRIV]
29_CD
for_PIN
details_NN
relating_VBG [WZPRES]
to_PIN
the_DT
SERP_NN
._.
55_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
56_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
23_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
continued_VBD
Subject_JJ
to_PIN
the_DT
conditions_NOMZ
below_PLACE
,_,
borrowings_GER
are_VPRT [BEMA]
repayable_PRED
as_IN
follows_VPRT
:_:
Group_NN
Company_NN
2004 2003 2004 2003_CD
Notes_NN
000 000 000 000_CD
Convertible_JJ
loan_NN
notes_NN
:_:
i_FPP1
After_IN
five_CD
years_NN
60_CD
202,659_CD
Bank_NN
loans_NN
:_:
Between_PIN
one_CD
and_CC
two_CD
years_NN
424_CD
Obligations_NOMZ
under_IN
finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
contracts_NN
:_:
Between_PIN
one_CD
and_CC
two_CD
years_NN
142_CD
After_IN
five_CD
years_NN
3,096_CD
3,238_CD
60_CD
206,321_CD
i_FPP1
$_$
400_CD
million_CD
2_CD
%_NN
guaranteed_VBN [PUBV]
convertible_JJ
loan_NN
notes_NN
2011_CD
The_DT
guaranteed_VBN [PUBV]
convertible_JJ
notes_NN
due_JJ
2011_CD
,_,
were_VBD [PASS]
issued_VBN
in_PIN
August_NN
2001_CD
by_PIN
Shire_NN
Finance_NN
Limited_NN
the_DT
Issuer_NN
,_,
a_DT
wholly_RB
owned_VBN
subsidiary_NN
of_PIN
the_DT
Company_NN
._.
The_DT
convertible_JJ
notes_NN
were_VBD [BYPA]
guaranteed_VBN [PUBV]
by_PIN
Shire_NN
and_CC
were_VBD [BEMA]
convertible_PRED
into_PIN
redeemable_JJ
preference_NN
shares_NN
of_PIN
the_DT
Issuer_NN
which_WDT [WHOBJ]
upon_PIN
issuance_NN
will_PRMD
be_VB [SPAU] [PASS]
immediately_TIME
exchanged_VBN
for_PIN
either_DT
i_FPP1
Shire_FW
ordinary_JJ
shares_NN
,_,
ii_FW
Shire_FW
ADSs_FW
or_CC
iii_FW
at_PIN
the_DT
Issuers_NN
option_NOMZ
,_,
a_DT
cash_NN
amount_NN
based_VBN [WZPAST]
upon_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
volume-weighted_JJ
average_NN
prices_NN
of_PIN
Shires_NN
ordinary_JJ
shares_NN
on_PIN
the_DT
fourth_JJ
through_PIN
eighth_JJ
business_NOMZ
days_NN
following_VBG [WZPRES]
conversion_NN
._.
At_PIN
the_DT
choice_NN
of_PIN
investors_NN
,_,
each_QUAN
$_$
1,000_CD
of_PIN
nominal_JJ
value_NN
notes_NN
was_VBD [BEMA]
convertible_PRED
into_PIN
49.62_CD
Shire_NN
ordinary_JJ
shares_NN
subject_JJ
to_PIN
adjustment_NOMZ
or_CC
16.54_CD
Shire_NN
ADSs_NN
subject_NN
to_PIN
adjustment_NOMZ
at_PIN
any_QUAN
time_NN
up_RP
to_PIN
21_CD
August_NN
2011_CD
._.
Alternatively_CONJ
,_,
investors_NN
had_VBD
the_DT
alterative_JJ
to_TO
receive_VB
repayment_NOMZ
of_PIN
the_DT
nominal_JJ
principal_NN
in_PIN
cash_NN
either_CC
at_PIN
the_DT
maturity_NOMZ
date_NN
of_PIN
21_CD
August_NN
2011_CD
or_CC
by_PIN
exercising_VBG
a_DT
put_NN
option_NOMZ
on_PIN
any_QUAN
of_PIN
the_DT
three_CD
put_VBD
dates_NN
being_VBG [WZPRES] [BEMA]
21_CD
August_NN
2004_CD
,_,
21_CD
August_NN
2006_CD
and_CC
21_CD
August_NN
2008_CD
._.
On_PIN
21_CD
August_NN
2004_CD
,_,
upon_PIN
exercise_NN
of_PIN
the_DT
put_NN
option_NOMZ
by_PIN
substantially_RB
all_QUAN
of_PIN
the_DT
convertible_JJ
note_NN
holders_NN
,_,
the_DT
Company_NN
redeemed_VBN
202.6_CD
million_CD
$_$
370.1_CD
million_CD
at_PIN
par_NN
,_,
from_PIN
available_JJ
funds_NN
2003_CD
:_:
$_$
29.8_CD
million_CD
,_,
recording_VBG [PRESP]
a_DT
gain_NN
of_PIN
$_$
0.5_CD
million_CD
._.
The_DT
obligation_NOMZ
to_TO
pay_VB
the_DT
remaining_VBG
60,000_CD
$_$
116,000_CD
of_PIN
the_DT
convertible_JJ
loan_NN
notes_NN
outstanding_JJ
as_IN
of_PIN
31_CD
December_NN
2004_CD
is_VPRT [BEMA]
due_PRED
in_PIN
2011_CD
._.
24_CD
Derivatives_NN
and_CC
other_JJ
financial_JJ
instruments_NOMZ
The_DT
Financial_NN
Review_NN
on_PIN
pages_NN
7_CD
to_PIN
12_CD
provides_VPRT
an_DT
explanation_NOMZ
of_PIN
the_DT
role_NN
that_TOBJ
financial_JJ
instruments_NOMZ
have_VPRT [PEAS]
had_VBN
during_PIN
the_DT
year_NN
._.
The_DT
explanation_NOMZ
summarises_VPRT
the_DT
objectives_NN
and_PHC
policies_NN
for_PIN
holding_VBG [PRIV]
or_CC
issuing_VBG
financial_JJ
instruments_NOMZ
and_CC
similar_JJ
contracts_NN
,_,
and_ANDC
the_DT
strategies_NN
for_PIN
achieving_VBG
those_DEMO
objectives_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [PASS]
followed_VBN
during_PIN
the_DT
year_NN
._.
The_DT
numerical_JJ
disclosures_NN
in_PIN
this_DEMO
note_NN
deal_NN
with_PIN
financial_JJ
assets_NN
and_CC
financial_JJ
liabilities_NOMZ
as_IN
defined_VBN
in_PIN
FRS_NN
13_CD
derivatives_NN
and_CC
other_JJ
financial_JJ
instruments_NOMZ
:_:
disclosures_NN
._.
Certain_JJ
financial_JJ
assets_NN
such_JJ
as_IN
investments_NOMZ
in_PIN
subsidiary_NN
companies_NN
are_VPRT [PASS]
excluded_VBN
from_PIN
the_DT
scope_NN
of_PIN
these_DEMO
disclosures_NN
._.
As_IN
permitted_VBN
by_PIN
FRS_NN
13_CD
,_,
short-term_JJ
debtors_NN
and_PHC
creditors_NN
have_VPRT [PEAS]
been_VBN [PASS]
excluded_VBN
from_PIN
the_DT
disclosures_NN
,_,
other_JJ
than_PIN
the_DT
currency_NN
disclosures_NN
._.
56_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
57_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
24_CD
Derivatives_NN
and_CC
other_JJ
financial_JJ
instruments_NOMZ
continued_VBD
Interest_NN
rate_NN
profile_NN
The_DT
currency_NN
and_PHC
interest_NN
rate_NN
profile_NN
of_PIN
the_DT
Groups_NN
financial_JJ
assets_NN
,_,
excluding_VBG
short-term_JJ
debtors_NN
at_PIN
31_CD
December_NN
2004_CD
,_,
are_VPRT
as_RB
below_PLACE
._.
In_CONJ
addition_NULL
to_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
,_,
there_EX
are_VPRT
current_JJ
asset_NN
investments_NOMZ
as_IN
detailed_VBN
in_PIN
Note_NN
21_CD
._.
Weighted_JJ
average_JJ
Weighted_JJ
average_JJ
Weighted_JJ
average_JJ
Financial_NN
Financial_NN
interest_NN
period_NN
interest_NN
rate_NN
interest_NN
rate_NN
instruments_NOMZ
instruments_NOMZ
Fixed_VBN
rate_NN
Floating_VBG [WZPRES]
rate_NN
Fixed_VBN
rate_NN
Floating_VBG [WZPRES]
rate_NN
Fixed_VBN
rate_NN
Total_JJ
Days_NN
%_NN
%_NN
000 000 000_CD
Pounds_NN
sterling_GER
4.11_CD
19,683_CD
19,683_CD
US_FPP1
dollars_NN
678_CD
2.01_CD
2.05_CD
657,933_CD
22,247_CD
680,180_CD
Euro_NN
0.30_CD
8,752_CD
8,752_CD
Canadian_JJ
dollars_NN
2.52_CD
53,339_CD
53,339_CD
Other_JJ
0.25_CD
10_CD
10_CD
739,717_CD
22,247_CD
761,964_CD
The_DT
benchmark_NN
rates_NN
for_PIN
floating_VBG
rate_NN
assets_NN
are_VPRT
primarily_RB
:_:
US_FPP1
dollar_NN
7_CD
day_NN
,_,
1_CD
month_NN
and_CC
3_CD
month_NN
LIBID_NN
,_,
and_ANDC
Pounds_NN
sterling_GER
7_CD
day_NN
LIBID_NN
._.
The_DT
currency_NN
and_PHC
interest_NN
rate_NN
profile_NN
of_PIN
the_DT
Groups_NN
financial_JJ
assets_NN
excluding_VBG [WZPRES]
short-term_JJ
debtors_NN
at_PIN
31_CD
December_NN
2003_CD
are_VPRT
as_RB
below_PLACE
._.
Weighted_JJ
average_JJ
Weighted_JJ
average_JJ
Weighted_JJ
average_JJ
Financial_NN
Financial_NN
interest_NN
period_NN
interest_NN
rate_NN
interest_NN
rate_NN
instruments_NOMZ
instruments_NOMZ
Fixed_VBN
rate_NN
Floating_VBG [WZPRES]
rate_NN
Fixed_VBN
rate_NN
Floating_VBG [WZPRES]
rate_NN
Fixed_VBN
rate_NN
Total_JJ
Days_NN
%_NN
%_NN
000 000 000_CD
Pounds_NN
sterling_GER
7_CD
3.07_CD
3.50_CD
14,729_CD
3,875_CD
18,604_CD
US_FPP1
dollars_NN
204_CD
1.00_CD
1.32_CD
604,822_CD
113,889_CD
718,711_CD
Euro_NN
76_CD
0.89_CD
2.00_CD
9,027_CD
6,634_CD
15,661_CD
Canadian_JJ
dollars_NN
70_CD
0.25_CD
2.99_CD
3,093_CD
35,392_CD
38,485_CD
0.25_CD
104 104 631_CD
,775_CD
159,790_CD
791,565_CD
The_DT
interest_NN
rate_NN
profile_NN
of_PIN
the_DT
Groups_NN
financial_JJ
liabilities_NOMZ
at_PIN
31_CD
December_NN
2004_CD
was_VBD
as_IN
follows_VPRT
:_:
Floating_VBG
Fixed_NN
Interest_NN
free_JJ
Total_JJ
Currency_NN
000 000 000 000_CD
US_FPP1
dollars_NN
Convertible_JJ
debt_NN
60_CD
60_CD
The_DT
interest_NN
rate_NN
profile_NN
of_PIN
the_DT
Groups_NN
financial_JJ
liabilities_NOMZ
at_PIN
31_CD
December_NN
2003_CD
was_VBD
as_IN
follows_VPRT
:_:
Floating_VBG
Fixed_NN
Interest_NN
free_JJ
Total_JJ
Currency_NN
000 000 000 000_CD
Canadian_JJ
dollars_NN
Federal_NN
and_CC
provincial_JJ
government_NOMZ
loan_NN
855_CD
855_CD
US_FPP1
dollars_NN
Convertible_JJ
debt_NN
202,659_CD
202,659_CD
Total_JJ
202,659_CD
855_CD
203,514_CD
57_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
58_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
24_CD
Derivatives_NN
and_CC
other_JJ
financial_JJ
instruments_NOMZ
continued_VBD
Currency_NN
exposures_NN
The_DT
Groups_NN
objectives_NN
in_PIN
managing_VBG
the_DT
currency_NN
exposures_NN
arising_VBG [WZPRES]
from_PIN
its_PIT
net_JJ
investment_NOMZ
overseas_PLACE
in_CONJ
other_NULL
words_NULL
,_,
its_PIT
structural_JJ
currency_NN
exposures_NN
are_VPRT
to_TO
minimize_VB
currency_NN
related_VBN
exposures_NN
._.
Gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
from_PIN
structural_JJ
currency_NN
exposures_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
._.
The_DT
table_NN
below_PLACE
shows_NN
the_DT
Groups_NN
currency_NN
exposures_NN
:_:
in_CONJ
other_NULL
words_NULL
,_,
those_DEMO
transactional_JJ
or_CC
non-structural_JJ
exposures_NN
that_TSUB
give_VPRT
rise_VB
to_PIN
the_DT
net_JJ
currency_NN
gains_NN
and_PHC
losses_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
Such_JJ
exposures_NN
comprise_VPRT
the_DT
monetary_JJ
assets_NN
and_CC
monetary_JJ
liabilities_NOMZ
of_PIN
the_DT
Group_NN
that_TSUB
are_VPRT [PASS]
not_XX0
denominated_VBN
in_PIN
the_DT
operating_GER
or_CC
functional_JJ
currency_NN
of_PIN
the_DT
operating_VBG
unit_NN
involved_VBN
,_,
other_JJ
than_PIN
certain_JJ
non-sterling_JJ
borrowings_GER
treated_VBN
as_IN
hedges_NN
of_PIN
net_JJ
investments_NOMZ
in_PIN
overseas_PLACE
operations_NOMZ
._.
As_IN
at_PIN
31_CD
December_NN
2004_CD
these_DEMO
exposures_NN
were_VBD
as_IN
follows_VPRT
:_:
Net_JJ
foreign_JJ
currency_NN
monetary_JJ
assets_NN
Pounds_NN
sterling_GER
US_FPP1
dollars_NN
Euro_NN
Canadian_NN
dollars_NN
Other_JJ
Total_NN
Functional_NN
currency_NN
of_PIN
Group_NN
operation_NOMZ
000 000 000 000_CD
000_CD
000_CD
Pounds_NN
sterling_JJ
472,523_CD
11,355_CD
1_CD
149_CD
461,020_CD
US_FPP1
dollars_NN
178,025_CD
19,874_CD
35_CD
2_CD
158,114_CD
Euro_NN
523 269 792_CD
Canadian_JJ
dollars_NN
95,278_CD
155,354_CD
20_CD
250,652_CD
272,780_CD
317,438_CD
8,499_CD
36_CD
147_CD
53,046_CD
The_DT
exposures_NN
at_PIN
31_CD
December_NN
2003_CD
for_PIN
comparison_NN
purposes_NN
were_VBD
as_IN
follows_VPRT
:_:
Net_JJ
foreign_JJ
currency_NN
monetary_JJ
assets_NN
Pounds_NN
sterling_GER
US_FPP1
dollars_NN
Euro_NN
Canadian_NN
dollars_NN
Other_JJ
Total_NN
Functional_NN
currency_NN
of_PIN
Group_NN
operation_NOMZ
000 000 000 000_CD
000_CD
000_CD
Pounds_NN
sterling_JJ
333,969_CD
681_CD
436_CD
80_CD
332,772_CD
US_FPP1
dollars_NN
12,447_CD
8,171_CD
20_CD
25_CD
20,663_CD
Euro_NN
2,201_CD
5,455_CD
7,656_CD
Canadian_JJ
dollars_NN
49,183_CD
108,267_CD
26_CD
157,476_CD
63,831_CD
220,247_CD
8,878_CD
456 105 146_CD
,977_CD
Maturity_NOMZ
of_PIN
financial_JJ
liabilities_NOMZ
The_DT
maturity_NOMZ
profile_NN
of_PIN
the_DT
Groups_NN
financial_JJ
liabilities_NOMZ
at_PIN
31_CD
December_NN
2004_CD
is_VPRT [PASS]
shown_VBN [PRIV]
below_PLACE
:_:
Convertible_JJ
loan_NN
notes_NN
Bank_NN
loans_NN
Total_JJ
000 000 000_CD
Group_NN
Over_IN
five_CD
years_NN
60_CD
60_CD
See_VB [PRIV]
Note_VB [PRIV]
23_CD
i_FPP1
for_PIN
further_JJ
information_NOMZ
on_PIN
convertible_JJ
loan_NN
notes_NN
._.
Borrowing_GER
facilities_NOMZ
The_DT
Group_NN
had_VBD
no_SYNE
undrawn_JJ
committed_JJ
borrowing_GER
facilities_NOMZ
at_PIN
31_CD
December_NN
2004_CD
or_CC
2003_CD
._.
Fair_NN
values_VPRT
The_DT
quoted_VBN
market_NN
price_NN
of_PIN
the_DT
convertible_JJ
loan_NN
stock_NN
2011_CD
as_RB
at_PIN
31_CD
December_NN
2004_CD
was_VBD
$_$
100.53_CD
compared_VBN
with_PIN
an_DT
issue_NN
price_NN
of_PIN
$_$
100_CD
._.
If_COND
the_DT
remaining_VBG
loan_NN
is_VPRT [PASS]
not_XX0
converted_VBN
into_PIN
equity_NOMZ
,_,
it_PIT
would_PRMD
be_VB [BEMA]
repayable_PRED
at_PIN
$_$
100_CD
per_PIN
note_NN
._.
The_DT
total_JJ
fair_JJ
value_NN
of_PIN
the_DT
debt_NN
as_IN
at_PIN
31_CD
December_NN
2004_CD
,_,
based_VBN [PASTP]
on_PIN
the_DT
above_PLACE
quoted_VBN
market_NN
price_NN
,_,
was_VBD [BEMA]
61,000_CD
$_$
116,000_CD
compared_VBN
to_PIN
a_DT
carrying_VBG
value_NN
of_PIN
60,000_CD
._.
In_CONJ
addition_NULL
at_PIN
31_CD
December_NN
2004_CD
the_DT
fair_JJ
value_NN
of_PIN
listed_VBN
fixed_VBN
asset_NN
investments_NOMZ
,_,
based_VBN [PASTP]
on_PIN
their_TPP3
quoted_VBN
market_NN
price_NN
,_,
was_VBD [BEMA]
8.3_CD
million_CD
above_PLACE
carrying_VBG
value_NN
2003_CD
:_:
4.8_CD
million_CD
above_PLACE
._.
There_EX
were_VBD
no_SYNE
other_JJ
material_NN
differences_NN
between_PIN
the_DT
carrying_VBG
values_NN
and_CC
fair_JJ
values_NN
of_PIN
all_QUAN
other_JJ
Group_NN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
at_PIN
31_CD
December_NN
2004_CD
2003_CD
:_:
nil_NN
._.
Gains_NN
and_PHC
losses_NN
on_PIN
foreign_JJ
exchange_NN
contracts_NN
As_IN
at_PIN
31_CD
December_NN
2004_CD
the_DT
Company_NN
had_VBD
two_CD
outstanding_JJ
forward_RB
foreign_JJ
exchange_NN
contracts_NN
with_PIN
a_DT
total_JJ
principal_JJ
amount_NN
of_PIN
$_$
39_CD
million_CD
used_VBN
to_TO
manage_VB
the_DT
risk_NN
associated_VBN [WZPAST]
with_PIN
holding_VBG [PRIV]
Canadian_JJ
dollar_NN
investments_NOMZ
._.
There_EX
were_VBD
no_SYNE
material_NN
gains_NN
or_CC
losses_NN
on_PIN
these_DEMO
contracts_NN
._.
58_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
59_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
25_CD
Called-up_JJ
share_NN
capital_NN
Number_NN
Ordinary_NN
shares_NN
000_CD
000_CD
Authorised_VBN
At_PIN
31_CD
December_NN
2003_CD
ordinary_JJ
shares_NN
of_PIN
5p_JJ
each_QUAN
800,000_CD
40,000_CD
At_PIN
31_CD
December_NN
2004_CD
ordinary_JJ
shares_NN
of_PIN
5p_JJ
each_QUAN
800,000_CD
40,000_CD
Allotted_NN
,_,
issued_VBN
and_CC
fully_AMP
paid_VBN
At_PIN
1_CD
January_NN
2004_CD
ordinary_JJ
shares_NN
of_PIN
5p_JJ
each_QUAN
477,895_CD
23,895_CD
Issued_VBN
on_PIN
exercise_NN
of_PIN
options_NOMZ
for_PIN
cash_NN
consideration_NOMZ
2,098_CD
105_CD
Issued_VBN
on_PIN
exchange_NN
of_PIN
exchangeable_JJ
shares_NN
4,839_CD
242_CD
Issue_NN
of_PIN
ordinary_JJ
share_NN
capital_NN
84_CD
4_CD
At_PIN
31_CD
December_NN
2004_CD
ordinary_JJ
shares_NN
of_PIN
5p_JJ
each_QUAN
484,916_CD
24,246_CD
Number_NN
Special_JJ
ordinary_JJ
voting_NN
shares_NN
000_CD
000_CD
Authorised_VBN
At_PIN
31_CD
December_NN
2003_CD
special_JJ
ordinary_JJ
voting_NN
shares_NN
of_PIN
0.00001_CD
p_NN
17,500_CD
At_PIN
31_CD
December_NN
2004_CD
special_JJ
ordinary_JJ
voting_NN
shares_NN
of_PIN
0.00001_CD
p_NN
17,500_CD
Allotted_NN
,_,
issued_VBN
and_CC
fully_AMP
paid_VBN
At_PIN
1_CD
January_NN
2004_CD
5,840_CD
Cancelled_VBN
following_VBG
an_DT
exchange_NN
of_PIN
exchangeable_JJ
shares_NN
for_PIN
ordinary_JJ
shares_NN
1,613_CD
At_PIN
31_CD
December_NN
2004_CD
4,227_CD
Authorised_JJ
share_NN
capital_NN
As_IN
at_PIN
31_CD
December_NN
2004_CD
the_DT
authorised_JJ
share_NN
capital_NN
of_PIN
the_DT
Company_NN
was_VBD [BEMA]
40,000,000_CD
divided_VBN
into_PIN
799,999,965_CD
ordinary_JJ
shares_NN
of_PIN
5p_JJ
each_QUAN
and_CC
17,500,000_CD
Special_JJ
Ordinary_NN
Voting_GER
Shares_NN
of_PIN
0.00001_CD
p_NN
each_QUAN
._.
Issue_NN
of_PIN
ordinary_JJ
shares_NN
During_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
the_DT
Company_NN
allotted_VBD
4,839,249_CD
ordinary_JJ
shares_NN
with_PIN
a_DT
nominal_JJ
value_NN
of_PIN
241,962_CD
on_PIN
the_DT
exchange_NN
of_PIN
exchangeable_JJ
shares_NN
,_,
which_WDT [SERE]
were_VBD [PASS]
issued_VBN
following_VBG
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
in_PIN
2001_CD
._.
These_DEMO
shares_NN
were_VBD [PASS]
issued_VBN
at_PIN
a_DT
premium_NN
of_PIN
52,360,000_CD
._.
Exchange_NN
of_PIN
exchangeable_JJ
shares_NN
and_PHC
cancellation_NOMZ
of_PIN
special_JJ
ordinary_JJ
voting_NN
shares_NN
The_DT
Company_NN
exchanged_VBD
1,613,083_CD
exchangeable_JJ
shares_NN
and_CC
canceled_VBD
the_DT
equivalent_JJ
number_NN
of_PIN
special_JJ
ordinary_JJ
voting_NN
shares_NN
during_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
._.
Each_QUAN
exchangeable_JJ
share_NN
is_VPRT [BEMA]
capable_PRED
of_PIN
being_VBG [PASS]
exchanged_VBN
for_PIN
ordinary_JJ
shares_NN
or_CC
ADSs_NN
,_,
at_PIN
a_DT
rate_NN
of_PIN
one_CD
exchangeable_JJ
share_NN
for_PIN
three_CD
ordinary_JJ
shares_NN
or_CC
one_CD
exchangeable_JJ
share_NN
for_PIN
one_CD
ADS_NN
,_,
at_PIN
any_QUAN
time_NN
at_PIN
the_DT
request_NN
of_PIN
the_DT
holder_NN
._.
Only_DWNT
BioChem_NN
shareholders_NN
with_PIN
Canadian_JJ
residency_NN
had_VBD
the_DT
option_NOMZ
to_TO
receive_VB
exchangeable_JJ
shares_NN
for_PIN
their_TPP3
shares_NN
of_PIN
BioChem_NN
at_PIN
the_DT
time_NN
of_PIN
acquisition_NOMZ
._.
The_DT
exchangeable_JJ
shares_NN
were_VBD [BYPA]
issued_VBN
by_PIN
Shire_NN
Acquisition_NOMZ
Inc._NN
a_DT
company_NN
incorporated_VBN
under_IN
the_DT
Canada_NN
Business_NOMZ
Corporations_NOMZ
Act_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
a_DT
wholly_RB
owned_VBN
subsidiary_NN
of_PIN
the_DT
Company_NN
,_,
and_ANDC
is_VPRT [PASS]
listed_VBN
on_PIN
the_DT
Toronto_NN
Stock_NN
Exchange_NN
._.
Holders_NN
of_PIN
exchangeable_JJ
shares_NN
are_VPRT [PASS]
entitled_VBN
to_TO
vote_VB [SUAV]
at_PIN
shareholder_NN
meetings_GER
of_PIN
the_DT
Company_NN
and_CC
are_VPRT [PASS]
entitled_VBN
to_PIN
a_DT
dividend_NN
and_CC
other_JJ
rights_NN
that_TSUB
are_VPRT [BEMA]
economically_RB
equivalent_PRED
to_PIN
those_DEMO
of_PIN
ordinary_JJ
shares_NN
,_,
through_PIN
a_DT
voting_NN
trust_NN
and_CC
by_PIN
means_NN
of_PIN
the_DT
special_JJ
ordinary_JJ
voting_NN
shares_NN
in_PIN
Shire_NN
._.
As_IN
at_PIN
31_CD
December_NN
2004_CD
4,226,476_CD
exchangeable_JJ
shares_NN
remained_VBD
unconverted_JJ
._.
The_DT
Company_NN
can_POMD
redeem_VB
all_QUAN
outstanding_JJ
exchangeable_JJ
shares_NN
for_PIN
ordinary_JJ
shares_NN
after_IN
11_CD
May_POMD
2011_CD
,_,
or_CC
earlier_TIME
if_COND
the_DT
total_JJ
number_NN
of_PIN
exchangeable_JJ
shares_NN
falls_VPRT
below_PLACE
1_CD
million_CD
._.
The_DT
exchangeable_JJ
shares_NN
are_VPRT [PASS]
included_VBN
as_IN
part_NN
of_PIN
share_NN
capital_NN
in_PIN
the_DT
consolidated_JJ
balance_NN
sheet_NN
to_TO
present_VB
a_DT
true_JJ
and_PHC
fair_JJ
view_NN
of_PIN
the_DT
consolidated_JJ
Groups_NN
capital_NN
structure_NN
,_,
which_WDT [SERE]
differs_VPRT
from_PIN
the_DT
Companies_NN
Act_NN
1985_CD
requirements_NOMZ
to_TO
reflect_VB [PRIV]
these_DEMO
amounts_NN
as_IN
minority_NOMZ
interests_NN
,_,
as_IN
they_TPP3
will_PRMD
become_VB
,_,
and_ANDC
are_VPRT [BEMA]
equivalent_PRED
,_,
to_PIN
ordinary_JJ
shares_NN
._.
Share_NN
warrants_NN
On_PIN
24_CD
April_NN
2002_CD
the_DT
Company_NN
issued_VBN
741,812_CD
share_NN
warrants_NN
,_,
at_PIN
4.88_CD
per_PIN
warrant_NN
,_,
and_ANDC
on_PIN
21_CD
November_NN
2002_CD
the_DT
Company_NN
issued_VBD
a_DT
further_JJ
604,595_CD
share_NN
warrants_NN
,_,
at_PIN
4.895_CD
per_PIN
warrant_NN
,_,
both_DT
issues_NN
being_VBG [WZPRES] [PASS]
made_VBN
to_PIN
Technology_NN
Partnership_NN
Canada_NN
TPC_NN
,_,
pursuant_JJ
to_PIN
an_DT
agreement_NOMZ
between_PIN
BioChem_NN
and_CC
the_DT
Government_NOMZ
of_PIN
Canada_NN
GOC_NN
._.
Each_QUAN
warrant_NN
grants_NN
a_DT
right_NN
to_TO
subscribe_VB
for_PIN
a_DT
corresponding_JJ
number_NN
of_PIN
ordinary_JJ
shares_NN
of_PIN
the_DT
Company_NN
within_PIN
five_CD
years_NN
from_PIN
the_DT
date_NN
of_PIN
issue_NN
of_PIN
the_DT
warrant_NN
._.
59_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
60_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
25_CD
Called-up_JJ
share_NN
capital_NN
continued_VBD
The_DT
Groups_NN
Directors_NN
and_PHC
employees_NN
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
share_NN
options_NOMZ
over_IN
ordinary_JJ
shares_NN
under_IN
the_DT
following_JJ
share_NN
option_NOMZ
plans_NN
:_:
the_DT
Shire_NN
Pharmaceuticals_NN
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
Parts_NN
A_NN
and_PHC
B_NN
Executive_NN
Scheme_NN
,_,
the_DT
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
2000_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
Parts_NN
A_NN
and_PHC
B_NN
2000_CD
Executive_NN
Scheme_NN
,_,
the_DT
Pharmavene_NN
1991_CD
Stock_NN
Option_NOMZ
Plan_NN
SLI_NN
Plan_NN
,_,
the_DT
Roberts_NN
Stock_NN
Option_NOMZ
Plans_NN
Roberts_NN
Plans_NN
,_,
the_DT
BioChem_NN
Stock_NN
Option_NOMZ
Plan_NN
BioChem_NN
Plan_NN
,_,
the_DT
Shire_NN
Pharmaceuticals_NN
Sharesave_NN
Scheme_NN
Sharesave_NN
Scheme_NN
and_CC
the_DT
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Employee_NN
Stock_NN
Purchase_NN
Plan_NN
Stock_NN
Purchase_NN
Plan_NN
._.
The_DT
highest_JJ
and_PHC
lowest_JJ
market_NN
prices_NN
during_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
were_VBD [BEMA]
5.71_CD
and_CC
4.36_CD
respectively_RB
._.
62_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
63_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
25_CD
Called-up_JJ
share_NN
capital_NN
continued_VBD
Notes_NN
i_FPP1
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Executive_NN
Scheme_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
performance_NN
criteria_NN
and_CC
can_POMD
not_XX0
be_VB [PASS]
exercised_VBN
in_PIN
full_JJ
unless_COND
the_DT
Companys_NN
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
at_PIN
least_JJ
20.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
measurement_NOMZ
period_NN
._.
If_COND
the_DT
Companys_NN
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
14.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
measurement_NOMZ
period_NN
,_,
60_CD
%_NN
of_PIN
the_DT
options_NOMZ
may_POMD
be_VB [PASS]
exercised_VBN
._.
If_COND
these_DEMO
conditions_NOMZ
are_VPRT [PASS]
not_XX0
met_VBN
after_IN
the_DT
initial_JJ
three_CD
years_NN
,_,
they_TPP3
are_VPRT [SPAU] [PASS]
thereafter_RB
tested_VBN
quarterly_JJ
by_PIN
reference_NN
to_TO
share_VB
price_NN
growth_NN
over_IN
the_DT
extended_JJ
period_NN
._.
If_COND
the_DT
share_NN
price_NN
does_VPRT
not_XX0
meet_VB
these_DEMO
conditions_NOMZ
at_PIN
any_QUAN
time_NN
,_,
none_INPR
of_PIN
the_DT
options_NOMZ
will_PRMD
become_VB
exercisable_JJ
._.
ii_FW
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
vest_NN
six_CD
weeks_NN
prior_RB
to_PIN
the_DT
expiry_NN
date_NN
._.
Options_NOMZ
granted_VBN [SUAV]
under_IN
this_DEMO
scheme_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
performance_NN
criteria_NN
._.
In_PIN
respect_NN
of_PIN
any_QUAN
option_NOMZ
granted_VBN [SUAV] [WZPAST]
prior_RB
to_PIN
August_NN
2002_CD
,_,
if_COND
Shires_NN
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
at_PIN
least_JJ
20.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
measurement_NOMZ
period_NN
,_,
the_DT
option_NOMZ
will_PRMD
be_VB [BEMA]
exercisable_PRED
in_PIN
full_JJ
._.
If_COND
it_PIT
increases_VPRT
by_PIN
at_PIN
least_JJ
14.5_CD
%_NN
per_PIN
annum_NN
over_IN
the_DT
same_JJ
three-year_JJ
measurement_NOMZ
period_NN
,_,
the_DT
option_NOMZ
may_POMD
be_VB [PASS]
exercised_VBN
on_PIN
60_CD
%_NN
of_PIN
the_DT
shares_NN
covered_VBN [WZPAST]
by_PIN
the_DT
option_NOMZ
._.
If_COND
these_DEMO
conditions_NOMZ
are_VPRT [PASS]
not_XX0
met_VBN
after_IN
the_DT
initial_JJ
three-year_JJ
measurement_NOMZ
period_NN
,_,
they_TPP3
will_PRMD [SPAU]
thereafter_RB
be_VB [PASS]
tested_VBN
quarterly_JJ
by_PIN
reference_NN
to_TO
compound_VB
annual_JJ
share_NN
price_NN
growth_NN
over_IN
an_DT
extended_JJ
period_NN
._.
The_DT
performance_NN
criteria_NN
were_VBD [PASS]
reviewed_VBN
in_PIN
2002_CD
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
the_DT
criteria_NN
reflected_VBD [PRIV]
the_DT
market_NN
in_PIN
which_WDT [PIRE]
Shire_NN
operates_VPRT
._.
Given_VBN
Shires_NN
development_NOMZ
it_PIT
was_VBD [PASS]
considered_VBN [PRIV]
appropriate_JJ
that_THAC
an_DT
EPS_NN
based_VBN
measure_NN
should_NEMD
be_VB [PASS]
adopted_VBN
in_PIN
place_NN
of_PIN
share_NN
price_NN
growth_NN
targets_NN
._.
Therefore_CONJ
,_,
the_DT
performance_NN
criteria_NN
was_VBD [PASS]
amended_VBN
so_OSUB
that_NULL
an_DT
option_NOMZ
would_PRMD [SPAU]
only_DWNT
become_VB
exercisable_JJ
in_PIN
full_JJ
if_COND
Shires_NN
EPS_NN
growth_NN
over_IN
a_DT
three_CD
year_NN
period_NN
from_PIN
the_DT
date_NN
of_PIN
award_NN
exceeds_VPRT
the_DT
UK_NN
Retail_NN
Price_NN
Index_NN
RPI_NN
on_PIN
average_NN
a_DT
year_NN
for_PIN
the_DT
following_VBG
tranches_NN
of_PIN
grants_NN
:_:
Options_NOMZ
with_PIN
a_DT
grant_NN
value_NN
of_PIN
up_RB
to_PIN
100_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
3_CD
%_NN
Directors_NN
,_,
RPI_NN
plus_PIN
5_CD
%_NN
Between_PIN
101_CD
%_NN
and_CC
200_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
5_CD
%_NN
Between_PIN
201_CD
%_NN
and_CC
300_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
7_CD
%_NN
Over_IN
301_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
9_CD
%_NN
The_DT
new_JJ
EPS_NN
performance_NN
criteria_NN
apply_VPRT
to_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
from_PIN
August_NN
2002_CD
._.
After_IN
consultation_NOMZ
with_PIN
some_QUAN
of_PIN
its_PIT
institutional_JJ
shareholders_NN
,_,
the_DT
Company_NN
has_VPRT [PEAS]
decided_VBN [SUAV] [PRIV]
that_THVC
for_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
scheme_NN
from_PIN
2004_CD
onwards_NN
,_,
the_DT
performance_NN
condition_NOMZ
should_NEMD
be_VB [PASS]
retested_VBN
once_TIME
only_DWNT
,_,
at_PIN
five_CD
years_NN
after_IN
the_DT
grant_NN
._.
The_DT
retest_NN
will_PRMD
be_VB [PASS]
applied_VBN
only_DWNT
where_RB
Shires_NN
EPS_NN
growth_NN
has_VPRT [PEAS]
fallen_VBN
short_JJ
of_PIN
the_DT
minimum_JJ
annual_JJ
average_JJ
percentage_NN
increase_NN
over_IN
the_DT
three-year_JJ
period_NN
from_PIN
grant_NN
._.
Hence_CONJ
the_DT
level_NN
of_PIN
EPS_NN
growth_NN
in_PIN
the_DT
next_JJ
two_CD
years_NN
needs_VPRT
to_TO
be_VB [BEMA]
consequentially_RB
higher_PRED
to_TO
meet_VB
the_DT
test_NN
._.
The_DT
EPS_NN
used_VBD
will_PRMD
be_VB [BEMA]
the_DT
fully_AMP
diluted_VBN
EPS_NN
calculated_VBN [PRIV]
under_IN
US_FPP1
GAAP_NN
reporting_GER
._.
iii_FW
These_DEMO
options_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
over_IN
shares_NN
in_PIN
Shire_NN
Laboratories_NN
Inc._NN
._.
SLI_NN
,_,
formerly_TIME
Pharmavene_NN
Inc._NN
a_DT
US_FPP1
company_NN
acquired_VBN [WZPAST]
by_PIN
the_DT
Group_NN
on_PIN
23_CD
March_NN
1997_CD
._.
Exercise_NN
of_PIN
these_DEMO
options_NOMZ
results_NN
in_PIN
the_DT
option_NOMZ
holder_NN
receiving_VBG [WZPRES]
ordinary_JJ
shares_NN
in_PIN
the_DT
Company_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
acquisition_NOMZ
of_PIN
SLI_NN
,_,
and_ANDC
in_PIN
accordance_NN
with_PIN
the_DT
terms_NN
of_PIN
the_DT
original_JJ
SLI_NN
Plan_NN
,_,
all_QUAN
options_NOMZ
granted_VBN [SUAV]
under_IN
that_DEMO
plan_NN
became_VBD
immediately_TIME
capable_JJ
of_PIN
exercise_NN
and_CC
were_VBD [BEMA]
not_XX0
subject_PRED
to_PIN
performance_NN
criteria_NN
._.
iv_NN
These_DEMO
options_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
over_IN
shares_NN
in_PIN
Roberts_NN
Pharmaceutical_NN
Corporation_NOMZ
,_,
a_DT
US_FPP1
company_NN
acquired_VBN [WZPAST]
by_PIN
the_DT
Group_NN
on_PIN
23_CD
December_NN
1999_CD
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
acquisition_NOMZ
of_PIN
Roberts_NN
,_,
and_ANDC
in_PIN
accordance_NN
with_PIN
the_DT
terms_NN
of_PIN
the_DT
original_JJ
Roberts_NN
Plan_NN
,_,
all_QUAN
options_NOMZ
granted_VBN [SUAV]
under_IN
that_DEMO
plan_NN
became_VBD
immediately_TIME
capable_JJ
of_PIN
exercise_NN
and_CC
were_VBD [BEMA]
not_XX0
subject_PRED
to_PIN
any_QUAN
performance_NN
criteria_NN
._.
v_FW
Following_VBG
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
on_PIN
11_CD
May_POMD
2001_CD
,_,
the_DT
BioChem_NN
Plan_NN
was_VBD [PASS]
amended_VBN
such_OSUB
that_NULL
options_NOMZ
over_IN
BioChems_NN
common_JJ
stock_NN
became_VBD
options_NOMZ
over_IN
ordinary_JJ
shares_NN
of_PIN
the_DT
Company_NN
._.
All_QUAN
BioChem_NN
options_NOMZ
,_,
which_WDT [SERE]
were_VBD
not_XX0
already_RB
exercisable_PRED
,_,
vested_JJ
and_CC
became_VBD
exercisable_JJ
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
acquisition_NOMZ
and_CC
were_VBD [BEMA]
not_XX0
subject_PRED
to_PIN
any_QUAN
performance_NN
conditions_NOMZ
._.
vi_FW
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Sharesave_NN
Scheme_NN
are_VPRT [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
80_CD
%_NN
of_PIN
the_DT
mid-market_JJ
price_NN
on_PIN
the_DT
day_NN
before_IN
invitations_NOMZ
are_VPRT [PASS]
issued_VBN
to_PIN
employees_NN
._.
Employees_NN
may_POMD
enter_VB
into_PIN
three_CD
or_CC
five-year_JJ
savings_GER
contracts_NN
._.
The_DT
exercise_NN
of_PIN
options_NOMZ
under_IN
this_DEMO
Scheme_NN
is_VPRT [BEMA]
not_XX0
subject_PRED
to_PIN
any_QUAN
performance_NN
criteria_NN
._.
vii_FW
Under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
options_NOMZ
are_VPRT [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
85_CD
%_NN
of_PIN
the_DT
fair_JJ
market_NN
value_NN
of_PIN
a_DT
share_NN
on_PIN
the_DT
enrolment_NOMZ
date_NN
the_DT
first_JJ
day_NN
of_PIN
the_DT
offering_GER
period_NN
or_CC
the_DT
exercise_NN
date_NN
the_DT
last_JJ
day_NN
of_PIN
the_DT
offering_GER
period_NN
,_,
whichever_WDT
is_VPRT [BEMA]
the_DT
lower_JJ
._.
The_DT
offering_GER
period_NN
is_VPRT [BEMA]
for_PIN
27_CD
months_NN
._.
The_DT
exercise_NN
of_PIN
options_NOMZ
under_IN
this_DEMO
plan_NN
is_VPRT [BEMA]
not_XX0
subject_PRED
to_PIN
any_QUAN
performance_NN
condition_NOMZ
._.
63_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
64_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
26_CD
Reserves_NN
Group_NN
Share_NN
premium_NN
Exchangeable_JJ
Profit_NN
and_PHC
account_NN
shares_NN
Capital_NN
reserve_NN
Other_JJ
reserves_NN
loss_NN
account_NN
000 000 000 000_CD
000_CD
As_IN
at_PIN
1_CD
January_NN
2004_CD
3,218,695_CD
190,425_CD
3,135_CD
24,247_CD
1,151,897_CD
Exchange_NN
of_PIN
exchangeable_JJ
shares_NN
52,358_CD
52,600_CD
Issue_NN
of_PIN
ordinary_JJ
share_NN
capital_NN
419_CD
Options_NOMZ
exercised_VBN
7,180_CD
Foreign_JJ
exchange_NN
55,510_CD
Other_JJ
941_CD
941_CD
Loss_NN
for_PIN
the_DT
financial_JJ
year_NN
13,431_CD
Dividends_NN
paid_VBD
and_PHC
proposed_VBD [SUAV]
14,919_CD
As_IN
at_PIN
31_CD
December_NN
2004_CD
3,279,593_CD
137,825_CD
3,135_CD
24,247_CD
1,236,698_CD
The_DT
cumulative_JJ
goodwill_NN
resulting_VBG [WZPRES]
from_PIN
acquisitions_NOMZ
that_TSUB
has_VPRT [PEAS]
been_VBN [BEMA]
written-off_PIN
directly_RB
to_PIN
reserves_NN
amounts_NN
to_PIN
208,194,000_CD
as_IN
at_PIN
31_CD
December_NN
2004_CD
and_CC
31_CD
December_NN
2003_CD
._.
The_DT
capital_NN
and_CC
other_JJ
reserves_NN
arose_VBD
in_PIN
relation_NOMZ
to_PIN
various_JJ
Group_NN
reconstructions_NOMZ
and_CC
certain_JJ
financing_GER
transactions_NOMZ
,_,
and_ANDC
are_VPRT [BEMA]
not_XX0
distributable_PRED
._.
Company_NN
Share_NN
premium_NN
Exchangeable_JJ
Profit_NN
and_PHC
account_NN
shares_NN
Capital_NN
reserve_NN
Other_JJ
reserves_NN
loss_NN
account_NN
000 000 000 000_CD
000_CD
As_IN
at_PIN
1_CD
January_NN
2004_CD
3,219,636_CD
190,425_CD
2,054_CD
18,079_CD
130,437_CD
Exchange_NN
of_PIN
exchangeable_JJ
shares_NN
52,358_CD
52,600_CD
Issue_NN
of_PIN
ordinary_JJ
share_NN
capital_NN
419_CD
Options_NOMZ
exercised_VBN
7,180_CD
Foreign_JJ
exchange_NN
11,735_CD
Loss_NN
for_PIN
the_DT
financial_JJ
year_NN
17,492_CD
Dividends_NN
paid_VBD
and_PHC
proposed_VBD [SUAV]
14,536_CD
As_IN
at_PIN
31_CD
December_NN
2004_CD
3,279,593_CD
137,825_CD
2,054_CD
18,079_CD
86,674_CD
In_CONJ
addition_NULL
to_PIN
the_DT
dividends_NN
paid_VBN
and_PHC
proposed_VBN [SUAV]
by_PIN
the_DT
Company_NN
is_VPRT [BEMA]
an_DT
amount_NN
of_PIN
383,000_CD
payable_JJ
by_PIN
Shire_NN
Acquisition_NOMZ
Inc._NN
to_PIN
the_DT
holders_NN
of_PIN
the_DT
Groups_NN
exchangeable_JJ
shares_NN
see_VPRT [PRIV]
Note_NN
25_CD
for_PIN
more_EMPH
details_NN
on_PIN
the_DT
exchangeable_JJ
shares_NN
._.
27_CD
Reconciliation_NOMZ
of_PIN
movement_NOMZ
in_PIN
Group_NN
shareholders_NN
funds_NN
2004 2003 000 000_CD
Loss_NN
for_PIN
the_DT
financial_JJ
year_NN
13,431_CD
363,355_CD
Other_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
relating_VBG [WZPRES]
to_PIN
the_DT
year_NN
55,510_CD
47,157_CD
68,941_CD
410,512_CD
Dividends_NN
paid_VBD
and_PHC
proposed_VBD [SUAV]
14,919_CD
New_NN
shares_NN
issued_VBD
423_CD
Repurchase_NN
of_PIN
ordinary_JJ
share_NN
capital_NN
31,808_CD
Repurchase_NN
of_PIN
ordinary_JJ
share_NN
capital_NN
in_PIN
to_PIN
Treasury_NN
Stock_NN
137_CD
Proceeds_NN
on_PIN
exercise_NN
of_PIN
employee_NN
share_NN
options_NOMZ
7,285_CD
3,114_CD
Net_JJ
reduction_NOMZ
in_PIN
shareholders_NN
funds_NN
76,289_CD
439,206_CD
Opening_GER
shareholders_NN
funds_NN
2,308,500_CD
2,747,706_CD
Closing_GER
shareholders_NN
funds_NN
2,232,211_CD
2,308,500_CD
The_DT
cumulative_JJ
foreign_JJ
exchange_NN
differences_NN
on_PIN
translation_NOMZ
amount_NN
to_PIN
150,189,000_CD
losses_NN
as_IN
at_PIN
31_CD
December_NN
2004_CD
2003_CD
:_:
losses_NN
of_PIN
94,679,000_CD
._.
64_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
65_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
28_CD
Guarantees_NN
,_,
commitments_NOMZ
and_PHC
contingencies_NN
a_DT
Leases_NN
The_NN
Group_NN
leases_VPRT
property_NN
,_,
computer_NN
and_PHC
office_NN
equipment_NOMZ
and_PHC
motor_NN
vehicles_NN
on_PIN
short-term_JJ
operating_GER
leases_NN
._.
The_DT
rents_NN
payable_JJ
under_IN
property_NN
leases_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
renegotiation_NOMZ
at_PIN
various_JJ
intervals_NN
specified_VBN [WZPAST]
in_PIN
the_DT
leases_NN
._.
The_DT
Group_NN
pays_VPRT
for_PIN
substantially_RB
all_QUAN
of_PIN
the_DT
insurance_NN
,_,
maintenance_NN
and_PHC
repair_NN
of_PIN
these_DEMO
assets_NN
._.
The_DT
minimum_JJ
annual_JJ
rentals_NN
under_IN
the_DT
foregoing_VBG
operating_GER
leases_NN
are_VPRT
as_IN
follows_VPRT
:_:
2004_CD
2003_CD
Land_NN
and_PHC
Land_NN
and_PHC
buildings_GER
Equipment_NOMZ
Motor_NN
vehicles_NN
buildings_GER
Equipment_NOMZ
Motor_NN
vehicles_NN
000 000 000 000_CD
000_CD
000_CD
Group_NN
Operating_GER
leases_NN
which_WDT [WHSUB]
expire_VPRT
:_:
within_PIN
1_CD
year_NN
589 933 645_CD
30 538 973_CD
within_PIN
2-5_CD
years_NN
833_CD
1,442_CD
2,271_CD
1,010_CD
1,856_CD
1,756_CD
after_IN
5_CD
years_NN
1,655_CD
1,600_CD
5_CD
3,077_CD
2,375_CD
2,916_CD
2,640_CD
2,399_CD
2,729_CD
2004_CD
2003_CD
Land_NN
and_PHC
Land_NN
and_PHC
buildings_GER
Equipment_NOMZ
Motor_NN
vehicles_NN
buildings_GER
Equipment_NOMZ
Motor_NN
vehicles_NN
000 000 000 000_CD
000_CD
000_CD
Company_NN
Operating_GER
leases_NN
which_WDT [WHSUB]
expire_VPRT
:_:
within_PIN
1_CD
year_NN
9_CD
35_CD
within_PIN
2-5_CD
years_NN
145_CD
28_CD
145_CD
34_CD
145_CD
37_CD
145_CD
69_CD
b_NN
Guarantees_NN
and_PHC
collateral_NN
At_PIN
31_CD
December_NN
2004_CD
the_DT
Company_NN
had_VBD
$_$
5.3_CD
million_CD
2.8_CD
million_CD
of_PIN
restricted_VBN
cash_NN
held_VBN [PRIV]
as_IN
collateral_NN
for_PIN
certain_JJ
equipment_NOMZ
leases_NN
._.
c_NN
Letters_NN
of_PIN
credit_NN
As_IN
at_PIN
31_CD
December_NN
2004_CD
,_,
the_DT
Company_NN
had_VBD
outstanding_JJ
,_,
an_DT
irrevocable_JJ
standby_JJ
letter_NN
of_PIN
credit_NN
with_PIN
Barclays_NN
Bank_NN
plc_NN
in_PIN
the_DT
amount_NN
of_PIN
$_$
15.0_CD
million_CD
7.8_CD
million_CD
providing_VBG
security_NOMZ
on_PIN
the_DT
recoverability_NOMZ
of_PIN
insurance_NN
claims_NN
._.
The_DT
Company_NN
had_VBD [PEAS]
restricted_VBN
cash_NN
of_PIN
$_$
16.0_CD
million_CD
8.3_CD
million_CD
in_PIN
connection_NOMZ
with_PIN
this_DEMO
letter_NN
of_PIN
credit_NN
._.
d_LS
Capital_NN
commitments_NOMZ
i_FPP1
The_DT
Company_NN
has_VPRT [PEAS]
undertaken_VBN
to_TO
subscribe_VB
for_PIN
interests_NN
in_PIN
companies_NN
and_PHC
partnerships_NN
for_PIN
amounts_NN
totaling_VBG [WZPRES]
$_$
22.0_CD
million_CD
11.5_CD
million_CD
._.
As_IN
at_PIN
31_CD
December_NN
2004_CD
an_DT
amount_NN
of_PIN
$_$
48.6_CD
million_CD
25.3_CD
million_CD
has_VPRT [PEAS]
been_VBN [PASS]
subscribed_VBN
._.
ii_FW
MTS_FW
METHYPATCH_NN
In_PIN
connection_NOMZ
with_PIN
the_DT
Companys_NN
purchase_NN
of_PIN
MTS_NN
METHYPATCH_NN
in_PIN
2003_CD
,_,
the_DT
Company_NN
is_VPRT [PASS]
committed_VBN
to_TO
pay_VB
an_DT
additional_JJ
$_$
50.0_CD
million_CD
26.0_CD
million_CD
upon_PIN
regulatory_JJ
approval_NN
of_PIN
the_DT
product_NN
._.
In_CONJ
addition_NULL
the_DT
Company_NN
has_VPRT
an_DT
obligation_NOMZ
to_TO
make_VB
further_JJ
milestone_NN
payments_NOMZ
,_,
which_WDT [SERE]
are_VPRT [PASS]
linked_VBN
to_PIN
the_DT
future_JJ
sales_NN
performance_NN
of_PIN
the_DT
product_NN
._.
These_DEMO
payments_NOMZ
could_POMD
total_VB
$_$
75.0_CD
million_CD
39.1_CD
million_CD
._.
iii_FW
FOSRENOL_NN
patent_NN
rights_NN
In_PIN
connection_NOMZ
with_PIN
the_DT
Companys_NN
purchase_NN
of_PIN
the_DT
global_JJ
patents_NN
for_PIN
FOSRENOL_NN
,_,
Shire_NN
agreed_VBD [SUAV] [PUBV]
to_TO
pay_VB
AnorMED_NN
$_$
6.0_CD
million_CD
3.1_CD
million_CD
when_RB
it_PIT
is_VPRT [PASS]
approved_VBN
in_PIN
certain_JJ
European_JJ
countries_NN
and_CC
$_$
6.0_CD
million_CD
upon_PIN
receipt_NN
of_PIN
regulatory_JJ
approval_NN
in_PIN
Japan_NN
._.
iv_NN
Manufacturing_GER
facility_NOMZ
The_DT
Company_NN
has_VPRT [PEAS]
committed_VBN
to_PIN
the_DT
expansion_NN
and_PHC
modification_NOMZ
of_PIN
its_PIT
manufacturing_GER
facility_NOMZ
at_PIN
Owings_NN
Mills_NN
,_,
Maryland_NN
to_TO
facilitate_VB
the_DT
production_NOMZ
of_PIN
FOSRENOL_NN
._.
The_DT
Company_NN
has_VPRT [PEAS]
committed_VBN
to_TO
spend_VB
a_DT
further_JJ
$_$
10.6_CD
million_CD
5.5_CD
million_CD
by_PIN
the_DT
end_NN
of_PIN
2005_CD
._.
The_DT
Company_NN
has_VPRT
an_DT
additional_JJ
commitment_NOMZ
of_PIN
$_$
4.4_CD
million_CD
2.3_CD
million_CD
for_PIN
the_DT
design_NN
and_PHC
construction_NOMZ
of_PIN
a_DT
technology_NN
center_NN
at_PIN
Owings_NN
Mills_NN
,_,
Maryland_NN
._.
v_FW
Chesterbrook_NN
,_,
Pennsylvania_NN
fit_VBD
out_PIN
The_DT
Company_NN
is_VPRT [BEMA]
in_PIN
the_DT
process_NN
of_PIN
fitting_JJ
out_PIN
its_PIT
new_JJ
US_FPP1
headquarters_NN
at_PIN
Wayne_NN
,_,
Pennsylvania_NN
._.
At_PIN
31_CD
December_NN
2004_CD
the_DT
Company_NN
had_VBD
an_DT
outstanding_JJ
commitment_NOMZ
of_PIN
$_$
20.4_CD
million_CD
10.6_CD
million_CD
._.
65_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
66_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
28_CD
Guarantees_NN
,_,
commitments_NOMZ
and_PHC
contingencies_NN
continued_VBD
e_SYM
Contingent_JJ
liabilities_NOMZ
Shire_NN
is_VPRT [PASS]
involved_VBN
in_PIN
various_JJ
legal_JJ
proceedings_GER
considered_VBN [PRIV]
typical_JJ
to_PIN
its_PIT
business_NOMZ
,_,
including_VBG [PRESP]
those_DEMP
set_VBN
out_PIN
below_PLACE
._.
Although_CONC
there_EX
can_POMD
be_VB
no_SYNE
assurance_NN
regarding_VBG [WZPRES]
the_DT
outcome_NN
of_PIN
any_QUAN
of_PIN
the_DT
legal_JJ
proceedings_GER
referred_VBD
to_PIN
below_PLACE
,_,
Shire_NN
believes_VPRT [PRIV]
that_THVC
they_TPP3
will_PRMD
not_XX0
have_VB
a_DT
materially_RB
adverse_JJ
effect_NN
on_PIN
the_DT
Groups_NN
financial_JJ
position_NOMZ
._.
i_FPP1
Phentermine_NN
Shire_NN
US_FPP1
Inc._NN
._.
SUS_NN
,_,
a_DT
wholly-owned_JJ
subsidiary_NN
of_PIN
Shire_NN
,_,
is_VPRT [BEMA]
a_DT
defendant_NN
in_PIN
260_CD
lawsuits_NN
still_RB
pending_VBG
in_PIN
both_DT
US_FPP1
federal_JJ
and_CC
state_NN
courts_NN
which_WDT [WHSUB]
seek_VPRT
damages_NN
for_PIN [STPR]
,_,
among_PIN
other_JJ
things_NN
,_,
personal_JJ
injury_NN
arising_VBG [WZPRES]
from_PIN
phentermine_NN
products_NN
supplied_VBD
for_PIN
the_DT
treatment_NOMZ
of_PIN
obesity_NOMZ
by_PIN
SUS_NN
and_CC
several_QUAN
other_JJ
pharmaceutical_JJ
companies_NN
._.
SUS_NN
,_,
formerly_TIME
known_VBN [PRIV]
as_IN
Shire_NN
Richwood_NN
Inc._NN
has_VPRT [PEAS]
been_VBN [PASS]
sued_VBN
as_IN
a_DT
manufacturer_NN
and_PHC
distributor_NN
of_PIN
phentermine_NN
,_,
an_DT
anorectic_NN
used_VBN [WZPAST]
in_PIN
the_DT
short-term_JJ
treatment_NOMZ
of_PIN
obesity_NOMZ
and_CC
one_CD
of_PIN
the_DT
products_NN
addressed_VBN [WZPAST]
by_PIN
the_DT
lawsuits_NN
._.
The_DT
suits_NN
relate_VPRT
to_TO
phentermine_VB
either_CC
alone_RB
or_CC
together_RB
with_PIN
fenfluramine_NN
or_CC
dexenfluramine_NN
._.
The_DT
lawsuits_NN
generally_RB
allege_VPRT [PUBV]
the_DT
following_VBG
claims_NN
:_:
the_DT
defendants_NN
marketed_VBN
phentermine_NN
and_CC
other_JJ
products_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
obesity_NOMZ
and_CC
misled_VBD
users_NN
about_IN
the_DT
products_NN
and_PHC
dangers_NN
associated_VBN [WZPAST]
with_PIN
them_TPP3
:_:
the_DT
defendants_NN
failed_VBD
adequately_RB
to_PIN
test_NN
phentermine_NN
individually_RB
and_ANDC
when_RB
taken_VBN
in_PIN
combination_NOMZ
with_PIN
the_DT
other_JJ
drugs_NN
:_:
and_ANDC
the_DT
defendants_NN
knew_VBD [PRIV]
or_CC
should_NEMD
have_VB [PEAS]
known_VBN [PRIV]
about_IN
the_DT
negative_JJ
effects_NN
of_PIN
the_DT
drugs_NN
and_CC
should_NEMD
have_VB [PEAS]
informed_VBN
the_DT
public_JJ
about_IN
such_JJ
risks_NN
and_CC
or_CC
failed_VBD
to_TO
provide_VB
appropriate_JJ
warning_GER
labels_NN
._.
SUS_NN
has_VPRT [PEAS]
been_VBN [PASS]
named_VBN
as_IN
a_DT
defendant_NN
in_PIN
a_DT
total_NN
of_PIN
4,196_CD
such_JJ
phentermine_NN
lawsuits_NN
,_,
in_PIN
respect_NN
of_PIN
which_WDT [PIRE]
SUS_NN
has_VPRT [PEAS]
been_VBN [PASS]
dismissed_VBN
as_IN
a_DT
defendant_NN
in_PIN
3,936_CD
cases_NN
._.
Eight_CD
of_PIN
the_DT
4,196_CD
cases_NN
name_NN
Shire_NN
as_IN
a_DT
defendant_NN
,_,
but_CC
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
served_VBN
as_IN
required_VBN [SUAV]
by_PIN
state_NN
and_CC
federal_JJ
rules_NN
of_PIN
civil_JJ
procedure_NN
._.
It_PIT
is_VPRT [PASS]
expected_VBN [PRIV]
that_THVC
Shire_NN
will_PRMD
be_VB [PASS]
dismissed_VBN
from_PIN
the_DT
remaining_VBG
cases_NN
based_VBN [WZPAST]
upon_PIN
lack_NN
of_PIN
product_NN
identification_NOMZ
or_CC
agreement_NOMZ
of_PIN
the_DT
parties_NN
._.
SUS_NN
became_VBD
involved_VBN
with_PIN
phentermine_NN
through_PIN
its_PIT
acquisition_NOMZ
of_PIN
certain_JJ
assets_NN
of_PIN
Rexar_NN
Pharmacal_NN
Corporation_NOMZ
Rexar_NN
in_PIN
January_NN
1994_CD
._.
In_CONJ
addition_NULL
to_PIN
SUS_NN
potentially_RB
incurring_VBG
liability_NOMZ
as_CONJ
a_NULL
result_NULL
of_PIN
its_PIT
own_JJ
production_NOMZ
of_PIN
Oby-Cap_NN
,_,
a_DT
phentermine_JJ
product_NN
,_,
the_DT
plaintiffs_NN
may_POMD [SPAU]
additionally_RB
seek_VB
to_TO
impose_VB
liability_NOMZ
on_PIN
SUS_NN
as_IN
successor_NN
to_PIN
Rexar_NN
._.
SUS_NN
intends_VPRT [SUAV]
to_TO
defend_VB
vigorously_RB
all_QUAN
the_DT
lawsuits_NN
._.
SUS_NN
denies_VPRT [PUBV]
liability_NOMZ
on_PIN
a_DT
number_NN
of_PIN
grounds_NN
including_VBG [WZPRES]
lack_NN
of_PIN
scientific_JJ
evidence_NN
that_DEMO
phentermine_NN
,_,
properly_RB
prescribed_VBN
,_,
causes_VPRT
the_DT
alleged_JJ
side_NN
effects_NN
and_CC
that_THVC
SUS_NN
did_VBD
not_XX0
promote_VB
phentermine_NN
for_PIN
long-term_JJ
combined_VBN
use_NN
as_IN
part_NN
of_PIN
the_DT
fen_NN
phen_NN
diet_NN
._.
Accordingly_RB
,_,
SUS_NN
intends_VPRT [SUAV]
to_TO
defend_VB
vigorously_RB
any_QUAN
and_CC
all_QUAN
claims_NN
made_VBN [WZPAST]
against_PIN
the_DT
Group_NN
in_PIN
respect_NN
of_PIN
phentermine_NN
._.
Legal_JJ
expenses_NN
to_PIN
date_NN
have_VPRT [PEAS]
been_VBN [BYPA]
paid_VBN
by_PIN
Eon_NN
Labs_NN
,_,
Inc._NN
._.
Eon_NN
,_,
the_DT
supplier_NN
to_PIN
SUS_NN
,_,
or_CC
Eons_NN
insurance_NN
carriers_NN
but_CC
such_JJ
insurance_NN
is_VPRT [SPAU] [PASS]
now_TIME
exhausted_VBN
._.
Eon_NN
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
to_TO
defend_VB
and_PHC
indemnify_VB
SUS_NN
in_PIN
this_DEMO
litigation_NOMZ
pursuant_JJ
to_PIN
an_DT
agreement_NOMZ
dated_VBN
30_CD
November_NN
2000_CD
between_PIN
Eon_NN
and_PHC
SUS_NN
._.
ii_FW
ADDERALL_NN
XR_NN
a_DT
Barr_NN
Laboratories_NN
,_,
Inc._NN
._.
Shires_NN
extended_VBD
release_NN
once-daily_RB
version_NN
of_PIN
ADDERALL_NN
,_,
ADDERALL_NN
XR_NN
,_,
is_VPRT [BYPA]
covered_VBN
by_PIN
US_FPP1
patent_NN
No._NN
._.
In_PIN
January_NN
2003_CD
the_DT
Company_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Barr_NN
Laboratories_NN
,_,
Inc._NN
._.
Barr_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
Abbreviated_NN
New_NN
Drug_NN
Application_NOMZ
ANDA_NN
under_IN
the_DT
Hatch-Waxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
versions_NN
of_PIN
the_DT
5mg_JJ
,_,
10mg_JJ
,_,
15mg_JJ
,_,
20mg_JJ
,_,
25mg_JJ
and_PHC
30mg_JJ
strengths_NN
of_PIN
ADDERALL_NN
XR_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
Companys_NN
819_CD
Patent_NN
._.
The_DT
notification_NOMZ
alleged_VBD [PUBV]
that_THVC
the_DT
819_CD
Patent_NN
is_VPRT [BYPA]
not_XX0
infringed_VBN
by_PIN
Barrs_NN
extended_VBD
release_NN
mixed_JJ
amphetamine_NN
salt_NN
product_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
subject_NN
of_PIN
Barrs_NN
ANDA_NN
._.
On_PIN
24_CD
February_NN
2003_CD
Shire_NN
Laboratories_NN
Inc._NN
._.
Shire_NN
Laboratories_NN
filed_VBD
suit_NN
against_PIN
Barr_NN
in_PIN
the_DT
United_NN
States_NN
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
Barrs_NN
ANDA_NN
infringes_VPRT
the_DT
819_CD
Patent_NN
._.
The_DT
Company_NN
is_VPRT
seeking_VBG
a_DT
ruling_NN
that_TSUB
Barrs_VPRT
ANDA_NN
infringes_VPRT
the_DT
819_CD
Patent_NN
and_CC
should_NEMD
not_XX0
be_VB [PASS]
approved_VBN
before_IN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
819_CD
Patent_NN
._.
The_DT
Company_NN
is_VPRT [SPAU]
also_RB
seeking_VBG
an_DT
injunction_NOMZ
to_TO
prevent_VB
Barr_NN
from_PIN
commercialising_VBG
its_PIT
ANDA_NN
product_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
819_CD
Patent_NN
,_,
damages_NN
in_PIN
the_DT
event_NN
that_TOBJ
Barr_NN
should_NEMD
engage_VB
in_PIN
such_JJ
commercialisation_NOMZ
,_,
as_RB
well_RB
its_PIT
attorneys_NN
fees_NN
and_PHC
costs_NN
._.
Barr_NN
has_VPRT [PEAS]
counterclaimed_VBN
for_PIN
a_DT
declaration_NOMZ
that_TOBJ
its_PIT
ANDA_NN
product_NN
will_PRMD
not_XX0
infringe_VB
the_DT
claims_NN
of_PIN
the_DT
819_CD
Patent_NN
._.
Barr_NN
is_VPRT [SPAU]
also_RB
seeking_VBG
its_PIT
attorneys_NN
fees_NN
,_,
costs_NN
and_PHC
expenses_NN
._.
On_PIN
12_CD
August_NN
2003_CD
,_,
Shire_NN
Laboratories_NN
was_VBD [PASS]
issued_VBN
a_DT
new_JJ
US_FPP1
patent_NN
No._NN
._.
6,605,300_CD
the_DT
300_CD
Patent_NN
covering_VBG [WZPRES]
ADDERALL_NN
XR_NN
._.
In_PIN
August_NN
2003_CD
Shire_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Barr_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
under_IN
the_DT
Hatch-Waxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
version_NN
of_PIN
the_DT
5mg_JJ
,_,
10mg_JJ
,_,
15mg_JJ
,_,
20mg_JJ
,_,
25mg_JJ
and_PHC
30mg_JJ
strengths_NN
of_PIN
ADDERALL_NN
XR_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
300_CD
Patent_NN
and_CC
alleging_VBG [PUBV]
that_THVC
the_DT
300_CD
Patent_NN
is_VPRT [BEMA]
invalid_PRED
._.
In_PIN
September_NN
2003_CD
Shire_NN
Laboratories_NN
filed_VBD
a_DT
lawsuit_NN
in_PIN
the_DT
United_NN
States_NN
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
against_PIN
Barr_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
Barrs_NN
ANDA_NN
infringes_VPRT
the_DT
300_CD
Patent_NN
._.
The_DT
Company_NN
is_VPRT
seeking_VBG
a_DT
ruling_NN
that_TSUB
Barrs_VPRT
ANDA_NN
infringes_VPRT
the_DT
300_CD
Patent_NN
and_CC
should_NEMD
not_XX0
be_VB [PASS]
approved_VBN
before_IN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
300_CD
Patent_NN
._.
The_DT
Company_NN
is_VPRT [SPAU]
also_RB
seeking_VBG
an_DT
injunction_NOMZ
to_TO
prevent_VB
Barr_NN
from_PIN
commercialising_VBG
its_PIT
ANDA_NN
product_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
300_CD
Patent_NN
,_,
damages_NN
in_PIN
the_DT
event_NN
that_TOBJ
Barr_NN
should_NEMD
engage_VB
in_PIN
such_JJ
commercialisation_NOMZ
,_,
as_RB
well_RB
as_IN
its_PIT
attorneys_NN
fees_NN
and_PHC
costs_NN
._.
By_PIN
way_NN
of_PIN
a_DT
counterclaim_NN
,_,
Barr_NN
is_VPRT
seeking_VBG
a_DT
declaration_NOMZ
that_TOBJ
the_DT
300_CD
Patent_NN
is_VPRT [BEMA]
invalid_PRED
and_CC
Barr_NN
has_VPRT [SPAU] [PEAS]
also_RB
asked_VBN [SUAV]
for_PIN
its_PIT
attorneys_NN
fees_NN
,_,
costs_NN
and_PHC
expenses_NN
._.
The_DT
lawsuits_NN
against_PIN
Barr_NN
with_PIN
respect_NN
to_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
were_VBD [PASS]
consolidated_VBN
in_PIN
December_NN
2003_CD
and_CC
a_DT
trial_NN
date_NN
scheduled_VBN [WZPAST]
for_PIN
January_NN
2006_CD
._.
On_PIN
27_CD
September_NN
2004_CD
,_,
Barr_NN
filed_VBD
an_DT
amended_VBN
Answer_NN
,_,
Affirmative_NN
Defense_NN
and_PHC
Counterclaim_NN
in_PIN
which_WDT [PIRE]
Barr_NN
added_VBD [PUBV]
the_DT
following_VBG
counterclaims_NN
and_CC
affirmative_JJ
defences_NN
:_:
invalidity_NOMZ
of_PIN
the_DT
819_CD
patent_NN
,_,
non-infringement_NOMZ
of_PIN
the_DT
300_CD
Patent_NN
and_PHC
unenforceability_NOMZ
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
due_JJ
to_PIN
inequitable_JJ
conduct_NN
._.
Shire_NN
has_VPRT [PEAS]
asserted_VBN [PUBV]
affirmative_JJ
defenses_NN
,_,
alleging_VBG [PUBV]
,_,
among_PIN
other_JJ
things_NN
,_,
that_THVC
Barr_NN
has_VPRT [PEAS]
waived_VBN
its_PIT
right_NN
to_TO
assert_VB [PUBV] [THATD]
the_DT
counterclaims_NN
set_VBN [WZPAST]
forth_RB
in_PIN
its_PIT
27_CD
September_NN
2004_CD
amended_VBN
answers_NN
._.
66_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
67_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
28_CD
Guarantees_NN
,_,
commitments_NOMZ
and_PHC
contingencies_NN
continued_VBD
Barr_NN
may_POMD
not_XX0
launch_VB
a_DT
generic_JJ
version_NN
of_PIN
ADDERALL_NN
XR_NN
before_IN
it_PIT
receives_VPRT
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
from_PIN
the_DT
US_FPP1
Food_NN
and_PHC
Drug_NN
Administration_NOMZ
FDA_NN
._.
The_DT
lawsuits_NN
triggered_VBD
stays_NN
of_PIN
FDA_NN
approval_NN
of_PIN
up_RB
to_PIN
30_CD
months_NN
from_PIN
the_DT
Companys_NN
receipt_NN
of_PIN
Barrs_NN
notices_NN
to_TO
allow_VB [SUAV]
the_DT
court_NN
to_TO
resolve_VB [SUAV]
the_DT
suits_NN
._.
Even_RB
if_COND
Barr_NN
receives_VPRT
a_DT
tentative_JJ
approval_NN
from_PIN
the_DT
FDA_NN
,_,
it_PIT
can_POMD
not_XX0
lawfully_RB
launch_VB
its_PIT
generic_JJ
version_NN
before_IN
the_DT
earlier_TIME
of_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
latest_JJ
stay_NN
February_NN
2006_CD
or_CC
a_DT
district_NN
court_NN
decision_NN
in_PIN
its_PIT
favor_NN
._.
In_PIN
the_DT
event_NN
that_TOBJ
Barr_NN
receives_VPRT
a_DT
favourable_JJ
decision_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
stay_NN
,_,
then_RB
Barr_NN
could_POMD
be_VB [BEMA]
in_PIN
a_DT
position_NOMZ
to_TO
market_VB
its_PIT
extended_JJ
release_NN
mixed_JJ
amphetamine_NN
salt_NN
product_NN
,_,
upon_PIN
FDA_NN
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
,_,
following_VBG [PRESP]
the_DT
expiry_NN
of_PIN
the_DT
Hatch-Waxman_NN
exclusivity_NOMZ
period_NN
._.
HatchWaxman_NN
exclusivity_NOMZ
was_VBD [BEMA]
originally_TIME
due_PRED
to_TO
expire_VB
in_PIN
October_NN
2004_CD
._.
However_CONJ
,_,
on_PIN
28_CD
October_NN
2004_CD
the_DT
FDA_NN
granted_VBD [SUAV]
an_DT
additional_JJ
six_CD
months_NN
exclusivity_NOMZ
to_PIN
ADDERALL_NN
XR_NN
based_VBN [WZPAST]
upon_PIN
pediatric_JJ
studies_NN
carried_VBD
out_PIN
on_PIN
the_DT
drug_NN
product_NN
,_,
meaning_VBG [PRIV]
that_THVC
Barr_NN
may_POMD
not_XX0
market_VB
its_PIT
ANDA_NN
products_NN
until_IN
after_IN
Hatch-Waxman_NN
exclusivity_NOMZ
expires_VPRT
on_PIN
11_CD
April_NN
2005_CD
._.
b_NN
Impax_NN
Laboratories_NN
,_,
Inc._NN
._.
In_PIN
November_NN
2003_CD
,_,
Shire_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Impax_NN
Laboratories_NN
,_,
Inc._NN
._.
Impax_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
under_IN
the_DT
Hatch-Waxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
version_NN
of_PIN
the_DT
30mg_JJ
strength_NN
of_PIN
ADDERALL_NN
XR_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
dates_NN
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
and_CC
alleging_VBG [PUBV]
that_THVC
the_DT
819_CD
and_CC
300_CD
Patents_NN
are_VPRT [BYPA]
not_XX0
infringed_VBN
by_PIN
Impaxs_NN
extended_VBD
release_NN
mixed_JJ
amphetamine_NN
salt_NN
product_NN
,_,
the_DT
subject_NN
of_PIN
Impaxs_NN
ANDA_NN
._.
In_PIN
December_NN
2003_CD
,_,
Shire_NN
Laboratories_NN
filed_VBD
suit_NN
against_PIN
Impax_NN
for_PIN
infringement_NOMZ
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
._.
The_DT
Company_NN
is_VPRT
seeking_VBG
a_DT
ruling_NN
that_TSUB
Impaxs_VPRT
ANDA_NN
infringes_VPRT
the_DT
819_CD
and_CC
300_CD
Patents_NN
and_CC
should_NEMD
not_XX0
be_VB [PASS]
approved_VBN
before_IN
the_DT
expiration_NOMZ
dates_NN
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
._.
The_DT
Company_NN
is_VPRT [SPAU]
also_RB
seeking_VBG
an_DT
injunction_NOMZ
to_TO
prevent_VB
Impax_NN
from_PIN
commercialising_VBG
its_PIT
ANDA_NN
product_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
,_,
damages_NN
in_PIN
the_DT
event_NN
that_TOBJ
Impax_NN
should_NEMD
engage_VB
in_PIN
such_JJ
commercialisation_NOMZ
,_,
as_RB
well_RB
its_PIT
attorneys_NN
fees_NN
and_PHC
costs_NN
._.
Impaxs_NN
affirmative_JJ
defenses_NN
include_VPRT
non-infringement_JJ
and_CC
invalidity_NOMZ
of_PIN
both_DT
the_DT
819_CD
and_CC
300_CD
Patents_NN
._.
Impax_NN
is_VPRT [SPAU]
also_RB
requesting_VBG [SUAV]
that_THVC
costs_NN
be_VB [PASS]
assessed_VBN
against_PIN
the_DT
Company_NN
._.
A_DT
trial_NN
date_NN
of_PIN
11_CD
October_NN
2005_CD
has_VPRT [PEAS]
been_VBN [PASS]
set_VBN
._.
In_PIN
December_NN
2004_CD
,_,
Shire_NN
received_VBD
an_DT
additional_JJ
notification_NOMZ
from_PIN
Impax_NN
advising_VBG [WZPRES]
of_PIN
the_DT
filing_NN
of_PIN
an_DT
ANDA_NN
for_PIN
a_DT
generic_JJ
version_NN
of_PIN
the_DT
5mg_JJ
,_,
10mg_JJ
,_,
15mg_JJ
,_,
20mg_JJ
and_PHC
25mg_JJ
strengths_NN
of_PIN
ADDERALL_NN
XR_NN
in_CONJ
addition_NULL
to_PIN
the_DT
30mg_JJ
strength_NN
,_,
the_DT
subject_NN
of_PIN
Impaxs_NN
initial_JJ
ANDA_NN
._.
In_PIN
January_NN
2005_CD
,_,
Shire_NN
Laboratories_NN
filed_VBD
suit_NN
against_PIN
Impax_NN
for_PIN
infringement_NOMZ
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
._.
The_DT
Company_NN
is_VPRT
seeking_VBG
a_DT
ruling_NN
that_TSUB
Impaxs_VPRT
amended_VBN
ANDA_NN
infringes_VPRT
the_DT
819_CD
and_CC
300_CD
Patents_NN
and_CC
should_NEMD
not_XX0
be_VB [PASS]
approved_VBN
before_IN
the_DT
expiration_NOMZ
dates_NN
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
._.
The_DT
Company_NN
is_VPRT [SPAU]
also_RB
seeking_VBG
an_DT
injunction_NOMZ
to_TO
prevent_VB
Impax_NN
from_PIN
commercialising_VBG
its_PIT
amended_VBN
ANDA_NN
products_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
,_,
damages_NN
in_PIN
the_DT
event_NN
that_TOBJ
Impax_NN
should_NEMD
engage_VB
in_PIN
such_JJ
commercialisation_NOMZ
,_,
as_RB
well_RB
as_IN
its_PIT
attorneys_NN
fees_NN
and_PHC
costs_NN
._.
Impaxs_NN
affirmative_JJ
defenses_NN
include_VPRT
non-infringement_JJ
,_,
invalidity_NOMZ
and_PHC
unenforceability_NOMZ
of_PIN
both_DT
the_DT
819_CD
and_CC
300_CD
Patents_NN
._.
Impax_NN
may_POMD
not_XX0
launch_VB
a_DT
generic_JJ
version_NN
of_PIN
ADDERALL_NN
XR_NN
before_IN
it_PIT
receives_VPRT
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
from_PIN
the_DT
FDA_NN
._.
The_DT
lawsuits_NN
triggered_VBD
stays_NN
of_PIN
FDA_NN
approval_NN
of_PIN
up_RB
to_PIN
30_CD
months_NN
from_PIN
the_DT
Companys_NN
receipt_NN
of_PIN
Impaxs_NN
notices_NN
to_TO
allow_VB [SUAV]
the_DT
court_NN
to_TO
resolve_VB [SUAV]
the_DT
suits_NN
._.
Even_RB
if_COND
Impax_NN
receives_VPRT
a_DT
tentative_JJ
approval_NN
from_PIN
the_DT
FDA_NN
,_,
it_PIT
can_POMD
not_XX0
lawfully_RB
launch_VB
its_PIT
generic_JJ
version_NN
before_IN
the_DT
earlier_TIME
of_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
stays_NN
May_POMD
2006_CD
in_PIN
the_DT
case_NN
of_PIN
the_DT
30mg_JJ
strength_NN
and_PHC
June_NN
2007_CD
in_PIN
the_DT
case_NN
of_PIN
the_DT
5mg_JJ
,_,
10mg_JJ
,_,
15mg_JJ
,_,
20mg_JJ
and_PHC
25mg_JJ
strengths_NN
or_CC
a_DT
district_NN
court_NN
decision_NN
in_PIN
its_PIT
favor_NN
._.
In_PIN
the_DT
event_NN
that_TOBJ
Impax_NN
receives_VPRT
a_DT
favourable_JJ
decision_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
stays_NN
,_,
then_RB
Impax_NN
could_POMD
be_VB [BEMA]
in_PIN
a_DT
position_NOMZ
to_TO
market_VB
its_PIT
extended_JJ
release_NN
mixed_JJ
amphetamine_NN
salt_NN
products_NN
upon_PIN
FDA_NN
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
following_VBG [WZPRES]
the_DT
expiry_NN
of_PIN
the_DT
existing_VBG
Hatch-Waxman_NN
exclusivity_NOMZ
and_CC
upon_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
first_JJ
to_PIN
files_NN
exclusivity_NOMZ
rights_NN
._.
The_DT
FDA_NN
may_POMD
grant_VB [SUAV]
180_CD
days_NN
of_PIN
market_NN
exclusivity_NOMZ
to_PIN
the_DT
first_JJ
to_TO
file_VB
._.
Hatch-Waxman_NN
exclusivity_NOMZ
was_VBD [BEMA]
originally_TIME
due_PRED
to_TO
expire_VB
in_PIN
October_NN
2004_CD
._.
However_CONJ
,_,
on_PIN
28_CD
October_NN
2004_CD
the_DT
FDA_NN
granted_VBD [SUAV]
an_DT
additional_JJ
six_CD
months_NN
exclusivity_NOMZ
to_PIN
ADDERALL_NN
XR_NN
based_VBN [WZPAST]
upon_PIN
pediatric_JJ
studies_NN
carried_VBD
out_PIN
on_PIN
the_DT
drug_NN
product_NN
,_,
meaning_VBG [PRIV]
that_THVC
Impax_NN
may_POMD
not_XX0
market_VB
its_PIT
ANDA_NN
products_NN
until_IN
after_IN
Hatch-Waxman_NN
exclusivity_NOMZ
expires_VPRT
on_PIN
11_CD
April_NN
2005_CD
._.
c_NN
Colony_NN
Pharmaceuticals_NN
,_,
Inc._NN
._.
In_PIN
December_NN
2004_CD
,_,
Shire_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Colony_NN
Pharmaceuticals_NN
Inc_NN
Colony_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
under_IN
the_DT
Hatch-Waxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
versions_NN
of_PIN
the_DT
5mg_JJ
,_,
10mg_JJ
,_,
15mg_JJ
,_,
20mg_JJ
,_,
25mg_JJ
and_PHC
30mg_JJ
strengths_NN
of_PIN
ADDERALL_NN
XR_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
Companys_NN
819_CD
and_CC
300_CD
Patents_NN
._.
Shire_NN
has_VPRT [PEAS]
decided_VBN [SUAV] [PRIV]
not_XX0
to_TO
sue_VB
Colony_NN
._.
In_CONJ
any_NULL
event_NULL
,_,
Colony_NN
may_POMD
not_XX0
market_VB
its_PIT
ANDA_NN
products_NN
until_IN
FDA_NN
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
following_VBG [WZPRES]
the_DT
expiry_NN
of_PIN
Shires_NN
existing_VBG [WZPRES]
Hatch-Waxman_NN
exclusivity_NOMZ
on_PIN
11_CD
April_NN
2005_CD
and_CC
upon_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
first_JJ
to_PIN
files_NN
exclusivity_NOMZ
rights_NN
._.
In_PIN
February_NN
2005_CD
,_,
Shire_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Teva_NN
Pharmaceuticals_NN
USA_NN
,_,
Inc._NN
._.
Teva_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
under_IN
the_DT
Hatch-Waxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
versions_NN
of_PIN
the_DT
10mg_JJ
and_PHC
30mg_JJ
strengths_NN
of_PIN
ADDERALL_NN
XR_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
Companys_NN
819_CD
and_CC
300_CD
Patents_NN
._.
Shire_NN
is_VPRT
reviewing_VBG
the_DT
content_NN
of_PIN
the_DT
notice_NN
received_VBD
from_PIN
Teva_NN
and_CC
is_VPRT
considering_VBG [PRIV]
what_WP [WHCL]
action_NOMZ
,_,
if_COND
any_QUAN
,_,
it_PIT
will_PRMD
take_VB
against_PIN
Teva_NN
._.
In_CONJ
any_NULL
event_NULL
,_,
Teva_NN
may_POMD
not_XX0
market_VB
its_PIT
ANDA_NN
products_NN
until_IN
FDA_NN
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
following_VBG [WZPRES]
the_DT
expiry_NN
of_PIN
the_DT
existing_VBG
Hatch-Waxman_NN
exclusivity_NOMZ
on_PIN
11_CD
April_NN
2005_CD
and_CC
upon_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
first_JJ
to_PIN
files_NN
exclusivity_NOMZ
rights_NN
._.
67_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
68_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
28_CD
Guarantees_NN
,_,
commitments_NOMZ
and_PHC
contingencies_NN
continued_VBD
iv_JJ
CARBATROL_NN
In_PIN
August_NN
2003_CD
the_DT
Company_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Nostrum_NN
Pharmaceuticals_NN
,_,
Inc._NN
._.
Nostrum_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
under_IN
the_DT
HatchWaxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
version_NN
of_PIN
the_DT
300mg_JJ
strength_NN
of_PIN
CARBATROL_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
Companys_NN
US_FPP1
patents_NN
for_PIN
CARBATROL_NN
,_,
US_FPP1
patent_NN
No._NN
._.
5,912,013_CD
the_DT
013_CD
Patent_NN
and_PHC
US_FPP1
patent_NN
No._NN
._.
The_DT
notification_NOMZ
alleges_VPRT [PUBV]
that_THVC
the_DT
013_CD
and_CC
570_CD
Patents_NN
are_VPRT [BYPA]
not_XX0
infringed_VBN
by_PIN
Nostrums_NN
300mg_CD
extended_JJ
release_NN
carbamazepine_NN
product_NN
,_,
the_DT
subject_NN
of_PIN
Nostrums_NN
ANDA_NN
._.
This_DEMO
dosage_JJ
strength_NN
represents_VPRT
about_IN
half_NN
of_PIN
Shires_NN
current_JJ
sales_NN
in_PIN
epilepsy_NN
._.
On_PIN
18_CD
September_NN
2003_CD
Shire_NN
Laboratories_NN
filed_VBD
suit_NN
against_PIN
Nostrum_NN
in_PIN
the_DT
United_NN
States_NN
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
for_PIN
infringement_NOMZ
of_PIN
these_DEMO
two_CD
patents_NN
._.
The_DT
Company_NN
was_VBD
seeking_VBG
a_DT
ruling_NN
that_TSUB
Nostrums_VPRT
ANDA_NN
infringes_VPRT
the_DT
013_CD
and_CC
570_CD
Patents_NN
and_CC
should_NEMD
not_XX0
be_VB [PASS]
approved_VBN
before_IN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
013_CD
and_CC
570_CD
Patents_NN
._.
The_DT
Company_NN
was_VBD [SPAU]
also_RB
seeking_VBG
an_DT
injunction_NOMZ
to_TO
prevent_VB
Nostrum_NN
from_PIN
commercialising_VBG
its_PIT
ANDA_NN
product_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
013_CD
and_CC
570_CD
Patents_NN
,_,
damages_NN
in_PIN
the_DT
event_NN
that_TOBJ
Nostrum_NN
should_NEMD
engage_VB
in_PIN
such_JJ
commercialisation_NOMZ
,_,
as_RB
well_RB
as_IN
its_PIT
attorneys_NN
fees_NN
and_PHC
costs_NN
._.
On_PIN
23_CD
January_NN
2004_CD
the_DT
Company_NN
amended_VBD
the_DT
complaint_NN
to_TO
delete_VB
the_DT
allegations_NOMZ
with_PIN
respect_NN
to_PIN
the_DT
013_CD
Patent_NN
._.
By_PIN
way_NN
of_PIN
counterclaims_NN
Nostrum_NN
is_VPRT
seeking_VBG
a_DT
declaration_NOMZ
that_TOBJ
the_DT
570_CD
and_CC
013_CD
Patents_NN
are_VPRT [BYPA]
not_XX0
infringed_VBN
by_PIN
Nostrums_NN
ANDA_NN
product_NN
as_RB
well_RB
as_IN
actual_JJ
and_PHC
punitive_JJ
damages_NN
for_PIN
alleged_JJ
abuse_NN
of_PIN
process_NN
by_PIN
Shire_NN
._.
On_PIN
12_CD
July_NN
2004_CD
the_DT
United_NN
States_NN
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
dismissed_VBD
Nostrums_NN
abuse_NN
of_PIN
process_NN
counterclaim_NN
for_PIN
failure_NN
to_TO
state_VB [PUBV]
a_DT
claim_NN
upon_PIN
which_WDT [PIRE]
relief_NN
can_POMD
be_VB [PASS]
granted_VBN [SUAV]
._.
On_PIN
10_CD
December_NN
2004_CD
Nostrum_NN
filed_VBD
a_DT
summary_NN
judgment_NOMZ
motion_NOMZ
seeking_VBG [WZPRES]
a_DT
declaration_NOMZ
of_PIN
non-infringement_NOMZ
of_PIN
the_DT
570_CD
Patent_NN
._.
Shires_NN
opposition_NOMZ
to_PIN
this_DEMO
motion_NOMZ
was_VBD [PASS]
filed_VBN
on_PIN
14_CD
January_NN
2005_CD
._.
The_DT
case_NN
is_VPRT [BEMA]
now_TIME
in_PIN
the_DT
expert_NN
discovery_NN
phase_NN
._.
No_SYNE
trial_NN
date_NN
has_VPRT [PEAS]
been_VBN [PASS]
set_VBN
._.
Nostrum_NN
may_POMD
not_XX0
launch_VB
a_DT
generic_JJ
version_NN
of_PIN
CARBATROL_NN
before_IN
it_PIT
receives_VPRT
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
from_PIN
the_DT
FDA_NN
._.
The_DT
lawsuit_NN
triggered_VBD
a_DT
stay_NN
of_PIN
FDA_NN
approval_NN
of_PIN
up_RB
to_PIN
30_CD
months_NN
from_PIN
Shires_NN
receipt_NN
of_PIN
Nostrums_NN
notice_NN
to_TO
allow_VB [SUAV]
the_DT
court_NN
to_TO
resolve_VB [SUAV]
the_DT
suit_NN
._.
Even_RB
if_COND
Nostrum_NN
receives_VPRT
tentative_JJ
approval_NN
from_PIN
the_DT
FDA_NN
for_PIN
its_PIT
ANDA_NN
,_,
it_PIT
can_POMD
not_XX0
lawfully_RB
launch_VB
its_PIT
generic_JJ
version_NN
before_IN
the_DT
earlier_TIME
of_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
stay_NN
February_NN
2006_CD
or_CC
a_DT
district_NN
court_NN
decision_NN
in_PIN
its_PIT
favor_NN
._.
In_PIN
the_DT
event_NN
that_TOBJ
the_DT
Company_NN
does_VPRT
not_XX0
prevail_VB
,_,
then_RB
Nostrum_NN
could_POMD
be_VB [BEMA]
in_PIN
a_DT
position_NOMZ
to_TO
market_VB
its_PIT
300mg_JJ
extended_JJ
release_NN
carbamazepine_NN
product_NN
upon_PIN
FDA_NN
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
._.
29_CD
Pension_NN
arrangements_NOMZ
The_DT
Group_NN
has_VPRT
a_DT
number_NN
of_PIN
defined_VBN
contribution_NOMZ
retirement_NOMZ
plans_NN
that_TSUB
together_RB
cover_VPRT
substantially_RB
all_QUAN
employees_NN
._.
The_DT
Company_NN
contribution_NOMZ
is_VPRT [PASS]
fixed_VBN
as_IN
a_DT
set_VBN
percentage_NN
of_PIN
employees_NN
base_JJ
salary_NN
._.
The_DT
pension_NN
cost_NN
charge_NN
for_PIN
the_DT
defined_VBN
contribution_NOMZ
schemes_NN
for_PIN
the_DT
year_NN
was_VBD [BEMA]
4,914,000_CD
2003_CD
:_:
9,824,000_CD
._.
The_DT
closing_GER
creditor_NN
in_PIN
respect_NN
of_PIN
pension_NN
premiums_NN
at_PIN
31_CD
December_NN
2004_CD
is_VPRT [BEMA]
118,000_CD
31_CD
December_NN
2003_CD
:_:
605,000_CD
._.
The_DT
defined_VBN
benefit_NN
plan_NN
operated_VBN [WZPAST]
by_PIN
the_DT
Group_NN
was_VBD [BEMA]
a_DT
Supplemental_NN
Executive_NN
Retirement_NOMZ
Plan_NN
SERP_NN
for_PIN
certain_JJ
US_FPP1
employees_NN
of_PIN
the_DT
acquired_VBN
company_NN
,_,
Roberts_NN
Pharmaceutical_NN
Corporation_NOMZ
,_,
who_WP
met_VBD
certain_JJ
age_NN
and_PHC
service_NN
requirements_NOMZ
._.
The_DT
plan_NN
was_VBD [PASS]
discontinued_VBN
in_PIN
2000_CD
and_CC
there_EX
were_VBD
no_SYNE
contributions_NOMZ
payable_JJ
in_PIN
respect_NN
of_PIN
the_DT
years_NN
2004_CD
and_CC
2003_CD
._.
The_DT
Group_NN
paid_VBD
a_DT
lump_NN
sum_NN
of_PIN
9.4_CD
million_CD
$_$
18.0_CD
million_CD
into_PIN
the_DT
SERP_NN
,_,
which_WDT [SERE]
was_VBD [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
fair_JJ
value_NN
adjustment_NOMZ
on_PIN
the_DT
acquisition_NOMZ
of_PIN
Roberts_NN
Pharmaceutical_NN
Corporation_NOMZ
to_TO
make_VB
good_JJ
the_DT
deficit_NN
on_PIN
this_DEMO
scheme_NN
at_PIN
the_DT
time_NN
of_PIN
acquisition_NOMZ
._.
This_DEMO
lump_NN
sum_NN
payment_NOMZ
has_VPRT [PEAS]
led_VBN
to_PIN
the_DT
Group_NN
having_VBG [WZPRES]
no_SYNE
future_JJ
liability_NOMZ
under_IN
the_DT
SERP_NN
,_,
which_WDT [SERE]
has_VPRT [PEAS]
been_VBN [PASS]
closed_VBN
to_PIN
new_JJ
members_NN
with_PIN
contributions_NOMZ
no_RB
longer_RB
payable_JJ
by_PIN
existing_VBG
members_NN
._.
The_DT
asset_NN
and_PHC
liability_NOMZ
of_PIN
4.9_CD
million_CD
and_CC
2.9_CD
million_CD
respectively_RB
are_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
Notes_NN
20_CD
,_,
22_CD
and_CC
23_CD
respectively_RB
._.
30_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
cash_NN
flow_NN
statement_NOMZ
a_DT
Reconciliation_NOMZ
of_PIN
operating_GER
profit_NN
loss_NN
to_PIN
net_JJ
cash_NN
inflow_NN
from_PIN
operating_VBG
activities_NOMZ
2004 2003 000 000_CD
Group_NN
operating_GER
profit_NN
loss_NN
65,695_CD
299,935_CD
Depreciation_NOMZ
and_PHC
amounts_NN
written_VBN [PUBV] [WZPAST]
off_PIN
tangible_JJ
fixed_JJ
assets_NN
12,516_CD
19,369_CD
Amortisation_NOMZ
and_CC
amounts_VPRT
written_VBN [PUBV]
off_PIN
intellectual_JJ
property_NN
29,164_CD
30,405_CD
Amortisation_NOMZ
and_CC
amounts_VPRT
written_VBN [PUBV]
off_PIN
goodwill_NN
158,283_CD
533,115_CD
Loss_NN
profit_NN
on_PIN
sale_NN
of_PIN
tangible_JJ
fixed_JJ
assets_NN
205_CD
100_CD
Profit_NN
on_PIN
sale_NN
of_PIN
intellectual_JJ
property_NN
432_CD
Provision_NN
for_PIN
investments_NOMZ
8,801_CD
9,491_CD
Increase_VPRT
decrease_NN
in_PIN
stocks_NN
1,570_CD
3,320_CD
Increase_VPRT
in_PIN
debtors_NN
28,444_CD
27,868_CD
Increase_VPRT
in_PIN
creditors_NN
29,514_CD
12,478_CD
Net_JJ
cash_NN
inflow_NN
from_PIN
operating_VBG
activities_NOMZ
273,732_CD
280,275_CD
68_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
69_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
30_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
cash_NN
flow_NN
statement_NOMZ
continued_VBD
b_NN
Analysis_NN
and_PHC
reconciliation_NOMZ
of_PIN
net_JJ
debt_NN
Other_JJ
non-cash_JJ
Exchange_NN
Start_NN
of_PIN
year_NN
Cash_NN
flow_NN
changes_NN
movement_NOMZ
End_NN
of_PIN
year_NN
Year_NN
ended_VBD
31_CD
December_NN
2004 000 000 000_CD
000_CD
000_CD
Cash_NN
at_PIN
bank_NN
and_CC
in_PIN
hand_NN
621,670_CD
5,299_CD
23,606_CD
592,765_CD
Debt_NN
due_JJ
within_PIN
one_CD
year_NN
431_CD
429_CD
3_CD
1_CD
Finance_NN
leases_NN
158_CD
130_CD
28_CD
621,081_CD
4,740_CD
3_CD
23,579_CD
592,765_CD
Debt_NN
due_JJ
after_IN
one_CD
year_NN
203,083_CD
199,489_CD
3_CD
3,537_CD
60_CD
Finance_NN
leases_NN
3,238_CD
3,234_CD
4_CD
414,760_CD
197,983_CD
20,038_CD
592,705_CD
Current_JJ
assets_NN
investments_NOMZ
169,895_CD
9,017_CD
9,713_CD
169,199_CD
Net_JJ
funds_NN
584,655_CD
207,000_CD
29,751_CD
761,904_CD
Other_JJ
non-cash_JJ
Exchange_NN
Start_NN
of_PIN
year_NN
Cash_NN
flow_NN
changes_NN
movement_NOMZ
End_NN
of_PIN
year_NN
Year_NN
ended_VBD
31_CD
December_NN
2003 000 000 000_CD
000_CD
000_CD
Cash_NN
at_PIN
bank_NN
and_CC
in_PIN
hand_NN
558,432_CD
124,578_CD
61,340_CD
621,670_CD
Debt_NN
due_JJ
within_PIN
one_CD
year_NN
389 443 446_CD
39_CD
431_CD
Finance_NN
leases_NN
162 160 155_CD
1_CD
158_CD
557,881_CD
125,181_CD
601_CD
61,380_CD
621,081_CD
Debt_NN
due_JJ
after_IN
one_CD
year_NN
244,325_CD
17,610_CD
446_CD
23,186_CD
203,083_CD
Finance_NN
leases_NN
3,757_CD
155_CD
364_CD
3,238_CD
309,799_CD
142,791_CD
37,830_CD
414,760_CD
Current_JJ
assets_NN
investments_NOMZ
196,364_CD
17,848_CD
8,621_CD
169,895_CD
Net_JJ
funds_NN
506,163_CD
124,943_CD
46,451_CD
584,655_CD
2004 2003 000 000_CD
Decrease_NN
increase_NN
in_PIN
cash_NN
in_PIN
the_DT
year_NN
5,299_CD
124,578_CD
Cash_NN
outflow_NN
from_PIN
decrease_NN
in_PIN
debt_NN
and_PHC
lease_NN
financing_GER
203,282_CD
18,213_CD
Cash_NN
outflow_NN
inflow_NN
from_PIN
decrease_NN
in_PIN
liquid_JJ
resources_NN
9,017_CD
17,848_CD
Change_NN
in_PIN
net_JJ
debt_NN
resulting_VBG [WZPRES]
from_PIN
cash_NN
flows_NN
207,000_CD
124,943_CD
Translation_NOMZ
difference_NN
29,751_CD
46,451_CD
Movement_NOMZ
in_PIN
net_JJ
funds_NN
in_PIN
year_NN
177,249_CD
78,492_CD
Net_JJ
funds_NN
at_PIN
beginning_GER
of_PIN
year_NN
584,655_CD
506,163_CD
Net_JJ
funds_NN
at_PIN
end_NN
of_PIN
year_NN
761,904_CD
584,655_CD
c_NN
Major_JJ
non-cash_JJ
transactions_NOMZ
2004 2003 000 000_CD
Sale_NN
of_PIN
the_DT
vaccines_NN
business_NOMZ
4,931,864_CD
subscription_NOMZ
receipts_NN
in_PIN
IDB_NN
31,252_CD
Cash_NN
held_VBN [PRIV] [WZPAST]
in_PIN
Escrow_NN
15,626_CD
The_DT
4,931,864_CD
subscription_NOMZ
receipts_NN
were_VBD [PASS]
redeemed_VBN
on_PIN
7_CD
January_NN
2005_CD
for_PIN
a_DT
value_NN
of_PIN
31.3_CD
million_CD
$_$
60_CD
million_CD
._.
The_DT
receipts_NN
were_VBD [PASS]
received_VBN
as_IN
part_NN
of_PIN
the_DT
consideration_NOMZ
for_PIN
the_DT
sale_NN
of_PIN
the_DT
vaccines_NN
business_NOMZ
._.
See_VB [PRIV]
Note_VB [PRIV]
16_CD
for_PIN
further_JJ
details_NN
on_PIN
the_DT
sale_NN
of_PIN
the_DT
vaccines_NN
business_NOMZ
._.
69_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
70_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
31_CD
Related_VBN
party_NN
transactions_NOMZ
The_DT
Company_NN
incurred_VBN
professional_JJ
fees_NN
with_PIN
Stikeman_NN
Elliott_NN
,_,
a_DT
law_NN
firm_NN
in_PIN
which_WDT [PIRE]
The_DT
Hon_NN
James_NN
Grant_NN
is_VPRT [BEMA]
a_DT
partner_NN
,_,
totaling_VBG
$_$
2.1_CD
million_CD
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
2003_CD
:_:
$_$
0.8_CD
million_CD
._.
In_PIN
April_NN
2004_CD
Shire_NN
BioChem_NN
Inc._NN
._.
BioChem_NN
,_,
a_DT
subsidiary_NN
of_PIN
Shire_NN
,_,
sold_VBD
a_DT
Canadian_JJ
property_NN
to_PIN
NeuroChem_NN
Inc._NN
for_PIN
CAN$_NN
10.5_CD
million_CD
._.
Dr_NN
Bellini_NN
,_,
a_DT
non-executive_JJ
Director_NN
of_PIN
Biochem_NN
and_CC
,_,
until_IN
10_CD
May_POMD
2003_CD
,_,
a_DT
non-executive_JJ
Director_NN
of_PIN
Shire_NN
and_PHC
Mr_NN
Nordmann_NN
,_,
a_DT
nonexecutive_JJ
Director_NN
of_PIN
Shire_NN
are_VPRT [BEMA]
both_DT
directors_NN
of_PIN
NeuroChem_NN
Inc._NN
._.
Dr_NN
Bellini_NN
had_VBD
an_DT
indirect_JJ
substantial_JJ
interest_NN
in_PIN
the_DT
issued_VBN
share_NN
capital_NN
of_PIN
NeuroChem_NN
Inc._NN
at_PIN
the_DT
time_NN
of_PIN
the_DT
transaction_NOMZ
._.
In_PIN
April_NN
2004_CD
,_,
Biochem_NN
contributed_VBD
cash_NN
of_PIN
CAN$_NN
5.0_CD
million_CD
,_,
equipment_NOMZ
and_CC
intellectual_JJ
property_NN
to_PIN
the_DT
start-up_NN
of_PIN
a_DT
new_JJ
Canadianbased_JJ
pharmaceutical_JJ
research_NN
and_PHC
development_NOMZ
organization_NOMZ
,_,
ViroChem_NN
Pharma_NN
Inc._NN
in_PIN
return_NN
for_PIN
an_DT
equity_NOMZ
interest_NN
and_PHC
royalties_NN
on_PIN
the_DT
sale_NN
of_PIN
certain_JJ
products_NN
subsequently_TIME
launched_VBN
by_PIN
Virochem_NN
._.
Biochem_NN
has_VPRT [PEAS]
undertaken_VBN
to_TO
invest_VB
an_DT
additional_JJ
CAN$_NN
10.0_CD
million_CD
in_PIN
Virochem_NN
in_PIN
two_CD
equal_JJ
tranches_NN
of_PIN
CAN$_NN
5.0_CD
million_CD
in_PIN
April_NN
2005_CD
and_CC
April_NN
2006_CD
._.
Dr_NN
Bellini_NN
,_,
a_DT
non-executive_JJ
Director_NN
of_PIN
Biochem_NN
and_CC
,_,
until_IN
10_CD
May_POMD
2003_CD
,_,
a_DT
non-executive_JJ
Director_NN
of_PIN
Shire_NN
,_,
had_VBD
,_,
at_PIN
the_DT
time_NN
of_PIN
the_DT
transaction_NOMZ
,_,
an_DT
indirect_JJ
substantial_JJ
interest_NN
in_PIN
a_DT
company_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
a_DT
co-investor_NN
in_PIN
ViroChem_NN
Pharma_NN
Inc._NN
._.
In_PIN
accordance_NN
with_PIN
Financial_NN
Reporting_GER
Standard_NN
No._NN
._.
8_CD
related_JJ
party_NN
disclosures_NN
,_,
transactions_NOMZ
with_PIN
other_JJ
companies_NN
in_PIN [STPR]
,_,
and_ANDC
investee_NN
related_VBN
parties_NN
of_PIN [STPR]
,_,
the_DT
Shire_NN
Pharmaceuticals_NN
Group_NN
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
disclosed_VBN [PUBV]
in_PIN
these_DEMO
financial_JJ
statements_NOMZ
._.
32_CD
Subsequent_JJ
events_NN
a_DT
NRP_NN
104_CD
In_PIN
January_NN
2005_CD
,_,
Shire_NN
entered_VBD
into_PIN
an_DT
agreement_NOMZ
with_PIN
New_NN
River_NN
Pharmaceuticals_NN
Inc._NN
to_TO
collaborate_VB
in_PIN
developing_VBG
,_,
manufacturing_VBG
,_,
marketing_GER
and_CC
selling_VBG
NRP104_NN
in_PIN
the_DT
US_FPP1
._.
In_PIN
the_DT
rest_NN
of_PIN
the_DT
world_NN
,_,
Shire_NN
acquired_VBD
the_DT
license_NN
to_TO
develop_VB
and_PHC
commercialise_VB
NRP104_NN
._.
Shire_NN
paid_VBD
an_DT
initial_JJ
sum_NN
of_PIN
$_$
50_CD
million_CD
26.0_CD
million_CD
on_PIN
signing_GER
,_,
and_ANDC
there_EX
is_VPRT
a_DT
further_JJ
$_$
50_CD
million_CD
due_JJ
upon_PIN
acceptance_NN
of_PIN
filing_NN
of_PIN
the_DT
New_NN
Drug_NN
Application_NOMZ
by_PIN
the_DT
FDA_NN
and_CC
up_RB
to_TO
$_$
300_CD
million_CD
156.3_CD
million_CD
in_PIN
milestone_NN
payments_NOMZ
following_VBG [WZPRES]
the_DT
first_JJ
commercial_JJ
sale_NN
depending_VBG [WZPRES]
on_PIN
the_DT
characteristics_NN
of_PIN
the_DT
FDA_NN
approved_VBD
product_NN
labeling_VBG [WZPRES]
._.
A_DT
$_$
5_CD
million_CD
2.6_CD
million_CD
milestone_NN
payment_NOMZ
is_VPRT [BEMA]
payable_PRED
following_VBG
the_DT
first_JJ
commercial_JJ
sale_NN
in_PIN
specified_VBN
European_JJ
countries_NN
._.
An_DT
additional_JJ
$_$
100_CD
million_CD
52.1_CD
million_CD
milestone_NN
would_PRMD
be_VB [BEMA]
payable_PRED
as_IN
a_DT
sales_NN
bonus_NN
upon_PIN
achieving_VBG
a_DT
significant_JJ
sales_NN
target_NN
._.
Shire_NN
may_POMD
be_VB [PASS]
entitled_VBN
to_PIN
refunds_NN
of_PIN
amounts_NN
previously_TIME
paid_VBN
in_PIN
the_DT
event_NN
of_PIN
a_DT
delayed_JJ
product_NN
approval_NN
._.
b_NN
ADDERALL_NN
XR_NN
in_PIN
Canada_NN
ADDERALL_NN
XR_NN
was_VBD [PASS]
made_VBN
commercially_RB
available_JJ
for_PIN
the_DT
treatment_NOMZ
of_PIN
children_NN
in_PIN
Canada_NN
during_PIN
February_NN
2004_CD
._.
On_PIN
9_CD
February_NN
2005_CD
,_,
Shire_NN
announced_VBD [PUBV]
that_THVC
Health_NN
Canada_NN
had_VBD [PEAS]
suspended_VBN
sales_NN
of_PIN
ADDERALL_NN
XR_NN
in_PIN
Canada_NN
where_RB
sales_NN
in_PIN
2004_CD
amounted_VBD
to_TO
$_$
7.8_CD
million_CD
._.
Following_VBG [PRESP]
the_DT
Health_NN
Canada_NN
announcement_NOMZ
,_,
the_DT
FDA_NN
issued_VBD
a_DT
statement_NOMZ
in_PIN
which_WDT [PIRE]
it_PIT
advised_VBD
that_DEMO
after_IN
consultation_NOMZ
with_PIN
the_DT
Canadian_JJ
authorities_NOMZ
regarding_VBG [WZPRES]
the_DT
basis_NN
for_PIN
their_TPP3
action_NOMZ
,_,
it_PIT
did_VBD
not_XX0
feel_VB [PRIV]
that_THVC
any_QUAN
immediate_JJ
changes_NN
were_VBD [PASS]
warranted_VBN
in_PIN
the_DT
FDA_NN
labeling_VBG [WZPRES]
or_CC
approved_VBN
use_NN
of_PIN
ADDERALL_NN
XR_NN
in_PIN
the_DT
US_FPP1
based_VBN [WZPAST]
on_PIN
its_PIT
preliminary_JJ
understanding_GER
of_PIN
Health_NN
Canadas_NN
analyses_NN
of_PIN
adverse_JJ
event_NN
reports_NN
and_CC
the_DT
FDAs_NN
own_VPRT
knowledge_NN
and_PHC
assessment_NOMZ
of_PIN
those_DEMO
reports_NN
._.
Although_CONC
Shire_NN
is_VPRT
complying_VBG
with_PIN
Health_NN
Canadas_NN
suspension_NN
request_NN
,_,
Shire_NN
strongly_AMP
disagrees_VPRT
with_PIN
the_DT
conclusions_NN
drawn_VBN [WZPAST]
by_PIN
Health_NN
Canada_NN
and_CC
has_VPRT [PEAS]
lodged_VBN
an_DT
appeal_NN
and_CC
taken_VBN
other_JJ
actions_NOMZ
to_TO
preserve_VB
its_PIT
legal_JJ
rights_NN
and_PHC
options_NOMZ
._.
70_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
71_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Shire_NN
head_NN
office_NN
and_CC
main_JJ
operating_GER
locations_NOMZ
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Shire_NN
Italia_NN
S._NN
p._NN
A._NN
Chief_NN
Executive_NN
Officer_NN
:_:
Matthew_NN
Emmens_NN
Managing_VBG [WZPRES]
Director_NN
:_:
Gian_NN
Piero_NN
Reverberi_NN
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
Via_PIN
Provinciale_NN
Lucchese_NN
,_,
70_CD
Basingstoke_NN
,_,
Hampshire_NN
RG24_NN
8EP_NN
50019_CD
Sesto_NN
F._NN
No_SYNE
FI_NN
United_NN
Kingdom_NN
Italy_NN
Tel_NN
44_CD
0_CD
1256 894000_CD
Tel_NN
39_CD
0_CD
55 3025050_CD
Fax_NN
44_CD
0_CD
1256 894708_CD
Fax_NN
39_CD
0_CD
55 3025051_CD
Shire_NN
Pharmaceuticals_NN
Ltd_NN
Shire_NN
Pharmaceuticals_NN
Iberica_NN
SL_NN
Managing_VBG [WZPRES]
Director_NN
:_:
John_NN
Freeman_NN
Managing_VBG [WZPRES]
Director_NN
:_:
Jos_NN
Antonio_NN
Senz_NN
fide_NN
Broto_NN
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
P_NN
Pintor_NN
Rosales_NN
,_,
n_NN
40_CD
,_,
Bajo_NN
Izda_NN
._.
Basingstoke_NN
,_,
Hampshire_NN
RG24_NN
8EP_NN
28008_CD
Madrid_NN
United_NN
Kingdom_NN
Spain_NN
Tel_NN
44_CD
0_CD
1256 894000_CD
Tel_NN
34 915 500 691_CD
Fax_NN
44_CD
0_CD
1256 894708_CD
Fax_NN
34 915 493 695_CD
Shire_NN
Pharmaceuticals_NN
Ireland_NN
Ltd_NN
Shire_NN
US_FPP1
Inc._NN
._.
General_NN
Manager_NN
:_:
Brian_NN
Martin_NN
President_NN
:_:
Matthew_NN
Emmens_NN
Building_GER
1A_NN
,_,
Citylink_NN
Business_NOMZ
Park_NN
725_CD
Chesterbrook_NN
Blvd._NN
._.
Old_NN
Naas_NN
Road_NN
,_,
Dublin_NN
12_CD
Wayne_NN
,_,
Pennsylvania_NN
19087-5637_CD
Ireland_NN
USA_NN
Tel_NN
353_CD
1_CD
429_CD
7700_CD
Tel_NN
1_CD
484 595 8800_CD
Fax_NN
353_CD
1_CD
429_CD
7701_CD
Fax_NN
1_CD
484 595 8900_CD
Shire_NN
Pharmaceutical_NN
Contracts_NN
Ltd_NN
Shire_NN
US_FPP1
Manufacturing_GER
Inc._NN
._.
Singapore_NN
representative_JJ
office_NN
EVP_NN
Global_NN
Supply_NN
Chain_NN
&_CC
Quality_NOMZ
:_:
John_NN
Lee_NN
Managing_VBG [WZPRES]
Director_NN
:_:
Tony_NN
Ooi_NN
11200_CD
Gundry_NN
Lane_NN
LiFung_NN
Centre_NN
Owings_NN
Mills_NN
,_,
Maryland_NN
21117_CD
5_CD
B_NN
,_,
Toh_NN
Guan_NN
Road_NN
East_NN
,_,
#_#
03-09A_CD
USA_NN
Singapore_NN
608829_CD
Tel_NN
1_CD
410 413 1000_CD
Tel_NN
65 6665 2795_CD
Fax_NN
1_CD
410 413 2000_CD
Fax_NN
65 6665 2797_CD
Shire_NN
Laboratories_NN
Inc._NN
._.
Shire_NN
Deutschland_NN
GmbH_NN
&_CC
Co_NN
KG_NN
President_NN
and_PHC
Chief_NN
Executive_NN
Officer_NN
:_:
Jack_NN
Khattar_NN
Managing_VBG [WZPRES]
Director_NN
:_:
Leonhard_NN
Terp_NN
1550_CD
East_NN
Gude_NN
Drive_NN
Siegburger_NN
Strae_NN
126_CD
Rockville_NN
,_,
Maryland_NN
20850_CD
D-50679_NN
Kln_NN
USA_NN
Germany_NN
Tel_NN
1_CD
301 838 2500_CD
Tel_NN
49_CD
221_CD
8_CD
80_CD
47_CD
30_CD
Fax_NN
1_CD
301 838 2501_CD
Fax_NN
49_CD
221_CD
8_CD
80_CD
47_CD
41_CD
Shire_NN
Pharmaceutical_NN
Development_NOMZ
Inc._NN
._.
Shire_NN
France_NN
S._NN
A._NN
Senior_NN
Vice_NN
President_NN
:_:
Simon_NN
Tulloch_NN
Managing_VBG [WZPRES]
Director_NN
:_:
Vincent_NN
Lucet_NN
725_CD
Chesterbrook_NN
Blvd._NN
._.
88_CD
,_,
rue_NN
du_NN
Dme_NN
Wayne_NN
,_,
Pennsylvania_NN
19087-5637_CD
92514_CD
Boulogne-Billancourt_NN
Cedex_NN
USA_NN
France_NN
Tel_NN
1_CD
484 595 8800_CD
Tel_NN
33_CD
0_CD
146_CD
10_CD
90_CD
00_CD
Fax_NN
1_CD
484 595 8900_CD
Fax_NN
33_CD
0_CD
146_CD
08_CD
21_CD
49_CD
Shire_NN
BioChem_NN
Inc._NN
._.
Vice_NN
President_NN
and_PHC
General_NN
Manager_NN
:_:
Claude_NN
Perron_NN
2250_CD
Alfred-Nobel_NN
Blvd._NN
._.
Suite_NN
500_CD
Ville_NN
Saint-Laurent_NN
,_,
Qubec_NN
H4S_NN
2C9_NN
Canada_NN
Tel_NN
1_CD
514 787 2300_CD
Fax_NN
1_CD
514 787 2427_CD
71_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
72_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Shareholder_NN
information_NOMZ
Registered_NN
office_NN
address_NN
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
Basingstoke_NN
,_,
Hampshire_NN
RG24_NN
8EP_NN
United_NN
Kingdom_NN
Registered_NN
in_PIN
England_NN
No._NN
._.
2883758_CD
Investor_NN
relations_NOMZ
Europe_NN
and_CC
Rest_VB
of_PIN
the_DT
World_NN
:_:
Cla_NN
Rosenfeld_NN
Tel_NN
44_CD
0_CD
1256 894160_CD
Fax_NN
44_CD
0_CD
1256 894708_CD
Email_NN
investorrelations@uk_NN
._.
com_NN
North_NN
America_NN
:_:
Brian_NN
Piper_NN
Tel_NN
1_CD
484 595 8800_CD
Fax_NN
1_CD
484 595 8151_CD
Email_NN
bpiper@us_FPP1
._.
com_NN
Registrars_NN
and_CC
transfer_VB
office_NN
All_QUAN
administrative_JJ
enquiries_NN
relating_VBG [WZPRES]
to_PIN
shareholdings_GER
should_NEMD
be_VB [PASS]
addressed_VBN
to_PIN
Lloyds_NN
TSB_NN
Registrars_NN
,_,
clearly_RB
stating_VBG [PUBV]
the_DT
registered_VBN
shareholders_NN
name_NN
and_PHC
address_NN
._.
Lloyds_NN
TSB_NN
Registrars_NN
Customer_NN
Services_NN
,_,
The_DT
Causeway_NN
Worthing_GER
,_,
West_NN
Sussex_NN
BN99_NN
6DA_NN
United_NN
Kingdom_NN
Tel_NN
44 870 600 3970_CD
72_CD
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
IBC73_NN
Designed_NN
and_CC
produced_VBN
by_PIN
Bostock_NN
and_PHC
Pollitt_NN
Limited_NN
,_,
London_NN
Printed_NN
in_PIN
the_DT
UK_NN
by_PIN
Butler_NN
and_PHC
Tanner_NN
The_DT
paper_NN
used_VBN [WZPAST]
in_PIN
this_DEMO
publication_NOMZ
is_VPRT [BEMA]
Elemental_JJ
Chlorine_NN
Free_NN
ECF_NN
sourced_VBD
from_PIN
sustainably_RB
managed_VBN
forests_NN
._.
The_DT
mill_NN
is_VPRT [PASS]
accredited_VBN
to_PIN
both_DT
ISO14001_CD
and_CC
EMAS_NN
._.
6169_CD
UK_NN
GAAP_NN
2004_CD
._.
qxd_NN
7_CD
12_CD
05_CD
1:57_CD
PM_NN
Page_NN
BC2_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
Basingstoke_NN
,_,
Hampshire_NN
RG24_NN
8EP_NN
United_NN
Kingdom_NN
Tel_NN
44_CD
0_CD
1256 894000_CD
Fax_NN
44_CD
0_CD
1256 894708_CD
www_NN
._.
com_NN
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
FC1_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2004_CD
Delivering_VBG
on_PIN
promises_NN
building_VBG [WZPRES]
a_DT
foundation_NOMZ
for_PIN
future_JJ
growth_NN
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
IFC2_NN
Mission_NN
Shires_NN
mission_NN
is_VPRT
to_TO
develop_VB
and_PHC
market_VB
medicines_NN
that_TSUB
improve_VPRT
the_DT
quality_NOMZ
of_PIN
life_NN
for_PIN
patients_NN
and_CC
their_TPP3
caregivers_NN
._.
We_FPP1
focus_VPRT
on_PIN
meeting_GER
our_FPP1
commitments_NOMZ
and_PHC
obligations_NOMZ
to_PIN
all_QUAN
our_FPP1
stakeholders_NN
:_:
patients_NN
,_,
physicians_NN
,_,
employees_NN
,_,
shareholders_NN
and_CC
the_DT
communities_NOMZ
in_PIN
which_WDT [PIRE]
we_FPP1
live_VPRT
and_PHC
work_VPRT
._.
Contents_NN
01_CD
Financial_NN
highlights_VPRT
02_CD
Chairmans_NN
statement_NOMZ
We_FPP1
maintain_VPRT [PUBV]
the_DT
highest_JJ
professional_JJ
and_CC
04_CD
Chief_NN
Executives_NN
review_VPRT
06_CD
Product_NN
portfolio_NN
ethical_JJ
standards_NN
,_,
building_VBG
value-added_JJ
08_CD
Operating_GER
review_NN
24_CD
CSR_NN
:_:
Corporate_NN
and_PHC
relationships_NN
with_PIN
physicians_NN
._.
social_JJ
responsibility_NOMZ
28_CD
Financial_NN
review_NN
32_CD
The_NN
Board_NN
of_PIN
Directors_NN
We_FPP1
focus_VPRT
resources_NN
and_CC
organize_VB
our_FPP1
work_NN
34_CD
The_DT
Executive_NN
Committee_NN
36_CD
Directors_NN
remuneration_NOMZ
around_PLACE
select_JJ
therapeutic_JJ
areas_NN
as_RB
well_RB
report_VB [PUBV]
46_CD
Audit_NN
Committee_NN
report_NN
as_IN
implementing_VBG
effective_JJ
processes_NN
for_PIN
48_CD
Corporate_JJ
governance_NN
statements_NOMZ
identifying_VBG [WZPRES]
compounds_NN
and_CC
optimizing_VBG
Financial_JJ
statements_NOMZ
our_FPP1
drug_NN
development_NOMZ
activities_NOMZ
to_TO
bring_VB
53_CD
Statement_NOMZ
of_PIN
Directors_NN
responsibilities_NOMZ
the_DT
best_JJ
drugs_NN
to_PIN
market_NN
._.
54_CD
Report_NN
of_PIN
independent_JJ
registered_JJ
public_JJ
accounting_GER
firm_NN
We_FPP1
galvanize_VPRT
the_DT
entire_JJ
company_NN
around_PLACE
55_CD
Consolidated_NN
balance_NN
sheets_NN
growing_VBG [WZPRES]
our_FPP1
business_NOMZ
and_CC
executing_VBG
56_CD
Consolidated_NN
statements_NOMZ
of_PIN
operations_NOMZ
our_FPP1
strategy_NN
,_,
fostering_VBG [PRESP]
a_DT
rewarding_JJ
and_CC
57_CD
Consolidated_NN
statements_NOMZ
of_PIN
changes_NN
in_PIN
shareholders_NN
enjoyable_JJ
workplace_NN
for_PIN
our_FPP1
employees_NN
._.
equity_NOMZ
58_CD
Consolidated_NN
statements_NOMZ
of_PIN
comprehensive_JJ
income_NN
Above_PLACE
all_QUAN
,_,
we_FPP1
have_VPRT
an_DT
underlying_JJ
passion_NN
59_CD
Consolidated_NN
statements_NOMZ
of_PIN
cash_NN
flows_NN
for_PIN
our_FPP1
work_NN
._.
61_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
97_CD
Five-year_JJ
review_NN
Vision_NN
98_CD
Summary_NN
financial_JJ
statement_NOMZ
We_FPP1
will_PRMD [SPAU]
consistently_RB
be_VB [PASS]
recognized_VBN [PRIV]
as_IN
103_CD
Notes_NN
to_PIN
the_DT
summary_NN
financial_JJ
statement_NOMZ
the_DT
leading_VBG
global_JJ
company_NN
serving_VBG [WZPRES]
Other_JJ
specialist_NN
physicians_NN
and_CC
their_TPP3
105_CD
Shire_NN
head_NN
office_NN
and_CC
main_JJ
operating_GER
locations_NOMZ
patients_NN
through_PIN
distinctive_JJ
medicines_NN
106_CD
Shareholder_NN
information_NOMZ
107_CD
Shire_NN
Trade_NN
Marks_NN
and_CC
effective_JJ
education_NOMZ
programs_NN
._.
01_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
flap2_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Project_NN
development_NOMZ
pipeline_NN
In_PIN
2004_CD
we_FPP1
received_VBD
6_CD
regulatory_JJ
approvals_NN
and_CC
further_JJ
regulatory_JJ
filings_GER
are_VPRT [PASS]
planned_VBN
for_PIN
2005_CD
Indication_NOMZ
Product_NN
Pre-clinical_JJ
Phase_NN
1_CD
Phase_NN
2_CD
Phase_NN
3_CD
Registration_NOMZ
Central_NN
nervous_JJ
system_NN
1_CD
ADHD_NN
MTS_NN
METHYPATCH_NN
ADHD_NN
SPD503_CD
ADHD_NN
NRP104_CD
ADHD_NN
SPD465_CD
ADHD_NN
SPD483_NN
Indication_NOMZ
Product_NN
General_NN
products_NN
Hyperphosphatemia_NN
FOSRENOL_NN
Approved_VBD
launch_NN
underway_NN
in_PIN
Europe_NN
and_PHC
US_FPP1
2_CD
ET_NN
XAGRID_NN
Approved_VBD
launch_NN
underway_NN
in_PIN
Europe_NN
Indication_NOMZ
Product_NN
Pre-clinical_JJ
Phase_NN
1_CD
Phase_NN
2_CD
Phase_NN
3_CD
Registration_NOMZ
Gastro-intestinal_JJ
3_CD
IBD_NN
SPD476_CD
IBD_NN
SPD480_CD
1_CD
Attention_NOMZ
Deficit_NN
Hyperactivity_NOMZ
Disorder_NN
ADHD_NN
2_CD
Essential_NN
Thrombocythemia_NN
ET_NN
3_CD
Inflammatory_NN
Bowel_NN
Disease_NN
IBD_NN
4_CD
Canadian_JJ
marketing_GER
authorization_NOMZ
is_VPRT [SPAU] [PASS]
currently_RB
suspended_VBN
5_CD
Janssen_NN
Pharmaceutica_NN
N._NN
V._NN
Janssen_NN
part_NN
of_PIN
the_DT
Johnson_NN
&_CC
Johnson_NN
Group_NN
6_CD
Also_RB
distributed_VBN
in_PIN
other_JJ
worldwide_JJ
markets_NN
on_PIN
Shires_NN
behalf_NN
7_CD
This_DEMP
is_VPRT [BEMA]
not_XX0
a_DT
comprehensive_JJ
list_NN
of_PIN
trademarks_NN
for_PIN
this_DEMO
product_NN
as_IN
various_JJ
others_NN
are_VPRT [PASS]
used_VBN
in_PIN
smaller_JJ
markets_NN
8_CD
Also_RB
distributed_VBN
in_PIN
other_JJ
European_JJ
markets_NN
on_PIN
Shires_NN
behalf_NN
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
flap3_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Marketed_VBN
products_NN
Shire_NN
has_VPRT
an_DT
established_JJ
portfolio_NN
of_PIN
marketed_VBN
products_NN
to_TO
serve_VB
specialist_NN
physicians_NN
and_CC
their_TPP3
patients_NN
Products_NN
Principal_NN
indications_NOMZ
Marketed_VBN [WZPAST]
by_PIN
relevant_JJ
territory_NN
Central_NN
4_CD
ADDERALL_NN
XR_NN
ADHD_NN
Shire_NN
US_FPP1
and_PHC
Canada_NN
ADDERALL_NN
ADHD_NN
Shire_NN
US_FPP1
nervous_JJ
CARBATROL_NN
Epilepsy_NN
Shire_NN
US_FPP1
system_NN
EQUETRO_NN
Bipolar_NN
1_CD
disorder_NN
Approved_VBN
2004_CD
launch_NN
planned_VBD
Q2_CD
2005_CD
REMINYL_NN
Alzheimer_NN
s_VPRT
disease_NN
Shire_NN
UK_NN
and_PHC
Republic_NN
of_PIN
Ireland_NN
5_CD
Janssen_NN
Rest_VB
of_PIN
the_DT
World_NN
Products_NN
Principal_NN
indications_NOMZ
Marketed_VBN [WZPAST]
by_PIN
relevant_JJ
territory_NN
General_NN
6_CD
AGRYLIN_NN
Thrombocythemia_NN
secondary_JJ
Shire_NN
US_FPP1
and_PHC
Canada_NN
to_PIN
a_DT
myeloproliferative_JJ
disorder_NN
products_NN
XAGRID_NN
Thrombocythemia_NN
Shire_NN
Germany_NN
,_,
France_NN
,_,
UK_NN
and_CC
2_CD
7_CD
second_JJ
line_NN
treatment_NOMZ
in_PIN
ET_NN
Republic_NN
of_PIN
Ireland_NN
FOSRENOL_NN
Hyperphosphatemia_NN
in_PIN
end-stage_JJ
Shire_NN
US_FPP1
renal_JJ
disease_NN
PROAMATINE_NN
Symptomatic_NN
orthostatic_JJ
Shire_NN
US_FPP1
and_PHC
Canada_NN
AMATINE_NN
hypotension_NN
CALCICHEW_NN
Adjunct_NN
in_PIN
osteoporosisShire_NN
UK_NN
and_PHC
Republic_NN
of_PIN
Ireland_NN
Products_NN
Principal_NN
indications_NOMZ
Marketed_VBN [WZPAST]
by_PIN
relevant_JJ
territory_NN
Royalty_NN
3TC_NN
EPIVIR_NN
HIV_NN
Shire_NN
and_PHC
GSK_NN
Canada_NN
:_:
GSK_NN
Rest_VB
of_PIN
the_DT
World_NN
revenues_NN
COMBIVIR_NN
HIV_NN
Shire_NN
and_PHC
GSK_NN
Canada_NN
:_:
GSK_NN
Rest_VB
of_PIN
the_DT
World_NN
TRIZIVIR_NN
HIV_NN
Shire_NN
and_PHC
GSK_NN
Canada_NN
:_:
GSK_NN
Rest_VB
of_PIN
the_DT
World_NN
ZEFFIX_NN
Hepatitis_NN
B_NN
infection_NOMZ
Shire_NN
and_PHC
GSK_NN
Canada_NN
:_:
EPIVIR_NN
HBV_NN
GSK_NN
Rest_VPRT
of_PIN
the_DT
World_NN
7_CD
HEPTOVIR_NN
Products_NN
Principal_NN
indications_NOMZ
Marketed_VBN [WZPAST]
by_PIN
relevant_JJ
territory_NN
GastroPENTASA_NN
Ulcerative_NN
colitisShire_NN
US_FPP1
8_CD
COLAZIDE_NN
Ulcerative_NN
colitis_VPRT
Shire_NN
UK_NN
intestinal_JJ
Future_NN
expansion_NN
and_PHC
growth_NN
opportunities_NOMZ
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
02_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Chairmans_NN
statement_NOMZ
2004_CD
was_VBD [PASS]
dedicated_VBN
to_TO
creating_VBG
the_DT
structure_NN
that_TSUB
will_PRMD
enable_VB
us_FPP1
to_TO
grow_VB
the_DT
Company_NN
of_PIN
our_FPP1
head_NN
office_NN
,_,
and_ANDC
Wayne_NN
,_,
Pennsylvania_NN
in_PIN
the_DT
US_FPP1
._.
These_DEMO
geographies_NN
give_VPRT
us_FPP1
a_DT
firm_NN
presence_NN
in_PIN
two_CD
of_PIN
the_DT
worlds_NN
largest_JJ
pharmaceutical_JJ
markets_NN
._.
In_PIN
line_NN
with_PIN
this_DEMO
strategy_NN
,_,
we_FPP1
are_VPRT [SPAU] [PASS]
also_RB
well_RB
advanced_VBN
in_PIN
implementing_VBG
a_DT
new_JJ
organizational_JJ
structure_NN
that_TSUB
allows_VPRT [SUAV]
Shire_NN
to_TO
operate_VB
crossfunctionally_RB
through_PIN
dedicated_VBN
,_,
global_JJ
teams_NN
._.
These_DEMO
teams_NN
are_VPRT [BEMA]
accountable_PRED
for_PIN
delivering_VBG
results_NN
in_PIN
each_QUAN
of_PIN
our_FPP1
main_JJ
therapeutic_JJ
areas_NN
Central_NN
Nervous_NN
System_NN
CNS_NN
,_,
Gastro-Intestinal_NN
GI_NN
and_PHC
General_NN
Products_NN
GP_NN
._.
This_DEMO
structure_NN
enables_VPRT
people_NN
from_PIN
different_JJ
geographic_JJ
and_PHC
functional_JJ
areas_NN
to_TO
work_VB
together_RB
closely_RB
and_PHC
collaboratively_RB
to_TO
solve_VB
problems_NN
and_CC
to_TO
create_VB
new_JJ
and_CC
better_RB
products_NN
._.
More_EMPH
importantly_RB
,_,
it_PIT
provides_VPRT
Shire_NN
with_PIN
the_DT
flexibility_NOMZ
and_PHC
nimbleness_NOMZ
required_VBN [SUAV] [WZPAST]
for_PIN
continued_JJ
growth_NN
in_PIN
an_DT
industry_NN
marked_VBN [WZPAST]
by_PIN
rapid_JJ
change_NN
and_CC
ever-increasing_JJ
competition_NOMZ
._.
During_PIN
the_DT
year_NN
,_,
renewed_VBN
emphasis_NN
has_VPRT [SPAU] [PEAS]
also_RB
been_VBN [PASS]
placed_VBN
on_PIN
business_NOMZ
development_NOMZ
activities_NOMZ
M&A_NN
._.
The_DT
pharmaceutical_JJ
environment_NOMZ
continues_VPRT
We_FPP1
have_VPRT
a_DT
newly_RB
charged_VBN
global_JJ
team_NN
with_PIN
a_DT
to_TO
be_VB [BEMA]
more_EMPH
challenging_PRED
than_PIN
in_PIN
the_DT
past_NN
._.
clear_JJ
mandate_NN
to_TO
examine_VB
all_QUAN
opportunities_NOMZ
for_PIN
In_PIN
what_WP
some_QUAN
have_VPRT [PEAS]
called_VBN
the_DT
perfect_JJ
storm_NN
,_,
partnership_NN
that_TSUB
fit_VPRT
our_FPP1
strategic_JJ
focus_NN
._.
It_PIT
is_VPRT [BEMA]
our_FPP1
big_JJ
pharma_NN
companies_NN
have_VPRT [PEAS]
faced_VBN
significant_JJ
intention_NOMZ
to_TO
fill_VB
our_FPP1
earlier-stage_JJ
pipeline_NN
with_PIN
inchallenges_NN
including_VBG [WZPRES]
technical_JJ
,_,
regulatory_JJ
and_PHC
licensed_JJ
projects_NN
that_TOBJ
we_FPP1
will_PRMD [SPAU]
then_RB
manage_VB
through_PIN
economic_JJ
issues_NN
._.
to_PIN
approval_NN
and_PHC
launch_NN
over_IN
the_DT
next_JJ
few_QUAN
years_NN
._.
Dr_NN
James_NN
Cavanaugh_NN
Chairman_NN
Rather_NN
than_PIN
inhibiting_VBG
Shires_NN
future_NN
,_,
this_DEMO
2004_CD
results_NN
environment_NOMZ
has_VPRT [SPAU] [PEAS]
actually_RB
provided_VBN
an_DT
attractive_JJ
Shires_NN
highly_AMP
focused_VBD
growth_NN
strategy_NN
produced_VBD
platform_NN
for_PIN
Shire_NN
to_TO
occupy_VB
._.
Under_IN
the_DT
leadership_NN
solid_JJ
results_NN
in_PIN
2004_CD
._.
Revenues_NN
were_VBD [BEMA]
up_RB
13_CD
%_NN
of_PIN
our_FPP1
Chief_NN
Executive_NN
Officer_NN
,_,
Matthew_NN
Emmens_NN
,_,
to_TO
$_$
1,363.2_CD
million_CD
._.
Net_JJ
income_NN
of_PIN
$_$
269.0_CD
million_CD
we_FPP1
have_VPRT
a_DT
strategy_NN
that_TSUB
differentiates_VPRT
us_FPP1
from_PIN
2003_CD
:_:
$_$
276.1_CD
million_CD
was_VBD [BYPA]
impacted_VBN
by_PIN
the_DT
big_JJ
pharma_NN
:_:
we_FPP1
concentrate_VPRT
our_FPP1
resources_NN
on_PIN
$_$
44.2_CD
million_CD
loss_NN
on_PIN
disposal_NN
of_PIN
the_DT
vaccines_NN
specialist_NN
physicians_NN
who_WP [WHSUB]
treat_VPRT
serious_JJ
diseases_NN
._.
business_NOMZ
and_CC
$_$
48.5_CD
million_CD
of_PIN
reorganization_NOMZ
costs_NN
._.
The_DT
ability_NOMZ
to_TO
develop_VB
and_PHC
register_VB
distinctive_JJ
products_NN
and_CC
then_RB
deploy_JJ
small-scale_JJ
sales_NN
Shires_VPRT
cash_NN
position_NOMZ
remained_VBD
strong_JJ
with_PIN
forces_NN
helps_VPRT
us_FPP1
build_VB
relationships_NN
with_PIN
high_JJ
net_JJ
cash_NN
of_PIN
$_$
1,457.5_CD
million_CD
,_,
compared_VBN [PASTP]
with_PIN
prescribers_NN
in_PIN
niche_NN
markets_NN
and_CC
achieve_VB
$_$
1,037.7_CD
million_CD
in_PIN
2003_CD
._.
This_DEMO
cash_NN
will_PRMD
be_VB [PASS]
used_VBN
significant_JJ
market_NN
shares_NN
._.
Additionally_RB
,_,
our_FPP1
Company_NN
is_VPRT
focusing_VBG
on_PIN
fewer_JJ
,_,
Corporate_JJ
governance_NN
later-stage_NN
,_,
low-risk_JJ
projects_NN
that_TSUB
have_VPRT
the_DT
best_JJ
Good_JJ
corporate_JJ
governance_NN
and_CC
prudent_JJ
chances_NN
of_PIN
reaching_VBG
the_DT
market_NN
._.
We_FPP1
intend_VPRT [SUAV]
to_PIN
enterprise-wide_JJ
risk_NN
management_NOMZ
have_VPRT [PEAS]
taken_VBN
maximize_VB
our_FPP1
return_NN
on_PIN
Research_NN
&_CC
Development_NOMZ
on_PIN
critical_JJ
importance_NN
for_PIN
corporations_NOMZ
the_DT
world_NN
R&D_NN
investments_NOMZ
and_CC
optimize_VB
our_FPP1
sales_NN
network_NN
over_IN
._.
Shire_NN
understands_VPRT [PRIV]
the_DT
key_JJ
risks_NN
that_TOBJ
it_PIT
faces_VPRT
by_PIN
extending_VBG
our_FPP1
global_JJ
reach_NN
._.
Accordingly_RB
,_,
and_ANDC
has_VPRT [PEAS]
taken_VBN
appropriate_JJ
steps_NN
to_TO
manage_VB
them_TPP3
we_FPP1
have_VPRT [PEAS]
established_VBN [PRIV]
leading_VBG
strategic_JJ
functions_NOMZ
as_IN
our_FPP1
business_NOMZ
has_VPRT [PEAS]
grown_VBN
in_PIN
size_NN
and_ANDC
therefore_CONJ
at_PIN
two_CD
main_JJ
sites_NN
:_:
Basingstoke_NN
in_PIN
the_DT
UK_NN
,_,
location_NOMZ
complexity_NOMZ
._.
Our_FPP1
implementation_NOMZ
of_PIN
a_DT
rigorous_JJ
risk_NN
management_NOMZ
process_NN
has_VPRT [PEAS]
added_VBN [PUBV]
and_CC
will_PRMD
continue_VB
to_TO
add_VB [PUBV]
value_NN
to_PIN
our_FPP1
business_NOMZ
._.
02_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
03_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Chairmans_NN
statement_NOMZ
Shires_NN
highly_AMP
Our_FPP1
Board_NN
is_VPRT [PASS]
committed_VBN
to_PIN
the_DT
highest_JJ
standards_NN
Talented_VBN
people_NN
of_PIN
corporate_JJ
governance_NN
._.
As_IN
a_DT
FTSE_NN
100_CD
Shires_NN
accomplishments_NOMZ
over_IN
the_DT
past_JJ
few_QUAN
focused_VBN
strategy_NN
company_NN
,_,
we_FPP1
are_VPRT [BEMA]
subject_PRED
to_PIN
the_DT
UK_NN
Listing_GER
years_NN
speak_VPRT
volumes_NN
about_IN
its_PIT
talented_JJ
team_NN
continued_VBD
to_TO
produce_VB
Rules_NN
and_CC
The_DT
Combined_NN
Code_NN
on_PIN
Corporate_NN
of_PIN
employees_NN
worldwide_JJ
,_,
who_WP
have_VPRT
firmly_RB
solid_JJ
results_NN
in_PIN
2004_CD
Governance_NN
._.
We_FPP1
are_VPRT [BYPA]
required_VBN [SUAV]
by_PIN
the_DT
UK_NN
Listing_GER
embraced_VBD
the_DT
Companys_NN
vision_NN
._.
They_TPP3
are_VPRT
to_TO
and_CC
the_DT
Company_NN
is_VPRT
Rules_NN
to_TO
report_VB [PUBV]
annually_RB
on_PIN
our_FPP1
compliance_NN
be_VB [PASS]
thanked_VBN
and_PHC
congratulated_VBN
for_PIN
their_TPP3
many_QUAN
set_NN
for_PIN
future_JJ
growth_NN
with_PIN
the_DT
Combined_NN
Code_NN
and_CC
on_PIN
our_FPP1
risk_NN
contributions_NOMZ
and_CC
ongoing_JJ
support_NN
._.
Where_RB
we_FPP1
fail_VPRT
to_TO
comply_VB
with_PIN
the_DT
provisions_NN
of_PIN
the_DT
Combined_VBN
We_FPP1
had_VBD
1,833_CD
employees_NN
as_IN
of_PIN
December_NN
31_CD
,_,
Code_NN
,_,
we_FPP1
are_VPRT [PASS]
required_VBN [SUAV]
to_TO
explain_VB [PUBV]
why_RB [WHCL]
._.
Shires_NN
2004_CD
,_,
with_PIN
strong_JJ
skills_NN
sets_VPRT
spanning_VBG
compliance_NN
with_PIN
the_DT
provisions_NN
of_PIN
the_DT
Combined_VBN
pharmaceutical_JJ
research_NN
,_,
sales_NN
and_PHC
marketing_GER
,_,
Code_NN
is_VPRT [PASS]
described_VBN
in_PIN
the_DT
corporate_JJ
governance_NN
operations_NOMZ
and_PHC
management_NOMZ
and_PHC
administration_NOMZ
,_,
statements_NOMZ
on_PIN
pages_NN
48_CD
to_PIN
52_CD
._.
among_PIN
others_NN
._.
As_IN
many_QUAN
as_IN
300_CD
new_JJ
people_NN
joined_VBD
Shire_NN
this_DEMO
year_NN
to_TO
work_VB
in_PIN
our_FPP1
newly_RB
As_IN
a_DT
NASDAQ_NN
company_NN
,_,
we_FPP1
are_VPRT [BEMA]
subject_PRED
to_PIN
the_DT
established_VBN [PRIV]
US_FPP1
Corporate_NN
Headquarters_NN
in_PIN
rules_NN
of_PIN
the_DT
Sarbanes-Oxley_NN
Act_NN
,_,
implemented_VBD
Philadelphia_NN
._.
In_CONJ
addition_NULL
,_,
over_IN
100_CD
employees_NN
in_PIN
2002_CD
._.
In_PIN
order_NN
for_PIN
Shire_NN
to_TO
comply_VB
with_PIN
Section_NOMZ
relocated_VBN [WZPAST]
from_PIN
our_FPP1
offices_NN
in_PIN
Kentucky_NN
and_CC
404_CD
of_PIN
Sarbanes-Oxley_NN
,_,
Shire_NN
,_,
along_IN
with_PIN
all_QUAN
Maryland_NN
._.
We_FPP1
believe_VPRT [PRIV]
that_THVC
our_FPP1
new_JJ
operating_GER
Securities_NOMZ
Exchange_NN
Commission_NN
SEC_NN
regulated_VBD
model_NN
,_,
designed_VBN
to_TO
build_VB
an_DT
integrated_VBN
and_CC
companies_NN
,_,
must_NEMD
review_VB
its_PIT
material_NN
financial_JJ
global_JJ
company_NN
based_VBN [WZPAST]
on_PIN
therapeutic_JJ
areas_NN
,_,
reporting_VBG [PUBV]
processes_NN
and_CC
then_RB
document_NOMZ
,_,
review_NN
makes_VPRT
Shire_NN
an_DT
attractive_JJ
new_JJ
type_NN
of_PIN
and_CC
test_VB
all_QUAN
internal_JJ
controls_NN
over_IN
financial_JJ
pharmaceutical_JJ
company_NN
in_PIN
which_WDT [PIRE]
people_NN
can_POMD
reporting_VBG [PUBV]
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
these_DEMP
operate_VPRT
effectively_RB
._.
Consequently_CONJ
we_FPP1
In_PIN
2004_CD
,_,
Shire_NN
completed_VBD
a_DT
global_JJ
review_NN
of_PIN
its_PIT
were_VBD [BEMA]
able_PRED
to_TO
recruit_VB
a_DT
wide_JJ
range_NN
of_PIN
very_AMP
highsystems_NN
of_PIN
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
caliber_NN
people_NN
many_QUAN
from_PIN
well-established_JJ
so_RB
as_IN
to_TO
enable_VB
compliance_NN
with_PIN
Section_NOMZ
404_CD
industry_NN
players_NN
._.
Our_FPP1
model_NN
will_PRMD [SPAU]
further_RB
enhance_VB
by_PIN
the_DT
end_NN
of_PIN
2004_CD
._.
Shire_NN
undertook_VBD
this_DEMO
review_NN
opportunities_NOMZ
for_PIN
our_FPP1
employees_NN
within_PIN
Shire_NN
._.
during_PIN
a_DT
year_NN
of_PIN
considerable_JJ
internal_JJ
change_NN
We_FPP1
are_VPRT [SPAU]
currently_RB
developing_VBG
consistent_JJ
and_ANDC
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
restructuring_GER
exercise_NN
._.
competitive_JJ
policies_NN
and_PHC
programs_NN
to_TO
position_VB
I_FPP1
am_VPRT [BEMA]
particularly_RB
pleased_PRED
,_,
therefore_CONJ
,_,
that_DEMP
this_DEMO
Shire_NN
as_IN
one_CD
of_PIN
the_DT
top_JJ
global_JJ
pharmaceutical_JJ
process_NN
has_VPRT [PEAS]
run_VBN
smoothly_RB
and_CC
that_THVC
no_SYNE
material_NN
companies_NN
and_PHC
FTSE_NN
100_CD
companies_NN
for_PIN
which_WDT [PIRE]
weaknesses_NOMZ
were_VBD [PASS]
identified_VBN
._.
We_FPP1
are_VPRT
continuing_VBG
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
we_FPP1
have_VPRT
the_DT
right_JJ
resources_NN
to_TO
manage_VB
the_DT
exciting_JJ
Shires_NN
Board_NN
is_VPRT [PASS]
comprised_VBN
of_PIN
eight_CD
members_NN
from_PIN
products_NN
and_PHC
projects_NN
that_TOBJ
we_FPP1
have_VPRT
underway_JJ
both_DT
Europe_NN
and_PHC
North_NN
America_NN
with_PIN
extensive_JJ
or_CC
will_PRMD
be_VB
bringing_VBG
on_PIN
board_NN
._.
knowledge_NN
and_PHC
experience_NN
in_PIN
business_NOMZ
and_CC
the_DT
pharmaceutical_JJ
industry_NN
._.
We_FPP1
are_VPRT
continuing_VBG
to_PIN
A_DT
bright_JJ
future_NN
strengthen_VB
our_FPP1
Board_NN
:_:
during_PIN
2004_CD
David_NN
Kappler_NN
Shire_NN
has_VPRT
considerable_JJ
strengths_NN
:_:
a_DT
most_EMPH
joined_VBN
as_IN
a_DT
non-executive_JJ
Director_NN
and_CC
assumed_VBD [PRIV]
talented_JJ
group_NN
of_PIN
employees_NN
,_,
a_DT
growing_VBG
chairmanship_NN
of_PIN
the_DT
Audit_NN
Committee_NN
._.
Mr_NN
Kappler_NN
presence_NN
in_PIN
the_DT
worlds_NN
key_JJ
pharmaceutical_NN
was_VBD
formerly_TIME
Chief_NN
Financial_NN
Officer_NN
of_PIN
Cadbury_NN
markets_NN
and_CC
a_DT
leading_VBG
portfolio_NN
of_PIN
products_NN
Schweppes_NN
plc._NN
._.
Wilson_NN
Totten_NN
,_,
Chief_NN
Scientific_NN
with_PIN
many_QUAN
more_EMPH
in_PIN
the_DT
pipeline_NN
._.
Over_IN
the_DT
next_JJ
Officer_NN
,_,
left_VBD
Shire_NN
during_PIN
2004_CD
and_CC
has_VPRT [PEAS]
resigned_VBN
few_QUAN
years_NN
,_,
we_FPP1
intend_VPRT [SUAV]
to_TO
build_VB
on_PIN
our_FPP1
strengths_NN
from_PIN
the_DT
Board_NN
._.
I_FPP1
would_PRMD
like_VB
to_TO
take_VB
this_DEMP
and_CC
successes_NN
through_PIN
the_DT
disciplined_JJ
opportunity_NOMZ
to_TO
thank_VB
him_TPP3
for_PIN
his_TPP3
many_QUAN
years_NN
implementation_NOMZ
of_PIN
our_FPP1
growth_NN
strategy_NN
._.
of_PIN
valuable_JJ
contributions_NOMZ
to_PIN
Shire_NN
,_,
including_VBG [PRESP]
In_CONJ
addition_NULL
to_TO
growing_VBG
our_FPP1
current_JJ
franchises_NN
,_,
the_DT
successful_JJ
development_NOMZ
and_PHC
registration_NOMZ
we_FPP1
will_PRMD
continue_VB
to_TO
search_VB
for_PIN
and_CC
develop_VB
of_PIN
FOSRENOL_NN
in_PIN
both_DT
Europe_NN
and_CC
the_DT
US_FPP1
._.
new_JJ
products_NN
that_TSUB
deliver_VPRT
significant_JJ
value_NN
for_PIN
shareholders_NN
,_,
physicians_NN
,_,
patients_NN
and_CC
other_JJ
stakeholders_NN
._.
The_DT
ultimate_JJ
goal_NN
is_VPRT
to_TO
become_VB
a_DT
more_EMPH
globally_RB
focused_VBN
and_PHC
integrated_VBN
company_NN
with_PIN
a_DT
number_NN
of_PIN
successful_JJ
global_JJ
products_NN
._.
More_EMPH
than_PIN
ever_RB
,_,
I_FPP1
am_VPRT [BEMA]
confident_PRED
that_THAC
we_FPP1
will_PRMD
achieve_VB
this_DEMO
goal_NN
._.
03_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
04_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Chief_NN
Executives_NN
review_NN
Everything_QUPR
that_DEMO
we_FPP1
have_VPRT [PEAS]
done_VBN
this_DEMO
year_NN
has_VPRT [PEAS]
positioned_VBN
us_FPP1
to_PIN
leverage_NN
on_PIN
our_FPP1
strengths_NN
and_CC
create_VB
an_DT
organization_NOMZ
with_PIN
sustainable_JJ
growth_NN
Key_NN
milestones_NN
We_FPP1
achieved_VBD
a_EMPH
lot_NULL
this_DEMO
year_NN
._.
Our_FPP1
operating_GER
profits_NN
were_VBD [BEMA]
good_PRED
and_CC
we_FPP1
made_VBD
real_JJ
progress_NN
with_PIN
our_FPP1
new_JJ
business_NOMZ
strategy_NN
,_,
which_WDT [SERE]
I_FPP1
outlined_VBD
in_PIN
this_DEMO
section_NOMZ
of_PIN
last_JJ
years_NN
report_NN
._.
In_CONJ
particular_NULL
:_:
we_FPP1
increased_VBD
product_NN
sales_NN
and_CC
received_VBD
more_EMPH
income_NN
from_PIN
royalties_NN
:_:
we_FPP1
turned_VBD
in_PIN
a_DT
solid_JJ
financial_JJ
performance_NN
,_,
with_PIN
revenues_NN
up_IN
13_CD
%_NN
:_:
we_FPP1
paid_VBD
our_FPP1
first_JJ
dividend_NN
:_:
we_FPP1
moved_VBD [SUAV]
our_FPP1
pipeline_NN
forward_RB
and_CC
achieved_VBD
six_CD
new_JJ
product_NN
approvals_NN
or_CC
line_NN
extensions_NN
in_PIN
Europe_NN
and_CC
the_DT
US_FPP1
:_:
and_ANDC
we_FPP1
made_VBD
the_DT
business_NOMZ
more_EMPH
focused_JJ
,_,
strengthened_VBD
the_DT
management_NOMZ
team_NN
and_CC
increased_VBD
our_FPP1
R&D_NN
capabilities_NOMZ
._.
You_SPP2
may_POMD
remember_VB [PRIV]
that_THVC
last_JJ
year_NN
I_FPP1
described_VBD
how_RB
we_FPP1
intended_VBD [SUAV]
to_TO
change_VB
the_DT
structure_NN
of_PIN
the_DT
Company_NN
so_OSUB
that_NULL
we_FPP1
could_POMD
work_VB
more_EMPH
laterally_RB
and_PHC
internationally_RB
across_PLACE
the_DT
organization_NOMZ
,_,
rather_CONJ
than_PIN
in_PIN
isolated_JJ
silos_NN
._.
We_FPP1
wanted_VBD
simpler_JJ
reporting_GER
lines_NN
and_CC
a_DT
business_NOMZ
model_NN
that_TSUB
brought_VBD
our_FPP1
drug_NN
development_NOMZ
and_CC
commercial_JJ
activities_NOMZ
closer_RB
together_RB
and_CC
that_DEMP
is_VPRT
what_WP
we_FPP1
Matthew_NN
Emmens_NN
now_TIME
have_VPRT
._.
As_CONJ
a_NULL
result_NULL
,_,
we_FPP1
are_VPRT [BEMA]
more_EMPH
competitive_PRED
,_,
Chief_NN
Executive_NN
Officer_NN
more_EMPH
accountable_JJ
and_CC
more_EMPH
attuned_JJ
to_PIN
the_DT
particular_JJ
needs_NN
of_PIN
the_DT
specialist_NN
doctors_NN
who_WP [WHSUB]
are_VPRT [BEMA]
our_FPP1
main_JJ
customers_NN
._.
Our_FPP1
technological_JJ
and_PHC
R&D_JJ
efforts_NN
are_VPRT [SPAU] [PASS]
now_TIME
concentrated_VBN
on_PIN
highpotential_JJ
treatments_NOMZ
that_TSUB
are_VPRT [BEMA]
in_PIN
the_DT
latter_JJ
stages_NN
of_PIN
development_NOMZ
,_,
which_WDT [SERE]
significantly_RB
reduces_VPRT
our_FPP1
risk_NN
profile_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
we_FPP1
had_VBD
six_CD
projects_NN
in_PIN
registration_NOMZ
at_PIN
the_DT
end_NN
of_PIN
the_DT
first_JJ
quarter_NN
2004_CD
,_,
two_CD
more_EMPH
in_PIN
Phase_NN
3_CD
of_PIN
development_NOMZ
and_CC
two_CD
in_PIN
Phase_NN
2_CD
and_CC
by_PIN
the_DT
end_NN
of_PIN
the_DT
year_NN
wed_VBD
received_VBN
six_CD
drugs_NN
approvals_NN
in_PIN
Europe_NN
and_CC
in_PIN
the_DT
US_FPP1
,_,
including_VBG
:_:
FOSRENOL_NN
in_PIN
both_DT
the_DT
US_FPP1
and_CC
in_PIN
Europe_NN
:_:
PENTASA_NN
500mg_CD
in_PIN
the_DT
US_FPP1
:_:
ADDERALL_NN
XR_NN
for_PIN
adult_NN
patients_NN
in_PIN
the_DT
US_FPP1
:_:
EQUETRO_NN
in_PIN
the_DT
US_FPP1
:_:
and_ANDC
XAGRID_NN
in_PIN
Europe_NN
._.
04_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
05_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Chief_NN
Executives_NN
review_NN
We_FPP1
will_PRMD
add_VB [PUBV]
to_PIN
current_JJ
Shire_NN
has_VPRT
a_DT
particularly_RB
strong_JJ
portfolio_NN
of_PIN
lateCorporate_NN
social_JJ
responsibility_NOMZ
stage_NN
projects_NN
._.
Methylphenidate_NN
transdermal_JJ
We_FPP1
take_VPRT
a_DT
practical_JJ
and_PHC
contemporary_JJ
approach_NN
therapeutic_JJ
areas_NN
as_IN
system_NN
MTS_NN
METHYPATCH_NN
for_PIN
ADHD_NN
is_VPRT [BEMA]
now_TIME
to_PIN
corporate_JJ
social_JJ
responsibility_NOMZ
and_CC
this_DEMP
is_VPRT
well_RB
as_IN
pursue_VB
new_JJ
in_PIN
registration_NOMZ
and_CC
we_FPP1
plan_VPRT
to_TO
register_VB
three_CD
an_DT
area_NN
where_RB
a_EMPH
lot_NULL
has_VPRT [PEAS]
been_VBN [PASS]
achieved_VBN
in_PIN
the_DT
opportunities_NOMZ
to_TO
grow_VB
more_EMPH
products_NN
in_PIN
the_DT
US_FPP1
by_PIN
2006_CD
:_:
SPD503_CD
last_JJ
year_NN
,_,
for_CONJ
instance_NULL
:_:
our_FPP1
business_NOMZ
in_PIN
the_DT
guanfacine_NN
and_CC
SPD465_CD
longer-acting_JJ
US_FPP1
and_PHC
Europe_NN
ADDERALL_NN
XR_NN
,_,
both_DT
for_PIN
the_DT
treatment_NOMZ
of_PIN
we_FPP1
appointed_VBD
a_DT
global_JJ
Environment_NOMZ
and_PHC
ADHD_NN
and_PHC
SPD476_NN
for_PIN
ulcerative_JJ
colitis_NN
._.
Health_NN
and_PHC
Safety_NN
Officer_NN
for_PIN
the_DT
Company_NN
:_:
Shires_NN
strategy_NN
we_FPP1
completed_VBD
a_DT
risk_NN
management_NOMZ
exercise_NN
:_:
We_FPP1
are_VPRT [BEMA]
a_DT
specialty_NN
pharmaceutical_JJ
company_NN
and_CC
that_DEMP
focuses_VPRT
on_PIN
meeting_VBG
the_DT
needs_NN
of_PIN
the_DT
specialist_NN
physician_NN
._.
Geographically_NN
,_,
our_FPP1
key_NN
we_FPP1
took_VBD
on_PIN
a_DT
range_NN
of_PIN
community_NOMZ
initiatives_NN
markets_NN
are_VPRT [BEMA]
the_DT
US_FPP1
and_CC
the_DT
larger_JJ
European_JJ
in_PIN
both_DT
Philadelphia_NN
and_PHC
Basingstoke_NN
._.
markets_NN
of_PIN
the_DT
United_NN
Kingdom_NN
,_,
France_NN
,_,
Germany_NN
,_,
Italy_NN
and_PHC
Spain_NN
._.
Angus_NN
Russell_NN
,_,
our_FPP1
Chief_NN
Financial_NN
Officer_NN
,_,
leads_VPRT
the_DT
committee_NN
that_TSUB
looks_VPRT
after_IN
corporate_JJ
We_FPP1
deliberately_RB
concentrate_VPRT
our_FPP1
R&D_NN
resources_NN
social_JJ
responsibility_NOMZ
and_CC
monitors_VPRT
the_DT
progress_NN
on_PIN
products_NN
that_TSUB
are_VPRT [BEMA]
in_PIN
the_DT
late_TIME
stages_NN
of_PIN
were_VBD
making_VBG
._.
As_IN
last_JJ
year_NN
,_,
we_FPP1
will_PRMD
be_VB
issuing_VBG
development_NOMZ
._.
This_DEMP
is_VPRT
where_RB
we_FPP1
expect_VPRT [PRIV]
to_TO
get_VB
a_DT
separate_JJ
report_NN
on_PIN
this_DEMO
whole_JJ
area_NN
which_WDT [WHOBJ]
you_SPP2
the_DT
optimum_JJ
combination_NOMZ
of_PIN
better_JJ
returns_NN
,_,
can_POMD
download_RB
from_PIN
the_DT
website_NN
or_CC
request_NN
from_PIN
more_EMPH
predictability_NOMZ
and_CC
lower_JJ
risk_NN
._.
We_FPP1
are_VPRT [BEMA]
quite_RB
our_FPP1
Corporate_JJ
Communications_NOMZ
department_NOMZ
._.
open_JJ
about_IN
the_DT
fact_NN
that_TOBJ
we_FPP1
dont_VPRT
compete_VB
with_PIN
the_DT
very_AMP
large_JJ
pharmaceutical_JJ
companies_NN
The_DT
future_NN
the_DT
products_NN
we_FPP1
want_VPRT
are_VPRT [BEMA]
those_DEMO
that_DEMP
could_POMD
In_PIN
last_JJ
years_NN
report_VPRT [PUBV] [THATD]
I_FPP1
said_VBD [PUBV]
that_THVC
we_FPP1
were_VBD
going_VBG
to_TO
achieve_VB
sales_NN
of_PIN
between_PIN
US$_$
150_CD
million_CD
and_CC
reinforce_VB
our_FPP1
position_NOMZ
in_PIN
the_DT
market_NN
and_CC
make_VB
US$_$
500_CD
million_CD
at_PIN
their_TPP3
peak_NN
._.
In_PIN
practice_NN
we_FPP1
Shire_VPRT
one_CD
of_PIN
the_DT
leading_VBG
specialty_NN
pharmaceutical_JJ
do_VPRT
this_DEMO
by_PIN
seeking_VBG
to_TO
add_VB [PUBV]
new_JJ
projects_NN
to_PIN
the_DT
companies_NN
in_PIN
the_DT
world_NN
._.
Thats_NN
what_WDT
weve_NN
done_VBN [PROD]
pipeline_NN
every_QUAN
year_NN
._.
We_FPP1
look_VPRT
for_PIN
projects_NN
where_RB
and_CC
will_PRMD
strive_VB
to_TO
maintain_VB [PUBV]
._.
we_FPP1
can_POMD
exploit_VB
the_DT
intellectual_JJ
property_NN
involved_VBN [WZPAST]
fully_AMP
,_,
which_WDT [SERE]
means_VPRT [PRIV]
that_THVC
we_FPP1
actively_RB
look_VPRT
for_PIN
Our_FPP1
profits_NN
are_VPRT [BEMA]
very_AMP
strong_PRED
,_,
the_DT
business_NOMZ
is_VPRT
licensing_VBG
opportunities_NOMZ
._.
This_DEMP
is_VPRT
why_RB
I_FPP1
stepped_VBD
up_RP
growing_VBG
and_PHC
thats_VPRT
despite_PIN
all_QUAN
the_DT
work_NN
done_VBN [PROD]
our_FPP1
business_NOMZ
development_NOMZ
efforts_NN
this_DEMO
year_NN
,_,
by_PIN
to_TO
reorganize_VB
the_DT
Company_NN
this_DEMO
year_NN
._.
This_DEMO
time_NN
bringing_VBG [WZPRES]
in_PIN
Barbara_NN
Deptula_NN
to_TO
head_VB
up_RP
business_NOMZ
last_JJ
year_NN
I_FPP1
predicted_VBD [PUBV]
a_DT
promising_JJ
future_NN
and_CC
we_FPP1
development_NOMZ
._.
In_CONJ
addition_NULL
,_,
Eliseo_NN
Salinas_NN
joined_VBD
can_POMD
see_VB [PRIV]
the_DT
proof_NN
of_PIN
this_DEMO
in_PIN
six_CD
product_NN
approvals_NN
us_FPP1
to_TO
head_VB
up_RP
the_DT
R&D_NN
function_NOMZ
._.
and_ANDC
the_DT
strength_NN
and_PHC
depth_NN
of_PIN
our_FPP1
pipeline_NN
._.
Patent_NN
challenges_NN
Our_FPP1
strategy_NN
is_VPRT [BEMA]
simple_PRED
but_CC
it_PIT
is_VPRT [BEMA]
compelling_PRED
and_CC
In_PIN
todays_NN
markets_NN
,_,
we_FPP1
know_VPRT [PRIV]
that_THVC
manufacturers_NN
it_PIT
is_VPRT
working_VBG
._.
This_DEMP
is_VPRT [BEMA]
largely_RB
due_PRED
to_PIN
the_DT
dedication_NOMZ
of_PIN
generic_JJ
drugs_NN
will_PRMD
challenge_VB
our_FPP1
portfolio_NN
._.
and_ANDC
professionalism_NN
of_PIN
all_QUAN
Shire_NN
employees_NN
,_,
and_ANDC
But_CC
as_IN
I_FPP1
said_VBD [PUBV]
last_JJ
year_NN
,_,
we_FPP1
are_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
this_DEMO
report_NN
gives_VPRT
me_FPP1
the_DT
chance_NN
to_TO
thank_VB
them_TPP3
all_QUAN
._.
to_TO
defend_VB
our_FPP1
intellectual_JJ
property_NN
vigorously_RB
and_CC
we_FPP1
will_PRMD
continue_VB
to_TO
file_VB
new_JJ
patents_NN
on_PIN
our_FPP1
projects_NN
and_PHC
products_NN
._.
05_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
06_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Product_NN
portfolio_NN
With_PIN
the_DT
approvals_NN
secured_VBN [WZPAST]
in_PIN
2004_CD
,_,
a_DT
number_NN
of_PIN
new_JJ
products_NN
entered_VBD
the_DT
portfolio_NN
._.
FOSRENOL_NN
and_PHC
XAGRID_NN
are_VPRT
Shires_NN
first_JJ
global_JJ
products_NN
ADDERALL_NN
XR_NN
AGRYLIN_NN
CARBATROL_NN
ADDERALL_NN
XR_NN
mixed_JJ
amphetamine_NN
salts_NN
AGRYLIN_NN
anagrelide_NN
hydrochloride_NN
CARBATROL_NN
carbamazepine_NN
extendedis_VPRT
indicated_VBN [PRIV]
for_PIN
the_DT
treatment_NOMZ
of_PIN
ADHD_NN
and_CC
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
the_DT
treatment_NOMZ
of_PIN
release_NN
capsules_NN
is_VPRT [PASS]
marketed_VBN
for_PIN
the_DT
is_VPRT [BEMA]
a_DT
once-daily_JJ
formulation_NOMZ
of_PIN
ADDERALL_NN
._.
thrombocythemia_NN
,_,
secondary_JJ
to_PIN
a_DT
treatment_NOMZ
of_PIN
epilepsy_NN
,_,
combining_VBG
proven_VBN
It_PIT
offers_VPRT
convenience_NN
to_PIN
patients_NN
and_CC
myeloproliferative_JJ
disorder_NN
._.
Research_NN
medication_NOMZ
with_PIN
advanced_JJ
drug_NN
delivery_NN
caregivers_NN
,_,
and_ANDC
the_DT
potential_NN
for_PIN
improved_VBN
indicates_VPRT [PRIV]
that_THVC
a_DT
key_JJ
benefit_NN
of_PIN
AGRYLIN_NN
technology_NN
to_TO
enable_VB
a_DT
convenient_JJ
twicepatient_NN
compliance_NN
._.
is_VPRT [BEMA]
its_PIT
platelet_NN
selectivity_NOMZ
,_,
targeting_VBG [PRESP]
only_DWNT
daily_JJ
treatment_NOMZ
._.
those_DEMO
cells_NN
that_TSUB
develop_VPRT
into_PIN
platelets_NN
._.
REMINYL_NN
SOLARAZE_NN
VANIQA_NN
REMINYL_NN
galantamine_NN
hydrobromide_NN
SOLARAZE_NN
diclofenac_JJ
sodium_NN
3_CD
%_NN
gel_NN
VANIQA_NN
eflornithine_NN
11.5_CD
%_NN
cream_NN
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
the_DT
symptomatic_JJ
treatment_NOMZ
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
the_DT
treatment_NOMZ
of_PIN
actinic_NN
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
the_DT
treatment_NOMZ
of_PIN
facial_JJ
of_PIN
mild_JJ
to_TO
moderately_RB
severe_JJ
dementia_NN
keratosis_NN
,_,
a_DT
pre-cancerous_JJ
skin_NN
condition_NOMZ
._.
VANIQA_NN
inhibits_VPRT
an_DT
of_PIN
the_DT
Alzheimer_NN
type_NN
._.
REMINYL_NN
differs_VPRT
enzyme_NN
involved_VBN [WZPAST]
in_PIN
the_DT
production_NOMZ
of_PIN
from_PIN
other_JJ
compounds_NN
in_PIN
its_PIT
class_NN
in_PIN
that_DEMO
the_DT
hair_NN
shaft_NN
by_PIN
the_DT
hair_NN
follicle_NN
._.
VANIQA_NN
it_PIT
has_VPRT
a_DT
dual_JJ
mechanism_NN
of_PIN
action_NOMZ
._.
has_VPRT [PEAS]
been_VBN [PASS]
shown_VBN [PRIV]
to_TO
reduce_VB
the_DT
rate_NN
of_PIN
facial_JJ
hair_NN
growth_NN
._.
06_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
07_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Product_NN
portfolio_NN
EQUETRO_NN
FOSRENOL_NN
PENTASA_NN
EQUETRO_NN
carbamazepine_NN
extendedFOSRENOL_NN
lanthanum_NN
carbonate_NN
PENTASA_NN
mesalamine_NN
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
release_NN
capsules_NN
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
the_DT
is_VPRT [PASS]
indicated_VBN [PRIV]
to_TO
reduce_VB
serum_NN
phosphate_VB
the_DT
induction_NOMZ
of_PIN
remission_NN
and_PHC
treatment_NOMZ
treatment_NOMZ
of_PIN
acute_JJ
manic_NN
and_CC
mixed_JJ
in_PIN
patients_NN
with_PIN
end-stage_JJ
renal_JJ
disease_NN
._.
of_PIN
patients_NN
with_PIN
mild_JJ
to_TO
moderately_RB
active_JJ
episodes_NN
associated_VBN [WZPAST]
with_PIN
bipolar_NN
1_CD
Approved_VBN
in_PIN
2004_CD
,_,
FOSRENOL_NN
will_PRMD
ulcerative_VB
colitis_NN
,_,
using_VBG [PRESP]
a_DT
unique_JJ
delivery_NN
disorder_NN
._.
Advanced_NN
drug_NN
delivery_NN
become_VB
one_CD
of_PIN
the_DT
first_JJ
global_JJ
products_NN
mechanism_NN
._.
technology_NN
enables_VPRT
the_DT
convenience_NN
for_PIN
Shire_NN
._.
XAGRID_NN
ZEFFIX_NN
3TC_NN
XAGRID_NN
anagrelide_NN
hydrochloride_NN
ZEFFIX_NN
lamivudine_NN
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
3TC_NN
lamivudine_NN
,_,
also_RB
marketed_VBN
as_IN
EPIVIR_NN
,_,
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
the_DT
reduction_NOMZ
of_PIN
elevated_VBN
the_DT
treatment_NOMZ
of_PIN
chronic_JJ
hepatitis_NN
B_NN
in_PIN
combination_NOMZ
with_PIN
other_JJ
anti-retroviral_JJ
platelet_NN
counts_NN
in_PIN
at-risk_JJ
essential_JJ
infection_NOMZ
associated_VBN [WZPAST]
with_PIN
evidence_NN
of_PIN
agents_NN
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
the_DT
treatment_NOMZ
thrombocythemia_NN
patients_NN
who_WP [WHSUB]
are_VPRT
hepatitis_NN
B_NN
viral_JJ
replication_NOMZ
and_CC
acute_JJ
of_PIN
human_JJ
immuno-deficiency_NN
virus_NN
HIV_NN
intolerant_NN
to_PIN
their_TPP3
current_JJ
therapy_NN
or_CC
whose_WPS
liver_NN
inflammation_NOMZ
._.
Lamivudine_NN
is_VPRT [BEMA]
a_DT
component_NN
elevated_VBD
platelet_NN
counts_NN
are_VPRT [PASS]
not_XX0
reduced_VBN
to_PIN
of_PIN
the_DT
combination_NOMZ
HIV_NN
treatments_NOMZ
,_,
an_DT
acceptable_JJ
level_NN
by_PIN
their_TPP3
current_JJ
therapy_NN
._.
07_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
08_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
CNS_NN
Central_NN
nervous_JJ
system_NN
Simon_NN
Tulloch_NN
Senior_NN
Vice_NN
President_NN
and_PHC
CNS_NN
Strategic_NN
Therapeutic_NN
Area_NN
Leader_NN
08_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
09_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
CNS_NN
Shire_NN
will_PRMD
continue_VB
to_TO
build_VB
upon_PIN
its_PIT
successful_JJ
ADHD_NN
platform_NN
,_,
thereby_RB
helping_VBG
thousands_NN
of_PIN
patients_NN
suffering_VBG [WZPRES]
from_PIN
the_DT
disease_NN
09_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
10_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
CNS_NN
Our_FPP1
business_NOMZ
strategy_NN
going_VBG [WZPRES]
forward_RB
is_VPRT
to_TO
continue_VB
to_TO
optimize_VB
our_FPP1
current_JJ
portfolio_NN
of_PIN
products_NN
and_CC
to_PIN
in-license_JJ
projects_NN
in_PIN
clinical_JJ
development_NOMZ
Disorders_NN
of_PIN
the_DT
CNS_NN
are_VPRT [BEMA]
a_DT
very_AMP
important_JJ
for_PIN
delivering_VBG
results_NN
for_PIN
those_DEMO
products_NN
._.
The_DT
new_JJ
segment_NOMZ
of_PIN
the_DT
global_JJ
pharmaceutical_JJ
market_NN
structure_NN
allows_VPRT [SUAV]
people_NN
from_PIN
different_JJ
geographic_JJ
one_NN
that_DEMP
is_VPRT [SPAU] [PASS]
still_RB
relatively_RB
underserved_VBD
._.
Shire_NN
has_VPRT
and_CC
functional_JJ
areas_NN
to_TO
work_VB
together_RB
to_TO
solve_VB
developed_VBN
a_DT
strong_JJ
heritage_NN
in_PIN
this_DEMO
area_NN
by_PIN
problems_NN
collaboratively_RB
._.
The_DT
new_JJ
STAT_NN
structure_NN
successfully_RB
finding_VBG [PRIV]
,_,
developing_VBG
and_PHC
marketing_VBG
also_RB
puts_VPRT
us_FPP1
in_PIN
a_DT
better_JJ
position_NOMZ
to_TO
focus_VB
on_PIN
drugs_NN
that_TSUB
meet_VPRT
the_DT
needs_NN
of_PIN
specialist_NN
making_VBG [WZPRES]
a_DT
global_JJ
success_NN
of_PIN
our_FPP1
products_NN
and_PHC
physicians_NN
in_PIN
treating_VBG
patients_NN
suffering_VBG [WZPRES]
from_PIN
to_TO
build_VB
truly_RB
global_JJ
franchises_NN
._.
disorders_NN
such_JJ
as_IN
attention_NOMZ
deficit_NN
hyperactivity_NOMZ
disorder_NN
ADHD_NN
and_PHC
bipolar_NN
1_CD
disorder_NN
._.
Shires_NN
CNS_NN
STAT_NN
is_VPRT [SPAU]
already_RB
delivering_VBG
solid_JJ
My_FPP1
experience_NN
with_PIN
results_NN
._.
During_PIN
the_DT
year_NN
considerable_JJ
progress_NN
ADDERALL_NN
XR_NN
has_VPRT [PEAS]
been_VBN
Shire_NN
has_VPRT
a_DT
world-class_JJ
team_NN
of_PIN
researchers_NN
was_VBD [PASS]
made_VBN
in_PIN
finalizing_VBG
the_DT
CNS_NN
team_NN
structure_NN
very_AMP
positive_JJ
._.
I_FPP1
have_VPRT
an_DT
and_CC
scientists_NN
focused_VBD
on_PIN
the_DT
later_TIME
stages_NN
of_PIN
and_CC
in_PIN
rolling_VBG
out_PIN
the_DT
CNS_NN
business_NOMZ
plan_NN
._.
adult_NN
patient_NN
with_PIN
ADHD_NN
product_NN
development_NOMZ
and_CC
a_DT
strong_JJ
business_NOMZ
We_FPP1
have_VPRT [PEAS]
achieved_VBN
major_JJ
successes_NN
with_PIN
our_FPP1
who_WP
has_VPRT [SPAU] [PEAS]
only_DWNT
responded_VBD
development_NOMZ
group_NN
with_PIN
global_JJ
reach_NN
actively_RB
key_JJ
CNS_NN
marketed_VBD
products_NN
and_PHC
projects_NN
under_IN
to_PIN
ADDERALL_NN
XR_NN
._.
In_PIN
my_FPP1
seeking_VBG
new_JJ
opportunities_NOMZ
to_TO
bring_VB
marketed_VBN
and_CC
development_NOMZ
,_,
such_JJ
as_IN
receiving_VBG
US_FPP1
marketing_GER
opinion_NN
it_PIT
is_VPRT [BEMA]
a_DT
valuable_JJ
development_NOMZ
products_NN
into_PIN
Shires_NN
portfolio_NN
._.
The_DT
approval_NN
for_PIN
EQUETRO_NN
only_DWNT
ten_CD
months_NN
after_IN
tool_NN
in_PIN
managing_GER
patients_NN
Company_NN
can_POMD
add_VB [PUBV]
significant_JJ
value_NN
to_PIN
potential_JJ
its_PIT
New_NN
Drug_NN
Application_NOMZ
NDA_NN
submission_NN
._.
partners_NN
with_PIN
its_PIT
expertise_NN
in_PIN
drug_NN
development_NOMZ
,_,
its_PIT
knowledge_NN
of_PIN
regulatory_JJ
processes_NN
and_PHC
ADHD_NN
:_:
a_DT
core_NN
business_NOMZ
for_PIN
Shire_NN
Dr_NN
David_NN
Baron_NN
its_PIT
excellent_JJ
sales_NN
and_PHC
marketing_GER
capability_NOMZ
._.
ADDERALL_NN
XR_NN
mixed_JJ
amphetamine_NN
salts_NN
,_,
Professor_NN
and_PHC
Chair_NN
,_,
By_PIN
leveraging_VBG
these_DEMO
strengths_NN
and_CC
employing_VBG
Shires_NN
patented_VBD
novel_JJ
formulation_NOMZ
of_PIN
ADDERALL_NN
Department_NOMZ
of_PIN
Psychiatry_NN
,_,
our_FPP1
considerable_JJ
financial_JJ
resources_NN
we_FPP1
have_VPRT
that_DEMP
provides_VPRT
all-day_JJ
treatment_NOMZ
for_PIN
ADHD_NN
with_PIN
Temple_NN
University_NOMZ
School_NN
the_DT
ability_NOMZ
to_TO
take_VB
on_PIN
both_DT
new_JJ
projects_NN
or_CC
one_CD
daily_JJ
dose_NN
,_,
continues_VPRT
to_TO
build_VB
market_NN
share_NN
of_PIN
Medicine_NN
existing_VBG [WZPRES]
products_NN
and_CC
maximize_VB
their_TPP3
potential_JJ
,_,
since_OSUB
being_VBG [PASS]
launched_VBN
in_PIN
late_TIME
2001_CD
._.
In_PIN
July_NN
2004_CD
,_,
for_CONJ
example_NULL
in_PIN
new_JJ
indications_NOMZ
or_CC
populations_NOMZ
._.
it_PIT
became_VBD
the_DT
most_EMPH
prescribed_JJ
ADHD_NN
treatment_NOMZ
One_CD
example_NN
of_PIN
product_NN
optimization_NOMZ
in_PIN
CNS_NN
in_PIN
the_DT
United_NN
States_NN
with_PIN
a_DT
25_CD
%_NN
share_NN
of_PIN
the_DT
US_FPP1
is_VPRT
ADDERALL_NN
XR_NN
which_WDT [WHSUB]
was_VBD [PASS]
developed_VBN
as_IN
a_DT
prescription_NOMZ
ADHD_NN
market_NN
._.
Sales_NN
of_PIN
ADDERALL_NN
long-acting_JJ
version_NN
of_PIN
ADDERALL_NN
for_PIN
children_NN
,_,
XR_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
were_VBD [SPAU] [PASS]
then_RB
later_TIME
developed_VBD
for_PIN
the_DT
treatment_NOMZ
of_PIN
US_FPP1
$_$
606.7_CD
million_CD
compared_VBN
with_PIN
$_$
474.5_CD
million_CD
adults_NN
with_PIN
ADHD_NN
._.
Our_FPP1
business_NOMZ
strategy_NN
going_VBG [WZPRES]
forward_RB
is_VPRT [BEMA]
to_PIN
The_DT
size_NN
of_PIN
the_DT
US_FPP1
ADHD_NN
market_NN
increased_VBD
continue_VPRT
to_TO
optimize_VB
our_FPP1
current_JJ
portfolio_NN
by_PIN
17_CD
%_NN
in_PIN
2004_CD
and_CC
it_PIT
is_VPRT [PASS]
anticipated_VBN [PRIV]
to_TO
continue_VB
of_PIN
products_NN
and_CC
to_PIN
in-license_JJ
projects_NN
in_PIN
growing_VBG
as_IN
awareness_NOMZ
of_PIN
the_DT
condition_NOMZ
increases_VPRT
clinical_JJ
development_NOMZ
which_WDT [WHSUB]
have_VPRT
meaningful_JJ
in_PIN
pediatric_JJ
,_,
adolescent_JJ
and_PHC
adult_JJ
populations_NOMZ
._.
commercial_JJ
value_NN
to_PIN
Shire_NN
by_PIN
virtue_NN
of_PIN
their_TPP3
ADDERALL_NN
XR_NN
has_VPRT [PEAS]
developed_VBN
a_DT
strong_JJ
clinical_JJ
uniqueness_NOMZ
and_ANDC
hence_CONJ
their_TPP3
benefit_NN
reputation_NOMZ
among_PIN
doctors_NN
for_PIN
being_VBG [BEMA]
highly_AMP
for_PIN
patients_NN
,_,
strong_JJ
patent_NN
protection_NOMZ
and_CC
effective_JJ
._.
ADDERALL_NN
XR_NN
has_VPRT [PEAS]
been_VBN [PASS]
supported_VBN
significant_JJ
market_NN
opportunity_NOMZ
._.
by_PIN
a_DT
focused_JJ
marketing_GER
strategy_NN
,_,
implemented_VBN [PASTP]
by_PIN
our_FPP1
specialist_NN
sales_NN
force_NN
that_TSUB
calls_VPRT
on_PIN
key_JJ
A_DT
responsive_JJ
organization_NOMZ
psychiatrists_NN
,_,
pediatricians_NN
and_PHC
neurologists_NN
._.
Our_FPP1
new_JJ
organizational_JJ
structure_NN
based_VBN
Our_FPP1
sales_NN
force_NN
targets_VPRT
the_DT
highest_JJ
prescribing_VBG
around_PLACE
Strategic_NN
Therapeutic_NN
Area_NN
Teams_NN
specialists_NN
and_CC
is_VPRT [BYPA]
backed_VBN
by_PIN
a_DT
well-structured_JJ
and_CC
STATs_NN
,_,
supported_VBN [PASTP]
by_PIN
strong_JJ
functions_NOMZ
such_JJ
comprehensive_JJ
professional_JJ
education_NOMZ
program_NN
._.
as_IN
marketing_GER
,_,
business_NOMZ
development_NOMZ
and_PHC
R&D_NN
,_,
Educating_VBG [PRESP]
the_DT
medical_JJ
community_NOMZ
about_IN
ADHD_NN
will_PRMD
allow_VB [SUAV]
Shire_NN
to_TO [SPIN]
better_RB
manage_VB
our_FPP1
existing_VBG
and_CC
the_DT
various_JJ
treatments_NOMZ
available_JJ
is_VPRT [BEMA]
a_DT
critical_JJ
products_NN
and_CC
identify_VB
and_PHC
add_VB [PUBV]
innovative_JJ
new_JJ
success_NN
factor_NN
for_PIN
Shire_NN
in_PIN
this_DEMO
field_NN
._.
The_DT
STAT_NN
structure_NN
should_NEMD [SPAU]
also_RB
enable_VB
us_FPP1
to_TO
respond_VB
quickly_RB
and_CC
In_PIN
October_NN
2004_CD
,_,
the_DT
United_NN
States_NN
Food_NN
&_CC
Drug_NN
more_EMPH
effectively_RB
to_TO
changing_VBG
market_NN
dynamics_NN
._.
Administration_NOMZ
FDA_NN
granted_VBD [SUAV]
an_DT
additional_JJ
six_CD
Within_PIN
each_QUAN
of_PIN
the_DT
STATs_NN
we_FPP1
have_VPRT [PEAS]
dedicated_VBN
months_NN
US_FPP1
market_NN
exclusivity_NOMZ
to_PIN
ADDERALL_NN
XR_NN
,_,
cross-functional_JJ
global_JJ
teams_NN
organized_VBN [WZPAST]
by_PIN
until_IN
April_NN
11_CD
,_,
2005_CD
,_,
under_IN
the_DT
Hatch-Waxman_NN
product_NN
who_WP [WHSUB]
are_VPRT [BEMA]
responsible_PRED
and_PHC
accountable_PRED
regulations_NOMZ
._.
ADDERALL_NN
XR_NN
is_VPRT [SPAU] [BYPA]
also_RB
protected_VBN
by_PIN
10_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
11_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
CNS_NN
Shire_NN
intends_VPRT [SUAV]
to_TO
serve_VB
each_QUAN
of_PIN
the_DT
ADHD_NN
areas_NN
with_PIN
clinically_RB
beneficial_JJ
products_NN
ADDERALL_NN
XR_NN
patents_NN
that_TSUB
expire_VPRT
in_PIN
2018_CD
._.
As_IN
Shire_NN
has_VPRT
with_PIN
clinically_RB
beneficial_JJ
products_NN
._.
Accordingly_RB
,_,
mixed_JJ
amphetamine_NN
salts_NN
previously_TIME
announced_VBD [PUBV]
,_,
a_DT
number_NN
of_PIN
generic_JJ
drug_NN
we_FPP1
are_VPRT
developing_VBG
the_DT
following_VBG
drugs_NN
:_:
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
the_DT
treatment_NOMZ
manufacturers_NN
have_VPRT [PEAS]
filed_VBN
abbreviated_JJ
NDAs_NN
with_PIN
of_PIN
ADHD_NN
and_CC
is_VPRT [BEMA]
a_DT
once-daily_RB
the_DT
FDA_NN
,_,
seeking_VBG [PRESP]
to_PIN
market_NN
generic_JJ
versions_NN
SPD503_VPRT
a_DT
modified_VBN
release_NN
formulation_NOMZ
of_PIN
formulation_NOMZ
of_PIN
ADDERALL_NN
._.
Litigation_NOMZ
proceedings_GER
are_VPRT [BEMA]
in_PIN
guanfacine_NN
:_:
a_DT
non-scheduled_JJ
,_,
non-stimulant_JJ
It_PIT
offers_VPRT
convenience_NN
to_TO
progress_VB
against_PIN
some_QUAN
of_PIN
these_DEMO
manufacturers_NN
product_NN
._.
Thanks_NN
to_TO
progress_VB
in_PIN
development_NOMZ
patients_NN
and_PHC
caregivers_NN
,_,
and_ANDC
and_CC
are_VPRT [PASS]
described_VBN
in_PIN
more_EMPH
detail_NN
in_PIN
Note_NN
20_CD
during_PIN
2004_CD
,_,
Shire_NN
could_POMD
file_VB
an_DT
NDA_NN
for_PIN
the_DT
potential_NN
for_PIN
improved_VBN
in_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
Shire_NN
registration_NOMZ
in_PIN
the_DT
US_FPP1
for_PIN
SPD503_NN
in_PIN
2005_CD
,_,
patient_JJ
compliance_NN
remains_VPRT
committed_JJ
to_TO
protecting_VBG
its_PIT
patents_NN
._.
subject_JJ
to_PIN
agreement_NOMZ
with_PIN
the_DT
FDA_NN
._.
In_PIN
February_NN
2005_CD
,_,
Health_NN
Canada_NN
announced_VBD [PUBV]
the_DT
Methylphenidate_NN
transdermal_NN
system_NN
suspension_NN
of_PIN
sales_NN
of_PIN
ADDERALL_NN
XR_NN
in_PIN
Canada_NN
._.
MTS_NN
METHYPATCH_NN
:_:
a_DT
transdermal_JJ
delivery_NN
The_DT
FDA_NN
subsequently_TIME
issued_VBD
a_DT
statement_NOMZ
in_PIN
product_NN
for_PIN
the_DT
methylphenidate_NN
market_NN
:_:
which_WDT [SERE]
it_PIT
advised_VBD
that_DEMO
after_IN
consultation_NOMZ
with_PIN
the_DT
Shire_NN
is_VPRT [BEMA]
on_PIN
track_NN
to_TO
submit_VB [PUBV]
a_DT
response_NN
to_PIN
the_DT
Canadian_JJ
authorities_NOMZ
regarding_VBG [WZPRES]
the_DT
basis_NN
for_PIN
their_TPP3
April_NN
2003_CD
non-approvable_JJ
letter_NN
from_PIN
the_DT
action_NOMZ
,_,
it_PIT
did_VBD
not_XX0
feel_VB [PRIV]
that_THVC
any_QUAN
immediate_JJ
changes_NN
FDA_NN
,_,
including_VBG
new_JJ
clinical_JJ
data_NN
,_,
in_PIN
mid-2005_NN
._.
were_VBD [PASS]
warranted_VBN
in_PIN
the_DT
FDA_NN
labeling_VBG [WZPRES]
or_CC
approved_VBN
use_NN
of_PIN
ADDERALL_NN
XR_NN
,_,
based_VBN [PASTP]
on_PIN
its_PIT
preliminary_JJ
NRP104_NN
,_,
a_DT
prodrug_NN
of_PIN
amphetamine_NN
:_:
understanding_GER
of_PIN
Health_NN
Canadas_NN
analysis_NN
in_PIN
January_NN
2005_CD
,_,
Shire_NN
signed_VBD
a_DT
collaborative_NN
of_PIN
adverse_JJ
event_NN
reports_NN
and_CC
the_DT
FDAs_NN
own_JJ
agreement_NOMZ
with_PIN
New_NN
River_NN
Pharmaceuticals_NN
knowledge_NN
and_PHC
assessment_NOMZ
of_PIN
those_DEMO
reports_NN
._.
Inc._NN
._.
New_NN
River_NN
for_PIN
the_DT
global_JJ
commercialization_NOMZ
Although_CONC
Shire_NN
is_VPRT
complying_VBG
with_PIN
Health_NN
of_PIN
NRP104_NN
,_,
a_DT
product_NN
in_PIN
Phase_NN
3_CD
development_NOMZ
Canadas_NN
suspension_NN
request_NN
,_,
the_DT
Company_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
ADHD_NN
and_CC
other_JJ
potential_JJ
strongly_AMP
disagrees_VPRT
with_PIN
the_DT
conclusions_NN
drawn_VBN
indications_NOMZ
._.
Shire_NN
expects_VPRT [PRIV]
the_DT
NDA_NN
for_PIN
NRP104_NN
by_PIN
Health_NN
Canada_NN
,_,
and_ANDC
has_VPRT [PEAS]
lodged_VBN
an_DT
appeal_NN
to_TO
be_VB [PASS]
filed_VBN
for_PIN
US_FPP1
registration_NOMZ
in_PIN
late_TIME
2005_CD
and_CC
taken_VBN
other_JJ
actions_NOMZ
to_TO
preserve_VB
its_PIT
legal_JJ
to_PIN
early_TIME
2006_CD
._.
NRP104_CD
is_VPRT [BEMA]
a_DT
new_JJ
chemical_NN
rights_NN
and_PHC
obligations_NOMZ
._.
entity_NOMZ
an_DT
amphetamine_NN
prodrug_NN
where_RB
an_DT
amphetamine_NN
is_VPRT [PASS]
linked_VBN
to_PIN
a_DT
specific_JJ
amino_JJ
acid_NN
._.
The_DT
US_FPP1
ADHD_NN
market_NN
is_VPRT [BEMA]
segmented_PRED
into_PIN
three_CD
NRP104_NN
is_VPRT [PASS]
intended_VBN [SUAV]
to_TO
provide_VB
better_JJ
overdose_JJ
types_NN
of_PIN
treatments_NOMZ
amphetamine-based_JJ
protection_NOMZ
and_CC
a_DT
reduced_VBN
potential_NN
for_PIN
abuse_NN
products_NN
,_,
methylphenidate_NN
products_NN
,_,
and_ANDC
nonthan_JJ
currently_RB
marketed_VBN
amphetamine_NN
stimulant_NN
products_NN
._.
As_IN
we_FPP1
look_VPRT
to_PIN
the_DT
future_NN
,_,
Shire_NN
products_NN
,_,
while_OSUB
providing_VBG
effective_JJ
treatment_NOMZ
intends_VPRT [SUAV]
to_TO
serve_VB
each_QUAN
of_PIN
these_DEMO
therapeutic_JJ
needs_NN
of_PIN
ADHD_NN
symptoms_NN
when_RB
taken_VBN
as_IN
directed_VBN
._.
11_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
12_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
CNS_NN
Shire_NN
will_PRMD
continue_VB
to_TO
strengthen_VB
its_PIT
US_FPP1
ADHD_NN
franchise_NN
and_CC
explore_VB
ways_NN
to_TO
build_VB
a_DT
successful_JJ
European_JJ
ADHD_NN
franchise_NN
In_PIN
March_NN
2005_CD
,_,
New_NN
River_NN
published_VBD
the_DT
results_NN
proper_JJ
diagnosis_NN
and_PHC
treatment_NOMZ
can_POMD
usually_RB
of_PIN
a_DT
Phase_NN
2_CD
trial_NN
with_PIN
NRP104_NN
._.
A_DT
total_NN
of_PIN
52_CD
alter_VPRT
the_DT
course_NN
of_PIN
the_DT
illness_NOMZ
._.
Each_QUAN
year_NN
it_PIT
is_VPRT [PASS]
children_NN
aged_VBN
6-12_CD
with_PIN
ADHD_NN
were_VBD [PASS]
enrolled_VBN
in_PIN
estimated_VBN [PRIV]
that_THVC
more_EMPH
than_PIN
two_CD
million_CD
American_NN
a_DT
double-blind_JJ
,_,
placeboand_JJ
active-controlled_JJ
,_,
adults_NN
,_,
about_IN
1_CD
%_NN
of_PIN
the_DT
population_NOMZ
aged_VBN
18_CD
randomized_VBN
,_,
crossover_NN
study_NN
that_TSUB
compared_VBN
and_CC
older_JJ
,_,
are_VPRT [PASS]
afflicted_VBN
with_PIN
bipolar_JJ
disorder_NN
._.
NRP104s_NN
efficacy_NN
,_,
duration_NOMZ
and_PHC
incidence_NN
The_DT
market_NN
for_PIN
pharmaceuticals_NN
to_TO
treat_VB
bipolar_NN
of_PIN
adverse_JJ
events_NN
to_PIN
placebo_NN
._.
disorder_NN
in_PIN
the_DT
United_NN
States_NN
is_VPRT [SPAU] [PASS]
currently_RB
valued_VBN
at_HDG
about_NULL
$_$
1.9_CD
billion_CD
and_CC
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
grow_VB
The_DT
primary_JJ
efficacy_NN
endpoint_NN
in_PIN
this_DEMO
study_NN
was_VBD
to_TO
$_$
2.4_CD
billion_CD
by_PIN
2007_CD
._.
EQUETRO_NN
is_VPRT [BEMA]
an_DT
extendedthe_NN
SKAMP-Deportment_JJ
Swanson_NN
,_,
Kotkin_NN
,_,
release_NN
preparation_NOMZ
Agler_NN
,_,
M._NN
Flynn_NN
and_PHC
Pelham_NN
rating_NN
scale_NN
._.
In_PIN
the_DT
Shire_NN
intends_VPRT [SUAV]
to_TO
grow_VB
its_PIT
market_NN
share_NN
in_PIN
this_DEMO
of_PIN
carbamazepine_NN
which_WDT [WHOBJ]
study_NN
,_,
patients_NN
treated_VBD
with_PIN
NRP104_CD
showed_VBD [PRIV]
a_DT
high-potential_JJ
treatment_NOMZ
area_NN
._.
The_DT
FDA_NN
approved_VBD
is_VPRT [BEMA]
better_RB
tolerated_PRED
than_PIN
statistically_RB
significant_JJ
improvement_NOMZ
on_PIN
primary_JJ
EQUETRO_NN
carbamazepine_NN
extended-release_NN
immediate_JJ
release_NN
forms_NN
._.
endpoint_NN
compared_VBN [WZPAST]
to_PIN
placebo_NN
across_PLACE
all_QUAN
three_CD
capsules_NN
,_,
previously_TIME
known_VBN [PRIV]
as_IN
SPD417_NN
I_FPP1
expect_VPRT [PRIV]
EQUETRO_NN
to_PIN
doses_NN
p_VPRT
values_NN
0.0001_CD
._.
and_ANDC
Bipotrol_NN
,_,
for_PIN
the_DT
treatment_NOMZ
of_PIN
acute_JJ
manic_JJ
be_VB [BEMA]
a_DT
significant_JJ
advance_NN
and_CC
mixed_JJ
episodes_NN
associated_VBN [WZPAST]
with_PIN
bipolar_NN
1_CD
in_PIN
the_DT
pharmacotherapy_JJ
The_DT
significant_JJ
therapeutic_JJ
effects_NN
of_PIN
NRP104_NN
disorder_NN
,_,
in_PIN
December_NN
2004_CD
._.
The_DT
US_FPP1
marketing_GER
of_PIN
bipolar_NN
disorder_NN
._.
continued_VBN [PASTP]
throughout_PIN
the_DT
last_JJ
assessment_NOMZ
approval_NN
from_PIN
the_DT
FDA_NN
came_VBD
just_EMPH
ten_CD
months_NN
time_NN
point_NN
i._FW
e._FW
12_CD
hours_NN
post-morning_JJ
dose_NN
,_,
after_IN
submission_NN
,_,
which_WDT [SERE]
represents_VPRT
a_DT
significant_JJ
Wade_NN
Berrettini_NN
MD_NN
,_,
PhD_NN
compared_VBD
to_PIN
placebo_NN
,_,
suggesting_VBG [SUAV] [PUBV] [PRESP]
a_DT
12-hour_JJ
achievement_NOMZ
._.
In_CONJ
addition_NULL
,_,
the_DT
unique_JJ
three-bead_JJ
Karl_NN
E_NN
Rickels_NN
duration_NOMZ
of_PIN
drug_NN
action_NOMZ
._.
extended-release_NN
delivery_NN
system_NN
of_PIN
EQUETRO_NN
Professor_NN
of_PIN
Psychiatry_NN
provides_VPRT
for_PIN
convenient_JJ
twice-daily_JJ
administration_NOMZ
._.
University_NOMZ
of_PIN
Pennsylvania_NN
NRP104_NN
was_VBD
generally_RB
well_RB
tolerated_JJ
,_,
with_PIN
School_NN
of_PIN
Medicine_NN
adverse_JJ
events_NN
of_PIN
a_DT
nature_NN
consistent_JJ
with_PIN
EQUETRO_NN
has_VPRT
patents_NN
around_PLACE
its_PIT
formulation_NOMZ
,_,
Director_NN
,_,
Center_NN
for_PIN
those_DEMO
in_PIN
the_DT
approved_VBN
labeling_VBG
for_PIN
ADDERALL_NN
and_CC
will_PRMD
have_VB
at_PIN
least_JJ
three_CD
years_NN
of_PIN
market_NN
Neurobiology_NN
and_PHC
Behavior_NN
XR_NN
and_CC
other_JJ
stimulant_NN
therapies_NN
._.
exclusivity_NOMZ
under_IN
the_DT
US_FPP1
Hatch-Waxman_NN
Act_NN
._.
It_PIT
will_PRMD
be_VB [BEMA]
available_PRED
for_PIN
prescribing_VBG
in_PIN
the_DT
US_FPP1
SPD465_NN
:_:
a_DT
long-acting_JJ
amphetamine_JJ
product_NN
._.
Shire_NN
has_VPRT
Shire_NN
is_VPRT
developing_VBG
a_DT
longer-acting_JJ
amphetamine_NN
obtained_VBD
a_DT
dedicated_JJ
sales_NN
force_NN
to_TO
promote_VB
product_NN
for_PIN
patients_NN
such_JJ
as_IN
adults_NN
who_WP [WHSUB]
need_VPRT
EQUETRO_NN
in_PIN
the_DT
US_FPP1
._.
therapeutic_JJ
coverage_NN
throughout_PIN
a_DT
long_JJ
day_NN
._.
Epilepsy_NN
:_:
an_DT
existing_VBG
business_NOMZ
for_PIN
Shire_NN
with_PIN
CARBATROL_NN
Shire_NN
will_PRMD
continue_VB
to_TO
build_VB
and_PHC
strengthen_VB
Epilepsy_NN
is_VPRT [BEMA]
one_CD
of_PIN
the_DT
most_EMPH
common_JJ
chronic_NN
its_PIT
position_NOMZ
as_IN
the_DT
leading_VBG
ADHD_NN
specialty_NN
neurological_JJ
disorders_NN
,_,
affecting_VBG [PRESP]
approximately_RB
pharmaceutical_JJ
company_NN
in_PIN
the_DT
US_FPP1
by_PIN
optimizing_VBG
2.5_CD
million_CD
people_NN
in_PIN
the_DT
US_FPP1
alone_RB
._.
CARBATROL_NN
,_,
its_PIT
existing_VBG
portfolio_NN
and_CC
adding_VBG [PUBV]
to_PIN
its_PIT
pipeline_NN
._.
Shires_NN
extended-release_NN
formulation_NOMZ
of_PIN
We_FPP1
will_PRMD [SPAU]
also_RB
be_VB
working_VBG
to_TO
explore_VB
ways_NN
to_TO
build_VB
carbamazepine_NN
,_,
uses_VPRT
the_DT
patented_JJ
MICROTROL_NN
a_DT
successful_JJ
ADHD_NN
franchise_NN
in_PIN
Europe_NN
,_,
where_RB
delivery_NN
system_NN
technology_NN
._.
This_DEMO
twice-daily_JJ
the_DT
market_NN
is_VPRT
evolving_VBG
._.
A_DT
number_NN
of_PIN
our_FPP1
projects_NN
extended-release_VPRT
formulation_NOMZ
is_VPRT [BEMA]
more_EMPH
patientin_JJ
development_NOMZ
have_VPRT
the_DT
potential_NN
to_TO
serve_VB
the_DT
friendly_JJ
than_PIN
immediate-release_JJ
formulations_NOMZ
on_PIN
emerging_VBG
European_JJ
ADHD_NN
market_NN
._.
the_DT
market_NN
,_,
which_WDT [SERE]
require_VPRT [SUAV]
three_CD
to_PIN
four_CD
doses_NN
a_DT
day_NN
._.
CARBATROL_NN
can_POMD [SPAU]
also_RB
be_VB [PASS]
sprinkled_VBN
on_PIN
food_NN
._.
Bipolar_NN
disorder_NN
:_:
a_DT
new_JJ
CNS_NN
disease_NN
area_NN
In_PIN
2004_CD
,_,
US_FPP1
prescription_NOMZ
growth_NN
of_PIN
11_CD
%_NN
was_VBD [BEMA]
for_PIN
Shire_NN
with_PIN
EQUETRO_NN
achieved_VBD
and_CC
CARBATROL_NN
had_VBD
a_DT
46_CD
%_NN
share_NN
Bipolar_NN
disorder_NN
is_VPRT [BEMA]
a_DT
leading_VBG
neuropsychiatric_NN
of_PIN
the_DT
total_JJ
US_FPP1
extended-release_NN
carbamazepine_NN
disorder_NN
according_VBG [WZPRES]
to_PIN
the_DT
World_NN
Health_NN
prescription_NOMZ
market_NN
._.
Litigation_NOMZ
relating_VBG [WZPRES]
to_PIN
an_DT
Organization_NOMZ
WHO_WP [WHOBJ]
._.
Also_RB
known_VBN [PRIV]
as_IN
manic_JJ
application_NOMZ
by_PIN
a_DT
generic_JJ
drug_NN
manufacturer_NN
depression_NN
,_,
it_PIT
is_VPRT [BYPA]
characterized_VBN
by_PIN
episodes_NN
of_PIN
to_TO
market_VB
a_DT
generic_JJ
version_NN
of_PIN
CARBATROL_NN
is_VPRT
mania_NN
and_PHC
depression_NN
with_PIN
periods_NN
of_PIN
normal_JJ
in_PIN
progress_NN
._.
More_EMPH
detail_NN
is_VPRT [PASS]
provided_VBN
in_PIN
Note_NN
20_CD
mood_NN
in_PIN
between_PIN [STPR]
._.
The_DT
disorder_NN
can_POMD
have_VB
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
devastating_VBG
effects_NN
on_PIN
an_DT
individuals_NN
life_NN
but_CC
12_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
13_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
CNS_NN
Each_QUAN
year_NN
it_PIT
is_VPRT [PASS]
estimated_VBN [PRIV]
that_THVC
more_EMPH
than_PIN
two_CD
million_CD
American_JJ
adults_NN
are_VPRT [PASS]
afflicted_VBN
with_PIN
bipolar_JJ
disorder_NN
EQUETRO_NN
carbamazepine_NN
Alzheimers_NN
disease_NN
:_:
the_DT
first_JJ
During_PIN
2004_CD
5_CD
the_DT
National_NN
Institute_NN
for_PIN
Clinical_NN
extended-release_NN
capsules_NN
CNS_NN
success_NN
for_PIN
Shire_NN
with_PIN
REMINYL_NN
Excellence_NN
NICE_NN
has_VPRT [PEAS]
been_VBN
reviewing_VBG
its_PIT
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
the_DT
treatment_NOMZ
Alzheimers_NN
disease_NN
,_,
one_CD
of_PIN
the_DT
most_EMPH
common_JJ
guidance_NN
for_PIN
the_DT
drug_NN
treatment_NOMZ
of_PIN
Alzheimers_NN
of_PIN
acute_JJ
manic_NN
and_CC
mixed_JJ
forms_NN
of_PIN
dementia_NN
,_,
affects_VPRT
approximately_RB
disease_NN
,_,
which_WDT [SERE]
includes_VPRT
the_DT
three_CD
acetylepisodes_NN
associated_VBN [WZPAST]
with_PIN
18_CD
million_CD
people_NN
worldwide_JJ
,_,
mainly_RB
those_DEMO
cholinesterase_JJ
inhibitors_NN
donepezil_NN
,_,
rivastigmine_JJ
bipolar_NN
1_CD
disorder_NN
._.
It_PIT
is_VPRT [BEMA]
a_DT
progressive_JJ
disorder_NN
and_PHC
galantamine_NN
._.
drug_NN
delivery_NN
technology_NN
that_TSUB
gradually_RB
robs_VPRT
individuals_NN
of_PIN
their_TPP3
ability_NOMZ
to_TO
enables_VPRT
the_DT
convenience_NN
remember_VPRT [PRIV]
,_,
learn_VPRT [PRIV]
new_JJ
information_NOMZ
and_CC
perform_VB
NICE_NN
published_VBD
a_DT
preliminary_JJ
Appraisal_NN
of_PIN
twice-daily_JJ
dosing_NN
basic_JJ
activities_NOMZ
of_PIN
daily_JJ
living_NN
._.
This_DEMO
document_NOMZ
states_VPRT [PUBV]
that_THVC
donepezil_NN
,_,
rivastigmine_JJ
REMINYL_NN
slows_VPRT
the_DT
progression_NN
of_PIN
the_DT
symptoms_NN
and_PHC
galantamine_NN
are_VPRT [PASS]
not_XX0
recommended_VBN [SUAV]
for_PIN
of_PIN
Alzheimers_NN
disease_NN
for_PIN
up_RB
to_PIN
four_CD
years_NN
._.
use_NN
in_PIN
the_DT
treatment_NOMZ
of_PIN
mild_JJ
to_PIN
moderate_JJ
REMINYL_NN
is_VPRT [BEMA]
an_DT
acetylcholinesterase_NN
inhibitor_NN
with_PIN
Alzheimers_NN
disease_NN
by_PIN
the_DT
National_NN
Health_NN
an_DT
additional_JJ
nicotinic_JJ
mode_NN
of_PIN
action_NOMZ
._.
It_PIT
is_VPRT [BEMA]
one_CD
Service_NN
in_PIN
England_NN
and_PHC
Wales_NN
for_PIN
new_JJ
patients_NN
,_,
of_PIN
the_DT
fastest-growing_JJ
products_NN
for_PIN
treating_VBG
mild_JJ
due_JJ
to_PIN
NICEs_NN
economic_JJ
assessment_NOMZ
._.
to_TO
moderately_RB
severe_JJ
dementia_NN
of_PIN
the_DT
Alzheimer_NN
Pharmaceutical_NN
manufacturers_NN
,_,
physicians_NN
,_,
type_NN
._.
Developed_VBN [PASTP]
by_PIN
Johnson_NN
&_CC
Johnson_NN
patients_NN
and_PHC
parliamentarians_NN
have_VPRT
already_RB
Pharmaceutical_NN
Research_NN
and_PHC
Development_NOMZ
voiced_VBD
their_TPP3
objection_NOMZ
to_PIN
this_DEMO
proposal_NN
._.
It_PIT
is_VPRT
under_IN
a_DT
co-development_NOMZ
and_PHC
licensing_GER
agreement_NOMZ
expected_VBD [PRIV]
that_THVC
NICEs_NN
final_JJ
recommendation_NOMZ
with_PIN
Shire_NN
,_,
it_PIT
is_VPRT [PASS]
licensed_VBN
for_PIN
use_NN
in_PIN
69_CD
countries_NN
._.
will_PRMD
be_VB [BYPA]
published_VBN
by_PIN
June_NN
1_CD
,_,
2005_CD
._.
With_PIN
the_DT
exception_NOMZ
of_PIN
the_DT
UK_NN
and_CC
the_DT
Republic_NN
of_PIN
Ireland_NN
,_,
REMINYL_NN
is_VPRT [BYPA]
marketed_VBN
by_PIN
Janssen-Cilag_NN
worldwide_NN
._.
Janssen-Cilag_NN
pays_VPRT
Shire_NN
a_DT
royalty_NN
on_PIN
its_PIT
net_JJ
sales_NN
of_PIN
REMINYL_NN
._.
Shire_NN
and_PHC
JanssenCilag_NN
co-promoted_VBD
REMINYL_NN
in_PIN
the_DT
UK_NN
and_PHC
Republic_NN
of_PIN
Ireland_NN
until_IN
May_POMD
2004_CD
,_,
when_RB
full_JJ
marketing_GER
and_PHC
promotion_NOMZ
rights_NN
in_PIN
these_DEMO
countries_NN
was_VBD [BYPA]
acquired_VBN
by_PIN
Shire_NN
._.
Shire_NN
is_VPRT
seeking_VBG
to_TO
expand_VB
its_PIT
REMINYL_NN
franchise_NN
,_,
including_VBG [PRESP]
the_DT
introduction_NOMZ
of_PIN
a_DT
once-a-day_JJ
formulation_NOMZ
,_,
during_PIN
the_DT
first_JJ
half_NN
of_PIN
2005_CD
._.
13_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
14_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
General_NN
products_NN
&_CC
royalty_NN
revenues_NN
General_JJ
products_NN
royalty_NN
&_CC
revenues_NN
David_NN
Milton_NN
Senior_NN
Vice_NN
President_NN
and_PHC
General_NN
Products_NN
Strategic_NN
Therapeutic_NN
Area_NN
Leader_NN
14_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
15_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
General_NN
products_NN
&_CC
royalty_NN
revenues_NN
I_FPP1
found_VBD [PRIV]
FOSRENOL_NN
a_DT
much_QUAN
more_EMPH
convenient_JJ
product_NN
to_TO
take_VB
compared_VBN
to_PIN
my_FPP1
previous_JJ
treatments_NOMZ
,_,
not_XX0
only_DWNT
because_CAUS
I_FPP1
had_VBD
to_TO
take_VB
fewer_JJ
tablets_NN
but_CC
also_RB
because_CAUS
FOSRENOL_NN
was_VBD
far_PLACE
more_EMPH
palatable_JJ
._.
These_DEMO
benefits_NN
helped_VBD
me_FPP1
to_TO
deal_VB
with_PIN
my_FPP1
illness_NOMZ
more_EMPH
easily_RB
until_IN
I_FPP1
received_VBD
a_DT
successful_JJ
kidney_NN
transplant_NN
._.
Simon_NN
Jenkins_NN
FOSRENOL_NN
patient_JJ
FOSRENOL_NN
lanthanum_NN
carbonate_NN
is_VPRT [PASS]
indicated_VBN [PRIV]
to_TO
reduce_VB
serum_NN
phosphate_NN
in_PIN
patients_NN
with_PIN
end-stage_JJ
renal_JJ
disease_NN
._.
Approved_VBN [PASTP]
in_PIN
2004_CD
,_,
FOSRENOL_NN
will_PRMD
s_PRP
become_VB
one_CD
of_PIN
the_DT
first_JJ
global_JJ
products_NN
for_PIN
Shire_NN
15_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
16_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
General_NN
products_NN
&_CC
royalty_NN
revenues_NN
FOSRENOL_NN
is_VPRT
strategically_RB
very_AMP
important_JJ
to_PIN
our_FPP1
business_NOMZ
and_CC
nearly_DWNT
2,000_CD
patients_NN
have_VPRT [PEAS]
taken_VBN
the_DT
drug_NN
so_RB
far_PLACE
Shire_NN
aims_VPRT
to_TO
deliver_VB
superior_JJ
results_NN
by_PIN
FOSRENOL_NN
is_VPRT [BEMA]
the_DT
first_JJ
Shire_NN
compound_NN
taken_VBN
developing_VBG
and_PHC
marketing_VBG
products_NN
that_TSUB
meet_VPRT
from_PIN
the_DT
laboratory_NN
bench_NN
to_PIN
approval_NN
and_CC
the_DT
needs_NN
of_PIN
specialist_NN
physicians_NN
and_CC
their_TPP3
commercialization_NOMZ
and_CC
it_PIT
is_VPRT
strategically_RB
very_AMP
patients_NN
._.
It_PIT
does_VPRT
so_RB
by_PIN
leveraging_VBG
its_PIT
extensive_JJ
important_JJ
for_PIN
our_FPP1
business_NOMZ
._.
The_DT
drug_NN
has_VPRT [PEAS]
been_VBN
expertise_NN
in_PIN
R&D_NN
and_CC
regulatory_JJ
affairs_NN
,_,
as_RB
well_RB
as_IN
studied_VBN
more_EMPH
extensively_RB
than_PIN
any_QUAN
other_JJ
its_PIT
dedicated_JJ
sales_NN
forces_NN
strategically_RB
located_VBN
in_PIN
phosphate-binder_NN
prior_RB
to_PIN
launch_NN
and_CC
up_RB
to_PIN
five_CD
North_NN
America_NN
and_PHC
Europe_NN
._.
Our_FPP1
diverse_JJ
portfolio_NN
years_NN
of_PIN
pharmacological_JJ
data_NN
has_VPRT [SPAU] [PEAS]
already_RB
been_VBN
includes_VPRT
specialist_NN
products_NN
and_PHC
projects_NN
that_TSUB
collected_VBD
._.
Nearly_DWNT
2,000_CD
patients_NN
have_VPRT [PEAS]
taken_VBN
the_DT
fit_NN
well_RB
into_PIN
this_DEMO
strategic_JJ
model_NN
and_CC
to_PIN
which_WDT [PIRE]
we_FPP1
drug_NN
so_RB
far_PLACE
._.
Hyperphosphatemia_NN
is_VPRT
believe_VB [PRIV] [THATD]
we_FPP1
can_POMD
add_VB [PUBV]
considerable_JJ
value_NN
._.
a_DT
very_AMP
serious_JJ
condition_NOMZ
Starting_VBG [WZPRES]
in_PIN
the_DT
first_JJ
quarter_NN
of_PIN
2005_CD
,_,
FOSRENOL_NN
for_PIN
ESRD_NN
patients_NN
._.
Effective_JJ
During_PIN
2004_CD
,_,
we_FPP1
focused_VBD
on_PIN
the_DT
impending_JJ
market_NN
is_VPRT [BEMA]
available_PRED
in_PIN
the_DT
US_FPP1
in_PIN
250mg_CD
and_CC
500mg_CD
reduction_NOMZ
of_PIN
phosphate_NN
launches_NN
of_PIN
two_CD
key_JJ
products_NN
in_PIN
our_FPP1
General_NN
strengths_NN
._.
It_PIT
is_VPRT [PASS]
formulated_VBN
as_IN
a_DT
chewable_JJ
tablet_NN
levels_NN
in_PIN
patients_NN
with_PIN
Products_NN
portfolio_NN
FOSRENOL_NN
for_PIN
the_DT
treatment_NOMZ
that_TSUB
does_VPRT
not_XX0
need_VB
water_NN
to_TO
be_VB [PASS]
swallowed_VBN
,_,
kidney_NN
disease_NN
could_POMD
make_VB
of_PIN
hyperphosphatemia_NN
in_PIN
end-stage_JJ
renal_JJ
disease_NN
an_DT
important_JJ
benefit_NN
for_PIN
ESRD_NN
patients_NN
who_WP [WHOBJ]
a_DT
real_JJ
impact_NN
on_PIN
their_TPP3
lives_NN
._.
ESRD_NN
and_PHC
XAGRID_NN
in_PIN
essential_JJ
thrombocythemia_NN
have_VPRT
to_TO
restrict_VB
fluid_JJ
intake_NN
._.
The_DT
launch_NN
in_PIN
the_DT
US_FPP1
In_PIN
my_FPP1
opinion_NN
,_,
existing_VBG
ET_NN
which_WDT [WHSUB]
are_VPRT [PASS]
poised_VBN
to_TO
become_VB
our_FPP1
first_JJ
truly_RB
has_VPRT [SPAU] [PEAS]
already_RB
showed_VBN [PRIV]
promising_JJ
signs_NN
of_PIN
success_NN
._.
therapies_NN
have_VPRT
numerous_JJ
global_JJ
products_NN
._.
The_DT
new_JJ
General_NN
Products_NN
According_VBG [WZPRES]
to_PIN
IMS_NN
data_NN
,_,
FOSRENOL_NN
captured_VBD
shortcomings_GER
from_PIN
longStrategic_NN
Therapeutic_NN
Area_NN
Team_NN
STAT_NN
is_VPRT
allowing_VBG [SUAV]
a_DT
share_NN
of_PIN
13.8_CD
%_NN
of_PIN
the_DT
new_JJ
prescriptions_NOMZ
written_VBN [PUBV]
term_NN
safety_NN
issues_NN
to_PIN
high_JJ
us_FPP1
to_TO
harness_VB
Shires_NN
resources_NN
in_PIN
the_DT
most_EMPH
for_PIN
phosphate_NN
binders_NN
in_PIN
ESRD_NN
patients_NN
in_PIN
the_DT
pill_NN
burdens_NN
and_CC
poor_JJ
effective_JJ
way_NN
,_,
by_PIN
having_VBG
global_JJ
,_,
cross-functional_JJ
US_FPP1
market_NN
by_PIN
April_NN
1_CD
,_,
2005_CD
,_,
only_DWNT
four_CD
months_NN
intestinal_JJ
tolerability_NOMZ
._.
I_FPP1
believe_VPRT [PRIV]
leadership_NN
responsible_JJ
and_PHC
accountable_JJ
for_PIN
after_IN
launch_NN
._.
FOSRENOL_NN
moves_VPRT [SUAV]
us_FPP1
closer_JJ
drug_NN
development_NOMZ
through_PIN
to_PIN
commercialization_NOMZ
._.
to_PIN
the_DT
ideal_JJ
phosphate_NN
binder_NN
,_,
It_PIT
will_PRMD
ensure_VB [SUAV] [PRIV]
successful_JJ
campaigns_NN
on_PIN
both_DT
FOSRENOL_NN
is_VPRT
reaching_VBG
the_DT
market_NN
as_IN
rates_NN
since_OSUB
it_PIT
can_POMD
be_VB [PASS]
integrated_VBN
sides_NN
of_PIN
the_DT
Atlantic_NN
for_PIN
these_DEMO
exciting_JJ
of_PIN
ESRD_NN
in_PIN
the_DT
US_FPP1
and_PHC
Europe_NN
are_VPRT [PASS]
forecast_VBN [PUBV]
to_TO
easily_RB
into_PIN
patients_NN
day_NN
to_PIN
new_JJ
products_NN
and_PHC
others_NN
to_TO
follow_VB
in_PIN
future_NN
._.
soar_VB
,_,
largely_RB
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
growing_VBG
worldwide_JJ
day_NN
schedules_NN
and_CC
has_VPRT
a_DT
incidence_NN
of_PIN
diabetes_NN
one_CD
of_PIN
the_DT
leading_VBG
proven_JJ
efficacy_NN
and_PHC
safety_NN
Renal_NN
:_:
FOSRENOL_NN
set_VBD
for_PIN
launch_NN
causes_NN
of_PIN
renal_JJ
disease_NN
._.
The_DT
WHO_WP
estimates_VPRT [PRIV]
profile_NN
from_PIN
a_DT
number_NN
of_PIN
After_IN
nine_CD
years_NN
of_PIN
R&D_NN
,_,
clinical_JJ
studies_NN
and_CC
the_DT
incidence_NN
of_PIN
diabetes_NN
worldwide_NN
will_PRMD
rise_VB
from_PIN
well-designed_JJ
clinical_JJ
trials_NN
._.
regulatory_JJ
reviews_NN
,_,
Shire_NN
has_VPRT [SPAU] [PEAS]
already_RB
started_VBN
171_CD
million_CD
affected_JJ
people_NN
in_PIN
2000_CD
to_PIN
about_IN
launching_VBG
FOSRENOL_NN
lanthanum_NN
carbonate_NN
366_CD
million_CD
by_PIN
2030_CD
._.
FOSRENOL_NN
is_VPRT [BEMA]
a_DT
new_JJ
phosphate-binder_NN
Consultant_NN
Nephrologist_NN
and_CC
that_DEMP
reduces_VPRT
elevated_JJ
blood_NN
levels_NN
of_PIN
phosphate_NN
Approximately_RB
70_CD
%_NN
of_PIN
ESRD_NN
patients_NN
undergoing_VBG [WZPRES]
Clinical_JJ
Director_NN
of_PIN
the_DT
Renal_NN
in_PIN
patients_NN
with_PIN
ESRD_NN
._.
regular_JJ
dialysis_NN
suffer_VPRT
from_PIN
hyperphosphatemia_NN
Unit_NN
at_PIN
The_DT
Royal_NN
Infirmary_NN
,_,
elevated_VBD
concentrations_NOMZ
of_PIN
phosphate_NN
in_PIN
the_DT
Manchester_NN
,_,
UK_NN
The_NN
FDA_NN
approved_VBD
FOSRENOL_NN
in_PIN
October_NN
2004_CD
,_,
plasma_NN
._.
Changes_NN
in_PIN
mineral_NN
metabolism_NN
and_CC
the_DT
seven_CD
months_NN
after_IN
Shire_NN
received_VBD
approval_NN
for_PIN
use_NN
of_PIN
calcium_NN
containing_VBG [WZPRES]
phosphate-binders_NN
the_DT
drug_NN
from_PIN
the_DT
Swedish_JJ
regulatory_JJ
authorities_NOMZ
._.
have_VPRT [PEAS]
been_VBN [PASS]
associated_VBN
with_PIN
the_DT
deposition_NOMZ
of_PIN
Following_VBG
FDA_NN
approval_NN
,_,
Shire_NN
immediately_TIME
calcium_NN
and_PHC
phosphates_NN
._.
started_VBD
promoting_VBG
FOSRENOL_NN
at_PIN
the_DT
American_NN
Society_NN
of_PIN
Nephrology_NN
annual_JJ
conference_NN
in_PIN
St._NN
Calcification_NOMZ
of_PIN
the_DT
heart_NN
,_,
heart_NN
valves_NN
Louis_NN
,_,
Missouri_NN
,_,
where_RB
it_PIT
received_VBD
considerable_JJ
and_PHC
coronary_JJ
arteries_NN
is_VPRT [BEMA]
frequently_RB
observed_JJ
attention_NOMZ
._.
With_PIN
FDA_NN
approval_NN
,_,
we_FPP1
are_VPRT
escalating_VBG
in_PIN
patients_NN
with_PIN
ESRD_NN
._.
Hyperphosphatemia_NN
our_FPP1
efforts_NN
to_TO
ensure_VB [SUAV] [PRIV]
a_DT
successful_JJ
US_FPP1
launch_NN
and_CC
is_VPRT [PASS]
associated_VBN
with_PIN
significant_JJ
clinical_JJ
problems_NN
,_,
to_TO
realize_VB [PRIV]
the_DT
full_JJ
value_NN
of_PIN
this_DEMO
product_NN
through_PIN
including_VBG
the_DT
development_NOMZ
of_PIN
cardiovascular_JJ
the_DT
establishment_NOMZ
of_PIN
specialized_VBN
sales_NN
teams_NN
disease_NN
,_,
which_WDT [SERE]
accounts_VPRT
for_PIN
nearly_DWNT
50_CD
%_NN
of_PIN
all_QUAN
in_PIN
the_DT
US_FPP1
,_,
backed_VBN [PASTP]
by_PIN
comprehensive_JJ
educational_JJ
deaths_NN
in_PIN
ESRD_NN
patients_NN
._.
Patients_NN
with_PIN
and_CC
promotional_JJ
campaigns_NN
._.
Regulatory_NN
hyperphosphatemia_NN
have_VPRT
a_DT
52_CD
%_NN
higher_JJ
relative_JJ
approvals_NN
in_PIN
a_DT
number_NN
of_PIN
other_JJ
EU_NN
member_NN
risk_NN
of_PIN
dying_VBG
from_PIN
coronary_JJ
artery_NN
disease_NN
,_,
states_NN
have_VPRT [PEAS]
been_VBN [PASS]
sought_VBN
pursuant_JJ
to_PIN
the_DT
mutual_JJ
a_DT
34_CD
%_NN
higher_JJ
relative_JJ
risk_NN
of_PIN
dying_VBG
from_PIN
other_JJ
recognition_NOMZ
process_NN
._.
Following_VBG [PRESP]
the_DT
conclusion_NN
cardiac_JJ
diseases_NN
and_CC
a_DT
26_CD
%_NN
higher_JJ
relative_JJ
risk_NN
of_PIN
pricing_GER
and_PHC
reimbursement_NOMZ
discussions_NN
with_PIN
of_PIN
sudden_JJ
death_NN
._.
individual_JJ
countries_NN
,_,
the_DT
launch_NN
of_PIN
FOSRENOL_NN
will_PRMD
begin_VB
in_PIN
European_JJ
territories_NN
during_PIN
2005_CD
._.
16_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
17_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
General_NN
products_NN
&_CC
royalty_NN
revenues_NN
In_PIN
the_DT
past_JJ
eight_CD
years_NN
in_PIN
the_DT
US_FPP1
,_,
AGRYLIN_NN
has_VPRT [PEAS]
developed_VBN
a_DT
proven_JJ
track_NN
record_NN
for_PIN
lowering_VBG
the_DT
platelet_NN
count_NN
in_PIN
patients_NN
suffering_VBG [WZPRES]
from_PIN
myeloproliferative_JJ
disorders_NN
AGRYLIN_NN
lets_VPRT
me_FPP1
get_VB
on_PIN
with_PIN
my_FPP1
life_NN
._.
Teresa_NN
Adcock_NN
AGRYLIN_NN
patient_JJ
AGRYLIN_NN
anagrelide_NN
Hyperphosphatemia_NN
also_RB
causes_VPRT
persistent_JJ
at_PIN
the_DT
beginning_GER
of_PIN
2005_CD
._.
XAGRID_NN
is_VPRT
also_RB
hydrochloride_NN
is_VPRT [PASS]
indicated_VBN [PRIV]
and_CC
severe_JJ
hyperparathyroidism_NN
hormone_NN
marketed_VBN [WZPAST]
in_PIN
the_DT
US_FPP1
under_IN
the_DT
trade_NN
name_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
imbalance_NN
that_DEMO
in_PIN
turn_NN
causes_NN
changes_NN
in_PIN
mineral_NN
AGRYLIN_NN
anagrelide_NN
hydrochloride_NN
,_,
and_ANDC
thrombocythemia_NN
,_,
secondary_JJ
balance_NN
associated_VBN [WZPAST]
with_PIN
bone_NN
disease_NN
renal_JJ
therefore_CONJ
the_DT
product_NN
is_VPRT [BEMA]
the_DT
second_JJ
truly_RB
global_JJ
to_PIN
a_DT
myeloproliferative_JJ
osteodystrophy_NN
._.
Bone_NN
disease_NN
is_VPRT [BEMA]
common_PRED
in_PIN
product_NN
for_PIN
Shire_NN
._.
Shire_NN
sales_NN
teams_NN
are_VPRT [BEMA]
in_PIN
place_NN
disorder_NN
._.
Research_NN
indicates_VPRT [PRIV]
patients_NN
with_PIN
chronic_JJ
ESRD_NN
and_CC
is_VPRT [PASS]
associated_VBN
or_CC
being_VBG [PASS]
established_VBN [PRIV]
to_TO
commercialize_VB
the_DT
that_DEMO
a_DT
key_JJ
benefit_NN
of_PIN
AGRYLIN_NN
with_PIN
bone_NN
pain_NN
,_,
skeletal_JJ
deformity_NOMZ
,_,
bone_NN
product_NN
,_,
backed_VBN [PASTP]
by_PIN
comprehensive_JJ
educational_JJ
is_VPRT [BEMA]
its_PIT
platelet_NN
selectivity_NOMZ
,_,
weakness_NOMZ
and_PHC
fractures_NN
._.
targeting_VBG [PRESP]
only_DWNT
those_DEMO
cells_NN
that_TSUB
develop_VPRT
into_PIN
platelets_NN
FOSRENOL_NN
has_VPRT [PEAS]
been_VBN [PASS]
shown_VBN [PRIV]
in_PIN
numerous_JJ
XAGRID_NN
has_VPRT [PEAS]
been_VBN [PASS]
designated_VBN
an_DT
orphan_JJ
clinical_JJ
studies_NN
to_TO
offer_VB
a_DT
promising_JJ
option_NOMZ
for_PIN
medicinal_JJ
product_NN
,_,
providing_VBG [PRESP]
it_PIT
with_PIN
up_RB
to_TO
ten_VB
hyperphosphatemia_NN
management_NOMZ
compared_VBN [WZPAST]
with_PIN
years_NN
market_NN
exclusivity_NOMZ
in_PIN
Europe_NN
._.
These_DEMO
studies_NN
estimates_VPRT [PRIV]
that_THVC
over_IN
40,000_CD
patients_NN
suffer_VPRT
confirm_VPRT [PUBV]
that_THVC
it_PIT
is_VPRT [BEMA]
an_DT
effective_JJ
and_PHC
well-tolerated_JJ
from_PIN
ET_NN
across_PLACE
the_DT
European_NN
Union_NN
._.
XAGRID_NN
phosphate-binder_NN
,_,
lowering_VBG
serum_NN
phosphate_NN
to_TO
is_VPRT [BEMA]
the_DT
only_DWNT
platelet-selective_JJ
treatment_NOMZ
with_PIN
target_NN
levels_NN
within_PIN
eight_CD
weeks_NN
and_CC
maintaining_VBG [PUBV]
approval_NN
throughout_PIN
the_DT
European_NN
Union_NN
,_,
this_DEMO
long_JJ
term_NN
,_,
with_PIN
some_QUAN
patients_NN
treated_VBD
for_PIN
Iceland_NN
and_PHC
Norway_NN
._.
We_FPP1
are_VPRT [BEMA]
therefore_CONJ
hopeful_PRED
that_THAC
FOSRENOL_NN
will_PRMD
become_VB
a_DT
widely_RB
used_VBN
treatment_NOMZ
AGRYLIN_NN
is_VPRT [SPAU]
also_RB
being_VBG [PASS]
sold_VBN
successfully_RB
in_PIN
Israel_NN
,_,
for_PIN
hyperphosphatemia_NN
in_PIN
ESRD_NN
patients_NN
._.
South_NN
Africa_NN
,_,
Brazil_NN
and_CC
the_DT
Pacific_NN
Rim_NN
and_CC
has_VPRT [SPAU] [PEAS]
also_RB
been_VBN [BEMA]
available_PRED
on_PIN
a_DT
named_VBN
patient_NN
XAGRID_NN
AGRYLIN_NN
basis_NN
in_PIN
a_DT
number_NN
of_PIN
European_JJ
countries_NN
for_PIN
XAGRID_NN
anagrelide_NN
hydrochloride_NN
Shires_VPRT
several_QUAN
years_NN
._.
Shire_NN
,_,
therefore_CONJ
,_,
already_RB
has_VPRT
an_DT
treatment_NOMZ
for_PIN
ET_NN
received_VBD
approval_NN
from_PIN
the_DT
established_VBN [PRIV]
business_NOMZ
base_NN
and_CC
a_DT
product_NN
profile_NN
European_JJ
Medicines_NN
Evaluation_NOMZ
Agency_NN
in_PIN
for_PIN
XAGRID_NN
among_PIN
key_JJ
opinion_NN
leaders_NN
._.
With_PIN
2004_CD
for_PIN
second-line_NN
,_,
monotherapy_JJ
treatment_NOMZ
the_DT
recent_JJ
EU_NN
approval_NN
,_,
it_PIT
has_VPRT [PEAS]
been_VBN [BEMA]
successfully_RB
in_PIN
patients_NN
suffering_VBG [WZPRES]
from_PIN
ET_NN
,_,
in_PIN
the_DT
European_JJ
launched_VBN
in_PIN
six_CD
EU_NN
countries_NN
as_RB
well_RB
as_IN
Union_NN
,_,
Iceland_NN
and_PHC
Norway_NN
._.
Promotional_JJ
and_PHC
educational_JJ
disorder_NN
of_PIN
bone_NN
marrow_NN
associated_VBN [WZPAST]
with_PIN
the_DT
activities_NOMZ
are_VPRT [BEMA]
well_RB
underway_PRED
to_PIN
further_JJ
build_VB
increased_VBN
production_NOMZ
of_PIN
blood_NN
platelets_NN
._.
XAGRID_NN
launch_NN
commenced_VBD
across_PLACE
Europe_NN
17_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
18_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
General_NN
products_NN
&_CC
royalty_NN
revenues_NN
In_PIN
the_DT
past_JJ
eight_CD
years_NN
in_PIN
the_DT
US_FPP1
,_,
AGRYLIN_NN
VANIQA_NN
has_VPRT [PEAS]
developed_VBN
a_DT
proven_JJ
track_NN
record_NN
for_PIN
In_PIN
2004_CD
,_,
VANIQA_NN
,_,
an_DT
innovative_JJ
new_JJ
product_NN
lowering_VBG [WZPRES]
the_DT
platelet_NN
count_NN
in_PIN
patients_NN
suffering_VBG [WZPRES]
designed_VBN
to_TO
slow_VB
unwanted_JJ
facial_JJ
hair_NN
growth_NN
from_PIN
myeloproliferative_JJ
disorders_NN
._.
Platelets_NN
are_VPRT [BEMA]
in_PIN
women_NN
,_,
was_VBD [BYPA]
launched_VBN
by_PIN
Shire_NN
in_PIN
the_DT
UK_NN
,_,
involved_VBN [PASTP]
in_PIN
blood_NN
clotting_GER
and_CC
lowering_VBG
the_DT
the_DT
Republic_NN
of_PIN
Ireland_NN
,_,
Germany_NN
,_,
France_NN
,_,
Italy_NN
elevated_VBD
count_NN
helps_VPRT
decrease_VB
symptoms_NN
such_JJ
and_CC
Spain_NN
._.
The_DT
market_NN
response_NN
to_PIN
date_NN
has_VPRT
as_IN
blood_NN
vessel_NN
blockages_NN
and_CC
bleeding_VBG
events_NN
._.
Sales_NN
continued_VBD
to_TO
grow_VB
in_PIN
2004_CD
,_,
totalling_VBG
$_$
152.5_CD
million_CD
,_,
up_RB
15_CD
%_NN
from_PIN
the_DT
previous_JJ
year_NN
._.
Anti-infectives_NN
:_:
HIV_NN
and_PHC
hepatitis_NN
B_NN
XAGRID_NN
is_VPRT [BEMA]
platelet_JJ
selective_JJ
,_,
$_$
34_CD
million_CD
of_PIN
2004_CD
AGRYLIN_NN
sales_NN
were_VBD
Shire_NN
receives_VPRT
royalties_NN
from_PIN
GlaxoSmithKline_NN
targeting_VBG [WZPRES]
only_DWNT
those_DEMO
cells_NN
attributed_VBD
to_PIN
Europe_NN
._.
plc_NN
GSK_NN
on_PIN
the_DT
worldwide_JJ
sales_NN
of_PIN
3TC_NN
that_TSUB
develop_VPRT
into_PIN
platelets_NN
:_:
lamivudine_NN
,_,
a_DT
key_JJ
component_NN
in_PIN
most_EMPH
of_PIN
the_DT
it_PIT
is_VPRT [SPAU] [BYPA]
well_RB
tolerated_VBN
by_PIN
most_EMPH
Orphan_JJ
drug_NN
exclusivity_NOMZ
for_PIN
AGRYLIN_NN
in_PIN
the_DT
HIV_NN
combination_NOMZ
treatment_NOMZ
regimes_VPRT
,_,
such_JJ
as_IN
patients_NN
and_CC
is_VPRT [BEMA]
a_DT
welcome_JJ
US_FPP1
expired_VBD
in_PIN
March_NN
2004_CD
and_CC
a_DT
subsequent_JJ
COMBIVIR_NN
and_PHC
TRIZIVIR_NN
._.
In_PIN
Canada_NN
,_,
Shire_NN
addition_NOMZ
to_PIN
the_DT
drugs_NN
we_FPP1
six-month_JJ
US_FPP1
market_NN
exclusivity_NOMZ
period_NN
granted_VBN [SUAV]
markets_NN
3TC_NN
jointly_RB
with_PIN
GSK_NN
._.
Lamivudine_NN
is_VPRT [SPAU]
also_RB
have_VPRT
available_JJ
to_TO
treat_VB
ET_NN
._.
by_PIN
the_DT
FDA_NN
Pediatric_NN
Board_NN
ending_VBG [WZPRES]
September_NN
marketed_VBD
for_PIN
the_DT
treatment_NOMZ
of_PIN
chronic_JJ
hepatitis_NN
B_NN
2004_CD
has_VPRT [SPAU] [PEAS]
also_RB
expired_VBN
._.
Shire_NN
is_VPRT
therefore_CONJ
as_IN
HEPTOVIR_NN
in_PIN
Canada_NN
,_,
EPIVIR_NN
HBV_NN
in_PIN
the_DT
US_FPP1
,_,
Dr_NN
Claire_NN
Harrison_NN
anticipating_VBG [PRIV] [WZPRES]
the_DT
launch_NN
of_PIN
generic_JJ
versions_NN
and_PHC
ZEFFIX_NN
elsewhere_RB
in_PIN
the_DT
world_NN
._.
Shire_NN
also_RB
Consultant_NN
Hematologist_NN
of_PIN
the_DT
product_NN
in_PIN
the_DT
US_FPP1
market_NN
._.
receives_VPRT
royalties_NN
on_PIN
sales_NN
of_PIN
lamivudine_NN
by_PIN
at_PIN
Guys_NN
and_PHC
St_NN
Thomas_NN
GSK_NN
for_PIN
hepatitis_NN
B._NN
In_PIN
2004_CD
,_,
royalty_NN
income_NN
for_PIN
Foundation_NOMZ
Trust_NN
Other_JJ
general_JJ
products_NN
lamivudine_NN
,_,
including_VBG
ZEFFIX_NN
and_PHC
3TC_NN
,_,
totalled_VBD
$_$
183.2_CD
million_CD
._.
SOLARAZE_NN
SOLARAZE_NN
is_VPRT [BEMA]
a_DT
leading_VBG
topical_JJ
treatment_NOMZ
for_PIN
In_PIN
July_NN
2004_CD
,_,
global_JJ
research_NN
,_,
development_NOMZ
and_CC
actinic_JJ
keratosis_NN
AK_NN
which_WDT [WHOBJ]
,_,
if_COND
left_VBN
untreated_JJ
,_,
marketing_GER
rights_NN
for_PIN
TROXATYL_NN
troxacitabine_NN
could_POMD
lead_VB
to_PIN
squamous_JJ
cell_NN
carcinoma_NN
,_,
a_DT
form_NN
were_VBD [BEMA]
out-licensed_PRED
to_PIN
Structural_NN
GenomiX_NN
Inc._NN
of_PIN
skin_NN
cancer_NN
._.
It_PIT
is_VPRT [BYPA]
marketed_VBN
by_PIN
Shire_NN
in_PIN
five_CD
In_CONJ
addition_NULL
,_,
in_PIN
January_NN
2005_CD
,_,
Shire_NN
out-licensed_JJ
European_JJ
countries_NN
and_CC
marketed_VBN
in_PIN
another_DT
its_PIT
HIV_NN
compound_NN
,_,
SPD754_NN
,_,
to_PIN
Avexa_NN
Limited_NN
,_,
a_DT
seven_CD
countries_NN
through_PIN
Shire_NN
distributors_NN
._.
publicly-listed_JJ
Australian_JJ
specialty_NN
anti-infectives_NN
SOLARAZE_NN
gel_NN
offers_VPRT
an_DT
alternative_NN
to_TO
existing_VBG
company_NN
._.
These_DEMO
transactions_NOMZ
represented_VBD
some_QUAN
treatment_NOMZ
options_NOMZ
,_,
which_WDT [SERE]
may_POMD
cause_VB
burning_GER
of_PIN
the_DT
final_JJ
steps_NN
in_PIN
our_FPP1
divestment_NOMZ
program_NN
or_CC
peeling_VBG
during_PIN
the_DT
treatment_NOMZ
of_PIN
AK_NN
lesions_NN
._.
designed_VBN
to_TO
ensure_VB [SUAV] [PRIV]
focus_NN
on_PIN
later-stage_JJ
pipeline_NN
It_PIT
is_VPRT [BEMA]
particularly_RB
useful_PRED
for_PIN
patients_NN
with_PIN
AK_NN
on_PIN
investment_NOMZ
in_PIN
our_FPP1
core_NN
therapeutic_JJ
areas_NN
._.
the_DT
face_NN
or_CC
scalp_NN
,_,
where_RB
other_JJ
treatments_NOMZ
such_JJ
as_IN
cryotherapy_JJ
freezing_GER
would_PRMD
be_VB [BEMA]
too_RB
painful_JJ
Vaccines_NN
or_CC
risk_VB
leaving_VBG
scarring_GER
._.
Shire_NN
completed_VBD
the_DT
sale_NN
of_PIN
its_PIT
vaccines_NN
business_NOMZ
to_PIN
ID_NN
Biomedical_NN
Corporation_NOMZ
IDB_NN
in_PIN
September_NN
CALCICHEW_NN
2004_CD
for_PIN
proceeds_NN
of_PIN
$_$
120_CD
million_CD
$_$
60_CD
million_CD
in_PIN
Shire_JJ
markets_NN
the_DT
CALCICHEW_NN
range_NN
of_PIN
calcium_NN
cash_NN
and_CC
$_$
60_CD
million_CD
in_PIN
IDB_NN
subscription_NOMZ
receipts_NN
._.
and_ANDC
calcium_NN
vitamin_NN
D_NN
supplements_NOMZ
in_PIN
the_DT
UK_NN
The_NN
subscription_NOMZ
receipts_NN
were_VBD [BYPA]
redeemed_VBN
by_PIN
and_CC
the_DT
Republic_NN
of_PIN
Ireland_NN
as_IN
adjuncts_NN
in_PIN
the_DT
IDB_NN
for_PIN
$_$
60_CD
million_CD
in_PIN
cash_NN
in_PIN
January_NN
2005_CD
._.
Shire_NN
treatment_NOMZ
of_PIN
osteoporosis_NN
,_,
a_DT
disease_NN
characterized_VBD
considers_VPRT [PRIV]
IDB_NN
to_TO
be_VB [BEMA]
the_DT
ideal_JJ
company_NN
to_TO
take_VB
by_PIN
a_DT
progressive_JJ
loss_NN
of_PIN
bone_NN
mass_NN
that_TSUB
renders_VPRT
the_DT
vaccines_NN
business_NOMZ
into_PIN
its_PIT
next_JJ
stage_NN
of_PIN
bone_NN
fragile_JJ
and_PHC
liable_JJ
to_PIN
fracture_NN
._.
Shire_NN
decided_VBD [SUAV] [PRIV]
to_PIN
exit_NN
the_DT
vaccines_NN
three_CD
million_CD
people_NN
in_PIN
the_DT
UK_NN
are_VPRT [PASS]
estimated_VBN [PRIV]
to_PIN
business_NOMZ
,_,
because_CAUS
it_PIT
is_VPRT
no_RB
longer_RB
core_NN
to_PIN
our_FPP1
suffer_VPRT
with_PIN
this_DEMO
condition_NOMZ
._.
Osteoporosis_NN
affects_VPRT
global_JJ
strategy_NN
of_PIN
focusing_VBG
on_PIN
therapeutic_JJ
both_DT
sexes_NN
but_CC
is_VPRT [BEMA]
more_EMPH
rapid_PRED
and_PHC
profound_PRED
products_NN
meeting_VBG [WZPRES]
the_DT
needs_NN
of_PIN
specialist_NN
doctors_NN
._.
in_PIN
women_NN
,_,
largely_RB
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
decline_NN
in_PIN
estrogen_NN
production_NOMZ
following_VBG [WZPRES]
menopause_NN
._.
18_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
19_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
General_NN
products_NN
&_CC
royalty_NN
revenues_NN
XAGRID_NN
European_NN
launch_NN
early_TIME
2005_CD
XAGRID_NN
anagrelide_NN
hydrochloride_NN
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
the_DT
reduction_NOMZ
of_PIN
elevated_JJ
platelet_NN
counts_NN
in_PIN
at-risk_JJ
essential_JJ
thrombocythemia_NN
patients_NN
who_WP [WHSUB]
are_VPRT [BEMA]
intolerant_PRED
to_PIN
their_TPP3
current_JJ
therapy_NN
or_CC
whose_WPS
elevated_JJ
platelet_NN
counts_NN
are_VPRT [PASS]
not_XX0
reduced_VBN
to_PIN
an_DT
acceptable_JJ
level_NN
by_PIN
their_TPP3
current_JJ
therapy_NN
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
20_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
Gastro-intestinal_JJ
Gastrointestinal_NN
Greg_NN
Flexter_NN
Executive_NN
Vice_NN
President_NN
&_CC
General_NN
Manager_NN
,_,
North_NN
America_NN
and_PHC
GI_NN
Strategic_NN
Therapeutic_NN
Area_NN
Leader_NN
20_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
21_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
Gastro-intestinal_JJ
The_DT
worldwide_JJ
diagnosed_VBN
population_NOMZ
for_PIN
ulcerative_JJ
colitis_NN
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
reach_VB
1.3_CD
million_CD
by_PIN
2012_CD
21_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
22_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
Gastro-intestinal_JJ
The_DT
gastro-intestinal_JJ
GI_NN
therapeutic_JJ
area_NN
is_VPRT [BEMA]
a_DT
convenient_JJ
and_CC
less_RB
burdensome_JJ
formulation_NOMZ
,_,
as_IN
specialty_NN
market_NN
with_PIN
high_JJ
,_,
unmet_JJ
needs_NN
._.
Its_PIT
size_NN
,_,
well_DPAR
as_IN
allowing_VBG [SUAV]
physicians_NN
another_DT
prescribing_GER
in_PIN
terms_NN
of_PIN
both_DT
revenue_NN
and_CC
the_DT
number_NN
of_PIN
option_NOMZ
._.
Shire_NN
also_RB
markets_VPRT
COLAZIDE_NN
specialist_NN
physicians_NN
practicing_VBG [WZPRES]
in_PIN
the_DT
area_NN
,_,
balsalazide_NN
,_,
an_DT
oral_JJ
mesalamine_NN
formulation_NOMZ
for_PIN
makes_NN
this_DEMO
an_DT
attractive_JJ
market_NN
that_TSUB
fits_VPRT
well_RB
with_PIN
the_DT
treatment_NOMZ
of_PIN
ulcerative_JJ
colitis_NN
,_,
in_PIN
the_DT
UK_NN
and_PHC
Shires_NN
specialty-driven_JJ
model_NN
._.
We_FPP1
can_POMD
add_VB [PUBV]
value_NN
other_JJ
European_JJ
markets_NN
._.
Both_DT
products_NN
in_PIN
this_DEMO
sector_NN
by_PIN
using_VBG
our_FPP1
particular_JJ
capabilities_NOMZ
,_,
performed_VBN
according_VBG
to_PIN
expectations_NOMZ
in_PIN
2004_CD
,_,
resources_NN
and_PHC
expertise_NN
to_TO
bring_VB
specialist_NN
with_PIN
PENTASA_NN
holding_VBG [PRIV] [WZPRES]
a_DT
17.6_CD
%_NN
share_NN
of_PIN
the_DT
US_FPP1
projects_NN
through_PIN
the_DT
development_NOMZ
and_PHC
mesalamine_NN
market_NN
and_PHC
COLAZIDE_NN
a_DT
6_CD
%_NN
share_NN
The_DT
commitment_NOMZ
to_PIN
patients_NN
registration_NOMZ
phases_NN
quickly_RB
._.
Our_FPP1
focused_VBN
sales_NN
of_PIN
the_DT
UK_NN
market_NN
._.
and_ANDC
gastroenterology_NN
that_DEMP
and_CC
marketing_GER
network_NN
,_,
which_WDT [SERE]
targets_VPRT
specialist_NN
Shire_NN
has_VPRT [PEAS]
demonstrated_VBN [PRIV]
is_VPRT
GI_NN
physicians_NN
,_,
is_VPRT [SPAU] [PASS]
well_RB
positioned_VBN
to_TO
ensure_VB [SUAV] [PRIV]
A_DT
growing_VBG
pipeline_NN
:_:
SPD476_CD
and_CC
SPD480_CD
exemplary_JJ
._.
The_DT
use_NN
of_PIN
market_NN
success_NN
in_PIN
the_DT
commercialization_NOMZ
phase_NN
._.
SPD476_CD
,_,
a_DT
novel_NN
system_NN
for_PIN
the_DT
delivery_NN
of_PIN
an_DT
PENTASA_NN
in_PIN
patients_NN
with_PIN
unprecedented_JJ
1.2_CD
g_NN
mesalamine_NN
,_,
is_VPRT [BEMA]
in_PIN
Phase_NN
3_CD
inflammatory_JJ
bowel_NN
disease_NN
Shire_NN
already_RB
has_VPRT
a_DT
long_JJ
and_PHC
successful_JJ
history_NN
clinical_JJ
development_NOMZ
and_CC
nearing_VBG
completion_NOMZ
such_JJ
as_IN
ulcerative_JJ
colitis_NN
of_PIN
working_VBG
in_PIN
GI_NN
therapeutic_JJ
areas_NN
with_PIN
PENTASA_NN
of_PIN
pivotal_JJ
clinical_JJ
trials_NN
._.
This_DEMO
technology_NN
uses_VPRT
allows_VPRT [SUAV]
many_QUAN
of_PIN
them_TPP3
to_PIN
in_PIN
the_DT
US_FPP1
and_PHC
COLAZIDE_NN
in_PIN
Europe_NN
and_CC
we_FPP1
are_VPRT [BEMA]
a_DT
proprietary_JJ
system_NN
for_PIN
targeting_VBG
the_DT
release_NN
of_PIN
enjoy_VB
a_DT
better_JJ
quality_NOMZ
of_PIN
life_NN
._.
planning_VBG
to_TO
expand_VB
our_FPP1
presence_NN
in_PIN
GI_NN
medicine_NN
._.
high_JJ
concentrations_NOMZ
of_PIN
mesalamine_NN
throughout_PIN
With_PIN
proper_JJ
management_NOMZ
The_DT
establishment_NOMZ
of_PIN
a_DT
Strategic_NN
Therapeutic_NN
the_DT
length_NN
of_PIN
the_DT
colon_NN
,_,
with_PIN
the_DT
potential_JJ
to_PIN
many_QUAN
patients_NN
and_PHC
physicians_NN
Area_NN
Team_NN
STAT_NN
dedicated_VBD
to_PIN
this_DEMO
segment_NOMZ
will_PRMD
reduce_VB
the_DT
burden_NN
for_PIN
ulcerative_JJ
colitis_NN
patients_NN
have_VPRT [PEAS]
seen_VBN [PRIV] [THATD]
lower_JJ
incidence_NN
enable_VB
us_FPP1
to_TO
work_VB
better_JJ
and_PHC
more_EMPH
collaboratively_RB
of_PIN
having_VBG
to_TO
take_VB
large_JJ
numbers_NN
of_PIN
tablets_NN
._.
Shires_NN
across_PLACE
borders_NN
to_TO
meet_VB
common_JJ
goals_NN
._.
In_PIN
In_PIN
May_POMD
2002_CD
Shire_NN
announced_VBD [PUBV]
the_DT
in-licensing_JJ
commitment_NOMZ
to_PIN
research_NN
addition_NOMZ
to_TO
bringing_VBG
a_DT
more_EMPH
global_JJ
focus_NN
to_PIN
our_FPP1
of_PIN
the_DT
rights_NN
to_PIN
this_DEMO
technology_NN
in_PIN
North_NN
America_NN
,_,
in_PIN
gastroenterology_NN
will_PRMD
product_NN
strategy_NN
,_,
it_PIT
will_PRMD [SPAU]
also_RB
be_VB [BEMA]
conducive_PRED
to_PIN
Europe_NN
excluding_VBG [WZPRES]
Italy_NN
and_PHC
Japan_NN
under_IN
an_DT
expand_VB
the_DT
medical_JJ
faster_JJ
product_NN
development_NOMZ
,_,
registration_NOMZ
and_PHC
agreement_NOMZ
with_PIN
Giuliani_NN
S._NN
p._NN
A._NN
this_DEMP
was_VBD
armamentarium_NN
to_TO
combat_VB
commercialization_NOMZ
._.
At_PIN
the_DT
same_JJ
time_NN
,_,
it_PIT
will_PRMD
extended_VBD
to_PIN
the_DT
Pacific_NN
Rim_NN
,_,
Australia_NN
and_PHC
New_NN
these_DEMO
devastating_JJ
diseases_NN
._.
enable_VB
Shire_NN
to_TO
evaluate_VB
potential_JJ
GI_NN
products_NN
Zealand_NN
in_PIN
2003_CD
._.
Filings_GER
for_PIN
regulatory_JJ
approval_NN
for_PIN
their_TPP3
multinational_JJ
potential_NN
more_EMPH
effectively_RB
._.
of_PIN
SPD476_NN
are_VPRT [PASS]
scheduled_VBN
to_TO
be_VB [PASS]
made_VBN
in_PIN
the_DT
US_FPP1
Gary_NN
R_NN
Lichtenstein_NN
,_,
MD_NN
and_PHC
Europe_NN
in_PIN
the_DT
second_JJ
half_NN
of_PIN
2005_CD
,_,
and_ANDC
it_PIT
will_PRMD
Director_NN
Inflammatory_NN
We_FPP1
intend_VPRT [SUAV]
to_TO
extend_VB
and_PHC
optimize_VB
new_JJ
uses_NN
for_PIN
be_VB [BEMA]
Shires_JJ
third_JJ
global_JJ
product_NN
after_IN
FOSRENOL_NN
Bowel_NN
Disease_NN
Program_NN
our_FPP1
products_NN
through_PIN
the_DT
STAT_NN
,_,
both_DT
in_PIN
existing_VBG
and_CC
XAGRID_NN
AGRYLIN_NN
._.
Division_NN
of_PIN
Gastroenterology_NN
and_CC
in_PIN
new_JJ
territories_NN
and_CC
to_TO
build_VB
a_DT
truly_RB
global_JJ
University_NOMZ
of_PIN
Pennsylvania_NN
,_,
franchise_NN
in_PIN
this_DEMO
promising_JJ
market_NN
segment_NOMZ
._.
Although_CONC
mesalamine_NN
is_VPRT [BEMA]
an_DT
existing_VBG
and_CC
wellPhiladelphia_NN
known_VBN [PRIV]
treatment_NOMZ
for_PIN
ulcerative_JJ
colitis_NN
,_,
we_FPP1
believe_VPRT [PRIV]
Ulcerative_JJ
colitis_NN
:_:
PENTASA_NN
and_PHC
COLAZIDE_NN
SPD476_NN
may_POMD
improve_VB
its_PIT
ease_NN
of_PIN
use_NN
by_PIN
being_VBG [BEMA]
Ulcerative_JJ
colitis_NN
is_VPRT [BEMA]
a_DT
chronic_NN
,_,
relapsing_VBG
type_NN
of_PIN
available_JJ
in_PIN
a_DT
once-daily_JJ
or_CC
twice-daily_JJ
formulation_NOMZ
._.
inflammatory_JJ
bowel_NN
disease_NN
in_PIN
which_WDT [PIRE]
part_NN
,_,
or_CC
all_QUAN
,_,
This_DEMP
will_PRMD
help_VB
patients_NN
adhere_VB
to_PIN
their_TPP3
medication_NOMZ
of_PIN
the_DT
large_JJ
intestine_JJ
becomes_VPRT
inflamed_VBN
and_CC
and_CC
live_VB
better_JJ
lives_NN
._.
Patients_NN
experience_VPRT
intermittent_JJ
attacks_NN
separated_VBN [WZPAST]
by_PIN
periods_NN
of_PIN
remission_NN
,_,
and_ANDC
SPD480_NN
is_VPRT [BEMA]
a_DT
rectally_RB
administered_VBN
mesalamine_NN
can_POMD
suffer_VB
from_PIN
diarrhoea_NN
,_,
bleeding_VBG
and_CC
abdominal_JJ
aerosol_NN
foam_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
certain_JJ
types_NN
pain_NN
._.
About_IN
30_CD
%_NN
of_PIN
people_NN
with_PIN
ulcerative_JJ
colitis_NN
of_PIN
ulcerative_JJ
colitis_NN
and_CC
is_VPRT [BEMA]
also_RB
in_PIN
the_DT
advanced_JJ
eventually_TIME
undergo_VB
surgery_NN
,_,
typically_RB
after_IN
15_CD
to_PIN
stages_NN
of_PIN
development_NOMZ
Phase_NN
2_CD
._.
This_DEMO
formulation_NOMZ
,_,
25_CD
years_NN
of_PIN
disease_NN
._.
in-licensed_JJ
from_PIN
Giuliani_NN
S._NN
p._NN
A._NN
may_POMD [SPAU]
also_RB
assist_VB
patients_NN
to_TO
adhere_VB
to_PIN
their_TPP3
medication_NOMZ
,_,
as_IN
it_PIT
may_POMD
The_DT
mainstay_NN
treatment_NOMZ
for_PIN
inflammatory_JJ
bowel_NN
be_VB [BEMA]
more_EMPH
acceptable_PRED
and_PHC
easier_PRED
to_TO
use_VB
than_PIN
disease_NN
is_VPRT [BEMA]
mesalamine_JJ
5-ASA_NN
products_NN
._.
Our_FPP1
leading_VBG
ulcerative_JJ
colitis_NN
product_NN
,_,
PENTASA_NN
,_,
delivers_VPRT
mesalamine_NN
throughout_PIN
the_DT
small_JJ
and_ANDC
In_CONJ
addition_NULL
to_TO
developing_VBG
SPD476_NN
and_PHC
SPD480_NN
,_,
large_JJ
bowel_NN
._.
In_PIN
the_DT
US_FPP1
,_,
Shire_NN
markets_NN
PENTASA_NN
Shire_NN
is_VPRT [SPAU]
actively_RB
evaluating_VBG
a_DT
variety_NN
of_PIN
GI_NN
as_IN
a_DT
250mg_JJ
capsule_NN
and_CC
in_PIN
2004_CD
introduced_VBD
a_DT
licensing_GER
and_PHC
acquisition_NOMZ
opportunities_NOMZ
that_TSUB
will_PRMD
500mg_VB
capsule_NN
to_TO
offer_VB
patients_NN
a_DT
more_EMPH
expand_VB
our_FPP1
GI_NN
product_NN
portfolio_NN
and_CC
contribute_VPRT
to_PIN
our_FPP1
future_JJ
growth_NN
._.
22_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
23_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Operating_GER
review_NN
:_:
Gastro-intestinal_JJ
Shire_NN
believes_VPRT [PRIV] [THATD]
SPD476_NN
may_POMD
improve_VB
the_DT
ease_NN
of_PIN
use_NN
of_PIN
mesalamine_NN
for_PIN
patients_NN
by_PIN
being_VBG [BEMA]
available_PRED
in_PIN
a_DT
once-daily_JJ
or_CC
twice-daily_JJ
formulation_NOMZ
With_PIN
symptoms_NN
under_IN
control_NN
,_,
I_FPP1
can_POMD
get_VB
on_PIN
with_PIN
my_FPP1
life_NN
._.
PENTASA_NN
mesalamine_NN
is_VPRT [PASS]
indicated_VBN [PRIV]
for_PIN
the_DT
induction_NOMZ
of_PIN
remission_NN
and_PHC
treatment_NOMZ
of_PIN
patients_NN
with_PIN
mild_JJ
to_TO
moderately_RB
active_JJ
ulcerative_JJ
colitis_NN
,_,
using_VBG [PRESP]
a_DT
unique_JJ
delivery_NN
mechanism_NN
23_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
24_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
CSR_NN
:_:
Corporate_NN
social_JJ
responsibility_NOMZ
Our_FPP1
business_NOMZ
touches_NN
many_QUAN
peoples_NN
lives_VPRT
Our_FPP1
business_NOMZ
touches_NN
many_QUAN
peoples_NN
lives_NN
:_:
Customer_NN
focus_NN
our_FPP1
employees_NN
,_,
our_FPP1
shareholders_NN
,_,
the_DT
physicians_NN
We_FPP1
are_VPRT [PASS]
customer_NN
driven_VBN
,_,
focusing_VBG [PRESP]
on_PIN
quality_NOMZ
who_WP [WHSUB]
prescribe_VPRT
our_FPP1
products_NN
and_CC
most_EMPH
importantly_RB
and_CC
the_DT
needs_NN
of_PIN
both_DT
the_DT
internal_JJ
and_PHC
external_JJ
the_DT
patients_NN
whose_WPS [WHOBJ]
lives_NN
benefit_VPRT
from_PIN
Shires_NN
customer_NN
._.
Global_JJ
teamwork_NN
As_IN
a_DT
corporation_NOMZ
,_,
we_FPP1
work_VPRT
with_PIN
many_QUAN
suppliers_NN
We_FPP1
achieve_VB
better_JJ
outcomes_NN
as_IN
a_DT
team_NN
._.
who_WP
provide_VPRT
invaluable_JJ
services_NN
that_TSUB
enable_VPRT
us_FPP1
The_DT
entire_JJ
company_NN
is_VPRT [PASS]
focused_VBN
on_PIN
growing_VBG
our_FPP1
to_TO
complete_VB
our_FPP1
day_NN
to_PIN
day_NN
tasks_NN
and_CC
we_FPP1
have_VPRT
business_NOMZ
and_CC
executing_VBG
our_FPP1
strategy_NN
as_IN
a_DT
team_NN
._.
operations_NOMZ
in_PIN
communities_NOMZ
where_RB
it_PIT
is_VPRT [BEMA]
important_PRED
to_PIN
us_FPP1
to_TO
be_VB [PASS]
respected_VBN
and_PHC
recognized_VBN [PRIV]
._.
Openness_NOMZ
and_PHC
innovation_NOMZ
We_FPP1
believe_VPRT [PRIV]
that_THVC
anything_QUPR
is_VPRT [BEMA]
possible_PRED
and_CC
that_THVC
We_FPP1
know_VPRT [PRIV] [THATD]
that_DEMP
maintaining_VBG [PUBV]
trust_NN
among_PIN
the_DT
prudent_JJ
risks_NN
are_VPRT [BEMA]
worth_PRED
taking_VBG
._.
people_NN
and_PHC
communities_NOMZ
in_PIN
which_WDT [PIRE]
we_FPP1
operate_VPRT
is_VPRT [BEMA]
essential_PRED
to_PIN
the_DT
success_NN
and_PHC
sustainability_NOMZ
Excellence_NN
in_PIN
execution_NOMZ
of_PIN
Shire_NN
as_IN
a_DT
whole_NN
._.
Personal_JJ
ownership_NN
and_CC
great_JJ
processes_NN
lead_VPRT
to_PIN
excellence_NN
in_PIN
decision-making_NN
and_PHC
execution_NOMZ
._.
This_DEMP
is_VPRT
what_WP
Corporate_NN
Social_NN
Responsibility_NOMZ
CSR_NN
means_VPRT [PRIV]
to_PIN
us_FPP1
._.
These_DEMO
values_NN
guide_VPRT
our_FPP1
daily_JJ
behaviors_NN
and_CC
serve_VB
as_IN
principles_NN
for_PIN
our_FPP1
approach_NN
to_PIN
CSR_NN
._.
As_IN
a_DT
leading_VBG
healthcare_NN
provider_NN
,_,
we_FPP1
recognize_VPRT [PRIV]
our_FPP1
responsibilities_NOMZ
to_PIN
the_DT
people_NN
who_WP [WHSUB]
depend_VPRT
The_DT
CSR_NN
Committee_NN
on_PIN
our_FPP1
products_NN
and_CC
to_PIN
the_DT
communities_NOMZ
in_PIN
which_WDT [PIRE]
The_DT
Shire_NN
CSR_NN
Committee_NN
the_DT
Committee_NN
we_FPP1
operate_VPRT
._.
We_FPP1
are_VPRT
and_CC
will_PRMD
remain_VB
committed_JJ
continues_VPRT
to_TO
steer_VB
and_PHC
monitor_VB
the_DT
Companys_NN
to_TO
sound_VB
CSR_NN
principles_NN
and_PHC
practices_NN
._.
overall_JJ
approach_NN
to_PIN
CSR_NN
in_PIN
line_NN
with_PIN
the_DT
agreed_JJ
policy_NN
that_DEMP
is_VPRT [BEMA]
available_PRED
on_PIN
the_DT
Shire_NN
website_NN
._.
We_FPP1
are_VPRT [SPAU]
again_TIME
producing_VBG
a_DT
stand-alone_JJ
CSR_NN
report_NN
that_TSUB
will_PRMD
provide_VB
more_EMPH
detail_NN
of_PIN
the_DT
Chaired_VBN
by_PIN
Chief_NN
Financial_NN
Officer_NN
Angus_NN
Russell_NN
,_,
social_JJ
and_PHC
environmental_JJ
activities_NOMZ
that_TSUB
were_VBD [BEMA]
the_DT
Committee_NN
comprises_VPRT
individuals_NN
whose_WPS [WHOBJ]
daily_JJ
undertaken_VBN
during_PIN
2004_CD
this_DEMP
will_PRMD
be_VB [BEMA]
available_JJ
responsibilities_NOMZ
involve_VPRT
leadership_NN
or_CC
management_NOMZ
as_IN
a_DT
printed_VBN
report_NN
as_RB
well_RB
as_IN
online_NN
from_PIN
our_FPP1
of_PIN
functions_NOMZ
that_TSUB
can_POMD
have_VB
significant_JJ
impact_NN
on_PIN
website_NN
later_TIME
in_PIN
the_DT
year_NN
._.
implementation_NOMZ
of_PIN
our_FPP1
CSR_NN
policy_NN
._.
Shire_NN
values_VPRT
During_PIN
the_DT
year_NN
,_,
Shire_NN
established_VBD [PRIV]
several_QUAN
At_PIN
the_DT
core_NN
of_PIN
our_FPP1
approach_NN
to_PIN
CSR_NN
are_VPRT [BEMA]
our_FPP1
new_JJ
global_JJ
functions_NOMZ
and_CC
the_DT
CSR_NN
Committee_NN
,_,
values_NN
._.
During_PIN
2004_CD
we_FPP1
undertook_VBD
an_DT
exercise_NN
recognizing_VBG [PRIV] [WZPRES]
that_THVC
some_QUAN
of_PIN
these_DEMO
functions_NOMZ
were_VBD [BEMA]
We_FPP1
know_VPRT [PRIV] [THATD]
that_DEMP
maintaining_VBG [PUBV]
to_TO
restate_VB
and_PHC
update_VB
these_DEMO
values_NN
,_,
in_PIN
line_NN
highly_AMP
relevant_JJ
to_PIN
CSR_NN
,_,
invited_VBD
the_DT
heads_NN
of_PIN
trust_NN
among_PIN
the_DT
people_NN
and_CC
with_PIN
our_FPP1
global_JJ
restructuring_GER
and_CC
new_JJ
strategic_JJ
these_DEMO
new_JJ
functions_NOMZ
to_TO
join_VB
the_DT
Committee_NN
._.
communities_NOMZ
in_PIN
which_WDT [PIRE]
we_FPP1
focus_VPRT
._.
In_PIN
consultation_NOMZ
with_PIN
groups_NN
of_PIN
employees_NN
These_DEMP
included_VBN
global_JJ
human_JJ
resources_NN
,_,
facilities_NOMZ
operate_VPRT
is_VPRT [BEMA]
essential_PRED
to_PIN
the_DT
from_PIN
all_QUAN
parts_NN
of_PIN
the_DT
business_NOMZ
,_,
we_FPP1
agreed_VBD [SUAV] [PUBV]
and_CC
management_NOMZ
,_,
environment_NOMZ
and_CC
occupational_JJ
success_NN
and_PHC
sustainability_NOMZ
adapted_VBD
new_JJ
descriptions_NOMZ
for_PIN
our_FPP1
values_NN
with_PIN
health_NN
and_PHC
safety_NN
EHS_NN
._.
Shires_NN
divestment_NOMZ
of_PIN
of_PIN
Shire_NN
as_IN
a_DT
whole_JJ
an_DT
emphasis_NN
on_PIN
teamwork_NN
and_CC
global_JJ
working_GER
._.
its_PIT
vaccines_NN
business_NOMZ
and_CC
internal_JJ
restructuring_GER
meant_VBD [PRIV]
that_THVC
two_CD
prior_JJ
members_NN
of_PIN
the_DT
Committee_NN
Integrity_NOMZ
and_PHC
respect_NN
were_VBD [BEMA]
no_SYNE
longer_JJ
Shire_NN
employees_NN
._.
Relationships_NN
are_VPRT [BEMA]
the_DT
foundation_NOMZ
of_PIN
our_FPP1
business_NOMZ
._.
They_TPP3
are_VPRT [PASS]
based_VBN
on_PIN
unwavering_VBG
ethics_NN
and_CC
The_DT
Committee_NN
met_VBD
three_CD
times_NN
in_PIN
2004_CD
._.
As_IN
an_DT
respect_NN
for_PIN
individuals_NN
._.
Executive_NN
Committee_NN
and_PHC
Board_NN
Member_NN
,_,
Angus_NN
Russell_NN
reports_VPRT [PUBV]
matters_NN
of_PIN
CSR_NN
relevance_NN
to_PIN
both_DT
the_DT
Executive_NN
Committee_NN
and_CC
the_DT
Board_NN
and_CC
offers_VPRT
guidance_NN
and_ANDC
where_RB
necessary_JJ
,_,
detailed_JJ
briefings_GER
to_PIN
Board_NN
members_NN
._.
24_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
25_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
CSR_NN
:_:
Corporate_NN
social_JJ
responsibility_NOMZ
The_DT
Committees_NN
main_JJ
responsibilities_NOMZ
are_VPRT
to_TO
:_:
facilitate_VB
an_DT
effective_JJ
and_PHC
cross-functional_JJ
implementation_NOMZ
of_PIN
Shires_NN
CSR_NN
policy_NN
:_:
advise_VB
and_PHC
inform_VB
the_DT
Board_NN
on_PIN
business_NOMZ
risks_NN
related_VBN [WZPAST]
to_PIN
Social_NN
,_,
Environmental_NN
and_PHC
Ethical_NN
SEE_VPRT [PRIV]
matters_NN
:_:
evaluate_VB
Shires_NN
compliance_NN
with_PIN
and_CC
the_DT
continuing_VBG
appropriateness_NOMZ
of_PIN
the_DT
Companys_NN
CSR_NN
policy_NN
:_:
and_ANDC
review_NN
and_CC
approve_VB
Shires_NN
CSR_NN
disclosures_NN
._.
CSR_NN
risk_NN
During_PIN
2004_CD
,_,
the_DT
CSR_NN
Committee_NN
initiated_VBD
a_DT
review_NN
of_PIN
the_DT
Companys_NN
approach_NN
to_TO
identifying_VBG
,_,
assessing_VBG
and_PHC
mitigating_VBG
CSR-related_JJ
risks_NN
._.
The_DT
main_JJ
purposes_NN
were_VBD
to_TO
continue_VB
enhancing_VBG
practices_NN
and_PHC
performance_NN
and_CC
further_JJ
embedding_VBG
the_DT
processes_NN
within_PIN
Shires_NN
risk_NN
management_NOMZ
framework_NN
._.
All-employee_JJ
meetings_GER
have_VPRT
The_DT
exercise_NN
is_VPRT [BEMA]
underway_PRED
with_PIN
input_NN
from_PIN
external_JJ
specialist_NN
consultants_NN
._.
The_DT
CSR_NN
Committee_NN
will_PRMD
taken_VBN
place_NN
at_PIN
our_FPP1
major_JJ
sites_NN
report_VPRT [PUBV]
to_PIN
the_DT
Board_NN
and_PHC
Executive_NN
Committee_NN
on_PIN
with_PIN
the_DT
chief_JJ
executive_NN
officer_NN
this_DEMO
in_PIN
2005_CD
._.
and_ANDC
executive_JJ
committee_NN
members_NN
leading_VBG [WZPRES]
each_QUAN
meeting_GER
Engagement_NOMZ
with_PIN
stakeholders_NN
In_PIN
2004_CD
employee_NN
communications_NOMZ
received_VBD
a_DT
new_JJ
emphasis_NN
in_PIN
order_NN
to_TO
help_VB
facilitate_VB
Shires_NN
internal_JJ
restructuring_GER
._.
All-employee_JJ
meetings_GER
have_VPRT [PEAS]
taken_VBN
place_NN
at_PIN
our_FPP1
major_JJ
sites_NN
with_PIN
the_DT
Chief_NN
Executive_NN
Officer_NN
and_PHC
members_NN
of_PIN
the_DT
Executive_NN
Committee_NN
leading_VBG [WZPRES]
each_QUAN
meeting_GER
._.
In_CONJ
addition_NULL
,_,
global_JJ
teleconferences_NN
have_VPRT [PEAS]
taken_VBN
place_NN
each_QUAN
quarter_NN
with_PIN
the_DT
Companys_NN
top_JJ
150_CD
managers_NN
where_RB
business_NOMZ
issues_NN
are_VPRT [PASS]
discussed_VBN
and_CC
executive_JJ
management_NOMZ
share_VB
their_TPP3
views_NN
on_PIN
progress_NN
and_PHC
achievements_NOMZ
._.
Global_JJ
emails_NN
have_VPRT [PEAS]
been_VBN [PASS]
issued_VBN
regularly_RB
and_PHC
face-to-face_RB
dialogue_NN
has_VPRT [PEAS]
been_VBN [PASS]
encouraged_VBN
with_PIN
line_NN
managers_NN
._.
We_FPP1
have_VPRT [SPAU] [PEAS]
also_RB
produced_VBN
two_CD
new_JJ
Shire_NN
videos_NN
articulating_VBG [WZPRES]
our_FPP1
global_JJ
One_CD
Shire_JJ
culture_NN
and_PHC
focus_NN
during_PIN
the_DT
year_NN
._.
25_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
26_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
CSR_NN
:_:
Corporate_NN
social_JJ
responsibility_NOMZ
Divesting_VBG [WZPRES]
our_FPP1
vaccines_NN
business_NOMZ
was_VBD [BEMA]
a_DT
key_JJ
part_NN
Some_QUAN
of_PIN
the_DT
patient_JJ
groups_NN
that_TOBJ
we_FPP1
have_VPRT
of_PIN
Shires_NN
new_JJ
business_NOMZ
strategy_NN
._.
All_QUAN
employees_NN
supported_VBN
and_CC
or_CC
had_VBD
regular_JJ
dialogue_NN
with_PIN
of_PIN
the_DT
vaccines_NN
business_NOMZ
were_VBD [PASS]
offered_VBN
during_PIN
2004_CD
include_VPRT
:_:
employment_NOMZ
with_PIN
the_DT
new_JJ
owner_NN
,_,
ID_NN
Biomedical_NN
Corporation_NOMZ
and_CC
many_QUAN
have_VPRT
bright_JJ
and_CC
CHADD_NN
,_,
CADDRA_NN
,_,
Alzheimers_NN
Society_NN
,_,
attractive_JJ
careers_NN
ahead_PLACE
with_PIN
a_DT
new_JJ
focused_JJ
Marie_NN
Curie_NN
,_,
National_NN
Osteoporosis_NN
Society_NN
,_,
and_ANDC
committed_JJ
owner_NN
whose_WPS [WHOBJ]
core_NN
business_NOMZ
Crohns_NN
Society_NN
,_,
Crohns_NN
and_PHC
Colitis_NN
Foundation_NOMZ
is_VPRT [BEMA]
the_DT
development_NOMZ
of_PIN
vaccines_NN
._.
of_PIN
America_NN
,_,
Susan_NN
G_NN
Komen_NN
BreastCancer_NN
Foundation_NOMZ
,_,
American_NN
College_NN
of_PIN
Patients_NN
are_VPRT [BEMA]
the_DT
ultimate_JJ
Shareholders_NN
have_VPRT [PEAS]
been_VBN [PASS]
kept_VBN
informed_VBN
of_PIN
Shires_NN
Gastroenterology_NN
,_,
Epilepsy_NN
Foundation_NOMZ
of_PIN
beneficiaries_NN
of_PIN
Shires_NN
performance_NN
through_PIN
regular_JJ
communications_NOMZ
America_NN
and_CC
the_DT
National_NN
Kidney_NN
Foundation_NOMZ
._.
It_PIT
is_VPRT
knowing_VBG [PRIV] [THATD]
that_DEMP
and_CC
disclosures_NN
._.
Senior_JJ
management_NOMZ
has_VPRT
also_RB
medicines_NN
have_VPRT
an_DT
impact_NN
on_PIN
regularly_RB
presented_VBN
at_PIN
investor_NN
conferences_NN
and_CC
As_IN
a_DT
global_JJ
business_NOMZ
,_,
we_FPP1
work_VPRT
with_PIN
many_QUAN
patients_NN
lives_VPRT
that_DEMP
motivates_VPRT
engaged_VBN
in_PIN
face-to-face_JJ
meetings_GER
._.
These_DEMO
relationships_NN
are_VPRT [BEMA]
important_PRED
to_PIN
many_QUAN
of_PIN
Shires_NN
employees_NN
us_FPP1
and_CC
the_DT
appointment_NOMZ
of_PIN
a_DT
new_JJ
Global_JJ
Head_NN
of_PIN
The_DT
establishment_NOMZ
of_PIN
our_FPP1
new_JJ
US_FPP1
headquarters_NN
Procurement_NOMZ
in_PIN
2004_CD
will_PRMD
enable_VB
us_FPP1
to_TO
introduce_VB
a_DT
in_PIN
Philadelphia_NN
was_VBD [BEMA]
a_DT
major_JJ
focus_NN
in_PIN
2004_CD
._.
more_EMPH
disciplined_JJ
approach_NN
to_PIN
this_DEMO
important_JJ
area_NN
._.
We_FPP1
have_VPRT [PEAS]
become_VBN
members_NN
of_PIN
the_DT
Philadelphia_NN
Chamber_NN
of_PIN
Commerce_NN
and_CC
have_VPRT [PEAS]
engaged_VBN
in_PIN
CSR_NN
objectives_NN
a_DT
varied_JJ
series_NN
of_PIN
activities_NOMZ
in_PIN
the_DT
Philadelphia_NN
The_NN
Committee_NN
set_VBD
specific_JJ
CSR_NN
objectives_NN
in_PIN
community_NOMZ
where_RB
we_FPP1
were_VBD
seeking_VBG
to_TO
attract_VB
2004_CD
and_CC
we_FPP1
will_PRMD
report_VB [PUBV]
on_PIN
them_TPP3
in_PIN
full_JJ
in_PIN
our_FPP1
full_JJ
new_JJ
employees_NN
and_CC
establish_VB [PRIV]
our_FPP1
presence_NN
CSR_NN
report_NN
._.
To_TO
summarize_VB
,_,
the_DT
areas_NN
of_PIN
focus_NN
and_PHC
reputation_NOMZ
._.
A_DT
full_JJ
report_NN
of_PIN
all_QUAN
these_DEMO
initiatives_NN
in_PIN
2004_CD
in_PIN
each_QUAN
of_PIN
the_DT
Companys_NN
key_JJ
impact_NN
will_PRMD
be_VB [PASS]
found_VBN [PRIV]
in_PIN
the_DT
2004_CD
CSR_NN
report_NN
._.
areas_NN
were_VBD
as_IN
follows_VPRT
:_:
Specialist_NN
doctors_NN
are_VPRT [BEMA]
our_FPP1
key_JJ
customers_NN
and_PHC
Workplace_NN
we_FPP1
focus_VPRT
intently_RB
on_PIN
the_DT
development_NOMZ
of_PIN
strong_JJ
Living_VBG
up_RP
to_TO
what_WP
we_FPP1
believe_VPRT [PRIV]
in_PIN
:_:
encouraging_JJ
relationships_NN
with_PIN
them_TPP3
through_PIN
the_DT
provision_NN
the_DT
widest_JJ
possible_JJ
diversity_NOMZ
in_PIN
our_FPP1
workplace_NN
:_:
of_PIN
data_NN
and_PHC
information_NOMZ
on_PIN
the_DT
therapeutic_JJ
areas_NN
giving_VBG [WZPRES]
people_NN
the_DT
chance_NN
to_TO
develop_VB
their_TPP3
in_PIN
which_WDT [PIRE]
we_FPP1
specialize_VPRT
._.
Patients_NN
are_VPRT [BEMA]
the_DT
ultimate_JJ
beneficiaries_NN
of_PIN
Shires_NN
Example_NN
:_:
new_JJ
performance_NN
management_NOMZ
business_NOMZ
._.
It_PIT
is_VPRT
knowing_VBG [PRIV]
that_THVC
medicines_NN
have_VPRT [PEAS]
system_NN
introduced_VBN [WZPAST]
with_PIN
Shires_NN
corporate_JJ
values_NN
an_DT
impact_NN
on_PIN
patients_NN
lives_VPRT
that_DEMP
motivates_VPRT
many_QUAN
as_IN
a_DT
performance_NN
measure_NN
._.
We_FPP1
have_VPRT [PEAS]
continued_VBN
a_DT
strong_JJ
dialogue_NN
with_PIN
the_DT
patient_JJ
groups_NN
and_PHC
Marketplace_NN
key_JJ
opinion_NN
leaders_NN
who_WP [WHSUB]
lead_VPRT
and_PHC
influence_VPRT
the_DT
Helping_VBG
to_TO
educate_VB
patients_NN
and_PHC
health_NN
therapeutic_JJ
areas_NN
in_PIN
which_WDT [PIRE]
we_FPP1
have_VPRT
products_NN
._.
professionals_NN
about_IN
the_DT
treatments_NOMZ
we_FPP1
make_VPRT
and_CC
the_DT
diseases_NN
in_PIN
which_WDT [PIRE]
we_FPP1
specialize_VPRT
:_:
providing_VBG
medicines_NN
for_PIN
those_DEMP
who_WP
can_POMD
not_XX0
afford_VB
them_TPP3
:_:
making_VBG
sure_JJ
our_FPP1
marketing_GER
and_PHC
selling_GER
is_VPRT [PASS]
done_VBN [PROD]
in_PIN
an_DT
ethical_JJ
and_PHC
appropriate_JJ
way_NN
._.
Example_NN
:_:
Shire_NN
participated_VBD
in_PIN
the_DT
American_NN
Society_NN
of_PIN
Nephrology_NN
ASN_NN
Conference_NN
,_,
held_VBN [PRIV] [PASTP]
in_PIN
St_NN
Louis_NN
,_,
Missouri_NN
,_,
USA_NN
,_,
from_PIN
October_NN
29_CD
until_IN
November_NN
1_CD
,_,
2004_CD
in_PIN
advance_NN
of_PIN
FOSRENOL_NN
launch_NN
26_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
27_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
CSR_NN
:_:
Corporate_NN
social_JJ
responsibility_NOMZ
We_FPP1
are_VPRT [PASS]
pleased_VBN
with_PIN
the_DT
steady_JJ
progress_NN
we_FPP1
are_VPRT
making_VBG
with_PIN
our_FPP1
approach_NN
to_PIN
CSR_NN
Community_NOMZ
Shire_NN
completed_VBD
a_DT
return_NN
for_PIN
The_DT
Giving_GER
List_NN
,_,
Getting_VBG
involved_VBN
with_PIN
our_FPP1
local_JJ
communities_NOMZ
:_:
published_VBN [PASTP]
by_PIN
The_DT
Guardian_NN
newspaper_NN
and_CC
talking_VBG
more_EMPH
about_IN
our_FPP1
community_NOMZ
activities_NOMZ
was_VBD [PASS]
ranked_VBN
broadly_RB
in_PIN
line_NN
with_PIN
its_PIT
position_NOMZ
in_PIN
inside_PLACE
the_DT
Company_NN
:_:
collecting_VBG [PRESP]
all_QUAN
the_DT
information_NOMZ
the_DT
FTSE_NN
100_CD
._.
Shire_NN
is_VPRT
taking_VBG
part_NN
in_PIN
the_DT
London_NN
about_IN
our_FPP1
community_NOMZ
involvement_NOMZ
in_PIN
one_CD
place_NN
._.
Stock_NN
Exchanges_NN
pilot_NN
online_NN
CSR_NN
Index_NN
this_DEMO
database_NN
will_PRMD
enable_VB
the_DT
Company_NN
to_TO
monitor_VB
Examples_NN
:_:
Sponsorship_NN
of_PIN
Franklin_NN
Institute_NN
and_CC
track_VB
data_NN
gathered_VBN [PRIV] [WZPAST]
from_PIN
across_PLACE
the_DT
Shire_NN
Day_NN
free_JJ
entrance_NN
for_PIN
children_NN
:_:
organization_NOMZ
in_PIN
order_NN
to_TO
provide_VB
information_NOMZ
on_PIN
participation_NOMZ
by_PIN
CSR_NN
Chairman_NN
in_PIN
the_DT
Business_NOMZ
a_DT
more_EMPH
regular_JJ
basis_NN
to_PIN
the_DT
numerous_JJ
external_JJ
in_PIN
the_DT
Communitys_NN
BITCs_NN
Seeing_VBG [PRIV] [WZPRES]
is_VPRT
Believing_VBG [PRIV]
researchers_NN
and_PHC
assessors_NN
who_WP [WHSUB]
contact_VPRT
the_DT
program_NN
and_CC
subsequent_JJ
donation_NOMZ
to_PIN
the_DT
company_NN
with_PIN
CSR_NN
questionnaires_NN
._.
Kids_NN
Company_NN
,_,
a_DT
charitable_JJ
organization_NOMZ
that_TSUB
provides_VPRT
refuge_NN
and_PHC
help_NN
for_PIN
children_NN
whose_WPS [WHSUB]
Looking_VBG
ahead_PLACE
young_JJ
lives_NN
have_VPRT [PEAS]
been_VBN [BEMA]
blighted_PRED
by_PIN
fear_NN
,_,
violence_NN
We_FPP1
are_VPRT [PASS]
pleased_VBN
with_PIN
the_DT
steady_JJ
progress_NN
and_PHC
neglect_NN
._.
we_FPP1
are_VPRT
making_VBG
with_PIN
our_FPP1
approach_NN
to_PIN
CSR_NN
and_ANDC
how_RB
we_FPP1
are_VPRT
gaining_VBG
more_EMPH
recognition_NOMZ
for_PIN
our_FPP1
Environment_NOMZ
initiatives_NN
following_VBG [WZPRES]
the_DT
issue_NN
of_PIN
our_FPP1
first_JJ
CSR_NN
Integrating_VBG [WZPRES]
a_DT
single_JJ
Environmental_NN
Health_NN
&_CC
Safety_NN
Report_NN
for_PIN
2003_CD
._.
Shire_NN
is_VPRT [PASS]
committed_VBN
to_PIN
CSR_NN
but_CC
Community_NOMZ
:_:
Getting_VBG
involved_JJ
management_NOMZ
system_NN
across_PLACE
the_DT
Company_NN
not_XX0
complacent_JJ
we_FPP1
are_VPRT [BEMA]
aware_PRED
that_THAC
there_EX
are_VPRT
with_PIN
our_FPP1
local_JJ
communities_NOMZ
:_:
globally_RB
:_:
encouraging_JJ
suppliers_NN
to_TO
improve_VB
their_TPP3
many_QUAN
ways_NN
in_PIN
which_WDT [PIRE]
we_FPP1
can_POMD
improve_VB
or_CC
talking_VBG
more_EMPH
about_IN
our_FPP1
Health_NN
&_CC
Safety_NN
practices_NN
:_:
developing_VBG
practical_JJ
enhance_VB
our_FPP1
activities_NOMZ
._.
community_NOMZ
activities_NOMZ
inside_PLACE
guidelines_NN
for_PIN
our_FPP1
offices_NN
._.
the_DT
Company_NN
:_:
collecting_VBG [PRESP]
We_FPP1
welcome_JJ
feedback_NN
and_PHC
suggestions_NOMZ
and_CC
all_QUAN
the_DT
information_NOMZ
about_IN
Example_NN
:_:
Appointment_NOMZ
of_PIN
a_DT
Global_JJ
Head_NN
of_PIN
will_PRMD
be_VB [BEMA]
happy_PRED
to_TO
receive_VB
emails_NN
to_PIN
our_FPP1
dedicated_VBN
our_FPP1
community_NOMZ
involvement_NOMZ
Environment_NOMZ
,_,
Health_NN
&_CC
Safety_NN
EHS_NN
:_:
creation_NOMZ
address_NN
:_:
CSR@shire_NN
._.
com_NN
in_PIN
one_CD
place_NN
of_PIN
EHS_NN
principles_NN
as_IN
part_NN
of_PIN
a_DT
Mission_NN
Statement_NOMZ
for_PIN
distribution_NOMZ
to_PIN
Shire_NN
employees_NN
and_PHC
suppliers_NN
:_:
establishment_NOMZ
of_PIN
a_DT
global_JJ
EHS_NN
network_NN
amongst_PIN
suppliers_NN
to_TO
ascertain_VB [PRIV]
and_PHC
implement_VB
best_JJ
practices_NN
._.
CSR_NN
indices_VPRT
Shire_NN
continues_VPRT
to_TO
be_VB [BEMA]
a_DT
constituent_NN
of_PIN
the_DT
FTSE4Good_NN
Index_NN
despite_PIN
the_DT
introduction_NOMZ
of_PIN
tougher_JJ
criteria_NN
in_PIN
2004_CD
._.
The_DT
Company_NN
has_VPRT [PEAS]
taken_VBN
part_NN
,_,
for_PIN
the_DT
second_JJ
year_NN
running_VBG [WZPRES]
,_,
in_PIN
the_DT
BITC_NN
Corporate_NN
Responsibility_NOMZ
Index_NN
._.
Feedback_NN
,_,
following_VBG
BITCs_NN
assessment_NOMZ
of_PIN
Shire_NN
in_PIN
2003_CD
,_,
has_VPRT [PEAS]
been_VBN [PASS]
taken_VBN
into_PIN
account_NN
and_CC
led_VBD
to_PIN
an_DT
increased_VBN
focus_NN
on_PIN
training_GER
and_CC
internal_JJ
Guardian_NN
awareness_NOMZ
programs_NN
for_PIN
Shire_NN
employees_NN
Giving_GER
List_NN
during_PIN
2004_CD
and_CC
beyond_IN
._.
27_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
28_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Financial_NN
review_NN
The_DT
following_VBG
review_NN
should_NEMD
be_VB [PASS]
read_VBN
in_PIN
conjunction_NOMZ
with_PIN
the_DT
Companys_NN
consolidated_JJ
financial_JJ
statements_NOMZ
and_CC
related_JJ
notes_NN
appearing_VBG [SMP] [WZPRES]
elsewhere_RB
in_PIN
this_DEMO
annual_JJ
review_NN
Results_NN
of_PIN
operations_NOMZ
ADDERALL_NN
XR_NN
The_NN
Company_NN
in_PIN
this_DEMO
Financial_JJ
review_NN
meaning_GER
Sales_NN
of_PIN
ADDERALL_NN
XR_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
the_DT
consolidated_JJ
group_NN
recorded_VBD
net_JJ
income_NN
of_PIN
31_CD
,_,
2004_CD
were_VBD
$_$
606.7_CD
million_CD
,_,
an_DT
increase_NN
of_PIN
28_CD
%_NN
$_$
269.0_CD
million_CD
2003_CD
:_:
$_$
276.1_CD
million_CD
and_CC
diluted_VBN
compared_VBN
to_PIN
prior_JJ
year_NN
2003_CD
:_:
$_$
474.5_CD
million_CD
._.
earnings_GER
per_PIN
ordinary_JJ
share_NN
of_PIN
53.3_CD
2003_CD
:_:
ADDERALL_NN
XR_NN
held_VBD [PRIV]
a_DT
25_CD
%_NN
share_NN
of_PIN
the_DT
total_JJ
54.2_CD
._.
Net_JJ
income_NN
for_PIN
2004_CD
was_VBD [PASS]
impacted_VBN
US_FPP1
ADHD_NN
market_NN
in_PIN
December_NN
2004_CD
December_NN
by_PIN
both_DT
the_DT
loss_NN
on_PIN
disposal_NN
of_PIN
the_DT
vaccines_NN
2003_CD
:_:
23_CD
%_NN
and_CC
at_PIN
that_DEMO
date_NN
was_VBD [BEMA]
the_DT
leading_VBG
business_NOMZ
of_PIN
$_$
44.2_CD
million_CD
and_CC
the_DT
$_$
48.5_CD
million_CD
brand_NN
in_PIN
the_DT
US_FPP1
ADHD_NN
market_NN
._.
As_IN
previously_TIME
of_PIN
reorganization_NOMZ
costs_NN
recorded_VBN [WZPAST]
in_PIN
2004_CD
._.
disclosed_VBN [PUBV]
,_,
legal_JJ
proceedings_GER
relating_VBG [WZPRES]
to_PIN
generic_JJ
competitors_NN
seeking_VBG [WZPRES]
to_PIN
market_NN
generic_JJ
versions_NN
Total_JJ
revenues_NN
of_PIN
ADDERALL_NN
XR_NN
are_VPRT [BEMA]
in_PIN
progress_NN
._.
Further_JJ
For_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
,_,
total_JJ
information_NOMZ
can_POMD
be_VB [PASS]
found_VBN [PRIV]
in_PIN
Note_NN
20_CD
to_PIN
the_DT
revenues_NN
increased_VBN [WZPAST]
by_PIN
13_CD
%_NN
to_TO
$_$
1,363.2_CD
million_CD
consolidated_JJ
financial_JJ
statements_NOMZ
._.
Although_CONC
Angus_NN
Russell_NN
compared_VBD
to_TO
$_$
1,211.6_CD
million_CD
in_PIN
2003_CD
._.
Shire_NN
rigorously_RB
defends_VPRT
its_PIT
patent_NN
rights_NN
Chief_NN
Financial_NN
Officer_NN
against_PIN
generic_JJ
and_PHC
other_JJ
challenges_NN
,_,
the_DT
loss_NN
Revenue_NN
is_VPRT [SPAU] [PASS]
primarily_RB
derived_VBN
from_PIN
sales_NN
of_PIN
or_CC
expiration_NOMZ
of_PIN
patent_NN
protection_NOMZ
on_PIN
this_DEMO
product_NN
pharmaceutical_JJ
products_NN
and_PHC
royalties_NN
earned_VBN
could_POMD
have_VB
a_DT
material_NN
adverse_JJ
effect_NN
on_PIN
Shires_NN
on_PIN
products_NN
out-licensed_JJ
to_PIN
third_JJ
parties_NN
._.
financial_JJ
condition_NOMZ
and_PHC
results_NN
of_PIN
operations_NOMZ
._.
For_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
,_,
82_CD
%_NN
of_PIN
revenues_NN
were_VBD [BEMA]
in_PIN
respect_NN
of_PIN
pharmaceutical_JJ
AGRYLIN_NN
product_NN
sales_NN
2003_CD
:_:
83_CD
%_NN
._.
Royalties_NN
comprised_VBD
Sales_NN
of_PIN
AGRYLIN_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
17_CD
%_NN
of_PIN
total_JJ
revenues_NN
in_PIN
both_DT
2003_CD
and_CC
2004_CD
._.
2004_CD
were_VBD
$_$
152.5_CD
million_CD
,_,
an_DT
increase_NN
of_PIN
15_CD
%_NN
Income_NN
from_PIN
out-licensing_JJ
product_NN
rights_NN
compared_VBN [WZPAST]
to_PIN
the_DT
prior_JJ
year_NN
2003_CD
:_:
$_$
132.5_CD
million_CD
._.
has_VPRT [PEAS]
increased_VBN
slightly_DWNT
as_IN
a_DT
proportion_NOMZ
of_PIN
US_FPP1
sales_NN
were_VBD [BEMA]
up_RB
13_CD
%_NN
in_PIN
the_DT
year_NN
and_PHC
AGRYLIN_NN
revenues_NN
and_CC
represented_VBD
1_CD
%_NN
of_PIN
revenues_NN
had_VBD
a_DT
28_CD
%_NN
share_NN
of_PIN
the_DT
total_JJ
US_FPP1
AGRYLIN_NN
,_,
in_PIN
2004_CD
._.
hydrea_NN
and_CC
generic_JJ
hydroxyurea_NN
prescription_NOMZ
market_NN
in_PIN
December_NN
2004_CD
December_NN
2003_CD
:_:
27_CD
%_NN
._.
a_DT
Product_NN
sales_NN
For_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
,_,
the_DT
US_FPP1
pediatric_JJ
exclusivity_NOMZ
expired_VBD
in_PIN
September_NN
Companys_NN
product_NN
sales_NN
increased_VBN [WZPAST]
by_PIN
11_CD
%_NN
2004_CD
and_CC
in_PIN
August_NN
2004_CD
Shire_NN
filed_VBD
a_DT
Citizens_NN
to_TO
$_$
1,112.5_CD
million_CD
compared_VBN
to_TO
$_$
1,004.3_CD
million_CD
Petition_NOMZ
with_PIN
the_DT
FDA_NN
._.
Shire_NN
has_VPRT [PEAS]
petitioned_VBN
that_DEMO
in_PIN
the_DT
prior_JJ
year_NN
._.
The_DT
main_JJ
products_NN
driving_VBG [WZPRES]
this_DEMO
any_QUAN
generic_JJ
anagrelide_NN
product_NN
should_NEMD
be_VB
growth_NN
are_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
table_NN
below_PLACE
:_:
demonstrated_VBD [PRIV]
to_TO
be_VB [BEMA]
bio-equivalent_PRED
to_PIN
AGRYLIN_NN
._.
Product_NN
highlights_VPRT
1_CD
,_,
2_CD
SalesSales_NN
US_FPP1
Rx_NN
US_FPP1
market_NN
1_CD
2_CD
Product_NN
$_$
million_CD
growth_NN
growth_NN
share_NN
ADDERALL_NN
XR_NN
606.7_CD
28_CD
%_NN
21_CD
%_NN
25_CD
%_NN
AGRYLIN_NN
US_FPP1
market_NN
105.7_CD
13_CD
%_NN
6_CD
%_NN
28_CD
%_NN
AGRYLIN_NN
International_NN
market_NN
46.8_CD
20_CD
%_NN
n_VBD
a_DT
n_NN
a_DT
PENTASA_NN
115.0_CD
16_CD
%_NN
2_CD
%_NN
18_CD
%_NN
CARBATROL_NN
54.3_CD
4_CD
%_NN
11_CD
%_NN
46_CD
%_NN
1_CD
Compared_VBN
to_PIN
2003_CD
._.
2_CD
IMS_NN
Prescription_NOMZ
Data_NN
Product_NN
specific_NN
at_PIN
December_NN
31_CD
,_,
2004_CD
IMS_NN
Health_NN
is_VPRT [BEMA]
a_DT
leading_VBG
global_JJ
provider_NN
of_PIN
business_NOMZ
intelligence_NN
for_PIN
the_DT
pharmaceutical_JJ
and_CC
healthcare_NN
industries_NN
._.
28_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
29_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Financial_NN
review_NN
The_DT
Company_NN
is_VPRT
anticipating_VBG [PRIV]
the_DT
launch_NN
of_PIN
with_PIN
the_DT
exception_NOMZ
of_PIN
the_DT
UK_NN
and_CC
the_DT
Republic_NN
generic_JJ
versions_NN
of_PIN
AGRYLIN_NN
in_PIN
the_DT
US_FPP1
market_NN
of_PIN
Ireland_NN
where_RB
Shire_NN
acquired_VBD
the_DT
exclusive_JJ
but_CC
no_SYNE
generic_JJ
products_NN
have_VPRT [PEAS]
come_VBN
to_PIN
market_NN
marketing_GER
rights_NN
in_PIN
May_POMD
2004_CD
._.
to_PIN
date_NN
._.
The_DT
launch_NN
of_PIN
generic_JJ
versions_NN
of_PIN
AGRYLIN_NN
may_POMD [SPAU]
negatively_RB
affect_VB
the_DT
sales_NN
Cost_NN
of_PIN
sales_NN
and_CC
net_JJ
operating_GER
expenses_NN
of_PIN
AGRYLIN_NN
in_PIN
the_DT
future_NN
._.
For_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
,_,
the_DT
cost_NN
of_PIN
product_NN
sales_NN
amounted_VBD
to_PIN
13_CD
%_NN
of_PIN
product_NN
sales_NN
International_NN
sales_NN
all_QUAN
sales_NN
outside_PLACE
of_PIN
the_DT
US_FPP1
2003_CD
:_:
14_CD
%_NN
._.
The_DT
decrease_NN
can_POMD
be_VB [PASS]
attributed_VBN
to_TO
reported_VBN [PUBV]
in_PIN
US_FPP1
dollars_NN
were_VBD [BEMA]
up_RB
20_CD
%_NN
,_,
due_JJ
to_PIN
product_NN
mix_NN
,_,
with_PIN
a_DT
greater_JJ
proportion_NOMZ
of_PIN
sales_NN
strong_JJ
growth_NN
in_PIN
Canadian_JJ
and_PHC
European_JJ
coming_VBG
from_PIN
higher_JJ
margin_NN
products_NN
._.
markets_NN
and_CC
,_,
because_CAUS
these_DEMO
sales_NN
revenues_NN
are_VPRT [PASS]
earned_VBN
in_PIN
currencies_NN
other_JJ
than_PIN
the_DT
US_FPP1
dollar_NN
,_,
R&D_NN
expenditure_NN
increased_VBD
from_PIN
$_$
187.7_CD
million_CD
the_DT
benefit_NN
of_PIN
favorable_JJ
translation_NOMZ
effects_NN
._.
Sales_NN
in_PIN
2003_CD
to_TO
$_$
196.3_CD
million_CD
in_PIN
2004_CD
,_,
with_PIN
savings_GER
outside_PLACE
the_DT
US_FPP1
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
from_PIN
the_DT
closure_NN
of_PIN
the_DT
Canada-based_JJ
Lead_JJ
2004_CD
were_VBD
$_$
46.8_CD
million_CD
2003_CD
:_:
$_$
38.9_CD
million_CD
._.
Optimization_NOMZ
business_NOMZ
in_PIN
2003_CD
partially_DWNT
reinvested_VBN
to_TO
fund_VB
late_TIME
stage_NN
Phase_NN
3_CD
trials_NN
._.
Shires_NN
AGRYLIN_NN
gained_VBD
EU_NN
approval_NN
in_PIN
November_NN
pipeline_NN
is_VPRT [SPAU] [PASS]
now_TIME
well_RB
advanced_VBN
with_PIN
four_CD
projects_NN
2004_CD
and_CC
trades_VPRT
under_IN
the_DT
name_NN
XAGRID_NN
._.
in_PIN
late_TIME
stage_NN
development_NOMZ
or_CC
registration_NOMZ
._.
In_PIN
The_DT
product_NN
will_PRMD
have_VB
up_RP
to_TO
ten_VB
years_NN
market_NN
addition_NOMZ
,_,
five_CD
projects_NN
were_VBD [PASS]
approved_VBN
during_PIN
the_DT
exclusivity_NOMZ
in_PIN
accordance_NN
with_PIN
current_JJ
orphan_JJ
second_JJ
half_NN
of_PIN
2004_CD
._.
Expressed_VBN
as_IN
a_DT
percentage_NN
medicinal_JJ
product_NN
legislation_NOMZ
in_PIN
the_DT
EU_NN
._.
of_PIN
total_JJ
revenues_NN
,_,
R&D_NN
expenditure_NN
was_VBD [BEMA]
14_CD
%_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
2003_CD
:_:
15_CD
%_NN
._.
PENTASA_NN
Shire_NN
has_VPRT [SPAU] [PEAS]
historically_RB
invested_VBN
between_PIN
17-20_CD
%_NN
Sales_NN
of_PIN
PENTASA_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
of_PIN
revenues_NN
in_PIN
R&D_NN
._.
With_PIN
the_DT
refocusing_GER
of_PIN
the_DT
2004_CD
were_VBD
$_$
115.0_CD
million_CD
,_,
an_DT
increase_NN
of_PIN
16_CD
%_NN
project_NN
pipeline_NN
this_DEMO
year_NN
and_CC
the_DT
successful_JJ
compared_VBN
to_PIN
prior_JJ
year_NN
2003_CD
:_:
$_$
99.3_CD
million_CD
._.
out-licensing_GER
of_PIN
certain_JJ
products_NN
,_,
this_DEMO
percentage_NN
PENTASA_NN
had_VBD
an_DT
18_CD
%_NN
share_NN
of_PIN
the_DT
total_JJ
US_FPP1
oral_JJ
fell_VBD
in_PIN
2004_CD
._.
Shire_NN
anticipates_VPRT [PRIV]
that_THVC
the_DT
level_NN
of_PIN
mesalamine_NN
olsalazine_NN
prescription_NOMZ
market_NN
in_PIN
R&D_NN
spend_VPRT
will_PRMD
be_VB [BEMA]
approximately_RB
15_CD
%_NN
excluding_VBG [WZPRES]
December_NN
2004_CD
December_NN
2003_CD
:_:
18_CD
%_NN
._.
the_DT
impact_NN
of_PIN
payments_NOMZ
relating_VBG [WZPRES]
to_PIN
NRP104_NN
going_VBG [WZPRES]
forward_RB
._.
CARBATROL_NN
Sales_NN
of_PIN
CARBATROL_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
SG&A_NN
31_CD
,_,
2004_CD
were_VBD
$_$
54.3_CD
million_CD
,_,
an_DT
increase_NN
of_PIN
4_CD
%_NN
expenses_NN
increased_VBD
from_PIN
$_$
409.7_CD
million_CD
in_PIN
2003_CD
compared_VBN
to_PIN
prior_JJ
year_NN
2003_CD
:_:
$_$
52.4_CD
million_CD
._.
CARBATROL_NN
had_VBD
a_DT
46_CD
%_NN
share_NN
of_PIN
the_DT
total_JJ
US_FPP1
This_DEMP
is_VPRT [BEMA]
primarily_RB
due_PRED
to_PIN
an_DT
increase_NN
in_PIN
marketing_GER
extended_VBN
release_NN
carbamazepine_NN
prescription_NOMZ
expenses_NN
,_,
related_VBN [PASTP]
to_PIN
new_JJ
product_NN
launches_NN
market_NN
in_PIN
December_NN
2004_CD
December_NN
2003_CD
:_:
including_VBG
FOSRENOL_NN
,_,
XAGRID_NN
and_PHC
ADDERALL_NN
43_CD
%_NN
._.
As_IN
previously_TIME
disclosed_VBN [PUBV]
,_,
legal_JJ
proceedings_GER
XR_NN
adult_NN
,_,
and_ANDC
sales_NN
costs_NN
,_,
due_JJ
to_PIN
the_DT
relating_VBG
to_PIN
CARBATROL_NN
are_VPRT [BEMA]
in_PIN
progress_NN
._.
recruitment_NOMZ
in_PIN
Q4_NN
2004_CD
of_PIN
a_DT
sales_NN
force_NN
of_PIN
about_IN
Further_JJ
information_NOMZ
can_POMD
be_VB [PASS]
found_VBN [PRIV]
in_PIN
Note_NN
20_CD
85_CD
people_NN
exclusively_RB
to_TO
promote_VB
FOSRENOL_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
As_IN
a_DT
percentage_NN
of_PIN
product_NN
sales_NN
,_,
SG&A_NN
expenses_NN
were_VBD [BEMA]
41_CD
%_NN
2003_CD
:_:
37_CD
%_NN
._.
The_DT
b_NN
Royalties_NN
depreciation_NOMZ
charge_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
Royalty_NN
revenue_NN
increased_VBD
13_CD
%_NN
to_TO
$_$
230.4_CD
million_CD
2004_CD
was_VBD
$_$
19.8_CD
million_CD
2003_CD
:_:
$_$
11.5_CD
million_CD
._.
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
,_,
compared_VBN
The_DT
increase_NN
was_VBD [BEMA]
primarily_RB
due_PRED
to_PIN
a_DT
shortening_VBG
to_TO
$_$
203.6_CD
million_CD
in_PIN
2003_CD
._.
of_PIN
the_DT
useful_JJ
economic_JJ
lives_NN
on_PIN
certain_JJ
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
US_FPP1
site_NN
Shire_NN
receives_VPRT
royalties_NN
from_PIN
GlaxoSmithKline_NN
rationalization_NOMZ
._.
Amortization_NOMZ
charges_NN
were_VBD [BEMA]
plc_JJ
GSK_NN
on_PIN
worldwide_JJ
sales_NN
of_PIN
3TC_NN
and_CC
$_$
38.7_CD
million_CD
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
ZEFFIX_NN
._.
Other_JJ
royalties_NN
are_VPRT [BEMA]
primarily_RB
in_PIN
respect_NN
2003_CD
:_:
$_$
26.4_CD
million_CD
,_,
with_PIN
the_DT
increase_NN
due_JJ
to_PIN
the_DT
of_PIN
REMINYL_NN
galantamine_NN
hydrobromide_NN
,_,
a_DT
purchase_NN
of_PIN
$_$
49.2_CD
million_CD
of_PIN
intangible_JJ
assets_NN
in_PIN
product_NN
marketed_VBN [WZPAST]
in_PIN
the_DT
US_FPP1
and_CC
the_DT
rest_NN
of_PIN
the_DT
2004_CD
and_CC
the_DT
reassessment_NOMZ
of_PIN
the_DT
useful_JJ
world_NN
by_PIN
Janssen_NN
Pharmaceutica_NN
NV_NN
Janssen_NN
,_,
economic_JJ
lives_NN
of_PIN
certain_JJ
intangibles_NN
._.
29_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
30_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Financial_NN
review_NN
Intangible_JJ
asset_NN
impairments_NOMZ
for_PIN
the_DT
year_NN
to_TO
increased_VBN
investment_NOMZ
in_PIN
trade_NN
debtors_NN
and_PHC
December_NN
31_CD
,_,
2004_CD
were_VBD
$_$
13.5_CD
million_CD
2003_CD
:_:
stock_NN
levels_NN
which_WDT [WHSUB]
may_POMD
arise_VB
as_IN
sales_NN
levels_NN
$_$
27.5_CD
million_CD
see_VPRT [PRIV]
Note_NN
12_CD
to_PIN
the_DT
consolidated_JJ
increase_NN
:_:
financial_JJ
statements_NOMZ
for_PIN
further_JJ
information_NOMZ
._.
competitive_JJ
and_PHC
technological_JJ
developments_NOMZ
:_:
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
,_,
$_$
48.5_CD
million_CD
of_PIN
reorganization_NOMZ
costs_NN
were_VBD [BEMA]
the_DT
timing_NN
and_PHC
cost_NN
of_PIN
obtaining_VBG
required_VBN [SUAV]
recorded_VBN
relating_VBG
to_PIN
the_DT
US_FPP1
site_NN
consolidation_NOMZ
._.
regulatory_JJ
approvals_NN
for_PIN
new_JJ
products_NN
:_:
and_ANDC
The_DT
costs_NN
related_VBN [WZPAST]
to_PIN
employee_NN
severance_NN
$_$
20.0_CD
million_CD
,_,
relocation_NOMZ
$_$
13.8_CD
million_CD
and_CC
other_JJ
the_DT
continuing_VBG
revenues_NN
generated_VBD
from_PIN
sales_NN
costs_NN
associated_VBN [WZPAST]
with_PIN
the_DT
reorganization_NOMZ
of_PIN
key_JJ
products_NN
._.
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2003_CD
the_DT
Company_NN
recorded_VBN
reorganization_NOMZ
As_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
,_,
the_DT
Company_NN
had_VBD
costs_NN
of_PIN
$_$
23.9_CD
million_CD
._.
These_DEMP
related_VBN
to_PIN
cash_NN
,_,
restricted_VBN
cash_NN
and_CC
short-term_JJ
investments_NOMZ
$_$
13.2_CD
million_CD
of_PIN
costs_NN
in_PIN
connection_NOMZ
with_PIN
the_DT
of_PIN
$_$
1,457.5_CD
million_CD
2003_CD
:_:
$_$
1,414.0_CD
million_CD
._.
closure_NN
of_PIN
the_DT
Lead_JJ
Optimization_NOMZ
division_NN
,_,
Total_JJ
long-term_JJ
debt_NN
excluding_VBG [WZPRES]
capital_NN
leases_NN
primarily_RB
for_PIN
employee_NN
severance_NN
$_$
6.4_CD
million_CD
as_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
was_VBD
$_$
116,000_CD
and_CC
the_DT
write-off_PIN
of_PIN
property_NN
,_,
plant_NN
and_CC
2003_CD
:_:
$_$
370.2_CD
million_CD
in_PIN
respect_NN
of_PIN
guaranteed_JJ
equipment_NOMZ
$_$
6.0_CD
million_CD
._.
In_CONJ
addition_NULL
,_,
the_DT
convertible_JJ
notes_NN
._.
Company_NN
made_VBD
the_DT
decision_NN
to_TO
close_VB
certain_JJ
properties_NN
:_:
a_DT
write-down_NN
of_PIN
$_$
10.7_CD
million_CD
was_VBD [BEMA]
During_PIN
the_DT
third_JJ
quarter_NN
of_PIN
2004_CD
,_,
Shire_NN
redeemed_VBD
made_VBN
to_TO
record_VB
the_DT
assets_NN
at_PIN
fair_JJ
value_NN
._.
$_$
370.1_CD
million_CD
of_PIN
the_DT
$_$
400_CD
million_CD
2_CD
%_NN
guaranteed_VBN [PUBV]
convertible_JJ
notes_NN
due_JJ
2011_CD
2003_CD
:_:
$_$
29.8_CD
million_CD
._.
Discontinued_VBN
operations_NOMZ
The_DT
Company_NN
completed_VBD
the_DT
disposal_NN
of_PIN
its_PIT
Treasury_NN
policies_NN
and_CC
financial_JJ
risk_NN
vaccines_NN
business_NOMZ
to_PIN
ID_NN
Biomedical_NN
Corporation_NOMZ
management_NOMZ
IDB_NN
on_PIN
September_NN
9_CD
,_,
2004_CD
._.
The_DT
vaccines_NN
Shires_VPRT
principal_JJ
treasury_NN
operations_NOMZ
are_VPRT [PASS]
business_NOMZ
impacted_VBD
operating_GER
profit_NN
with_PIN
losses_NN
of_PIN
managed_VBN
by_PIN
the_DT
corporate_JJ
treasury_NN
function_NOMZ
$_$
20.1_CD
million_CD
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
based_VBN
in_PIN
the_DT
UK_NN
._.
All_QUAN
treasury_NN
operations_NOMZ
are_VPRT [BEMA]
2003_CD
:_:
$_$
21.9_CD
million_CD
._.
In_CONJ
addition_NULL
the_DT
Company_NN
conducted_VBN [WZPAST]
within_PIN
a_DT
framework_NN
of_PIN
policies_NN
and_CC
recorded_VBD
a_DT
loss_NN
on_PIN
the_DT
disposal_NN
of_PIN
the_DT
vaccines_NN
procedures_NN
approved_VBN [WZPAST]
by_PIN
the_DT
Board_NN
._.
As_IN
a_DT
business_NOMZ
of_PIN
$_$
44.2_CD
million_CD
in_PIN
the_DT
year_NN
to_PIN
December_NN
matter_NN
of_PIN
policy_NN
,_,
the_DT
Company_NN
does_VPRT
not_XX0
31_CD
,_,
2004_CD
._.
See_VB [PRIV]
Note_VB [PRIV]
3_CD
ii_FW
to_PIN
the_DT
consolidated_JJ
undertake_VPRT
speculative_JJ
transactions_NOMZ
that_TSUB
would_PRMD
financial_JJ
statements_NOMZ
for_PIN
further_JJ
information_NOMZ
._.
increase_NN
currency_NN
or_CC
interest_NN
rate_NN
exposure_NN
._.
The_DT
Board_NN
reviews_NN
and_CC
agrees_VPRT [SUAV] [PUBV]
policies_NN
for_PIN
managing_VBG
Capital_NN
structure_NN
these_DEMO
risks_NN
and_CC
they_TPP3
are_VPRT [PASS]
summarized_VBN
below_PLACE
._.
The_DT
Company_NN
has_VPRT [PEAS]
financed_VBN
its_PIT
operations_NOMZ
since_OSUB
inception_NOMZ
through_PIN
private_JJ
and_PHC
public_JJ
offerings_GER
Foreign_JJ
currency_NN
risk_NN
of_PIN
equity_NOMZ
securities_NOMZ
,_,
the_DT
issuance_NN
of_PIN
loan_NN
notes_NN
The_DT
Company_NN
is_VPRT [PASS]
exposed_VBN
to_PIN
movements_NOMZ
in_PIN
and_CC
convertible_JJ
notes_NN
,_,
collaborative_JJ
licensing_GER
foreign_JJ
exchange_NN
rates_NN
against_PIN
the_DT
US_FPP1
dollar_NN
and_PHC
development_NOMZ
fees_NN
,_,
product_NN
sales_NN
and_CC
for_PIN
trading_GER
transactions_NOMZ
and_CC
the_DT
translation_NOMZ
of_PIN
investment_NOMZ
income_NN
._.
net_JJ
assets_NN
and_PHC
earnings_GER
of_PIN
non-US_FPP1
subsidiaries_NN
._.
The_DT
main_JJ
trading_GER
currencies_NN
of_PIN
the_DT
Company_NN
The_DT
Companys_NN
funding_GER
requirements_NOMZ
depend_VPRT
are_VPRT [BEMA]
the_DT
US_FPP1
dollar_NN
,_,
the_DT
Canadian_JJ
dollar_NN
,_,
Pounds_NN
on_PIN
a_DT
number_NN
of_PIN
factors_NN
,_,
including_VBG
:_:
sterling_GER
and_CC
the_DT
Euro_NN
._.
The_DT
financial_JJ
statements_NOMZ
of_PIN
foreign_JJ
entities_NOMZ
are_VPRT [PASS]
translated_VBN
using_VBG
the_DT
the_DT
Companys_NN
product_NN
development_NOMZ
accounting_GER
policies_NN
described_VBN [WZPAST]
in_PIN
Note_NN
2_CD
k_NN
to_PIN
programs_NN
,_,
business_NOMZ
and_PHC
product_NN
acquisitions_NOMZ
:_:
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
the_DT
level_NN
of_PIN
resources_NN
required_VBN [SUAV] [WZPAST]
for_PIN
the_DT
The_DT
Company_NN
reports_VPRT [PUBV]
its_PIT
results_NN
in_PIN
US_FPP1
dollars_NN
._.
expansion_NN
of_PIN
marketing_GER
capabilities_NOMZ
as_IN
the_DT
As_IN
the_DT
majority_NOMZ
of_PIN
the_DT
Companys_NN
transactions_NOMZ
product_NN
base_NN
expands_VPRT
:_:
are_VPRT [SPAU] [PASS]
also_RB
denominated_VBN
in_PIN
US_FPP1
dollars_NN
,_,
this_DEMP
reduces_VPRT
the_DT
impact_NN
of_PIN
currency_NN
movements_NOMZ
on_PIN
the_DT
Companys_NN
results_NN
._.
30_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
31_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Financial_NN
review_NN
The_DT
exposure_NN
to_PIN
foreign_JJ
exchange_NN
risk_NN
is_VPRT [BEMA]
For_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
net_JJ
cash_NN
managed_VBD
and_PHC
monitored_VBD
by_PIN
the_DT
treasury_NN
provided_VBN [WZPAST]
by_PIN
operating_VBG
activities_NOMZ
amounted_VBD
to_TO
function_VB
._.
Exposures_NN
are_VPRT [SPAU] [PASS]
generally_RB
managed_VBN
$_$
520.7_CD
million_CD
compared_VBN
to_TO
$_$
379.1_CD
million_CD
in_PIN
2003_CD
._.
through_PIN
natural_JJ
hedging_GER
via_PIN
the_DT
currency_NN
denomination_NOMZ
of_PIN
cash_NN
balances_NN
._.
As_IN
of_PIN
December_NN
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
net_JJ
cash_NN
31_CD
,_,
2004_CD
,_,
the_DT
Company_NN
had_VBD
two_CD
outstanding_JJ
generated_VBN
from_PIN
operations_NOMZ
was_VBD [PASS]
used_VBN
primarily_RB
forward_RB
foreign_JJ
exchange_NN
contracts_NN
with_PIN
a_DT
total_NN
to_TO
fund_VB
the_DT
Companys_NN
tax_NN
payments_NOMZ
,_,
capital_NN
principal_NN
amount_NN
of_PIN
$_$
39_CD
million_CD
hedging_GER
expenditures_NN
including_VBG [WZPRES]
the_DT
purchase_NN
of_PIN
intangible_JJ
investments_NOMZ
held_VBN [PRIV] [WZPAST]
in_PIN
its_PIT
Canadian_JJ
subsidiary_NN
._.
assets_NN
and_PHC
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
,_,
and_ANDC
There_EX
were_VBD
no_SYNE
material_NN
gains_NN
or_CC
losses_NN
on_PIN
the_DT
repayment_NOMZ
of_PIN
debt_NN
._.
Capital_NN
expenditure_NN
Market_NN
risk_NN
of_PIN
investments_NOMZ
Expenditure_NN
on_PIN
intangible_JJ
assets_NN
of_PIN
$_$
30.2_CD
million_CD
As_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
the_DT
Company_NN
had_VBD
2003_CD
:_:
$_$
47.0_CD
million_CD
comprised_VBN
payments_NOMZ
$_$
63.3_CD
million_CD
2003_CD
:_:
$_$
73.0_CD
million_CD
of_PIN
investments_NOMZ
made_VBN
to_TO
acquire_VB
additional_JJ
rights_NN
for_PIN
REMINYL_NN
comprising_VBG [WZPRES]
equity_NOMZ
investment_NOMZ
funds_NN
,_,
private_JJ
and_CC
FOSRENOL_NN
._.
companies_NN
and_CC
public_JJ
quoted_VBN
companies_NN
._.
The_DT
public_JJ
quoted_VBN
companies_NN
are_VPRT [PASS]
exposed_VBN
to_PIN
market_NN
Capital_NN
expenditure_NN
on_PIN
property_NN
,_,
plant_NN
and_PHC
risk_NN
._.
No_SYNE
financial_JJ
instruments_NOMZ
or_CC
derivatives_NN
have_VPRT
equipment_NOMZ
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
was_VBD [PASS]
been_VBN [PASS]
employed_VBN
to_TO
hedge_VB
this_DEMO
risk_NN
._.
This_DEMO
expenditure_NN
included_VBD
the_DT
ongoing_JJ
implementation_NOMZ
of_PIN
an_DT
Interest_NN
rate_NN
risk_VB
Enterprise_NN
Resource_NN
Planning_GER
system_NN
by_PIN
the_DT
The_DT
majority_NOMZ
of_PIN
the_DT
Companys_NN
debt_NN
was_VBD [PASS]
repaid_VBN
Company_NN
$_$
9.1_CD
million_CD
and_CC
further_JJ
upgrades_NN
during_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
and_CC
to_PIN
the_DT
US_FPP1
manufacturing_GER
facility_NOMZ
$_$
19.5_CD
million_CD
._.
consequently_CONJ
it_PIT
has_VPRT [PEAS]
limited_VBN
exposure_NN
to_PIN
interest_NN
rate_NN
movements_NOMZ
._.
Dividend_NN
policy_NN
Historically_NN
,_,
the_DT
Company_NN
has_VPRT [PEAS]
not_XX0
paid_VBN
any_QUAN
In_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
the_DT
average_NN
dividends_NN
._.
Given_VBN
the_DT
stage_NN
of_PIN
development_NOMZ
and_PHC
interest_NN
rate_NN
received_VBN [WZPAST]
on_PIN
cash_NN
and_PHC
liquid_NN
size_NN
of_PIN
the_DT
Company_NN
and_CC
related_VBN
strong_JJ
cash_NN
investments_NOMZ
was_VBD [BEMA]
approximately_RB
1.44_CD
%_NN
per_PIN
flows_NN
,_,
the_DT
Board_NN
announced_VBD [PUBV]
its_PIT
intention_NOMZ
to_TO
begin_VB
annum_NN
._.
The_DT
largest_JJ
proportion_NOMZ
of_PIN
investments_NOMZ
payment_NOMZ
of_PIN
dividends_NN
to_PIN
shareholders_NN
in_PIN
2004_CD
._.
was_VBD [BEMA]
in_PIN
US_FPP1
dollar_NN
liquidity_NOMZ
funds_NN
._.
An_DT
interim_JJ
dividend_NN
for_PIN
the_DT
first_JJ
half_NN
of_PIN
2004_CD
of_PIN
one_CD
penny_NN
sterling_GER
1.82_CD
per_PIN
ordinary_JJ
share_NN
Taxation_NOMZ
was_VBD [PASS]
paid_VBN
in_PIN
October_NN
2004_CD
and_CC
an_DT
interim_NN
For_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
the_DT
tax_NN
charge_NN
dividend_NN
for_PIN
the_DT
second_JJ
half_NN
of_PIN
2004_CD
of_PIN
two_CD
increased_VBN
by_PIN
$_$
21.7_CD
million_CD
to_TO
$_$
129.1_CD
million_CD
._.
pence_NN
sterling_GER
3.85_CD
per_PIN
ordinary_JJ
share_NN
was_VBD [PASS]
paid_VBN
in_PIN
April_NN
2005_CD
._.
Shire_NN
intends_VPRT [SUAV]
to_TO
pursue_VB
a_DT
A_DT
reconciliation_NOMZ
of_PIN
the_DT
current_JJ
tax_NN
charge_NN
for_PIN
progressive_JJ
dividend_NN
policy_NN
._.
It_PIT
is_VPRT [PASS]
expected_VBN [PRIV]
that_THVC
2004_CD
to_PIN
the_DT
profit_NN
before_IN
tax_NN
for_PIN
the_DT
year_NN
at_PIN
the_DT
the_DT
first_JJ
interim_JJ
payment_NOMZ
each_QUAN
year_NN
will_PRMD
be_VB [BEMA]
statutory_JJ
tax_NN
rate_NN
of_PIN
30_CD
%_NN
is_VPRT [PASS]
given_VBN
in_PIN
Note_NN
26_CD
maintained_VBD [PUBV]
at_PIN
a_DT
consistent_JJ
level_NN
and_CC
any_QUAN
growth_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
will_PRMD [SPAU]
typically_RB
come_VB
through_PIN
increasing_VBG
the_DT
second_JJ
interim_JJ
dividend_NN
in_PIN
a_DT
financial_JJ
year_NN
._.
Any_QUAN
payment_NOMZ
Cash_NN
flows_VPRT
of_PIN
dividends_NN
is_VPRT [BEMA]
at_PIN
the_DT
discretion_NOMZ
of_PIN
the_DT
Board_NN
As_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
,_,
cash_NN
,_,
restricted_VBN [PASTP]
of_PIN
Directors_NN
and_CC
will_PRMD
be_VB [PASS]
made_VBN
in_PIN
Pounds_NN
sterling_GER
cash_NN
and_CC
short-term_JJ
investments_NOMZ
totalled_VBD
to_PIN
ordinary_JJ
shareholders_NN
,_,
US_FPP1
dollars_NN
to_PIN
holders_NN
$_$
1,457.5_CD
million_CD
,_,
an_DT
increase_NN
of_PIN
$_$
43.5_CD
million_CD
of_PIN
American_JJ
depositary_JJ
shares_NN
and_CC
Canadian_JJ
from_PIN
$_$
1,414.0_CD
million_CD
at_PIN
December_NN
31_CD
,_,
2003_CD
._.
dollars_NN
to_PIN
exchangeable_JJ
shareholders_NN
._.
Short-term_JJ
investments_NOMZ
consisted_VBD
of_PIN
money_NN
market_NN
fund_NN
balances_NN
and_PHC
investment_NOMZ
grade_NN
securities_NOMZ
._.
31_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
32_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
The_NN
Board_NN
of_PIN
Directors_NN
The_DT
Board_NN
of_PIN
Directors_NN
Dr_NN
James_NN
Cavanaugh_NN
68_CD
Mr_NN
Matthew_NN
Emmens_NN
53_CD
Mr_NN
Angus_NN
Russell_NN
49_CD
Dr_NN
Barry_NN
Price_NN
61_CD
Chairman_NN
Chief_NN
Executive_NN
Officer_NN
Chief_NN
Financial_NN
Officer_NN
and_CC
Non-executive_JJ
Director_NN
Dr_NN
James_NN
Cavanaugh_NN
joined_VBD
Matthew_NN
Emmens_NN
joined_VBD
Shire_NN
Executive_NN
Vice_NN
President_NN
Dr_NN
Barry_NN
Price_NN
joined_VBD
the_DT
Board_NN
the_DT
Board_NN
of_PIN
Shire_NN
on_PIN
March_NN
24_CD
,_,
as_IN
Chief_NN
Executive_NN
Officer_NN
of_PIN
Global_NN
Finance_NN
of_PIN
Shire_NN
on_PIN
January_NN
16_CD
,_,
1996_CD
1997_CD
and_CC
was_VBD [PASS]
appointed_VBN
as_IN
and_CC
member_NN
of_PIN
the_DT
Board_NN
of_PIN
Angus_NN
Russell_NN
joined_VBD
Shire_NN
having_VBG [WZPRES] [PEAS]
spent_VBN
28_CD
years_NN
with_PIN
Chairman_NN
with_PIN
effect_NN
from_PIN
Shire_NN
on_PIN
March_NN
12_CD
,_,
2003_CD
._.
in_PIN
1999_CD
as_IN
Chief_NN
Financial_NN
Glaxo_NN
holding_VBG [PRIV] [WZPRES]
a_DT
succession_NN
May_POMD
11_CD
,_,
1999_CD
._.
Dr_NN
Cavanaugh_NN
is_VPRT
Mr_NN
Emmens_NN
began_VBD
his_TPP3
career_NN
Officer_NN
._.
Mr_NN
Russell_NN
previously_TIME
of_PIN
executive_NN
positions_NOMZ
with_PIN
a_DT
General_NN
Partner_NN
of_PIN
HealthCare_NN
in_PIN
international_JJ
pharmaceuticals_NN
worked_VBD
for_PIN
ICI_NN
,_,
Zeneca_NN
and_PHC
Glaxo_NN
Group_NN
Research_NN
._.
He_TPP3
is_VPRT
Partners_NN
,_,
the_DT
General_NN
Partner_NN
of_PIN
with_PIN
Merck_NN
&_CC
Co_NN
,_,
Inc._NN
in_PIN
1974_CD
._.
His_TPP3
last_JJ
position_NOMZ
Chairman_NN
of_PIN
Antisoma_NN
plc_NN
and_PHC
HealthCare_NN
Ventures_NN
,_,
a_DT
venture_NN
There_EX
he_TPP3
held_VBD [PRIV] [THATD]
a_DT
wide_JJ
range_NN
was_VBD
Vice_NN
President_NN
Corporate_NN
also_RB
Biowisdom_NN
Ltd_NN
and_CC
is_VPRT
capital_NN
fund_NN
devoted_VBN [WZPAST]
exclusively_RB
of_PIN
sales_NN
,_,
marketing_GER
and_PHC
Finance_NN
at_PIN
AstraZeneca_NN
plc._NN
._.
on_PIN
the_DT
board_NN
of_PIN
directors_NN
of_PIN
to_PIN
healthcare_NN
._.
Formerly_TIME
he_TPP3
administrative_JJ
positions_NOMZ
before_IN
Prior_RB
to_PIN
this_DEMP
,_,
he_TPP3
held_VBD [PRIV]
a_DT
number_NN
Pharmagene_NN
plc._NN
._.
Dr_NN
Price_NN
was_VBD [PASS]
was_VBD
president_NN
of_PIN
SmithKline_NN
volunteering_VBG [WZPRES]
in_PIN
1992_CD
to_TO
help_VB
of_PIN
positions_NOMZ
within_PIN
the_DT
Zeneca_NN
Chairman_NN
of_PIN
the_DT
Remuneration_NOMZ
&_CC
French_NN
Laboratories_NN
,_,
the_DT
establish_VB [PRIV]
Astra_NN
Merck_NN
,_,
the_DT
Group_NN
from_PIN
1993_CD
until_IN
1999_CD
Committee_NN
and_CC
a_DT
member_NN
of_PIN
US_FPP1
pharmaceutical_JJ
division_NN
joint_JJ
venture_NN
between_PIN
Merck_NN
including_VBG [WZPRES]
Group_NN
Treasurer_NN
,_,
and_ANDC
both_DT
the_DT
Audit_NN
Committee_NN
and_CC
of_PIN
SmithKline_NN
Beecham_NN
and_PHC
Astra_NN
AB_NN
of_PIN
Sweden_NN
._.
before_IN
that_DEMO
in_PIN
ICI_NN
from_PIN
1980_CD
the_DT
Nomination_NOMZ
Committee_NN
in_PIN
Corporation_NOMZ
._.
Prior_RB
to_PIN
that_DEMP
,_,
he_TPP3
He_TPP3
later_TIME
became_VBD
President_NN
until_IN
1992_CD
._.
Dr_NN
Price_NN
is_VPRT
Shires_NN
senior_JJ
was_VBD
president_NN
of_PIN
SmithKline_NN
and_PHC
Chief_NN
Executive_NN
Officer_NN
._.
chartered_JJ
accountant_NN
,_,
having_VBG
non-executive_JJ
Director_NN
._.
Beecham_NN
Corporations_NOMZ
In_PIN
1999_CD
he_TPP3
joined_VBD
Merck_NN
qualified_VBD
with_PIN
Coopers_NN
&_CC
clinical_JJ
laboratory_NN
business_NOMZ
KGaA_NN
and_CC
established_VBN [PRIV]
EMD_NN
Lybrand_NN
,_,
and_ANDC
is_VPRT [BEMA]
a_DT
fellow_NN
of_PIN
and_CC
,_,
before_IN
that_DEMP
,_,
President_NN
Pharmaceuticals_NN
,_,
the_DT
the_DT
Association_NOMZ
of_PIN
Corporate_NN
of_PIN
Allergan_NN
International_NN
._.
Prior_RB
companys_VPRT
US_FPP1
prescription_NOMZ
Treasurers_NN
._.
Mr_NN
Russell_NN
is_VPRT [BEMA]
a_DT
to_PIN
his_TPP3
industry_NN
experience_NN
,_,
pharmaceutical_JJ
business_NOMZ
._.
member_NN
of_PIN
the_DT
Executive_NN
Dr_NN
Cavanaugh_NN
served_VBD
as_IN
Deputy_NN
He_TPP3
was_VBD [SPAU] [PASS]
later_TIME
promoted_VBN
to_PIN
Committee_NN
._.
He_TPP3
is_VPRT [BEMA]
also_RB
a_DT
nonAssistant_JJ
to_PIN
the_DT
President_NN
of_PIN
the_DT
President_NN
of_PIN
the_DT
global_JJ
executive_NN
director_NN
of_PIN
the_DT
City_NOMZ
US_FPP1
on_PIN
the_DT
White_NN
House_NN
Staff_NN
prescription_NOMZ
business_NOMZ
and_CC
lived_VBD
of_PIN
London_NN
Investment_NOMZ
Trust_NN
plc._NN
._.
Mr_NN
Emmens_NN
is_VPRT [BEMA]
a_DT
executive_NN
Chairman_NN
of_PIN
Diversa_NN
graduate_NN
of_PIN
Fairleigh_NN
Dickinson_NN
Corporation_NOMZ
and_PHC
Vicuron_NN
,_,
Inc._NN
._.
University_NOMZ
New_NN
Jersey_NN
,_,
USA_NN
and_CC
a_DT
non-executive_JJ
director_NN
of_PIN
with_PIN
a_DT
BS_NN
in_PIN
Business_NOMZ
MedImmune_NN
Inc._NN
and_PHC
Advancis_NN
Management_NOMZ
._.
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
the_DT
Board_NN
Dr_NN
Cavanaugh_NN
was_VBD [BEMA]
a_DT
member_NN
of_PIN
Directors_NN
,_,
and_ANDC
Chairman_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
of_PIN
the_DT
Executive_NN
and_PHC
Portfolio_NN
until_IN
April_NN
2004_CD
and_CC
a_DT
member_NN
Review_NN
Committees_NN
._.
of_PIN
the_DT
Audit_NN
Committee_NN
until_IN
November_NN
2004_CD
._.
He_TPP3
acted_VBD
as_IN
Chairman_NN
of_PIN
the_DT
Nomination_NOMZ
Committee_NN
throughout_PIN
2004_CD
._.
32_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
33_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
The_NN
Board_NN
of_PIN
Directors_NN
The_DT
Hon_NN
James_NN
Grant_NN
,_,
Mr_NN
Ronald_NN
Nordmann_NN
63_CD
Mr_NN
Robin_NN
Buchanan_NN
52_CD
Mr_NN
David_NN
Kappler_NN
57_CD
P._NN
C._NN
C._NN
M._NN
Q._NN
C._NN
67_CD
Non-executive_JJ
Director_NN
Non-executive_JJ
Director_NN
Non-executive_JJ
Director_NN
Non-executive_JJ
Director_NN
Ronald_NN
Nordmann_NN
joined_VBD
the_DT
Robin_NN
Buchanan_NN
joined_VBD
the_DT
David_NN
Kappler_NN
joined_VBD
the_DT
Board_NN
The_DT
Hon_NN
James_NN
Grant_NN
joined_VBD
Board_NN
of_PIN
Shire_NN
on_PIN
December_NN
23_CD
,_,
Board_NN
of_PIN
Shire_NN
on_PIN
July_NN
30_CD
,_,
of_PIN
Shire_NN
as_IN
a_DT
non-executive_JJ
the_DT
Board_NN
of_PIN
Shire_NN
on_PIN
May_POMD
11_CD
,_,
1999_CD
having_VBG [SPAU] [PEAS]
previously_TIME
served_VBD
2003_CD
._.
He_TPP3
is_VPRT [BEMA]
the_DT
Senior_JJ
Partner_NN
Director_NN
on_PIN
April_NN
5_CD
,_,
2004_CD
._.
Mr_NN
2001_CD
as_IN
a_DT
non-executive_JJ
as_IN
a_DT
non-executive_JJ
director_NN
of_PIN
the_DT
UK_NN
operations_NOMZ
and_PHC
Kappler_NN
retired_VBD
as_IN
Chief_NN
Financial_NN
Director_NN
._.
Prior_RB
to_PIN
its_PIT
merger_NN
of_PIN
Roberts_NN
Pharmaceutical_NN
director_NN
of_PIN
the_DT
global_JJ
business_NOMZ
Officer_NN
of_PIN
Cadbury_NN
Schweppes_NN
with_PIN
Shire_NN
,_,
Mr_NN
Grant_NN
had_VBD [PEAS]
been_VBN
Corporation_NOMZ
since_OSUB
May_POMD
1999_CD
._.
consultants_NN
Bain_NN
&_CC
Company_NN
plc_NN
,_,
the_DT
FTSE_NN
and_PHC
NYSE_NN
listed_VBD
a_DT
director_NN
of_PIN
BioChem_NN
Pharma_NN
Mr_NN
Nordmann_NN
has_VPRT [PEAS]
been_VBN [BEMA]
a_DT
Inc._NN
and_CC
a_DT
member_NN
of_PIN
the_DT
firms_NN
global_JJ
confectionery_NN
and_PHC
Inc._NN
since_OSUB
1986_CD
._.
He_TPP3
is_VPRT [BEMA]
a_DT
partner_NN
financial_JJ
analyst_NN
in_PIN
healthcare_NN
worldwide_NN
management_NOMZ
beverages_NN
group_NN
in_PIN
April_NN
2004_CD
,_,
and_ANDC
Chair_NN
Emeritus_NN
with_PIN
the_DT
equities_NOMZ
since_OSUB
1971_CD
._.
Prior_RB
to_PIN
his_TPP3
career_NN
having_VBG [WZPRES] [PEAS]
held_VBN [PRIV]
that_THVC
position_NOMZ
since_OSUB
law_NN
firm_NN
Stikeman_NN
Elliott_NN
in_PIN
September_NN
1994_CD
to_PIN
January_NN
with_PIN
Bain_NN
&_CC
Company_NN
Inc._NN
1995_CD
._.
He_TPP3
worked_VBD
for_PIN
the_DT
Montreal_NN
._.
Mr_NN
Grant_NN
sits_VPRT
on_PIN
the_DT
2000_CD
he_TPP3
was_VBD [BEMA]
an_DT
analyst_NN
Mr_NN
Buchanan_NN
worked_VBD
for_PIN
Cadbury_NN
Schweppes_NN
group_NN
boards_NN
of_PIN
two_CD
Canadian_JJ
public_NN
and_PHC
partner_NN
at_PIN
Deerfield_NN
American_NN
Express_NN
International_NN
between_PIN
1965_CD
and_CC
1984_CD
and_CC
corporations_NOMZ
,_,
in_CONJ
addition_NULL
to_PIN
Management_NOMZ
._.
He_TPP3
is_VPRT
currently_RB
Banking_GER
Corporation_NOMZ
in_PIN
New_NN
rejoined_VBD
it_PIT
in_PIN
1989_CD
,_,
following_VBG [PRESP]
the_DT
other_JJ
private_JJ
corporations_NOMZ
and_PHC
Co-President_NN
of_PIN
Global_NN
Health_NN
York_NN
,_,
McKinsey_NN
&_CC
Company_NN
acquisition_NOMZ
of_PIN
the_DT
Trebor_NN
Group_NN
foundations_NOMZ
and_PHC
councils_NN
that_TOBJ
Associates_NN
and_CC
has_VPRT [PEAS]
held_VBN [PRIV]
senior_JJ
and_CC
Deloitte_NN
&_CC
Touche_NN
where_RB
of_PIN
which_WDT [PIRE]
he_TPP3
was_VBD
Financial_NN
are_VPRT [BEMA]
not-for-profit_JJ
organizations_NOMZ
._.
positions_NOMZ
with_PIN
PaineWebber_NN
,_,
he_TPP3
qualified_VBD
as_IN
a_DT
chartered_JJ
Director_NN
._.
From_PIN
1989_CD
to_PIN
1995_CD
He_TPP3
attended_VBD
McGill_NN
University_NOMZ
,_,
Oppenheimer_NN
&_CC
Co._NN
accountant_NN
FCA_NN
._.
Mr_NN
he_TPP3
held_VBD [PRIV]
a_DT
number_NN
of_PIN
senior_JJ
receiving_VBG
a_DT
BA_NN
in_PIN
Arts_NN
in_PIN
1958_CD
F_NN
Eberstadt_NN
&_CC
Co._NN
and_PHC
Buchanan_NN
currently_RB
serves_VPRT
positions_NOMZ
in_PIN
Cadbury_NN
and_CC
a_DT
BCL_NN
in_PIN
Law_NN
in_PIN
1961_CD
._.
Warner-Chilcott_NN
Laboratories_NN
,_,
as_IN
a_DT
non-executive_JJ
director_NN
Schweppes_NN
,_,
including_VBG
director_NN
Mr_NN
Grant_NN
was_VBD [BEMA]
a_DT
member_NN
of_PIN
the_DT
a_DT
division_NN
of_PIN
Warner-Lambert_NN
._.
Mr_NN
Kappler_NN
Nomination_NOMZ
Committee_NN
in_PIN
2004_CD
._.
Mr_NN
Nordmann_NN
received_VBD
his_TPP3
Mr_NN
Buchanan_NN
has_VPRT
an_DT
MBA_NN
with_PIN
has_VPRT [PEAS]
served_VBN
on_PIN
a_DT
number_NN
of_PIN
other_JJ
undergraduate_JJ
degree_NN
from_PIN
Distinction_NOMZ
Baker_NN
Scholar_NN
boards_NN
around_PLACE
the_DT
world_NN
in_PIN
The_DT
Johns_NN
Hopkins_NN
University_NOMZ
from_PIN
Harvard_NN
Business_NOMZ
School_NN
._.
which_WDT [SERE]
Cadbury_NN
Schweppes_NN
held_VBD [PRIV]
and_CC
an_DT
MBA_NN
from_PIN
Fairleigh_NN
Mr_NN
Buchanan_NN
was_VBD [BEMA]
a_DT
member_NN
of_PIN
interests_NN
._.
He_TPP3
was_VBD [BEMA]
a_DT
director_NN
of_PIN
Dickinson_NN
University_NOMZ
._.
Mr_NN
the_DT
Remuneration_NOMZ
Committee_NN
Camelot_NN
Group_NN
plc_NN
from_PIN
1996_CD
Nordmann_NN
is_VPRT [BEMA]
also_RB
a_DT
director_NN
of_PIN
in_PIN
2004_CD
._.
to_PIN
2002_CD
and_CC
he_TPP3
currently_RB
serves_VPRT
Guilford_NN
Pharmaceuticals_NN
Inc._NN
as_IN
a_DT
non-executive_JJ
director_NN
and_PHC
Neurochem_NN
Inc._NN
and_PHC
Par_NN
Chairman_NN
of_PIN
the_DT
Audit_NN
Committee_NN
Pharmaceuticals_NN
,_,
Inc._NN
._.
Mr_NN
at_PIN
HMV_NN
Group_NN
plc_NN
and_PHC
Nordmann_NN
was_VBD
Chairman_NN
of_PIN
Intercontinental_NN
Hotels_NN
Group_NN
the_DT
Audit_NN
Committee_NN
until_IN
July_NN
plc._NN
._.
Additionally_RB
,_,
he_TPP3
is_VPRT
non_SYM
-_:
2004_CD
and_CC
he_TPP3
remains_VPRT
a_DT
member_NN
executive_NN
Chairman_NN
at_PIN
Premier_NN
of_PIN
that_DEMO
Committee_NN
._.
Mr_NN
Kappler_NN
is_VPRT [BEMA]
a_DT
fellow_NN
a_DT
member_NN
of_PIN
the_DT
Nomination_NOMZ
of_PIN
the_DT
Chartered_NN
Institute_NN
of_PIN
Committee_NN
throughout_PIN
2004_CD
Management_NOMZ
Accountants_NN
._.
Mr_NN
and_CC
he_TPP3
became_VBD
a_DT
member_NN
of_PIN
Kappler_NN
became_VBD
a_DT
member_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
Shires_NN
Audit_NN
Committee_NN
upon_PIN
in_PIN
April_NN
2004_CD
._.
his_TPP3
appointment_NOMZ
to_PIN
the_DT
Board_NN
and_CC
took_VBD
over_RP
the_DT
Chairmanship_NN
of_PIN
that_DEMO
Committee_NN
in_PIN
July_NN
2004_CD
._.
33_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
34_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
The_DT
Executive_NN
Committee_NN
The_NN
Executive_NN
Committee_NN
Mr_NN
Matthew_NN
Emmens_NN
Mr_NN
Angus_NN
Russell_NN
Ms_NN
Barbara_NN
Deptula_NN
Mr_NN
Greg_NN
Flexter_NN
Chief_NN
Executive_NN
Officer_NN
and_PHC
Chief_NN
Financial_NN
Officer_NN
and_PHC
Executive_NN
Vice_NN
President_NN
Executive_NN
Vice_NN
President_NN
Chairman_NN
of_PIN
the_DT
Executive_NN
Executive_NN
Vice_NN
President_NN
of_PIN
Business_NOMZ
Development_NOMZ
and_PHC
General_NN
Manager_NN
,_,
Committee_NN
joined_VBD
Shire_NN
Global_NN
Finance_NN
joined_VBD
Shire_NN
joined_VBD
Shire_NN
in_PIN
September_NN
2004_CD
North_NN
America_NN
joined_VBD
Shire_NN
as_IN
Chief_NN
Executive_NN
Officer_NN
in_PIN
1999_CD
as_IN
Chief_NN
Financial_NN
from_PIN
Sicor_NN
Inc_NN
,_,
where_RB
she_TPP3
was_VBD [BEMA]
in_PIN
April_NN
2001_CD
from_PIN
Novartis_NN
and_PHC
member_NN
of_PIN
the_DT
Board_NN
Officer_NN
._.
Mr_NN
Russell_NN
previously_TIME
President_NN
of_PIN
the_DT
biotechnology_NN
Pharmaceuticals_NN
,_,
where_RB
he_TPP3
was_VBD [BEMA]
of_PIN
Shire_NN
on_PIN
March_NN
12_CD
,_,
2003_CD
._.
worked_VBD
for_PIN
ICI_NN
,_,
Zeneca_NN
and_PHC
division_NN
._.
Prior_RB
to_TO
joining_VBG
Sicor_NN
,_,
Vice_NN
President_NN
and_PHC
Head_NN
of_PIN
the_DT
Mr_NN
Emmens_NN
began_VBD
his_TPP3
career_NN
AstraZeneca_NN
._.
His_TPP3
last_JJ
position_NOMZ
Ms_NN
Deptula_NN
was_VBD [BEMA]
Senior_JJ
Vice_NN
Neuroscience_NN
Business_NOMZ
Unit_NN
in_PIN
international_JJ
pharmaceuticals_NN
was_VBD
Vice_NN
President_NN
Corporate_NN
President_NN
for_PIN
commercial_JJ
and_CC
with_PIN
accountability_NOMZ
for_PIN
US_FPP1
with_PIN
Merck_NN
&_CC
Co_NN
,_,
Inc._NN
in_PIN
1974_CD
._.
product_NN
development_NOMZ
at_PIN
Coley_NN
Marketing_GER
,_,
Sales_NN
and_CC
Medical_JJ
There_EX
he_TPP3
held_VBD [PRIV]
a_DT
wide_JJ
range_NN
Prior_RB
to_PIN
this_DEMP
,_,
he_TPP3
held_VBD [PRIV]
a_DT
number_NN
Pharmaceutical_NN
Group_NN
in_PIN
Research_NN
._.
Mr_NN
Flexter_NN
brought_VBD
of_PIN
sales_NN
,_,
marketing_GER
and_CC
of_PIN
positions_NOMZ
within_PIN
the_DT
Zeneca_NN
Wellesley_NN
,_,
Massachusetts_NN
,_,
with_PIN
with_PIN
him_TPP3
over_IN
22_CD
years_NN
administrative_JJ
positions_NOMZ
before_IN
Group_NN
from_PIN
1993_CD
until_IN
1999_CD
responsibility_NOMZ
for_PIN
key_JJ
operations_NOMZ
experience_NN
in_PIN
global_JJ
and_CC
volunteering_VBG
in_PIN
1992_CD
to_TO
help_VB
including_VBG
Group_NN
Treasurer_NN
,_,
and_ANDC
and_CC
business_NOMZ
development_NOMZ
domestic_JJ
marketing_GER
,_,
business_NOMZ
establish_VB [PRIV]
Astra_NN
Merck_NN
,_,
the_DT
before_IN
that_DEMO
in_PIN
ICI_NN
from_PIN
1980_CD
activities_NOMZ
._.
She_TPP3
has_VPRT [PEAS]
held_VBN [PRIV]
various_JJ
development_NOMZ
,_,
and_ANDC
R&D_NN
,_,
and_ANDC
joint_JJ
venture_NN
between_PIN
Merck_NN
until_IN
1992_CD
._.
Mr_NN
Russell_NN
is_VPRT [BEMA]
a_DT
senior_JJ
management_NOMZ
positions_NOMZ
is_VPRT [BEMA]
also_RB
a_DT
qualified_VBN
pharmacist_NN
._.
chartered_JJ
accountant_NN
,_,
having_VBG [PEAS]
focused_VBN
on_PIN
licensing_GER
and_CC
He_TPP3
later_TIME
became_VBD
President_NN
qualified_VBD
with_PIN
Coopers_NN
&_CC
business_NOMZ
development_NOMZ
with_PIN
US_FPP1
and_PHC
Chief_NN
Executive_NN
Officer_NN
._.
Lybrand_NN
,_,
and_ANDC
is_VPRT [BEMA]
a_DT
fellow_NN
of_PIN
Bioscience_NN
,_,
Schering-Plough_NN
,_,
In_PIN
1999_CD
he_TPP3
joined_VBD
Merck_NN
the_DT
Association_NOMZ
of_PIN
Corporate_JJ
American_NN
Cyanamid_NN
,_,
and_ANDC
KGaA_NN
and_CC
established_VBN [PRIV]
EMD_NN
Treasurers_NN
._.
Mr_NN
Russell_NN
is_VPRT [BEMA]
a_DT
Genetics_NN
Institute_NN
._.
Pharmaceuticals_NN
,_,
the_DT
member_NN
of_PIN
the_DT
Executive_NN
companys_VPRT
US_FPP1
prescription_NOMZ
Committee_NN
._.
He_TPP3
is_VPRT [BEMA]
also_RB
a_DT
nonDr_NN
Eliseo_NN
Salinas_NN
pharmaceutical_JJ
business_NOMZ
._.
executive_JJ
director_NN
of_PIN
the_DT
City_NOMZ
Chief_NN
Scientific_NN
Officer_NN
and_CC
He_TPP3
was_VBD [SPAU] [PASS]
later_TIME
promoted_VBN
to_PIN
of_PIN
London_NN
Investment_NOMZ
Trust_NN
plc._NN
._.
Executive_NN
Vice_NN
President_NN
President_NN
of_PIN
the_DT
global_JJ
Global_JJ
R&D_NN
joined_VBD
Shire_NN
in_PIN
June_NN
prescription_NOMZ
business_NOMZ
and_CC
lived_VBD
2004_CD
from_PIN
Wyeth_NN
Research_NN
,_,
one_CD
of_PIN
in_PIN
Germany_NN
._.
Mr_NN
Emmens_NN
is_VPRT [BEMA]
a_DT
the_DT
worlds_NN
leading_VBG [WZPRES]
pharmaceutical_JJ
graduate_NN
of_PIN
Fairleigh_NN
Dickinson_NN
companies_NN
,_,
where_RB
he_TPP3
was_VBD
Head_NN
of_PIN
University_NOMZ
New_NN
Jersey_NN
,_,
USA_NN
Global_NN
Central_NN
Nervous_NN
Systems_NN
with_PIN
a_DT
BS_NN
in_PIN
Business_NOMZ
and_PHC
Vice_NN
President_NN
for_PIN
Regional_NN
Management_NOMZ
._.
Mr_NN
Emmens_NN
Clinical_NN
Research_NN
&_CC
Development_NOMZ
._.
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
the_DT
Board_NN
Eliseo_NN
graduated_VBD
from_PIN
the_DT
Medical_NN
of_PIN
Directors_NN
,_,
and_ANDC
Chairman_NN
School_NN
of_PIN
the_DT
University_NOMZ
of_PIN
Buenos_NN
of_PIN
the_DT
Executive_NN
and_PHC
Portfolio_NN
Aires_NN
,_,
Argentina_NN
and_CC
performed_VBD
Review_NN
Committees_NN
._.
a_DT
residency_NN
in_PIN
psychiatry_NN
in_PIN
Paris_NN
,_,
where_RB
he_TPP3
lived_VBD
for_PIN
18_CD
years_NN
._.
He_TPP3
began_VBD
his_TPP3
career_NN
in_PIN
the_DT
pharmaceutical_JJ
industry_NN
at_PIN
Synthelabo_NN
Research_NN
in_PIN
Paris_NN
._.
Dr_NN
Eliseo_NN
Salinas_NN
Mr_NN
Matthew_NN
Emmens_NN
Mr_NN
Angus_NN
Russell_NN
Ms_NN
Barbara_NN
Deptula_NN
Mr_NN
Greg_NN
Flexter_NN
34_CD
5977_CD
Review_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:21_CD
PM_NN
Page_NN
35_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
The_DT
Executive_NN
Committee_NN
Ms_NN
Anita_NN
Graham_NN
Mr_NN
John_NN
Lee_NN
Ms_NN
Tatjana_NN
May_POMD
Mr_NN
Joseph_NN
Rus_NN
Executive_NN
Vice_NN
President_NN
Executive_NN
Vice_NN
President_NN
General_NN
Counsel_NN
,_,
Company_NN
Executive_NN
Vice_NN
President_NN
Global_NN
Human_NN
Resources_NN
Global_NN
Supply_NN
Chain_NN
&_CC
Quality_NOMZ
Secretary_NN
and_PHC
Executive_NN
and_PHC
General_NN
Manager_NN
,_,
joined_VBD
Shire_NN
in_PIN
January_NN
2004_CD
joined_VBD
Shire_NN
in_PIN
April_NN
2000_CD
from_PIN
Vice_NN
President_NN
Global_NN
Legal_NN
International_NN
joined_VBD
Shire_NN
from_PIN
Cytyc_NN
Corporation_NOMZ
,_,
where_RB
Schwarz_NN
Pharma_NN
,_,
where_RB
he_TPP3
Affairs_NN
joined_VBD
Shire_NN
in_PIN
May_POMD
in_PIN
1999_CD
following_VBG
more_EMPH
than_PIN
she_TPP3
was_VBD
Vice_NN
President_NN
of_PIN
was_VBD
Vice_NN
President_NN
,_,
Operations_NOMZ
._.
2001_CD
from_PIN
AstraZeneca_NN
plc_NN
25_CD
years_NN
experience_NN
with_PIN
Human_NN
Resources_NN
._.
Prior_RB
to_PIN
this_DEMP
,_,
Prior_RB
to_PIN
this_DEMO
he_TPP3
held_VBD [PRIV]
supply_NN
where_RB
she_TPP3
was_VBD
Assistant_NN
other_JJ
leading_JJ
international_JJ
she_TPP3
held_VBD [PRIV]
senior_JJ
HR_NN
positions_NOMZ
chain_NN
responsibilities_NOMZ
for_PIN
Central_NN
General_NN
Counsel_NN
in_PIN
Corporate_NN
pharmaceutical_JJ
companies_NN
,_,
with_PIN
Serono_NN
,_,
Inc._NN
and_PHC
Scudder_NN
Pharmaceuticals_NN
,_,
The_DT
Vitarine_NN
Headquarters_NN
._.
Prior_RB
to_TO
joining_VBG
both_DT
in_PIN
Canada_NN
and_CC
abroad_PLACE
._.
Kemper_NN
Investments_NOMZ
,_,
Inc._NN
._.
Company_NN
now_TIME
Eon_NN
,_,
and_ANDC
AstraZeneca_NN
in_PIN
1995_CD
,_,
Ms_NN
May_POMD
With_PIN
the_DT
merger_NN
of_PIN
Shire_NN
now_TIME
part_NN
of_PIN
Deutsche_NN
Bank_NN
._.
worked_VBN [PASTP]
at_PIN
Slaughter_NN
and_PHC
May_POMD
._.
Pharmaceuticals_NN
and_PHC
BioChem_NN
Her_TPP3
experience_NN
spans_NN
all_QUAN
He_TPP3
brought_VBD
with_PIN
him_TPP3
Pharma_NN
in_PIN
May_POMD
2001_CD
,_,
he_TPP3
was_VBD
aspects_NN
of_PIN
HR_NN
including_VBG [WZPRES]
31_CD
years_NN
experience_NN
in_PIN
the_DT
appointed_VBN
President_NN
and_CC
managing_VBG
mergers_NN
and_CC
pharmaceutical_JJ
industry_NN
._.
CEO_NN
of_PIN
Shire_NN
BioChem_NN
Inc._NN
acquisitions_NOMZ
,_,
organizational_JJ
development_NOMZ
,_,
employee_NN
relations_NOMZ
and_PHC
compensation_NOMZ
and_PHC
benefits_NN
._.
She_TPP3
has_VPRT [PEAS]
worked_VBN
both_DT
in_PIN
Europe_NN
and_CC
in_PIN
the_DT
United_NN
States_NN
._.
Ms_NN
Anita_NN
Graham_NN
Mr_NN
John_NN
Lee_NN
Ms_NN
Tatjana_NN
May_POMD
Mr_NN
Joseph_NN
Rus_NN
35_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
36_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Directors_NN
remuneration_JJ
report_NN
Directors_NN
remuneration_JJ
report_NN
This_DEMO
Report_NN
sets_VPRT
out_PIN
the_DT
Companys_NN
approach_NN
to_PIN
Directors_NN
remuneration_NOMZ
._.
It_PIT
complies_VPRT
with_PIN
:_:
Dear_RB
Shareholder_NN
During_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
the_DT
Remuneration_NOMZ
the_DT
2003_CD
Combined_NN
Code_NN
on_PIN
Corporate_NN
Governance_NN
:_:
Committee_NN
continued_VBD
its_PIT
work_NN
,_,
on_PIN
behalf_NN
of_PIN
the_DT
Board_NN
,_,
on_PIN
Directors_NN
remuneration_NOMZ
._.
the_DT
Directors_NN
Remuneration_NOMZ
Report_NN
Regulations_NOMZ
2002_CD
:_:
and_ANDC
The_DT
Company_NN
operates_VPRT
in_PIN
a_DT
highly_AMP
competitive_JJ
multinational_JJ
the_DT
requirements_NOMZ
of_PIN
the_DT
Listing_GER
Rules_NN
of_PIN
the_DT
Financial_NN
Services_NN
environment_NOMZ
._.
In_PIN
2004_CD
approximately_RB
90_CD
%_NN
of_PIN
Shires_NN
revenues_NN
Authority_NOMZ
._.
and_ANDC
more_EMPH
than_PIN
80_CD
%_NN
of_PIN
its_PIT
employees_NN
were_VBD [PASS]
based_VBN
outside_PLACE
the_DT
UK_NN
._.
Indeed_RB
most_EMPH
of_PIN
Shires_NN
revenues_NN
come_VPRT
from_PIN
the_DT
US_FPP1
and_CC
Unaudited_JJ
information_NOMZ
most_EMPH
of_PIN
its_PIT
employees_NN
are_VPRT [PASS]
located_VBN
there_RB
._.
The_DT
Remuneration_NOMZ
Committee_NN
Shire_NN
largely_RB
completed_VBD
a_DT
major_JJ
internal_JJ
reorganisation_NOMZ
in_PIN
2004_CD
The_DT
Remuneration_NOMZ
Committee_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
all_QUAN
elements_NOMZ
which_WDT [WHSUB]
resulted_VBD
in_PIN
the_DT
introduction_NOMZ
of_PIN
a_DT
new_JJ
organisational_NN
of_PIN
the_DT
executive_NN
Directors_NN
remuneration_NOMZ
,_,
as_RB
well_RB
as_IN
their_TPP3
structure_NN
and_CC
in_PIN
the_DT
consolidation_NOMZ
of_PIN
its_PIT
US_FPP1
sites_NN
from_PIN
14_CD
to_PIN
6_CD
._.
performance_NN
management_NOMZ
._.
During_PIN
the_DT
year_NN
,_,
the_DT
Committee_NN
initiated_VBD
a_DT
review_NN
of_PIN
the_DT
Companys_NN
compensation_NOMZ
and_PHC
benefits_NN
philosophy_NN
and_PHC
practice_NN
The_DT
constitution_NOMZ
of_PIN
the_DT
Committee_NN
was_VBD [PASS]
reviewed_VBN
in_PIN
2004_CD
and_CC
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
remuneration_JJ
arrangements_NOMZ
support_VPRT
the_DT
needs_NN
of_PIN
changes_NN
were_VBD [PASS]
made_VBN
to_TO
ensure_VB [SUAV] [PRIV]
compliance_NN
with_PIN
the_DT
2003_CD
the_DT
Company_NN
as_IN
it_PIT
adapts_VPRT
to_PIN
its_PIT
new_JJ
business_NOMZ
model_NN
._.
The_DT
Company_NN
considers_VPRT [PRIV]
all_QUAN
members_NN
of_PIN
the_DT
is_VPRT [BEMA]
ongoing_PRED
._.
The_DT
Committee_NN
will_PRMD
consult_VB
with_PIN
its_PIT
major_JJ
shareholders_NN
Committee_NN
to_TO
be_VB [BEMA]
independent_PRED
._.
on_PIN
the_DT
outcomes_NN
of_PIN
the_DT
review_NN
later_TIME
in_PIN
the_DT
year_NN
._.
The_DT
importance_NN
of_PIN
the_DT
US_FPP1
to_PIN
the_DT
growth_NN
of_PIN
the_DT
Company_NN
,_,
coupled_VBN [PASTP]
with_PIN
the_DT
fact_NN
The_DT
Chief_NN
Executive_NN
Officer_NN
attends_VPRT
meetings_GER
of_PIN
the_DT
Committee_NN
that_TOBJ
most_EMPH
of_PIN
its_PIT
senior_JJ
executives_NN
are_VPRT [PASS]
based_VBN
in_PIN
the_DT
US_FPP1
,_,
presents_VPRT
at_PIN
its_PIT
invitation_NOMZ
,_,
but_CC
is_VPRT [PASS]
not_XX0
involved_VBN
in_PIN
any_QUAN
decisions_NN
relating_VBG [WZPRES]
to_PIN
his_TPP3
the_DT
Committee_NN
with_PIN
particular_JJ
challenges_NN
._.
While_OSUB
the_DT
Committee_NN
own_JJ
remuneration_NOMZ
._.
does_VPRT
not_XX0
espouse_VB
a_DT
US_FPP1
pay_NN
policy_NN
,_,
it_PIT
does_EMPH
take_VB
this_DEMO
operating_GER
environment_NOMZ
into_PIN
account_NN
._.
The_DT
members_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
during_PIN
2004_CD
were_VBD
:_:
As_IN
part_NN
of_PIN
the_DT
compensation_NOMZ
review_NN
,_,
the_DT
Committee_NN
has_VPRT
already_RB
Dr_NN
Barry_NN
Price_NN
,_,
the_DT
Senior_JJ
Independent_NN
Director_NN
of_PIN
the_DT
Company_NN
decided_VBD [SUAV] [PRIV]
to_TO
phase_VB
out_PIN
the_DT
Deferred_NN
Bonus_NN
Plan_NN
and_CC
to_TO
modify_VB
the_DT
and_CC
Chairman_NN
of_PIN
the_DT
Committee_NN
:_:
structure_NN
of_PIN
the_DT
Annual_JJ
Incentive_NN
Plan_NN
._.
The_DT
changes_NN
are_VPRT [PASS]
described_VBN
below_PLACE
._.
The_DT
modified_VBN
incentive_NN
structure_NN
enables_VPRT
Shire_NN
to_TO
operate_VB
Mr_NN
Robin_NN
Buchanan_NN
,_,
an_DT
independent_JJ
non-executive_JJ
Director_NN
:_:
a_DT
common_JJ
framework_NN
for_PIN
the_DT
senior_JJ
executive_NN
team_NN
,_,
irrespective_RB
of_PIN
location_NOMZ
,_,
and_ANDC
to_TO
be_VB [BEMA]
competitive_PRED
in_PIN
both_DT
the_DT
UK_NN
and_PHC
US_FPP1
._.
Under_IN
Mr_NN
Ronald_NN
Nordmann_NN
,_,
an_DT
independent_JJ
non-executive_JJ
Director_NN
,_,
the_DT
revised_VBN
Annual_JJ
Incentive_NN
Plan_NN
,_,
target_NN
incentives_NN
will_PRMD
be_VB [PASS]
earned_VBN
who_WP
joined_VBD
the_DT
Committee_NN
in_PIN
April_NN
2004_CD
:_:
and_ANDC
only_DWNT
where_RB
executives_NN
have_VPRT [PEAS]
achieved_VBN
Board-approved_JJ
corporate_JJ
objectives_NN
and_CC
Committee-approved_JJ
individual_JJ
objectives_NN
._.
Dr_NN
James_NN
Cavanaugh_NN
,_,
the_DT
Chairman_NN
of_PIN
the_DT
Company_NN
,_,
who_WP
stepped_VBD
down_RP
as_IN
a_DT
Committee_NN
member_NN
in_PIN
April_NN
2004_CD
._.
The_DT
Remuneration_NOMZ
Committee_NN
is_VPRT [PASS]
committed_VBN
to_PIN
a_DT
continuing_VBG
dialogue_NN
with_PIN
shareholders_NN
and_CC
we_FPP1
strive_VPRT
to_TO
accommodate_VB
your_SPP2
Details_NN
of_PIN
the_DT
number_NN
of_PIN
Committee_NN
meetings_GER
in_PIN
2004_CD
and_CC
the_DT
views_NN
._.
We_FPP1
hope_VPRT [PRIV] [THATD]
that_DEMP
this_DEMO
report_NN
provides_VPRT
helpful_JJ
context_NN
and_PHC
attendance_NN
at_PIN
those_DEMO
meetings_GER
is_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
section_NOMZ
headed_VBD
explanation_NOMZ
about_IN
the_DT
policies_NN
and_CC
practical_JJ
considerations_NOMZ
that_TOBJ
Corporate_JJ
governance_NN
statements_NOMZ
._.
The_DT
Remuneration_NOMZ
Committee_NN
was_VBD [SPAU] [PASS]
materially_RB
assisted_VBN
in_PIN
2004_CD
by_PIN
Mrs_NN
Anita_NN
Graham_NN
,_,
EVP_NN
Global_NN
Human_NN
Resources_NN
,_,
Ms_NN
Tatjana_NN
May_POMD
,_,
EVP_NN
,_,
General_NN
Counsel_NN
and_PHC
Mr_NN
Matthew_NN
Emmens_NN
,_,
the_DT
Chief_NN
Executive_NN
Officer_NN
._.
No_SYNE
individual_NN
is_VPRT [PASS]
involved_VBN
in_PIN
the_DT
determination_NOMZ
of_PIN
their_TPP3
own_JJ
remuneration_NOMZ
._.
The_DT
following_VBG
external_JJ
advisers_NN
were_VBD
Dr_NN
Barry_NN
Price_NN
appointed_VBN [WZPAST]
by_PIN
and_CC
materially_RB
assisted_VBD
the_DT
Committee_NN
:_:
Chairman_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
Towers_NN
Perrin_NN
:_:
and_ANDC
Slaughter_NN
and_PHC
May_POMD
,_,
who_WP
provided_VBD
general_JJ
legal_JJ
advice_NN
to_PIN
the_DT
Company_NN
._.
Remuneration_NOMZ
policy_NN
The_DT
Remuneration_NOMZ
Committee_NN
considers_VPRT [PRIV]
that_THVC
an_DT
effective_JJ
remuneration_NOMZ
policy_NN
is_VPRT [BEMA]
an_DT
important_JJ
contributor_NN
to_PIN
the_DT
Companys_NN
success_NN
._.
It_PIT
directly_RB
impacts_VPRT
the_DT
Companys_NN
ability_NOMZ
to_TO
recruit_VB
,_,
retain_VB
and_PHC
motivate_VB
high_JJ
calibre_NN
executives_NN
who_WP [WHSUB]
embody_VPRT
the_DT
Companys_NN
values_NN
and_CC
deliver_VB
value_NN
to_PIN
shareholders_NN
._.
36_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
37_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Directors_NN
remuneration_JJ
report_NN
The_DT
Remuneration_NOMZ
Committee_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
developing_VBG
,_,
10-K_NN
under_IN
US_FPP1
GAAP_NN
._.
The_DT
detailed_JJ
objectives_NN
and_PHC
performance_NN
reviewing_VBG [WZPRES]
and_PHC
overseeing_VBG
the_DT
implementation_NOMZ
of_PIN
the_DT
Companys_NN
standards_NN
contain_VPRT
commercially_RB
sensitive_JJ
information_NOMZ
and_PHC
compensation_NOMZ
and_PHC
benefits_NN
policy_NN
._.
The_DT
effectiveness_NOMZ
of_PIN
the_DT
current_JJ
therefore_CONJ
are_VPRT [PASS]
not_XX0
summarised_VBN
here_RB
._.
However_CONJ
,_,
the_DT
2004_CD
corporate_JJ
policy_NN
is_VPRT [SPAU] [BYPA]
regularly_RB
monitored_VBN
by_PIN
the_DT
Remuneration_NOMZ
Committee_NN
._.
objectives_NN
included_VBD
specific_JJ
targets_NN
in_PIN
the_DT
following_VBG
areas_NN
:_:
The_DT
existing_VBG
policy_NN
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
following_VBG
principles_NN
,_,
which_WDT [SERE]
growth_NN
in_PIN
revenue_NN
:_:
are_VPRT
currently_RB
under_IN
review_NN
:_:
growth_NN
in_PIN
net_JJ
income_NN
:_:
Base_NN
pay_NN
is_VPRT [BEMA]
market-driven_PRED
and_CC
is_VPRT [PASS]
targeted_VBN
at_PIN
or_CC
around_PLACE
the_DT
median_NN
relative_JJ
to_PIN
the_DT
appropriate_JJ
comparator_NN
groups_NN
._.
progression_NN
of_PIN
R&D_NN
portfolio_NN
:_:
The_DT
Annual_JJ
Incentive_NN
Plan_NN
is_VPRT [BEMA]
performance-based_PRED
and_CC
is_VPRT [PASS]
linked_VBN
operational_JJ
objectives_NN
,_,
including_VBG [PRESP]
the_DT
sale_NN
of_PIN
Shires_NN
vaccines_NN
to_PIN
the_DT
achievement_NOMZ
of_PIN
an_DT
appropriate_JJ
mix_NN
of_PIN
corporate_JJ
and_CC
business_NOMZ
:_:
and_ANDC
individual_JJ
performance_NN
targets_NN
._.
minimizing_VBG
disruption_NOMZ
to_PIN
the_DT
business_NOMZ
while_OSUB
implementing_VBG
The_DT
Committee_NN
currently_RB
aims_VPRT
for_PIN
the_DT
performance-related_JJ
the_DT
Companys_NN
internal_JJ
reorganisation_NOMZ
._.
elements_NOMZ
of_PIN
executive_NN
Director_NN
compensation_NOMZ
to_TO
represent_VB
over_IN
half_NN
of_PIN
total_JJ
remuneration_NOMZ
._.
The_DT
Remuneration_NOMZ
Committee_NN
assesses_VPRT
performance_NN
against_PIN
objectives_NN
in_PIN
the_DT
first_JJ
quarter_NN
of_PIN
the_DT
following_JJ
year_NN
._.
The_DT
annual_JJ
Share-based_JJ
compensation_NOMZ
is_VPRT [BEMA]
a_DT
key_JJ
element_NOMZ
of_PIN
the_DT
Companys_NN
incentive_NN
is_VPRT [BEMA]
payable_PRED
in_PIN
cash_NN
and_CC
is_VPRT [BEMA]
not_XX0
pensionable_PRED
._.
The_DT
target_NN
remuneration_NOMZ
policy_NN
as_IN
it_PIT
aligns_VPRT
the_DT
interests_NN
of_PIN
the_DT
Companys_NN
incentive_NN
is_VPRT [PASS]
paid_VBN
where_RB
executive_JJ
Directors_NN
have_VPRT [SPAU] [PEAS]
fully_AMP
achieved_VBN
executives_NN
with_PIN
the_DT
interests_NN
of_PIN
its_PIT
shareholders_NN
._.
their_TPP3
individual_JJ
objectives_NN
and_CC
the_DT
corporate_JJ
objectives_NN
have_VPRT [PEAS]
been_VBN [PASS]
met_VBN
in_PIN
full_JJ
._.
The_DT
maximum_NN
incentive_NN
is_VPRT [PASS]
paid_VBN
only_DWNT
if_COND
the_DT
The_DT
remuneration_NOMZ
package_NN
Remuneration_NOMZ
Committee_NN
determines_VPRT [SUAV] [PRIV]
that_THVC
individual_JJ
and_CC
or_CC
The_DT
main_JJ
elements_NOMZ
of_PIN
the_DT
remuneration_NOMZ
package_NN
for_PIN
executive_JJ
corporate_JJ
performance_NN
has_VPRT [PEAS]
been_VBN [BEMA]
exceptional_PRED
._.
Maximum_NN
incentive_NN
Directors_NN
and_CC
senior_JJ
management_NOMZ
are_VPRT
:_:
payments_NOMZ
for_PIN
2004_CD
were_VBD [PASS]
capped_VBN
at_PIN
100_CD
%_NN
of_PIN
salary_NN
for_PIN
the_DT
Chief_NN
Executive_NN
Officer_NN
and_CC
75_CD
%_NN
of_PIN
salary_NN
for_PIN
the_DT
Chief_NN
Financial_NN
Officer_NN
._.
1_CD
Salary_NN
Target_NN
Maximum_NN
Weighting_GER
of_PIN
target_NN
incentive_NN
incentive_NN
incentive_NN
objectives_NN
2_CD
Annual_JJ
Incentive_NN
Plan_NN
as_IN
a_DT
%_NN
as_IN
a_DT
%_NN
of_PIN
salary_NN
of_PIN
salary_NN
Corporate_JJ
Individual_JJ
3_CD
Long-term_JJ
incentives_NN
Mr_NN
Matthew_NN
Emmens_NN
a_DT
Share_NN
options_NOMZ
Chief_NN
Executive_NN
Officer_NN
55_CD
%_NN
100_CD
%_NN
80_CD
%_NN
20_CD
%_NN
b_NN
Long_NN
Term_NN
Incentive_NN
Plan_NN
c_NN
Deferred_NN
Bonus_NN
Plan_NN
Mr_NN
Angus_NN
Russell_NN
Chief_NN
Financial_NN
Officer_NN
50_CD
%_NN
75_CD
%_NN
60_CD
%_NN
40_CD
%_NN
4_CD
Pension_NN
and_CC
other_JJ
benefits_NN
The_DT
incentive_NN
payments_NOMZ
awarded_VBD
to_PIN
each_QUAN
executive_NN
Director_NN
for_PIN
2004_CD
1_CD
Salary_NN
reflects_VPRT [PRIV]
the_DT
corporate_JJ
and_PHC
individual_JJ
achievements_NOMZ
and_CC
amounted_VBD
The_DT
Remuneration_NOMZ
Committee_NN
reviews_VPRT
salaries_NN
annually_RB
._.
In_PIN
doing_VBG [PROD]
to_PIN
80_CD
%_NN
of_PIN
salary_NN
for_PIN
Mr_NN
Emmens_NN
and_CC
75_CD
%_NN
of_PIN
salary_NN
for_PIN
Mr_NN
Russell_NN
._.
so_RB
,_,
it_PIT
looks_VPRT
at_PIN
a_DT
range_NN
of_PIN
factors_NN
such_JJ
as_IN
competitive_JJ
market_NN
These_DEMO
incentive_NN
awards_NN
are_VPRT [BEMA]
consistent_PRED
with_PIN
the_DT
overall_JJ
performance_NN
data_NN
provided_VBN [WZPAST]
by_PIN
independent_JJ
external_JJ
consultants_NN
,_,
local_JJ
market_NN
of_PIN
the_DT
Company_NN
in_PIN
2004_CD
which_WDT
included_VBD
achieving_VBG
13_CD
%_NN
revenue_NN
conditions_NOMZ
,_,
performance-related_JJ
pay_NN
increases_NN
across_PLACE
the_DT
growth_NN
,_,
12_CD
%_NN
growth_NN
in_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
and_PHC
Company_NN
and_CC
individual_JJ
skills_NN
and_PHC
performance_NN
._.
The_DT
Remuneration_NOMZ
the_DT
highly_AMP
successful_JJ
implementation_NOMZ
of_PIN
all_QUAN
objectives_NN
focused_VBD
on_PIN
Committees_NN
policy_NN
is_VPRT [BEMA]
for_PIN
salary_NN
to_TO
be_VB [PASS]
targeted_VBN
at_PIN
or_CC
around_PLACE
the_DT
realignment_NOMZ
of_PIN
the_DT
Companys_NN
business_NOMZ
model_NN
._.
the_DT
median_NN
of_PIN
the_DT
relevant_JJ
comparator_NN
groups_NN
,_,
with_PIN
appropriate_JJ
differentiation_NOMZ
based_VBN [WZPAST]
upon_PIN
skills_NN
and_PHC
experience_NN
as_RB
well_RB
as_IN
As_IN
part_NN
of_PIN
the_DT
broader_JJ
compensation_NOMZ
and_PHC
benefits_NN
review_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
individual_JJ
performance_NN
._.
continuing_VBG [PRESP]
into_PIN
2005_CD
,_,
the_DT
Annual_JJ
Incentive_NN
Plan_NN
has_VPRT [PEAS]
been_VBN [PASS]
modified_VBN
._.
For_PIN
the_DT
financial_JJ
year_NN
2005_CD
,_,
the_DT
target_NN
incentive_NN
amounts_NN
for_PIN
the_DT
2_CD
Annual_JJ
Incentive_NN
Plan_NN
Chief_NN
Executive_NN
Officer_NN
and_CC
the_DT
Chief_NN
Financial_NN
Officer_NN
are_VPRT
Shire_NN
operates_VPRT
an_DT
Annual_JJ
Incentive_NN
Plan_NN
which_WDT [WHSUB]
rewards_VPRT
respectively_RB
65_CD
%_NN
and_CC
55_CD
%_NN
of_PIN
salary_NN
and_CC
the_DT
maximum_NN
incentive_NN
performance_NN
dependent_JJ
on_PIN
achievement_NOMZ
of_PIN
pre-defined_JJ
Boardamounts_NN
are_VPRT [BEMA]
respectively_RB
115_CD
%_NN
and_CC
100_CD
%_NN
of_PIN
salary_NN
._.
The_DT
levels_NN
approved_VBD
corporate_JJ
objectives_NN
and_PHC
Committee_NN
approved_VBD
of_PIN
target_NN
and_PHC
maximum_NN
incentives_NN
have_VPRT [PEAS]
been_VBN [PASS]
set_VBN
to_TO
be_VB [BEMA]
individual_JJ
objectives_NN
._.
The_DT
objectives_NN
are_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
at_PIN
the_DT
start_NN
of_PIN
competitive_JJ
in_PIN
both_DT
the_DT
UK_NN
and_PHC
US_FPP1
and_CC
to_TO
enable_VB
Shire_NN
to_TO
operate_VB
each_QUAN
financial_JJ
year_NN
to_TO
ensure_VB [SUAV] [PRIV]
alignment_NOMZ
._.
The_DT
corporate_JJ
objectives_NN
a_DT
common_JJ
framework_NN
for_PIN
the_DT
senior_JJ
executive_NN
team_NN
irrespective_RB
apply_VB
to_PIN
all_QUAN
employees_NN
participating_VBG [WZPRES]
in_PIN
the_DT
Companys_NN
Annual_JJ
of_PIN
location_NOMZ
._.
The_DT
weighting_GER
between_PIN
corporate_JJ
and_PHC
individual_JJ
Incentive_NN
Plan_NN
._.
Each_QUAN
objective_NN
,_,
whether_IN
corporate_JJ
or_CC
individual_JJ
,_,
objectives_NN
remains_VPRT
the_DT
same_JJ
for_PIN
the_DT
Chief_NN
Executive_NN
Officer_NN
and_CC
is_VPRT [BEMA]
weighted_PRED
and_CC
is_VPRT [PASS]
described_VBN
in_PIN
specific_JJ
and_PHC
measurable_JJ
terms_NN
shifts_NN
from_PIN
60_CD
%_NN
corporate_JJ
and_CC
40_CD
%_NN
individual_NN
to_PIN
70_CD
%_NN
corporate_JJ
with_PIN
allocated_VBN
deadlines_NN
._.
Performance_NN
standards_NN
are_VPRT [PASS]
set_VBN
for_PIN
and_CC
30_CD
%_NN
individual_NN
for_PIN
the_DT
Chief_NN
Financial_NN
Officer_NN
._.
each_QUAN
objective_NN
so_RB
that_DEMO
target_NN
incentives_NN
are_VPRT [PASS]
awarded_VBN
only_DWNT
when_RB
exacting_VBG
levels_NN
of_PIN
performance_NN
have_VPRT [PEAS]
been_VBN [PASS]
achieved_VBN
._.
Objectives_NN
measured_VBN [WZPAST]
by_PIN
the_DT
Companys_NN
financial_JJ
performance_NN
are_VPRT [PASS]
assessed_VBN
on_PIN
the_DT
Companys_NN
results_NN
,_,
as_IN
reported_VBN [PUBV]
in_PIN
the_DT
Companys_NN
Form_NN
37_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
38_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Directors_NN
remuneration_JJ
report_NN
3_CD
Long-term_JJ
incentives_NN
Retesting_GER
has_VPRT [PEAS]
been_VBN [PASS]
retained_VBN
so_RB
far_PLACE
on_PIN
this_DEMO
limited_JJ
basis_NN
in_PIN
order_NN
to_PIN
a_DT
Share_NN
options_NOMZ
maintain_VPRT [PUBV]
the_DT
Schemes_NN
international_JJ
competitiveness_NOMZ
._.
In_CONJ
particular_NULL
,_,
Executive_NN
Directors_NN
are_VPRT [BEMA]
eligible_PRED
to_TO
participate_VB
in_PIN
the_DT
Companys_NN
the_DT
Committee_NN
is_VPRT [BEMA]
conscious_PRED
of_PIN
the_DT
fact_NN
that_DEMO
performance_NN
tests_NN
2000_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
._.
Share_NN
options_NOMZ
,_,
which_WDT [SERE]
are_VPRT [PASS]
not_XX0
attached_VBN
to_PIN
the_DT
vesting_GER
of_PIN
options_NOMZ
in_PIN
many_QUAN
markets_NN
,_,
form_NN
part_NN
of_PIN
the_DT
executive_NN
Directors_NN
long-term_JJ
compensation_NOMZ
,_,
including_VBG [PRESP]
the_DT
US_FPP1
,_,
and_ANDC
that_DEMP
phased_VBD
vesting_GER
of_PIN
options_NOMZ
is_VPRT [SPAU]
also_RB
are_VPRT [PASS]
used_VBN
to_TO
align_VB
Directors_NN
interests_NN
with_PIN
those_DEMO
of_PIN
shareholders_NN
common_JJ
in_PIN
the_DT
US_FPP1
._.
and_ANDC
to_TO
promote_VB
sustained_VBN
long-term_JJ
Company_NN
performance_NN
._.
Any_QUAN
new_JJ
share_NN
option_NOMZ
scheme_NN
established_VBN [PRIV] [WZPAST]
in_PIN
the_DT
future_NN
will_PRMD
The_DT
grant_NN
of_PIN
options_NOMZ
to_PIN
executive_JJ
Directors_NN
is_VPRT [BEMA]
wholly_RB
at_PIN
the_DT
not_XX0
contain_VB
a_DT
retesting_GER
feature_NN
._.
discretion_NOMZ
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
._.
The_DT
face_NN
value_NN
of_PIN
annual_JJ
option_NOMZ
grants_NN
under_IN
the_DT
Scheme_NN
is_VPRT [PASS]
capped_VBN
at_PIN
three_CD
times_NN
The_DT
table_NN
below_PLACE
sets_NN
out_PIN
the_DT
share_NN
options_NOMZ
that_TSUB
were_VBD [PASS]
granted_VBN [SUAV]
salary_NN
per_PIN
year_NN
for_PIN
executive_NN
Directors_NN
and_CC
senior_JJ
managers_NN
._.
This_DEMO
to_PIN
executive_JJ
Directors_NN
during_PIN
2004_CD
._.
annual_JJ
grant_NN
level_NN
is_VPRT [BEMA]
consistent_PRED
with_PIN
the_DT
Companys_NN
emphasis_NN
on_PIN
Number_NN
of_PIN
Exercise_NN
performance-linked_JJ
share-based_JJ
remuneration_NOMZ
for_PIN
its_PIT
executives_NN
._.
Executive_NN
Director_NN
and_CC
ordinary_JJ
price_NN
The_DT
Committee_NN
recognizes_VPRT [PRIV]
that_THVC
the_DT
total_NN
expected_VBN [PRIV]
value_NN
of_PIN
share_NN
option_NOMZ
scheme_NN
Date_NN
of_PIN
grant_NN
shares_NN
Shires_VPRT
long-term_JJ
incentive_NN
arrangements_NOMZ
is_VPRT
above_PLACE
upper_JJ
quartile_NN
Mr_NN
Matthew_NN
Emmens_NN
in_PIN
the_DT
UK_NN
._.
However_CONJ
it_PIT
is_VPRT [PASS]
satisfied_VBN
with_PIN
this_DEMO
on_PIN
the_DT
basis_NN
that_TOBJ
2000_CD
Executive_NN
Scheme_NN
25.03.04_CD
315,777_CD
5.26_CD
executive_NN
Directors_NN
will_PRMD [SPAU]
only_DWNT
benefit_VB
from_PIN
the_DT
arrangements_NOMZ
when_RB
shareholder_NN
interests_NN
have_VPRT [PEAS]
been_VBN [PASS]
met_VBN
._.
Mr_NN
Angus_NN
Russell_NN
2000_CD
Executive_NN
Scheme_NN
25.03.04_CD
195,285_CD
5.26_CD
The_DT
current_JJ
performance_NN
measure_NN
for_PIN
the_DT
vesting_GER
of_PIN
options_NOMZ
was_VBD [PASS]
introduced_VBN
in_PIN
2002_CD
following_VBG
consultation_NOMZ
with_PIN
major_JJ
institutional_JJ
Where_RB
accounting_GER
changes_NN
have_VPRT
an_DT
impact_NN
on_PIN
the_DT
calculation_NOMZ
shareholders_NN
._.
The_DT
performance_NN
tests_NN
for_PIN
executive_NN
Directors_NN
of_PIN
EPS_NN
,_,
the_DT
Remuneration_NOMZ
Committee_NN
will_PRMD
seek_VB
at_PIN
all_QUAN
times_NN
to_PIN
options_NOMZ
were_VBD [PASS]
toughened_VBN
following_VBG
this_DEMO
consultation_NOMZ
process_NN
._.
The_DT
ensure_VB [SUAV] [PRIV]
consistency_NN
of_PIN
measurement_NOMZ
when_RB
determining_VBG [SUAV] [PRIV]
whether_IN [WHCL]
performance_NN
tests_NN
are_VPRT [PASS]
based_VBN
on_PIN
real_JJ
growth_NN
in_PIN
diluted_JJ
earnings_GER
performance_NN
tests_NN
have_VPRT [PEAS]
been_VBN [PASS]
met_VBN
._.
per_PIN
share_NN
EPS_NN
as_IN
measured_VBN
by_PIN
diluted_JJ
EPS_NN
and_CC
as_IN
reported_VBN [PUBV]
in_PIN
the_DT
Companys_NN
Form_NN
10-K_NN
under_IN
US_FPP1
GAAP_NN
._.
This_DEMO
measure_NN
Details_NN
of_PIN
the_DT
Companys_NN
share_NN
option_NOMZ
schemes_NN
are_VPRT [PASS]
set_VBN
out_PIN
in_PIN
is_VPRT [BYPA]
favored_VBN
by_PIN
the_DT
Remuneration_NOMZ
Committee_NN
because_CAUS
it_PIT
is_VPRT
Note_NN
28_CD
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
Performance_NN
transparent_JJ
and_CC
is_VPRT [BEMA]
a_DT
relevant_JJ
indicator_NN
of_PIN
financial_JJ
performance_NN
._.
conditions_NOMZ
attaching_VBG [WZPRES]
to_PIN
previous_JJ
executive_NN
option_NOMZ
grants_NN
are_VPRT [PASS]
detailed_VBN
on_PIN
page_NN
44_CD
in_PIN
the_DT
audited_JJ
section_NOMZ
of_PIN
this_DEMO
report_NN
._.
The_DT
minimum_JJ
performance_NN
test_NN
attaching_VBG [WZPRES]
to_PIN
the_DT
exercise_NN
of_PIN
share_NN
options_NOMZ
for_PIN
executive_NN
Directors_NN
is_VPRT [BEMA]
higher_PRED
than_PIN
for_PIN
other_JJ
employees_NN
._.
b_NN
Long_NN
Term_NN
Incentive_NN
Plan_NN
No_SYNE
options_NOMZ
vest_NN
unless_COND
Shires_NN
EPS_NN
meets_VPRT
the_DT
minimum_JJ
growth_NN
The_DT
Long_NN
Term_NN
Incentive_NN
Plan_NN
the_DT
Plan_NN
was_VBD [PASS]
adopted_VBN
at_PIN
the_DT
threshold_NN
set_NN
of_PIN
15_CD
%_NN
in_PIN
excess_NN
of_PIN
the_DT
Retail_NN
Price_NN
Index_NN
RPI_NN
Companys_NN
1998_CD
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
and_PHC
amended_VBN
in_PIN
2000_CD
._.
or_CC
5_CD
%_NN
on_PIN
average_NN
a_DT
year_NN
in_PIN
the_DT
three_CD
years_NN
following_VBG [WZPRES]
the_DT
date_NN
of_PIN
Under_IN
the_DT
Plan_NN
,_,
the_DT
Remuneration_NOMZ
Committee_NN
has_VPRT
discretion_NOMZ
grant_NN
._.
In_PIN
the_DT
case_NN
of_PIN
an_DT
annual_JJ
grant_NN
of_PIN
options_NOMZ
worth_JJ
three_CD
times_NN
to_TO
make_VB
awards_NN
of_PIN
shares_NN
,_,
subject_JJ
to_PIN
a_DT
maximum_NN
of_PIN
100_CD
%_NN
salary_NN
,_,
Shires_NN
EPS_NN
must_NEMD
grow_VB
by_PIN
21_CD
%_NN
in_PIN
excess_NN
of_PIN
RPI_NN
or_CC
on_PIN
of_PIN
salary_NN
a_DT
year_NN
._.
Awards_NN
are_VPRT [PASS]
made_VBN
to_PIN
executive_JJ
Directors_NN
and_CC
average_JJ
7_CD
%_NN
a_DT
year_NN
in_PIN
the_DT
three_CD
years_NN
following_VBG [WZPRES]
the_DT
date_NN
of_PIN
grant_NN
senior_JJ
managers_NN
._.
for_PIN
all_QUAN
the_DT
options_NOMZ
to_PIN
vest_NN
._.
The_DT
performance_NN
condition_NOMZ
attached_VBN [WZPAST]
to_PIN
the_DT
vesting_GER
of_PIN
the_DT
share_NN
Options_NOMZ
with_PIN
a_DT
value_NN
on_PIN
grant_NN
as_IN
a_DT
%_NN
of_PIN
salary_NN
Three-year_JJ
EPS_NN
growth_NN
awards_NN
made_VBN
under_IN
the_DT
Plan_NN
is_VPRT
Shires_NN
Total_NN
Shareholder_NN
Return_NN
TSR_NN
relative_JJ
to_PIN
the_DT
FTSE_NN
100_CD
Index_NN
over_IN
a_DT
three-year_JJ
period_NN
._.
Up_IN
to_PIN
100_CD
%_NN
Retail_NN
Price_NN
Index_NN
RPI_NN
plus_PIN
15_CD
%_NN
The_DT
Committee_NN
considers_VPRT [PRIV] [THATD]
that_DEMP
this_DEMO
measure_NN
is_VPRT [BEMA]
a_DT
reliable_JJ
and_CC
for_PIN
executive_JJ
Directors_NN
appropriate_JJ
measure_NN
of_PIN
the_DT
Companys_NN
performance_NN
and_CC
that_THVC
the_DT
RPI_NN
plus_PIN
9_CD
%_NN
for_PIN
all_QUAN
other_JJ
employees_NN
FTSE_VPRT
100_CD
is_VPRT [BEMA]
an_DT
appropriate_JJ
benchmark_NN
given_VBN
that_DEMO
the_DT
Company_NN
101_CD
%_NN
to_PIN
200_CD
%_NN
RPI_NN
plus_PIN
15_CD
%_NN
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
the_DT
Index_NN
._.
201_CD
%_NN
to_PIN
300_CD
%_NN
RPI_NN
plus_PIN
21_CD
%_NN
Under_IN
the_DT
current_JJ
Plan_NN
:_:
Over_IN
301_CD
%_NN
RPI_NN
plus_PIN
27_CD
%_NN
all_QUAN
shares_NN
vest_NN
if_COND
Shires_NN
TSR_NN
is_VPRT [BEMA]
in_PIN
the_DT
top_JJ
10_CD
%_NN
of_PIN
the_DT
FTSE_NN
100_CD
:_:
The_DT
2000_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
,_,
which_WDT [SERE]
was_VBD [PASS]
approved_VBN
20_CD
%_NN
of_PIN
the_DT
shares_NN
vest_NN
if_COND
Shires_NN
TSR_NN
is_VPRT [BEMA]
at_PIN
the_DT
median_NN
of_PIN
the_DT
by_PIN
shareholders_NN
in_PIN
2000_CD
,_,
contains_VPRT
an_DT
unlimited_JJ
retesting_GER
feature_NN
FTSE_NN
100_CD
,_,
with_PIN
vesting_VBG
between_PIN
these_DEMO
points_NN
on_PIN
a_DT
linear_JJ
basis_NN
:_:
from_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
decided_VBD [SUAV] [PRIV]
,_,
and_ANDC
after_IN
consultation_NOMZ
with_PIN
some_QUAN
of_PIN
the_DT
Companys_NN
major_JJ
institutional_JJ
shareholders_NN
in_PIN
2003_CD
,_,
that_DEMO
for_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
scheme_NN
no_SYNE
shares_NN
vest_NN
if_COND
Shires_NN
TSR_NN
is_VPRT
below_PLACE
the_DT
median_NN
of_PIN
the_DT
from_PIN
2004_CD
onwards_NN
,_,
the_DT
performance_NN
condition_NOMZ
should_NEMD
be_VB [PASS]
retested_VBN
FTSE_NN
100_CD
._.
once_TIME
only_DWNT
,_,
at_PIN
five_CD
years_NN
after_IN
the_DT
grant_NN
._.
The_DT
retest_NN
will_PRMD
be_VB [PASS]
applied_VBN
only_DWNT
where_RB
Shires_NN
EPS_NN
growth_NN
has_VPRT [PEAS]
not_XX0
met_VBN
the_DT
minimum_JJ
performance_NN
test_NN
described_VBN
above_PLACE
._.
The_DT
annual_JJ
average_JJ
growth_NN
required_VBN [SUAV]
over_IN
the_DT
first_JJ
three_CD
years_NN
must_NEMD
be_VB [PASS]
achieved_VBN
over_IN
the_DT
extended_JJ
performance_NN
period_NN
._.
38_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
39_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Directors_NN
remuneration_JJ
report_NN
The_DT
Remuneration_NOMZ
Committee_NN
determines_VPRT [SUAV] [PRIV]
whether_IN [WHCL]
and_CC
to_TO
what_WP
4_CD
Pension_NN
and_CC
other_JJ
benefits_NN
extent_NN
the_DT
performance_NN
condition_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
met_VBN
on_PIN
the_DT
basis_NN
of_PIN
The_DT
Companys_NN
policy_NN
is_VPRT
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
pension_NN
benefits_NN
are_VPRT [BYPA]
data_NN
provided_VBN [WZPAST]
by_PIN
an_DT
independent_JJ
third_JJ
party_NN
._.
To_PIN
date_NN
,_,
all_QUAN
awards_NN
competitive_JJ
in_PIN
the_DT
markets_NN
in_PIN
which_WDT [PIRE]
Shire_NN
operates_VPRT
._.
Shire_NN
made_VBD
under_IN
the_DT
Plan_NN
have_VPRT [PEAS]
been_VBN [PASS]
made_VBN
as_IN
a_DT
conditional_JJ
allocation_NOMZ
,_,
contributes_VPRT
30_CD
%_NN
of_PIN
the_DT
Chief_NN
Executive_NN
Officers_NN
annual_JJ
salary_NN
thereby_RB
allowing_VBG [SUAV]
,_,
at_PIN
the_DT
Remuneration_NOMZ
Committees_NN
discretion_NOMZ
,_,
to_PIN
a_DT
SERP_NN
and_CC
401_CD
k_NN
Plan_NN
in_PIN
the_DT
US_FPP1
._.
In_PIN
the_DT
UK_NN
,_,
Shire_NN
operates_VPRT
for_PIN
a_DT
cash_NN
equivalent_NN
to_TO
be_VB [PASS]
paid_VBN
on_PIN
maturity_NOMZ
of_PIN
the_DT
award_NN
._.
The_DT
Company_NN
contributes_VPRT
25_CD
%_NN
the_DT
performance_NN
period_NN
is_VPRT [PASS]
measured_VBN
over_IN
three_CD
years_NN
,_,
an_DT
award_NN
of_PIN
salary_NN
for_PIN
the_DT
Chief_NN
Financial_NN
Officer_NN
to_PIN
pension_NN
benefits_NN
._.
The_DT
is_VPRT [SPAU] [PASS]
normally_RB
transferred_VBN
after_IN
the_DT
fourth_JJ
anniversary_NN
of_PIN
grant_NN
,_,
to_PIN
the_DT
implications_NOMZ
of_PIN
the_DT
forthcoming_JJ
UK_NN
pension_NN
tax_NN
reforms_NN
which_WDT [WHOBJ]
extent_NN
the_DT
performance_NN
condition_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
met_VBN
._.
become_VBN
effective_JJ
in_PIN
2006_CD
will_PRMD
be_VB [PASS]
considered_VBN [PRIV]
during_PIN
the_DT
course_NN
of_PIN
the_DT
year_NN
and_CC
the_DT
Committee_NN
will_PRMD
agree_VB [SUAV] [PUBV]
any_QUAN
policy_NN
changes_NN
Directors_NN
were_VBD [PASS]
granted_VBN [SUAV]
awards_NN
under_IN
the_DT
Plan_NN
in_PIN
2004_CD
as_RB
necessary_JJ
in_PIN
respect_NN
of_PIN
the_DT
pension_NN
arrangements_NOMZ
of_PIN
the_DT
a_DT
conditional_JJ
allocation_NOMZ
as_IN
defined_VBN
in_PIN
the_DT
Plan_NN
,_,
as_IN
follows_VPRT
:_:
Chief_NN
Financial_NN
Officer_NN
and_CC
other_JJ
UK_NN
executives_NN
._.
Earliest_JJ
date_NN
In_CONJ
addition_NULL
to_PIN
salary_NN
,_,
the_DT
executive_NN
Directors_NN
receive_VPRT
certain_JJ
on_PIN
which_WDT [PIRE]
benefits_NN
in_PIN
kind_NN
,_,
principally_RB
a_DT
car_NN
or_CC
car_NN
allowance_NN
,_,
life_NN
insurance_NN
,_,
Value_NN
of_PIN
an_DT
award_NN
conditional_JJ
Total_NN
can_POMD
be_VB [BEMA]
private_JJ
medical_JJ
insurance_NN
and_CC
dental_JJ
cover_NN
._.
These_DEMO
benefits_NN
are_VPRT
award_NN
at_PIN
number_NN
of_PIN
transferred_VBN
not_XX0
pensionable_JJ
._.
Date_NN
of_PIN
grant_NN
date_NN
ordinary_JJ
to_PIN
a_DT
award_NN
shares_NN
Director_NN
Service_NN
contracts_NN
Mr_NN
Matthew_NN
Emmens_NN
25.03.04_CD
563,136_CD
105,259_CD
25.03.08_CD
The_DT
Remuneration_NOMZ
Committee_NN
continues_VPRT
to_TO
believe_VB [PRIV]
that_THVC
executive_JJ
Directors_NN
service_NN
contracts_NN
should_NEMD
be_VB [BEMA]
for_PIN
a_DT
rolling_VBG
Mr_NN
Angus_NN
Russell_NN
25.03.04_CD
348,258_CD
65,095_CD
25.03.08_CD
term_NN
and_CC
,_,
for_PIN
UK_NN
contracts_NN
,_,
incorporate_VB
notice_NN
periods_NN
of_PIN
12_CD
months_NN
._.
The_DT
Committee_NN
also_RB
believes_VPRT [PRIV]
that_THVC
the_DT
Company_NN
c_NN
Deferred_NN
Bonus_NN
Plan_NN
should_NEMD
retain_VB
the_DT
right_NN
to_TO
make_VB
a_DT
payment_NOMZ
in_PIN
lieu_NN
of_PIN
notice_NN
to_PIN
The_DT
Deferred_NN
Bonus_NN
Plan_NN
,_,
in_PIN
which_WDT [PIRE]
executive_JJ
Directors_NN
can_POMD
a_DT
Director_NN
._.
The_DT
contracts_NN
contain_VPRT
obligations_NOMZ
on_PIN
the_DT
executive_NN
participate_VB
,_,
provides_VPRT
for_PIN
participants_NN
to_TO
use_VB
up_RP
to_PIN
50_CD
%_NN
of_PIN
their_TPP3
Directors_NN
in_PIN
respect_NN
of_PIN
intellectual_JJ
property_NN
,_,
together_RB
with_PIN
postannual_JJ
incentive_NN
to_TO
buy_VB
shares_NN
in_PIN
the_DT
Company_NN
._.
The_DT
Committees_NN
view_VPRT
is_VPRT
that_DEMP
,_,
in_PIN
the_DT
will_PRMD
match_VB
any_QUAN
shares_NN
bought_VBD
,_,
but_CC
the_DT
matched_VBN
shares_NN
will_PRMD
vest_NN
,_,
event_NN
of_PIN
early_TIME
termination_NOMZ
,_,
executive_NN
Directors_NN
should_NEMD
be_VB [PASS]
treated_VBN
for_PIN
executive_NN
Directors_NN
,_,
only_DWNT
if_COND
the_DT
Companys_NN
EPS_NN
as_IN
measured_VBN
fairly_RB
but_CC
paid_VBD
no_SYNE
more_EMPH
than_PIN
is_VPRT [BEMA]
necessary_PRED
._.
Moreover_CONJ
,_,
there_EX
by_PIN
diluted_JJ
EPS_NN
and_CC
as_IN
reported_VBN [PUBV]
in_PIN
the_DT
Companys_NN
Form_NN
10-K_NN
should_NEMD
be_VB [BEMA]
no_SYNE
element_NOMZ
of_PIN
reward_NN
for_PIN
failure_NN
._.
under_IN
US_FPP1
GAAP_NN
grows_VPRT
by_PIN
more_EMPH
than_PIN
15_CD
%_NN
in_PIN
excess_NN
of_PIN
RPI_NN
over_IN
a_DT
three-year_JJ
period_NN
9_CD
%_NN
in_PIN
excess_NN
of_PIN
RPI_NN
for_PIN
other_JJ
eligible_JJ
The_DT
executive_NN
Directors_NN
contracts_NN
of_PIN
employment_NOMZ
,_,
which_WDT [SERE]
employees_NN
._.
Diluted_VBN
EPS_NN
was_VBD [PASS]
chosen_VBN
since_OSUB
it_PIT
is_VPRT [BEMA]
consistent_PRED
with_PIN
were_VBD [PASS]
revised_VBN
following_VBG
consultation_NOMZ
with_PIN
some_QUAN
of_PIN
the_DT
Companys_NN
the_DT
minimum_JJ
performance_NN
test_NN
that_TSUB
applies_VPRT
to_PIN
the_DT
vesting_GER
of_PIN
major_JJ
shareholders_NN
in_PIN
2003_CD
,_,
are_VPRT [PASS]
dated_VBN
10_CD
March_NN
2004_CD
in_PIN
the_DT
options_NOMZ
see_VPRT [PRIV]
above_PLACE
._.
case_NN
of_PIN
Mr_NN
Russell_NN
and_CC
12_CD
March_NN
2004_CD
in_PIN
the_DT
case_NN
of_PIN
Mr_NN
Emmens_NN
._.
Mr_NN
Russells_NN
contract_NN
requires_VPRT [SUAV]
him_TPP3
to_TO
give_VB
the_DT
Company_NN
This_DEMO
Plan_NN
was_VBD [PASS]
designed_VBN
to_TO
deliver_VB
value_NN
to_PIN
shareholders_NN
by_PIN
12_CD
months_NN
notice_NN
and_CC
expires_VPRT
on_PIN
him_TPP3
reaching_VBG
65_CD
._.
Mr_NN
Emmens_NN
encouraging_JJ
executive_NN
share_NN
ownership_NN
._.
However_CONJ
,_,
recent_JJ
contract_NN
requires_VPRT [SUAV]
him_TPP3
to_TO
give_VB
the_DT
Company_NN
six_CD
months_NN
notice_VPRT [PRIV]
fiscal_JJ
changes_NN
in_PIN
the_DT
US_FPP1
have_VPRT [PEAS]
made_VBN
the_DT
Plan_NN
less_RB
attractive_JJ
to_TO
and_CC
no_SYNE
age_NN
is_VPRT [PASS]
specified_VBN
for_PIN
retirement_NOMZ
._.
The_DT
Company_NN
is_VPRT [PASS]
required_VBN [SUAV]
participants_NN
and_CC
the_DT
Remuneration_NOMZ
Committee_NN
has_VPRT [PEAS]
determined_VBN [SUAV] [PRIV]
to_TO
give_VB
Mr_NN
Russell_NN
12_CD
months_NN
notice_NN
of_PIN
termination_NOMZ
,_,
other_JJ
than_PIN
that_DEMO
it_PIT
will_PRMD
discontinue_VB
the_DT
Plan_NN
after_IN
bonus_NN
awards_NN
for_PIN
the_DT
2004_CD
if_COND
termination_NOMZ
is_VPRT [BEMA]
for_PIN
cause_NN
,_,
whereas_OSUB
it_PIT
is_VPRT [PASS]
not_XX0
obliged_VBN
to_TO
give_VB
financial_JJ
year_NN
._.
The_DT
Committee_NN
is_VPRT
reviewing_VBG
the_DT
design_NN
and_PHC
implementation_NOMZ
of_PIN
its_PIT
In_PIN
the_DT
event_NN
of_PIN
termination_NOMZ
of_PIN
employment_NOMZ
within_PIN
12_CD
months_NN
current_JJ
long_JJ
term_NN
incentive_NN
plans_NN
as_IN
part_NN
of_PIN
its_PIT
compensation_NOMZ
and_CC
of_PIN
a_DT
change_NN
of_PIN
control_NN
,_,
the_DT
amount_NN
payable_JJ
is_VPRT [BEMA]
one_CD
years_NN
salary_NN
benefits_NN
review_NN
._.
Shareholders_NN
will_PRMD
be_VB [PASS]
consulted_VBN
on_PIN
this_DEMO
during_PIN
the_DT
and_CC
the_DT
cash_NN
equivalent_NN
of_PIN
one_CD
years_NN
pension_NN
,_,
car_NN
and_CC
other_JJ
course_NN
of_PIN
the_DT
year_NN
._.
Any_QUAN
incentive_NN
payable_JJ
is_VPRT [BEMA]
at_PIN
the_DT
discretion_NOMZ
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
and_CC
is_VPRT [PASS]
capped_VBN
at_PIN
the_DT
contractual_JJ
maximum_NN
incentive_NN
._.
The_DT
amount_NN
of_PIN
incentive_NN
payable_JJ
upon_PIN
termination_NOMZ
of_PIN
employment_NOMZ
in_PIN
any_QUAN
other_JJ
circumstances_NN
,_,
other_JJ
than_PIN
for_PIN
cause_NN
,_,
is_VPRT [BEMA]
at_PIN
the_DT
discretion_NOMZ
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
and_CC
is_VPRT [PASS]
capped_VBN
at_PIN
the_DT
contractual_JJ
target_NN
incentive_NN
._.
39_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
40_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Directors_NN
remuneration_JJ
report_NN
Non-executive_JJ
Directors_NN
and_CC
the_DT
Chairman_NN
Performance_NN
graph_NN
Each_QUAN
non-executive_JJ
Director_NN
is_VPRT [PASS]
paid_VBN
a_DT
fee_NN
for_PIN
serving_VBG
as_IN
a_DT
Director_NN
The_NN
graph_NN
below_PLACE
sets_NN
out_PIN
the_DT
Total_JJ
Shareholder_NN
Return_NN
TSR_NN
for_PIN
and_CC
additional_JJ
fees_NN
are_VPRT [PASS]
paid_VBN
for_PIN
membership_NN
or_CC
chairmanship_NN
the_DT
five_CD
years_NN
ending_VBG [WZPRES]
31_CD
December_NN
2004_CD
._.
The_DT
graph_NN
compares_VPRT
of_PIN
the_DT
Audit_NN
,_,
Remuneration_NOMZ
and_PHC
Nomination_NOMZ
Committees_NN
._.
The_DT
the_DT
performance_NN
of_PIN
a_DT
holding_GER
of_PIN
the_DT
Companys_NN
shares_NN
with_PIN
Chairman_NN
of_PIN
the_DT
Company_NN
receives_VPRT
an_DT
inclusive_JJ
fee_NN
._.
Fees_NN
are_VPRT
that_DEMO
of_PIN
a_DT
holding_GER
of_PIN
shares_NN
in_PIN
the_DT
FTSE_NN
UK_NN
Pharma_NN
and_PHC
Biotech_NN
determined_VBN [SUAV] [PRIV] [WZPAST]
by_PIN
the_DT
Board_NN
,_,
with_PIN
the_DT
exception_NOMZ
of_PIN
the_DT
Chairmans_NN
Index_NN
over_IN
the_DT
relevant_JJ
period_NN
,_,
calculated_VBN [PRIV] [PASTP]
in_PIN
accordance_NN
with_PIN
fee_NN
,_,
which_WDT [SERE]
is_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
Remuneration_NOMZ
Committee_NN
and_CC
the_DT
Directors_NN
Remuneration_NOMZ
Report_NN
Regulations_NOMZ
2002_CD
._.
The_DT
confirmed_VBN [PUBV]
by_PIN
the_DT
Board_NN
._.
Fees_NN
are_VPRT [PASS]
benchmarked_VBN
against_PIN
nonFTSE_JJ
UK_NN
Pharma_NN
and_PHC
Biotech_NN
Index_NN
has_VPRT [PEAS]
been_VBN [PASS]
selected_VBN
to_TO
show_VB [PRIV]
executive_JJ
Director_NN
fees_NN
of_PIN
comparable_JJ
companies_NN
._.
The_DT
fees_NN
shareholders_NN
how_RB
Shires_NN
TSR_NN
has_VPRT [PEAS]
performed_VBN
relative_JJ
to_PIN
other_JJ
paid_VBN
to_PIN
non-executive_JJ
Directors_NN
are_VPRT [BEMA]
not_XX0
performance-related_PRED
._.
companies_NN
in_PIN
its_PIT
sector_NN
over_IN
a_DT
five-year_JJ
period_NN
._.
Details_NN
of_PIN
fees_NN
paid_VBN [WZPAST]
to_PIN
the_DT
Chairman_NN
and_CC
non-executive_JJ
Directors_NN
in_PIN
2004_CD
are_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
table_NN
on_PIN
page_NN
41_CD
._.
Change_NN
in_PIN
the_DT
Value_NN
of_PIN
a_DT
Hypothetical_JJ
100_CD
Holding_GER
Over_IN
Five_CD
Years_NN
._.
The_DT
non-executive_JJ
Directors_NN
are_VPRT [BEMA]
not_XX0
eligible_PRED
to_TO
join_VB
the_DT
Companys_NN
FTSE_NN
UK_NN
Pharma_NN
and_PHC
Biotech_NN
Index_NN
Comparison_NN
Based_VBD
pension_NN
scheme_NN
._.
200_CD
Non-executive_JJ
Directors_NN
do_VPRT
not_XX0
participate_VB
in_PIN
any_QUAN
of_PIN
the_DT
Company_NN
share_NN
schemes_NN
or_CC
other_JJ
employee_NN
benefit_NN
schemes_NN
and_CC
no_SYNE
options_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
to_PIN
non-executive_JJ
Directors_NN
in_PIN
their_TPP3
capacity_NOMZ
as_IN
non-executive_JJ
Directors_NN
of_PIN
Shire_NN
._.
On_PIN
the_DT
merger_NN
of_PIN
Shire_NN
with_PIN
BioChem_NN
Pharma_NN
Inc._NN
in_PIN
2001_CD
,_,
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
150_CD
to_PIN
The_DT
Hon_NN
James_NN
Grant_NN
in_PIN
replacement_NOMZ
for_PIN
Mr_NN
Grants_NN
BioChem_NN
Pharma_NN
options_NOMZ
._.
The_DT
grant_NN
of_PIN
these_DEMO
replacement_NOMZ
options_NOMZ
and_CC
the_DT
original_JJ
BioChem_NN
Pharma_NN
option_NOMZ
grant_NN
were_VBD [PASS]
made_VBN
on_PIN
the_DT
same_JJ
terms_NN
as_IN
applied_VBN
to_PIN
other_JJ
employees_NN
at_PIN
the_DT
time_NN
,_,
including_VBG
that_DEMO
100_CD
these_DEMO
options_NOMZ
are_VPRT [BEMA]
not_XX0
subject_PRED
to_PIN
any_QUAN
performance_NN
conditions_NOMZ
._.
The_DT
Chairman_NN
and_CC
the_DT
non-executive_JJ
Directors_NN
have_VPRT
letters_NN
of_PIN
appointment_NOMZ
detailing_VBG [WZPRES]
their_TPP3
specific_JJ
terms_NN
of_PIN
engagement_NOMZ
which_WDT [WHOBJ]
,_,
other_JJ
than_PIN
for_PIN
Dr_NN
Price_NN
,_,
are_VPRT [BEMA]
for_PIN
a_DT
two-year_JJ
term_NN
which_WDT [WHSUB]
may_POMD
be_VB [BEMA]
50_CD
renewed_VBN
._.
Dr_NN
Prices_NN
re-appointment_NOMZ
in_PIN
January_NN
2005_CD
is_VPRT [BEMA]
for_PIN
a_DT
oneDec_JJ
1999_CD
Dec_NN
2000_CD
Dec_NN
2001_CD
Dec_NN
2002_CD
Dec_NN
2003_CD
Dec_NN
2004_CD
year_NN
term_NN
which_WDT [WHSUB]
may_POMD
be_VB [PASS]
renewed_VBN
._.
Details_NN
of_PIN
the_DT
unexpired_JJ
terms_NN
of_PIN
the_DT
letters_NN
of_PIN
appointment_NOMZ
and_PHC
notice_NN
periods_NN
are_VPRT
as_IN
follows_VPRT
:_:
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
FTSE_NN
UK_NN
Pharma_NN
and_PHC
Biotech_NN
Index_NN
Date_NN
of_PIN
Date_NN
of_PIN
Notice_NN
Director_NN
appointment_NOMZ
term_NN
expiry_JJ
period_NN
Termination_NOMZ
payments_NOMZ
Dr_NN
James_NN
Cavanaugh_NN
24.03.05_CD
23.03.07_CD
3_CD
months_NN
Dr_NN
Wilson_NN
Totten_NN
stepped_VBD
down_RP
as_IN
Chief_NN
Scientific_NN
Officer_NN
in_PIN
May_POMD
2004_CD
._.
He_TPP3
remained_VBD
an_DT
employee_NN
of_PIN
the_DT
Company_NN
responsible_JJ
Dr_NN
Barry_NN
Price_NN
25.01.05_CD
24.01.06_CD
3_CD
months_NN
for_PIN
special_JJ
corporate_JJ
projects_NN
,_,
including_VBG
M&A_NN
and_CC
the_DT
continued_VBN
The_DT
Hon_NN
James_NN
Grant_NN
11.05.03_CD
10.05.05_CD
3_CD
months_NN
development_NOMZ
of_PIN
FOSRENOL_NN
until_IN
his_TPP3
contract_NN
was_VBD [BYPA]
terminated_VBN
by_PIN
the_DT
Company_NN
._.
No_SYNE
change_NN
was_VBD [PASS]
made_VBN
to_PIN
Dr_NN
Tottens_NN
terms_NN
and_PHC
Mr_NN
Ronald_NN
Nordmann_NN
23.12.03_CD
22.12.05_CD
3_CD
months_NN
conditions_NOMZ
of_PIN
employment_NOMZ
on_PIN
his_TPP3
ceasing_VBG
to_TO
be_VB [BEMA]
a_DT
Director_NN
and_PHC
Mr_NN
Robin_NN
Buchanan_NN
30.07.03_CD
29.07.05_CD
3_CD
months_NN
he_TPP3
was_VBD [PASS]
paid_VBN
no_SYNE
compensation_NOMZ
for_PIN
loss_NN
of_PIN
his_TPP3
office_NN
as_IN
a_DT
Director_NN
._.
Mr_NN
David_NN
Kappler_NN
06.04.04_CD
05.04.06_CD
3_CD
months_NN
Dr_NN
Tottens_NN
employment_NOMZ
ended_VBD
on_PIN
31_CD
August_NN
2004_CD
._.
Payment_NOMZ
was_VBD [PASS]
made_VBN
to_PIN
him_TPP3
in_PIN
accordance_NN
with_PIN
the_DT
payment_NOMZ
in_PIN
lieu_NN
of_PIN
notice_NN
Related_VBN
party_NN
transactions_NOMZ
provisions_NN
in_PIN
his_TPP3
contract_NN
of_PIN
employment_NOMZ
,_,
amounting_VBG [PRESP]
to_PIN
639,265_CD
._.
Details_NN
of_PIN
transactions_NOMZ
relating_VBG [WZPRES]
to_PIN
The_DT
Hon_NN
James_NN
Grant_NN
,_,
who_WP
is_VPRT [BEMA]
a_DT
partner_NN
of_PIN
a_DT
Canadian_JJ
law_NN
firm_NN
with_PIN
which_WDT [PIRE]
the_DT
Company_NN
incurred_VBN
Details_NN
of_PIN
Dr_NN
Tottens_NN
options_NOMZ
,_,
LTIP_NN
awards_NN
,_,
emoluments_NOMZ
for_PIN
2004_CD
professional_JJ
fees_NN
during_PIN
the_DT
year_NN
,_,
and_ANDC
with_PIN
Mr_NN
Ronald_NN
Nordmann_NN
and_PHC
pension_NN
contributions_NOMZ
are_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
next_JJ
part_NN
of_PIN
this_DEMP
and_CC
Dr_NN
Francesco_NN
Bellini_NN
,_,
a_DT
former_JJ
non-executive_JJ
Director_NN
,_,
are_VPRT
report_NN
,_,
under_IN
Audited_NN
Information_NOMZ
._.
given_VBN [PASTP]
in_PIN
Note_NN
21_CD
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
Other_JJ
remuneration_NOMZ
Mr_NN
Emmens_NN
was_VBD [PASS]
appointed_VBN
a_DT
non-executive_JJ
director_NN
of_PIN
Vertex_NN
Pharmaceuticals_NN
Inc._NN
during_PIN
2004_CD
._.
In_PIN
this_DEMO
capacity_NOMZ
he_TPP3
was_VBD [PASS]
paid_VBN
$_$
14,000_CD
in_PIN
2004_CD
,_,
which_WDT [SERE]
he_TPP3
will_PRMD
retain_VB
._.
Mr_NN
Russell_NN
is_VPRT [BEMA]
a_DT
non-executive_JJ
director_NN
of_PIN
The_DT
City_NOMZ
of_PIN
London_NN
Investment_NOMZ
Trust_NN
plc_NN
and_CC
its_PIT
associated_VBN
companies_NN
,_,
The_DT
City_NOMZ
of_PIN
London_NN
European_NN
Trust_NN
Limited_NN
,_,
The_NN
City_NOMZ
of_PIN
London_NN
Investments_NOMZ
Limited_NN
and_PHC
The_NN
City_NOMZ
of_PIN
London_NN
Finance_NN
Company_NN
Limited_NN
._.
In_PIN
this_DEMO
capacity_NOMZ
,_,
he_TPP3
was_VBD [PASS]
paid_VBN
16,500_CD
in_PIN
2004_CD
,_,
which_WDT [SERE]
he_TPP3
will_PRMD
retain_VB
._.
40_CD
Value_NN
of_PIN
Hypothetical_JJ
100_CD
Holding_GER
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
41_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Directors_NN
remuneration_JJ
report_NN
Audited_VBN
information_NOMZ
Aggregate_NN
Directors_NN
remuneration_VPRT
The_DT
total_JJ
amounts_NN
for_PIN
Directors_NN
remuneration_NOMZ
were_VBD
as_IN
follows_VPRT
:_:
2004 2003 000 000_CD
Emoluments_NOMZ
2,592_CD
2,256_CD
Money_NN
purchase_NN
pension_NN
contributions_NOMZ
278_CD
4,676_CD
Gains_NN
on_PIN
exercise_NN
of_PIN
share_NN
options_NOMZ
118_CD
114_CD
Amounts_NN
receivable_JJ
under_IN
long-term_JJ
incentive_NN
schemes_NN
86_CD
276_CD
Compensation_NOMZ
for_PIN
loss_NN
of_PIN
office_NN
1,335_CD
3,074_CD
8,657_CD
Directors_NN
emoluments_VPRT
Cash_NN
Non-cash_JJ
benefits_NN
benefits_NN
Total_JJ
Total_JJ
Salary_NN
Incentive_NN
Fees_NN
in_PIN
kind_NN
in_PIN
kind_NN
2004_CD
2003_CD
Director_NN
000 000 000 000_CD
000 000 000_CD
Executive_NN
i_FPP1
ii_FW
Mr_NN
Matthew_NN
Emmens_NN
545 437 437_CD
1,419_CD
699_CD
Mr_NN
Angus_NN
Russell_NN
342_CD
257_CD
11_CD
4_CD
614_CD
499_CD
iii_FW
Dr_FW
Wilson_NN
Totten_NN
142_CD
107_CD
4_CD
3_CD
256_CD
531_CD
iv_NN
Mr_NN
Rolf_NN
Stahel_NN
311_CD
1,029_CD
801_CD
452_CD
7_CD
2,289_CD
2,040_CD
Non-executive_JJ
v_NN
Dr_NN
James_NN
Cavanaugh_NN
75_CD
75_CD
54_CD
Dr_NN
Barry_NN
Price_NN
60_CD
60_CD
43_CD
The_DT
Hon_NN
James_NN
Grant_NN
40_CD
40_CD
35_CD
Mr_NN
Ronald_NN
Nordmann_NN
54_CD
54_CD
45_CD
Mr_NN
Robin_NN
Buchanan_NN
40_CD
40_CD
16_CD
vi_FW
Mr_NN
David_NN
Kappler_NN
34_CD
34_CD
vii_NN
Dr_NN
Francesco_NN
Bellini_NN
11_CD
vii_FW
Mr_NN
Gerard_NN
Veilleux_NN
12 303 303 216_CD
Total_JJ
1,029_CD
801 303 452_CD
7_CD
2,592_CD
2,256_CD
Notes_NN
i_FPP1
Paid_NN
in_PIN
US$_$
,_,
Mr_NN
Emmens_NN
annual_JJ
salary_NN
in_PIN
2004_CD
was_VBD
$_$
999,319_CD
._.
ii_FW
The_DT
Company_NN
underwent_VBD
a_DT
major_JJ
internal_JJ
reorganisation_NOMZ
in_PIN
2004_CD
,_,
which_WDT [SERE]
resulted_VBD
in_PIN
the_DT
Company_NN
selecting_VBG [WZPRES]
Philadelphia_NN
as_IN
its_PIT
US_FPP1
corporate_JJ
headquarters_NN
._.
Mr_NN
Emmens_NN
was_VBD [PASS]
paid_VBN
420,339_CD
in_PIN
connection_NOMZ
with_PIN
costs_NN
associated_VBN [WZPAST]
with_PIN
his_TPP3
relocation_NOMZ
to_PIN
the_DT
Philadelphia_NN
area_NN
._.
iii_FW
Dr_FW
Totten_FW
stepped_VBD
down_RP
as_IN
a_DT
Director_NN
of_PIN
the_DT
Company_NN
on_PIN
25_CD
May_POMD
2004_CD
._.
iv_VB
Mr_NN
Stahel_NN
stepped_VBD
down_RP
as_IN
a_DT
Director_NN
of_PIN
the_DT
Company_NN
on_PIN
19_CD
March_NN
2003_CD
._.
v_FW
The_DT
Chairmans_NN
fee_NN
in_PIN
2004_CD
was_VBD [BEMA]
100,000_CD
._.
Dr_NN
Cavanaugh_NN
elected_VBD
to_TO
receive_VB
75,000_CD
._.
vi_FW
Mr_NN
Kappler_NN
was_VBD [PASS]
appointed_VBN
a_DT
non-executive_JJ
Director_NN
on_PIN
6_CD
April_NN
2004_CD
._.
vii_FW
Dr_FW
Bellini_NN
and_PHC
Mr_NN
Veilleux_NN
stepped_VBD
down_RP
as_IN
non-executive_JJ
Directors_NN
of_PIN
the_DT
Company_NN
on_PIN
10_CD
May_POMD
2003_CD
._.
Cash_NN
benefits_NN
in_PIN
kind_NN
represent_VPRT
expense_NN
allowances_NN
including_VBG [WZPRES]
dental_JJ
costs_NN
and_CC
,_,
in_PIN
the_DT
case_NN
of_PIN
Mr_NN
Emmens_NN
,_,
relocation_NOMZ
costs_NN
and_CC
non-cash_JJ
benefits_NN
represent_VPRT
emoluments_NOMZ
._.
Non-cash_JJ
benefits_NN
in_PIN
kind_NN
consist_VPRT
of_PIN
private_JJ
medical_JJ
insurance_NN
._.
Details_NN
of_PIN
the_DT
exercise_NN
of_PIN
share_NN
options_NOMZ
are_VPRT [PASS]
disclosed_VBN [PUBV]
on_PIN
page_NN
43_CD
._.
Non-executive_JJ
Director_NN
remuneration_NOMZ
is_VPRT [BEMA]
to_PIN
from_PIN
the_DT
date_NN
of_PIN
resignation_NOMZ
appointment_NOMZ
._.
41_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
42_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Directors_NN
remuneration_JJ
report_NN
Dr_NN
Totten_NN
Directors_NN
shareholdings_GER
Dr_NN
Totten_NN
stepped_VBD
down_RP
as_IN
the_DT
Chief_NN
Scientific_NN
Officer_NN
on_PIN
25_CD
May_POMD
Directors_NN
who_WP [WHSUB]
held_VBD [PRIV]
office_NN
at_PIN
the_DT
end_NN
of_PIN
the_DT
year_NN
had_VBD
interests_NN
in_PIN
the_DT
2004_CD
._.
The_DT
table_NN
above_PLACE
details_NN
Dr_NN
Tottens_NN
emoluments_VPRT
for_PIN
the_DT
share_NN
capital_NN
of_PIN
the_DT
Company_NN
as_IN
follows_VPRT
:_:
period_NN
of_PIN
2004_CD
while_OSUB
he_TPP3
was_VBD [BEMA]
a_DT
Director_NN
of_PIN
the_DT
Company_NN
._.
These_DEMO
31_CD
December_NN
31_CD
December_NN
emoluments_NOMZ
include_VPRT
incentive_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
2004_CD
2003_CD
awarded_VBN
Dr_NN
Totten_NN
the_DT
maximum_NN
incentive_NN
,_,
of_PIN
75_CD
%_NN
of_PIN
salary_NN
,_,
for_PIN
Number_NN
of_PIN
Number_NN
of_PIN
that_DEMO
part_NN
of_PIN
2004_CD
he_TPP3
worked_VBD
both_DT
as_IN
a_DT
Director_NN
and_CC
then_RB
as_IN
an_DT
Name_NN
of_PIN
Director_NN
shares_NN
shares_NN
employee_NN
in_PIN
recognition_NOMZ
of_PIN
Dr_NN
Tottens_NN
significant_JJ
contribution_NOMZ
to_TO
i_FPP1
Dr_FW
James_NN
Cavanaugh_NN
412,849_CD
8,806,368_CD
the_DT
Company_NN
._.
106,690_CD
of_PIN
this_DEMO
incentive_NN
is_VPRT [PASS]
included_VBN
in_PIN
the_DT
table_NN
above_PLACE
._.
Dr_NN
Totten_NN
continued_VBD
as_IN
an_DT
employee_NN
of_PIN
the_DT
Company_NN
Mr_NN
Matthew_NN
Emmens_NN
responsible_JJ
for_PIN
special_JJ
corporate_JJ
projects_NN
,_,
including_VBG [PRESP]
the_DT
continued_VBN
Mr_NN
Angus_NN
Russell_NN
development_NOMZ
of_PIN
FOSRENOL_NN
,_,
from_PIN
25_CD
May_POMD
until_IN
31_CD
August_NN
2004_CD
,_,
at_PIN
which_WDT [PIRE]
point_VPRT
the_DT
Company_NN
terminated_VBD
his_TPP3
employment_NOMZ
in_PIN
Dr_NN
Barry_NN
Price_NN
31,350_CD
31,350_CD
accordance_NN
with_PIN
his_TPP3
service_NN
contract_NN
._.
No_SYNE
change_NN
was_VBD [PASS]
made_VBN
to_TO
ii_VB
The_DT
Hon_NN
James_NN
Grant_NN
36,410_CD
4,551_CD
Dr_NN
Tottens_NN
terms_NN
and_PHC
conditions_NOMZ
of_PIN
employment_NOMZ
on_PIN
his_TPP3
ceasing_VBG
to_PIN
Mr_NN
Ronald_NN
Nordmann_NN
46,966_CD
46,966_CD
be_VB [BEMA]
a_DT
Director_NN
or_CC
whilst_OSUB
he_TPP3
remained_VBD
an_DT
employee_NN
._.
Upon_PIN
termination_NOMZ
of_PIN
Dr_NN
Tottens_NN
employment_NOMZ
,_,
the_DT
total_JJ
amount_NN
paid_VBN [WZPAST]
to_PIN
Dr_NN
Totten_NN
,_,
Mr_NN
Robin_NN
Buchanan_NN
in_PIN
accordance_NN
with_PIN
the_DT
payment_NOMZ
in_PIN
lieu_NN
of_PIN
notice_NN
provisions_NN
in_PIN
Mr_NN
David_NN
Kappler_NN
5,000_CD
his_TPP3
contract_NN
of_PIN
employment_NOMZ
,_,
was_VBD [BEMA]
639,265_CD
._.
This_DEMP
comprises_VPRT
one_CD
years_NN
salary_NN
and_CC
contractual_JJ
benefits_NN
and_PHC
target_NN
incentive_NN
of_PIN
50_CD
%_NN
of_PIN
salary_NN
,_,
which_WDT [SERE]
the_DT
Remuneration_NOMZ
Committee_NN
determined_VBD [SUAV] [PRIV]
,_,
in_PIN
All_QUAN
interests_NN
are_VPRT [BEMA]
beneficial_PRED
unless_COND
otherwise_CONJ
stated_VBN [PUBV]
._.
accordance_NN
with_PIN
the_DT
terms_NN
of_PIN
Dr_NN
Tottens_NN
contract_NN
,_,
to_PIN
award_NN
him_TPP3
._.
Notes_NN
Directors_NN
pension_NN
entitlements_NOMZ
i_FPP1
Dr_FW
Cavanaugh_NN
is_VPRT [BEMA]
a_DT
general_JJ
partner_NN
of_PIN
HealthCare_NN
Ventures_NN
LLC_NN
,_,
The_DT
following_VBG
Directors_NN
are_VPRT
members_NN
of_PIN
money_NN
purchase_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
the_DT
management_NOMZ
company_NN
for_PIN
a_DT
number_NN
of_PIN
limited_JJ
schemes_NN
._.
Contributions_NOMZ
paid_VBN [WZPAST]
by_PIN
the_DT
Company_NN
in_PIN
respect_NN
of_PIN
2004_CD
partnerships_NN
._.
On_PIN
11_CD
November_NN
2004_CD
investment_NOMZ
partnerships_NN
were_VBD
as_IN
follows_VPRT
:_:
managed_VBN [PASTP]
by_PIN
HealthCare_NN
Ventures_NN
LLC_NN
distributed_VBN [WZPAST]
to_PIN
their_TPP3
general_JJ
and_PHC
limited_JJ
partners_NN
8,666,090_CD
ordinary_JJ
shares_NN
of_PIN
the_DT
2004_CD
2003_CD
Company_NN
._.
7,125,560_CD
of_PIN
these_DEMO
shares_NN
were_VBD [PASS]
purchased_VBN
from_PIN
time_NN
Name_NN
of_PIN
Director_NN
000_CD
000_CD
to_PIN
time_NN
from_PIN
1993_CD
to_PIN
1996_CD
._.
An_DT
additional_JJ
1,534,530_CD
shares_NN
Mr_NN
Matthew_NN
Emmens_NN
156_CD
138_CD
were_VBD [PASS]
purchased_VBN
in_PIN
1998_CD
._.
Dr_NN
Cavanaugh_NN
and_PHC
members_NN
of_PIN
his_TPP3
family_NN
received_VBD
296,571_CD
of_PIN
the_DT
shares_NN
distributed_VBN
._.
None_INPR
of_PIN
the_DT
Mr_NN
Angus_NN
Russell_NN
86_CD
80_CD
270,277_CD
shares_NN
received_VBN [WZPAST]
by_PIN
Dr_NN
Cavanaugh_NN
in_PIN
the_DT
distribution_NOMZ
Dr_NN
Wilson_NN
Totten_NN
36_CD
85_CD
have_VPRT [PEAS]
been_VBN [PASS]
sold_VBN
._.
stepped_VBD
down_RP
as_IN
a_DT
Director_NN
on_PIN
25_CD
May_POMD
2004_CD
ii_FW
On_PIN
15_CD
June_NN
2004_CD
,_,
The_DT
Hon_NN
James_NN
Grant_NN
exercised_VBD
an_DT
option_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
him_TPP3
under_IN
the_DT
BioChem_NN
Stock_NN
Option_NOMZ
Plan_NN
for_PIN
31,859_CD
Mr_NN
Rolf_NN
Stahel_NN
4,347_CD
shares_NN
at_PIN
the_DT
option_NOMZ
price_NN
of_PIN
1.24_CD
per_PIN
share_NN
._.
stepped_VBD
down_RP
as_IN
a_DT
Director_NN
on_PIN
19_CD
March_NN
2003_CD
Directors_NN
share_VPRT
options_NOMZ
Dr_NN
Francesco_NN
Bellini_NN
26_CD
Aggregate_NN
emoluments_NOMZ
disclosed_VBD [PUBV]
above_PLACE
do_VPRT
not_XX0
include_VB
any_QUAN
stepped_VBD
down_RB
as_IN
a_DT
non-executive_JJ
amounts_NN
for_PIN
the_DT
value_NN
of_PIN
options_NOMZ
to_TO
acquire_VB
ordinary_JJ
shares_NN
in_PIN
the_DT
Director_NN
on_PIN
10_CD
May_POMD
2003_CD
Company_NN
granted_VBN [SUAV]
to_TO
or_CC
held_VBN [PRIV]
by_PIN
the_DT
Directors_NN
._.
278_CD
4,676_CD
Directors_NN
and_PHC
employees_NN
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
options_NOMZ
over_IN
ordinary_JJ
shares_NN
under_IN
the_DT
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
2000_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
Parts_NN
A_NN
and_PHC
B_NN
2000_CD
Executive_NN
Scheme_NN
,_,
the_DT
Shire_NN
Holdings_GER
Limited_NN
Share_NN
Option_NOMZ
Scheme_NN
SHL_NN
Scheme_NN
,_,
the_DT
Pharmavene_NN
1991_CD
Stock_NN
Option_NOMZ
Plan_NN
SLI_NN
Plan_NN
,_,
the_DT
Shire_NN
Pharmaceuticals_NN
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
Parts_NN
A_NN
and_PHC
B_NN
Executive_NN
Scheme_NN
,_,
the_DT
Shire_NN
Pharmaceuticals_NN
Sharesave_NN
Scheme_NN
Sharesave_NN
Scheme_NN
,_,
the_DT
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Employee_NN
Stock_NN
Purchase_NN
Plan_NN
Stock_NN
Purchase_NN
Plan_NN
,_,
the_DT
Roberts_NN
Stock_NN
Option_NOMZ
Plan_NN
Roberts_NN
Plan_NN
and_CC
the_DT
BioChem_NN
Stock_NN
Option_NOMZ
Plan_NN
BioChem_NN
Plan_NN
._.
For_PIN
those_DEMO
options_NOMZ
which_WDT [WHSUB]
remained_VBD
unexercised_JJ
during_PIN
the_DT
year_NN
,_,
no_SYNE
payment_NOMZ
was_VBD [BYPA]
made_VBN
by_PIN
any_QUAN
Director_NN
in_PIN
consideration_NOMZ
of_PIN
the_DT
grant_NN
award_NN
._.
There_EX
have_VPRT [PEAS]
been_VBN
no_SYNE
variations_NOMZ
to_PIN
the_DT
terms_NN
and_PHC
conditions_NOMZ
or_CC
performance_NN
criteria_NN
for_PIN
share_NN
options_NOMZ
during_PIN
2004_CD
,_,
except_PIN
as_IN
stated_VBN [PUBV]
in_PIN
note_NN
iii_NN
below_PLACE
as_IN
regards_VPRT
retesting_GER
._.
Notes_NN
i_FPP1
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Executive_NN
Scheme_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
performance_NN
criteria_NN
and_CC
can_POMD
not_XX0
be_VB [PASS]
exercised_VBN
in_PIN
full_JJ
,_,
unless_COND
the_DT
Companys_NN
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
at_PIN
least_JJ
20.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
measurement_NOMZ
period_NN
._.
ii_FW
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Sharesave_NN
Scheme_NN
are_VPRT [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
80_CD
%_NN
of_PIN
the_DT
mid-market_JJ
price_NN
on_PIN
the_DT
day_NN
before_IN
invitations_NOMZ
are_VPRT [PASS]
issued_VBN
to_PIN
employees_NN
._.
iii_FW
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
vest_NN
six_CD
weeks_NN
prior_RB
to_PIN
the_DT
expiry_NN
date_NN
._.
Therefore_CONJ
,_,
the_DT
performance_NN
criteria_NN
were_VBD [PASS]
amended_VBN
so_OSUB
that_NULL
an_DT
option_NOMZ
would_PRMD
become_VB
exercisable_JJ
in_PIN
full_JJ
only_DWNT
if_COND
Shires_NN
EPS_NN
growth_NN
over_IN
a_DT
three-year_JJ
period_NN
from_PIN
the_DT
date_NN
of_PIN
award_NN
exceeds_VPRT
the_DT
UK_NN
Retail_NN
Price_NN
Index_NN
RPI_NN
on_PIN
average_NN
a_DT
year_NN
for_PIN
the_DT
following_VBG
tranches_NN
of_PIN
grants_NN
:_:
Options_NOMZ
with_PIN
a_DT
grant_NN
value_NN
of_PIN
up_RB
to_PIN
100_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
3_CD
%_NN
Directors_NN
,_,
RPI_NN
plus_PIN
5_CD
%_NN
Between_PIN
101_CD
%_NN
and_CC
200_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
5_CD
%_NN
Between_PIN
201_CD
%_NN
and_CC
300_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
7_CD
%_NN
Over_IN
301_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
9_CD
%_NN
The_DT
new_JJ
EPS_NN
performance_NN
criteria_NN
apply_VPRT
to_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
from_PIN
August_NN
2002_CD
._.
iv_NN
Following_VBG [WZPRES]
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
on_PIN
11_CD
May_POMD
2001_CD
,_,
the_DT
BioChem_NN
Plan_NN
was_VBD [PASS]
amended_VBN
such_OSUB
that_NULL
options_NOMZ
over_IN
BioChems_NN
common_JJ
stock_NN
became_VBD
options_NOMZ
over_IN
ordinary_JJ
shares_NN
of_PIN
the_DT
Company_NN
._.
v_FW
Under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
,_,
options_NOMZ
are_VPRT [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
85_CD
%_NN
of_PIN
the_DT
fair_JJ
market_NN
value_NN
of_PIN
a_DT
share_NN
on_PIN
the_DT
enrolment_NOMZ
date_NN
the_DT
first_JJ
day_NN
of_PIN
the_DT
offering_GER
period_NN
or_CC
the_DT
exercise_NN
date_NN
the_DT
last_JJ
day_NN
of_PIN
the_DT
offering_GER
period_NN
,_,
whichever_WDT
is_VPRT [BEMA]
the_DT
lower_JJ
._.
44_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
45_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Directors_NN
remuneration_JJ
report_NN
vi_FW
In_PIN
connection_NOMZ
with_PIN
the_DT
termination_NOMZ
of_PIN
Dr_NN
Tottens_NN
employment_NOMZ
,_,
the_DT
Remuneration_NOMZ
Committee_NN
agreed_VBD [SUAV] [PUBV]
to_TO
exercise_VB
its_PIT
discretion_NOMZ
under_IN
the_DT
Rules_NN
of_PIN
the_DT
respective_JJ
option_NOMZ
schemes_NN
to_TO
allow_VB [SUAV]
Dr_NN
Totten_NN
to_TO
retain_VB
these_DEMO
options_NOMZ
for_PIN
up_RB
to_PIN
24_CD
months_NN
following_VBG [WZPRES]
his_TPP3
termination_NOMZ
._.
The_DT
market_NN
price_NN
of_PIN
the_DT
ordinary_JJ
shares_NN
at_PIN
31_CD
December_NN
2004_CD
was_VBD [BEMA]
5.47_CD
and_CC
the_DT
range_NN
during_PIN
the_DT
year_NN
was_VBD [BEMA]
4.36_CD
to_PIN
5.71_CD
._.
Long_NN
Term_NN
Incentive_NN
Plan_NN
LTIP_NN
Long_NN
Term_NN
Incentive_NN
Plan_NN
maturities_NOMZ
during_PIN
the_DT
year_NN
2004_CD
are_VPRT
as_IN
follows_VPRT
:_:
Market_NN
price_NN
Actual_NN
Market_NN
price_NN
Value_NN
at_PIN
Initial_JJ
award_NN
at_PIN
grant_NN
date_NN
performanceat_NN
maturity_NOMZ
maturity_NOMZ
Date_NN
of_PIN
Director_NN
Date_NN
of_PIN
award_NN
made_VBN
related_JJ
award_NN
maturity_NOMZ
i_FPP1
Mr_NN
Angus_NN
Russell_NN
01.03.00_CD
1,789_CD
10.06_CD
1,296_CD
5.515_CD
7,147_CD
01.03.04_CD
i_FPP1
ii_FW
Dr_FW
Wilson_NN
Totten_NN
01.03.00_CD
19,881_CD
10.06_CD
14,398_CD
5.515_CD
79,405_CD
01.03.04_CD
Total_JJ
86,552_CD
Notes_NN
i_FPP1
For_PIN
awards_NN
made_VBN
under_IN
the_DT
LTIP_NN
prior_RB
to_PIN
June_NN
2001_CD
,_,
performance_NN
is_VPRT [PASS]
measured_VBN
over_IN
a_DT
three-year_JJ
period_NN
but_CC
the_DT
performance_NN
conditions_NOMZ
are_VPRT [PASS]
based_VBN
on_PIN
criteria_NN
of_PIN
i_FPP1
50_CD
%_NN
TSR_NN
benchmarked_VBD
against_PIN
FTSE_NN
mid-250_CD
index_NN
and_CC
ii_FW
50_CD
%_NN
subject_NN
to_PIN
an_DT
EPS_NN
condition_NOMZ
measured_VBN [WZPAST]
against_PIN
the_DT
diluted_VBN
EPS_NN
of_PIN
the_DT
Company_NN
for_PIN
the_DT
financial_JJ
year_NN
ended_VBD
before_IN
the_DT
commencement_NOMZ
of_PIN
the_DT
performance_NN
period_NN
and_CC
the_DT
diluted_VBN
EPS_NN
of_PIN
the_DT
Company_NN
for_PIN
the_DT
financial_JJ
year_NN
ended_VBN [WZPAST]
on_PIN
or_CC
before_IN
the_DT
end_NN
of_PIN
the_DT
performance_NN
period_NN
._.
For_PIN
awards_NN
made_VBN [WZPAST]
on_PIN
1_CD
March_NN
2000_CD
,_,
the_DT
Committee_NN
determined_VBD [SUAV] [PRIV]
that_THVC
44.84_CD
%_NN
of_PIN
the_DT
part_NN
of_PIN
the_DT
award_NN
subject_NN
to_PIN
TSR_NN
performance_NN
measures_NN
and_CC
100_CD
%_NN
of_PIN
the_DT
part_NN
of_PIN
the_DT
award_NN
subject_NN
to_PIN
EPS_NN
performance_NN
measures_NN
could_POMD
be_VB [PASS]
transferred_VBN
,_,
resulting_VBG [PRESP]
in_PIN
72.42_CD
%_NN
of_PIN
the_DT
total_JJ
award_NN
being_VBG [WZPRES] [PASS]
transferred_VBN
to_PIN
participants_NN
._.
These_DEMO
calculations_NOMZ
were_VBD [BYPA]
verified_VBN
by_PIN
external_JJ
advisers_NN
._.
ii_FW
On_PIN
Dr_NN
Tottens_NN
termination_NOMZ
of_PIN
employment_NOMZ
,_,
the_DT
Remuneration_NOMZ
Committee_NN
determined_VBD [SUAV] [PRIV]
in_PIN
accordance_NN
with_PIN
the_DT
LTIP_NN
Rules_NN
,_,
that_THVC
the_DT
2001_CD
,_,
2002_CD
,_,
2003_CD
and_CC
2004_CD
awards_NN
would_PRMD
lapse_NN
and_CC
no_SYNE
payment_NOMZ
would_PRMD
be_VB [PASS]
made_VBN
to_PIN
Dr_NN
Totten_NN
in_PIN
respect_NN
of_PIN
them_TPP3
._.
Performance_NN
conditions_NOMZ
attaching_VBG [WZPRES]
to_PIN
awards_NN
made_VBN
under_IN
the_DT
Long_NN
Term_NN
Incentive_NN
Plan_NN
are_VPRT [PASS]
detailed_VBN
on_PIN
pages_NN
38_CD
to_PIN
39_CD
._.
Approval_NN
This_DEMO
report_NN
was_VBD [BYPA]
approved_VBN
by_PIN
the_DT
Board_NN
of_PIN
Directors_NN
on_PIN
1_CD
March_NN
2005_CD
and_CC
signed_VBN
on_PIN
its_PIT
behalf_NN
by_PIN
:_:
Dr_NN
Barry_NN
Price_NN
Chairman_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
45_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
46_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Audit_NN
Committee_NN
report_NN
Audit_NN
Committee_NN
report_NN
ensure_VB [SUAV] [PRIV]
clarity_NOMZ
of_PIN
disclosure_NN
in_PIN
financial_JJ
reporting_GER
and_CC
the_DT
presentation_NOMZ
of_PIN
a_DT
balanced_JJ
and_PHC
understandable_JJ
assessment_NOMZ
Audit_NN
Committee_NN
membership_NN
of_PIN
the_DT
Companys_NN
financial_JJ
position_NOMZ
:_:
The_DT
members_NN
of_PIN
the_DT
Audit_NN
Committee_NN
as_IN
at_PIN
31_CD
December_NN
2004_CD
were_VBD
David_NN
Kappler_NN
Chairman_NN
,_,
Ronald_NN
Nordmann_NN
and_PHC
Barry_NN
have_VPRT
the_DT
primary_JJ
responsibility_NOMZ
for_PIN
making_VBG
a_DT
recommendation_NOMZ
Price_NN
._.
They_TPP3
are_VPRT [BEMA]
all_QUAN
independent_JJ
non-executive_JJ
Directors_NN
for_PIN
the_DT
to_TO
be_VB [PASS]
put_VBN
to_PIN
shareholders_NN
for_PIN
approval_NN
at_PIN
the_DT
Annual_JJ
General_NN
purposes_NN
of_PIN
The_DT
UK_NN
Combined_NN
Code_NN
on_PIN
Corporate_NN
Governance_NN
Meeting_VBG [WZPRES]
in_PIN
relation_NOMZ
to_PIN
the_DT
appointment_NOMZ
,_,
re-appointment_NOMZ
,_,
the_DT
Combined_NN
Code_NN
._.
Dr_NN
James_NN
Cavanaugh_NN
the_DT
Chairman_NN
of_PIN
removal_NN
and_PHC
remuneration_NOMZ
of_PIN
the_DT
external_JJ
auditor_NN
and_CC
to_PIN
the_DT
Company_NN
was_VBD [BEMA]
a_DT
member_NN
of_PIN
the_DT
Audit_NN
Committee_NN
until_IN
he_TPP3
assess_VB
at_PIN
least_JJ
annually_RB
,_,
the_DT
objectivity_NOMZ
and_PHC
independence_NN
stood_VBD
down_RP
on_PIN
30_CD
November_NN
2004_CD
._.
Dr_NN
Cavanaugh_NN
stepped_VBD
down_RB
of_PIN
the_DT
external_JJ
auditor_NN
:_:
as_IN
in_PIN
his_TPP3
capacity_NOMZ
as_IN
Chairman_NN
of_PIN
the_DT
Company_NN
,_,
he_TPP3
is_VPRT [SPAU] [PASS]
no_RB
longer_RB
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
independent_PRED
under_IN
the_DT
new_JJ
Combined_NN
Code_NN
._.
review_NN
and_CC
discuss_VB
issues_NN
and_PHC
recommendations_NOMZ
arising_VBG [WZPRES]
from_PIN
the_DT
external_JJ
audit_NN
,_,
and_ANDC
any_QUAN
matters_NN
the_DT
external_JJ
auditor_NN
may_POMD
wish_VB
Mr_NN
Ronald_NN
Nordmann_NN
chaired_VBD
the_DT
Audit_NN
Committee_NN
until_IN
July_NN
2004_CD
,_,
to_TO
discuss_VB
:_:
after_IN
completion_NOMZ
of_PIN
the_DT
preparation_NOMZ
of_PIN
the_DT
Companys_NN
second_JJ
quarter_NN
results_NN
._.
Mr_NN
David_NN
Kappler_NN
,_,
who_WP
joined_VBD
Shires_NN
Board_NN
and_CC
set_VBN
and_PHC
apply_VB
a_DT
formal_JJ
policy_NN
in_PIN
relation_NOMZ
to_PIN
the_DT
provision_NN
of_PIN
nonbecame_NN
a_DT
member_NN
of_PIN
Shires_NN
Audit_NN
Committee_NN
on_PIN
5_CD
April_NN
2004_CD
,_,
audit_NN
services_NN
by_PIN
the_DT
external_JJ
auditor_NN
with_PIN
a_DT
view_NN
to_TO
preserving_VBG
took_VBD
over_RP
the_DT
chairmanship_NN
of_PIN
the_DT
Audit_NN
Committee_NN
from_PIN
the_DT
external_JJ
auditors_NN
independence_NN
and_PHC
objectivity_NOMZ
:_:
Mr_NN
Nordmann_NN
._.
The_DT
Board_NN
is_VPRT [PASS]
satisfied_VBN
that_DEMO
both_DT
Mr_NN
Nordmann_NN
and_PHC
Mr_NN
Kappler_NN
,_,
in_PIN
their_TPP3
capacity_NOMZ
as_IN
Chairmen_NN
of_PIN
the_DT
Committee_NN
,_,
establish_VB [PRIV]
procedures_NN
for_PIN
the_DT
receipt_NN
,_,
retention_NOMZ
and_PHC
treatment_NOMZ
have_VPRT
recent_JJ
and_PHC
relevant_JJ
financial_JJ
experience_NN
._.
The_DT
Board_NN
has_VPRT
of_PIN
complaints_NN
received_VBN [WZPAST]
by_PIN
the_DT
Company_NN
regarding_VBG [WZPRES]
accounting_GER
,_,
determined_VBD [SUAV] [PRIV]
that_THVC
Mr_NN
Kappler_NN
is_VPRT [BEMA]
the_DT
Audit_NN
Committee_NN
financial_JJ
expert_NN
internal_JJ
accounting_GER
controls_NN
or_CC
auditing_GER
matters_NN
:_:
for_PIN
the_DT
purposes_NN
of_PIN
the_DT
Sarbanes-Oxley_NN
Act_NN
2002_CD
._.
Mr_NN
Kappler_NN
retired_VBD
as_IN
Chief_NN
Financial_NN
Officer_NN
of_PIN
Cadbury_NN
Schweppes_NN
plc_NN
,_,
the_DT
review_NN
at_PIN
least_JJ
annually_RB
the_DT
effectiveness_NOMZ
of_PIN
the_DT
Companys_NN
FTSE_NN
and_PHC
NYSE_NN
listed_VBD
global_JJ
confectionery_NN
and_PHC
beverages_NN
group_NN
internal_JJ
control_NN
system_NN
in_PIN
the_DT
overall_JJ
context_NN
of_PIN
the_DT
Companys_NN
in_PIN
April_NN
2004_CD
having_VBG [PEAS]
held_VBN [PRIV]
that_THVC
position_NOMZ
since_OSUB
1995_CD
._.
He_TPP3
worked_VBD
risk_NN
management_NOMZ
system_NN
:_:
for_PIN
the_DT
Cadbury_NN
Schweppes_NN
group_NN
between_PIN
1965_CD
and_CC
1984_CD
and_CC
rejoined_VBD
it_PIT
in_PIN
1989_CD
,_,
following_VBG [PRESP]
the_DT
acquisition_NOMZ
of_PIN
the_DT
Trebor_NN
Group_NN
oversee_VPRT
the_DT
Companys_NN
anti-fraud_JJ
programs_NN
and_PHC
controls_NN
of_PIN
which_WDT [PIRE]
he_TPP3
was_VBD
Finance_NN
Director_NN
._.
From_PIN
1989_CD
to_PIN
1995_CD
he_TPP3
held_VBD [PRIV]
and_CC
to_TO
oversee_VB
the_DT
investigation_NOMZ
and_PHC
remediation_NOMZ
of_PIN
any_QUAN
alleged_VBN [PUBV]
a_DT
number_NN
of_PIN
senior_JJ
positions_NOMZ
in_PIN
Cadbury_NN
Schweppes_NN
,_,
including_VBG
or_CC
suspected_VBN [PRIV]
fraud_NN
:_:
and_ANDC
Director_NN
of_PIN
Corporate_NN
Finance_NN
._.
Mr_NN
Kappler_NN
has_VPRT [PEAS]
served_VBN
on_PIN
a_DT
number_NN
of_PIN
other_JJ
boards_NN
around_PLACE
the_DT
world_NN
in_PIN
which_WDT [PIRE]
Cadbury_NN
Schweppes_NN
monitor_NN
and_CC
review_VB
the_DT
internal_JJ
operational_JJ
audit_NN
program_NN
,_,
held_VBD [PRIV]
interests_NN
._.
He_TPP3
was_VBD [BEMA]
a_DT
director_NN
of_PIN
Camelot_NN
Group_NN
plc_NN
from_PIN
1996_CD
consider_VPRT [PRIV]
the_DT
findings_GER
of_PIN
internal_JJ
operational_JJ
audit_NN
reviews_NN
and_CC
to_PIN
2002_CD
and_CC
he_TPP3
currently_RB
serves_VPRT
as_IN
a_DT
non-executive_JJ
Director_NN
managements_NOMZ
response_NN
to_PIN
them_TPP3
._.
and_ANDC
Chairman_NN
of_PIN
the_DT
Audit_NN
Committee_NN
at_PIN
HMV_NN
Group_NN
plc_NN
and_PHC
Intercontinental_NN
Hotels_NN
Group_NN
plc._NN
._.
Additionally_RB
,_,
he_TPP3
is_VPRT [BEMA]
non-executive_PRED
The_DT
Audit_NN
Committee_NN
reports_VPRT [PUBV]
to_PIN
the_DT
Board_NN
on_PIN
any_QUAN
matter_NN
on_PIN
which_WDT [PIRE]
Chairman_NN
at_PIN
Premier_NN
Foods_NN
plc._NN
._.
Mr_NN
Kappler_NN
is_VPRT [BEMA]
a_DT
fellow_NN
of_PIN
the_DT
it_PIT
considers_VPRT [PRIV]
that_THVC
action_NOMZ
is_VPRT [PASS]
required_VBN [SUAV]
and_PHC
makes_VPRT
recommendations_NOMZ
Chartered_NN
Institute_NN
of_PIN
Management_NOMZ
Accountants_NN
._.
The_DT
Terms_NN
of_PIN
Reference_NN
of_PIN
the_DT
Committee_NN
give_VB
it_PIT
authority_NOMZ
to_TO
investigate_VB
any_QUAN
activity_NOMZ
within_PIN
its_PIT
Terms_NN
of_PIN
The_DT
members_NN
of_PIN
the_DT
Committee_NN
are_VPRT [PASS]
chosen_VBN
from_PIN
amongst_PIN
the_DT
Reference_NN
and_CC
to_TO
be_VB [BEMA]
responsible_PRED
for_PIN
the_DT
resolution_NOMZ
of_PIN
non-executive_JJ
Directors_NN
of_PIN
the_DT
Company_NN
who_WP [WHSUB]
are_VPRT [BEMA]
independent_JJ
disagreements_NOMZ
between_PIN
management_NOMZ
and_CC
the_DT
auditor_NN
regarding_VBG [WZPRES]
for_PIN
the_DT
purposes_NN
of_PIN
the_DT
Combined_NN
Code_NN
and_CC
the_DT
NASDAQ_NN
the_DT
Companys_NN
financial_JJ
reporting_GER
._.
The_DT
Committee_NN
is_VPRT
also_RB
rules_NN
and_CC
are_VPRT [PASS]
selected_VBN
on_PIN
the_DT
basis_NN
of_PIN
their_TPP3
knowledge_NN
and_CC
authorised_VBN
to_TO
seek_VB
any_QUAN
information_NOMZ
it_PIT
requires_VPRT [SUAV]
from_PIN
any_QUAN
employee_NN
experience_NN
of_PIN
financial_JJ
matters_NN
and_CC
financial_JJ
reporting_GER
._.
Committee_NN
of_PIN
the_DT
Company_NN
in_PIN
order_NN
to_TO
perform_VB
its_PIT
duties_NN
and_CC
to_TO
call_VB
any_QUAN
members_NN
hold_VPRT [PRIV]
office_NN
for_PIN
an_DT
initial_JJ
period_NN
of_PIN
two_CD
years_NN
,_,
subject_JJ
employee_NN
to_TO
be_VB [PASS]
questioned_VBN
at_PIN
a_DT
meeting_GER
of_PIN
the_DT
Committee_NN
._.
to_TO
continuing_VBG
as_IN
a_DT
Director_NN
of_PIN
the_DT
Company_NN
,_,
for_PIN
such_JJ
duration_NOMZ
as_IN
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
Board_NN
._.
Details_NN
of_PIN
the_DT
fees_NN
paid_VBN [WZPAST]
to_PIN
members_NN
The_DT
Audit_NN
Committee_NN
met_VBD
on_PIN
4_CD
occasions_NN
in_PIN
2004_CD
._.
Each_QUAN
meeting_GER
of_PIN
the_DT
Committee_NN
are_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
Directors_NN
remuneration_NOMZ
report_NN
was_VBD [BYPA]
attended_VBN
by_PIN
all_QUAN
members_NN
of_PIN
the_DT
Committee_NN
._.
At_PIN
the_DT
invitation_NOMZ
on_PIN
page_NN
41_CD
._.
of_PIN
the_DT
Chairman_NN
,_,
the_DT
Chief_NN
Executive_NN
Officer_NN
,_,
the_DT
Chief_NN
Financial_NN
Officer_NN
,_,
the_DT
Group_NN
Financial_NN
Controller_NN
and_CC
the_DT
Chief_NN
Risk_NN
Officer_NN
Role_NN
of_PIN
Audit_NN
Committee_NN
attended_VBD
all_QUAN
of_PIN
the_DT
Committees_NN
meetings_GER
in_PIN
2004_CD
,_,
save_VB
that_DEMO
the_DT
In_PIN
the_DT
latter_JJ
part_NN
of_PIN
2004_CD
,_,
the_DT
Terms_NN
of_PIN
Reference_NN
of_PIN
the_DT
Audit_NN
Group_NN
Financial_NN
Controller_NN
was_VBD [BEMA]
unable_PRED
to_TO
attend_VB
one_CD
meeting_GER
Committee_NN
were_VBD [PASS]
reviewed_VBN
and_PHC
updated_VBN
._.
The_DT
amended_VBN
Terms_NN
due_JJ
to_PIN
a_DT
previous_JJ
commitment_NOMZ
._.
of_PIN
Reference_NN
were_VBD [BYPA]
approved_VBN
by_PIN
the_DT
Board_NN
on_PIN
22_CD
February_NN
2005_CD
._.
The_DT
revised_VBN
Terms_NN
of_PIN
Reference_NN
of_PIN
the_DT
Audit_NN
Committee_NN
are_VPRT [BEMA]
In_PIN
accordance_NN
with_PIN
its_PIT
Terms_NN
of_PIN
Reference_NN
,_,
the_DT
Committee_NN
met_VBD
available_JJ
for_PIN
review_NN
on_PIN
Shires_NN
website_NN
._.
The_DT
key_JJ
functions_NOMZ
of_PIN
the_DT
with_PIN
the_DT
external_JJ
and_PHC
internal_JJ
auditors_NN
during_PIN
the_DT
course_NN
of_PIN
the_DT
Audit_NN
Committee_NN
under_IN
the_DT
revised_VBN
Terms_NN
of_PIN
Reference_NN
are_VPRT
to_TO
:_:
year_NN
without_PIN
any_QUAN
executive_NN
member_NN
of_PIN
the_DT
Board_NN
in_PIN
attendance_NN
._.
monitor_VB
the_DT
integrity_NOMZ
of_PIN
the_DT
financial_JJ
statements_NOMZ
of_PIN
the_DT
Company_NN
,_,
Auditor_NN
services_NN
including_VBG [WZPRES]
its_PIT
annual_JJ
and_PHC
quarterly_JJ
reports_NN
,_,
preliminary_JJ
results_NN
The_DT
Audit_NN
Committee_NN
has_VPRT [PEAS]
adopted_VBN
a_DT
formal_JJ
policy_NN
in_PIN
relation_NOMZ
to_PIN
announcements_NOMZ
and_CC
any_QUAN
other_JJ
Board_NN
announcement_NOMZ
relating_VBG [WZPRES]
the_DT
provision_NN
of_PIN
non-audit_JJ
services_NN
by_PIN
the_DT
external_JJ
auditor_NN
,_,
which_WDT [SERE]
to_PIN
its_PIT
financial_JJ
performance_NN
or_CC
other_JJ
financial_JJ
information_NOMZ
to_TO
be_VB [PASS]
was_VBD [SPAU] [PASS]
most_EMPH
recently_TIME
revised_VBN
in_PIN
March_NN
2004_CD
._.
The_DT
Sarbanes-Oxley_NN
made_VBD
public_NN
:_:
Act_NN
2002_CD
and_CC
accordingly_RB
the_DT
Committees_NN
policy_NN
prohibits_VPRT
the_DT
provision_NN
of_PIN
certain_JJ
non-audit_JJ
services_NN
to_PIN
the_DT
Company_NN
by_PIN
the_DT
external_JJ
auditor_NN
,_,
including_VBG
:_:
46_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
47_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Audit_NN
Committee_NN
report_NN
bookkeeping_GER
or_CC
other_JJ
services_NN
related_VBN [WZPAST]
to_PIN
the_DT
accounting_GER
records_NN
audit_VPRT
adjustments_NOMZ
proposed_VBN [SUAV]
and_ANDC
whether_IN
they_TPP3
were_VBD [PASS]
corrected_VBN
or_CC
financial_JJ
statements_NOMZ
of_PIN
the_DT
Company_NN
:_:
by_PIN
management_NOMZ
:_:
and_ANDC
design_NN
and_PHC
implementation_NOMZ
of_PIN
financial_JJ
information_NOMZ
systems_NN
:_:
significant_JJ
accounting_GER
policies_NN
and_CC
unusual_JJ
transactions_NOMZ
._.
appraisal_NN
or_CC
valuation_NOMZ
services_NN
,_,
fairness_NOMZ
opinions_NN
or_CC
contribution_NOMZ
-_:
2_CD
Internal_NN
financial_JJ
control_NN
and_PHC
risk_NN
management_NOMZ
systems_NN
in-kind_JJ
reports_NN
:_:
and_ANDC
The_DT
Audit_NN
Committee_NN
reviewed_VBD
the_DT
risk_NN
management_NOMZ
strategy_NN
,_,
the_DT
corporate_JJ
risk_NN
schedules_NN
,_,
the_DT
internal_JJ
audit_NN
strategy_NN
and_PHC
plan_NN
and_CC
actuarial_JJ
or_CC
internal_JJ
audit_NN
outsourcing_VBG [WZPRES]
services_NN
._.
progress_NN
in_PIN
complying_VBG
with_PIN
Section_NOMZ
404_CD
of_PIN
the_DT
Sarbanes-Oxley_NN
Act_NN
2002_CD
and_CC
the_DT
effectiveness_NOMZ
of_PIN
the_DT
system_NN
of_PIN
internal_JJ
control_NN
The_DT
Committees_NN
policy_NN
requires_VPRT [SUAV]
all_QUAN
audit_NN
and_CC
permissible_JJ
non-audit_JJ
during_PIN
the_DT
year_NN
._.
The_DT
risk_NN
management_NOMZ
and_CC
internal_JJ
financial_JJ
control_NN
services_NN
proposed_VBN [SUAV]
to_TO
be_VB [BYPA]
provided_VBN
by_PIN
the_DT
Companys_NN
auditor_NN
to_PIN
systems_NN
were_VBD [BEMA]
the_DT
subject_NN
of_PIN
significant_JJ
focus_NN
at_PIN
all_QUAN
the_DT
meetings_GER
be_VB [BYPA]
approved_VBN
by_PIN
the_DT
Audit_NN
Committee_NN
._.
Certain_JJ
audit_NN
and_CC
non-audit_JJ
held_VBN [PRIV]
throughout_PIN
the_DT
year_NN
,_,
with_PIN
in_PIN
depth_NN
discussions_NN
held_VBD [PRIV]
between_PIN
services_NN
have_VPRT [PEAS]
been_VBN [BYPA]
pre-approved_VBN
by_PIN
the_DT
Audit_NN
Committee_NN
and_CC
may_POMD
the_DT
Audit_NN
Committee_NN
,_,
Shire_NN
management_NOMZ
,_,
internal_JJ
audit_NN
and_CC
the_DT
therefore_CONJ
be_VB [BYPA]
provided_VBN
by_PIN
the_DT
auditor_NN
provided_VBD
that_DEMO
management_NOMZ
external_JJ
auditors_NN
._.
does_VPRT
not_XX0
need_VB
to_TO
exercise_VB
any_QUAN
discretion_NOMZ
in_PIN
determining_VBG [SUAV] [PRIV]
whether_IN [WHCL]
a_DT
proposed_JJ
service_NN
falls_VPRT
within_PIN
one_CD
of_PIN
the_DT
pre-approved_JJ
categories_NN
._.
In_CONJ
addition_NULL
and_CC
as_IN
part_NN
of_PIN
the_DT
work_NN
in_PIN
this_DEMO
area_NN
,_,
a_DT
revised_VBN
treasury_NN
In_PIN
all_QUAN
cases_NN
,_,
the_DT
Audit_NN
Committee_NN
is_VPRT [PASS]
notified_VBN
of_PIN
any_QUAN
pre-approved_JJ
policy_NN
was_VBD [PASS]
approved_VBN
in_PIN
July_NN
and_PHC
reports_NN
on_PIN
the_DT
treasury_NN
service_NN
provided_VBN
._.
Certain_JJ
services_NN
have_VPRT [PEAS]
been_VBN [BYPA]
pre-approved_VBN
by_PIN
investments_NOMZ
were_VBD [PASS]
discussed_VBN
each_QUAN
quarter_NN
._.
At_PIN
the_DT
same_JJ
July_NN
the_DT
Audit_NN
Committee_NN
as_IN
part_NN
of_PIN
its_PIT
pre-approval_JJ
policy_NN
,_,
including_VBG
:_:
meeting_VBG [PRESP]
the_DT
Audit_NN
Committee_NN
also_RB
approved_VBD
the_DT
insurance_NN
renewal_NN
program_NN
for_PIN
2004_CD
5_CD
._.
audit_NN
services_NN
and_PHC
audit_NN
related_VBN
services_NN
,_,
such_JJ
as_IN
audit_NN
work_NN
performed_VBN [WZPAST]
in_PIN
the_DT
preparation_NOMZ
of_PIN
financial_JJ
statements_NOMZ
,_,
work_NN
The_DT
Audit_NN
Committee_NN
also_RB
received_VBD
reports_NN
from_PIN
management_NOMZ
,_,
that_DEMO
generally_RB
only_DWNT
the_DT
auditors_NN
can_POMD [SPAU]
reasonably_RB
be_VB [PASS]
expected_VBN [PRIV]
the_DT
internal_JJ
audit_NN
function_NOMZ
,_,
and_ANDC
the_DT
external_JJ
auditor_NN
on_PIN
the_DT
to_TO
provide_VB
,_,
including_VBG
comfort_NN
letters_NN
,_,
statutory_JJ
audits_NN
and_PHC
effectiveness_NOMZ
of_PIN
the_DT
Companys_NN
system_NN
of_PIN
internal_JJ
controls_NN
._.
consultation_NOMZ
regarding_VBG [WZPRES]
financial_JJ
accounting_GER
and_CC
or_CC
reporting_VBG [PUBV]
standards_NN
,_,
due_JJ
diligence_NN
related_VBN [WZPAST]
to_PIN
mergers_NN
and_PHC
acquisitions_NOMZ
,_,
3_CD
External_NN
auditor_NN
employee_NN
benefit_NN
plan_NN
audits_NN
and_CC
special_JJ
procedures_NN
required_VBN [SUAV]
The_DT
Audit_NN
Committee_NN
reviewed_VBD
the_DT
performance_NN
of_PIN
the_DT
external_JJ
to_TO
meet_VB
certain_JJ
regulatory_JJ
requirements_NOMZ
:_:
auditor_NN
following_VBG [WZPRES]
the_DT
completion_NOMZ
of_PIN
the_DT
2003_CD
audit_NN
process_NN
,_,
which_WDT [SERE]
resulted_VBD
in_PIN
the_DT
Audit_NN
Committee_NN
resolving_VBG [SUAV] [WZPRES]
to_TO
recommend_VB [SUAV]
tax_NN
services_NN
,_,
such_JJ
as_IN
tax_NN
compliance_NN
services_NN
,_,
tax_NN
advice_NN
on_PIN
that_DEMO
the_DT
Company_NN
submit_VB [PUBV]
a_DT
resolution_NOMZ
to_PIN
the_DT
2004_CD
Annual_JJ
General_NN
the_DT
tax_NN
consequences_NN
of_PIN
proposed_VBN [SUAV]
transactions_NOMZ
and_PHC
tax_NN
advice_NN
Meeting_VBG [WZPRES]
to_TO
re-appoint_VB
Deloitte_NN
&_CC
Touche_NN
LLP_NN
as_IN
the_DT
Companys_NN
on_PIN
employee_NN
remuneration_NOMZ
strategies_NN
,_,
and_ANDC
external_JJ
auditor_NN
._.
At_PIN
forthcoming_JJ
meetings_GER
in_PIN
2005_CD
,_,
the_DT
Audit_NN
Committee_NN
will_PRMD
conduct_VB
a_DT
formal_JJ
review_NN
of_PIN
the_DT
performance_NN
of_PIN
the_DT
advice_NN
on_PIN
internal_JJ
reorganisations_NOMZ
,_,
group_NN
financing_GER
external_JJ
auditor_NN
and_CC
the_DT
effectiveness_NOMZ
of_PIN
the_DT
audit_NN
process_NN
in_PIN
arrangements_NOMZ
,_,
share_NN
schemes_NN
and_PHC
VAT_NN
compliance_NN
._.
connection_NOMZ
with_PIN
the_DT
2004_CD
financial_JJ
year_NN
audit_NN
._.
Any_QUAN
services_NN
proposed_VBN [SUAV]
to_TO
be_VB [BYPA]
provided_VBN
by_PIN
the_DT
auditor_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
not_XX0
In_PIN
March_NN
2004_CD
the_DT
Audit_NN
Committee_NN
revised_VBD
its_PIT
pre-approval_JJ
a_DT
pre-approved_JJ
service_NN
must_NEMD
be_VB [PASS]
approved_VBN
in_PIN
advance_NN
by_PIN
the_DT
Audit_NN
process_NN
of_PIN
all_QUAN
audit_NN
services_NN
and_CC
permitted_VBD
non-audit_JJ
services_NN
Committee_NN
,_,
which_WDT [SERE]
will_PRMD
consider_VB [PRIV]
whether_IN [WHCL]
the_DT
skills_NN
and_PHC
experience_NN
undertaken_VBN [WZPAST]
by_PIN
the_DT
external_JJ
auditor_NN
._.
The_DT
Audit_NN
Committee_NN
of_PIN
the_DT
auditor_NN
make_VB
it_PIT
a_DT
suitable_JJ
supplier_NN
of_PIN
the_DT
proposed_VBN [SUAV] [THATD]
audit_NN
approved_VBD
all_QUAN
non-audit_JJ
services_NN
during_PIN
2004_CD
and_CC
there_EX
is_VPRT
now_TIME
or_CC
non-audit_JJ
service_NN
._.
a_DT
standing_GER
agenda_NN
item_NN
at_PIN
Audit_NN
Committee_NN
meetings_GER
covering_VBG [WZPRES]
the_DT
operation_NOMZ
of_PIN
the_DT
procedures_NN
._.
Audit_NN
Committee_NN
activities_NOMZ
During_PIN
2004_CD
,_,
the_DT
business_NOMZ
discussed_VBN [WZPAST]
by_PIN
the_DT
Audit_NN
Committee_NN
Throughout_PIN
the_DT
year_NN
,_,
the_DT
Audit_NN
Committee_NN
has_VPRT [PEAS]
kept_VBN
the_DT
objectivity_NOMZ
included_VBD
the_DT
matters_NN
set_VBN [WZPAST]
out_PIN
below_PLACE
._.
and_ANDC
independence_NN
of_PIN
the_DT
external_JJ
auditor_NN
under_IN
review_NN
and_CC
has_VPRT [PEAS]
obtained_VBN
reports_NN
from_PIN
the_DT
Companys_NN
external_JJ
auditor_NN
1_CD
Financial_NN
statements_NOMZ
describing_VBG [WZPRES]
all_QUAN
relationships_NN
between_PIN
the_DT
auditor_NN
and_CC
the_DT
Company_NN
._.
The_DT
financial_JJ
disclosures_NN
contained_VBN [WZPAST]
in_PIN
the_DT
Companys_NN
annual_JJ
and_CC
The_DT
Audit_NN
Committee_NN
has_VPRT [PEAS]
remained_VBN
satisfied_JJ
that_THAC
the_DT
level_NN
quarterly_JJ
reports_NN
to_PIN
shareholders_NN
were_VBD [BYPA]
discussed_VBN
by_PIN
the_DT
Audit_NN
of_PIN
non-audit_JJ
services_NN
or_CC
the_DT
nature_NN
of_PIN
the_DT
work_NN
performed_VBN [WZPAST]
by_PIN
the_DT
Committee_NN
each_QUAN
quarter_NN
and_CC
at_PIN
year-end_NN
._.
Various_JJ
accounting_GER
external_JJ
auditors_NN
has_VPRT
not_XX0
in_PIN
any_QUAN
way_NN
impaired_VBN
their_TPP3
objectivity_NOMZ
and_PHC
matters_NN
were_VBD [SPAU] [BYPA]
also_RB
discussed_VBN
by_PIN
the_DT
Audit_NN
Committee_NN
,_,
including_VBG
independence_NN
._.
The_DT
detail_NN
of_PIN
the_DT
fees_NN
paid_VBN [WZPAST]
to_PIN
the_DT
external_JJ
auditors_NN
the_DT
application_NOMZ
of_PIN
the_DT
critical_JJ
accounting_GER
policies_NN
applied_VBN [WZPAST]
by_PIN
the_DT
is_VPRT [PASS]
disclosed_VBN [PUBV]
in_PIN
Note_NN
4_CD
to_PIN
the_DT
summary_NN
financial_JJ
statements_NOMZ
._.
The_DT
application_NOMZ
of_PIN
new_JJ
accounting_GER
standards_NN
was_VBD [SPAU] [PASS]
also_RB
discussed_VBN
,_,
where_RB
appropriate_JJ
,_,
during_PIN
these_DEMO
meetings_GER
._.
Quarterly_JJ
reports_NN
from_PIN
the_DT
external_JJ
auditors_NN
were_VBD [BYPA]
received_VBN
by_PIN
the_DT
Audit_NN
Committee_NN
and_CC
discussed_VBN
._.
The_DT
reports_NN
addressed_VBD
the_DT
following_VBG
key_JJ
additional_JJ
areas_NN
:_:
David_NN
Kappler_NN
Chairman_NN
of_PIN
the_DT
Audit_NN
Committee_NN
auditor_NN
responsibility_NOMZ
and_PHC
independence_NN
:_:
significant_JJ
accounting_GER
estimates_NN
and_PHC
judgements_NOMZ
made_VBN [WZPAST]
by_PIN
management_NOMZ
:_:
47_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
48_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Corporate_JJ
governance_NN
statements_NOMZ
Corporate_JJ
governance_NN
statements_NOMZ
The_DT
Board_NN
has_VPRT [PEAS]
taken_VBN
into_PIN
consideration_NOMZ
that_TOBJ
The_DT
Hon_NN
James_NN
Grant_NN
is_VPRT [BEMA]
a_DT
partner_NN
of_PIN
Stikeman_NN
Elliot_NN
,_,
a_DT
Canadian_JJ
law_NN
firm_NN
which_WDT [WHOBJ]
,_,
from_PIN
time_NN
The_DT
Company_NN
is_VPRT [PASS]
committed_VBN
to_PIN
high_JJ
standards_NN
to_PIN
time_NN
,_,
provides_VPRT
legal_JJ
advice_NN
to_PIN
the_DT
Group_NN
._.
The_DT
Board_NN
considers_VPRT [PRIV]
of_PIN
corporate_JJ
governance_NN
Mr_NN
Grant_NN
to_TO
be_VB [BEMA]
independent_PRED
notwithstanding_CONJ
his_TPP3
position_NOMZ
as_IN
he_TPP3
is_VPRT [BEMA]
The_DT
Board_NN
is_VPRT [PASS]
committed_VBN
to_PIN
high_JJ
standards_NN
of_PIN
corporate_JJ
not_XX0
involved_VBN
in_PIN
the_DT
provision_NN
of_PIN
legal_JJ
advice_NN
to_PIN
the_DT
Company_NN
and_PHC
governance_NN
and_CC
supports_VPRT
the_DT
provisions_NN
and_PHC
principles_NN
set_VBN [WZPAST]
out_PIN
in_PIN
is_VPRT [PASS]
not_XX0
engaged_VBN
in_PIN
marketing_VBG
the_DT
services_NN
of_PIN
Stikeman_NN
Elliott_NN
to_PIN
the_DT
The_DT
Combined_NN
Code_NN
on_PIN
Corporate_NN
Governance_NN
issued_VBN [WZPAST]
by_PIN
the_DT
UK_NN
Company_NN
._.
Stikeman_NN
Elliott_NN
is_VPRT [BEMA]
one_CD
of_PIN
a_DT
range_NN
of_PIN
legal_JJ
and_PHC
other_JJ
Financial_JJ
Reporting_GER
Council_NN
in_PIN
July_NN
2003_CD
the_DT
Combined_NN
Code_NN
._.
professional_JJ
advisors_NN
engaged_VBN [WZPAST]
by_PIN
the_DT
Company_NN
from_PIN
time_NN
to_PIN
time_NN
._.
The_DT
Combined_NN
Code_NN
took_VBD
full_JJ
effect_NN
for_PIN
the_DT
first_JJ
time_NN
for_PIN
the_DT
Accordingly_RB
,_,
the_DT
Board_NN
does_VPRT
not_XX0
consider_VB [PRIV]
the_DT
relationship_NN
between_PIN
Company_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
._.
the_DT
Company_NN
and_PHC
Stikeman_NN
Elliott_NN
to_TO
be_VB [BEMA]
material_PRED
and_CC
accordingly_RB
the_DT
fact_NN
that_TOBJ
Mr_NN
Grant_NN
is_VPRT [BEMA]
a_DT
partner_NN
at_PIN
that_DEMO
firm_NN
does_VPRT
not_XX0
,_,
in_PIN
the_DT
Statement_NOMZ
of_PIN
compliance_NN
with_PIN
the_DT
Combined_NN
Code_NN
Boards_NN
assessment_NOMZ
,_,
affect_VB
his_TPP3
independence_NN
._.
Mr_NN
Grant_NN
was_VBD [BEMA]
a_DT
Throughout_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
the_DT
Company_NN
Board_NN
member_NN
of_PIN
BioChem_NN
Pharma_NN
Inc._NN
prior_RB
to_PIN
its_PIT
merger_NN
with_PIN
the_DT
has_VPRT
,_,
in_PIN
the_DT
Directors_NN
opinion_NN
,_,
complied_VBN [PASTP]
with_PIN
the_DT
provisions_NN
set_VBN
Company_NN
in_PIN
2001_CD
._.
Mr_NN
Grant_NN
has_VPRT
an_DT
extensive_JJ
knowledge_NN
of_PIN
Shires_NN
out_PIN
in_PIN
Section_NOMZ
1_CD
of_PIN
the_DT
Combined_NN
Code_NN
,_,
save_VB
that_DEMO
the_DT
Chairman_NN
business_NOMZ
and_CC
he_TPP3
brings_VPRT
a_DT
wealth_NN
of_PIN
expertise_NN
to_PIN
the_DT
Board_NN
._.
of_PIN
the_DT
Company_NN
,_,
Dr_NN
James_NN
Cavanaugh_NN
,_,
sat_VBD
on_PIN
the_DT
Remuneration_NOMZ
Committee_NN
until_IN
28_CD
April_NN
2004_CD
and_CC
on_PIN
the_DT
Audit_NN
Committee_NN
until_IN
Board_NN
and_PHC
Committee_NN
changes_NN
30_CD
November_NN
2004_CD
._.
2.1_CD
and_CC
C._NN
3.1_CD
of_PIN
the_DT
Combined_VBN
There_EX
were_VBD
changes_NN
to_PIN
the_DT
Board_NN
and_CC
to_PIN
certain_JJ
of_PIN
the_DT
Board_NN
Code_NN
require_VPRT [SUAV]
each_QUAN
of_PIN
these_DEMO
committees_NN
to_TO
be_VB [PASS]
comprised_VBN
entirely_AMP
Committees_NN
in_PIN
2004_CD
._.
Dr_NN
Wilson_NN
Totten_NN
,_,
the_DT
Companys_NN
former_JJ
Chief_NN
of_PIN
independent_JJ
directors_NN
and_CC
under_IN
the_DT
Combined_NN
Code_NN
as_IN
Scientific_NN
Officer_NN
,_,
stepped_VBD
down_RB
from_PIN
the_DT
Board_NN
on_PIN
25_CD
May_POMD
2004_CD
._.
revised_VBN
,_,
a_DT
Chairman_NN
is_VPRT [SPAU] [PASS]
no_RB
longer_RB
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
independent_PRED
._.
Mr_NN
David_NN
Kappler_NN
joined_VBD
the_DT
Board_NN
as_IN
a_DT
non-executive_JJ
Director_NN
Dr_NN
Cavanaugh_NN
sat_VBD
on_PIN
the_DT
Audit_NN
and_PHC
Remuneration_NOMZ
Committees_NN
and_CC
a_DT
member_NN
of_PIN
the_DT
Audit_NN
Committee_NN
on_PIN
5_CD
April_NN
2004_CD
._.
With_PIN
for_PIN
part_NN
of_PIN
2004_CD
pending_VBG
the_DT
appointment_NOMZ
of_PIN
an_DT
additional_JJ
noneffect_NN
from_PIN
July_NN
2004_CD
,_,
Mr_NN
Kappler_NN
took_VBD
over_RP
the_DT
Chairmanship_NN
executive_NN
Director_NN
which_WDT [WHSUB]
occurred_VBD
in_PIN
April_NN
with_PIN
David_NN
Kapplers_NN
of_PIN
the_DT
Audit_NN
Committee_NN
from_PIN
Mr_NN
Ronald_NN
Nordmann_NN
._.
He_TPP3
remained_VBD
on_PIN
the_DT
Audit_NN
Committee_NN
for_PIN
a_DT
Nordmann_NN
joined_VBD
the_DT
Remuneration_NOMZ
Committee_NN
in_PIN
place_NN
of_PIN
transitional_JJ
period_NN
to_TO
ensure_VB [SUAV] [PRIV]
a_DT
smooth_JJ
handover_NN
of_PIN
responsibilities_NOMZ
._.
Dr_NN
James_NN
Cavanaugh_NN
on_PIN
28_CD
April_NN
2004_CD
._.
Dr_NN
James_NN
Cavanaugh_NN
stepped_VBD
down_RB
from_PIN
the_DT
Remuneration_NOMZ
Committee_NN
on_PIN
28_CD
April_NN
The_NN
Board_NN
2004_CD
and_CC
from_PIN
the_DT
Audit_NN
Committee_NN
on_PIN
30_CD
November_NN
2004_CD
._.
The_DT
Board_NN
comprises_VPRT
the_DT
Chairman_NN
,_,
two_CD
executive_NN
and_CC
five_CD
non-executive_JJ
Directors_NN
and_CC
meets_VPRT
at_PIN
least_JJ
six_CD
times_NN
a_DT
year_NN
._.
The_DT
Board_NN
meetings_GER
non-executive_JJ
Directors_NN
bring_VPRT
judgement_NOMZ
which_WDT [WHSUB]
is_VPRT [BEMA]
independent_PRED
During_PIN
2004_CD
,_,
there_EX
were_VBD
11_CD
Board_NN
meetings_GER
of_PIN
which_WDT [PIRE]
six_CD
were_VBD [BEMA]
of_PIN
management_NOMZ
to_PIN
Board_NN
deliberations_NOMZ
._.
The_DT
executive_NN
Directors_NN
face-to-face_JJ
meetings_GER
and_CC
five_CD
held_VBN [PRIV]
by_PIN
telephone_NN
._.
Board_NN
meetings_GER
have_VPRT
responsibility_NOMZ
for_PIN
day-to-day_TIME
business_NOMZ
operations_NOMZ
._.
The_DT
record_NN
of_PIN
attendance_NN
by_PIN
Directors_NN
at_PIN
Board_NN
meetings_GER
is_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
:_:
The_NN
Board_NN
has_VPRT
overall_JJ
responsibility_NOMZ
for_PIN
managing_VBG
the_DT
Company_NN
Number_NN
of_PIN
and_CC
its_PIT
strategic_JJ
direction_NOMZ
and_CC
seeks_VPRT
to_TO
provide_VB
effective_JJ
leadership_NN
meetings_GER
Out_PIN
of_PIN
Attendance_NN
and_CC
the_DT
control_NN
required_VBN [SUAV] [WZPAST]
for_PIN
a_DT
listed_VBN
company_NN
._.
The_DT
Board_NN
has_VPRT [PEAS]
Directors_NN
attended_VBD
possible_JJ
%_NN
formally_RB
reserved_VBD
specific_JJ
matters_NN
to_PIN
itself_PIT
for_PIN
determination_NOMZ
which_WDT [WHOBJ]
James_NN
Cavanaugh_NN
11_CD
11_CD
100_CD
include_VPRT
strategic_JJ
issues_NN
,_,
budgeting_GER
,_,
changes_NN
in_PIN
share_NN
capital_NN
,_,
Chairman_NN
approval_NN
of_PIN
the_DT
Companys_NN
financial_JJ
statements_NOMZ
and_PHC
entry_NN
into_PIN
material_NN
contracts_NN
._.
Matters_NN
not_XX0
formally_RB
reserved_VBN
to_PIN
the_DT
Board_NN
Matthew_NN
Emmens_NN
11_CD
11_CD
100_CD
are_VPRT [PASS]
delegated_VBN
to_PIN
the_DT
Executive_NN
Committee_NN
and_CC
to_PIN
various_JJ
other_JJ
Chief_NN
Executive_NN
Officer_NN
Board_NN
committees_NN
whose_WPS [WHOBJ]
functions_NOMZ
are_VPRT [PASS]
described_VBN
below_PLACE
._.
Angus_NN
Russell_NN
11_CD
11_CD
100_CD
Chief_NN
Financial_NN
Officer_NN
The_NN
Board_NN
members_NN
receive_VPRT
detailed_VBN
information_NOMZ
from_PIN
executive_JJ
Directors_NN
,_,
the_DT
Company_NN
Secretary_NN
and_CC
other_JJ
senior_JJ
managers_NN
Barry_NN
Price_NN
10_CD
11_CD
91_CD
to_TO
enable_VB
them_TPP3
to_TO
discharge_VB
their_TPP3
responsibilities_NOMZ
efficiently_RB
Senior_JJ
non-executive_JJ
Director_NN
and_CC
effectively_RB
._.
The_DT
Hon_NN
James_NN
Grant_NN
10_CD
11_CD
91_CD
non-executive_JJ
Director_NN
All_QUAN
Directors_NN
have_VPRT
access_NN
to_PIN
the_DT
advice_NN
and_PHC
guidance_NN
of_PIN
the_DT
Company_NN
Secretary_NN
and_CC
are_VPRT [PASS]
encouraged_VBN
to_TO
seek_VB
independent_JJ
Ronald_NN
Nordmann_NN
11_CD
11_CD
100_CD
advice_NN
at_PIN
the_DT
Companys_NN
expense_NN
,_,
where_RB
they_TPP3
feel_VPRT [PRIV] [THATD]
it_PIT
is_VPRT [BEMA]
appropriate_PRED
._.
non-executive_JJ
Director_NN
The_NN
Board_NN
is_VPRT [BEMA]
of_PIN
the_DT
opinion_NN
that_TOBJ
each_QUAN
of_PIN
its_PIT
members_NN
has_VPRT
the_DT
Robin_NN
Buchanan_NN
10_CD
11_CD
91_CD
knowledge_NN
,_,
aptitude_NN
and_PHC
experience_NN
to_TO
perform_VB
the_DT
functions_NOMZ
non-executive_JJ
Director_NN
required_VBN [SUAV] [WZPAST]
of_PIN
a_DT
director_NN
of_PIN
a_DT
listed_VBN
company_NN
._.
David_NN
Kappler_NN
non-executive_JJ
Director_NN
8_CD
8_CD
100_CD
Biographical_NN
details_NN
of_PIN
the_DT
members_NN
of_PIN
the_DT
Board_NN
are_VPRT [PASS]
shown_VBN [PRIV]
appointed_VBN
5_CD
April_NN
2004_CD
on_PIN
pages_NN
32_CD
to_PIN
33_CD
._.
Wilson_NN
Totten_NN
Chief_NN
Scientific_NN
Officer_NN
5_CD
5_CD
100_CD
stepped_VBD
down_RB
as_IN
a_DT
Director_NN
on_PIN
Independent_NN
Directors_NN
25_CD
May_POMD
2004_CD
The_NN
Board_NN
considers_VPRT [PRIV]
Dr_NN
Barry_NN
Price_NN
,_,
Mr_NN
Ronald_NN
Nordmann_NN
,_,
The_DT
Hon_NN
James_NN
Grant_NN
,_,
Mr_NN
Robin_NN
Buchanan_NN
and_PHC
Mr_NN
David_NN
Kappler_NN
to_TO
be_VB [BEMA]
independent_JJ
non-executive_JJ
Directors_NN
._.
The_DT
Board_NN
views_VPRT
The_DT
Chairman_NN
and_CC
the_DT
non-executive_JJ
Directors_NN
met_VBD
during_PIN
the_DT
each_QUAN
of_PIN
these_DEMO
non-executive_JJ
Directors_NN
to_TO
be_VB [BEMA]
independent_PRED
of_PIN
year_NN
without_PIN
the_DT
executive_NN
Directors_NN
being_VBG [WZPRES] [BEMA]
present_PRED
._.
management_NOMZ
,_,
independent_JJ
in_PIN
judgement_NOMZ
and_PHC
character_NN
and_CC
free_JJ
from_PIN
any_QUAN
business_NOMZ
or_CC
other_JJ
relationship_NN
which_WDT [WHSUB]
could_POMD [SPAU]
materially_RB
interfere_VB
with_PIN
the_DT
exercise_NN
of_PIN
their_TPP3
independent_JJ
judgement_NOMZ
._.
48_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
49_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Corporate_JJ
governance_NN
statements_NOMZ
Chairman_NN
and_PHC
Chief_NN
Executive_NN
Officer_NN
refreshening_GER
of_PIN
the_DT
Board_NN
._.
In_PIN
this_DEMO
regard_NN
it_PIT
should_NEMD
be_VB [PASS]
noted_VBN [PRIV]
that_THVC
The_DT
offices_NN
of_PIN
Chairman_NN
and_PHC
Chief_NN
Executive_NN
Officer_NN
are_VPRT [PASS]
held_VBN [PRIV]
there_EX
have_VPRT [PEAS]
been_VBN
substantial_JJ
changes_NN
to_PIN
the_DT
Board_NN
membership_NN
separately_RB
._.
The_DT
Chairman_NN
,_,
Dr_NN
James_NN
Cavanaugh_NN
,_,
is_VPRT [BEMA]
responsible_PRED
over_IN
this_DEMO
period_NN
of_PIN
time_NN
,_,
including_VBG [PRESP]
the_DT
appointments_NOMZ
since_OSUB
2003_CD
for_PIN
the_DT
conduct_NN
of_PIN
the_DT
Board_NN
and_CC
ensures_VPRT [SUAV] [PRIV]
that_THVC
Board_NN
discussions_NN
of_PIN
Mr_NN
Buchanan_NN
,_,
Mr_NN
Kappler_NN
and_PHC
Mr_NN
Emmens_NN
._.
In_CONJ
addition_NULL
,_,
there_EX
are_VPRT [PASS]
conducted_VBN
in_PIN
such_EMPH
a_NULL
way_NN
that_TOBJ
all_QUAN
views_NN
are_VPRT [PASS]
taken_VBN
into_PIN
account_NN
,_,
have_VPRT [PEAS]
been_VBN [BEMA]
recent_JJ
significant_JJ
changes_NN
to_PIN
the_DT
Companys_NN
Executive_NN
so_OSUB
that_NULL
no_SYNE
individual_JJ
Director_NN
or_CC
small_JJ
group_NN
of_PIN
Directors_NN
Committee_NN
,_,
such_OSUB
that_NULL
most_EMPH
of_PIN
its_PIT
members_NN
have_VPRT [PEAS]
been_VBN [PASS]
appointed_VBN
dominates_VPRT
proceedings_GER
._.
The_DT
Chief_NN
Executive_NN
Officer_NN
has_VPRT
the_DT
in_PIN
the_DT
last_JJ
two_CD
years_NN
._.
Having_VBG
deliberated_JJ
carefully_RB
on_PIN
the_DT
issue_NN
,_,
general_JJ
responsibility_NOMZ
for_PIN
running_VBG
the_DT
business_NOMZ
on_PIN
a_DT
day-to-day_TIME
and_CC
taken_VBN
into_PIN
account_NN
recent_JJ
performance_NN
evaluations_NOMZ
basis_NN
and_CC
chairs_VPRT
the_DT
Executive_NN
Committee_NN
._.
conducted_VBN [PASTP]
with_PIN
the_DT
assistance_NN
of_PIN
an_DT
external_JJ
consultant_NN
,_,
the_DT
Board_NN
has_VPRT
no_SYNE
hesitation_NOMZ
in_PIN
asking_VBG [SUAV]
Dr_NN
Price_NN
to_TO
remain_VB
on_PIN
the_DT
Board_NN
._.
The_DT
roles_NN
and_PHC
responsibilities_NOMZ
of_PIN
the_DT
Chairman_NN
and_CC
the_DT
Chief_NN
Dr_NN
Prices_NN
commitment_NOMZ
to_PIN
the_DT
Company_NN
is_VPRT [BEMA]
undiminished_PRED
and_CC
his_TPP3
Executive_NN
Officer_NN
are_VPRT [SPAU] [PASS]
clearly_RB
defined_VBN
,_,
separate_JJ
and_CC
have_VPRT [PEAS]
been_VBN
performance_NN
continues_VPRT
to_TO
be_VB [BEMA]
effective_PRED
._.
Further_JJ
information_NOMZ
concerning_VBG [WZPRES]
the_DT
Directors_NN
standing_VBG [WZPRES]
for_PIN
Senior_JJ
non-executive_JJ
Director_NN
re-election_NOMZ
at_PIN
the_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
,_,
including_VBG [PRESP]
their_TPP3
Dr_NN
Barry_NN
Price_NN
is_VPRT [BEMA]
the_DT
Senior_JJ
independent_JJ
non-executive_JJ
Director_NN
._.
biographies_NN
,_,
will_PRMD
be_VB [PASS]
included_VBN
in_PIN
the_DT
Notice_NN
of_PIN
Meeting_VBG
to_PIN
Dr_NN
Price_NN
is_VPRT [BEMA]
the_DT
Companys_NN
longest-serving_JJ
Director_NN
and_CC
as_IN
such_JJ
Shareholders_NN
._.
he_TPP3
has_VPRT
significant_JJ
knowledge_NN
of_PIN
the_DT
Company_NN
and_CC
its_PIT
business_NOMZ
._.
Dr_NN
Prices_NN
in-depth_JJ
knowledge_NN
of_PIN
the_DT
Company_NN
in_CONJ
particular_NULL
and_CC
The_DT
terms_NN
of_PIN
appointment_NOMZ
of_PIN
each_QUAN
of_PIN
the_DT
non-executive_JJ
the_DT
pharmaceutical_JJ
industry_NN
in_PIN
general_JJ
is_VPRT [BYPA]
acknowledged_VBN [PUBV]
by_PIN
the_DT
Directors_NN
will_PRMD
be_VB [PASS]
made_VBN
available_JJ
for_PIN
inspection_NOMZ
at_PIN
the_DT
Companys_NN
Board_NN
and_CC
he_TPP3
is_VPRT [BYPA]
consulted_VBN
by_PIN
other_JJ
non-executive_JJ
Directors_NN
on_PIN
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
in_PIN
2005_CD
._.
matters_NN
pertaining_VBG [WZPRES]
to_PIN
the_DT
Company_NN
._.
Dr_NN
Price_NN
chairs_VPRT
meetings_GER
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
non-executive_JJ
Directors_NN
during_PIN
the_DT
year_NN
in_PIN
the_DT
absence_NN
Performance_NN
appraisals_NN
of_PIN
the_DT
executive_NN
Directors_NN
and_CC
the_DT
Chairman_NN
._.
Dr_NN
Price_NN
is_VPRT [BEMA]
available_PRED
The_DT
Company_NN
conducted_VBN
evaluations_NOMZ
of_PIN
the_DT
performance_NN
as_IN
required_VBN [SUAV]
for_PIN
consultation_NOMZ
with_PIN
major_JJ
shareholders_NN
on_PIN
any_QUAN
of_PIN
the_DT
Board_NN
,_,
its_PIT
committees_NN
and_CC
each_QUAN
of_PIN
its_PIT
Directors_NN
in_PIN
2004_CD
._.
matter_NN
of_PIN
concern_NN
._.
An_DT
external_JJ
consultant_NN
was_VBD [PASS]
engaged_VBN
to_TO
facilitate_VB
this_DEMO
process_NN
._.
The_DT
consultant_NN
designed_VBN
and_PHC
conducted_VBN
a_DT
series_NN
of_PIN
one-on-one_JJ
Supply_NN
of_PIN
information_NOMZ
appraisal_NN
interviews_NN
with_PIN
each_QUAN
Director_NN
and_CC
presented_VBD
the_DT
results_NN
The_DT
executive_NN
Directors_NN
and_CC
the_DT
Company_NN
Secretary_NN
are_VPRT [BEMA]
to_PIN
the_DT
Chairman_NN
and_CC
the_DT
Board_NN
._.
It_PIT
was_VBD [PASS]
concluded_VBN [PRIV]
that_THVC
each_QUAN
of_PIN
responsible_JJ
for_PIN
ensuring_VBG [SUAV] [PRIV] [THATD]
that_DEMP
detailed_VBN
information_NOMZ
is_VPRT [PASS]
provided_VBN
to_PIN
the_DT
members_NN
of_PIN
the_DT
Board_NN
had_VBD [PEAS]
demonstrated_VBN [PRIV]
commitment_NOMZ
to_PIN
his_TPP3
Board_NN
members_NN
in_PIN
advance_NN
of_PIN
any_QUAN
scheduled_VBN
Board_NN
meeting_GER
._.
role_NN
and_CC
that_THVC
the_DT
performance_NN
of_PIN
each_QUAN
Director_NN
continues_VPRT
to_TO
be_VB
Before_IN
decisions_NN
are_VPRT [PASS]
made_VBN
,_,
consideration_NOMZ
is_VPRT [PASS]
given_VBN
to_PIN
the_DT
adequacy_NN
effective_JJ
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
evaluation_NOMZ
the_DT
Board_NN
discussed_VBD
areas_NN
of_PIN
information_NOMZ
available_JJ
to_PIN
the_DT
Board_NN
and_CC
,_,
if_COND
necessary_JJ
,_,
decisions_NN
where_RB
improvement_NOMZ
could_POMD
be_VB [PASS]
made_VBN
and_CC
these_DEMO
areas_NN
will_PRMD
be_VB [BEMA]
the_DT
are_VPRT [PASS]
deferred_VBN
if_COND
further_JJ
information_NOMZ
is_VPRT [PASS]
required_VBN [SUAV]
._.
Re-election_NOMZ
of_PIN
Directors_NN
Committees_NN
of_PIN
the_DT
Board_NN
Non-executive_JJ
Directors_NN
are_VPRT [PASS]
appointed_VBN
for_PIN
a_DT
term_NN
of_PIN
two_CD
years_NN
,_,
The_DT
Board_NN
has_VPRT [PEAS]
established_VBN [PRIV]
the_DT
Audit_NN
Committee_NN
,_,
the_DT
subject_JJ
to_PIN
shareholder_NN
approval_NN
._.
Re-appointment_NOMZ
of_PIN
non-executive_JJ
Remuneration_NOMZ
Committee_NN
,_,
the_DT
Nomination_NOMZ
Committee_NN
and_CC
the_DT
Directors_NN
following_VBG [WZPRES]
the_DT
expiry_NN
of_PIN
such_JJ
two-year_JJ
period_NN
is_VPRT [BEMA]
subject_JJ
Executive_NN
Committee_NN
._.
Each_QUAN
committee_NN
has_VPRT
its_PIT
own_JJ
written_VBN [PUBV]
terms_NN
to_PIN
satisfactory_JJ
performance_NN
and_CC
to_PIN
Board_NN
approval_NN
._.
of_PIN
reference_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [BYPA]
approved_VBN
by_PIN
the_DT
Board_NN
._.
The_DT
Terms_NN
of_PIN
Reference_NN
of_PIN
the_DT
Audit_NN
,_,
Nomination_NOMZ
and_PHC
Remuneration_NOMZ
At_PIN
each_QUAN
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
,_,
any_QUAN
Director_NN
who_WP [WHSUB]
has_VPRT [PEAS]
been_VBN
Committees_NN
are_VPRT [BEMA]
available_PRED
on_PIN
the_DT
Companys_NN
website_NN
._.
Details_NN
appointed_VBN [WZPAST]
by_PIN
the_DT
Board_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
seek_VB
re-election_NOMZ
,_,
together_RB
of_PIN
each_QUAN
committee_NN
are_VPRT
as_IN
follows_VPRT
:_:
with_PIN [STPR]
,_,
but_CC
not_XX0
exceeding_VBG
,_,
one_CD
third_NN
of_PIN
the_DT
other_JJ
Directors_NN
._.
Accordingly_RB
,_,
no_SYNE
Director_NN
should_NEMD
serve_VB
for_PIN
more_EMPH
than_PIN
three_CD
years_NN
1_CD
Audit_NN
Committee_NN
without_PIN
being_VBG [BEMA]
subject_PRED
to_PIN
re-election_NOMZ
by_PIN
shareholders_NN
._.
The_DT
Audit_NN
Committee_NN
has_VPRT [PEAS]
been_VBN [PASS]
established_VBN [PRIV]
for_PIN
the_DT
purpose_NN
of_PIN
overseeing_VBG
the_DT
accounting_GER
and_CC
financial_JJ
reporting_GER
processes_VPRT
At_PIN
the_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
to_TO
be_VB [PASS]
held_VBN [PRIV]
in_PIN
2005_CD
,_,
Mr_NN
Ronald_NN
of_PIN
the_DT
Company_NN
and_CC
the_DT
audit_NN
of_PIN
its_PIT
financial_JJ
statements_NOMZ
._.
For_PIN
Nordmann_NN
and_PHC
Mr_NN
Matthew_NN
Emmens_NN
will_PRMD
retire_VB
by_PIN
rotation_NOMZ
and_CC
further_JJ
information_NOMZ
about_IN
the_DT
Audit_NN
Committee_NN
,_,
its_PIT
membership_NN
offer_VPRT
themselves_TPP3
for_PIN
re-election_NOMZ
._.
In_CONJ
addition_NULL
,_,
in_PIN
accordance_NN
with_PIN
and_CC
activities_NOMZ
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
,_,
please_VB
the_DT
provisions_NN
of_PIN
the_DT
Combined_NN
Code_NN
,_,
Dr_NN
Barry_NN
Price_NN
,_,
who_WP
has_VPRT
refer_VPRT
to_PIN
the_DT
Audit_NN
Committee_NN
Report_NN
on_PIN
pages_NN
46_CD
and_CC
47_CD
._.
now_DPAR
served_VBN
on_PIN
the_DT
Board_NN
for_PIN
nine_CD
years_NN
,_,
will_PRMD
offer_VB
himself_TPP3
for_PIN
annual_JJ
re-election_NOMZ
by_PIN
shareholders_NN
._.
2_CD
Remuneration_NOMZ
Committee_NN
The_NN
Remuneration_NOMZ
Committee_NN
determines_VPRT [SUAV] [PRIV]
on_PIN
behalf_NN
of_PIN
the_DT
Board_NN
Dr_NN
Price_NN
is_VPRT [BEMA]
the_DT
Companys_NN
longest-serving_JJ
Director_NN
and_CC
as_IN
such_JJ
the_DT
policy_NN
for_PIN
the_DT
setting_GER
of_PIN
remuneration_NOMZ
and_PHC
incentivisation_NOMZ
of_PIN
he_TPP3
has_VPRT
significant_JJ
knowledge_NN
of_PIN
the_DT
Company_NN
and_CC
its_PIT
business_NOMZ
._.
the_DT
executive_NN
Directors_NN
and_CC
other_JJ
senior_JJ
executives_NN
and_CC
the_DT
fixing_VBG
In_CONJ
addition_NULL
to_PIN
his_TPP3
experience_NN
at_PIN
Shire_NN
,_,
Dr_NN
Price_NN
has_VPRT
many_QUAN
years_NN
of_PIN
of_PIN
the_DT
terms_NN
of_PIN
their_TPP3
employment_NOMZ
._.
The_DT
remuneration_NOMZ
of_PIN
the_DT
nonexperience_NN
in_PIN
the_DT
pharmaceutical_JJ
industry_NN
,_,
including_VBG [PRESP]
28_CD
years_NN
with_PIN
executive_JJ
Directors_NN
is_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
Board_NN
._.
The_DT
remuneration_NOMZ
the_DT
Glaxo_NN
group_NN
._.
The_DT
Board_NN
,_,
when_RB
making_VBG
its_PIT
determination_NOMZ
on_PIN
of_PIN
the_DT
members_NN
of_PIN
the_DT
Executive_NN
Committee_NN
,_,
other_JJ
than_PIN
the_DT
the_DT
independence_NN
of_PIN
Dr_NN
Price_NN
,_,
gave_VBD
particular_JJ
consideration_NOMZ
to_PIN
the_DT
executive_NN
Directors_NN
,_,
is_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
Chief_NN
Executive_NN
Officer_NN
fact_NN
that_TOBJ
Dr_NN
Price_NN
has_VPRT [PEAS]
been_VBN [BEMA]
a_DT
serving_VBG
member_NN
of_PIN
the_DT
Board_NN
for_PIN
nine_CD
following_VBG
discussion_NN
with_PIN
the_DT
Remuneration_NOMZ
Committee_NN
and_CC
is_VPRT
years_NN
,_,
that_THVC
the_DT
Combined_NN
Code_NN
suggests_VPRT [SUAV] [PUBV]
that_THVC
length_NN
of_PIN
service_NN
of_PIN
dependent_JJ
on_PIN
performance_NN
._.
The_DT
remuneration_NOMZ
of_PIN
the_DT
executive_NN
nine_CD
years_NN
or_CC
more_EMPH
is_VPRT [BEMA]
relevant_PRED
to_PIN
a_DT
determination_NOMZ
of_PIN
independence_NN
Directors_NN
and_CC
the_DT
Chairman_NN
is_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
Remuneration_NOMZ
and_CC
that_DEMO
re-appointment_JJ
should_NEMD
be_VB [BEMA]
subject_PRED
to_PIN
rigorous_JJ
review_NN
._.
Committee_NN
and_CC
confirmed_VBN [PUBV]
by_PIN
the_DT
Board_NN
._.
The_DT
Board_NN
were_VBD [BEMA]
also_RB
mindful_PRED
of_PIN
the_DT
need_NN
to_TO
ensure_VB [SUAV] [PRIV]
progressive_JJ
49_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
50_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Corporate_JJ
governance_NN
statements_NOMZ
The_DT
Remuneration_NOMZ
Committee_NN
may_POMD
engage_VB
external_JJ
consultants_NN
Directors_NN
remuneration_NOMZ
to_TO
advise_VB
on_PIN
any_QUAN
aspects_NN
of_PIN
remuneration_NOMZ
._.
The_DT
Companys_NN
remuneration_NOMZ
policy_NN
is_VPRT [PASS]
described_VBN
in_PIN
the_DT
Directors_NN
remuneration_NOMZ
report_NN
on_PIN
pages_NN
36_CD
to_PIN
45_CD
._.
The_DT
report_NN
details_NN
the_DT
level_NN
The_DT
Remuneration_NOMZ
Committee_NN
met_VBD
on_PIN
11_CD
occasions_NN
in_PIN
2004_CD
._.
of_PIN
remuneration_NOMZ
for_PIN
Directors_NN
and_CC
the_DT
basis_NN
upon_PIN
which_WDT [PIRE]
executive_JJ
Dr_NN
Barry_NN
Price_NN
chaired_VBD
the_DT
Remuneration_NOMZ
Committee_NN
throughout_PIN
remuneration_NOMZ
is_VPRT [PASS]
fixed_VBN
._.
the_DT
year_NN
and_PHC
Mr_NN
Robin_NN
Buchanan_NN
was_VBD [BEMA]
a_DT
member_NN
of_PIN
this_DEMO
committee_NN
throughout_PIN
2004_CD
._.
Dr_NN
James_NN
Cavanaugh_NN
was_VBD [BEMA]
a_DT
member_NN
until_IN
he_TPP3
Relations_NOMZ
with_PIN
shareholders_NN
stepped_VBD
down_RP
on_PIN
28_CD
April_NN
2004_CD
._.
Mr_NN
Ronald_NN
Nordmann_NN
joined_VBD
the_DT
The_DT
Company_NN
is_VPRT [PASS]
committed_VBN
to_TO
maintaining_VBG [PUBV]
constructive_JJ
Remuneration_NOMZ
Committee_NN
on_PIN
28_CD
April_NN
2004_CD
._.
Mr_NN
Buchanan_NN
was_VBD
relationships_NN
with_PIN
shareholders_NN
._.
The_DT
Chief_NN
Executive_NN
Officer_NN
and_CC
unable_JJ
to_TO
attend_VB
one_CD
of_PIN
the_DT
11_CD
Remuneration_NOMZ
Committee_NN
meetings_GER
the_DT
Chief_NN
Financial_NN
Officer_NN
,_,
supported_VBN [PASTP]
by_PIN
other_JJ
senior_JJ
executives_NN
,_,
which_WDT [SERE]
took_VBD
place_NN
in_PIN
2004_CD
due_JJ
to_PIN
a_DT
previous_JJ
commitment_NOMZ
,_,
but_CC
arrange_VPRT [SUAV]
individual_JJ
and_CC
group_NN
meetings_GER
with_PIN
major_JJ
shareholders_NN
otherwise_CONJ
all_QUAN
members_NN
attended_VBD
all_QUAN
meetings_GER
._.
throughout_PIN
the_DT
year_NN
to_TO
discuss_VB
the_DT
Companys_NN
strategy_NN
and_PHC
performance_NN
and_CC
to_TO
understand_VB [PRIV]
the_DT
views_NN
of_PIN
major_JJ
shareholders_NN
,_,
For_PIN
further_JJ
information_NOMZ
about_IN
the_DT
Remuneration_NOMZ
Committee_NN
,_,
which_WDT [SERE]
are_VPRT [SPAU] [PASS]
then_RB
communicated_VBN
to_PIN
the_DT
Board_NN
as_IN
a_DT
whole_NN
._.
The_DT
its_PIT
membership_NN
and_PHC
activities_NOMZ
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
Chairman_NN
and_CC
the_DT
Senior_JJ
independent_JJ
non-executive_JJ
Director_NN
2004_CD
,_,
please_VB
refer_VPRT
to_PIN
the_DT
Directors_NN
remuneration_NOMZ
report_NN
on_PIN
also_RB
are_VPRT [BEMA]
available_PRED
to_TO
meet_VB
with_PIN
major_JJ
shareholders_NN
._.
The_DT
Company_NN
maintains_VPRT [PUBV]
a_DT
flow_NN
of_PIN
information_NOMZ
to_PIN
its_PIT
shareholders_NN
3_CD
Nomination_NOMZ
Committee_NN
through_PIN
the_DT
announcement_NOMZ
of_PIN
quarterly_JJ
results_NN
and_CC
the_DT
provision_NN
The_DT
Nomination_NOMZ
Committee_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
identifying_VBG
and_CC
of_PIN
annual_JJ
reports_NN
._.
The_DT
Companys_NN
website_NN
at_PIN
www_NN
._.
com_NN
also_RB
nominating_VBG
,_,
for_PIN
the_DT
approval_NN
of_PIN
the_DT
Board_NN
,_,
candidates_NN
to_TO
fill_VB
provides_VPRT
information_NOMZ
about_IN
the_DT
Company_NN
and_CC
its_PIT
business_NOMZ
and_CC
is_VPRT
vacancies_NN
to_PIN
the_DT
Board_NN
._.
Before_IN
any_QUAN
appointment_NOMZ
is_VPRT [PASS]
made_VBN
,_,
the_DT
regularly_RB
updated_VBN
._.
The_DT
Companys_NN
Investor_NN
Relations_NOMZ
department_NOMZ
Nomination_NOMZ
Committee_NN
evaluates_VPRT
the_DT
balance_NN
of_PIN
skills_NN
,_,
knowledge_NN
acts_NN
as_IN
a_DT
contact_NN
point_NN
for_PIN
investors_NN
throughout_PIN
the_DT
year_NN
._.
and_ANDC
experience_NN
on_PIN
the_DT
Board_NN
and_CC
,_,
in_PIN
light_NN
of_PIN
this_DEMO
evaluation_NOMZ
,_,
identifies_VPRT
the_DT
capabilities_NOMZ
required_VBN [SUAV] [WZPAST]
for_PIN
a_DT
particular_JJ
appointment_NOMZ
._.
The_DT
Company_NN
holds_VPRT [PRIV] [THATD]
its_PIT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
in_PIN
London_NN
The_NN
Committee_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
consider_VB [PRIV]
candidates_NN
from_PIN
a_DT
wide_JJ
at_PIN
which_WDT [PIRE]
shareholders_NN
are_VPRT [PASS]
given_VBN
the_DT
opportunity_NOMZ
to_TO
ask_VB [SUAV]
questions_NOMZ
range_NN
of_PIN
backgrounds_NN
,_,
on_PIN
merit_NN
and_CC
against_PIN
objective_JJ
criteria_NN
._.
It_PIT
is_VPRT [SPAU] [PASS]
also_RB
required_VBN [SUAV]
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
candidates_NN
have_VPRT
sufficient_JJ
time_NN
to_TO
devote_VB
to_PIN
the_DT
position_NOMZ
._.
This_DEMO
Committee_NN
meets_VPRT
as_IN
required_VBN [SUAV]
Balanced_NN
and_CC
timely_JJ
assessment_NOMZ
of_PIN
positions_NOMZ
and_PHC
prospects_NN
and_CC
in_PIN
2004_CD
was_VBD [BYPA]
chaired_VBN
by_PIN
Dr_NN
James_NN
Cavanaugh_NN
._.
Mr_NN
Ronald_NN
The_NN
Company_NN
strives_VPRT
to_TO
give_VB
timely_JJ
assessments_NOMZ
of_PIN
matters_NN
Nordmann_NN
,_,
The_DT
Hon_NN
James_NN
Grant_NN
and_PHC
Dr_NN
Barry_NN
Price_NN
also_RB
that_DEMO
impact_NN
on_PIN
its_PIT
business_NOMZ
and_CC
financial_JJ
position_NOMZ
and_CC
to_TO
present_VB
served_VBN
on_PIN
this_DEMO
Committee_NN
in_PIN
2004_CD
._.
All_QUAN
members_NN
participated_VBD
scientific_JJ
and_PHC
other_JJ
price-sensitive_JJ
data_NN
in_PIN
a_DT
balanced_JJ
way_NN
._.
in_PIN
all_QUAN
discussions_NN
of_PIN
this_DEMO
Committee_NN
in_PIN
2004_CD
._.
Corporate_JJ
Social_NN
Responsibility_NOMZ
CSR_NN
The_NN
Nomination_NOMZ
Committee_NN
retains_VPRT
the_DT
services_NN
of_PIN
executive_NN
The_DT
Company_NN
recognizes_VPRT [PRIV]
the_DT
impact_NN
that_TOBJ
its_PIT
business_NOMZ
may_POMD
have_VB
search_NN
consultants_NN
to_TO
assist_VB
it_PIT
in_PIN
the_DT
identification_NOMZ
and_PHC
nomination_NOMZ
on_PIN
people_NN
and_CC
the_DT
environment_NOMZ
as_RB
well_RB
as_IN
the_DT
social_JJ
implications_NOMZ
of_PIN
new_JJ
Board_NN
candidates_NN
._.
of_PIN
its_PIT
operations_NOMZ
on_PIN
the_DT
general_JJ
community_NOMZ
._.
The_DT
Company_NN
therefore_CONJ
attaches_VPRT
great_JJ
importance_NN
to_PIN
social_JJ
and_PHC
environmental_JJ
4_CD
Executive_NN
Committee_NN
issues_NN
and_CC
to_PIN
ethical_JJ
business_NOMZ
practices_NN
._.
Accordingly_RB
,_,
ultimate_JJ
The_NN
Board_NN
has_VPRT [PEAS]
delegated_VBN
the_DT
day-to-day_TIME
management_NOMZ
of_PIN
the_DT
responsibility_NOMZ
for_PIN
them_TPP3
is_VPRT [PASS]
taken_VBN
at_PIN
the_DT
highest_JJ
levels_NN
._.
The_DT
Board_NN
Company_NN
to_PIN
the_DT
Executive_NN
Committee_NN
,_,
which_WDT [SERE]
operates_VPRT
within_PIN
reviews_NN
and_CC
is_VPRT [PASS]
satisfied_VBN
with_PIN
the_DT
Companys_NN
approach_NN
to_PIN
clear_JJ
and_PHC
formal_JJ
parameters_NN
._.
The_DT
Executive_NN
Committee_NN
meets_VPRT
corporate_JJ
social_JJ
responsibility_NOMZ
generally_RB
._.
The_DT
Board_NN
also_RB
reviews_VPRT
at_PIN
least_JJ
11_CD
times_NN
per_PIN
year_NN
._.
The_DT
Chief_NN
Executive_NN
is_VPRT [BEMA]
the_DT
Chairman_NN
of_PIN
the_DT
specific_JJ
business_NOMZ
risks_NN
related_VBN [WZPAST]
to_PIN
Social_NN
,_,
Environmental_NN
and_CC
the_DT
Executive_NN
Committee_NN
,_,
which_WDT [SERE]
on_PIN
31_CD
December_NN
2004_CD
consisted_VBD
Ethical_NN
SEE_VB [PRIV]
matters_NN
annually_RB
._.
of_PIN
nine_CD
Executive_NN
Vice_NN
Presidents_NN
including_VBG [WZPRES]
the_DT
two_CD
executive_NN
Directors_NN
._.
The_DT
Executive_NN
Committee_NN
reports_VPRT [PUBV]
to_TO
and_CC
seeks_VPRT
guidance_NN
The_DT
Board_NN
receives_VPRT
advice_NN
and_PHC
information_NOMZ
from_PIN
the_DT
Corporate_JJ
from_PIN
the_DT
Board_NN
on_PIN
a_DT
regular_JJ
basis_NN
._.
Social_NN
Responsibility_NOMZ
Committee_NN
CSR_NN
Committee_NN
to_TO
make_VB
this_DEMO
assessment_NOMZ
._.
The_DT
CSR_NN
Committee_NN
,_,
which_WDT [SERE]
is_VPRT [BYPA]
chaired_VBN
by_PIN
the_DT
Chief_NN
The_DT
Members_NN
of_PIN
the_DT
Executive_NN
Committee_NN
as_IN
at_PIN
31_CD
December_NN
Financial_NN
Officer_NN
,_,
meets_VPRT
three_CD
times_NN
a_DT
year_NN
and_CC
is_VPRT [BEMA]
responsible_PRED
2004_CD
were_VBD
Matthew_NN
Emmens_NN
Chief_NN
Executive_NN
Officer_NN
,_,
Angus_NN
for_PIN
setting_VBG
the_DT
policies_NN
and_PHC
procedures_NN
that_TSUB
manage_VPRT
SEE_VB [PRIV]
issues_NN
,_,
Russell_NN
Chief_NN
Financial_NN
Officer_NN
and_PHC
Executive_NN
Vice_NN
President_NN
of_PIN
risks_NN
and_PHC
opportunities_NOMZ
._.
SEE_VB [PRIV] [THATD]
risks_NN
are_VPRT [PASS]
managed_VBN
within_PIN
the_DT
overall_JJ
Global_JJ
Finance_NN
,_,
Tatjana_NN
May_POMD
General_NN
Counsel_NN
and_PHC
Executive_NN
Vice_NN
framework_NN
of_PIN
risk_NN
management_NOMZ
,_,
explained_VBD [PUBV]
below_PLACE
under_IN
the_DT
President_NN
of_PIN
Global_NN
Legal_NN
Affairs_NN
,_,
Anita_NN
Graham_NN
Executive_NN
Vice_NN
heading_VBG [WZPRES]
internal_JJ
control_NN
._.
President_NN
of_PIN
Human_NN
Resources_NN
,_,
Eliseo_NN
Salinas_NN
Executive_NN
Vice_NN
President_NN
of_PIN
Global_NN
R&D_NN
,_,
Greg_NN
Flexter_NN
Executive_NN
Vice_NN
President_NN
This_DEMO
year_NN
the_DT
Company_NN
has_VPRT [SPAU] [PEAS]
again_TIME
decided_VBN [SUAV] [PRIV]
to_TO
produce_VB
a_DT
standof_JJ
Sales_NN
and_PHC
Marketing_GER
,_,
North_NN
America_NN
,_,
Joseph_NN
Rus_NN
Executive_NN
alone_RB
report_NN
on_PIN
Corporate_JJ
Social_NN
Responsibility_NOMZ
._.
This_DEMP
is_VPRT [BEMA]
available_JJ
Vice_NN
President_NN
of_PIN
Sales_NN
and_PHC
Marketing_GER
,_,
International_NN
,_,
Barbara_NN
on_PIN
request_NN
or_CC
from_PIN
the_DT
Shire_NN
website_NN
._.
Deptula_NN
Executive_NN
Vice_NN
President_NN
of_PIN
Business_NOMZ
Development_NOMZ
,_,
John_NN
Lee_NN
Executive_NN
Vice_NN
President_NN
of_PIN
Supply_NN
Chain_NN
and_PHC
Quality_NOMZ
._.
Code_NN
of_PIN
Ethics_NN
The_DT
Company_NN
is_VPRT [PASS]
committed_VBN
to_PIN
the_DT
maintenance_NN
of_PIN
high_JJ
ethical_JJ
The_DT
Executive_NN
Committee_NN
normally_RB
meets_VPRT
once_TIME
a_DT
month_NN
to_PIN
standards_NN
in_PIN
its_PIT
dealings_GER
with_PIN
all_QUAN
persons_NN
with_PIN
whom_WP [PIRE]
it_PIT
is_VPRT [PASS]
involved_VBN
._.
deliberate_JJ
on_PIN
major_JJ
business_NOMZ
issues_NN
._.
It_PIT
also_RB
considers_VPRT [PRIV]
those_DEMO
The_DT
Groups_NN
Code_NN
of_PIN
Ethics_NN
applies_VPRT
to_PIN
all_QUAN
Directors_NN
and_PHC
employees_NN
matters_NN
that_TSUB
are_VPRT [BEMA]
of_PIN
a_DT
size_NN
and_PHC
significance_NN
as_IN
to_TO
require_VB [SUAV]
referral_NN
and_CC
is_VPRT [BEMA]
available_PRED
for_PIN
review_NN
on_PIN
the_DT
Companys_NN
website_NN
._.
to_PIN
the_DT
Board_NN
before_IN
such_JJ
matters_NN
are_VPRT [PASS]
referred_VBN
to_PIN
the_DT
Board_NN
for_PIN
final_JJ
consideration_NOMZ
and_PHC
decision_NN
._.
50_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
51_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Corporate_JJ
governance_NN
statements_NOMZ
Dividends_NN
Following_VBG [WZPRES]
the_DT
enactment_NOMZ
of_PIN
the_DT
Sarbanes-Oxley_NN
Act_NN
2002_CD
in_PIN
the_DT
The_NN
Company_NN
announced_VBD [PUBV]
in_PIN
July_NN
2004_CD
its_PIT
intention_NOMZ
to_TO
commence_VB
United_NN
States_NN
,_,
the_DT
Chief_NN
Executive_NN
Officer_NN
and_CC
the_DT
Chief_NN
Financial_NN
the_DT
payment_NOMZ
of_PIN
a_DT
semi-annual_JJ
dividend_NN
with_PIN
the_DT
aim_NN
to_TO
grow_VB
the_DT
Officer_NN
are_VPRT [PASS]
required_VBN [SUAV]
to_TO
complete_VB
formal_JJ
certifications_NOMZ
,_,
which_WDT [SERE]
total_VPRT
dividend_NN
paid_VBN [WZPAST]
for_PIN
each_QUAN
year_NN
progressively_RB
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
confirm_VPRT [PUBV]
,_,
inter_VPRT
alia_NN
,_,
that_DEMP
:_:
adoption_NOMZ
of_PIN
this_DEMO
dividend_NN
policy_NN
,_,
the_DT
Company_NN
intends_VPRT [SUAV]
to_TO
declare_VB [PUBV]
interim_JJ
dividends_NN
twice_RB
per_PIN
year_NN
,_,
with_PIN
the_DT
first_JJ
payment_NOMZ
made_VBD
the_DT
annual_JJ
report_NN
on_PIN
Form_NN
10-K_NN
in_PIN
the_DT
United_NN
States_NN
does_VPRT
not_XX0
around_PLACE
September_NN
October_NN
,_,
following_VBG
determination_NOMZ
of_PIN
first-half_JJ
contain_VPRT
any_QUAN
material_NN
misstatements_NOMZ
or_CC
omissions_NN
:_:
results_NN
,_,
and_ANDC
the_DT
second_JJ
payment_NOMZ
around_PLACE
April_NN
May_POMD
of_PIN
each_QUAN
year_NN
,_,
following_VBG
finalisation_NOMZ
of_PIN
the_DT
full-year_JJ
results_NN
._.
If_COND
the_DT
Company_NN
was_VBD [BEMA]
financial_JJ
information_NOMZ
reported_VBN [PUBV] [WZPAST]
in_PIN
Form_NN
10-K_JJ
fairly_RB
presents_VPRT
the_DT
to_TO
delay_VB
payment_NOMZ
of_PIN
the_DT
second-half_JJ
final_JJ
dividend_NN
by_PIN
seeking_VBG
financial_JJ
condition_NOMZ
,_,
results_NN
of_PIN
operations_NOMZ
and_PHC
cash_NN
flows_NN
of_PIN
the_DT
shareholder_NN
approval_NN
for_PIN
the_DT
payment_NOMZ
at_PIN
the_DT
Annual_JJ
General_NN
Company_NN
:_:
Meeting_VBG [PRESP]
which_WDT
is_VPRT [PASS]
held_VBN [PRIV]
in_PIN
June_NN
each_QUAN
year_NN
,_,
the_DT
Company_NN
would_PRMD
not_XX0
be_VB [BEMA]
able_PRED
to_TO
maintain_VB [PUBV]
an_DT
even_JJ
payment_NOMZ
cycle_NN
at_PIN
approximately_RB
the_DT
Chief_NN
Executive_NN
Officer_NN
and_CC
the_DT
Chief_NN
Financial_NN
Officer_NN
are_VPRT [BEMA]
six_CD
month_NN
intervals_NN
unless_COND
first-half_JJ
dividend_NN
payments_NOMZ
were_VBD [BEMA]
responsible_PRED
for_PIN
determining_VBG [SUAV] [PRIV]
and_PHC
maintaining_VBG [PUBV]
disclosure_NN
controls_NN
also_RB
delayed_VBN
._.
Accordingly_RB
,_,
the_DT
Company_NN
does_VPRT
not_XX0
intend_VB [SUAV]
to_TO
put_VB
a_DT
and_CC
procedures_NN
for_PIN
the_DT
purposes_NN
of_PIN
US_FPP1
financial_JJ
reporting_GER
:_:
resolution_NOMZ
to_PIN
shareholders_NN
at_PIN
the_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
approving_VBG
the_DT
payment_NOMZ
of_PIN
the_DT
second-half_JJ
dividend_NN
._.
This_DEMP
is_VPRT [BEMA]
beneficial_PRED
for_PIN
the_DT
the_DT
Chief_NN
Executive_NN
Officer_NN
and_CC
the_DT
Chief_NN
Financial_NN
Officer_NN
have_VPRT
Company_NN
,_,
both_DT
from_PIN
a_DT
cash_NN
flow_NN
planning_GER
and_CC
from_PIN
an_DT
accounting_GER
evaluated_VBD
the_DT
effectiveness_NOMZ
of_PIN
those_DEMO
disclosure_NN
controls_NN
and_PHC
perspective_NN
and_CC
beneficial_JJ
for_PIN
shareholders_NN
as_IN
dividends_NN
are_VPRT [PASS]
paid_VBN
procedures_NN
:_:
promptly_RB
and_CC
a_DT
smooth_JJ
payment_NOMZ
cycle_NN
is_VPRT [PASS]
maintained_VBN [PUBV]
._.
the_DT
Chief_NN
Executive_NN
Officer_NN
and_CC
the_DT
Chief_NN
Financial_NN
Officer_NN
have_VPRT
Financial_JJ
disclosure_NN
,_,
internal_JJ
control_NN
and_CC
the_DT
role_NN
indicated_VBD [PRIV]
in_PIN
Form_NN
10-K_JJ
whether_IN
there_EX
were_VBD
any_QUAN
significant_JJ
of_PIN
the_DT
auditors_NN
changes_NN
in_PIN
the_DT
Companys_NN
internal_JJ
control_NN
over_IN
financial_JJ
The_NN
Board_NN
has_VPRT
,_,
through_PIN
the_DT
Audit_NN
Committee_NN
,_,
established_VBD [PRIV]
formal_JJ
reporting_GER
:_:
and_ANDC
and_CC
transparent_JJ
arrangements_NOMZ
for_PIN
financial_JJ
reporting_GER
,_,
internal_JJ
control_NN
and_CC
external_JJ
auditing_GER
._.
The_DT
Audit_NN
Committees_NN
terms_NN
based_VBN [WZPAST]
on_PIN
the_DT
evaluation_NOMZ
of_PIN
the_DT
Chief_NN
Executive_NN
Officer_NN
and_CC
the_DT
of_PIN
reference_NN
extend_VPRT
to_PIN
the_DT
Companys_NN
risk_NN
management_NOMZ
activities_NOMZ
Chief_NN
Financial_NN
Officer_NN
,_,
all_QUAN
significant_JJ
deficiencies_NN
and_PHC
material_NN
as_IN
a_DT
whole_JJ
and_CC
not_XX0
just_EMPH
the_DT
financial_JJ
aspects_NN
of_PIN
internal_JJ
control_NN
._.
weaknesses_NOMZ
in_PIN
the_DT
design_NN
or_CC
operation_NOMZ
of_PIN
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
which_WDT [WHSUB]
are_VPRT [BEMA]
reasonably_RB
likely_PRED
to_TO
affect_VB
adversely_RB
All_QUAN
employees_NN
can_POMD
raise_VB
any_QUAN
concerns_NN
in_PIN
any_QUAN
of_PIN
these_DEMO
areas_NN
with_PIN
the_DT
Companys_NN
ability_NOMZ
to_PIN
record_NN
,_,
process_NN
,_,
summarise_NN
and_CC
report_VB [PUBV]
the_DT
Chairman_NN
of_PIN
the_DT
Audit_NN
Committee_NN
in_PIN
the_DT
strictest_JJ
confidence_NN
._.
financial_JJ
information_NOMZ
included_VBD
in_PIN
Form_NN
10-K_NN
have_VPRT [PEAS]
been_VBN [PASS]
disclosed_VBN [PUBV] [THATD]
The_DT
Company_NN
operates_VPRT
a_DT
whistle-blowing_JJ
policy_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
to_PIN
the_DT
Companys_NN
auditors_NN
._.
framework_NN
for_PIN
a_DT
confidential_JJ
process_NN
through_PIN
which_WDT [PIRE]
all_QUAN
employees_NN
are_VPRT [BEMA]
able_PRED
to_TO
report_VB [PUBV] [THATD]
concerns_NN
relating_VBG [WZPRES]
to_PIN
financial_JJ
disclosure_NN
,_,
internal_JJ
The_DT
Chief_NN
Executive_NN
Officer_NN
and_CC
the_DT
Chief_NN
Financial_NN
Officer_NN
have_VPRT
control_NN
and_CC
other_JJ
compliance_NN
issues_NN
in_PIN
good_JJ
faith_NN
without_PIN
fear_NN
completed_VBN
these_DEMO
certifications_NOMZ
and_CC
they_TPP3
have_VPRT [PEAS]
been_VBN [PASS]
filed_VBN
with_PIN
the_DT
of_PIN
discrimination_NOMZ
or_CC
reprisal_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
Audit_NN
Committee_NN
SEC_NN
in_PIN
the_DT
United_NN
States_NN
as_IN
part_NN
of_PIN
the_DT
Companys_NN
annual_JJ
report_NN
has_VPRT [PEAS]
introduced_VBN
a_DT
procedure_NN
for_PIN
the_DT
receipt_NN
and_PHC
monitoring_GER
of_PIN
in_PIN
the_DT
United_NN
States_NN
on_PIN
Form_NN
10-K_NN
._.
complaints_NN
relating_VBG [WZPRES]
to_PIN
internal_JJ
controls_NN
._.
2_CD
Risk_NN
management_NOMZ
and_CC
internal_JJ
control_NN
1_CD
Financial_NN
reporting_VBG [PUBV] [WZPRES]
The_DT
Board_NN
,_,
in_PIN
accordance_NN
with_PIN
the_DT
Turnbull_NN
Guidance_NN
on_PIN
internal_JJ
The_NN
Board_NN
has_VPRT
ultimate_JJ
responsibility_NOMZ
for_PIN
the_DT
preparation_NOMZ
of_PIN
control_NN
,_,
recognizes_VPRT [PRIV]
its_PIT
overall_JJ
responsibility_NOMZ
to_TO
maintain_VB [PUBV]
a_DT
sound_JJ
accounts_NN
and_CC
for_PIN
the_DT
monitoring_GER
of_PIN
systems_NN
of_PIN
internal_JJ
financial_JJ
system_NN
of_PIN
internal_JJ
control_NN
to_TO
safeguard_VB
shareholders_NN
investments_NOMZ
control_NN
._.
The_DT
Board_NN
strives_VPRT
to_TO
present_VB
a_DT
balanced_JJ
and_CC
and_CC
the_DT
Companys_NN
assets_NN
and_CC
to_TO [SPIN]
regularly_RB
review_VB
its_PIT
effectiveness_NOMZ
._.
understandable_JJ
assessment_NOMZ
of_PIN
the_DT
Companys_NN
position_NOMZ
and_CC
its_PIT
Whilst_OSUB
the_DT
Board_NN
acknowledges_VPRT [PUBV]
its_PIT
responsibility_NOMZ
for_PIN
the_DT
system_NN
prospects_NN
and_PHC
endeavors_NN
to_TO
present_VB
scientific_JJ
and_PHC
other_JJ
priceof_JJ
internal_JJ
control_NN
,_,
there_EX
are_VPRT
limitations_NOMZ
in_PIN
any_QUAN
system_NN
of_PIN
internal_JJ
sensitive_JJ
information_NOMZ
in_PIN
a_DT
balanced_JJ
way_NN
._.
The_DT
Company_NN
publishes_VPRT
control_NN
and_CC
accordingly_RB
even_RB
the_DT
most_EMPH
effective_JJ
system_NN
can_POMD
quarterly_RB
financial_JJ
reports_NN
so_OSUB
that_NULL
its_PIT
shareholders_NN
can_POMD
monitor_VB
provide_VB
only_DWNT
reasonable_JJ
and_CC
not_XX0
absolute_JJ
assurance_NN
._.
Such_JJ
the_DT
Companys_NN
financial_JJ
position_NOMZ
regularly_RB
._.
a_DT
system_NN
is_VPRT [PASS]
designed_VBN
to_TO
manage_VB
rather_RB
than_PIN
eliminate_VB
the_DT
risk_NN
of_PIN
failure_NN
to_TO
achieve_VB
business_NOMZ
objectives_NN
and_CC
can_POMD
provide_VB
On_PIN
behalf_NN
of_PIN
the_DT
Board_NN
,_,
the_DT
Audit_NN
Committee_NN
has_VPRT
the_DT
responsibility_NOMZ
only_DWNT
reasonable_JJ
and_CC
not_XX0
absolute_JJ
assurance_NN
against_PIN
material_NN
for_PIN
reviewing_VBG
the_DT
effectiveness_NOMZ
of_PIN
the_DT
system_NN
of_PIN
internal_JJ
financial_JJ
misstatement_NOMZ
or_CC
loss_NN
._.
controls_NN
and_CC
the_DT
audit_NN
process_NN
._.
The_DT
Audit_NN
Committee_NN
has_VPRT
independent_JJ
access_NN
to_PIN
the_DT
auditor_NN
throughout_PIN
the_DT
year_NN
in_PIN
The_DT
Board_NN
has_VPRT [PEAS]
reviewed_VBN
both_DT
the_DT
key_JJ
risks_NN
faced_VBN [WZPAST]
by_PIN
the_DT
Company_NN
addition_NOMZ
to_PIN
presentations_NOMZ
from_PIN
the_DT
auditor_NN
on_PIN
a_DT
quarterly_JJ
basis_NN
._.
and_ANDC
the_DT
effectiveness_NOMZ
of_PIN
the_DT
Companys_NN
internal_JJ
control_NN
systems_NN
Any_QUAN
significant_JJ
findings_GER
or_CC
identified_VBN
risks_NN
are_VPRT [SPAU] [PASS]
closely_RB
examined_VBN
in_PIN
2004_CD
._.
Outside_PLACE
of_PIN
its_PIT
review_NN
,_,
the_DT
Board_NN
delegates_NN
responsibility_NOMZ
and_CC
are_VPRT [PASS]
reported_VBN [PUBV]
to_PIN
the_DT
Board_NN
with_PIN
recommendations_NOMZ
for_PIN
action_NOMZ
._.
to_PIN
the_DT
Audit_NN
Committee_NN
for_PIN
more_EMPH
regular_JJ
review_NN
of_PIN
both_DT
key_JJ
risks_NN
and_CC
internal_JJ
controls_NN
and_CC
for_PIN
monitoring_VBG
the_DT
activities_NOMZ
of_PIN
the_DT
The_DT
Company_NN
has_VPRT [PEAS]
established_VBN [PRIV]
a_DT
Disclosure_NN
Committee_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
internal_JJ
audit_NN
function_NOMZ
._.
The_DT
Audit_NN
Committee_NN
has_VPRT [PEAS]
kept_VBN
these_DEMO
areas_NN
chaired_VBN [WZPAST]
by_PIN
the_DT
Chief_NN
Financial_NN
Officer_NN
._.
Its_PIT
membership_NN
comprises_VPRT
under_IN
review_NN
in_PIN
2004_CD
._.
senior_JJ
managers_NN
from_PIN
the_DT
legal_JJ
,_,
finance_NN
and_PHC
risk_NN
departments_NOMZ
._.
Its_PIT
responsibility_NOMZ
is_VPRT
to_TO
establish_VB [PRIV]
and_PHC
maintain_VB [PUBV]
controls_NN
and_CC
other_JJ
procedures_NN
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
information_NOMZ
disclosed_VBN [PUBV] [WZPAST]
to_PIN
investors_NN
is_VPRT [PASS]
recorded_VBN
,_,
summarised_VBN
and_PHC
reported_VBN [PUBV]
accurately_RB
and_CC
to_TO
monitor_VB
the_DT
effectiveness_NOMZ
of_PIN
these_DEMO
procedures_NN
._.
The_DT
Disclosure_NN
Committee_NN
also_RB
has_VPRT
the_DT
responsibility_NOMZ
for_PIN
review_NN
and_PHC
oversight_NN
of_PIN
the_DT
Companys_NN
periodic_JJ
reporting_GER
._.
51_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
52_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Corporate_JJ
governance_NN
statements_NOMZ
The_DT
Company_NN
has_VPRT
an_DT
integrated_JJ
risk_NN
management_NOMZ
and_CC
internal_JJ
Effective_JJ
internal_JJ
audit_NN
audit_NN
strategy_NN
that_TSUB
was_VBD [PASS]
reviewed_VBN
,_,
updated_VBN
and_PHC
approved_VBN
by_PIN
the_DT
The_DT
internal_JJ
review_NN
of_PIN
the_DT
Companys_NN
control_VPRT
procedures_NN
and_PHC
Audit_NN
Committee_NN
during_PIN
2004_CD
._.
Following_VBG [PRESP]
this_DEMO
review_NN
,_,
the_DT
roles_NN
compliance_NN
with_PIN
them_TPP3
is_VPRT [SPAU] [PASS]
mostly_RB
undertaken_VBN
through_PIN
internal_JJ
audit_NN
._.
of_PIN
Chief_NN
Risk_NN
Officer_NN
and_PHC
Director_NN
of_PIN
Internal_NN
Audit_NN
were_VBD [PASS]
split_VBN
._.
The_DT
The_DT
Audit_NN
Committee_NN
monitors_VPRT
and_PHC
reviews_VPRT
the_DT
internal_JJ
audit_NN
two_CD
positions_NOMZ
,_,
both_DT
of_PIN
which_WDT [PIRE]
have_VPRT [PEAS]
been_VBN [BYPA]
confirmed_VBN [PUBV]
by_PIN
the_DT
Audit_NN
program_NN
,_,
considers_VPRT [PRIV]
the_DT
findings_GER
of_PIN
internal_JJ
audit_NN
reviews_NN
and_PHC
Committee_NN
,_,
report_NN
to_PIN
the_DT
Chief_NN
Financial_NN
Officer_NN
but_CC
have_VPRT
direct_JJ
managements_NOMZ
response_NN
to_PIN
them_TPP3
,_,
and_ANDC
ensures_VPRT [SUAV] [PRIV]
efficient_JJ
coaccess_NN
to_PIN
the_DT
Chairman_NN
,_,
the_DT
Chairman_NN
of_PIN
the_DT
Audit_NN
Committee_NN
ordination_NOMZ
between_PIN
the_DT
Companys_NN
internal_JJ
and_PHC
external_JJ
auditors_NN
._.
and_ANDC
the_DT
other_JJ
members_NN
of_PIN
the_DT
Audit_NN
Committee_NN
._.
They_TPP3
also_RB
both_DT
The_DT
Companys_NN
internal_JJ
audit_NN
function_NOMZ
,_,
comprising_VBG [PRESP]
a_DT
mixture_NN
of_PIN
attend_VB
and_PHC
present_VB
regularly_RB
at_PIN
Audit_NN
Committee_NN
meetings_GER
._.
internal_JJ
and_PHC
out-sourced_JJ
resource_NN
,_,
was_VBD [BEMA]
operational_PRED
throughout_PIN
2004_CD
._.
A_DT
new_JJ
Director_NN
of_PIN
Internal_NN
Audit_NN
was_VBD [PASS]
appointed_VBN
in_PIN
2004_CD
and_CC
The_DT
Companys_NN
risk_NN
management_NOMZ
and_CC
internal_JJ
audit_NN
strategy_NN
is_VPRT [BEMA]
this_DEMO
appointment_NOMZ
was_VBD [BYPA]
approved_VBN
by_PIN
the_DT
Audit_NN
Committee_NN
._.
The_DT
based_VBN
on_PIN
a_DT
risk_NN
and_PHC
control_NN
framework_NN
containing_VBG [WZPRES]
the_DT
following_VBG
majority_NOMZ
of_PIN
internal_JJ
audit_NN
work_NN
during_PIN
2004_CD
has_VPRT [PEAS]
been_VBN [PASS]
concentrated_VBN
key_JJ
elements_NOMZ
:_:
on_PIN
internal_JJ
financial_JJ
controls_NN
and_CC
on_PIN
achieving_VBG
compliance_NN
with_PIN
Sarbanes-Oxley_NN
Act_NN
requirements_NOMZ
._.
The_DT
Audit_NN
Committee_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
an_DT
effective_JJ
control_NN
environment_NOMZ
:_:
responsible_JJ
for_PIN
monitoring_VBG
the_DT
activity_NOMZ
of_PIN
the_DT
internal_JJ
audit_NN
function_NOMZ
,_,
has_VPRT [PEAS]
reviewed_VBN
the_DT
effectiveness_NOMZ
of_PIN
the_DT
internal_JJ
audit_NN
during_PIN
2004_CD
._.
an_DT
effective_JJ
process_NN
to_TO
identify_VB
,_,
assess_VB
and_PHC
manage_VB
risks_NN
:_:
3_CD
External_NN
auditing_GER
effective_JJ
internal_JJ
control_NN
procedures_NN
:_:
and_ANDC
The_DT
Audit_NN
Committee_NN
has_VPRT
the_DT
primary_JJ
responsibility_NOMZ
for_PIN
determining_VBG [SUAV] [PRIV]
the_DT
remuneration_NOMZ
of_PIN
and_CC
overseeing_VBG
the_DT
work_NN
of_PIN
effective_JJ
internal_JJ
audit_NN
._.
any_QUAN
accounting_GER
firm_NN
engaged_VBD
to_TO
conduct_VB
the_DT
external_JJ
audit_NN
._.
The_DT
Audit_NN
Committee_NN
assesses_VPRT
at_PIN
least_JJ
annually_RB
the_DT
objectivity_NOMZ
and_CC
Effective_JJ
control_NN
environment_NOMZ
independence_NN
of_PIN
the_DT
external_JJ
auditor_NN
taking_VBG [WZPRES]
into_PIN
account_NN
relevant_JJ
The_DT
key_JJ
elements_NOMZ
of_PIN
the_DT
Companys_NN
control_VPRT
environment_NOMZ
are_VPRT [BEMA]
regulatory_JJ
requirements_NOMZ
._.
The_DT
Audit_NN
Committee_NN
reviews_VPRT
and_CC
as_IN
follows_VPRT
:_:
i_FPP1
the_DT
Board_NN
has_VPRT
overall_JJ
responsibility_NOMZ
to_TO
maintain_VB [PUBV]
the_DT
approves_VPRT
the_DT
annual_JJ
external_JJ
audit_NN
plan_NN
each_QUAN
year_NN
and_CC
ensures_VPRT [SUAV] [PRIV]
internal_JJ
control_NN
system_NN
and_CC
has_VPRT [PEAS]
delegated_VBN
certain_JJ
responsibilities_NOMZ
it_PIT
is_VPRT [BEMA]
consistent_PRED
with_PIN
the_DT
scope_NN
of_PIN
the_DT
auditors_NN
engagement_NOMZ
._.
The_DT
to_PIN
the_DT
Executive_NN
Committee_NN
and_CC
or_CC
the_DT
Audit_NN
Committee_NN
:_:
Audit_NN
Committee_NN
also_RB
considers_VPRT [PRIV]
whether_IN [WHCL]
the_DT
skills_NN
and_PHC
experience_NN
ii_VPRT
a_DT
framework_NN
of_PIN
Corporate_JJ
Values_NN
and_CC
Company-wide_JJ
Code_NN
of_PIN
the_DT
external_JJ
audit_NN
firm_NN
make_VPRT
it_PIT
a_DT
suitable_JJ
supplier_NN
of_PIN
non-audit_NN
of_PIN
Ethics_NN
which_WDT [WHSUB]
sets_VPRT
appropriate_JJ
standards_NN
of_PIN
ethical_JJ
behavior_NN
services_NN
._.
The_DT
Audit_NN
Committee_NN
set_NN
and_CC
apply_VB
a_DT
formal_JJ
policy_NN
is_VPRT [BEMA]
operational_PRED
throughout_PIN
the_DT
Group_NN
:_:
iii_VB
the_DT
internal_JJ
structure_NN
in_PIN
relation_NOMZ
to_PIN
the_DT
provision_NN
of_PIN
non-audit_JJ
services_NN
by_PIN
the_DT
external_JJ
of_PIN
the_DT
organization_NOMZ
is_VPRT [SPAU] [PASS]
well_RB
documented_VBN
with_PIN
clear_JJ
reporting_GER
lines_NN
auditor_NN
specifying_VBG [WZPRES]
the_DT
types_NN
of_PIN
non-audit_JJ
work_NN
:_:
i_FPP1
for_PIN
which_WDT [PIRE]
the_DT
and_CC
clear_JJ
limits_NN
of_PIN
authority_NOMZ
for_PIN
different_JJ
matters_NN
:_:
iv_VB
a_DT
range_NN
external_JJ
auditors_NN
are_VPRT [PASS]
excluded_VBN
:_:
ii_VB
for_PIN
which_WDT [PIRE]
the_DT
external_JJ
auditors_NN
of_PIN
corporate_JJ
policies_NN
and_PHC
procedures_NN
have_VPRT [PEAS]
been_VBN [PASS]
implemented_VBN
:_:
can_POMD
be_VB [PASS]
engaged_VBN
without_PIN
referral_NN
to_PIN
the_DT
Committee_NN
:_:
and_ANDC
iii_FW
for_PIN
v_NN
the_DT
internal_JJ
audit_NN
department_NOMZ
,_,
overseen_VBN [PASTP]
by_PIN
the_DT
Director_NN
of_PIN
which_WDT [PIRE]
a_DT
case_NN
by_PIN
case_NN
decision_NN
is_VPRT [BEMA]
necessary_PRED
,_,
with_PIN
a_DT
view_NN
to_PIN
Internal_NN
Audit_NN
,_,
carries_VPRT
out_PIN
regular_JJ
reviews_NN
of_PIN
control_NN
activities_NOMZ
preserving_VBG [WZPRES]
the_DT
auditors_NN
independence_NN
and_PHC
objectivity_NOMZ
._.
The_DT
Audit_NN
and_PHC
report_NN
findings_GER
to_PIN
management_NOMZ
:_:
vi_VB
the_DT
Audit_NN
Committee_NN
Committee_NN
also_RB
considers_VPRT [PRIV] [THATD]
the_DT
fees_NN
paid_VBN [WZPAST]
to_PIN
the_DT
external_JJ
auditors_NN
considers_VPRT [PRIV]
the_DT
major_JJ
findings_GER
of_PIN
any_QUAN
internal_JJ
investigations_NOMZ
and_CC
and_ANDC
whether_IN
the_DT
fee_NN
levels_NN
for_PIN
non-audit_JJ
services_NN
,_,
individually_RB
and_CC
managements_NOMZ
response_NN
to_PIN
them_TPP3
._.
in_PIN
aggregate_NN
,_,
relative_JJ
to_PIN
the_DT
audit_NN
fee_NN
are_VPRT [BEMA]
appropriate_PRED
to_TO
enable_VB
a_DT
proper_JJ
audit_NN
to_TO
be_VB [PASS]
conducted_VBN
._.
Effective_JJ
identification_NOMZ
,_,
assessment_NOMZ
and_PHC
management_NOMZ
of_PIN
risks_NN
The_DT
management_NOMZ
of_PIN
business_NOMZ
risk_NN
is_VPRT [BEMA]
essential_PRED
for_PIN
ensuring_VBG [SUAV] [PRIV]
that_THVC
the_DT
Going_VBG
concern_NN
basis_NN
Company_NN
creates_VPRT
and_PHC
preserves_VPRT
shareholder_NN
value_NN
._.
Accordingly_RB
,_,
After_IN
making_VBG
enquiries_NN
,_,
the_DT
Directors_NN
have_VPRT [PEAS]
formed_VBN
a_DT
judgement_NOMZ
,_,
the_DT
Company_NN
has_VPRT
an_DT
ongoing_JJ
process_NN
for_PIN
identifying_VBG
,_,
evaluating_VBG [PRESP]
at_PIN
the_DT
time_NN
of_PIN
approving_VBG
the_DT
financial_JJ
statements_NOMZ
,_,
that_THVC
there_EX
is_VPRT
a_DT
and_CC
managing_VBG
the_DT
significant_JJ
risks_NN
that_TOBJ
it_PIT
faces_VPRT
._.
This_DEMO
process_NN
has_VPRT
reasonable_JJ
expectation_NOMZ
that_TOBJ
the_DT
Group_NN
has_VPRT
adequate_JJ
resources_NN
been_VBN [WZPAST] [BEMA]
in_PIN
operation_NOMZ
throughout_PIN
the_DT
period_NN
under_IN
review_NN
and_CC
up_RB
to_TO
to_TO
continue_VB
in_PIN
operational_JJ
existence_NN
for_PIN
the_DT
foreseeable_JJ
future_NN
._.
the_DT
date_NN
of_PIN
the_DT
signing_GER
of_PIN
the_DT
accounts_NN
._.
All_QUAN
risks_NN
are_VPRT [PASS]
recorded_VBN
on_PIN
For_PIN
this_DEMO
reason_NN
the_DT
Directors_NN
continue_VPRT
to_TO
adopt_VB
the_DT
going_VBG
concern_NN
a_DT
corporate_JJ
risk_NN
schedule_NN
which_WDT [WHSUB]
allocates_VPRT
specific_JJ
responsibility_NOMZ
basis_NN
in_PIN
preparing_VBG
the_DT
financial_JJ
statements_NOMZ
._.
to_PIN
members_NN
of_PIN
the_DT
Executive_NN
Committee_NN
._.
This_DEMO
schedule_NN
has_VPRT [PEAS]
been_VBN [BYPA]
reviewed_VBN
by_PIN
the_DT
Audit_NN
Committee_NN
during_PIN
2004_CD
._.
Effective_JJ
internal_JJ
control_NN
procedures_NN
The_DT
Company_NN
has_VPRT
a_DT
system_NN
of_PIN
control_NN
procedures_NN
._.
Compliance_NN
with_PIN
these_DEMO
procedures_NN
is_VPRT [PASS]
monitored_VBN
through_PIN
a_DT
system_NN
of_PIN
internal_JJ
review_NN
and_CC
regular_JJ
reports_NN
on_PIN
financial_JJ
performance_NN
._.
Any_QUAN
significant_JJ
issues_NN
arising_VBG [WZPRES]
are_VPRT [PASS]
reported_VBN [PUBV]
to_PIN
the_DT
Audit_NN
Committee_NN
._.
During_PIN
2004_CD
,_,
the_DT
Company_NN
has_VPRT [PEAS]
made_VBN
a_DT
significant_JJ
investment_NOMZ
in_PIN
its_PIT
internal_JJ
financial_JJ
control_NN
procedures_NN
as_IN
part_NN
of_PIN
compliance_NN
with_PIN
s404_CD
Sarbanes-Oxley_NN
Act_NN
requirements_NOMZ
._.
This_DEMP
has_VPRT [PEAS]
included_VBN
the_DT
review_NN
,_,
documentation_NOMZ
and_PHC
testing_GER
of_PIN
all_QUAN
key_JJ
internal_JJ
financial_JJ
controls_NN
._.
The_DT
conclusion_NN
of_PIN
this_DEMO
exercise_NN
is_VPRT
that_DEMO
the_DT
Company_NN
had_VBD
an_DT
effective_JJ
system_NN
of_PIN
internal_JJ
controls_NN
over_IN
its_PIT
US_FPP1
GAAP_NN
Form_NN
10-K_JJ
financial_JJ
reporting_GER
at_PIN
31_CD
December_NN
2004_CD
._.
52_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
53_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Statement_NOMZ
of_PIN
Directors_NN
responsibilities_NOMZ
Statement_NOMZ
of_PIN
Directors_NN
responsibilities_NOMZ
The_DT
Companys_NN
management_NOMZ
assessed_VBD
the_DT
effectiveness_NOMZ
of_PIN
the_DT
Companys_NN
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
as_IN
of_PIN
United_NN
Kingdom_NN
company_NN
law_NN
requires_VPRT [SUAV]
the_DT
Directors_NN
to_TO
prepare_VB
December_NN
31_CD
,_,
2004_CD
._.
In_PIN
making_VBG
this_DEMO
assessment_NOMZ
,_,
the_DT
Companys_NN
financial_JJ
statements_NOMZ
for_PIN
each_QUAN
financial_JJ
year_NN
which_WDT [WHSUB]
give_VPRT
a_DT
true_JJ
and_CC
management_NOMZ
used_VBD
the_DT
criteria_NN
set_VBN [WZPAST]
forth_RB
by_PIN
the_DT
Committee_NN
of_PIN
fair_JJ
view_NN
of_PIN
the_DT
state_NN
of_PIN
affairs_NN
of_PIN
the_DT
Company_NN
and_CC
the_DT
Group_NN
Sponsoring_GER
Organizations_NOMZ
of_PIN
the_DT
Treadway_NN
Commission_NN
COSO_NN
as_IN
at_PIN
the_DT
end_NN
of_PIN
the_DT
financial_JJ
year_NN
and_CC
of_PIN
the_DT
profit_NN
or_CC
loss_NN
of_PIN
the_DT
in_PIN
Internal_NN
Control-Integrated_NN
Framework_NN
._.
In_PIN
preparing_VBG
those_DEMO
financial_JJ
statements_NOMZ
,_,
the_DT
Directors_NN
are_VPRT [PASS]
required_VBN [SUAV]
to_TO
:_:
Based_VBN [PASTP]
on_PIN
its_PIT
assessment_NOMZ
,_,
management_NOMZ
believes_VPRT [PRIV] [THATD]
that_DEMP
,_,
as_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
,_,
the_DT
Companys_NN
internal_JJ
control_NN
over_IN
financial_JJ
select_JJ
suitable_JJ
accounting_GER
policies_NN
and_CC
then_RB
apply_VB
them_TPP3
reporting_VBG [PUBV]
is_VPRT [BEMA]
effective_PRED
based_VBN
on_PIN
those_DEMO
criteria_NN
._.
consistently_RB
:_:
Deloitte_NN
&_CC
Touche_NN
LLP_NN
,_,
an_DT
independent_JJ
registered_JJ
public_NN
make_VPRT
judgments_NOMZ
and_PHC
estimates_NN
that_TSUB
are_VPRT [BEMA]
reasonable_PRED
and_PHC
accounting_PRED
firm_NN
,_,
has_VPRT [PEAS]
issued_VBN
an_DT
audit_NN
report_NN
on_PIN
managements_NOMZ
prudent_JJ
:_:
and_ANDC
assessment_NOMZ
of_PIN
the_DT
Companys_NN
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
._.
This_DEMO
report_NN
appears_VPRT [SMP]
on_PIN
page_NN
54_CD
of_PIN
this_DEMO
Annual_JJ
Review_NN
._.
state_NN
whether_IN
applicable_JJ
accounting_GER
standards_NN
have_VPRT [PEAS]
been_VBN [PASS]
followed_VBN
._.
Changes_NN
in_PIN
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
In_PIN
2004_CD
,_,
the_DT
Company_NN
commenced_VBD
the_DT
implementation_NOMZ
of_PIN
a_DT
new_JJ
The_DT
Directors_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
keeping_VBG
proper_JJ
accounting_GER
integrated_VBN
information_NOMZ
system_NN
covering_VBG [WZPRES]
financial_JJ
processes_NN
,_,
records_NN
which_WDT [WHSUB]
disclose_VPRT [PUBV]
with_PIN
reasonable_JJ
accuracy_NN
at_PIN
any_QUAN
time_NN
the_DT
production_NOMZ
,_,
logistics_NN
and_PHC
quality_NOMZ
management_NOMZ
._.
As_IN
of_PIN
December_NN
31_CD
,_,
financial_JJ
position_NOMZ
of_PIN
the_DT
Company_NN
and_CC
enable_VB
them_TPP3
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
2004_CD
,_,
a_DT
number_NN
of_PIN
the_DT
Companys_NN
business_NOMZ
units_NN
were_VBD
using_VBG
the_DT
the_DT
financial_JJ
statements_NOMZ
comply_VPRT
with_PIN
the_DT
Companies_NN
Act_NN
1985_CD
._.
new_JJ
system_NN
._.
Further_JJ
implementations_NOMZ
have_VPRT [SPAU] [PEAS]
already_RB
been_VBN [PASS]
made_VBN
They_TPP3
are_VPRT [BEMA]
also_RB
responsible_PRED
for_PIN
the_DT
system_NN
of_PIN
internal_JJ
control_NN
,_,
for_PIN
in_PIN
2005_CD
and_CC
more_EMPH
are_VPRT [PASS]
planned_VBN
for_PIN
2006_CD
._.
The_DT
implementations_NOMZ
safeguarding_VBG [WZPRES]
the_DT
assets_NN
of_PIN
the_DT
Company_NN
and_ANDC
hence_CONJ
for_PIN
taking_VBG
have_VPRT [PEAS]
involved_VBN
changes_NN
in_PIN
the_DT
Companys_NN
information_NOMZ
systems_NN
reasonable_JJ
steps_NN
for_PIN
the_DT
prevention_NOMZ
and_PHC
detection_NOMZ
of_PIN
fraud_NN
and_CC
that_DEMP
included_VBD
aspects_NN
of_PIN
the_DT
Companys_NN
internal_JJ
control_NN
other_JJ
irregularities_NOMZ
._.
over_IN
financial_JJ
reporting_GER
and_CC
,_,
accordingly_RB
,_,
these_DEMO
changes_NN
have_VPRT [PEAS]
required_VBN [SUAV]
changes_NN
to_PIN
the_DT
Companys_NN
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
._.
The_DT
Company_NN
has_VPRT [PEAS]
reviewed_VBN
each_QUAN
system_NN
Controls_NN
and_PHC
procedures_NN
as_IN
it_PIT
is_VPRT
being_VBG [PASS]
implemented_VBN
and_CC
the_DT
controls_NN
affected_VBN [WZPAST]
by_PIN
the_DT
implementation_NOMZ
of_PIN
the_DT
new_JJ
systems_NN
and_CC
made_VBN
appropriate_JJ
Disclosure_NN
controls_NN
and_PHC
procedures_NN
changes_NN
to_PIN
affected_JJ
internal_JJ
controls_NN
as_IN
it_PIT
implemented_VBD
the_DT
new_JJ
The_DT
Company_NN
,_,
under_IN
the_DT
supervision_NN
and_CC
with_PIN
the_DT
participation_NOMZ
systems_NN
._.
Management_NOMZ
believes_VPRT [PRIV]
that_THVC
the_DT
controls_NN
as_IN
modified_VBN
of_PIN
the_DT
Companys_NN
management_NOMZ
,_,
including_VBG [PRESP]
the_DT
Chief_NN
Executive_NN
are_VPRT [BEMA]
appropriate_PRED
and_CC
functioning_VBG
effectively_RB
._.
Officer_NN
and_CC
the_DT
Chief_NN
Financial_NN
Officer_NN
,_,
has_VPRT [PEAS]
performed_VBN
an_DT
evaluation_NOMZ
of_PIN
the_DT
effectiveness_NOMZ
of_PIN
the_DT
Companys_NN
disclosure_NN
In_CONJ
addition_NULL
,_,
during_PIN
the_DT
first_JJ
quarter_NN
of_PIN
2005_CD
the_DT
Companys_NN
controls_NN
and_PHC
procedures_NN
,_,
as_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
._.
The_DT
Finance_NN
Shared_NN
Services_NN
operations_NOMZ
in_PIN
Newport_NN
,_,
Kentucky_NN
will_PRMD
Companys_NN
management_NOMZ
necessarily_RB
applied_VBD
its_PIT
judgement_NOMZ
in_PIN
be_VB [PASS]
moved_VBN [SUAV]
to_PIN
Philadelphia_NN
,_,
as_IN
part_NN
of_PIN
the_DT
relocation_NOMZ
of_PIN
the_DT
majority_NOMZ
assessing_VBG [WZPRES]
the_DT
costs_NN
and_PHC
benefits_NN
of_PIN
such_JJ
controls_NN
and_PHC
procedures_NN
,_,
of_PIN
the_DT
Companys_NN
US_FPP1
operations_NOMZ
to_PIN
Philadelphia_NN
._.
As_IN
part_NN
of_PIN
this_DEMP
which_WDT
by_PIN
their_TPP3
nature_NN
can_POMD
provide_VB
only_DWNT
reasonable_JJ
assurance_NN
transition_NOMZ
,_,
the_DT
Companys_NN
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
regarding_VBG [WZPRES]
managements_NOMZ
control_VPRT
objectives_NN
._.
Based_VBN [PASTP]
on_PIN
this_DEMP
will_PRMD
be_VB [PASS]
reviewed_VBN
and_CC
changes_NN
may_POMD
be_VB [PASS]
made_VBN
._.
evaluation_NOMZ
,_,
the_DT
Companys_NN
Chief_NN
Executive_NN
Officer_NN
and_PHC
Chief_NN
Financial_NN
Officer_NN
concluded_VBD [PRIV]
that_THVC
the_DT
Companys_NN
disclosure_NN
controls_NN
and_PHC
procedures_NN
are_VPRT [BEMA]
effective_PRED
at_PIN
the_DT
reasonable_JJ
level_NN
of_PIN
assurance_NN
for_PIN
gathering_GER
,_,
analyzing_VBG
and_PHC
disclosing_VBG [PUBV]
the_DT
information_NOMZ
that_TOBJ
the_DT
Company_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
disclose_VB [PUBV]
in_PIN
the_DT
reports_NN
it_PIT
files_VPRT
under_IN
the_DT
Securities_NOMZ
Exchange_NN
Act_NN
of_PIN
1934_CD
,_,
within_PIN
the_DT
time_NN
periods_NN
specified_VBN [WZPAST]
in_PIN
the_DT
SECs_NN
rules_NN
and_PHC
forms_NN
._.
Managements_NOMZ
report_VPRT [PUBV]
on_PIN
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
The_DT
Companys_NN
management_NOMZ
is_VPRT [BEMA]
responsible_PRED
for_PIN
establishing_VBG [PRIV]
and_PHC
maintaining_VBG [PUBV]
adequate_JJ
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
as_IN
defined_VBN
in_PIN
Rule_NN
13_CD
a_DT
to_PIN
15_CD
f_SYM
or_CC
15_CD
d_SYM
to_PIN
15_CD
f_SYM
promulgated_VBN
under_IN
the_DT
Securities_NOMZ
Exchange_NN
Act_NN
of_PIN
1934_CD
._.
Because_CAUS
of_PIN
its_PIT
inherent_JJ
limitations_NOMZ
,_,
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
may_POMD
not_XX0
prevent_VB
or_CC
detect_VB
misstatements_NOMZ
._.
Projections_NOMZ
of_PIN
any_QUAN
evaluation_NOMZ
of_PIN
effectiveness_NOMZ
to_PIN
future_JJ
periods_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
the_DT
risk_NN
that_TOBJ
controls_NN
may_POMD
become_VB
inadequate_JJ
because_CAUS
of_PIN
changes_NN
in_PIN
conditions_NOMZ
,_,
or_CC
that_THVC
the_DT
degree_NN
of_PIN
compliance_NN
with_PIN
the_DT
policies_NN
or_CC
procedures_NN
may_POMD
deteriorate_VB
._.
53_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
54_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Report_NN
of_PIN
independent_JJ
registered_JJ
public_JJ
accounting_GER
firm_NN
Report_NN
of_PIN
independent_JJ
registered_JJ
public_JJ
accounting_GER
firm_NN
directors_NN
of_PIN
the_DT
company_NN
:_:
and_ANDC
3_CD
provide_VPRT
reasonable_JJ
assurance_NN
regarding_VBG [WZPRES]
prevention_NOMZ
or_CC
timely_JJ
detection_NOMZ
of_PIN
unauthorized_JJ
To_PIN
the_DT
Board_NN
of_PIN
Directors_NN
and_PHC
Stockholders_NN
of_PIN
acquisition_NOMZ
,_,
use_NN
,_,
or_CC
disposition_NOMZ
of_PIN
the_DT
companys_NN
assets_NN
that_TOBJ
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
,_,
Basingstoke_NN
,_,
England_NN
could_POMD
have_VB
a_DT
material_NN
effect_NN
on_PIN
the_DT
financial_JJ
statements_NOMZ
._.
We_FPP1
have_VPRT [PEAS]
audited_VBN
the_DT
accompanying_VBG
consolidated_JJ
balance_NN
sheets_NN
of_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
and_PHC
subsidiaries_NN
the_DT
Because_CAUS
of_PIN
the_DT
inherent_JJ
limitations_NOMZ
of_PIN
internal_JJ
control_NN
over_IN
financial_JJ
Company_NN
as_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
and_CC
2003_CD
,_,
and_ANDC
the_DT
related_JJ
reporting_GER
,_,
including_VBG [PRESP]
the_DT
possibility_NOMZ
of_PIN
collusion_NN
or_CC
improper_JJ
consolidated_JJ
statements_NOMZ
of_PIN
operations_NOMZ
,_,
stockholders_NN
equity_NOMZ
,_,
management_NOMZ
override_NN
of_PIN
controls_NN
,_,
material_NN
misstatements_NOMZ
due_RB
comprehensive_JJ
income_NN
and_PHC
cash_NN
flows_NN
for_PIN
each_QUAN
of_PIN
the_DT
three_CD
to_PIN
error_NN
or_CC
fraud_NN
may_POMD
not_XX0
be_VB [PASS]
prevented_VBN
or_CC
detected_VBN
on_PIN
a_DT
timely_JJ
years_NN
in_PIN
the_DT
period_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
._.
We_FPP1
also_RB
have_VPRT [PEAS]
audited_VBN
basis_NN
._.
Also_RB
,_,
projections_NOMZ
of_PIN
any_QUAN
evaluation_NOMZ
of_PIN
the_DT
effectiveness_NOMZ
of_PIN
the_DT
managements_NOMZ
assessment_NOMZ
,_,
included_VBD
in_PIN
the_DT
accompanying_VBG
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
to_PIN
future_JJ
periods_NN
are_VPRT [BEMA]
subject_JJ
Management_NOMZ
Report_NN
on_PIN
Internal_NN
Controls_NN
over_IN
Financial_NN
Reporting_GER
,_,
to_PIN
the_DT
risk_NN
that_TOBJ
the_DT
controls_NN
may_POMD
become_VB
inadequate_JJ
because_CAUS
of_PIN
that_DEMO
the_DT
Company_NN
maintained_VBD [PUBV]
effective_JJ
internal_JJ
control_NN
over_IN
changes_NN
in_PIN
conditions_NOMZ
,_,
or_CC
that_THVC
the_DT
degree_NN
of_PIN
compliance_NN
with_PIN
the_DT
financial_JJ
reporting_GER
as_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
,_,
based_VBN [PASTP]
on_PIN
criteria_NN
policies_NN
or_CC
procedures_NN
may_POMD
deteriorate_VB
._.
established_VBN [PRIV] [PASTP]
in_PIN
Internal_NN
Control_NN
Integrated_NN
Framework_NN
issued_VBN [WZPAST]
by_PIN
the_DT
Committee_NN
of_PIN
Sponsoring_GER
Organizations_NOMZ
of_PIN
the_DT
Treadway_NN
In_PIN
our_FPP1
opinion_NN
,_,
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
referred_VBD
to_PIN
Commission_NN
._.
The_DT
Companys_NN
management_NOMZ
is_VPRT [BEMA]
responsible_PRED
for_PIN
above_PLACE
present_JJ
fairly_RB
,_,
in_PIN
all_QUAN
material_NN
respects_VPRT
,_,
the_DT
financial_JJ
position_NOMZ
these_DEMO
financial_JJ
statements_NOMZ
and_CC
the_DT
financial_JJ
statement_NOMZ
schedule_NN
,_,
of_PIN
the_DT
Company_NN
as_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
and_CC
2003_CD
,_,
and_ANDC
the_DT
for_PIN
maintaining_VBG [PUBV]
effective_JJ
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
,_,
results_NN
of_PIN
its_PIT
operations_NOMZ
and_CC
its_PIT
cash_NN
flows_VPRT
for_PIN
each_QUAN
of_PIN
the_DT
three_CD
and_CC
for_PIN
its_PIT
assessment_NOMZ
of_PIN
the_DT
effectiveness_NOMZ
of_PIN
internal_JJ
control_NN
over_IN
years_NN
in_PIN
the_DT
period_NN
ended_VBD
December_NN
31_CD
,_,
2004_CD
,_,
in_PIN
conformity_NOMZ
with_PIN
financial_JJ
reporting_GER
._.
Our_FPP1
responsibility_NOMZ
is_VPRT
to_TO
express_VB
an_DT
opinion_NN
on_PIN
accounting_GER
principles_NN
generally_RB
accepted_VBN [PRIV]
in_PIN
the_DT
United_NN
States_NN
of_PIN
these_DEMO
financial_JJ
statements_NOMZ
and_CC
the_DT
financial_JJ
statement_NOMZ
schedule_NN
,_,
America_NN
._.
Also_RB
,_,
in_PIN
our_FPP1
opinion_NN
,_,
such_JJ
financial_JJ
statement_NOMZ
schedule_NN
,_,
an_DT
opinion_NN
on_PIN
managements_NOMZ
assessment_NOMZ
,_,
and_ANDC
an_DT
opinion_NN
on_PIN
when_RB
considered_VBN [PRIV]
in_PIN
relation_NOMZ
to_PIN
the_DT
basic_JJ
consolidated_JJ
financial_JJ
the_DT
effectiveness_NOMZ
of_PIN
the_DT
Companys_NN
internal_JJ
control_NN
over_IN
financial_JJ
statements_NOMZ
taken_VBN
as_IN
a_DT
whole_NN
,_,
presents_VPRT
fairly_RB
,_,
in_PIN
all_QUAN
material_NN
reporting_GER
based_VBN [WZPAST]
on_PIN
our_FPP1
audits_NN
._.
respects_NN
,_,
the_DT
information_NOMZ
set_VBN [WZPAST]
forth_RB
therein_RB
._.
Also_RB
,_,
in_PIN
our_FPP1
opinion_NN
,_,
managements_NOMZ
assessment_NOMZ
that_TOBJ
the_DT
Company_NN
maintained_VBD [PUBV] [THATD]
We_FPP1
conducted_VBD
our_FPP1
audits_NN
in_PIN
accordance_NN
with_PIN
the_DT
standards_NN
of_PIN
effective_JJ
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
as_IN
of_PIN
December_NN
31_CD
,_,
the_DT
Public_NN
Company_NN
Accounting_GER
Oversight_NN
Board_NN
United_NN
States_NN
._.
2004_CD
,_,
is_VPRT [SPAU] [PASS]
fairly_RB
stated_VBN [PUBV]
,_,
in_PIN
all_QUAN
material_NN
respects_VPRT
,_,
based_VBN [PASTP]
on_PIN
the_DT
criteria_NN
Those_DEMO
standards_NN
require_VPRT [SUAV]
that_THVC
we_FPP1
plan_VPRT
and_PHC
perform_VPRT
the_DT
audit_NN
to_TO
established_VBN [PRIV]
in_PIN
Internal_NN
Control_NN
Integrated_NN
Framework_NN
issued_VBD
obtain_VB
reasonable_JJ
assurance_NN
about_IN
whether_IN
the_DT
financial_JJ
by_PIN
the_DT
Committee_NN
of_PIN
Sponsoring_GER
Organizations_NOMZ
of_PIN
the_DT
Treadway_NN
statements_NOMZ
are_VPRT [BEMA]
free_PRED
of_PIN
material_NN
misstatement_NOMZ
and_ANDC
whether_IN
effective_JJ
Commission_NN
._.
Furthermore_CONJ
,_,
in_PIN
our_FPP1
opinion_NN
,_,
the_DT
Company_NN
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
was_VBD [PASS]
maintained_VBN [PUBV]
in_PIN
all_QUAN
maintained_VBN [PUBV]
,_,
in_PIN
all_QUAN
material_NN
respects_VPRT
,_,
effective_JJ
internal_JJ
control_NN
material_NN
respects_VPRT
._.
Our_FPP1
audit_NN
of_PIN
financial_JJ
statements_NOMZ
included_VBD
over_IN
financial_JJ
reporting_GER
as_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
,_,
based_VBN [PASTP]
on_PIN
the_DT
examining_VBG
,_,
on_PIN
a_DT
test_NN
basis_NN
,_,
evidence_NN
supporting_VBG [WZPRES]
the_DT
amounts_NN
and_PHC
criteria_NN
established_VBN [PRIV] [WZPAST]
in_PIN
Internal_NN
Control_NN
Integrated_NN
Framework_NN
disclosures_NN
in_PIN
the_DT
financial_JJ
statements_NOMZ
,_,
assessing_VBG [PRESP]
the_DT
accounting_GER
issued_VBN [WZPAST]
by_PIN
the_DT
Committee_NN
of_PIN
Sponsoring_GER
Organizations_NOMZ
of_PIN
the_DT
principles_NN
used_VBN
and_CC
significant_JJ
estimates_NN
made_VBN [WZPAST]
by_PIN
management_NOMZ
,_,
Treadway_NN
Commission_NN
._.
and_ANDC
evaluating_VBG
the_DT
overall_JJ
financial_JJ
statement_NOMZ
presentation_NOMZ
._.
Our_FPP1
audit_NN
of_PIN
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
included_VBD
Deloitte_NN
&_CC
Touche_NN
LLP_NN
obtaining_VBG [WZPRES]
an_DT
understanding_GER
of_PIN
internal_JJ
control_NN
over_IN
financial_JJ
Reading_VBG
,_,
England_NN
reporting_GER
,_,
evaluating_VBG
managements_NOMZ
assessment_NOMZ
,_,
testing_GER
and_PHC
March_NN
15_CD
,_,
2005_CD
evaluating_VBG
the_DT
design_NN
and_CC
operating_VBG
effectiveness_NOMZ
of_PIN
internal_JJ
control_NN
,_,
and_ANDC
performing_VBG
such_JJ
other_JJ
procedures_NN
as_IN
we_FPP1
considered_VBD [PRIV]
necessary_JJ
in_PIN
the_DT
circumstances_NN
._.
We_FPP1
believe_VPRT [PRIV]
that_THVC
our_FPP1
audits_NN
provide_VB
a_DT
reasonable_JJ
basis_NN
for_PIN
our_FPP1
opinions_NN
._.
A_DT
companys_NN
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
is_VPRT [BEMA]
a_DT
process_NN
designed_VBN [WZPAST]
by_PIN [STPR]
,_,
or_CC
under_IN
the_DT
supervision_NN
of_PIN [STPR]
,_,
the_DT
companys_NN
principal_JJ
executive_NN
and_CC
principal_JJ
financial_JJ
officers_NN
,_,
or_CC
persons_NN
performing_VBG [WZPRES]
similar_JJ
functions_NOMZ
,_,
and_ANDC
effected_VBN
by_PIN
the_DT
companys_NN
board_NN
of_PIN
directors_NN
,_,
management_NOMZ
,_,
and_ANDC
other_JJ
personnel_NN
to_TO
provide_VB
reasonable_JJ
assurance_NN
regarding_VBG [WZPRES]
the_DT
reliability_NOMZ
of_PIN
financial_JJ
reporting_GER
and_CC
the_DT
preparation_NOMZ
of_PIN
financial_JJ
statements_NOMZ
for_PIN
external_JJ
purposes_NN
in_PIN
accordance_NN
with_PIN
generally_RB
accepted_VBN [PRIV]
accounting_GER
principles_NN
._.
A_DT
companys_NN
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
includes_VPRT
those_DEMO
policies_NN
and_PHC
procedures_NN
that_TOBJ
1_CD
pertain_NN
to_PIN
the_DT
maintenance_NN
of_PIN
records_NN
that_DEMP
,_,
in_PIN
reasonable_JJ
detail_NN
,_,
accurately_RB
and_PHC
fairly_RB
reflect_VPRT [PRIV]
the_DT
transactions_NOMZ
and_PHC
dispositions_NOMZ
of_PIN
the_DT
assets_NN
of_PIN
the_DT
company_NN
:_:
2_CD
provide_VPRT
reasonable_JJ
assurance_NN
that_TOBJ
transactions_NOMZ
are_VPRT [PASS]
recorded_VBN
as_RB
necessary_JJ
to_TO
permit_VB
preparation_NOMZ
of_PIN
financial_JJ
statements_NOMZ
in_PIN
accordance_NN
with_PIN
generally_RB
accepted_VBN [PRIV]
accounting_GER
principles_NN
and_CC
that_THVC
receipts_NN
and_PHC
expenditures_NN
of_PIN
the_DT
company_NN
are_VPRT
being_VBG [PASS]
made_VBN
only_DWNT
in_PIN
accordance_NN
with_PIN
authorizations_NOMZ
of_PIN
management_NOMZ
and_CC
54_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
55_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Consolidated_NN
balance_NN
sheets_NN
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
share_NN
data_NN
Restated_VBN
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2004_CD
2003_CD
Notes_NN
$_$
000_CD
$_$
000_CD
Assets_NN
Current_JJ
assets_NN
:_:
Cash_NN
and_PHC
cash_NN
equivalents_NN
1,111,477_CD
1,063,362_CD
Restricted_VBN
cash_NN
21,627_CD
46,474_CD
Short-term_JJ
investments_NOMZ
9_CD
324,411_CD
304,129_CD
Accounts_NN
receivable_NN
,_,
net_JJ
6_CD
222,546_CD
194,583_CD
Inventories_NN
7_CD
41,230_CD
43,128_CD
Deferred_JJ
tax_NN
asset_NN
26_CD
70,387_CD
64,532_CD
Prepaid_NN
expenses_NN
and_CC
other_JJ
current_JJ
assets_NN
8_CD
137,271_CD
53,814_CD
Current_JJ
assets_NN
from_PIN
continuing_VBG
operations_NOMZ
1,928,949_CD
1,770,022_CD
Current_JJ
assets_NN
from_PIN
discontinued_VBN
operations_NOMZ
3_CD
24,096_CD
Total_JJ
current_JJ
assets_NN
1,928,949_CD
1,794,118_CD
Investments_NOMZ
10_CD
63,267_CD
72,975_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
,_,
net_JJ
11_CD
131,351_CD
94,495_CD
Goodwill_NN
12_CD
235,396_CD
221,231_CD
Other_JJ
intangible_JJ
assets_NN
,_,
net_JJ
12_CD
309,297_CD
307,882_CD
Deferred_JJ
tax_NN
asset_NN
26_CD
7,724_CD
Other_JJ
non-current_JJ
assets_NN
13_CD
38,895_CD
22,420_CD
Long-term_JJ
assets_NN
from_PIN
continuing_VBG
operations_NOMZ
785,930_CD
719,003_CD
Long-term_JJ
assets_NN
from_PIN
discontinued_VBN
operations_NOMZ
3_CD
72,070_CD
Total_JJ
assets_NN
2,714,879_CD
2,585,191_CD
Liabilities_NOMZ
and_PHC
shareholders_NN
equity_NOMZ
Current_JJ
liabilities_NOMZ
:_:
Current_JJ
installments_NOMZ
of_PIN
long-term_JJ
debt_NN
17_CD
290_CD
Accounts_NN
payable_JJ
and_CC
accrued_VBN
expenses_NN
14_CD
311,231_CD
205,779_CD
Loan_NN
facility_NOMZ
16_CD
43,162_CD
Other_JJ
current_JJ
liabilities_NOMZ
15_CD
77,558_CD
37,127_CD
Total_JJ
current_JJ
liabilities_NOMZ
from_PIN
continuing_VBG
operations_NOMZ
431,951_CD
243,196_CD
Current_JJ
liabilities_NOMZ
from_PIN
discontinued_VBN
operations_NOMZ
3_CD
10,479_CD
Total_JJ
current_JJ
liabilities_NOMZ
431,951_CD
253,675_CD
Long-term_JJ
debt_NN
,_,
excluding_VBG
current_JJ
installments_NOMZ
17 116 376_CD
,017_CD
Deferred_JJ
tax_NN
liability_NOMZ
26_CD
1,400_CD
Other_JJ
non-current_JJ
liabilities_NOMZ
18_CD
32,159_CD
30,194_CD
Long-term_JJ
liabilities_NOMZ
from_PIN
continuing_VBG
operations_NOMZ
32,275_CD
407,611_CD
Long-term_JJ
liabilities_NOMZ
from_PIN
discontinued_VBN
operations_NOMZ
3_CD
779_CD
Total_JJ
liabilities_NOMZ
464,226_CD
662,065_CD
Shareholders_NN
equity_NOMZ
:_:
Common_JJ
stock_NN
of_PIN
5p_JJ
par_JJ
value_NN
:_:
800,000,000_CD
shares_NN
authorized_VBN
:_:
and_ANDC
484,916,034_CD
shares_NN
issued_VBN
and_CC
outstanding_JJ
2003_CD
:_:
477,894,726_CD
40,064_CD
39,521_CD
Exchangeable_JJ
shares_NN
:_:
4,226,476_CD
shares_NN
issued_VBN
and_CC
outstanding_JJ
2003_CD
:_:
5,839,559_CD
195,830_CD
270,667_CD
Treasury_NN
stock_NN
264_CD
Additional_JJ
paid-in_PIN
capital_NN
1,072,407_CD
983,356_CD
Accumulated_VBN
other_JJ
comprehensive_JJ
income_NN
131,939_CD
79,007_CD
Retained_VBN
earnings_GER
810,677_CD
550,575_CD
Total_JJ
shareholders_NN
equity_NOMZ
2,250,653_CD
1,923,126_CD
Total_JJ
liabilities_NOMZ
and_PHC
shareholders_NN
equity_NOMZ
2,714,879_CD
2,585,191_CD
The_DT
balance_NN
sheet_NN
for_PIN
December_NN
31_CD
,_,
2003_CD
has_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
to_TO
reflect_VB [PRIV]
the_DT
disposal_NN
of_PIN
the_DT
vaccines_NN
business_NOMZ
that_TSUB
has_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
discontinued_VBN
operation_NOMZ
._.
The_DT
accompanying_JJ
notes_NN
are_VPRT [BEMA]
an_DT
integral_JJ
part_NN
of_PIN
these_DEMO
consolidated_JJ
financial_JJ
statements_NOMZ
._.
55_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
56_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Consolidated_NN
statements_NOMZ
of_PIN
operations_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
share_NN
data_NN
Restated_VBN
Restated_VBN
2004 2003 2002_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
Notes_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
Revenues_NN
Product_NN
sales_NN
1,112,457_CD
1,004,307_CD
845,340_CD
Royalties_NN
230,364_CD
203,573_CD
174,812_CD
Licensing_GER
and_PHC
development_NOMZ
13,479_CD
3,677_CD
3,064_CD
Other_JJ
revenues_NN
6,907_CD
13_CD
34_CD
Total_JJ
revenues_NN
1,363,207_CD
1,211,570_CD
1,023,250_CD
Costs_NN
and_PHC
expenses_NN
Cost_NN
of_PIN
product_NN
sales_NN
141,909_CD
143,160_CD
120,435_CD
Research_NN
and_PHC
development_NOMZ
196,265_CD
187,677_CD
173,380_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
516,645_CD
409,717_CD
361,699_CD
Intangible_JJ
asset_NN
impairment_NOMZ
12_CD
13,477_CD
27,489_CD
18,777_CD
Reorganization_NOMZ
costs_NN
3_CD
48,469_CD
23,940_CD
Total_JJ
operating_GER
expenses_NN
916,765_CD
791,983_CD
674,291_CD
Operating_GER
income_NN
446,442_CD
419,587_CD
348,959_CD
Interest_NN
income_NN
21,901_CD
16,856_CD
19,536_CD
Interest_NN
expense_NN
12,294_CD
9,451_CD
9,169_CD
Other_JJ
income_NN
expense_NN
,_,
net_JJ
24_CD
3,845_CD
20,645_CD
12,499_CD
Total_JJ
other_JJ
income_NN
expense_NN
,_,
net_JJ
13,452_CD
13,240_CD
2,132_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
before_IN
income_NN
taxes_NN
,_,
equity_NOMZ
in_PIN
earnings_GER
losses_NN
of_PIN
equity-method_JJ
investees_NN
and_CC
discontinued_VBN
operations_NOMZ
459,894_CD
406,347_CD
346,827_CD
Income_NN
taxes_NN
26_CD
129,103_CD
107,353_CD
88,350_CD
Equity_NOMZ
in_PIN
earnings_GER
losses_NN
of_PIN
equity-method_JJ
investees_NN
27_CD
2,508_CD
1,057_CD
1,668_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
333,299_CD
297,937_CD
260,145_CD
Loss_NN
from_PIN
discontinued_VBN
operations_NOMZ
net_NN
of_PIN
income_NN
tax_NN
expense_NN
of_PIN
$_$
nil_CD
,_,
$_$
nil_JJ
and_CC
$_$
3,588_CD
respectively_RB
3,5_CD
20,135_CD
21,886_CD
11,659_CD
Loss_NN
gain_NN
on_PIN
disposition_NOMZ
of_PIN
discontinued_VBN
operations_NOMZ
net_NN
of_PIN
income_NN
tax_NN
expense_NN
of_PIN
$_$
nil_CD
,_,
nil_NN
and_CC
$_$
1,224_CD
respectively_RB
3,5_CD
44,157_CD
2,083_CD
Net_JJ
income_NN
269,007_CD
276,051_CD
250,569_CD
Earnings_GER
per_PIN
share_NN
basic_JJ
22_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
67.2_CD
59.8_CD
51.9_CD
Loss_NN
from_PIN
discontinued_VBN
operations_NOMZ
4.1_CD
4.4_CD
2.3_CD
Loss_NN
gain_NN
on_PIN
disposal_NN
of_PIN
discontinued_VBN
operations_NOMZ
8.9_CD
0.4_CD
54.2_CD
55.4_CD
50.0_CD
Earnings_GER
per_PIN
share_NN
diluted_VBN
22_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
65.9_CD
58.4_CD
50.8_CD
Loss_NN
from_PIN
discontinued_VBN
operations_NOMZ
4.0_CD
4.2_CD
2.2_CD
Loss_NN
gain_NN
on_PIN
disposal_NN
of_PIN
discontinued_VBN
operations_NOMZ
8.6_CD
0.4_CD
53.3_CD
54.2_CD
49.0_CD
Weighted_VBN
average_JJ
number_NN
of_PIN
shares_NN
Basic_JJ
496,306,604_CD
498,212,826_CD
500,687,594_CD
Diluted_NN
511,267,432_CD
518,967,395_CD
522,418,246_CD
The_DT
results_NN
for_PIN
the_DT
years_NN
to_PIN
December_NN
31_CD
,_,
2003_CD
and_CC
2002_CD
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
to_TO
reflect_VB [PRIV]
the_DT
disposal_NN
of_PIN
the_DT
vaccines_NN
business_NOMZ
in_PIN
2004_CD
._.
The_DT
results_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2002_CD
reflect_VPRT [PRIV]
the_DT
disposal_NN
of_PIN
the_DT
Over-The-Counter_NN
OTC_NN
business_NOMZ
in_PIN
2002_CD
,_,
that_DEMP
was_VBD [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
discontinued_VBN
operation_NOMZ
._.
56_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
57_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Consolidated_NN
statements_NOMZ
of_PIN
changes_NN
in_PIN
shareholders_NN
equity_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
share_NN
data_NN
Accumulated_VBN
other_JJ
Common_JJ
Exchangeable_JJ
comprestock_NN
shares_NN
Additionalhensive_NN
Total_NN
Common_NN
number_NN
Exchangeable_JJ
number_NN
Treasury_NN
paid-in_PIN
income_NN
Retained_VBN
shareholders_NN
stock_NN
shares_NN
shares_NN
shares_NN
stock_NN
capital_NN
losses_NN
earnings_GER
equity_NOMZ
$_$
000_CD
000s_CD
$_$
000_CD
000s_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
As_IN
of_PIN
December_NN
31_CD
,_,
2001_CD
39,861_CD
481,817_CD
277,386_CD
5,979_CD
1,014,796_CD
93,009_CD
23,955_CD
1,262,989_CD
Net_JJ
income_NN
250,569250,569_CD
Foreign_JJ
currency_NN
translation_NOMZ
50,314_CD
50,314_CD
Issue_NN
of_PIN
common_JJ
stock_NN
for_PIN
conversion_NN
of_PIN
loan_NN
note_NN
21_CD
268_CD
1,479_CD
1,500_CD
Exchange_NN
of_PIN
exchangeable_JJ
shares_NN
22_CD
315_CD
4,863_CD
105_CD
4,841_CD
Options_NOMZ
exercised_VBN
147_CD
1,944_CD
5,861_CD
6,008_CD
Stock_NN
option_NOMZ
compensation_NOMZ
166_CD
166_CD
Tax_NN
benefit_NN
associated_VBN [WZPAST]
with_PIN
exercise_NN
of_PIN
stock_NN
options_NOMZ
688_CD
688_CD
Unrealized_JJ
holding_VBG [PRIV]
gain_NN
on_PIN
available-for-sale_JJ
securities_NOMZ
1,264_CD
1,264_CD
As_IN
of_PIN
December_NN
31_CD
,_,
2002_CD
40,051_CD
484,344_CD
272,523_CD
5,874_CD
1,027,499_CD
41,431_CD
274,524_CD
1,573,166_CD
Net_JJ
income_NN
276,051_CD
276,051_CD
Foreign_JJ
currency_NN
translation_NOMZ
114,116_CD
114,116_CD
Redemption_NOMZ
of_PIN
common_JJ
stock_NN
625_CD
7,593_CD
51,767_CD
52,392_CD
Exchange_NN
of_PIN
exchangeable_JJ
shares_NN
8_CD
104_CD
1,856_CD
34_CD
1,848_CD
Options_NOMZ
exercised_VBN
87_CD
1,040_CD
5,108_CD
5,195_CD
Stock_NN
option_NOMZ
compensation_NOMZ
and_PHC
warrants_NN
24_CD
24_CD
Tax_NN
benefit_NN
associated_VBN [WZPAST]
with_PIN
exercise_NN
of_PIN
stock_NN
options_NOMZ
692_CD
692_CD
Unrealized_JJ
holding_VBG [PRIV]
gain_NN
on_PIN
available-for-sale_JJ
securities_NOMZ
6,322_CD
6,322_CD
As_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
39,521_CD
477,895_CD
270,667_CD
5,840_CD
983,356_CD
79,007_CD
550,575_CD
1,923,126_CD
Net_JJ
income_NN
269,007_CD
269,007_CD
Foreign_JJ
currency_NN
translation_NOMZ
46,801_CD
46,801_CD
Exchange_NN
of_PIN
exchangeable_JJ
shares_NN
344_CD
4,839_CD
74,837_CD
1,614_CD
74,493_CD
Options_NOMZ
exercised_VBN
191_CD
2,098_CD
13,225_CD
13,416_CD
Stock_NN
option_NOMZ
compensation_NOMZ
and_PHC
warrants_NN
216_CD
216_CD
Tax_NN
benefit_NN
associated_VBN [WZPAST]
with_PIN
exercise_NN
of_PIN
stock_NN
options_NOMZ
354_CD
354_CD
New_NN
shares_NN
issued_VBD
8_CD
84 763 771_CD
Treasury_NN
stock_NN
51,286_CD
shares_NN
264_CD
264_CD
Unrealized_JJ
holding_VBG [PRIV]
gain_NN
on_PIN
available-for-sale_JJ
securities_NOMZ
27,01127,011_CD
Realized_VBN [PRIV]
gain_NN
on_PIN
available-for-sale_JJ
securities_NOMZ
20,880_CD
20,880_CD
Dividends_NN
8,905_CD
8,905_CD
As_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
40,064_CD
484,916_CD
195,830_CD
4,226_CD
264_CD
1,072,407_CD
131,939_CD
810,677_CD
2,250,653_CD
The_DT
accompanying_JJ
notes_NN
are_VPRT [BEMA]
an_DT
integral_JJ
part_NN
of_PIN
these_DEMO
consolidated_JJ
financial_JJ
statements_NOMZ
._.
57_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
58_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Consolidated_NN
statements_NOMZ
of_PIN
comprehensive_JJ
income_NN
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
2004 2003 2002_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
Net_JJ
income_NN
269,007_CD
276,051_CD
250,569_CD
Other_JJ
comprehensive_JJ
income_NN
:_:
Foreign_JJ
currency_NN
translation_NOMZ
46,801_CD
114,116_CD
50,314_CD
Unrealized_JJ
holding_GER
gains_NN
on_PIN
available-for-sale_JJ
securities_NOMZ
27,011_CD
6,322_CD
1,264_CD
Realized_VBN [PRIV]
gain_NN
on_PIN
available-for-sale_JJ
securities_NOMZ
20,880_CD
Comprehensive_JJ
income_NN
321,939_CD
396,489_CD
302,147_CD
The_DT
components_NN
of_PIN
accumulated_VBN
other_JJ
comprehensive_JJ
income_NN
as_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
and_CC
2003_CD
are_VPRT
as_IN
follows_VPRT
:_:
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2004_CD
2003_CD
$_$
000_CD
$_$
000_CD
Foreign_JJ
currency_NN
translation_NOMZ
118,222_CD
71,421_CD
Unrealized_JJ
holding_GER
gains_NN
on_PIN
available-for-sale_JJ
securities_NOMZ
13,717_CD
7,586_CD
Accumulated_VBN
other_JJ
comprehensive_JJ
income_NN
131,939_CD
79,007_CD
There_EX
are_VPRT
no_SYNE
material_NN
tax_NN
effects_NN
related_VBN [WZPAST]
to_PIN
the_DT
items_NN
included_VBD
above_PLACE
._.
58_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
59_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Consolidated_NN
statements_NOMZ
of_PIN
cash_NN
flows_NN
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
Restated_NN
Restated_NN
2004 2003 2002_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
Cash_NN
flows_VPRT
from_PIN
operating_VBG
activities_NOMZ
Net_JJ
income_NN
from_PIN
continuing_VBG
operations_NOMZ
333,299_CD
297,937_CD
260,145_CD
Adjustments_NOMZ
to_TO
reconcile_VB
net_JJ
income_NN
to_PIN
net_JJ
cash_NN
provided_VBN [WZPAST]
by_PIN
operating_VBG
activities_NOMZ
Depreciation_NOMZ
and_PHC
amortization_NOMZ
61,253_CD
38,192_CD
33,093_CD
Increase_VPRT
decrease_NN
in_PIN
provision_NN
for_PIN
sales_NN
reductions_NOMZ
50,746_CD
20,357_CD
3,436_CD
Stock_NN
option_NOMZ
compensation_NOMZ
216_CD
24_CD
166_CD
Movement_NOMZ
in_PIN
deferred_JJ
taxes_NN
14,979_CD
22,193_CD
9,904_CD
Equity_NOMZ
in_PIN
earnings_GER
losses_NN
of_PIN
equity-method_JJ
investees_NN
2,508_CD
1,057_CD
1,668_CD
Investments_NOMZ
552_CD
15,616_CD
7,686_CD
Movements_NOMZ
in_PIN
long-term_JJ
assets_NN
14,601_CD
44,035_CD
20,153_CD
Other_JJ
1,468_CD
Changes_NN
in_PIN
operating_VBG
assets_NN
and_PHC
liabilities_NOMZ
,_,
net_NN
of_PIN
acquisitions_NOMZ
:_:
Increase_VB
decrease_NN
in_PIN
accounts_NN
receivable_JJ
28,066_CD
45,408_CD
70,588_CD
Decrease_NN
increase_NN
in_PIN
inventory_NN
2,185_CD
6,261_CD
3,924_CD
Decrease_NN
increase_NN
in_PIN
prepayments_NOMZ
and_CC
other_JJ
current_JJ
assets_NN
2,509_CD
11,765_CD
11,666_CD
Increase_VPRT
in_PIN
property_NN
plant_NN
and_PHC
equipment_NOMZ
held_VBN [PRIV] [WZPAST]
for_PIN
sale_NN
12,470_CD
Decrease_NN
in_PIN
other_JJ
assets_NN
13,520_CD
291_CD
3,618_CD
Increase_VPRT
decrease_NN
in_PIN
accounts_NN
and_PHC
notes_NN
payable_JJ
and_PHC
other_JJ
liabilities_NOMZ
76,793_CD
890_CD
14,635_CD
Increase_VPRT
decrease_NN
in_PIN
deferred_JJ
revenue_NN
6,151_CD
19,372_CD
11,394_CD
Dividends_NN
received_VBD
from_PIN
investments_NOMZ
5,493_CD
2,289_CD
Net_JJ
cash_NN
provided_VBN [WZPAST]
by_PIN
operating_VBG
activities_NOMZ
520,661_CD
379,065_CD
361,822_CD
Cash_NN
flows_VPRT
from_PIN
investing_VBG
activities_NOMZ
Net_JJ
increase_NN
decrease_NN
in_PIN
short-term_JJ
investments_NOMZ
20,282_CD
11,997_CD
407,653_CD
Movements_NOMZ
in_PIN
restricted_JJ
cash_NN
24,847_CD
5,531_CD
52,005_CD
Loans_NN
made_VBD
to_PIN
IDB_NN
56,838_CD
Purchase_NN
of_PIN
subsidiary_NN
undertakings_GER
17,300_CD
Purchase_NN
of_PIN
long-term_JJ
investments_NOMZ
6,124_CD
5,643_CD
5,933_CD
Purchase_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
57,603_CD
44,681_CD
18,881_CD
Purchase_NN
of_PIN
intangible_JJ
assets_NN
30,209_CD
47,049_CD
24,032_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
a_DT
business_NOMZ
34,912_CD
71,000_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
long-term_JJ
investments_NOMZ
26,733_CD
1,000_CD
4,108_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
3,527_CD
1,262_CD
721_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
intangible_JJ
assets_NN
3,701_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
sale_NN
11,289_CD
Net_JJ
cash_NN
used_VBN [WZPAST]
in_PIN
provided_VBN
by_PIN
investing_VBG
activities_NOMZ
66,047_CD
77,583_CD
365,331_CD
Cash_NN
flows_VPRT
from_PIN
financing_VBG
activities_NOMZ
Redemption_NOMZ
of_PIN
2_CD
%_NN
convertible_JJ
loan_NN
notes_NN
370,109_CD
29,775_CD
Repayment_NOMZ
of_PIN
long-term_JJ
debt_NN
,_,
capital_NN
leases_NN
and_PHC
notes_NN
6,079_CD
231_CD
172_CD
Proceeds_NN
from_PIN
issue_NN
of_PIN
common_JJ
stock_NN
,_,
net_JJ
771_CD
Proceeds_NN
from_PIN
exercise_NN
of_PIN
options_NOMZ
13,416_CD
5,195_CD
6,008_CD
Tax_NN
benefit_NN
of_PIN
stock_NN
option_NOMZ
compensation_NOMZ
,_,
charged_VBN [PASTP]
directly_RB
to_PIN
equity_NOMZ
354 692 688_CD
Payments_NOMZ
for_PIN
redemption_NOMZ
of_PIN
common_JJ
stock_NN
264_CD
52,392_CD
Payment_NOMZ
of_PIN
dividend_NN
8,905_CD
Net_JJ
cash_NN
used_VBN [WZPAST]
in_PIN
provided_VBN
by_PIN
financing_VBG
activities_NOMZ
370,816_CD
76,511_CD
6,868_CD
Effect_NN
of_PIN
foreign_JJ
exchange_NN
rate_NN
changes_NN
on_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
from_PIN
continuing_VBG
operations_NOMZ
7,567_CD
25,133_CD
6,957_CD
Net_JJ
increase_NN
in_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
91,365_CD
250,104_CD
740,978_CD
Cash_NN
flows_NN
used_VBN [WZPAST]
in_PIN
discontinued_VBN
operations_NOMZ
43,250_CD
31,883_CD
13,689_CD
Net_JJ
increase_NN
in_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
48,115_CD
218,221_CD
727,289_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
at_PIN
beginning_GER
of_PIN
period_NN
1,063,362_CD
845,141_CD
117,852_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
at_PIN
end_NN
of_PIN
period_NN
1,111,477_CD
1,063,362_CD
845,141_CD
59_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
60_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Consolidated_NN
statements_NOMZ
of_PIN
cash_NN
flows_NN
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
Supplemental_NN
information_NOMZ
associated_VBN [WZPAST]
with_PIN
continuing_VBG
operations_NOMZ
:_:
Restated_VBN
Restated_VBN
2004 2003 2002_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
Interest_NN
paid_VBN
4,849_CD
7,716_CD
8,101_CD
Income_NN
taxes_NN
paid_VBD
123,510_CD
118,527_CD
101,779_CD
Non-cash_JJ
activities_NOMZ
Proceeds_NN
from_PIN
sale_NN
of_PIN
a_DT
business_NOMZ
:_:
4,931,864_CD
shares_NN
of_PIN
IDB_NN
60,000_CD
Escrow_NN
funds_NN
30,000_CD
Common_JJ
stock_NN
issued_VBN [WZPAST]
on_PIN
conversion_NN
of_PIN
zero-coupon_JJ
note_NN
1,500_CD
Capital_NN
leases_NN
assumed_VBD [PRIV]
on_PIN
acquisition_NOMZ
of_PIN
subsidiaries_NN
6,266_CD
The_DT
results_NN
for_PIN
the_DT
years_NN
to_PIN
December_NN
31_CD
,_,
2003_CD
and_CC
2002_CD
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
to_TO
reflect_VB [PRIV]
the_DT
disposal_NN
of_PIN
the_DT
vaccines_NN
business_NOMZ
in_PIN
2004_CD
._.
60_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
61_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
1_CD
Description_NOMZ
of_PIN
operations_NOMZ
General_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
and_CC
its_PIT
subsidiaries_NN
collectively_RB
referred_VBD
to_PIN
as_IN
Shire_NN
or_CC
the_DT
Company_NN
is_VPRT [BEMA]
a_DT
global_JJ
pharmaceutical_JJ
company_NN
with_PIN
a_DT
strategic_JJ
focus_NN
on_PIN
meeting_VBG
the_DT
needs_NN
of_PIN
the_DT
specialist_NN
physician_NN
._.
The_DT
Company_NN
has_VPRT
a_DT
particular_JJ
interest_NN
in_PIN
innovative_JJ
therapies_NN
that_TSUB
are_VPRT [BYPA]
prescribed_VBN
by_PIN
specialist_NN
doctors_NN
as_IN
opposed_VBN
to_PIN
primary-care_JJ
physicians_NN
._.
The_DT
Company_NN
is_VPRT [PASS]
focused_VBN
on_PIN
the_DT
development_NOMZ
of_PIN
late-stage_JJ
projects_NN
and_PHC
marketing_GER
products_NN
in_PIN
the_DT
areas_NN
of_PIN
Central_NN
Nervous_NN
System_NN
CNS_NN
,_,
Gastro-Intestinal_NN
GI_NN
and_PHC
General_NN
Products_NN
GP_NN
._.
Geographically_NN
,_,
the_DT
Company_NN
has_VPRT
operations_NOMZ
in_PIN
the_DT
worlds_NN
key_JJ
pharmaceutical_JJ
markets_NN
,_,
namely_CONJ
North_NN
America_NN
and_PHC
Europe_NN
._.
The_DT
Companys_NN
business_NOMZ
is_VPRT [PASS]
organized_VBN
across_PLACE
four_CD
operating_GER
segments_NOMZ
:_:
US_FPP1
,_,
International_NN
covering_VBG [WZPRES]
territories_NN
outside_PLACE
of_PIN
the_DT
US_FPP1
,_,
Research_NN
&_CC
Development_NOMZ
R&D_NN
and_PHC
Corporate_NN
._.
Revenues_NN
are_VPRT [PASS]
derived_VBN
primarily_RB
from_PIN
three_CD
sources_NN
:_:
sales_NN
of_PIN
the_DT
Companys_NN
own_JJ
products_NN
,_,
royalties_NN
where_RB
Shire_NN
has_VPRT
out-licensed_JJ
products_NN
to_PIN
third_JJ
parties_NN
and_PHC
licensing_GER
and_PHC
development_NOMZ
fees_NN
._.
Strategic_NN
review_NN
and_PHC
reorganization_NOMZ
In_PIN
2003_CD
,_,
the_DT
Company_NN
conducted_VBD
a_DT
detailed_JJ
strategic_JJ
review_NN
resulting_VBG [WZPRES]
in_PIN
revised_VBN
strategic_JJ
priorities_NOMZ
,_,
namely_CONJ
that_DEMO
the_DT
Company_NN
will_PRMD
:_:
search_NN
,_,
develop_VB
and_PHC
market_VB
but_CC
not_XX0
invent_VB
:_:
seek_VB
to_TO
acquire_VB
products_NN
with_PIN
substantive_JJ
patent_NN
protection_NOMZ
rather_RB
than_PIN
just_EMPH
three_CD
years_NN
Hatch-Waxman_NN
exclusivity_NOMZ
:_:
focus_VB
its_PIT
in-licensing_JJ
and_CC
merger_NN
and_PHC
acquisition_NOMZ
efforts_NN
on_PIN
the_DT
US_FPP1
market_NN
and_CC
obtain_VB
European_JJ
rights_NN
whenever_RB
possible_JJ
._.
As_IN
part_NN
of_PIN
this_DEMO
process_NN
,_,
Shire_NN
refocused_VBD
its_PIT
R&D_NN
efforts_NN
and_PHC
technology_NN
to_TO
concentrate_VB
on_PIN
areas_NN
where_RB
it_PIT
had_VBD
a_DT
commercial_JJ
presence_NN
and_CC
to_TO
create_VB
the_DT
flexibility_NOMZ
to_TO
add_VB [PUBV] [THATD]
new_JJ
therapeutic_JJ
areas_NN
based_VBN [WZPAST]
on_PIN
product_NN
acquisition_NOMZ
opportunities_NOMZ
._.
This_DEMO
approach_NN
aimed_VBN
to_TO
deliver_VB
the_DT
combined_VBN
benefit_NN
of_PIN
increased_VBN
returns_NN
and_CC
lower_JJ
risks_NN
._.
In_PIN
connection_NOMZ
with_PIN
the_DT
refocused_VBN
R&D_NN
efforts_NN
,_,
the_DT
Company_NN
decided_VBD [SUAV] [PRIV]
to_PIN
exit_NN
from_PIN
early-stage_JJ
therapeutic_JJ
research_NN
Lead_JJ
Optimization_NOMZ
in_PIN
2003_CD
,_,
to_TO
dispose_VB
of_PIN
certain_JJ
facilities_NOMZ
in_PIN
Canada_NN
see_VPRT [PRIV]
Note_NN
3_CD
and_CC
announced_VBD [PUBV]
the_DT
planned_VBN
disposal_NN
of_PIN
the_DT
vaccines_NN
business_NOMZ
._.
During_PIN
2004_CD
,_,
the_DT
Company_NN
announced_VBD [PUBV]
that_THVC
it_PIT
would_PRMD
continue_VB
to_TO
focus_VB
on_PIN
its_PIT
new_JJ
business_NOMZ
strategy_NN
,_,
including_VBG
taking_VBG
the_DT
following_JJ
actions_NOMZ
:_:
a_DT
North_PLACE
American_JJ
site_NN
consolidation_NOMZ
,_,
decreasing_VBG [PRESP]
the_DT
number_NN
of_PIN
operational_JJ
sites_NN
from_PIN
14_CD
to_PIN
6_CD
in_PIN
2004_CD
and_CC
the_DT
opening_GER
of_PIN
a_DT
new_JJ
US_FPP1
headquarters_NN
in_PIN
Wayne_NN
,_,
Pennsylvania_NN
:_:
the_DT
disposal_NN
of_PIN
the_DT
Companys_NN
vaccines_NN
business_NOMZ
to_PIN
ID_NN
Biomedical_NN
Corporation_NOMZ
IDB_NN
,_,
a_DT
Canadian_JJ
biotechnology_NN
company_NN
,_,
which_WDT [SERE]
was_VBD [PASS]
completed_VBN
in_PIN
the_DT
third_JJ
quarter_NN
of_PIN
2004_CD
see_VPRT [PRIV]
Note_NN
3_CD
:_:
and_ANDC
the_DT
out-licensing_GER
of_PIN
non-core_JJ
projects_NN
including_VBG [WZPRES]
the_DT
acute_JJ
myelogenous_JJ
leukemia_NN
treatment_NOMZ
TROXATYL_NN
troxacitabine_NN
to_PIN
Structural_NN
GenomiX_NN
Inc._NN
during_PIN
the_DT
third_JJ
quarter_NN
of_PIN
2004_CD
and_CC
SPD754_CD
for_PIN
the_DT
treatment_NOMZ
of_PIN
HIV_NN
to_PIN
Avexa_NN
Limited_NN
in_PIN
January_NN
2005_CD
._.
These_DEMO
changes_NN
have_VPRT [PEAS]
had_VBN
implications_NOMZ
for_PIN
both_DT
Shires_NN
organizational_JJ
structure_NN
and_CC
operating_VBG
sites_NN
._.
The_DT
Company_NN
has_VPRT
a_DT
new_JJ
global_JJ
management_NOMZ
structure_NN
aimed_VBN [WZPAST]
at_PIN
close_JJ
interaction_NOMZ
between_PIN
development_NOMZ
,_,
marketing_GER
and_PHC
sales_NN
,_,
and_ANDC
new_JJ
people_NN
in_PIN
key_JJ
positions_NOMZ
reporting_VBG [PUBV] [WZPRES]
directly_RB
to_PIN
the_DT
Chief_NN
Executive_NN
Officer_NN
._.
The_DT
Company_NN
expects_VPRT [PRIV]
to_TO
complete_VB
the_DT
North_PLACE
American_JJ
site_NN
consolidation_NOMZ
in_PIN
2005_CD
._.
To_TO
date_VB
the_DT
Company_NN
has_VPRT [PEAS]
recorded_VBN
$_$
48.5_CD
million_CD
of_PIN
costs_NN
associated_VBN [WZPAST]
with_PIN
this_DEMO
site_NN
consolidation_NOMZ
._.
Substantial_JJ
progress_NN
has_VPRT [PEAS]
been_VBN [PASS]
made_VBN
and_CC
the_DT
Company_NN
anticipates_VPRT [PRIV]
completing_VBG
the_DT
remaining_VBG
actions_NOMZ
in_PIN
2005_CD
._.
Remaining_VBG
costs_NN
associated_VBN [WZPAST]
with_PIN
the_DT
reorganization_NOMZ
are_VPRT [PASS]
estimated_VBN [PRIV]
to_TO
be_VB
approximately_RB
$_$
12_CD
million_CD
see_VPRT [PRIV]
Note_NN
3_CD
._.
There_EX
are_VPRT
inherent_JJ
risks_NN
associated_VBN [WZPAST]
with_PIN
any_QUAN
significant_JJ
organizational_JJ
change_NN
,_,
including_VBG [PRESP]
the_DT
possibility_NOMZ
of_PIN
disruption_NOMZ
to_PIN
the_DT
Companys_NN
business_NOMZ
or_CC
the_DT
loss_NN
of_PIN
key_JJ
personnel_NN
._.
Although_CONC
a_DT
project_NN
team_NN
has_VPRT [PEAS]
been_VBN [PASS]
set_VBN
up_RP
to_TO [SPIN]
actively_RB
manage_VB
the_DT
process_NN
and_CC
the_DT
associated_VBN
risks_NN
,_,
delays_NN
to_PIN
R&D_NN
projects_NN
,_,
failure_NN
to_TO
attain_VB
sales_NN
targets_NN
or_CC
other_JJ
disruption_NOMZ
to_PIN
the_DT
business_NOMZ
could_POMD
occur_VB
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
reorganization_NOMZ
._.
61_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
62_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
1_CD
Description_NOMZ
of_PIN
operations_NOMZ
continued_VBD
Markets_NN
The_DT
Companys_NN
principal_JJ
sources_NN
of_PIN
revenue_NN
from_PIN
its_PIT
primary_JJ
markets_NN
include_VPRT
:_:
in_PIN
the_DT
US_FPP1
,_,
ADDERALL_NN
XR_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
ADHD_NN
,_,
AGRYLIN_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
elevated_JJ
blood_NN
platelets_NN
,_,
PENTASA_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
ulcerative_JJ
colitis_NN
and_PHC
CARBATROL_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
epilepsy_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
Company_NN
receives_VPRT
royalties_NN
on_PIN
sales_NN
of_PIN
REMINYL_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
Alzheimers_NN
disease_NN
,_,
marketed_VBN [PASTP]
by_PIN
Janssen_NN
Pharmaceutica_NN
NV_NN
Janssen_NN
,_,
and_ANDC
on_PIN
EPIVIR_NN
,_,
COMBIVIR_NN
and_PHC
TRIZIVIR_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
HIV_NN
AIDS_NN
,_,
marketed_VBN [PASTP]
by_PIN
GSK_NN
:_:
in_PIN
the_DT
UK_NN
and_CC
the_DT
Republic_NN
of_PIN
Ireland_NN
,_,
the_DT
CALCICHEW_NN
range_NN
,_,
used_VBN [PASTP]
primarily_RB
as_IN
adjuncts_NN
in_PIN
the_DT
treatment_NOMZ
of_PIN
osteoporosis_NN
,_,
and_ANDC
REMINYL_NN
,_,
which_WDT [SERE]
was_VBD [PASS]
co-promoted_VBN
with_PIN
Janssen-Cilag_NN
until_IN
May_POMD
3_CD
,_,
2004_CD
._.
On_PIN
May_POMD
3_CD
,_,
2004_CD
,_,
the_DT
Company_NN
acquired_VBN [WZPAST]
from_PIN
Janssen-Cilag_NN
the_DT
exclusive_JJ
commercialization_NOMZ
rights_NN
to_PIN
REMINYL_NN
in_PIN
the_DT
UK_NN
and_PHC
Ireland_NN
:_:
in_PIN
Canada_NN
,_,
3TC_NN
and_PHC
COMBIVIR_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
HIV_NN
AIDS_NN
,_,
HEPTOVIR_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
hepatitis_NN
all_QUAN
marketed_VBN
in_PIN
partnership_NN
with_PIN
GSK_NN
and_PHC
AGRYLIN_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
elevated_JJ
blood_NN
platelets_NN
:_:
and_ANDC
in_PIN
the_DT
Rest_VB
of_PIN
the_DT
World_NN
,_,
royalties_NN
on_PIN
the_DT
sales_NN
of_PIN
ZEFFIX_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
Hepatitis_NN
B_NN
,_,
marketed_VBN [PASTP]
by_PIN
GSK_NN
,_,
and_ANDC
royalties_NN
on_PIN
sales_NN
of_PIN
REMINYL_NN
,_,
marketed_VBN [PASTP]
by_PIN
Janssen_NN
._.
In_CONJ
addition_NULL
to_PIN
the_DT
above_PLACE
,_,
the_DT
Company_NN
has_VPRT
a_DT
number_NN
of_PIN
products_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [SPAU] [PASS]
recently_TIME
approved_VBN
and_CC
projects_NN
that_TSUB
are_VPRT [BEMA]
currently_RB
in_PIN
registration_NOMZ
or_CC
late-stage_JJ
development_NOMZ
._.
These_DEMP
include_VPRT
:_:
Recently_TIME
approved_VBN
PENTASA_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
ulcerative_JJ
colitis_NN
._.
On_PIN
July_NN
8_CD
,_,
2004_CD
Shire_NN
received_VBD
FDA_NN
approval_NN
to_TO
market_VB
the_DT
500mg_JJ
dosage_NN
strength_NN
of_PIN
PENTASA_NN
in_PIN
the_DT
US_FPP1
:_:
ADDERALL_NN
XR_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
adults_NN
with_PIN
ADHD_NN
._.
On_PIN
August_NN
12_CD
,_,
2004_CD
,_,
the_DT
FDA_NN
approved_VBD
a_DT
once-daily_JJ
treatment_NOMZ
for_PIN
adults_NN
with_PIN
ADHD_NN
:_:
FOSRENOL_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
high_JJ
blood_NN
phosphate_NN
levels_NN
associated_VBN [WZPAST]
with_PIN
end-stage_JJ
renal_JJ
disease_NN
._.
On_PIN
October_NN
26_CD
,_,
2004_CD
Shire_NN
received_VBD
FDA_NN
approval_NN
to_PIN
market_NN
FOSRENOL_NN
in_PIN
250mg_CD
and_CC
500mg_CD
dosage_JJ
strength_NN
in_PIN
the_DT
US_FPP1
._.
Approval_NN
was_VBD [SPAU] [PASS]
also_RB
gained_VBN
in_PIN
Sweden_NN
on_PIN
March_NN
19_CD
,_,
2004_CD
,_,
and_ANDC
further_JJ
regulatory_JJ
approvals_NN
have_VPRT [PEAS]
been_VBN [PASS]
sought_VBN
in_PIN
a_DT
number_NN
of_PIN
other_JJ
EU_NN
Member_NN
States_NN
pursuant_JJ
to_PIN
the_DT
Mutual_JJ
Recognition_NOMZ
Process_NN
._.
Following_VBG
pricing_GER
and_PHC
reimbursement_NOMZ
discussions_NN
with_PIN
individual_JJ
countries_NN
,_,
the_DT
launch_NN
of_PIN
FOSRENOL_NN
in_PIN
Europe_NN
will_PRMD
be_VB [PASS]
phased_VBN
during_PIN
2005_CD
:_:
ADDERALL_NN
XR_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
ADHD_NN
._.
On_PIN
October_NN
28_CD
,_,
2004_CD
the_DT
FDA_NN
granted_VBD [SUAV]
an_DT
additional_JJ
six_CD
months_NN
of_PIN
market_NN
exclusivity_NOMZ
in_PIN
the_DT
US_FPP1
under_IN
the_DT
Hatch-Waxman_NN
regulations_NOMZ
._.
The_DT
additional_JJ
exclusivity_NOMZ
period_NN
will_PRMD
expire_VB
on_PIN
April_NN
11_CD
,_,
2005_CD
._.
The_DT
extension_NN
followed_VBD
submission_NN
of_PIN
data_NN
from_PIN
a_DT
clinical_JJ
program_NN
examining_VBG [WZPRES]
the_DT
effects_NN
of_PIN
ADDERALL_NN
XR_NN
in_PIN
adolescent_JJ
pediatric_JJ
patients_NN
._.
This_DEMO
data_NN
was_VBD [PASS]
submitted_VBN [PUBV]
in_PIN
response_NN
to_PIN
a_DT
Written_VBN [PUBV]
Request_NN
by_PIN
the_DT
FDA_NN
:_:
XAGRID_NN
trade_NN
name_NN
for_PIN
AGRYLIN_NN
in_PIN
EU_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
elevated_JJ
blood_NN
platelets_NN
._.
EU_NN
approval_NN
was_VBD [PASS]
received_VBN
in_PIN
November_NN
2004_CD
:_:
launch_NN
commenced_VBD
in_PIN
January_NN
2005_CD
and_CC
will_PRMD
be_VB [PASS]
phased_VBN
through_PIN
certain_JJ
countries_NN
in_PIN
Europe_NN
in_PIN
2005_CD
:_:
and_ANDC
EQUETRO_NN
previously_TIME
called_VBD
SPD417_NN
and_PHC
BIPOTROL_NN
for_PIN
bipolar_JJ
disorder_NN
._.
FDA_NN
approval_NN
was_VBD [PASS]
granted_VBN [SUAV]
in_PIN
December_NN
2004_CD
._.
Registration_NOMZ
MTS_NN
METHYPATCH_NN
,_,
a_DT
transdermal_JJ
delivery_NN
system_NN
for_PIN
the_DT
once-daily_JJ
treatment_NOMZ
of_PIN
ADHD_NN
._.
In_PIN
April_NN
2003_CD
Shire_NN
received_VBD
a_DT
not_XX0
approvable_JJ
letter_NN
from_PIN
the_DT
FDA_NN
._.
A_DT
program_NN
has_VPRT [PEAS]
been_VBN [PASS]
agreed_VBN [SUAV] [PUBV]
with_PIN
the_DT
FDA_NN
to_TO
address_VB
issues_NN
raised_VBN [WZPAST]
in_PIN
this_DEMO
letter_NN
and_CC
this_DEMO
work_NN
is_VPRT [BEMA]
currently_RB
ongoing_PRED
:_:
and_ANDC
ADDERALL_NN
XR_NN
adolescent_JJ
._.
In_PIN
September_NN
2004_CD
a_DT
supplemental_JJ
new_JJ
drug_NN
application_NOMZ
for_PIN
the_DT
use_NN
of_PIN
ADDERALL_NN
XR_NN
in_PIN
the_DT
adolescent_JJ
population_NOMZ
was_VBD [PASS]
submitted_VBN [PUBV]
to_PIN
the_DT
FDA_NN
._.
It_PIT
is_VPRT [PASS]
anticipated_VBN [PRIV]
that_THVC
a_DT
response_NN
to_PIN
this_DEMO
submission_NN
will_PRMD
be_VB [PASS]
received_VBN
during_PIN
the_DT
second_JJ
half_NN
of_PIN
2005_CD
._.
Late-stage_JJ
development_NOMZ
SPD503_CD
guanfacine_NN
for_PIN
ADHD_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
in_PIN
Phase_NN
III_NN
clinical_JJ
trials_NN
:_:
SPD476_CD
for_PIN
ulcerative_JJ
colitis_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
in_PIN
Phase_NN
III_NN
clinical_JJ
trials_NN
:_:
SPD465_NN
for_PIN
ADHD_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
in_PIN
Phase_NN
II_NN
clinical_JJ
trials_NN
:_:
SPD480_CD
,_,
which_WDT [SERE]
is_VPRT [BEMA]
a_DT
5-ASA_JJ
based_VBN
product_NN
formulated_VBN [WZPAST]
in_PIN
a_DT
single_JJ
dose_NN
,_,
2g_CD
and_CC
4g_CD
,_,
foam_NN
for_PIN
rectal_JJ
delivery_NN
in_PIN
the_DT
treatment_NOMZ
of_PIN
ulcerative_JJ
colitis_NN
._.
Rights_NN
to_PIN
key_JJ
global_JJ
markets_NN
were_VBD [PASS]
licensed_VBN
from_PIN
Giuliani_NN
SpA_NN
in_PIN
October_NN
2002_CD
._.
This_DEMO
product_NN
will_PRMD
provide_VB
an_DT
alternative_JJ
treatment_NOMZ
for_PIN
distal_JJ
rectal_JJ
ulcerative_JJ
colitis_NN
and_CC
has_VPRT [PEAS]
reached_VBN
Phase_NN
II_NN
development_NOMZ
:_:
and_ANDC
NRP104_NN
for_PIN
ADHD_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
in_PIN
Phase_NN
III_NN
clinical_JJ
trials_NN
._.
62_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
63_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
2_CD
Summary_NN
of_PIN
significant_JJ
accounting_GER
policies_NN
a_DT
Basis_NN
of_PIN
preparation_NOMZ
The_DT
accompanying_VBG
consolidated_JJ
financial_JJ
statements_NOMZ
include_VPRT
the_DT
accounts_NN
of_PIN
Shire_NN
and_CC
all_QUAN
of_PIN
its_PIT
subsidiary_NN
undertakings_GER
after_IN
elimination_NOMZ
of_PIN
intercompany_NN
accounts_NN
and_PHC
transactions_NOMZ
._.
b_NN
Use_NN
of_PIN
estimates_NN
in_PIN
consolidated_JJ
financial_JJ
statements_NOMZ
The_DT
preparation_NOMZ
of_PIN
consolidated_JJ
financial_JJ
statements_NOMZ
,_,
in_PIN
conformity_NOMZ
with_PIN
US_FPP1
generally_RB
accepted_VBD [PRIV]
accounting_GER
principles_NN
,_,
requires_VPRT [SUAV]
management_NOMZ
to_TO
make_VB
estimates_NN
and_PHC
assumptions_NOMZ
that_TSUB
affect_VPRT
the_DT
reported_VBN [PUBV]
amounts_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
,_,
the_DT
disclosure_NN
of_PIN
contingent_JJ
assets_NN
and_PHC
liabilities_NOMZ
at_PIN
the_DT
date_NN
of_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
and_CC
reported_VBD [PUBV]
amounts_NN
of_PIN
revenues_NN
and_PHC
expenses_NN
during_PIN
the_DT
reporting_GER
period_NN
._.
Actual_JJ
results_NN
could_POMD
differ_VB
from_PIN
those_DEMO
estimates_NN
._.
Estimates_NN
and_PHC
assumptions_NOMZ
are_VPRT [SPAU] [PASS]
primarily_RB
made_VBN
in_PIN
relation_NOMZ
to_PIN
provisions_NN
for_PIN
sales_NN
deductions_NOMZ
,_,
valuation_NOMZ
of_PIN
intangible_JJ
assets_NN
and_CC
fixed_VBN
asset_NN
investments_NOMZ
,_,
contingent_JJ
liabilities_NOMZ
and_CC
the_DT
valuation_NOMZ
of_PIN
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
._.
c_NN
Revenue_NN
recognition_NOMZ
The_DT
Company_NN
recognizes_VPRT [PRIV]
revenue_NN
when_RB
:_:
there_EX
is_VPRT
persuasive_JJ
evidence_NN
of_PIN
an_DT
agreement_NOMZ
or_CC
arrangement_NOMZ
:_:
delivery_NN
of_PIN
products_NN
has_VPRT [PEAS]
occurred_VBN
or_CC
services_NN
have_VPRT [PEAS]
been_VBN [PASS]
rendered_VBN
:_:
the_DT
sellers_NN
price_NN
to_PIN
the_DT
buyer_NN
is_VPRT [PASS]
fixed_VBN
or_CC
determinable_JJ
:_:
and_ANDC
collectability_NOMZ
is_VPRT [SPAU] [PASS]
reasonably_RB
assured_VBN
._.
The_DT
Companys_NN
principal_JJ
revenue_NN
streams_NN
and_CC
their_TPP3
respective_JJ
accounting_GER
treatments_NOMZ
are_VPRT [PASS]
discussed_VBN
below_PLACE
:_:
i_FPP1
Product_NN
sales_NN
Revenue_NN
for_PIN
the_DT
sales_NN
of_PIN
products_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
upon_PIN
shipment_NOMZ
to_PIN
customers_NN
or_CC
at_PIN
the_DT
time_NN
of_PIN
delivery_NN
depending_VBG [WZPRES]
on_PIN
the_DT
terms_NN
of_PIN
sale_NN
._.
Provisions_NN
for_PIN
rebates_NN
,_,
product_NN
returns_NN
and_PHC
discounts_NN
to_PIN
customers_NN
are_VPRT [PASS]
provided_VBN
for_PIN
as_IN
reductions_NOMZ
to_PIN
revenue_NN
in_PIN
the_DT
same_JJ
period_NN
as_IN
the_DT
related_JJ
sales_NN
are_VPRT [PASS]
recorded_VBN
._.
The_DT
Company_NN
monitors_NN
and_CC
tracks_VPRT
the_DT
amount_NN
of_PIN
rebates_NN
,_,
product_NN
returns_NN
and_PHC
discounts_NN
to_PIN
customers_NN
based_VBN [WZPAST]
on_PIN
historical_JJ
experience_NN
to_TO
estimate_VB [PRIV]
the_DT
amount_NN
of_PIN
reduction_NOMZ
to_PIN
revenue_NN
._.
ii_FW
Licensing_GER
and_PHC
development_NOMZ
fees_NN
Licensing_VBG [WZPRES]
and_CC
development_NOMZ
fees_NN
represent_VPRT
revenues_NN
derived_VBN [WZPAST]
from_PIN
product_NN
out-licensing_JJ
agreements_NOMZ
and_CC
from_PIN
contract_NN
R&D_NN
agreements_NOMZ
._.
Initial_JJ
license_NN
fees_NN
received_VBN [WZPAST]
in_PIN
connection_NOMZ
with_PIN
product_NN
out-licensing_JJ
agreements_NOMZ
,_,
even_RB
where_RB
such_JJ
fees_NN
are_VPRT [BEMA]
non-refundable_PRED
and_CC
not_XX0
creditable_JJ
against_PIN
future_JJ
royalty_NN
payments_NOMZ
,_,
are_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
over_IN
the_DT
period_NN
of_PIN
the_DT
license_NN
term_NN
,_,
or_CC
the_DT
period_NN
of_PIN
the_DT
associated_VBN
collaborative_JJ
assistance_NN
._.
In_PIN
circumstances_NN
where_RB
initial_JJ
license_NN
fees_NN
are_VPRT [BEMA]
not_XX0
for_PIN
a_DT
defined_VBN
period_NN
,_,
revenues_NN
are_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
over_IN
the_DT
period_NN
to_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
relevant_JJ
patent_NN
to_PIN
which_WDT [PIRE]
the_DT
license_NN
relates_VPRT
._.
Revenue_NN
from_PIN
contract_NN
R&D_NN
agreements_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
the_DT
services_NN
are_VPRT [PASS]
performed_VBN
._.
iii_FW
Royalty_NN
income_NN
Royalty_NN
income_NN
relating_VBG [WZPRES]
to_PIN
licensed_JJ
technology_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
the_DT
licensee_NN
sells_VPRT
the_DT
underlying_JJ
product_NN
._.
The_DT
Company_NN
receives_VPRT
sales_NN
information_NOMZ
from_PIN
the_DT
licensee_NN
on_PIN
a_DT
monthly_JJ
basis_NN
._.
For_PIN
any_QUAN
period_NN
that_TOBJ
the_DT
information_NOMZ
is_VPRT [BEMA]
not_XX0
available_PRED
,_,
the_DT
Company_NN
estimates_VPRT [PRIV]
sales_NN
amounts_NN
based_VBN [WZPAST]
on_PIN
the_DT
historical_JJ
product_NN
information_NOMZ
._.
Where_RB
applicable_JJ
,_,
all_QUAN
revenues_NN
are_VPRT [PASS]
stated_VBN [PUBV]
net_NN
of_PIN
value_NN
added_VBD [PUBV]
tax_NN
and_CC
similar_JJ
taxes_NN
,_,
and_ANDC
trade_NN
discounts_NN
._.
No_SYNE
revenue_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
for_PIN
consideration_NOMZ
,_,
the_DT
value_NN
or_CC
receipt_NN
of_PIN
which_WDT [PIRE]
is_VPRT [BEMA]
dependent_PRED
on_PIN
future_JJ
events_NN
,_,
future_JJ
performance_NN
,_,
or_CC
refund_NN
obligations_NOMZ
._.
iv_NN
Milestones_NN
During_PIN
the_DT
term_NN
of_PIN
certain_JJ
R&D_NN
agreements_NOMZ
and_PHC
licensing_GER
agreements_NOMZ
,_,
the_DT
Company_NN
receives_VPRT
non-refundable_JJ
milestones_NN
as_IN
certain_JJ
technical_JJ
targets_NN
are_VPRT [PASS]
achieved_VBN
._.
Revenues_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
achievement_NOMZ
of_PIN
such_JJ
milestones_NN
._.
The_DT
Company_NN
also_RB
receives_VPRT
non-refundable_JJ
clinical_JJ
milestones_NN
when_RB
certain_JJ
targets_NN
are_VPRT [PASS]
achieved_VBN
during_PIN
the_DT
clinical_JJ
phases_NN
of_PIN
development_NOMZ
,_,
such_JJ
as_IN
the_DT
submission_NN
of_PIN
clinical_JJ
data_NN
to_PIN
a_DT
regulatory_JJ
authority_NOMZ
._.
These_DEMO
clinical_JJ
milestones_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
receivable_JJ
i._NN
e._NN
on_PIN
completion_NOMZ
of_PIN
the_DT
relevant_JJ
phase_NN
._.
63_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
64_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
2_CD
Summary_NN
of_PIN
significant_JJ
accounting_GER
policies_NN
continued_VBD
d_SYM
Cost_NN
of_PIN
product_NN
sales_NN
Cost_NN
of_PIN
sales_NN
includes_VPRT
both_DT
the_DT
cost_NN
of_PIN
purchasing_VBG
finished_JJ
product_NN
for_PIN
sale_NN
,_,
together_RB
with_PIN
the_DT
cost_NN
of_PIN
raw_JJ
materials_NN
and_CC
manufacturing_VBG
for_PIN
those_DEMO
products_NN
that_TSUB
are_VPRT [BYPA]
manufactured_VBN
by_PIN
Shire_NN
._.
Royalties_NN
that_TSUB
are_VPRT [BEMA]
payable_PRED
on_PIN
those_DEMO
products_NN
that_TSUB
Shire_VPRT
does_VPRT
not_XX0
own_VB
the_DT
rights_NN
to_TO
are_VB [SPAU] [PASS]
also_RB
included_VBN
in_PIN
cost_NN
of_PIN
sales_NN
._.
e_LS
R&D_NN
R&D_NN
expenditures_NN
include_VPRT
funded_VBN
and_CC
unfunded_JJ
expenditures_NN
and_CC
are_VPRT [PASS]
charged_VBN
to_PIN
operations_NOMZ
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
the_DT
expense_NN
is_VPRT [PASS]
incurred_VBN
._.
f_LS
Leased_VBN
assets_NN
The_DT
costs_NN
of_PIN
operating_VBG
leases_NN
are_VPRT [PASS]
charged_VBN
to_PIN
operations_NOMZ
on_PIN
a_DT
straight-line_JJ
basis_NN
over_IN
the_DT
lease_NN
term_NN
,_,
even_RB
if_COND
rental_JJ
payments_NOMZ
are_VPRT [PASS]
not_XX0
made_VBN
on_PIN
such_EMPH
a_NULL
basis_NN
._.
Assets_NN
acquired_VBN
under_IN
capital_NN
leases_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
balance_NN
sheet_NN
as_IN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
are_VPRT [PASS]
depreciated_VBN
over_IN
the_DT
shorter_JJ
of_PIN
the_DT
period_NN
of_PIN
the_DT
lease_NN
or_CC
their_TPP3
useful_JJ
lives_NN
._.
The_DT
capital_NN
elements_NOMZ
of_PIN
future_JJ
lease_NN
payments_NOMZ
are_VPRT [PASS]
recorded_VBN
as_IN
liabilities_NOMZ
,_,
while_OSUB
the_DT
interest_NN
element_NOMZ
is_VPRT [PASS]
charged_VBN
to_PIN
operations_NOMZ
over_IN
the_DT
period_NN
of_PIN
the_DT
lease_NN
to_TO
produce_VB
a_DT
level_NN
yield_NN
on_PIN
the_DT
balance_NN
of_PIN
the_DT
capital_NN
lease_NN
obligation_NOMZ
._.
g_NN
Finance_NN
costs_NN
of_PIN
debt_NN
Finance_NN
costs_NN
of_PIN
debt_NN
are_VPRT [PASS]
recorded_VBN
as_IN
a_DT
deferred_JJ
asset_NN
and_CC
then_RB
amortized_VBD
to_PIN
the_DT
statement_NOMZ
of_PIN
operations_NOMZ
over_IN
the_DT
term_NN
of_PIN
the_DT
debt_NN
,_,
using_VBG [PRESP]
the_DT
effective_JJ
interest_NN
rate_NN
method_NN
._.
Deferred_JJ
financing_GER
costs_NN
relating_VBG [WZPRES]
to_PIN
debt_NN
extinguishments_NOMZ
are_VPRT [PASS]
written_VBN [PUBV]
off_PIN
and_CC
reflected_VBN [PRIV]
in_PIN
interest_NN
expense_NN
in_PIN
the_DT
consolidated_JJ
statements_NOMZ
of_PIN
operations_NOMZ
._.
h_NN
Income_NN
taxes_NN
The_DT
Company_NN
provides_VPRT
for_PIN
income_NN
taxes_NN
in_PIN
accordance_NN
with_PIN
Statement_NOMZ
of_PIN
Financial_NN
Accounting_GER
Standards_NN
SFAS_NN
No._NN
._.
Deferred_JJ
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
provided_VBN
for_PIN
differences_NN
between_PIN
the_DT
carrying_VBG
amounts_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
in_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
and_CC
the_DT
tax_NN
bases_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
that_TSUB
will_PRMD
result_VB
in_PIN
future_JJ
taxable_JJ
or_CC
deductible_JJ
amounts_NN
._.
The_DT
deferred_JJ
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
measured_VBN
using_VBG
the_DT
enacted_VBN
tax_NN
laws_NN
and_PHC
rates_NN
applicable_JJ
to_PIN
the_DT
periods_NN
in_PIN
which_WDT [PIRE]
the_DT
differences_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
affect_VB
taxable_JJ
income_NN
._.
Income_NN
tax_NN
expense_NN
is_VPRT [PASS]
computed_VBN
as_IN
the_DT
tax_NN
payable_JJ
or_CC
refundable_JJ
for_PIN
the_DT
period_NN
,_,
plus_PIN
or_CC
minus_PIN
the_DT
change_NN
during_PIN
the_DT
period_NN
in_PIN
deferred_JJ
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
._.
Deferred_JJ
tax_NN
assets_NN
are_VPRT [BYPA]
reduced_VBN
by_PIN
a_DT
valuation_NOMZ
allowance_NN
when_RB
,_,
in_PIN
the_DT
opinion_NN
of_PIN
management_NOMZ
,_,
it_PIT
is_VPRT [BEMA]
more_EMPH
likely_PRED
than_PIN
not_XX0
that_DEMO
some_QUAN
portion_NOMZ
or_CC
all_QUAN
of_PIN
the_DT
deferred_JJ
tax_NN
assets_NN
will_PRMD
not_XX0
be_VB [PASS]
realized_VBN [PRIV]
._.
i_FPP1
Earnings_GER
per_PIN
share_NN
Earnings_GER
per_PIN
share_NN
is_VPRT [PASS]
computed_VBN
in_PIN
accordance_NN
with_PIN
SFAS_NN
No._NN
._.
Basic_JJ
earnings_GER
per_PIN
share_NN
is_VPRT [PASS]
based_VBN
upon_PIN
net_JJ
income_NN
available_JJ
to_PIN
ordinary_JJ
shareholders_NN
divided_VBN [WZPAST]
by_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
ordinary_JJ
shares_NN
outstanding_JJ
during_PIN
the_DT
period_NN
._.
Diluted_JJ
earnings_GER
per_PIN
share_NN
is_VPRT [PASS]
based_VBN
upon_PIN
adjusted_JJ
net_JJ
income_NN
available_JJ
to_PIN
ordinary_JJ
shareholders_NN
divided_VBN [WZPAST]
by_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
ordinary_JJ
share_NN
equivalents_NN
outstanding_JJ
during_PIN
the_DT
period_NN
,_,
adjusted_VBN [PASTP]
for_PIN
the_DT
effect_NN
of_PIN
all_QUAN
dilutive_JJ
potential_JJ
ordinary_JJ
shares_NN
that_TSUB
were_VBD [BEMA]
outstanding_PRED
during_PIN
the_DT
year_NN
._.
Such_JJ
potentially_RB
dilutive_JJ
shares_NN
are_VPRT [PASS]
excluded_VBN
when_RB
the_DT
effect_NN
would_PRMD
be_VB
to_TO
increase_VB
earnings_GER
per_PIN
share_NN
or_CC
reduce_VB
a_DT
loss_NN
per_PIN
share_NN
._.
j_NN
Advertising_GER
expense_NN
The_DT
Company_NN
expenses_NN
the_DT
cost_NN
of_PIN
advertising_GER
as_IN
incurred_VBN
._.
Advertising_GER
costs_NN
amounted_VBD
to_TO
$_$
47.6_CD
million_CD
,_,
$_$
40.7_CD
million_CD
,_,
and_ANDC
$_$
45.6_CD
million_CD
for_PIN
the_DT
years_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
,_,
2003_CD
and_CC
2002_CD
respectively_RB
._.
k_NN
Foreign_JJ
currency_NN
Monetary_NN
assets_NN
and_PHC
liabilities_NOMZ
in_PIN
foreign_JJ
currencies_NN
are_VPRT [PASS]
translated_VBN
into_PIN
the_DT
relevant_JJ
functional_JJ
currency_NN
at_PIN
the_DT
rate_NN
of_PIN
exchange_NN
ruling_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Transactions_NOMZ
in_PIN
foreign_JJ
currencies_NN
are_VPRT [PASS]
translated_VBN
into_PIN
the_DT
relevant_JJ
functional_JJ
currency_NN
at_PIN
the_DT
rate_NN
of_PIN
exchange_NN
ruling_NN
at_PIN
the_DT
date_NN
of_PIN
the_DT
transaction_NOMZ
._.
Transaction_NOMZ
gains_NN
and_PHC
losses_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
arriving_VBG
at_PIN
operating_VBG
net_JJ
income_NN
._.
The_DT
results_NN
of_PIN
overseas_PLACE
operations_NOMZ
,_,
whose_WPS
functional_JJ
currency_NN
is_VPRT
not_XX0
US_FPP1
dollars_NN
,_,
are_VPRT [PASS]
translated_VBN
at_PIN
the_DT
average_JJ
rates_NN
of_PIN
exchange_NN
during_PIN
the_DT
period_NN
and_CC
their_TPP3
balance_NN
sheets_NN
at_PIN
the_DT
rates_NN
ruling_VBG [SUAV] [WZPRES]
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
The_DT
cumulative_JJ
effect_NN
of_PIN
exchange_NN
rate_NN
movements_NOMZ
is_VPRT [PASS]
included_VBN
in_PIN
a_DT
separate_JJ
component_NN
of_PIN
other_JJ
comprehensive_JJ
income_NN
._.
Foreign_JJ
currency_NN
exchange_NN
transaction_NOMZ
gains_NN
and_PHC
losses_NN
on_PIN
an_DT
after-tax_JJ
basis_NN
included_VBD
in_PIN
consolidated_JJ
net_JJ
income_NN
in_PIN
the_DT
years_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
,_,
2003_CD
and_CC
2002_CD
,_,
amounted_VBD
to_PIN
a_DT
$_$
2.5_CD
million_CD
loss_NN
,_,
$_$
6.7_CD
million_CD
loss_NN
and_CC
$_$
0.3_CD
million_CD
loss_NN
,_,
respectively_RB
._.
64_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
65_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
2_CD
Summary_NN
of_PIN
significant_JJ
accounting_GER
policies_NN
continued_VBD
l_NN
Employee_NN
stock_NN
plans_VPRT
The_DT
Company_NN
accounts_NN
for_PIN
its_PIT
stock_NN
options_NOMZ
using_VBG [WZPRES]
the_DT
intrinsic-value_JJ
method_NN
prescribed_VBN [WZPAST]
in_PIN
Accounting_GER
Principles_NN
Board_NN
Opinion_NN
No._NN
._.
25_CD
,_,
Accounting_GER
for_PIN
Stock_NN
Issued_NN
to_PIN
Employees_NN
APB_NN
No._NN
._.
Accordingly_RB
,_,
compensation_NOMZ
cost_NN
of_PIN
stock_NN
options_NOMZ
is_VPRT [PASS]
measured_VBN
as_IN
the_DT
excess_NN
,_,
if_COND
any_QUAN
,_,
of_PIN
the_DT
quoted_VBN
market_NN
price_NN
of_PIN
Shires_NN
ordinary_JJ
shares_NN
at_PIN
the_DT
measurement_NOMZ
date_NN
over_IN
the_DT
option_NOMZ
exercise_NN
price_NN
and_CC
is_VPRT [PASS]
charged_VBN
to_PIN
operations_NOMZ
over_IN
the_DT
vesting_JJ
period_NN
._.
For_PIN
plans_NN
where_RB
the_DT
measurement_NOMZ
date_NN
occurs_VPRT
after_IN
the_DT
grant_NN
date_NN
,_,
referred_VBD
to_PIN
as_IN
variable_JJ
plans_NN
,_,
compensation_NOMZ
cost_NN
is_VPRT [BEMA]
re-measured_PRED
on_PIN
the_DT
basis_NN
of_PIN
the_DT
current_JJ
market_NN
value_NN
of_PIN
Shires_NN
ordinary_JJ
shares_NN
at_PIN
the_DT
end_NN
of_PIN
each_QUAN
reporting_GER
period_NN
._.
The_DT
Company_NN
recognizes_VPRT [PRIV]
compensation_NOMZ
expense_NN
for_PIN
variable_JJ
plans_NN
with_PIN
performance_NN
conditions_NOMZ
if_COND
achievement_NOMZ
of_PIN
those_DEMO
conditions_NOMZ
becomes_VPRT
probable_JJ
._.
123_CD
,_,
Accounting_GER
for_PIN
Stock-Based_NN
Compensation_NOMZ
SFAS_NN
No._NN
._.
123_CD
,_,
the_DT
Company_NN
has_VPRT [PEAS]
included_VBN
in_PIN
these_DEMO
financial_JJ
statements_NOMZ
the_DT
required_JJ
pro-forma_FW
disclosures_NN
as_IN
if_COND
the_DT
fair-value_JJ
method_NN
of_PIN
accounting_GER
had_VBD [PEAS]
been_VBN [PASS]
applied_VBN
._.
As_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
,_,
the_DT
Company_NN
had_VBD
six_CD
stock-based_JJ
employee_NN
compensation_NOMZ
plans_NN
,_,
which_WDT [SERE]
are_VPRT [PASS]
described_VBN
more_EMPH
fully_AMP
in_PIN
Note_NN
28_CD
._.
The_DT
following_VBG
table_NN
illustrates_VPRT
the_DT
effect_NN
on_PIN
net_JJ
income_NN
and_PHC
earnings_GER
per_PIN
share_NN
if_COND
the_DT
Company_NN
had_VBD [PEAS]
applied_VBN
the_DT
fair_JJ
value_NN
recognition_NOMZ
provisions_NN
of_PIN
SFAS_NN
No._NN
._.
2004 2003 2002_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
Net_JJ
income_NN
,_,
as_IN
reported_VBN [PUBV]
269,007_CD
276,051_CD
250,569_CD
Add_VPRT [PUBV]
Stock-based_JJ
employee_NN
compensation_NOMZ
charge_NN
credit_NN
included_VBN [WZPAST]
in_PIN
reported_JJ
net_JJ
income_NN
,_,
net_NN
of_PIN
related_JJ
tax_NN
effects_NN
216_CD
24_CD
166_CD
Deduct_NN
Total_NN
stock-based_JJ
employee_NN
compensation_NOMZ
expense_NN
determined_VBN [SUAV] [PRIV]
under_IN
fair_JJ
value-based_JJ
method_NN
for_PIN
all_QUAN
awards_NN
32,966_CD
31,956_CD
24,084_CD
Pro-forma_JJ
net_JJ
income_NN
236,257_CD
244,071_CD
226,319_CD
2004 2003 2002_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
Earnings_GER
per_PIN
share_NN
As_IN
reported_VBN [PUBV]
basic_JJ
54.2_CD
55.4_CD
50.0_CD
As_IN
reported_VBN [PUBV]
diluted_VBN
53.3_CD
54.2_CD
49.0_CD
Pro-forma_JJ
basic_JJ
47.6_CD
49.0_CD
45.2_CD
Pro-forma_JJ
diluted_VBN
46.9_CD
48.0_CD
44.4_CD
The_DT
fair_JJ
value_NN
of_PIN
stock_NN
options_NOMZ
used_VBN
to_TO
compute_VB
pro-forma_FW
net_JJ
income_NN
and_CC
per_PIN
share_NN
disclosures_NN
represents_VPRT
the_DT
estimated_VBN [PRIV]
present_JJ
value_NN
at_PIN
grant_NN
date_NN
using_VBG [WZPRES]
the_DT
Black-Scholes_NN
option-pricing_GER
model_NN
with_PIN
the_DT
following_VBG
weighted_JJ
average_JJ
assumptions_NOMZ
:_:
Year_NN
to_PIN
December_NN
31_CD
,_,
2004 2003 2002_CD
Risk-free_JJ
interest_NN
rate_NN
2.46-4_CD
.19_CD
%_NN
1.89-3_CD
.40_CD
%_NN
1.90-5_CD
.33_CD
%_NN
Expected_VBN [PRIV]
dividend_NN
yield_NN
0_CD
%_NN
:_:
0.6_CD
%_NN
0_CD
%_NN
0_CD
%_NN
Expected_VBN [PRIV]
life_NN
5_CD
years_NN
5_CD
years_NN
5_CD
years_NN
Expected_VBN [PRIV]
volatility_NOMZ
48.8_CD
%_NN
60.0_CD
%_NN
55.2_CD
%_NN
m_NN
Cash_NN
and_PHC
cash_NN
equivalents_NN
Cash_NN
and_PHC
cash_NN
equivalents_NN
are_VPRT [PASS]
defined_VBN
as_IN
short-term_JJ
highly_AMP
liquid_JJ
investments_NOMZ
with_PIN
original_JJ
maturities_NOMZ
of_PIN
90_CD
days_NN
or_CC
less_JJ
._.
n_JJ
Short-term_JJ
investments_NOMZ
Short-term_JJ
investments_NOMZ
consist_VPRT
of_PIN
commercial_JJ
paper_NN
and_CC
institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
._.
In_PIN
accordance_NN
with_PIN
SFAS_NN
No._NN
._.
115_CD
,_,
Accounting_GER
for_PIN
Certain_NN
Investments_NOMZ
in_PIN
Debt_NN
and_PHC
Equity_NOMZ
Securities_NOMZ
SFAS_NN
No._NN
._.
115_CD
,_,
and_ANDC
based_VBN
on_PIN
the_DT
Companys_NN
intentions_NOMZ
regarding_VBG [WZPRES]
these_DEMO
instruments_NOMZ
,_,
the_DT
Company_NN
has_VPRT [PEAS]
classified_VBN
all_QUAN
short-term_JJ
investments_NOMZ
as_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
,_,
as_IN
available-for-sale_JJ
._.
Institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
are_VPRT [BEMA]
short-term_JJ
money_NN
market_NN
instruments_NOMZ
,_,
including_VBG
bank_NN
and_PHC
building_GER
society_NN
term_NN
deposits_NN
and_CC
other_JJ
debt_NN
securities_NOMZ
from_PIN
a_DT
variety_NN
of_PIN
companies_NN
with_PIN
strong_JJ
credit_NN
ratings_GER
._.
o_NN
Inventories_NN
Inventories_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
including_VBG [WZPRES]
manufacturing_GER
overheads_NN
,_,
where_RB
appropriate_JJ
or_CC
net_JJ
realizable_JJ
value_NN
._.
Net_JJ
realizable_JJ
value_NN
is_VPRT [PASS]
based_VBN
on_PIN
estimated_VBN [PRIV]
normal_JJ
selling_GER
price_NN
less_RB
further_JJ
costs_NN
expected_VBN [PRIV]
to_TO
be_VB [PASS]
incurred_VBN
to_PIN
completion_NOMZ
and_PHC
disposal_NN
._.
65_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
66_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
2_CD
Summary_NN
of_PIN
significant_JJ
accounting_GER
policies_NN
continued_VBD
p_JJ
Investments_NOMZ
The_DT
Company_NN
has_VPRT
certain_JJ
investments_NOMZ
in_PIN
pharmaceutical_JJ
and_CC
biotechnology_NN
companies_NN
._.
Investments_NOMZ
are_VPRT [PASS]
accounted_VBN
for_PIN
using_VBG
the_DT
equity-method_NN
of_PIN
accounting_GER
if_COND
the_DT
investment_NOMZ
gives_VPRT
the_DT
Company_NN
the_DT
ability_NOMZ
to_TO
exercise_VB
significant_JJ
influence_NN
,_,
but_CC
not_XX0
control_VB
over_RP
,_,
the_DT
investee_NN
._.
Significant_JJ
influence_NN
is_VPRT [SPAU] [PASS]
generally_RB
deemed_VBN [PRIV]
to_TO
exist_VB
if_COND
the_DT
Company_NN
has_VPRT
an_DT
ownership_NN
interest_NN
in_PIN
the_DT
voting_NN
stock_NN
of_PIN
the_DT
investee_NN
between_PIN
20_CD
%_NN
and_CC
50_CD
%_NN
,_,
although_CONC
other_JJ
factors_NN
,_,
such_JJ
as_IN
representation_NOMZ
on_PIN
the_DT
investees_NN
Board_NN
of_PIN
Directors_NN
and_CC
the_DT
impact_NN
of_PIN
commercial_JJ
arrangements_NOMZ
,_,
are_VPRT [PASS]
considered_VBN [PRIV]
in_PIN
determining_VBG [SUAV] [PRIV]
whether_IN [WHCL]
the_DT
equity-method_NN
of_PIN
accounting_GER
is_VPRT [BEMA]
appropriate_PRED
._.
Under_IN
the_DT
equity-method_NN
of_PIN
accounting_GER
,_,
the_DT
Company_NN
records_NN
its_PIT
investments_NOMZ
in_PIN
equity-method_JJ
investees_NN
in_PIN
the_DT
consolidated_JJ
balance_NN
sheet_NN
as_IN
Investments_NOMZ
equity-method_JJ
investments_NOMZ
and_CC
its_PIT
share_NN
of_PIN
the_DT
investees_NN
earnings_GER
or_CC
losses_NN
together_RB
with_PIN
other-than-temporary_JJ
impairments_NOMZ
in_PIN
value_NN
as_IN
Equity_NOMZ
in_PIN
losses_NN
earnings_GER
of_PIN
equity-method_JJ
investees_NN
in_PIN
the_DT
consolidated_JJ
statement_NOMZ
of_PIN
operations_NOMZ
._.
All_QUAN
other_JJ
equity_NOMZ
investments_NOMZ
,_,
which_WDT [SERE]
consist_VPRT
of_PIN
investments_NOMZ
for_PIN
which_WDT [PIRE]
the_DT
Company_NN
does_VPRT
not_XX0
have_VB
the_DT
ability_NOMZ
to_TO
exercise_VB
significant_JJ
influence_NN
,_,
are_VPRT [PASS]
accounted_VBN
for_PIN
under_IN
the_DT
cost_NN
method_NN
or_CC
at_PIN
fair_JJ
value_NN
._.
Investments_NOMZ
in_PIN
private_JJ
companies_NN
are_VPRT [PASS]
carried_VBN
at_PIN
cost_NN
,_,
less_JJ
provisions_NN
for_PIN
other-than-temporary_JJ
impairment_NOMZ
in_PIN
value_NN
._.
For_PIN
public_JJ
companies_NN
that_TSUB
have_VPRT
readily_RB
determinable_JJ
fair_JJ
values_NN
,_,
the_DT
Company_NN
classifies_VPRT
its_PIT
equity_NOMZ
investments_NOMZ
as_IN
available-for-sale_JJ
and_CC
,_,
accordingly_RB
,_,
records_NN
these_DEMO
investments_NOMZ
at_PIN
their_TPP3
fair_JJ
values_NN
with_PIN
unrealized_JJ
gains_NN
and_PHC
losses_NN
included_VBD
in_PIN
the_DT
consolidated_JJ
statements_NOMZ
of_PIN
comprehensive_JJ
income_NN
,_,
net_NN
of_PIN
any_QUAN
related_JJ
tax_NN
effect_NN
._.
Realized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
and_PHC
declines_NN
in_PIN
value_NN
judged_VBN [PRIV]
to_TO
be_VB [BEMA]
other-than-temporary_PRED
on_PIN
available-for-sale_JJ
securities_NOMZ
are_VPRT [PASS]
included_VBN
in_PIN
other_JJ
expense_NN
,_,
net_JJ
see_VPRT [PRIV]
Note_NN
24_CD
._.
The_DT
cost_NN
of_PIN
securities_NOMZ
sold_VBN [WZPAST]
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
specific_JJ
identification_NOMZ
method_NN
._.
Interest_NN
and_PHC
dividends_NN
on_PIN
securities_NOMZ
classified_VBN
as_IN
available-forsale_NN
are_VPRT [PASS]
included_VBN
as_IN
interest_NN
income_NN
._.
q_NN
Goodwill_NN
and_CC
other_JJ
intangible_JJ
assets_NN
i_FPP1
Goodwill_NN
In_PIN
a_DT
business_NOMZ
combination_NOMZ
,_,
goodwill_NN
represents_VPRT
the_DT
excess_NN
of_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
consideration_NOMZ
given_VBN
over_IN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
identifiable_JJ
assets_NN
and_PHC
liabilities_NOMZ
acquired_VBN
._.
Goodwill_NN
and_CC
other_JJ
intangibles_NN
with_PIN
indefinite_JJ
lives_NN
are_VPRT [PASS]
not_XX0
amortized_VBN
to_PIN
operations_NOMZ
,_,
but_CC
instead_CONJ
are_VPRT [PASS]
reviewed_VBN
for_PIN
impairment_NOMZ
,_,
at_PIN
least_JJ
annually_RB
,_,
or_CC
when_RB
there_EX
is_VPRT
an_DT
indicator_NN
of_PIN
impairment_NOMZ
._.
The_DT
Company_NN
has_VPRT
no_SYNE
intangible_JJ
assets_NN
with_PIN
indefinite_JJ
useful_JJ
lives_NN
,_,
other_JJ
than_PIN
goodwill_NN
._.
The_DT
Company_NN
has_VPRT [PEAS]
determined_VBN [SUAV] [PRIV]
that_THVC
there_EX
are_VPRT
no_SYNE
impairment_NOMZ
losses_NN
for_PIN
any_QUAN
of_PIN
the_DT
reporting_GER
periods_NN
covered_VBN [WZPAST]
by_PIN
these_DEMO
financial_JJ
statements_NOMZ
._.
ii_FW
Other_JJ
intangible_JJ
assets_NN
Other_JJ
intangible_JJ
assets_NN
,_,
which_WDT [SERE]
comprise_VPRT
intellectual_JJ
property_NN
including_VBG [WZPRES]
trade_NN
marks_NN
for_PIN
products_NN
with_PIN
a_DT
defined_VBN
revenue_NN
stream_NN
namely_CONJ
commercial_JJ
products_NN
or_CC
rights_NN
to_PIN
products_NN
awaiting_VBG [WZPRES]
final_JJ
regulatory_JJ
approval_NN
,_,
are_VPRT [PASS]
recorded_VBN
at_PIN
cost_NN
and_CC
amortized_VBN
over_IN
the_DT
estimated_VBN [PRIV]
useful_JJ
life_NN
of_PIN
the_DT
related_JJ
product_NN
,_,
which_WDT [SERE]
ranges_VPRT
from_PIN
5_CD
to_PIN
35_CD
years_NN
weighted_VBN
average_JJ
23_CD
years_NN
._.
Intellectual_NN
property_NN
with_PIN
no_DT
defined_VBN
revenue_NN
stream_NN
,_,
where_RB
the_DT
related_JJ
product_NN
has_VPRT [PEAS]
not_XX0
yet_RB
completed_VBN
the_DT
necessary_JJ
approval_NN
process_NN
,_,
is_VPRT [PASS]
written_VBN [PUBV]
off_PIN
to_PIN
operations_NOMZ
on_PIN
acquisition_NOMZ
._.
The_DT
following_VBG
factors_NN
are_VPRT [PASS]
considered_VBN [PRIV]
in_PIN
estimating_VBG [PRIV]
useful_JJ
lives_NN
._.
Where_RB
an_DT
intangible_JJ
asset_NN
is_VPRT [BEMA]
a_DT
composite_NN
of_PIN
a_DT
number_NN
of_PIN
factors_NN
,_,
the_DT
period_NN
of_PIN
amortization_NOMZ
is_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
from_PIN
considering_VBG [PRIV]
these_DEMO
factors_NN
together_RB
:_:
expected_VBN [PRIV]
use_NN
of_PIN
the_DT
asset_NN
:_:
regulatory_JJ
,_,
legal_JJ
or_CC
contractual_JJ
provisions_NN
,_,
including_VBG [PRESP]
the_DT
regulatory_JJ
approval_NN
and_PHC
review_NN
process_NN
,_,
patent_NN
issues_NN
and_PHC
actions_NOMZ
by_PIN
government_NOMZ
agencies_NN
:_:
the_DT
effects_NN
of_PIN
obsolescence_NN
,_,
changes_NN
in_PIN
demand_NN
,_,
competing_VBG
products_NN
and_CC
other_JJ
economic_JJ
factors_NN
,_,
including_VBG [PRESP]
the_DT
stability_NOMZ
of_PIN
the_DT
market_NN
,_,
known_VBN [PRIV]
technological_JJ
advances_NN
,_,
development_NOMZ
of_PIN
competing_VBG
drugs_NN
that_TSUB
are_VPRT [BEMA]
more_EMPH
effective_JJ
clinically_RB
or_CC
economically_RB
:_:
and_ANDC
actions_NOMZ
of_PIN
competitors_NN
,_,
suppliers_NN
,_,
regulatory_JJ
agencies_NN
or_CC
others_NN
that_TSUB
may_POMD
eliminate_VB
current_JJ
competitive_JJ
advantages_NN
._.
66_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
67_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
2_CD
Summary_NN
of_PIN
significant_JJ
accounting_GER
policies_NN
continued_VBD
r_NN
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
is_VPRT [PASS]
shown_VBN [PRIV]
at_PIN
cost_NN
,_,
less_JJ
accumulated_VBN
depreciation_NOMZ
and_CC
any_QUAN
impairment_NOMZ
._.
The_DT
cost_NN
of_PIN
significant_JJ
assets_NN
includes_VPRT
capitalized_JJ
interest_NN
incurred_VBN [WZPAST]
during_PIN
the_DT
construction_NOMZ
period_NN
._.
Depreciation_NOMZ
is_VPRT [PASS]
provided_VBN
on_PIN
a_DT
straight-line_JJ
basis_NN
at_PIN
rates_NN
calculated_VBN [PRIV]
to_TO
write_VB [PUBV]
off_PIN
the_DT
cost_NN
less_JJ
estimated_VBN [PRIV]
residual_JJ
value_NN
of_PIN
each_QUAN
asset_NN
over_IN
its_PIT
estimated_VBN [PRIV]
useful_JJ
life_NN
as_IN
follows_VPRT
:_:
Buildings_GER
20-50_CD
years_NN
Office_NN
furniture_NN
,_,
fittings_GER
and_PHC
equipment_NOMZ
4-10_CD
years_NN
Warehouse_NN
,_,
laboratory_NN
and_PHC
manufacturing_GER
equipment_NOMZ
4-10_CD
years_NN
The_DT
cost_NN
of_PIN
land_NN
is_VPRT [PASS]
not_XX0
depreciated_VBN
._.
Expenditures_NN
for_PIN
maintenance_NN
and_PHC
repairs_NN
are_VPRT [PASS]
charged_VBN
to_PIN
operations_NOMZ
as_IN
incurred_VBN
._.
The_DT
costs_NN
of_PIN
major_JJ
renewals_NN
and_PHC
improvements_NOMZ
are_VPRT [PASS]
capitalized_VBN
._.
At_PIN
the_DT
time_NN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
is_VPRT [PASS]
retired_VBN
or_CC
otherwise_CONJ
disposed_JJ
of_PIN [STPR]
,_,
the_DT
cost_NN
and_CC
accumulated_VBN
depreciation_NOMZ
are_VPRT [PASS]
eliminated_VBN
from_PIN
the_DT
asset_NN
and_CC
accumulated_VBN
depreciation_NOMZ
accounts_NN
._.
The_DT
profit_NN
or_CC
loss_NN
on_PIN
such_JJ
disposition_NOMZ
is_VPRT [PASS]
reflected_VBN [PRIV]
in_PIN
operating_VBG
income_NN
._.
s_PRP
Valuation_NOMZ
and_PHC
impairment_NOMZ
of_PIN
long-lived_JJ
assets_NN
other_JJ
than_PIN
goodwill_NN
and_PHC
investments_NOMZ
The_DT
Company_NN
evaluates_VPRT
the_DT
carrying_VBG
value_NN
of_PIN
long-lived_JJ
assets_NN
other_JJ
than_PIN
goodwill_NN
and_PHC
investments_NOMZ
for_PIN
impairment_NOMZ
whenever_RB
events_NN
or_CC
changes_NN
in_PIN
circumstances_NN
indicate_VPRT [PRIV]
that_THVC
the_DT
carrying_VBG
amounts_NN
of_PIN
the_DT
assets_NN
may_POMD
not_XX0
be_VB [BEMA]
recoverable_PRED
._.
When_RB
such_EMPH
a_NULL
determination_NOMZ
is_VPRT [PASS]
made_VBN
,_,
managements_NOMZ
estimate_NN
of_PIN
undiscounted_JJ
cash_NN
flows_VPRT
to_TO
be_VB [BYPA]
generated_VBN
by_PIN
the_DT
assets_NN
is_VPRT [PASS]
compared_VBN
to_PIN
the_DT
carrying_VBG
value_NN
of_PIN
the_DT
assets_NN
to_TO
determine_VB [SUAV] [PRIV]
whether_IN [WHCL]
an_DT
impairment_NOMZ
has_VPRT [PEAS]
occurred_VBN
._.
If_COND
an_DT
impairment_NOMZ
is_VPRT [PASS]
indicated_VBN [PRIV]
,_,
the_DT
amount_NN
of_PIN
the_DT
impairment_NOMZ
recognized_VBN [PRIV] [WZPAST]
in_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
is_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
estimating_VBG [PRIV]
the_DT
fair_JJ
value_NN
of_PIN
the_DT
assets_NN
and_CC
recording_VBG
a_DT
loss_NN
for_PIN
the_DT
amount_NN
that_TOBJ
the_DT
carrying_VBG
value_NN
exceeds_VPRT
the_DT
estimated_VBN [PRIV]
fair_JJ
value_NN
._.
This_DEMO
fair_JJ
value_NN
is_VPRT [SPAU] [PASS]
usually_RB
determined_VBN [SUAV] [PRIV]
based_VBN
on_PIN
estimated_VBN [PRIV]
discounted_JJ
cash_NN
flows_NN
._.
t_NN
Assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
sale_NN
An_DT
asset_NN
is_VPRT [PASS]
classified_VBN
as_IN
held_VBN [PRIV]
for_PIN
sale_NN
when_RB
,_,
amongst_PIN
other_JJ
things_NN
,_,
the_DT
Company_NN
has_VPRT [PEAS]
committed_VBN
to_PIN
a_DT
plan_NN
of_PIN
disposition_NOMZ
,_,
the_DT
asset_NN
is_VPRT [BEMA]
available_PRED
for_PIN
immediate_JJ
sale_NN
,_,
and_ANDC
the_DT
plan_NN
is_VPRT [PASS]
not_XX0
expected_VBN [PRIV]
to_TO
change_VB
significantly_RB
._.
u_NN
Sales_NN
deductions_NOMZ
i_FPP1
Rebates_NN
Rebates_NN
primarily_RB
consist_VPRT
of_PIN
statutory_JJ
rebates_NN
to_PIN
state_NN
Medicaid_NN
agencies_NN
and_CC
contractual_JJ
rebates_NN
with_PIN
health-maintenance_NN
organizations_NOMZ
HMOs_NN
._.
These_DEMO
rebates_NN
are_VPRT [PASS]
based_VBN
on_PIN
price_NN
differentials_NN
between_PIN
a_DT
base_NN
price_NN
and_CC
the_DT
selling_GER
price_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
rebates_NN
generally_RB
increase_VB
as_IN
a_DT
percentage_NN
of_PIN
the_DT
selling_GER
price_NN
over_IN
the_DT
life_NN
of_PIN
the_DT
product_NN
as_IN
prices_NN
increase_NN
._.
Provisions_NN
for_PIN
rebates_NN
are_VPRT [PASS]
recorded_VBN
as_IN
reductions_NOMZ
to_PIN
revenue_NN
in_PIN
the_DT
same_JJ
period_NN
as_IN
the_DT
related_JJ
sales_NN
,_,
with_PIN
estimates_NN
of_PIN
future_JJ
utilization_NOMZ
derived_VBN [WZPAST]
from_PIN
historical_JJ
trends_NN
._.
ii_FW
Returns_NN
The_DT
Company_NN
estimates_VPRT [PRIV]
the_DT
proportion_NOMZ
of_PIN
recorded_JJ
revenue_NN
that_TSUB
will_PRMD
result_VB
in_PIN
a_DT
return_NN
,_,
based_VBN [PASTP]
on_PIN
historical_JJ
trends_NN
and_CC
,_,
when_RB
applicable_JJ
,_,
specific_JJ
factors_NN
affecting_VBG [WZPRES]
certain_JJ
products_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
The_DT
accrual_NN
is_VPRT [PASS]
recorded_VBN
as_IN
a_DT
reduction_NOMZ
to_PIN
revenue_NN
in_PIN
the_DT
same_JJ
period_NN
as_IN
the_DT
related_JJ
sales_NN
are_VPRT [PASS]
recorded_VBN
._.
iii_FW
Coupons_NN
The_DT
Company_NN
uses_VPRT
coupons_NN
as_IN
a_DT
form_NN
of_PIN
sales_NN
incentive_NN
._.
An_DT
accrual_NN
is_VPRT [PASS]
established_VBN [PRIV]
based_VBN
on_PIN
the_DT
Companys_NN
expectation_NOMZ
of_PIN
the_DT
level_NN
of_PIN
coupon_NN
redemption_NOMZ
,_,
using_VBG
historical_JJ
trends_NN
._.
iv_FW
Discounts_NN
The_DT
Company_NN
offers_VPRT
cash_NN
discounts_NN
to_PIN
customers_NN
for_PIN
the_DT
early_TIME
payment_NOMZ
of_PIN
receivables_NN
._.
Those_DEMO
discounts_NN
are_VPRT [PASS]
recorded_VBN
as_IN
reductions_NOMZ
to_PIN
revenue_NN
and_PHC
accounts_NN
receivable_NN
in_PIN
the_DT
same_JJ
period_NN
that_TOBJ
the_DT
related_JJ
sale_NN
is_VPRT [PASS]
recorded_VBN
._.
v_FW
Wholesaler_NN
chargebacks_VPRT
The_DT
Company_NN
has_VPRT
contractual_JJ
agreements_NOMZ
with_PIN
third_JJ
parties_NN
to_TO
supply_VB
certain_JJ
products_NN
at_PIN
predetermined_VBN
prices_NN
._.
Wholesalers_NN
acting_VBG [WZPRES]
as_IN
intermediaries_NN
in_PIN
these_DEMO
transactions_NOMZ
are_VPRT [BYPA]
reimbursed_VBN
by_PIN
Shire_NN
,_,
if_COND
this_DEMO
price_NN
is_VPRT [BEMA]
less_PRED
than_PIN
the_DT
price_NN
paid_VBN [WZPAST]
by_PIN
the_DT
wholesaler_NN
to_PIN
Shire_NN
._.
Provisions_NN
for_PIN
wholesaler_NN
chargebacks_NN
based_VBN [WZPAST]
on_PIN
historical_JJ
trends_NN
are_VPRT [PASS]
recorded_VBN
as_IN
reductions_NOMZ
to_PIN
revenue_NN
in_PIN
the_DT
same_JJ
period_NN
as_IN
the_DT
related_JJ
sales_NN
are_VPRT [PASS]
recorded_VBN
._.
67_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
68_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
2_CD
Summary_NN
of_PIN
significant_JJ
accounting_GER
policies_NN
continued_VBD
v_JJ
Shareholders_NN
equity_NOMZ
i_FPP1
Common_JJ
stock_NN
The_DT
authorized_VBN
common_JJ
stock_NN
of_PIN
Shire_NN
as_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
was_VBD [BEMA]
799,999,965_CD
ordinary_JJ
shares_NN
and_CC
17,500,000_CD
special_JJ
ordinary_JJ
voting_NN
shares_NN
._.
The_DT
special_JJ
ordinary_JJ
voting_NN
shares_NN
are_VPRT [PASS]
entitled_VBN
to_PIN
dividend_NN
and_CC
other_JJ
rights_NN
that_TSUB
are_VPRT [BEMA]
economically_RB
equivalent_PRED
to_PIN
those_DEMO
of_PIN
the_DT
ordinary_JJ
shares_NN
._.
ii_FW
Dividends_NN
Under_IN
English_NN
law_NN
,_,
Shire_NN
can_POMD
pay_VB
dividends_NN
only_DWNT
out_PIN
of_PIN
its_PIT
distributable_JJ
profits_NN
,_,
defined_VBN
as_IN
the_DT
accumulated_VBN
realized_VBD [PRIV]
profits_NN
under_IN
UK_NN
generally_RB
accepted_VBD [PRIV]
accounting_GER
principles_NN
,_,
of_PIN
the_DT
parent_NN
company_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
and_CC
not_XX0
the_DT
consolidated_JJ
group_NN
,_,
so_RB
far_PLACE
as_IN
not_XX0
previously_TIME
utilized_VBN
by_PIN
distribution_NOMZ
or_CC
capitalization_NOMZ
,_,
less_JJ
accumulated_VBN
realized_VBN [PRIV]
and_CC
unrealized_JJ
losses_NN
,_,
so_RB
far_PLACE
as_IN
not_XX0
previously_TIME
written_VBN [PUBV]
off_PIN
in_PIN
a_DT
reduction_NOMZ
or_CC
reorganization_NOMZ
of_PIN
capital_NN
duly_RB
made_VBD
._.
The_DT
Company_NN
can_POMD
make_VB
a_DT
distribution_NOMZ
only_DWNT
if_COND
the_DT
distribution_NOMZ
does_VPRT
not_XX0
reduce_VB
net_JJ
assets_NN
below_PLACE
the_DT
aggregate_NN
of_PIN
the_DT
called-up_JJ
share_NN
capital_NN
and_CC
undistributable_JJ
reserves_NN
._.
Any_QUAN
payment_NOMZ
of_PIN
dividends_NN
is_VPRT [BEMA]
at_PIN
the_DT
discretion_NOMZ
of_PIN
the_DT
Board_NN
of_PIN
Directors_NN
and_CC
will_PRMD
be_VB [PASS]
made_VBN
in_PIN
Pounds_NN
sterling_GER
to_PIN
Ordinary_NN
Shareholders_NN
,_,
US_FPP1
dollars_NN
to_PIN
ADS_NN
holders_NN
and_CC
Canadian_JJ
dollars_NN
to_PIN
Exchangeable_JJ
Shareholders_NN
._.
At_PIN
December_NN
31_CD
,_,
2004_CD
,_,
Shires_NN
distributable_JJ
profits_NN
were_VBD [BEMA]
86.4_CD
million_CD
$_$
165.9_CD
million_CD
._.
iii_FW
Treasury_NN
stock_NN
The_DT
Company_NN
records_NN
the_DT
purchase_NN
of_PIN
its_PIT
own_JJ
shares_NN
as_IN
a_DT
reduction_NOMZ
of_PIN
shareholders_NN
equity_NOMZ
based_VBN [WZPAST]
on_PIN
the_DT
price_NN
paid_VBN [WZPAST]
for_PIN
the_DT
shares_NN
._.
w_VB
Concentration_NOMZ
of_PIN
risk_NN
Revenues_NN
are_VPRT [SPAU] [PASS]
mainly_RB
derived_VBN
in_PIN
the_DT
US_FPP1
69_CD
%_NN
of_PIN
total_JJ
revenues_NN
from_PIN
agreements_NOMZ
with_PIN
major_JJ
pharmaceutical_JJ
companies_NN
and_PHC
relationships_NN
with_PIN
pharmaceutical_JJ
wholesale_JJ
distributors_NN
and_CC
retail_JJ
pharmacy_NN
chains_NN
._.
Significant_JJ
customers_NN
are_VPRT [PASS]
disclosed_VBN [PUBV]
in_PIN
Note_NN
23_CD
._.
Such_JJ
clients_NN
have_VPRT
significant_JJ
cash_NN
resources_NN
and_ANDC
therefore_CONJ
any_QUAN
credit_NN
risk_NN
associated_VBN [WZPAST]
with_PIN
these_DEMO
transactions_NOMZ
is_VPRT [PASS]
considered_VBN [PRIV]
minimal_JJ
._.
Excess_JJ
cash_NN
is_VPRT [PASS]
invested_VBN
in_PIN
bank_NN
and_PHC
building_GER
society_NN
term_NN
deposits_NN
and_CC
commercial_JJ
paper_NN
from_PIN
a_DT
variety_NN
of_PIN
companies_NN
with_PIN
strong_JJ
credit_NN
ratings_GER
._.
These_DEMO
investments_NOMZ
typically_RB
bear_VPRT
minimal_JJ
credit_NN
risk_NN
._.
A_DT
significant_JJ
proportion_NOMZ
of_PIN
revenue_NN
is_VPRT [PASS]
derived_VBN
from_PIN
sales_NN
of_PIN
ADDERALL_NN
XR_NN
and_PHC
royalties_NN
received_VBN [WZPAST]
on_PIN
3TC_NN
._.
During_PIN
2004_CD
,_,
revenues_NN
from_PIN
these_DEMO
products_NN
were_VBD
$_$
606.7_CD
million_CD
and_CC
$_$
155.8_CD
million_CD
,_,
representing_VBG [PRESP]
45_CD
%_NN
and_CC
11_CD
%_NN
of_PIN
total_JJ
revenues_NN
respectively_RB
._.
As_CONJ
a_NULL
result_NULL
,_,
factors_NN
affecting_VBG [WZPRES]
the_DT
sale_NN
or_CC
production_NOMZ
of_PIN
ADDERALL_NN
XR_NN
or_CC
3TC_NN
would_PRMD
have_VB
a_DT
material_NN
adverse_JJ
effect_NN
on_PIN
the_DT
Companys_NN
financial_JJ
condition_NOMZ
and_PHC
results_NN
of_PIN
operation_NOMZ
._.
x_LS
Non-monetary_JJ
transactions_NOMZ
The_DT
Company_NN
enters_VPRT
into_PIN
certain_JJ
non-monetary_JJ
transactions_NOMZ
that_TSUB
involve_VPRT
either_CC
the_DT
granting_VBG [SUAV]
of_PIN
a_DT
license_NN
over_IN
the_DT
Companys_NN
patents_NN
or_CC
the_DT
disposal_NN
of_PIN
an_DT
asset_NN
or_CC
group_NN
of_PIN
assets_NN
in_PIN
exchange_NN
for_PIN
a_DT
non-monetary_JJ
asset_NN
,_,
usually_RB
equity_NOMZ
._.
The_DT
Company_NN
accounts_NN
for_PIN
these_DEMO
transactions_NOMZ
at_PIN
fair_JJ
value_NN
where_RB
the_DT
Company_NN
is_VPRT [BEMA]
able_PRED
to_TO
determine_VB [SUAV] [PRIV]
the_DT
fair_JJ
value_NN
within_PIN
reasonable_JJ
limits_NN
._.
To_PIN
the_DT
extent_NN
that_TOBJ
the_DT
Company_NN
concludes_VPRT [PRIV]
that_THVC
it_PIT
is_VPRT [BEMA]
unable_PRED
to_TO
determine_VB [SUAV] [PRIV]
the_DT
fair_JJ
value_NN
of_PIN
a_DT
transaction_NOMZ
,_,
that_DEMO
transaction_NOMZ
is_VPRT [PASS]
accounted_VBN
for_PIN
at_PIN
the_DT
recorded_JJ
amounts_NN
of_PIN
the_DT
assets_NN
._.
Management_NOMZ
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
exercise_VB
its_PIT
judgment_NOMZ
in_PIN
determining_VBG [SUAV] [PRIV]
whether_IN [WHCL]
or_CC
not_XX0
the_DT
fair_JJ
value_NN
of_PIN
the_DT
asset_NN
received_VBD
or_CC
that_DEMP
given_VBN
up_RP
can_POMD
be_VB [PASS]
determined_VBN [SUAV] [PRIV]
._.
In_PIN
doing_VBG
so_RB
,_,
management_NOMZ
considers_VPRT [PRIV]
,_,
amongst_PIN
other_JJ
things_NN
,_,
previous_JJ
license_NN
agreements_NOMZ
over_IN
similar_JJ
intellectual_JJ
property_NN
rights_NN
where_RB
there_EX
is_VPRT
monetary_JJ
consideration_NOMZ
._.
The_DT
Company_NN
has_VPRT
a_DT
limited_JJ
number_NN
of_PIN
comparable_JJ
historical_JJ
license_NN
agreements_NOMZ
._.
Management_NOMZ
has_VPRT [PEAS]
determined_VBN [SUAV] [PRIV]
that_THVC
for_PIN
all_QUAN
non-monetary_JJ
transactions_NOMZ
recorded_VBN
to_TO
date_VB
the_DT
fair_JJ
value_NN
of_PIN
the_DT
consideration_NOMZ
is_VPRT [BEMA]
not_XX0
determinable_PRED
:_:
consequently_CONJ
,_,
such_JJ
transactions_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
at_PIN
recorded_VBN
value_NN
._.
In_PIN
the_DT
future_NN
,_,
as_IN
Shire_NN
engages_VPRT
in_PIN
further_JJ
transactions_NOMZ
,_,
there_EX
may_POMD
be_VB
a_DT
fair_JJ
value_NN
assigned_VBN [WZPAST]
to_PIN
similar_JJ
transactions_NOMZ
resulting_VBG [WZPRES]
in_PIN
a_DT
different_JJ
accounting_GER
treatment_NOMZ
._.
y_RB
Reclassifications_NOMZ
Certain_NN
amounts_VPRT
reported_VBN [PUBV]
in_PIN
previous_JJ
years_NN
have_VPRT [PEAS]
been_VBN [PASS]
reclassified_VBN
to_TO
conform_VB
to_PIN
the_DT
2004_CD
presentation_NOMZ
._.
In_CONJ
addition_NULL
the_DT
2002_CD
and_CC
2003_CD
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
to_TO
reflect_VB [PRIV]
the_DT
disposal_NN
of_PIN
the_DT
vaccines_NN
business_NOMZ
,_,
which_WDT [SERE]
has_VPRT [PEAS]
been_VBN [PASS]
treated_VBN
as_IN
a_DT
discontinued_VBN
operation_NOMZ
._.
z_SYM
New_NN
accounting_GER
pronouncements_NOMZ
i_FPP1
Adopted_VBN
in_PIN
the_DT
current_JJ
year_NN
FIN_NN
46R_NN
In_PIN
December_NN
2003_CD
,_,
the_DT
Financial_NN
Accounting_GER
Standards_NN
Board_NN
FASB_NN
issued_VBD
a_DT
revision_NN
to_PIN
FASB_NN
Interpretation_NOMZ
No._NN
._.
46_CD
Consolidation_NOMZ
of_PIN
Variable_NN
Interest_NN
Entities_NOMZ
VIE_NN
,_,
an_DT
interpretation_NOMZ
of_PIN
Accounting_GER
Research_NN
Bulletin_NN
ARB_NN
No._NN
._.
51_CD
FIN_NN
46R_NN
,_,
which_WDT [SERE]
requires_VPRT [SUAV]
a_DT
VIE_NN
to_TO
be_VB [BYPA]
consolidated_VBN
by_PIN
a_DT
Company_NN
that_TSUB
will_PRMD
absorb_VB
a_DT
majority_NOMZ
of_PIN
the_DT
VIEs_NN
expected_VBN [PRIV]
losses_NN
,_,
receive_VPRT
a_DT
majority_NOMZ
of_PIN
the_DT
entitys_NN
expected_VBN [PRIV]
residual_JJ
returns_NN
,_,
or_CC
both_DT
,_,
as_CONJ
a_NULL
result_NULL
of_PIN
ownership_NN
,_,
contractual_JJ
or_CC
other_JJ
financial_JJ
interest_NN
in_PIN
the_DT
VIE_NN
._.
Prior_RB
to_PIN
the_DT
adoption_NOMZ
of_PIN
FIN_NN
46R_NN
,_,
VIEs_NN
were_VBD [SPAU] [BYPA]
generally_RB
consolidated_VBN
by_PIN
companies_NN
owning_VBG [WZPRES]
a_DT
majority_NOMZ
voting_NN
interest_NN
in_PIN
the_DT
VIE_NN
._.
The_DT
consolidation_NOMZ
requirements_NOMZ
of_PIN
FIN_NN
46R_NN
applied_VBD
immediately_TIME
to_PIN
VIEs_NN
created_VBN
after_IN
January_NN
31_CD
,_,
2003_CD
,_,
however_CONJ
,_,
the_DT
FASB_NN
deferred_VBD
the_DT
effective_JJ
date_NN
for_PIN
VIEs_NN
created_VBN
before_IN
February_NN
1_CD
,_,
2003_CD
to_PIN
the_DT
quarter_NN
ended_VBD
March_NN
31_CD
,_,
2004_CD
for_PIN
calendar-year_JJ
companies_NN
._.
Adoption_NOMZ
of_PIN
the_DT
provisions_NN
of_PIN
FIN_NN
46R_NN
prior_RB
to_PIN
the_DT
deferred_VBN
effective_JJ
date_NN
was_VBD [PASS]
permitted_VBN
._.
The_DT
adoption_NOMZ
of_PIN
FIN_NN
46R_NN
did_VBD
not_XX0
have_VB
a_DT
material_NN
impact_NN
on_PIN
the_DT
Company_NN
._.
68_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
69_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
2_CD
Summary_NN
of_PIN
significant_JJ
accounting_GER
policies_NN
continued_VBD
z_SYM
New_NN
accounting_GER
pronouncements_NOMZ
continued_VBD
ii_FW
To_TO
be_VB [PASS]
adopted_VBN
in_PIN
future_NN
periods_NN
EITF_NN
03-01_CD
In_PIN
March_NN
2004_CD
,_,
the_DT
Emerging_VBG
Issues_NN
Task_NN
Force_NN
EITF_NN
reached_VBD
a_DT
consensus_NN
on_PIN
Issue_NN
03-01_CD
,_,
The_DT
Meaning_GER
of_PIN
Other-Than-Temporary_NN
Impairment_NOMZ
and_CC
Its_PIT
Application_NOMZ
to_PIN
Certain_NN
Investments_NOMZ
EITF_NN
03-01_CD
or_CC
the_DT
Issue_NN
._.
EITF_NN
03-01_CD
is_VPRT [BEMA]
applicable_PRED
to_PIN
a_DT
debt_NN
and_PHC
equity_NOMZ
securities_NOMZ
within_PIN
the_DT
scope_NN
of_PIN
FAS_NN
No._NN
._.
115_CD
,_,
b_NN
debt_NN
and_PHC
equity_NOMZ
securities_NOMZ
within_PIN
the_DT
scope_NN
of_PIN
SFAS_NN
No._NN
._.
124_CD
and_CC
that_DEMP
are_VPRT [BYPA]
held_VBN [PRIV]
by_PIN
an_DT
investor_NN
that_TSUB
reports_VPRT [PUBV]
a_DT
performance_NN
indicator_NN
,_,
and_ANDC
c_NN
equity_NOMZ
securities_NOMZ
not_XX0
within_PIN
the_DT
scope_NN
of_PIN
SFAS_NN
No._NN
._.
115_CD
and_CC
not_XX0
accounted_VBD
for_PIN
under_IN
the_DT
Accounting_GER
Principles_NN
Board_NN
Opinion_NN
18s_VPRT
equity-method_JJ
e._FW
g._FW
investments_NOMZ
in_PIN
private_JJ
companies_NN
._.
EITF_NN
03-01_CD
provides_VPRT
a_DT
step_NN
model_NN
to_TO
determine_VB [SUAV] [PRIV]
whether_IN [WHCL]
an_DT
investment_NOMZ
is_VPRT [PASS]
impaired_VBN
and_ANDC
if_COND
an_DT
impairment_NOMZ
is_VPRT [BEMA]
other-than-temporary_PRED
._.
In_CONJ
addition_NULL
,_,
it_PIT
requires_VPRT [SUAV]
that_THVC
investors_NN
provide_VPRT
certain_JJ
disclosures_NN
for_PIN
investments_NOMZ
in_PIN
private_JJ
companies_NN
and_CC
,_,
if_COND
applicable_JJ
,_,
other_JJ
information_NOMZ
related_VBN [WZPAST]
specifically_RB
to_PIN
investments_NOMZ
in_PIN
private_JJ
companies_NN
,_,
such_JJ
as_IN
the_DT
aggregate_JJ
carrying_GER
amount_NN
of_PIN
investments_NOMZ
in_PIN
private_JJ
companies_NN
,_,
the_DT
aggregate_JJ
amount_NN
of_PIN
investments_NOMZ
in_PIN
private_JJ
companies_NN
that_TOBJ
the_DT
investor_NN
did_VBD
not_XX0
evaluate_VB
for_PIN
impairment_NOMZ
because_CAUS
an_DT
impairment_NOMZ
indicator_NN
was_VBD [BEMA]
not_XX0
present_PRED
,_,
and_ANDC
the_DT
situations_NOMZ
under_IN
which_WDT
the_DT
fair_JJ
value_NN
of_PIN
an_DT
investment_NOMZ
in_PIN
a_DT
private_JJ
company_NN
is_VPRT [PASS]
not_XX0
estimated_VBN [PRIV]
._.
The_DT
disclosures_NN
relating_VBG [WZPRES]
to_PIN
investments_NOMZ
in_PIN
private_JJ
companies_NN
should_NEMD
not_XX0
be_VB [PASS]
aggregated_VBN
with_PIN
other_JJ
types_NN
of_PIN
investments_NOMZ
._.
The_DT
effective_JJ
date_NN
for_PIN
the_DT
prospective_JJ
application_NOMZ
of_PIN
EITF_NN
03-01_CD
impairment_NOMZ
model_NN
to_PIN
all_QUAN
current_JJ
and_PHC
future_JJ
investments_NOMZ
has_VPRT [PEAS]
been_VBN [BYPA]
delayed_VBN
by_PIN
FASB_NN
Staff_NN
Position_NOMZ
EITF_NN
03-01_CD
._.
The_DT
disclosure_NN
requirements_NOMZ
are_VPRT [BEMA]
effective_PRED
for_PIN
annual_JJ
periods_NN
for_PIN
fiscal_JJ
years_NN
ending_VBG [WZPRES]
after_IN
June_NN
15_CD
,_,
2004_CD
,_,
therefore_CONJ
December_NN
31_CD
,_,
2004_CD
in_PIN
the_DT
case_NN
of_PIN
the_DT
Company_NN
._.
SFAS_NN
123R_NN
In_PIN
December_NN
2004_CD
,_,
the_DT
FASB_NN
issued_VBD
SFAS_NN
No._NN
._.
123_CD
revised_VBN
2004_CD
,_,
Share-Based_NN
Payment_NOMZ
SFAS_NN
No._NN
._.
123R_CD
requires_VPRT [SUAV]
that_THVC
the_DT
cost_NN
resulting_VBG [WZPRES]
from_PIN
all_QUAN
share-based_JJ
payment_NOMZ
transactions_NOMZ
be_VB [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
financial_JJ
statements_NOMZ
at_PIN
fair_JJ
value_NN
and_CC
that_DEMO
excess_JJ
tax_NN
benefits_NN
be_VB [PASS]
reported_VBN [PUBV]
as_IN
a_DT
financing_GER
cash_NN
inflow_NN
rather_RB
than_PIN
as_IN
a_DT
reduction_NOMZ
of_PIN
taxes_NN
paid_VBN
._.
123R_CD
is_VPRT [BEMA]
effective_PRED
for_PIN
the_DT
Company_NN
from_PIN
July_NN
1_CD
,_,
2005_CD
._.
123R_CD
permits_NN
public_JJ
companies_NN
to_TO
account_VB
for_PIN
share-based_JJ
payments_NOMZ
using_VBG [WZPRES]
one_CD
of_PIN
two_CD
methods_NN
:_:
modified-prospective_JJ
method_NN
or_CC
method_NN
._.
Under_IN
the_DT
modified-prospective_JJ
method_NN
,_,
from_PIN
the_DT
effective_JJ
date_NN
,_,
compensation_NOMZ
cost_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
based_VBN
on_PIN
the_DT
requirements_NOMZ
of_PIN
SFAS_NN
No._NN
._.
123R_CD
for_PIN
all_QUAN
new_JJ
share-based_JJ
awards_NN
and_CC
based_VBN
on_PIN
the_DT
requirements_NOMZ
of_PIN
SFAS_NN
No._NN
._.
123_CD
for_PIN
all_QUAN
awards_NN
granted_VBN [SUAV] [WZPAST]
prior_RB
to_PIN
the_DT
effective_JJ
date_NN
of_PIN
SFAS_NN
No._NN
._.
123R_CD
that_DEMP
remain_VPRT
unvested_JJ
on_PIN
the_DT
effective_JJ
date_NN
._.
The_DT
requirements_NOMZ
of_PIN
the_DT
method_NN
are_VPRT
as_IN
above_PLACE
,_,
with_PIN
the_DT
exception_NOMZ
that_TOBJ
companies_NN
are_VPRT [PASS]
permitted_VBN
to_TO
restate_VB
,_,
based_VBN [PASTP]
on_PIN
the_DT
amounts_NN
previously_TIME
recognized_VBN [PRIV]
under_IN
SFAS_NN
No._NN
._.
123_CD
for_PIN
pro-forma_FW
disclosure_NN
purposes_NN
,_,
either_CC
all_QUAN
prior_RB
periods_NN
presented_VBN
or_CC
prior_RB
interim_JJ
periods_NN
in_PIN
the_DT
year_NN
of_PIN
adoption_NOMZ
._.
123_CD
pro-forma_FW
disclosures_NN
given_VBN [WZPAST]
in_PIN
Note_NN
2_CD
above_PLACE
show_NN
the_DT
impact_NN
of_PIN
the_DT
Company_NN
adopting_VBG [WZPRES]
SFAS_NN
No._NN
._.
The_DT
Company_NN
has_VPRT
yet_RB
to_TO
determine_VB [SUAV] [PRIV]
which_WDT [WHCL]
method_NN
of_PIN
transition_NOMZ
will_PRMD
be_VB [PASS]
adopted_VBN
or_CC
the_DT
adoption_NOMZ
date_NN
._.
aa_NN
Statutory_JJ
accounts_NN
The_DT
consolidated_JJ
financial_JJ
statements_NOMZ
as_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
and_CC
2003_CD
and_CC
for_PIN
each_QUAN
of_PIN
the_DT
three_CD
years_NN
in_PIN
the_DT
period_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
do_VPRT
not_XX0
comprise_VB
statutory_JJ
accounts_NN
within_PIN
the_DT
meaning_GER
of_PIN
Section_NOMZ
240_CD
of_PIN
the_DT
UK_NN
Companies_NN
Act_NN
1985_CD
._.
Statutory_JJ
accounts_NN
prepared_VBN [WZPAST]
in_PIN
accordance_NN
with_PIN
generally_RB
accepted_VBN [PRIV]
accounting_GER
principles_NN
in_PIN
the_DT
United_NN
Kingdom_NN
for_PIN
the_DT
years_NN
to_PIN
December_NN
31_CD
,_,
2003_CD
and_CC
2002_CD
have_VPRT [PEAS]
been_VBN [PASS]
delivered_VBN
to_PIN
the_DT
Registrar_NN
of_PIN
Companies_NN
for_PIN
England_NN
and_PHC
Wales_NN
._.
The_DT
auditors_NN
report_VPRT [PUBV]
on_PIN
those_DEMO
accounts_NN
was_VBD [BEMA]
unqualified_PRED
._.
3_CD
Reorganizations_NOMZ
Actions_NOMZ
commenced_VBD
in_PIN
2004_CD
i_FPP1
North_PLACE
American_JJ
site_NN
consolidation_NOMZ
As_IN
previously_TIME
disclosed_VBN [PUBV]
,_,
Shire_NN
began_VBD
a_DT
consolidation_NOMZ
of_PIN
its_PIT
North_PLACE
American_JJ
sites_NN
in_PIN
2004_CD
,_,
decreasing_VBG [PRESP]
the_DT
number_NN
of_PIN
sites_NN
from_PIN
14_CD
to_PIN
6_CD
and_CC
opening_VBG
a_DT
new_JJ
US_FPP1
headquarters_NN
office_NN
in_PIN
Wayne_NN
,_,
Pennsylvania_NN
._.
The_DT
Company_NN
recorded_VBN
costs_NN
of_PIN
$_$
48.5_CD
million_CD
in_PIN
2004_CD
and_CC
estimates_VPRT [PRIV]
further_JJ
costs_NN
of_PIN
approximately_RB
$_$
12_CD
million_CD
in_PIN
2005_CD
._.
The_DT
site_NN
consolidation_NOMZ
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [BEMA]
complete_PRED
by_PIN
the_DT
end_NN
of_PIN
2005_CD
._.
The_DT
primary_JJ
costs_NN
associated_VBN [WZPAST]
with_PIN
the_DT
site_NN
consolidation_NOMZ
include_VPRT
:_:
severance_NN
costs_NN
relating_VBG [WZPRES]
to_PIN
138_CD
employees_NN
:_:
retention_NOMZ
payments_NOMZ
to_PIN
key_JJ
employees_NN
:_:
relocation_NOMZ
costs_NN
relating_VBG [WZPRES]
to_PIN
85_CD
employees_NN
who_WP [WHSUB]
were_VBD [PASS]
moved_VBN [SUAV]
to_PIN
Wayne_NN
,_,
Pennsylvania_NN
:_:
costs_NN
of_PIN
duplicate_VPRT
facilities_NOMZ
including_VBG [WZPRES]
lease_NN
exit_NN
costs_NN
:_:
and_ANDC
other_JJ
incremental_JJ
costs_NN
associated_VBN [WZPAST]
with_PIN
the_DT
site_NN
closures_NN
,_,
such_JJ
as_IN
legal_JJ
,_,
consultancy_NN
,_,
the_DT
write-down_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
and_PHC
information_NOMZ
technology_NN
costs_NN
._.
69_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
70_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV] [THATD]
3_CD
Reorganizations_NOMZ
continued_VBD
Actions_NOMZ
commenced_VBN [WZPAST]
in_PIN
2004_CD
continued_VBD
i_FPP1
North_PLACE
American_JJ
site_NN
consolidation_NOMZ
continued_VBD
As_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
,_,
107_CD
employees_NN
had_VBD [PEAS]
left_VBN
the_DT
Company_NN
._.
The_DT
cost_NN
of_PIN
the_DT
employee_NN
severance_NN
is_VPRT
being_VBG [SPAU] [PASS]
ratably_RB
recognized_VBN [PRIV]
over_IN
the_DT
period_NN
from_PIN
the_DT
communication_NOMZ
date_NN
to_PIN
the_DT
termination_NOMZ
date_NN
._.
In_CONJ
addition_NULL
,_,
all_QUAN
85_CD
employees_NN
had_VBD [PEAS]
relocated_VBN
._.
The_DT
cost_NN
of_PIN
relocation_NOMZ
is_VPRT
being_VBG [PASS]
recorded_VBN
as_IN
it_PIT
is_VPRT [PASS]
incurred_VBN
._.
The_DT
following_JJ
table_NN
presents_VPRT
the_DT
cost_NN
of_PIN
the_DT
reorganization_NOMZ
recorded_VBN [WZPAST]
to_PIN
date_NN
and_CC
the_DT
total_JJ
estimated_JJ
costs_NN
of_PIN
the_DT
reorganization_NOMZ
._.
After_IN
the_DT
plan_NN
is_VPRT [PASS]
finalized_VBN
and_CC
actions_NOMZ
are_VPRT [PASS]
completed_VBN
,_,
the_DT
Company_NN
will_PRMD
continue_VB
to_TO
update_VB
its_PIT
reorganization_NOMZ
accruals_VPRT
based_VBN
on_PIN
changes_NN
in_PIN
estimates_NN
._.
Total_JJ
costs_NN
Total_JJ
incurred_VBN
to_TO
estimated_VBN [PRIV]
December_NN
31_CD
,_,
costs_NN
of_PIN
2004_CD
reorganization_NOMZ
$_$
m_CD
$_$
m_CD
Employee_NN
severance_NN
20.0_CD
22_CD
Relocation_NOMZ
costs_VPRT
13.8_CD
14_CD
Write-off_PIN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
1.2_CD
1_CD
Consultancy_NN
costs_VPRT
2.9_CD
3_CD
Duplicate_NN
facilities_NOMZ
5.1_CD
15.5_CD
Information_NOMZ
technology_NN
costs_VPRT
2.1_CD
2_CD
Other_JJ
costs_NN
3.4_CD
3_CD
48.5_CD
60.5_CD
The_DT
charges_NN
have_VPRT [PEAS]
been_VBN [PASS]
reflected_VBN [PRIV]
within_PIN
reorganization_NOMZ
costs_NN
in_PIN
the_DT
statement_NOMZ
of_PIN
operations_NOMZ
and_CC
within_PIN
the_DT
reporting_GER
segments_NOMZ
as_IN
follows_VPRT
:_:
US_FPP1
International_NN
Corporate_NN
R&D_NN
Total_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Employee_NN
severance_NN
7.2_CD
5.1_CD
2.0_CD
5.7_CD
20.0_CD
Relocation_NOMZ
costs_VPRT
9.8_CD
4.0_CD
13.8_CD
Write-off_PIN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
1.2_CD
1.2_CD
Consultancy_NN
costs_NN
1.7_CD
1.2_CD
2.9_CD
Duplicate_NN
facilities_NOMZ
2.6_CD
2.5_CD
5.1_CD
Information_NOMZ
technology_NN
costs_VPRT
0.3_CD
1.8_CD
2.1_CD
Other_JJ
costs_NN
2.4_CD
1.0_CD
3.4_CD
24.0_CD
5.1_CD
6.0_CD
13.4_CD
48.5_CD
As_IN
noted_VBN [PRIV]
above_PLACE
,_,
certain_JJ
of_PIN
the_DT
costs_NN
associated_VBN [WZPAST]
with_PIN
the_DT
reorganization_NOMZ
will_PRMD
be_VB [PASS]
paid_VBN
in_PIN
subsequent_JJ
periods_NN
._.
The_DT
following_VBG
provides_VPRT
a_DT
reconciliation_NOMZ
of_PIN
the_DT
liability_NOMZ
to_PIN
date_NN
:_:
Costs_NN
recorded_VBN
Utilization_NOMZ
in_PIN
year_NN
to_PIN
in_PIN
year_NN
to_PIN
Opening_GER
December_NN
31_CD
,_,
December_NN
31_CD
,_,
Closing_GER
liability_NOMZ
2004_CD
2004_CD
liability_NOMZ
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Employee_NN
severance_NN
20.0_CD
18.3_CD
1.7_CD
Relocation_NOMZ
costs_VPRT
13.8_CD
13.8_CD
Write-off_PIN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
1.2_CD
1.2_CD
Consultancy_NN
costs_VPRT
2.9_CD
2.9_CD
Duplicate_NN
facilities_NOMZ
5.1_CD
2.6_CD
2.5_CD
Information_NOMZ
technology_NN
costs_VPRT
2.1_CD
2.1_CD
Other_JJ
costs_NN
3.4_CD
3.4_CD
48.5_CD
44.3_CD
4.2_CD
The_DT
employee_NN
severance_NN
costs_NN
will_PRMD
be_VB [PASS]
paid_VBN
in_PIN
2005_CD
._.
The_DT
duplicate_VPRT
facilities_NOMZ
will_PRMD
be_VB [PASS]
paid_VBN
over_IN
the_DT
remaining_VBG
life_NN
of_PIN
the_DT
lease_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
due_PRED
to_TO
terminate_VB
in_PIN
2009_CD
._.
70_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
71_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV] [THATD]
3_CD
Reorganizations_NOMZ
continued_VBD
Actions_NOMZ
commenced_VBN [WZPAST]
in_PIN
2004_CD
continued_VBD
ii_FW
Disposal_NN
of_PIN
the_DT
vaccines_NN
business_NOMZ
On_PIN
September_NN
9_CD
,_,
2004_CD
,_,
the_DT
Company_NN
completed_VBD
its_PIT
disposal_NN
of_PIN
the_DT
vaccines_NN
business_NOMZ
to_PIN
IDB_NN
._.
The_DT
total_JJ
consideration_NOMZ
for_PIN
the_DT
sale_NN
was_VBD
$_$
120_CD
million_CD
comprising_VBG
$_$
30_CD
million_CD
of_PIN
cash_NN
received_VBN [WZPAST]
at_PIN
completion_NOMZ
,_,
$_$
30_CD
million_CD
of_PIN
cash_NN
held_VBN [PRIV] [WZPAST]
in_PIN
escrow_NN
and_CC
due_JJ
on_PIN
the_DT
first_JJ
anniversary_NN
of_PIN
closing_GER
and_CC
$_$
60_CD
million_CD
received_VBN
at_PIN
completion_NOMZ
in_PIN
the_DT
form_NN
of_PIN
4,931,864_CD
subscription_NOMZ
receipts_NN
of_PIN
IDB_NN
._.
Each_QUAN
subscription_NOMZ
receipt_NN
entitled_VBN
Shire_NN
to_TO
acquire_VB
,_,
at_PIN
any_QUAN
time_NN
during_PIN
the_DT
period_NN
from_PIN
January_NN
10_CD
,_,
2005_CD
to_PIN
July_NN
9_CD
,_,
2006_CD
,_,
for_PIN
no_SYNE
additional_JJ
consideration_NOMZ
,_,
one_CD
fully_AMP
paid_VBN
common_JJ
share_NN
of_PIN
IDB_NN
._.
Prior_RB
to_PIN
January_NN
10_CD
,_,
2005_CD
,_,
if_COND
IDB_NN
were_VBD
to_TO
raise_VB
up_RP
to_TO
$_$
60_CD
million_CD
from_PIN
equity-related_JJ
issuances_NN
then_RB
they_TPP3
were_VBD [PASS]
required_VBN [SUAV]
to_TO
repurchase_VB
the_DT
subscription_NOMZ
receipts_NN
from_PIN
Shire_NN
for_PIN
$_$
60_CD
million_CD
in_PIN
cash_NN
._.
On_PIN
December_NN
21_CD
,_,
2004_CD
,_,
IDB_NN
gave_VBD
notification_NOMZ
that_TOBJ
it_PIT
intended_VBD [SUAV]
to_TO
complete_VB
a_DT
convertible_JJ
debt_NN
issuance_NN
on_PIN
January_NN
7_CD
,_,
2005_CD
and_CC
subsequently_TIME
repurchased_VBD
the_DT
subscription_NOMZ
receipts_NN
from_PIN
Shire_NN
on_PIN
January_NN
7_CD
,_,
2005_CD
._.
In_CONJ
addition_NULL
to_PIN
the_DT
$_$
120_CD
million_CD
consideration_NOMZ
,_,
IDB_NN
was_VBD [PASS]
required_VBN [SUAV]
to_TO
reimburse_VB
Shire_NN
in_PIN
full_JJ
for_PIN
the_DT
net_JJ
cost_NN
of_PIN
operating_VBG
the_DT
vaccines_NN
business_NOMZ
from_PIN
June_NN
30_CD
,_,
2004_CD
through_PIN
consummation_NOMZ
of_PIN
the_DT
sale_NN
._.
As_IN
part_NN
of_PIN
the_DT
transaction_NOMZ
,_,
Shire_NN
entered_VBD
into_PIN
an_DT
agreement_NOMZ
to_TO
provide_VB
IDB_NN
with_PIN
a_DT
loan_NN
facility_NOMZ
of_PIN
up_RB
to_TO
$_$
100_CD
million_CD
,_,
which_WDT [SERE]
can_POMD
be_VB [PASS]
drawn_VBN
down_RB
over_IN
the_DT
four_CD
years_NN
following_VBG [WZPRES]
completion_NOMZ
._.
Drawings_GER
under_IN
the_DT
loan_NN
facility_NOMZ
will_PRMD
be_VB [PASS]
segregated_VBN
into_PIN
two_CD
components_NN
:_:
i_FPP1
drawings_GER
for_PIN
injectable_JJ
flu_NN
development_NOMZ
of_PIN
up_RB
to_TO
$_$
30_CD
million_CD
._.
Such_JJ
drawings_GER
under_IN
the_DT
loan_NN
facility_NOMZ
will_PRMD
be_VB [BEMA]
repayable_PRED
out_PIN
of_PIN
income_NN
generated_VBN [WZPAST]
by_PIN
IDB_NN
on_PIN
future_JJ
non-Canadian_JJ
injectable_JJ
flu_NN
products_NN
,_,
subject_JJ
to_PIN
minimum_JJ
annual_JJ
repayments_NOMZ
in_PIN
respect_NN
of_PIN
the_DT
$_$
30_CD
million_CD
drawing_GER
,_,
to_TO
be_VB [PASS]
made_VBN
between_PIN
2007_CD
and_CC
2017_CD
:_:
and_ANDC
ii_FW
drawings_GER
for_PIN
pipeline_NN
development_NOMZ
from_PIN
the_DT
balance_NN
of_PIN
the_DT
$_$
100_CD
million_CD
loan_NN
facility_NOMZ
of_PIN
up_RB
to_TO
$_$
70_CD
million_CD
._.
Such_JJ
drawings_GER
will_PRMD
be_VB [BEMA]
repayable_PRED
out_PIN
of_PIN
income_NN
generated_VBN [WZPAST]
by_PIN
IDB_NN
on_PIN
future_JJ
pipeline_NN
products_NN
and_CC
will_PRMD
have_VB
no_DT
fixed_VBN
repayment_NOMZ
schedule_NN
._.
As_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
,_,
IDB_NN
had_VBD [PEAS]
drawn_VBN
down_RB
$_$
56.8_CD
million_CD
:_:
$_$
30.0_CD
million_CD
for_PIN
injectable_JJ
flu_NN
development_NOMZ
and_CC
$_$
26.8_CD
million_CD
for_PIN
pipeline_NN
development_NOMZ
._.
The_DT
transaction_NOMZ
gave_VBD
rise_NN
to_PIN
an_DT
overall_JJ
loss_NN
on_PIN
disposition_NOMZ
of_PIN
the_DT
vaccines_NN
business_NOMZ
of_PIN
$_$
44_CD
million_CD
,_,
which_WDT [SERE]
comprises_VPRT
a_DT
gain_NN
on_PIN
disposal_NN
of_PIN
net_JJ
assets_NN
of_PIN
$_$
26_CD
million_CD
together_RB
with_PIN
a_DT
provision_NN
for_PIN
a_DT
loss_NN
of_PIN
$_$
70_CD
million_CD
out_PIN
of_PIN
the_DT
$_$
100_CD
million_CD
loan_NN
facility_NOMZ
available_JJ
to_PIN
IDB_NN
._.
This_DEMO
provision_NN
is_VPRT [PASS]
made_VBN
on_PIN
the_DT
basis_NN
that_DEMO
loan_NN
repayments_NOMZ
based_VBN [WZPAST]
solely_RB
on_PIN
the_DT
future_JJ
sales_NN
of_PIN
pipeline_NN
products_NN
in_PIN
development_NOMZ
provide_VPRT
no_SYNE
certainty_NN
of_PIN
recovery_NN
._.
The_DT
historical_JJ
consolidated_JJ
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
to_TO
reflect_VB [PRIV]
the_DT
vaccines_NN
business_NOMZ
as_IN
a_DT
discontinued_VBN
operation_NOMZ
for_PIN
all_QUAN
periods_NN
presented_VBN
._.
The_DT
results_NN
of_PIN
the_DT
discontinued_VBN
operation_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
removed_VBN
from_PIN
all_QUAN
periods_NN
on_PIN
a_DT
line-by-line_JJ
basis_NN
from_PIN
product_NN
sales_NN
revenue_NN
to_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
._.
The_DT
net_JJ
loss_NN
from_PIN
the_DT
discontinued_VBN
operation_NOMZ
,_,
together_RB
with_PIN
the_DT
loss_NN
on_PIN
disposal_NN
,_,
are_VPRT [PASS]
shown_VBN [PRIV]
as_IN
separate_JJ
line_NN
items_NN
._.
Operating_VBG
results_NN
of_PIN
the_DT
discontinued_VBN
operations_NOMZ
are_VPRT [PASS]
summarized_VBN
below_PLACE
._.
2004 2003 2002_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
Revenues_NN
Product_NN
sales_NN
3,626_CD
25,531_CD
14,048_CD
Total_JJ
revenues_NN
3,626_CD
25,531_CD
14,048_CD
Costs_NN
and_PHC
expenses_NN
Cost_NN
of_PIN
product_NN
sales_NN
8,304_CD
19,954_CD
13,247_CD
Research_NN
and_PHC
development_NOMZ
9,222_CD
20,879_CD
15,799_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
5,614_CD
9,671_CD
6,923_CD
Total_JJ
operating_GER
expenses_NN
23,140_CD
50,504_CD
35,969_CD
Operating_GER
loss_NN
19,514_CD
24,973_CD
21,921_CD
Other_JJ
expense_NN
income_NN
,_,
net_JJ
621_CD
3,087_CD
4,154_CD
1_CD
Loss_NN
from_PIN
discontinued_VBN
operations_NOMZ
20,135_CD
21,886_CD
17,767_CD
Loss_NN
on_PIN
disposition_NOMZ
44,157_CD
64,292_CD
21,886_CD
17,767_CD
1_CD
The_DT
loss_NN
from_PIN
discontinued_VBN
operations_NOMZ
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2002_CD
of_PIN
$_$
11.7_CD
million_CD
comprises_VPRT
a_DT
loss_NN
from_PIN
the_DT
vaccines_NN
business_NOMZ
of_PIN
$_$
17.8_CD
million_CD
and_CC
a_DT
gain_NN
from_PIN
the_DT
Over-the-Counter_NN
OTC_NN
business_NOMZ
of_PIN
$_$
6.1_CD
million_CD
._.
71_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
72_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV] [THATD]
3_CD
Reorganizations_NOMZ
continued_VBD
Actions_NOMZ
commenced_VBN [WZPAST]
in_PIN
2004_CD
continued_VBD
ii_FW
Disposal_NN
of_PIN
the_DT
vaccines_NN
business_NOMZ
continued_VBD
The_DT
operating_GER
results_NN
of_PIN
the_DT
vaccines_NN
business_NOMZ
represented_VBD
the_DT
entire_JJ
Biologics_NN
segment_NOMZ
as_RB
well_RB
as_IN
certain_JJ
parts_NN
of_PIN
the_DT
International_NN
and_PHC
R&D_NN
segments_NOMZ
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
disposal_NN
of_PIN
the_DT
vaccines_NN
business_NOMZ
,_,
the_DT
Biologics_NN
segment_NOMZ
is_VPRT
no_RB
longer_RB
an_DT
operating_GER
segment_NOMZ
of_PIN
the_DT
Company_NN
and_CC
the_DT
International_NN
and_PHC
R&D_NN
segments_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
accordingly_RB
._.
The_DT
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
the_DT
discontinued_VBN
vaccines_NN
operation_NOMZ
are_VPRT [PASS]
summarized_VBN
below_PLACE
._.
December_NN
31_CD
,_,
2003_CD
$_$
000_CD
Current_JJ
assets_NN
Cash_NN
and_PHC
cash_NN
equivalents_NN
245_CD
Accounts_NN
receivable_NN
,_,
net_JJ
21,107_CD
Inventories_NN
,_,
net_JJ
2,130_CD
Prepaid_JJ
expenses_NN
and_CC
other_JJ
current_JJ
assets_NN
614_CD
Total_JJ
current_JJ
assets_NN
24,096_CD
Long-term_JJ
assets_NN
Investments_NOMZ
178_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
,_,
net_JJ
66,730_CD
Goodwill_NN
,_,
net_JJ
4,629_CD
Other_JJ
non-current_JJ
assets_NN
533_CD
Total_JJ
long-term_JJ
assets_NN
72,070_CD
Total_JJ
assets_NN
96,166_CD
Current_JJ
liabilities_NOMZ
Current_JJ
installments_NOMZ
of_PIN
long-term_JJ
debt_NN
764_CD
Accounts_NN
payable_JJ
and_CC
accrued_VBN
expenses_NN
9,715_CD
Total_JJ
current_JJ
liabilities_NOMZ
10,479_CD
Long-term_JJ
debt_NN
,_,
excluding_VBG
current_JJ
installments_NOMZ
764_CD
Other_JJ
long-term_JJ
liabilities_NOMZ
15_CD
Total_JJ
long-term_JJ
liabilities_NOMZ
779_CD
Total_JJ
assets_NN
less_RB
total_JJ
liabilities_NOMZ
84,908_CD
At_PIN
December_NN
31_CD
,_,
2004_CD
the_DT
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
the_DT
discontinued_VBN
vaccines_NN
operation_NOMZ
were_VBD
$_$
nil_JJ
._.
Actions_NOMZ
commenced_VBD
in_PIN
2003_CD
i_FPP1
Closure_NN
of_PIN
Lead_JJ
Optimization_NOMZ
The_DT
closure_NN
of_PIN
Lead_JJ
Optimization_NOMZ
resulted_VBD
in_PIN
:_:
the_DT
severance_NN
of_PIN
134_CD
employees_NN
._.
As_IN
of_PIN
December_NN
2004_CD
,_,
all_QUAN
employees_NN
had_VBD [PEAS]
left_VBN
the_DT
Company_NN
:_:
a_DT
$_$
6.0_CD
million_CD
write-off_PIN
of_PIN
tangible_JJ
fixed_JJ
assets_NN
._.
These_DEMO
assets_NN
,_,
primarily_RB
laboratory_NN
equipment_NOMZ
,_,
were_VBD [BYPA]
used_VBN
by_PIN
Lead_JJ
Optimization_NOMZ
for_PIN
R&D_NN
and_CC
had_VBD
no_SYNE
alternative_JJ
use_NN
:_:
and_ANDC
the_DT
cancellation_NOMZ
,_,
to_PIN
the_DT
extent_NN
possible_JJ
,_,
of_PIN
contracts_NN
directly_RB
relating_VBG
to_PIN
Lead_JJ
Optimization_NOMZ
._.
72_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
73_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV] [THATD]
3_CD
Reorganizations_NOMZ
continued_VBD
Actions_NOMZ
commenced_VBN [WZPAST]
in_PIN
2003_CD
continued_VBD
i_FPP1
Closure_NN
of_PIN
Lead_JJ
Optimization_NOMZ
continued_VBD
The_DT
costs_NN
associated_VBN [WZPAST]
with_PIN
these_DEMO
actions_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
reflected_VBN [PRIV]
in_PIN
reorganization_NOMZ
costs_NN
in_PIN
the_DT
statement_NOMZ
of_PIN
operations_NOMZ
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2003_CD
and_CC
within_PIN
the_DT
reporting_GER
segments_NOMZ
as_IN
follows_VPRT
:_:
Allocation_NOMZ
between_PIN
segments_NOMZ
R&D_NN
International_NN
$_$
000_CD
$_$
000_CD
Employee_NN
severance_NN
6,425_CD
Write-off_PIN
of_PIN
tangible_JJ
fixed_JJ
assets_NN
6,026_CD
Other_JJ
costs_NN
800_CD
7,225_CD
6,026_CD
The_DT
following_VBG
provides_VPRT
a_DT
roll-forward_NN
of_PIN
the_DT
liability_NOMZ
to_PIN
December_NN
31_CD
,_,
2004_CD
:_:
Costs_NN
recorded_VBN
Utilization_NOMZ
in_PIN
year_NN
to_PIN
in_PIN
year_NN
to_PIN
Opening_GER
December_NN
31_CD
,_,
December_NN
31_CD
,_,
Closing_GER
liability_NOMZ
2004_CD
2004_CD
liability_NOMZ
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Employee_NN
severance_NN
3,452_CD
118_CD
3,570_CD
Other_JJ
costs_NN
325_CD
9_CD
98_CD
236_CD
3,777_CD
127_CD
3,668_CD
236_CD
The_DT
following_VBG
provides_VPRT
a_DT
roll-forward_NN
of_PIN
the_DT
liability_NOMZ
as_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
:_:
Costs_NN
recorded_VBN
Utilization_NOMZ
in_PIN
year_NN
to_PIN
in_PIN
year_NN
to_PIN
Opening_GER
December_NN
31_CD
,_,
December_NN
31_CD
,_,
Closing_GER
liability_NOMZ
2003_CD
2003_CD
liability_NOMZ
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Employee_NN
severance_NN
6,425_CD
2,973_CD
3,452_CD
Write-down_NN
of_PIN
tangible_JJ
fixed_JJ
assets_NN
6,026_CD
6,026_CD
Other_JJ
costs_NN
800 475 325_CD
13,251_CD
9,474_CD
3,777_CD
ii_FW
Disposition_NOMZ
of_PIN
Canadian_NN
facilities_NOMZ
Subsequent_JJ
to_PIN
the_DT
closure_NN
of_PIN
Lead_JJ
Optimization_NOMZ
and_CC
the_DT
decision_NN
to_TO
dispose_VB
of_PIN
the_DT
vaccines_NN
business_NOMZ
,_,
the_DT
Company_NN
began_VBD
an_DT
assessment_NOMZ
of_PIN
its_PIT
property_NN
needs_VPRT
in_PIN
Canada_NN
and_CC
the_DT
United_NN
States_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
this_DEMO
initial_JJ
process_NN
the_DT
Company_NN
decided_VBD [SUAV] [PRIV]
to_TO
dispose_VB
of_PIN
its_PIT
building_GER
in_PIN
Laval_NN
,_,
Canada_NN
,_,
and_ANDC
to_TO
relocate_VB
the_DT
employees_NN
._.
The_DT
Company_NN
also_RB
decided_VBD [SUAV] [PRIV]
to_TO
sell_VB
its_PIT
building_GER
in_PIN
Buffalo_NN
Grove_NN
._.
As_IN
of_PIN
December_NN
31_CD
,_,
2003_CD
,_,
the_DT
Company_NN
had_VBD [PEAS]
obtained_VBN
valuations_NOMZ
of_PIN
the_DT
properties_NN
and_CC
entered_VBD
into_PIN
sale_NN
negotiations_NOMZ
with_PIN
third_JJ
parties_NN
on_PIN
the_DT
Laval_NN
property_NN
and_CC
was_VBD [SPAU]
actively_RB
seeking_VBG
buyers_NN
for_PIN
its_PIT
Buffalo_NN
Grove_NN
facility_NOMZ
._.
Based_VBN [PASTP]
on_PIN
these_DEMO
negotiations_NOMZ
,_,
the_DT
valuations_NOMZ
obtained_VBN
,_,
the_DT
limitations_NOMZ
on_PIN
use_NN
of_PIN
the_DT
building_GER
in_PIN
its_PIT
current_JJ
state_NN
and_CC
the_DT
overall_JJ
real_JJ
estate_NN
market_NN
,_,
the_DT
Company_NN
recorded_VBD
an_DT
impairment_NOMZ
charge_NN
of_PIN
$_$
10.7_CD
million_CD
in_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2003_CD
,_,
which_WDT [SERE]
is_VPRT [PASS]
included_VBN
in_PIN
reorganization_NOMZ
costs_NN
in_PIN
the_DT
consolidated_JJ
statement_NOMZ
of_PIN
operations_NOMZ
._.
The_DT
Company_NN
reclassified_VBD
to_PIN
prepaid_JJ
expenses_NN
and_CC
other_JJ
current_JJ
assets_NN
the_DT
assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
sale_NN
._.
73_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
74_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
4_CD
Business_NOMZ
combination_NOMZ
:_:
Shire_NN
US_FPP1
Manufacturing_GER
Inc._NN
._.
SUMI_NN
acquisition_NOMZ
On_PIN
September_NN
27_CD
,_,
2002_CD
,_,
the_DT
Company_NN
completed_VBD
its_PIT
acquisition_NOMZ
of_PIN
SUMI_NN
from_PIN
Niro_NN
Inc._NN
for_PIN
a_DT
cash_NN
consideration_NOMZ
of_PIN
$_$
17.3_CD
million_CD
,_,
including_VBG
$_$
0.3_CD
million_CD
costs_NN
of_PIN
acquisition_NOMZ
._.
This_DEMO
transaction_NOMZ
provided_VBD
the_DT
Company_NN
with_PIN
an_DT
in-house_JJ
facility_NOMZ
in_PIN
which_WDT [PIRE]
to_TO
manufacture_VB
several_QUAN
key_JJ
US_FPP1
products_NN
._.
The_DT
acquisition_NOMZ
was_VBD [PASS]
accounted_VBN
for_PIN
using_VBG
the_DT
purchase_NN
method_NN
and_PHC
goodwill_NN
of_PIN
$_$
10.2_CD
million_CD
was_VBD [PASS]
recorded_VBN
._.
The_DT
results_NN
of_PIN
operations_NOMZ
of_PIN
SUMI_NN
have_VPRT [PEAS]
been_VBN [PASS]
included_VBN
in_PIN
the_DT
consolidated_JJ
results_NN
of_PIN
the_DT
Company_NN
since_OSUB
the_DT
date_NN
of_PIN
acquisition_NOMZ
._.
The_DT
purchase_NN
price_NN
of_PIN
$_$
17.3_CD
million_CD
was_VBD [PASS]
allocated_VBN
as_IN
follows_VPRT
:_:
Fair_NN
value_NN
$_$
000_CD
Total_JJ
current_JJ
assets_NN
3,188_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
,_,
net_JJ
11,620_CD
Current_JJ
instalments_NOMZ
of_PIN
long-term_JJ
debt_NN
216_CD
Accounts_NN
payable_JJ
1,367_CD
Long-term_JJ
debt_NN
,_,
excluding_VBG
current_JJ
instalments_NOMZ
6,050_CD
Net_JJ
assets_NN
acquired_VBN
7,175_CD
Goodwill_NN
10,175_CD
17,350_CD
Represented_VBN
by_PIN
Purchase_NN
consideration_NOMZ
17,000_CD
Acquisition_NOMZ
fees_NN
350_CD
17,350_CD
The_DT
following_VBG
unaudited_JJ
consolidated_JJ
pro-forma_FW
results_NN
of_PIN
operations_NOMZ
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2002_CD
gave_VBD
effect_NN
to_PIN
the_DT
acquisition_NOMZ
of_PIN
SUMI_NN
as_IN
if_COND
it_PIT
were_VBD [PASS]
completed_VBN
at_PIN
the_DT
beginning_GER
of_PIN
the_DT
period_NN
._.
These_DEMO
pro-forma_FW
results_NN
reflect_VPRT [PRIV]
incremental_JJ
financing_GER
costs_NN
resulting_VBG [WZPRES]
from_PIN
acquisition_NOMZ
and_CC
the_DT
amortization_NOMZ
of_PIN
acquired_VBN
intangible_JJ
assets_NN
:_:
2002_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
Revenues_NN
1,042,748_CD
Net_JJ
income_NN
248,983_CD
Earnings_GER
per_PIN
share_NN
basic_JJ
49.7_CD
Earnings_GER
per_PIN
share_NN
diluted_VBN
48.7_CD
This_DEMO
unaudited_JJ
pro-forma_FW
financial_JJ
information_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
for_PIN
comparative_JJ
purposes_NN
only_DWNT
and_CC
does_VPRT
not_XX0
purport_VB
to_TO
represent_VB
the_DT
results_NN
of_PIN
operations_NOMZ
which_WDT [WHSUB]
would_PRMD [SPAU]
actually_RB
have_VB [PEAS]
occurred_VBN
had_VBD
the_DT
companies_NN
operated_VBD
as_IN
one_CD
during_PIN
the_DT
period_NN
,_,
nor_SYNE
to_TO
predict_VB [PUBV]
the_DT
Companys_NN
results_NN
of_PIN
future_JJ
operations_NOMZ
._.
5_CD
Disposal_NN
of_PIN
the_DT
Over-The-Counter_NN
OTC_NN
business_NOMZ
In_PIN
December_NN
1999_CD
the_DT
Company_NN
acquired_VBD
a_DT
group_NN
of_PIN
products_NN
,_,
collectively_RB
referred_VBD
to_PIN
as_IN
the_DT
OTC_NN
portfolio_NN
,_,
through_PIN
its_PIT
merger_NN
with_PIN
Roberts_NN
Pharmaceutical_NN
Corporation_NOMZ
Roberts_NN
._.
The_DT
OTC_NN
portfolio_NN
consisted_VBD
of_PIN
non-prescription_JJ
laxatives_NN
and_CC
dietary_JJ
supplements_NOMZ
sold_VBN [WZPAST]
by_PIN
the_DT
Companys_NN
US_FPP1
operating_VBG [WZPRES]
segment_NOMZ
._.
As_IN
a_DT
pharmaceuticals_NN
company_NN
that_TSUB
focuses_VPRT
on_PIN
prescription-only_DWNT
products_NN
,_,
this_DEMO
part_NN
of_PIN
the_DT
business_NOMZ
was_VBD [PASS]
not_XX0
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
a_DT
core_NN
part_NN
of_PIN
the_DT
Companys_NN
long-term_JJ
strategy_NN
and_ANDC
hence_CONJ
the_DT
decision_NN
was_VBD [PASS]
made_VBN
to_TO
divest_VB
the_DT
OTC_NN
portfolio_NN
._.
On_PIN
December_NN
27_CD
,_,
2002_CD
,_,
the_DT
Company_NN
completed_VBD
its_PIT
divestment_NOMZ
of_PIN
the_DT
OTC_NN
business_NOMZ
._.
The_DT
Company_NN
received_VBD
sale_NN
proceeds_NN
of_PIN
$_$
71.0_CD
million_CD
and_CC
recorded_VBD
a_DT
gain_NN
on_PIN
disposal_NN
of_PIN
$_$
2.1_CD
million_CD
._.
The_DT
historical_JJ
consolidated_JJ
financial_JJ
statements_NOMZ
were_VBD [PASS]
restated_VBN
to_TO
reflect_VB [PRIV]
the_DT
OTC_NN
business_NOMZ
as_IN
a_DT
discontinued_VBN
operation_NOMZ
for_PIN
all_QUAN
periods_NN
presented_VBN
._.
Operating_VBG
results_NN
of_PIN
the_DT
discontinued_VBN
operation_NOMZ
for_PIN
2002_CD
are_VPRT [PASS]
summarized_VBN
below_PLACE
._.
The_DT
amounts_NN
include_VPRT
income_NN
tax_NN
provisions_NN
based_VBN [WZPAST]
on_PIN
the_DT
stand-alone_JJ
results_NN
of_PIN
the_DT
OTC_NN
business_NOMZ
._.
There_EX
have_VPRT [PEAS]
been_VBN
no_SYNE
allocations_NOMZ
of_PIN
general_JJ
and_PHC
administrative_JJ
corporate_JJ
costs_NN
or_CC
interest_NN
expense_NN
related_VBN [WZPAST]
to_PIN
corporate_JJ
credit_NN
facilities_NOMZ
to_PIN
the_DT
business_NOMZ
._.
As_IN
the_DT
OTC_NN
business_NOMZ
functioned_VBD
within_PIN
the_DT
US_FPP1
,_,
which_WDT [SERE]
itself_PIT
essentially_RB
functions_NOMZ
as_IN
an_DT
independent_JJ
entity_NOMZ
,_,
no_SYNE
corporate_JJ
costs_NN
were_VBD [PASS]
eliminated_VBN
upon_PIN
discontinuance_NN
of_PIN
the_DT
operation_NOMZ
._.
Within_PIN
the_DT
US_FPP1
,_,
the_DT
OTC_NN
business_NOMZ
had_VBD
few_QUAN
dedicated_VBN
resources_NN
._.
All_QUAN
of_PIN
the_DT
products_NN
were_VBD [PASS]
manufactured_VBN
and_PHC
packaged_VBN
by_PIN
third-party_JJ
contract_NN
manufacturers_NN
._.
The_DT
products_NN
were_VBD [PASS]
distributed_VBN
through_PIN
a_DT
shared_VBN
warehouse_NN
facility_NOMZ
and_CC
sold_VBN
through_PIN
a_DT
small_JJ
sales_NN
team_NN
._.
74_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
75_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
5_CD
Disposal_NN
of_PIN
the_DT
Over-The-Counter_NN
OTC_NN
business_NOMZ
continued_VBD
2002_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
Product_NN
sales_NN
24,010_CD
Cost_NN
of_PIN
product_NN
sales_NN
5,764_CD
Gross_NN
profit_NN
18,246_CD
Operating_GER
expenses_NN
Selling_VBG [WZPRES]
,_,
general_JJ
and_PHC
administrative_JJ
8,550_CD
Operating_GER
income_NN
9,696_CD
Income_NN
taxes_NN
3,588_CD
1_CD
Income_NN
from_PIN
discontinued_VBN
operations_NOMZ
net_NN
of_PIN
tax_NN
6,108_CD
Gain_NN
on_PIN
sale_NN
net_NN
of_PIN
tax_NN
2,083_CD
8,191_CD
1_CD
The_DT
loss_NN
from_PIN
discontinued_VBN
operations_NOMZ
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2002_CD
of_PIN
$_$
11.7_CD
million_CD
comprises_VPRT
a_DT
loss_NN
from_PIN
the_DT
vaccines_NN
business_NOMZ
of_PIN
$_$
17.8_CD
million_CD
and_CC
a_DT
gain_NN
from_PIN
the_DT
OTC_NN
business_NOMZ
of_PIN
$_$
6.1_CD
million_CD
._.
6_CD
Accounts_NN
receivable_NN
,_,
net_JJ
Trade_NN
receivables_NN
at_PIN
December_NN
31_CD
,_,
2004_CD
of_PIN
$_$
222.5_CD
million_CD
December_NN
31_CD
,_,
2003_CD
:_:
$_$
194.6_CD
million_CD
,_,
are_VPRT [PASS]
stated_VBN [PUBV]
net_NN
of_PIN
a_DT
provision_NN
for_PIN
doubtful_JJ
accounts_NN
and_PHC
sales_NN
discounts_NN
of_PIN
$_$
4.3_CD
million_CD
December_NN
31_CD
,_,
2003_CD
:_:
$_$
7.9_CD
million_CD
._.
The_DT
movement_NOMZ
in_PIN
the_DT
provision_NN
for_PIN
doubtful_JJ
accounts_NN
and_PHC
sales_NN
discounts_NN
is_VPRT
as_IN
follows_VPRT
:_:
2004 2003 2002_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
As_IN
of_PIN
January_NN
1_CD
7,853_CD
4,585_CD
5,724_CD
Charged_VBN
to_PIN
operations_NOMZ
38,218_CD
42,841_CD
35,021_CD
Released_VBN
to_PIN
income_NN
3,395_CD
Utilization_NOMZ
38,412_CD
39,573_CD
36,160_CD
As_IN
of_PIN
December_NN
31_CD
4,264_CD
7,853_CD
4,585_CD
7_CD
Inventories_NN
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2004_CD
2003_CD
$_$
000_CD
$_$
000_CD
Finished_VBN
goods_NN
22,349_CD
26,226_CD
Work-in-process_JJ
11,831_CD
10,104_CD
Raw_NN
materials_NN
7,050_CD
6,798_CD
41,230_CD
43,128_CD
8_CD
Prepaid_NN
expenses_NN
and_CC
other_JJ
current_JJ
assets_NN
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2004_CD
2003_CD
$_$
000_CD
$_$
000_CD
Prepaid_NN
expenses_NN
31,401_CD
26,158_CD
Assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
sale_NN
see_VPRT [PRIV]
Note_NN
3_CD
12,470_CD
Deferred_JJ
financing_GER
costs_NN
see_VPRT [PRIV]
Note_NN
17_CD
1,004_CD
Subscription_NOMZ
receipts_NN
see_VPRT [PRIV]
Note_NN
3_CD
60,000_CD
Cash_NN
held_VBN [PRIV] [WZPAST]
in_PIN
escrow_NN
see_VPRT [PRIV]
Note_NN
3_CD
30,000_CD
Value_NN
added_VBD [PUBV]
taxes_NN
receivable_JJ
2,124_CD
3,819_CD
Supplemental_NN
Executive_NN
Retirement_NOMZ
Plan_NN
SERP_NN
investment_NOMZ
see_VPRT [PRIV]
Note_NN
25_CD
1,784_CD
Other_JJ
current_JJ
assets_NN
11,962_CD
10,363_CD
137,271_CD
53,814_CD
75_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
76_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
9_CD
Short-term_JJ
investments_NOMZ
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2004_CD
2003_CD
$_$
000_CD
$_$
000_CD
Commercial_JJ
paper_NN
149,659_CD
120,872_CD
Institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
174,752_CD
183,257_CD
324,411_CD
304,129_CD
10_CD
Investments_NOMZ
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2004_CD
2003_CD
$_$
000_CD
$_$
000_CD
1_CD
Investments_NOMZ
in_PIN
private_JJ
companies_NN
2,451_CD
46,068_CD
Available-for-sale_JJ
securities_NOMZ
29,970_CD
21,879_CD
1_CD
Equity-method_JJ
investments_NOMZ
30,846_CD
5,028_CD
63,267_CD
72,975_CD
1_CD
Prior_RB
to_PIN
the_DT
adoption_NOMZ
of_PIN
FIN_NN
46R_NN
the_DT
Company_NN
accounted_VBD
for_PIN
its_PIT
investments_NOMZ
in_PIN
the_DT
GeneChem_NN
Funds_NN
described_VBD
below_PLACE
as_IN
investments_NOMZ
in_PIN
private_JJ
companies_NN
and_CC
did_VBD
not_XX0
consolidate_VB
these_DEMO
investments_NOMZ
as_IN
the_DT
impact_NN
on_PIN
net_JJ
assets_NN
,_,
financial_JJ
position_NOMZ
and_PHC
results_NN
of_PIN
operations_NOMZ
of_PIN
the_DT
Company_NN
were_VBD
individually_RB
and_CC
in_PIN
the_DT
aggregate_JJ
immaterial_NN
._.
These_DEMO
investments_NOMZ
were_VBD [SPAU] [PASS]
appropriately_RB
reclassified_VBN
to_PIN
equity-method_JJ
investments_NOMZ
upon_PIN
the_DT
adoption_NOMZ
of_PIN
FIN_NN
46R_NN
._.
The_DT
Company_NN
recorded_VBN
impairments_NOMZ
of_PIN
$_$
15.4_CD
million_CD
on_PIN
its_PIT
investments_NOMZ
during_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
2003_CD
:_:
$_$
15.5_CD
million_CD
:_:
2002_CD
$_$
8.7_CD
million_CD
._.
All_QUAN
impairments_NOMZ
in_PIN
the_DT
three_CD
years_NN
presented_VBN [WZPAST]
were_VBD [PASS]
recorded_VBN
in_PIN
the_DT
International_NN
segment_NOMZ
._.
a_DT
Investments_NOMZ
in_PIN
private_JJ
companies_NN
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
the_DT
Company_NN
recorded_VBN
impairments_NOMZ
of_PIN
$_$
9.8_CD
million_CD
against_PIN
these_DEMO
investments_NOMZ
based_VBN [WZPAST]
on_PIN
changes_NN
in_PIN
the_DT
estimates_NN
of_PIN
their_TPP3
fair_JJ
value_NN
._.
This_DEMO
amount_NN
includes_VPRT
$_$
4.2_CD
million_CD
to_TO
reduce_VB
the_DT
value_NN
of_PIN
an_DT
investment_NOMZ
in_PIN
a_DT
private_JJ
company_NN
that_TSUB
gained_VBD
a_DT
listing_GER
on_PIN
March_NN
24_CD
,_,
2004_CD
:_:
the_DT
initial_JJ
listing_GER
price_NN
was_VBD
below_PLACE
the_DT
anticipated_JJ
flotation_NOMZ
price_NN
used_VBN
to_TO
value_VB
the_DT
investment_NOMZ
at_PIN
December_NN
31_CD
,_,
2003_CD
see_VPRT [PRIV]
below_PLACE
and_CC
the_DT
Company_NN
believes_VPRT [PRIV]
the_DT
decline_NN
in_PIN
value_NN
was_VBD [BEMA]
other-than-temporary_PRED
._.
After_IN
the_DT
date_NN
of_PIN
the_DT
listing_VBG
the_DT
investment_NOMZ
was_VBD [PASS]
reclassified_VBN
to_PIN
available-for-sale_JJ
securities_NOMZ
and_CC
so_RB
any_QUAN
changes_NN
since_OSUB
the_DT
initial_JJ
listing_GER
date_NN
have_VPRT [PEAS]
been_VBN [PASS]
recorded_VBN
in_PIN
other_JJ
comprehensive_JJ
income_NN
._.
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2003_CD
,_,
the_DT
Company_NN
recorded_VBN
impairments_NOMZ
of_PIN
$_$
15.5_CD
million_CD
._.
An_DT
impairment_NOMZ
of_PIN
$_$
6.2_CD
million_CD
was_VBD [PASS]
recorded_VBN
to_TO
reduce_VB
the_DT
carrying_VBG
value_NN
of_PIN
the_DT
investment_NOMZ
in_PIN
the_DT
private_JJ
company_NN
seeking_VBG [WZPRES]
a_DT
listing_GER
see_VPRT [PRIV]
above_PLACE
to_PIN
one_CD
based_VBN
on_PIN
the_DT
anticipated_JJ
flotation_NOMZ
price_NN
for_PIN
the_DT
share_NN
offering_GER
early_TIME
in_PIN
2004_CD
._.
Also_RB
,_,
an_DT
impairment_NOMZ
of_PIN
$_$
8.5_CD
million_CD
was_VBD [PASS]
recorded_VBN
in_PIN
relation_NOMZ
to_PIN
the_DT
GeneChem_NN
Funds_NN
investment_NOMZ
,_,
following_VBG
reviews_NN
of_PIN
the_DT
Funds_NN
investment_NOMZ
portfolios_NN
that_TSUB
identified_VBD
other-than-temporary_JJ
declines_NN
in_PIN
the_DT
value_NN
of_PIN
certain_JJ
private_JJ
and_CC
publicly_RB
quoted_VBN
securities_NOMZ
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
Funds_NN
._.
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2002_CD
,_,
the_DT
Company_NN
recorded_VBN
impairments_NOMZ
of_PIN
$_$
6.6_CD
million_CD
due_JJ
to_PIN
a_DT
decrease_NN
in_PIN
the_DT
market_NN
value_NN
of_PIN
its_PIT
investment_NOMZ
in_PIN
private_JJ
companies_NN
based_VBN [WZPAST]
on_PIN
changes_NN
in_PIN
estimates_NN
in_PIN
value_NN
from_PIN
the_DT
prior_JJ
year_NN
._.
The_DT
changes_NN
in_PIN
fair_JJ
market_NN
value_NN
which_WDT [WHSUB]
resulted_VBD
in_PIN
the_DT
write-downs_NN
referred_VBD
to_PIN
above_PLACE
were_VBD [PASS]
based_VBN
on_PIN
the_DT
Companys_NN
estimates_NN
of_PIN
fair_JJ
value_NN
._.
These_DEMO
estimates_NN
were_VBD [PASS]
derived_VBN
from_PIN
financial_JJ
and_PHC
other_JJ
publicly_RB
available_JJ
information_NOMZ
such_JJ
as_IN
press_NN
releases_NN
and_CC
recent_JJ
capital_NN
raising_VBG [WZPRES]
activities_NOMZ
._.
b_NN
Available-for-sale_JJ
securities_NOMZ
i_FPP1
Gain_NN
on_PIN
sale_NN
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
,_,
the_DT
Company_NN
sold_VBD
an_DT
investment_NOMZ
in_PIN
an_DT
available-for-sale_JJ
security_NOMZ
,_,
valued_VBN [PASTP]
at_PIN
$_$
11.9_CD
million_CD
,_,
realizing_VBG [PRIV] [PRESP]
a_DT
gain_NN
on_PIN
the_DT
sale_NN
of_PIN
$_$
14.8_CD
million_CD
2003_CD
:_:
$_$
nil_JJ
._.
See_VB [PRIV]
Note_VB [PRIV]
24_CD
._.
ii_FW
Other-than-temporary_JJ
impairment_NOMZ
The_DT
Company_NN
recorded_VBN
other-than-temporary_JJ
impairments_NOMZ
of_PIN
$_$
1.6_CD
million_CD
,_,
$_$
nil_JJ
and_CC
$_$
1.4_CD
million_CD
against_PIN
its_PIT
available-for-sale_JJ
securities_NOMZ
in_PIN
the_DT
years_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
,_,
2003_CD
and_CC
2002_CD
respectively_RB
._.
At_PIN
December_NN
31_CD
,_,
2004_CD
,_,
the_DT
Company_NN
had_VBD
no_SYNE
available-for-sale_JJ
investments_NOMZ
in_PIN
a_DT
significant_JJ
unrealized_JJ
loss_NN
position_NOMZ
for_PIN
which_WDT [PIRE]
other-thantemporary_JJ
impairments_NOMZ
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
recognized_VBN [PRIV]
._.
76_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
77_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBD [PRIV] [THATD]
10_CD
Investments_NOMZ
continued_VBD
c_NN
Equity-method_JJ
investments_NOMZ
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2004_CD
2003_CD
$_$
000_CD
$_$
000_CD
GSK_NN
6,179_CD
5,028_CD
GeneChem_NN
Funds_NN
18,343_CD
Other_JJ
6,324_CD
30,846_CD
5,028_CD
i_FPP1
GSK_NN
The_NN
Company_NN
has_VPRT [PEAS]
accounted_VBN
for_PIN
its_PIT
commercialization_NOMZ
partnership_NN
with_PIN
GSK_NN
through_PIN
which_WDT [PIRE]
the_DT
products_NN
3TC_NN
and_PHC
ZEFFIX_NN
are_VPRT [PASS]
marketed_VBN
in_PIN
Canada_NN
,_,
using_VBG [PRESP]
the_DT
equity-method_NN
of_PIN
accounting_GER
._.
The_DT
Companys_NN
50_CD
%_NN
share_NN
of_PIN
the_DT
partnership_NN
is_VPRT [PASS]
included_VBN
within_PIN
Equity_NOMZ
in_PIN
earnings_GER
of_PIN
equity-method_JJ
investees_NN
._.
ii_FW
GeneChem_NN
Funds_NN
The_DT
GeneChem_NN
Technologies_NN
Venture_NN
Fund_NN
and_CC
the_DT
GeneChem_NN
Therapeutics_NN
Venture_NN
Fund_NN
The_NN
Funds_NN
are_VPRT [BEMA]
Canadian_JJ
limited_JJ
partnerships_NN
investing_VBG [WZPRES]
in_PIN
healthcare_NN
research_NN
and_PHC
development_NOMZ
companies_NN
,_,
in_PIN
which_WDT [PIRE]
the_DT
Company_NN
owns_VPRT
30_CD
%_NN
and_CC
11_CD
%_NN
shares_NN
respectively_RB
._.
At_PIN
December_NN
31_CD
,_,
2004_CD
the_DT
Funds_NN
net_JJ
assets_NN
totalled_VBD
approximately_RB
$_$
107_CD
million_CD
._.
The_DT
Company_NN
is_VPRT [PASS]
involved_VBN
as_IN
a_DT
limited_JJ
partner_NN
and_CC
the_DT
general_JJ
partner_NN
of_PIN
the_DT
Funds_NN
:_:
involvement_NOMZ
in_PIN
the_DT
Funds_NN
dates_NN
from_PIN
between_PIN
1997_CD
and_CC
2000_CD
._.
The_DT
Companys_NN
exposure_NN
to_PIN
loss_NN
as_CONJ
a_NULL
result_NULL
of_PIN
its_PIT
involvement_NOMZ
with_PIN
the_DT
Funds_NN
is_VPRT [PASS]
limited_VBN
to_PIN
the_DT
carrying_VBG
value_NN
of_PIN
the_DT
investment_NOMZ
,_,
$_$
18.3_CD
million_CD
at_PIN
December_NN
31_CD
,_,
2004_CD
2003_CD
:_:
$_$
19.8_CD
million_CD
,_,
2002_CD
:_:
$_$
20.0_CD
million_CD
and_CC
its_PIT
commitment_NOMZ
to_PIN
further_JJ
investment_NOMZ
of_PIN
$_$
2.9_CD
million_CD
2003_CD
:_:
$_$
4.1_CD
million_CD
,_,
2002_CD
:_:
$_$
1.9_CD
million_CD
._.
During_PIN
the_DT
last_JJ
six_CD
months_NN
of_PIN
2004_CD
,_,
the_DT
Company_NN
recorded_VBD
an_DT
impairment_NOMZ
of_PIN
$_$
4.0_CD
million_CD
against_PIN
the_DT
investment_NOMZ
in_PIN
the_DT
Funds_NN
following_VBG [WZPRES]
reviews_NN
of_PIN
the_DT
Funds_NN
investment_NOMZ
portfolios_NN
that_TSUB
identified_VBD
other-than-temporary_JJ
declines_NN
in_PIN
the_DT
value_NN
of_PIN
certain_JJ
private_JJ
and_CC
publicly_RB
quoted_VBN
securities_NOMZ
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
Funds_NN
._.
11_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
,_,
net_JJ
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2004_CD
2003_CD
$_$
000_CD
$_$
000_CD
Land_NN
and_PHC
buildings_GER
80,631_CD
66,314_CD
Office_NN
furniture_NN
,_,
fittings_GER
and_PHC
equipment_NOMZ
67,301_CD
46,257_CD
Warehouse_NN
,_,
laboratory_NN
and_PHC
manufacturing_GER
equipment_NOMZ
34,823_CD
55,186_CD
182,755_CD
167,757_CD
Less_RB
:_:
Accumulated_VBN
depreciation_NOMZ
51,404_CD
73,262_CD
131,351_CD
94,495_CD
Depreciation_NOMZ
expense_NN
for_PIN
the_DT
years_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
,_,
2003_CD
and_CC
2002_CD
was_VBD
$_$
22.5_CD
million_CD
,_,
$_$
14.1_CD
million_CD
and_CC
$_$
11.5_CD
million_CD
respectively_RB
._.
12_CD
Goodwill_NN
and_CC
other_JJ
intangible_JJ
assets_NN
,_,
net_JJ
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2004_CD
2003_CD
$_$
000_CD
$_$
000_CD
Goodwill_NN
arising_VBG [WZPRES]
on_PIN
businesses_NOMZ
acquired_VBN
296,607_CD
275,594_CD
Less_RB
:_:
accumulated_VBN
amortization_NOMZ
61,211_CD
54,363_CD
235,396_CD
221,231_CD
Other_JJ
intangible_JJ
assets_NN
Intellectual_NN
property_NN
rights_NN
acquired_VBD
543,969_CD
469,137_CD
Less_RB
:_:
accumulated_VBN
amortization_NOMZ
234,672_CD
161,255_CD
309,297_CD
307,882_CD
Total_JJ
544,693_CD
529,113_CD
77_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
78_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
12_CD
Goodwill_NN
and_CC
other_JJ
intangible_JJ
assets_NN
,_,
net_JJ
continued_VBD
The_DT
increase_NN
in_PIN
the_DT
net_JJ
book_NN
value_NN
of_PIN
goodwill_NN
and_CC
other_JJ
intangible_JJ
assets_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
is_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
table_NN
below_PLACE
:_:
Other_JJ
intangible_JJ
Goodwill_NN
assets_NN
$_$
000_CD
$_$
000_CD
As_IN
of_PIN
January_NN
1_CD
,_,
2004_CD
221,231_CD
307,882_CD
Acquisitions_NOMZ
49,189_CD
Amortization_NOMZ
charged_VBN
38,724_CD
Asset_NN
impairments_NOMZ
13,477_CD
Disposals_NN
2,868_CD
Foreign_JJ
currency_NN
translation_NOMZ
14,165_CD
7,295_CD
As_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
235,396_CD
309,297_CD
The_DT
acquisition_NOMZ
of_PIN
other_JJ
intangible_JJ
assets_NN
is_VPRT [SPAU] [PASS]
primarily_RB
related_VBN
to_PIN
the_DT
purchase_NN
of_PIN
the_DT
exclusive_JJ
commercialization_NOMZ
rights_NN
of_PIN
REMINYL_NN
in_PIN
the_DT
UK_NN
and_PHC
Ireland_NN
$_$
30.0_CD
million_CD
,_,
and_ANDC
milestone_NN
payments_NOMZ
relating_VBG [WZPRES]
to_PIN
FOSRENOL_NN
$_$
19.0_CD
million_CD
._.
The_DT
weighted_JJ
average_JJ
amortization_NOMZ
period_NN
for_PIN
these_DEMO
additions_NOMZ
is_VPRT [BEMA]
9.5_CD
years_NN
._.
Amortization_NOMZ
charged_VBD
for_PIN
the_DT
three_CD
years_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
,_,
2003_CD
and_CC
2002_CD
was_VBD
$_$
38.7_CD
million_CD
,_,
$_$
26.4_CD
million_CD
and_CC
$_$
20.8_CD
million_CD
,_,
respectively_RB
._.
Goodwill_NN
was_VBD [SPAU] [PASS]
no_RB
longer_RB
amortized_VBN
with_PIN
effect_NN
from_PIN
January_NN
1_CD
,_,
2002_CD
following_VBG
the_DT
adoption_NOMZ
of_PIN
SFAS_NN
No._NN
._.
142_CD
,_,
Goodwill_NN
and_CC
Other_JJ
Intangible_NN
Assets_NN
SFAS_NN
No._NN
._.
The_DT
useful_JJ
economic_JJ
lives_NN
of_PIN
other_JJ
intangible_JJ
assets_NN
continue_VPRT
to_TO
be_VB [PASS]
amortized_VBN
under_IN
SFAS_NN
No._NN
._.
Management_NOMZ
estimates_VPRT [PRIV]
that_THVC
the_DT
annual_JJ
amortization_NOMZ
charges_NN
in_PIN
respect_NN
of_PIN
intangible_JJ
fixed_VBN
assets_NN
held_VBD [PRIV]
as_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
will_PRMD
average_VB
approximately_RB
$_$
40_CD
million_CD
for_PIN
each_QUAN
of_PIN
the_DT
five_CD
years_NN
to_PIN
December_NN
31_CD
,_,
2009_CD
._.
Estimated_VBN [PRIV]
amortization_NOMZ
expense_NN
can_POMD
be_VB [BYPA]
affected_VBN
by_PIN
various_JJ
factors_NN
including_VBG [WZPRES]
future_JJ
acquisitions_NOMZ
,_,
disposals_NN
of_PIN
product_NN
rights_NN
and_CC
the_DT
technological_JJ
advancement_NOMZ
and_CC
regulatory_JJ
approval_NN
of_PIN
competitor_NN
products_NN
._.
During_PIN
2004_CD
,_,
the_DT
Company_NN
recorded_VBN
impairments_NOMZ
of_PIN
$_$
13.5_CD
million_CD
._.
These_DEMO
impairments_NOMZ
resulted_VBD
from_PIN
a_DT
change_NN
of_PIN
operational_JJ
management_NOMZ
and_CC
its_PIT
views_NN
of_PIN
the_DT
economic_JJ
value_NN
and_CC
strategic_JJ
worth_NN
of_PIN
the_DT
products_NN
concerned_VBN
,_,
which_WDT [SERE]
decreased_VBD
estimated_VBN [PRIV]
future_JJ
cash_NN
flows_NN
._.
$_$
1.5_CD
million_CD
of_PIN
these_DEMO
impairments_NOMZ
were_VBD [PASS]
recorded_VBN
in_PIN
the_DT
US_FPP1
segment_NOMZ
and_CC
$_$
12.0_CD
million_CD
in_PIN
the_DT
International_NN
segment_NOMZ
._.
During_PIN
2003_CD
the_DT
Company_NN
recorded_VBN
asset_NN
impairments_NOMZ
of_PIN
$_$
12.1_CD
million_CD
2002_CD
:_:
$_$
18.8_CD
million_CD
and_CC
an_DT
asset_NN
write-down_NN
of_PIN
$_$
15.4_CD
million_CD
._.
The_DT
asset_NN
impairments_NOMZ
of_PIN
$_$
12.1_CD
million_CD
resulted_VBD
from_PIN
a_DT
decline_NN
in_PIN
product_NN
prices_NN
,_,
which_WDT [SERE]
decreased_VBD
estimated_VBN [PRIV]
future_JJ
cash_NN
flows_NN
._.
The_DT
asset_NN
write-down_NN
of_PIN
$_$
15.4_CD
million_CD
resulted_VBD
from_PIN
a_DT
decision_NN
not_XX0
to_TO
renew_VB
product_NN
licenses_NN
that_TSUB
were_VBD
not_XX0
core_NN
to_PIN
the_DT
business_NOMZ
._.
The_DT
impairments_NOMZ
and_PHC
write-downs_NN
totalling_VBG [WZPRES]
$_$
27.5_CD
million_CD
were_VBD [PASS]
recorded_VBN
in_PIN
the_DT
US_FPP1
segment_NOMZ
$_$
11.7_CD
million_CD
and_CC
the_DT
International_NN
segment_NOMZ
$_$
15.8_CD
million_CD
._.
During_PIN
2002_CD
the_DT
Company_NN
reviewed_VBD
its_PIT
existing_JJ
product_NN
base_NN
._.
On_PIN
completion_NOMZ
of_PIN
this_DEMO
review_NN
,_,
management_NOMZ
decided_VBD [SUAV] [PRIV]
to_TO
cease_VB
supporting_VBG
certain_JJ
products_NN
that_TSUB
were_VBD [PASS]
not_XX0
considered_VBN [PRIV]
to_TO
be_VB
core_NN
to_PIN
the_DT
business_NOMZ
and_CC
to_TO
redirect_VB
investment_NOMZ
toward_PIN
other_JJ
more_EMPH
profitable_JJ
products_NN
._.
Intangible_JJ
assets_NN
associated_VBN [WZPAST]
with_PIN
these_DEMO
products_NN
,_,
namely_CONJ
product_NN
rights_NN
and_PHC
licenses_NN
,_,
were_VBD [PASS]
written_VBN [PUBV]
down_RP
to_PIN
their_TPP3
fair_JJ
value_NN
based_VBN [WZPAST]
on_PIN
discounted_JJ
cash_NN
flow_NN
analyses_NN
._.
This_DEMP
resulted_VBD
in_PIN
the_DT
recording_GER
of_PIN
an_DT
impairment_NOMZ
loss_NN
of_PIN
$_$
18.8_CD
million_CD
$_$
10.8_CD
million_CD
in_PIN
the_DT
US_FPP1
segment_NOMZ
and_CC
$_$
8.0_CD
million_CD
in_PIN
the_DT
International_NN
segment_NOMZ
._.
The_DT
net_JJ
book_NN
value_NN
of_PIN
goodwill_NN
by_PIN
operating_VBG
segment_NOMZ
is_VPRT
as_IN
follows_VPRT
:_:
US_FPP1
International_NN
Corporate_NN
R&D_NN
Total_NN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000 2004 205_CD
,386_CD
30,010_CD
235,396_CD
2003_CD
193,023_CD
28,298_CD
221,321_CD
There_EX
were_VBD
no_SYNE
changes_NN
in_PIN
the_DT
allocation_NOMZ
of_PIN
goodwill_NN
in_PIN
either_CC
period_NN
._.
All_QUAN
the_DT
movements_NOMZ
relate_VPRT
to_PIN
foreign_JJ
exchange_NN
._.
78_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
79_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
13_CD
Other_JJ
non-current_JJ
assets_NN
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2004_CD
2003_CD
$_$
000_CD
$_$
000_CD
Deferred_VBN
financing_GER
costs_NN
see_VPRT [PRIV]
Note_NN
17_CD
6,441_CD
SERP_NN
investment_NOMZ
see_VPRT [PRIV]
Note_NN
25_CD
7,698_CD
12,042_CD
IDB_NN
loan_NN
see_VPRT [PRIV]
Note_NN
3_CD
30,000_CD
Other_JJ
assets_NN
1,197_CD
3,937_CD
38,895_CD
22,420_CD
Further_JJ
details_NN
of_PIN
the_DT
SERP_NN
investment_NOMZ
are_VPRT [PASS]
provided_VBN
in_PIN
Note_NN
25_CD
._.
The_DT
amount_NN
shown_VBN [PRIV]
above_PLACE
is_VPRT [BEMA]
the_DT
cash_NN
surrender_NN
value_NN
of_PIN
life_NN
insurance_NN
policies_NN
which_WDT [WHSUB]
is_VPRT [BYPA]
backed_VBN
by_PIN
short-term_JJ
investments_NOMZ
._.
A_DT
liability_NOMZ
of_PIN
$_$
5.5_CD
million_CD
is_VPRT [PASS]
included_VBN
within_PIN
Notes_NN
15_CD
and_CC
18_CD
2003_CD
:_:
$_$
8.9_CD
million_CD
._.
14_CD
Accounts_NN
payable_JJ
and_CC
accrued_VBN
expenses_NN
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2004_CD
2003_CD
$_$
000_CD
$_$
000_CD
Trade_NN
accounts_NN
payable_JJ
35,008_CD
21,301_CD
Accrued_VBN
rebates_NN
Medicaid_NN
84,758_CD
46,075_CD
Accrued_VBN
rebates_NN
Managed_VBN
care_NN
14,667_CD
13,202_CD
Sales_NN
return_VPRT
reserve_NN
22,530_CD
8,343_CD
Accrued_VBN
bonuses_NN
23,171_CD
18,920_CD
Accrued_VBN
coupons_NN
15,869_CD
4,078_CD
R&D_NN
accruals_NN
10,924_CD
27,676_CD
Marketing_GER
accrual_NN
26,095_CD
16,045_CD
Accrued_VBN
royalties_NN
8,250_CD
3,036_CD
Deferred_JJ
revenue_NN
14,472_CD
4,132_CD
Reorganization_NOMZ
accrual_NN
see_VPRT [PRIV]
Note_NN
3_CD
1,936_CD
3,541_CD
Other_JJ
accrued_VBN
expenses_NN
53,551_CD
39,430_CD
311,231_CD
205,779_CD
15_CD
Other_JJ
current_JJ
liabilities_NOMZ
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2004_CD
2003_CD
$_$
000_CD
$_$
000_CD
Income_NN
taxes_NN
payable_JJ
12,597_CD
19,102_CD
Deferred_JJ
payments_NOMZ
18,980_CD
Interest_NN
on_PIN
long-term_JJ
debt_NN
see_VPRT [PRIV]
Note_NN
17_CD
2,653_CD
Social_NN
security_NOMZ
liabilities_NOMZ
3,062_CD
2,216_CD
Value_NN
added_VBD [PUBV]
taxes_NN
1,503_CD
SERP_NN
see_VB [PRIV]
Note_VB [PRIV]
25_CD
1,904_CD
2,781_CD
Other_JJ
accrued_VBN
liabilities_NOMZ
41,015_CD
8,872_CD
77,558_CD
37,127_CD
16_CD
Loan_NN
facility_NOMZ
As_IN
part_NN
of_PIN
the_DT
transaction_NOMZ
which_WDT [WHSUB]
disposed_VBD
of_PIN
the_DT
vaccines_NN
business_NOMZ
Shire_NN
agreed_VBD [SUAV] [PUBV]
to_TO
provide_VB
IDB_NN
with_PIN
a_DT
loan_NN
facility_NOMZ
of_PIN
up_RB
to_TO
$_$
100_CD
million_CD
._.
A_DT
provision_NN
of_PIN
$_$
70_CD
million_CD
was_VBD [PASS]
made_VBN
against_PIN
this_DEMO
facility_NOMZ
representing_VBG [WZPRES]
the_DT
pipeline_NN
products_NN
element_NOMZ
._.
In_PIN
the_DT
period_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
,_,
IDB_NN
drew_VBD
down_RB
$_$
26.8_CD
million_CD
of_PIN
this_DEMO
facility_NOMZ
._.
An_DT
additional_JJ
$_$
43.2_CD
million_CD
is_VPRT [BEMA]
available_PRED
to_PIN
IDB_NN
to_TO
draw_VB
down_RP
through_PIN
September_NN
2008_CD
._.
79_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
80_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
17_CD
Long-term_JJ
debt_NN
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2004_CD
2003_CD
$_$
000_CD
$_$
000_CD
Total_JJ
obligations_NOMZ
116_CD
376,307_CD
Current_JJ
maturities_NOMZ
of_PIN
long-term_JJ
obligations_NOMZ
290_CD
Total_JJ
long-term_JJ
debt_NN
116_CD
376,017_CD
An_DT
analysis_NN
of_PIN
total_JJ
obligations_NOMZ
by_PIN
loan_NN
type_NN
is_VPRT [PASS]
presented_VBN
below_PLACE
:_:
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2004_CD
2003_CD
$_$
000_CD
$_$
000_CD
Convertible_JJ
notes_NN
due_JJ
2011 116 370_CD
,225_CD
Capital_NN
leases_NN
6,082_CD
116_CD
376,307_CD
i_FPP1
Convertible_JJ
notes_NN
due_JJ
2011_CD
The_DT
guaranteed_VBN [PUBV]
convertible_JJ
notes_NN
due_JJ
2011_CD
were_VBD [PASS]
issued_VBN
in_PIN
August_NN
2001_CD
by_PIN
Shire_NN
Finance_NN
Limited_NN
the_DT
Issuer_NN
,_,
a_DT
wholly-owned_JJ
finance_NN
subsidiary_NN
of_PIN
Shire_NN
._.
At_PIN
the_DT
choice_NN
of_PIN
investors_NN
,_,
each_QUAN
$_$
1,000_CD
of_PIN
nominal_JJ
value_NN
notes_NN
was_VBD [BEMA]
convertible_PRED
into_PIN
49.62_CD
Shire_NN
ordinary_JJ
shares_NN
subject_JJ
to_PIN
adjustment_NOMZ
or_CC
16.54_CD
Shire_NN
ADSs_NN
subject_NN
to_PIN
adjustment_NOMZ
at_PIN
any_QUAN
time_NN
up_RP
to_PIN
August_NN
21_CD
,_,
2011_CD
._.
Alternatively_CONJ
,_,
investors_NN
had_VBD
the_DT
option_NOMZ
to_TO
receive_VB
repayment_NOMZ
of_PIN
the_DT
nominal_JJ
principal_NN
in_PIN
cash_NN
either_CC
at_PIN
the_DT
maturity_NOMZ
date_NN
of_PIN
August_NN
21_CD
,_,
2011_CD
or_CC
by_PIN
exercising_VBG
a_DT
put_NN
option_NOMZ
on_PIN
any_QUAN
of_PIN
the_DT
three_CD
put_VBD
dates_NN
being_VBG [WZPRES]
August_NN
21_CD
,_,
2004_CD
,_,
August_NN
21_CD
,_,
2006_CD
and_CC
August_NN
21_CD
,_,
2008_CD
._.
On_PIN
August_NN
21_CD
,_,
2004_CD
,_,
upon_PIN
exercise_NN
of_PIN
the_DT
put_NN
option_NOMZ
by_PIN
substantially_RB
all_QUAN
of_PIN
the_DT
convertible_JJ
note_NN
holders_NN
and_CC
subsequently_TIME
,_,
the_DT
Company_NN
redeemed_VBD
$_$
370.1_CD
million_CD
at_PIN
par_NN
from_PIN
available_JJ
funds_NN
2003_CD
:_:
$_$
29.8_CD
million_CD
,_,
recording_VBG [PRESP]
a_DT
gain_NN
of_PIN
$_$
0.5_CD
million_CD
._.
The_DT
obligation_NOMZ
to_TO
pay_VB
the_DT
remaining_VBG
$_$
0.1_CD
million_CD
of_PIN
the_DT
convertible_JJ
loan_NN
notes_NN
outstanding_JJ
as_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
is_VPRT [BEMA]
due_PRED
in_PIN
2011_CD
._.
The_DT
interest_NN
expense_NN
recorded_VBN [WZPAST]
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
was_VBD
$_$
12.2_CD
million_CD
,_,
including_VBG [PRESP]
the_DT
write-off_PIN
of_PIN
$_$
7.4_CD
million_CD
of_PIN
deferred_VBN
financing_GER
costs_NN
2003_CD
:_:
$_$
7.5_CD
million_CD
,_,
2002_CD
:_:
$_$
8.0_CD
million_CD
._.
ii_NN
Capital_NN
leases_VPRT
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
the_DT
Company_NN
served_VBD
notice_NN
to_TO
buy_VB
out_PIN
its_PIT
remaining_VBG
capital_NN
leases_NN
,_,
totalling_VBG
$_$
5.7_CD
million_CD
,_,
relating_VBG [PRESP]
to_PIN
its_PIT
manufacturing_GER
facility_NOMZ
in_PIN
Maryland_NN
._.
Repayment_NOMZ
of_PIN
the_DT
leases_NN
occurred_VBD
in_PIN
October_NN
2004_CD
._.
December_NN
31_CD
,_,
2003_CD
Obligations_NOMZ
under_IN
capital_NN
leases_NN
$_$
000_CD
Current_JJ
290_CD
Non-current_JJ
5,792_CD
6,082_CD
The_DT
following_GER
is_VPRT [BEMA]
an_DT
analysis_NN
of_PIN
the_DT
leased_VBN
property_NN
under_IN
capital_NN
leases_NN
by_PIN
major_JJ
asset_NN
classes_NN
:_:
December_NN
31_CD
,_,
2003_CD
$_$
000_CD
Land_NN
and_PHC
buildings_GER
6,645_CD
Office_NN
furniture_NN
,_,
fittings_GER
and_PHC
equipment_NOMZ
172_CD
6,817_CD
Less_RB
:_:
accumulated_VBN
depreciation_NOMZ
888_CD
5,929_CD
80_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
81_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
18_CD
Other_JJ
non-current_JJ
liabilities_NOMZ
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2004_CD
2003_CD
$_$
000_CD
$_$
000_CD
SERP_NN
see_VB [PRIV]
Note_VB [PRIV]
25_CD
3,591_CD
6,102_CD
Long-term_JJ
bonuses_NN
4,425_CD
3,117_CD
Deferred_JJ
revenue_NN
9,074_CD
13,430_CD
Insurance_NN
provisions_NN
9,274_CD
5,770_CD
Reorganization_NOMZ
accrual_NN
see_VPRT [PRIV]
Note_NN
3_CD
2,488_CD
236_CD
Other_JJ
accrued_VBN
liabilities_NOMZ
3,307_CD
1,539_CD
32,159_CD
30,194_CD
Deferred_JJ
revenue_NN
relates_VPRT
to_PIN
amounts_NN
received_VBN [WZPAST]
from_PIN
the_DT
out-licensing_GER
of_PIN
AGRYLIN_NN
and_PHC
FOSRENOL_NN
in_PIN
Japan_NN
and_CC
the_DT
global_JJ
out-licensing_GER
of_PIN
TROXATYL_NN
._.
19_CD
Financial_NN
instruments_NOMZ
The_DT
estimated_VBN [PRIV]
fair_JJ
value_NN
of_PIN
the_DT
Companys_NN
financial_JJ
instruments_NOMZ
as_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
and_CC
2003_CD
is_VPRT [PASS]
summarized_VBN
below_PLACE
._.
Certain_JJ
estimates_NN
and_PHC
judgments_NOMZ
were_VBD [PASS]
required_VBN [SUAV]
to_TO
develop_VB
the_DT
fair_JJ
value_NN
amounts_NN
._.
The_DT
fair-value_JJ
amounts_NN
shown_VBN [PRIV]
below_PLACE
are_VPRT
not_XX0
necessarily_RB
indicative_PRED
of_PIN
the_DT
amounts_NN
that_TOBJ
the_DT
Company_NN
would_PRMD
realize_VB [PRIV]
upon_PIN
disposition_NOMZ
nor_SYNE
do_VPRT
they_TPP3
indicate_VPRT [PRIV]
the_DT
Companys_NN
intent_NN
or_CC
ability_NOMZ
to_TO
dispose_VB
of_PIN
the_DT
financial_JJ
instrument_NOMZ
._.
The_DT
following_VBG
methods_NN
and_PHC
assumptions_NOMZ
were_VBD [PASS]
used_VBN
to_TO
estimate_VB [PRIV]
the_DT
fair_JJ
value_NN
of_PIN
each_QUAN
material_NN
class_NN
of_PIN
financial_JJ
instrument_NOMZ
:_:
Short-term_JJ
investments_NOMZ
commercial_JJ
paper_NN
and_CC
institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
the_DT
carrying_GER
value_NN
approximates_VPRT
fair_JJ
value_NN
because_CAUS
of_PIN
the_DT
short-term_JJ
nature_NN
of_PIN
these_DEMO
instruments_NOMZ
._.
Investments_NOMZ
the_DT
carrying_VBG
value_NN
of_PIN
non-current_JJ
investments_NOMZ
with_PIN
readily_RB
determinable_JJ
market_NN
values_NN
equals_VPRT
the_DT
fair_JJ
value_NN
as_IN
such_JJ
instruments_NOMZ
are_VPRT [PASS]
marked_VBN
to_PIN
market_NN
._.
Long-term_JJ
debt_NN
the_DT
fair_JJ
value_NN
of_PIN
long-term_JJ
debt_NN
is_VPRT [PASS]
estimated_VBN [PRIV]
based_VBN
on_PIN
the_DT
discounted_JJ
future_JJ
cash_NN
flows_VPRT
using_VBG
currently_RB
available_JJ
interest_NN
rates_NN
or_CC
,_,
where_RB
the_DT
debt_NN
instrument_NOMZ
is_VPRT [PASS]
traded_VBN
,_,
by_PIN
reference_NN
to_PIN
the_DT
market_NN
price_NN
._.
IDB_NN
subscription_NOMZ
receipts_NN
the_DT
carrying_GER
value_NN
equals_VPRT
the_DT
fair_JJ
value_NN
as_IN
the_DT
subscription_NOMZ
receipts_NN
were_VBD [PASS]
repurchased_VBN
on_PIN
January_NN
7_CD
,_,
2005_CD
for_PIN
$_$
60_CD
million_CD
._.
The_DT
carrying_VBG
amounts_NN
and_CC
corresponding_JJ
fair_JJ
values_NN
of_PIN
financial_JJ
instruments_NOMZ
are_VPRT
as_IN
follows_VPRT
:_:
Carrying_VBG
amount_NN
Fair_NN
value_NN
December_NN
31_CD
,_,
2004_CD
$_$
000_CD
$_$
000_CD
Financial_JJ
assets_NN
:_:
Commercial_JJ
paper_NN
149,659_CD
149,659_CD
Institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
174,752_CD
175,185_CD
Investments_NOMZ
29,970_CD
29,970_CD
IDB_NN
subscription_NOMZ
receipts_NN
60,000_CD
60,000_CD
Financial_NN
liabilities_NOMZ
:_:
Long-term_JJ
debt_NN
116_CD
117_CD
Carrying_VBG
amount_NN
Fair_NN
value_NN
December_NN
31_CD
,_,
2003_CD
$_$
000_CD
$_$
000_CD
Financial_JJ
assets_NN
:_:
Commercial_JJ
paper_NN
120,872_CD
120,872_CD
Institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
183,257_CD
183,257_CD
Investments_NOMZ
21,879_CD
21,879_CD
Financial_NN
liabilities_NOMZ
:_:
Long-term_JJ
debt_NN
376,017_CD
378,005_CD
The_DT
carrying_VBG
amounts_NN
of_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
,_,
accounts_NN
receivable_JJ
,_,
accounts_NN
payable_JJ
and_CC
accrued_VBN
liabilities_NOMZ
approximate_JJ
fair_JJ
value_NN
because_CAUS
of_PIN
the_DT
short-term_JJ
maturity_NOMZ
of_PIN
these_DEMO
instruments_NOMZ
._.
81_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
82_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
20_CD
Commitments_NOMZ
and_PHC
contingencies_NN
a_DT
Leases_NN
Future_NN
minimum_NN
lease_NN
payments_NOMZ
presented_VBD
below_PLACE
include_VPRT
principal_JJ
lease_NN
payments_NOMZ
and_CC
other_JJ
fixed_VBN
executory_NN
fees_NN
under_IN
lease_NN
arrangements_NOMZ
as_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
:_:
Operating_GER
leases_VPRT
$_$
000_CD
2005_CD
16,374_CD
2006_CD
15,004_CD
2007_CD
12,928_CD
2008_CD
9,839_CD
2009_CD
6,892_CD
Thereafter_RB
37,708_CD
98,745_CD
i_FPP1
Operating_GER
leases_VPRT
The_DT
Company_NN
leases_VPRT
facilities_NOMZ
,_,
motor_NN
vehicles_NN
and_CC
certain_JJ
equipment_NOMZ
under_IN
operating_VBG
leases_NN
expiring_VBG [WZPRES]
through_PIN
2015_CD
._.
Lease_NN
and_CC
rental_JJ
expense_NN
included_VBD
in_PIN
selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenses_NN
in_PIN
the_DT
accompanying_VBG
statements_NOMZ
of_PIN
operations_NOMZ
amounted_VBD
to_TO
$_$
7.2_CD
million_CD
,_,
$_$
12.2_CD
million_CD
and_CC
$_$
6.7_CD
million_CD
for_PIN
the_DT
years_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
,_,
2003_CD
and_CC
2002_CD
,_,
respectively_RB
._.
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
,_,
Shire_NN
Inc._NN
a_DT
wholly-owned_JJ
subsidiary_NN
of_PIN
Shire_NN
,_,
signed_VBD
an_DT
eleven_JJ
year_NN
operating_VBG [WZPRES]
lease_NN
on_PIN
a_DT
property_NN
in_PIN
Wayne_NN
,_,
Pennsylvania_NN
._.
Shire_NN
US_FPP1
,_,
Inc._NN
another_DT
wholly-owned_JJ
subsidiary_NN
,_,
acts_VPRT
as_IN
guarantor_NN
in_PIN
respect_NN
of_PIN
this_DEMO
lease_NN
._.
The_DT
future_JJ
minimum_NN
lease_NN
payments_NOMZ
under_IN
the_DT
lease_NN
agreement_NOMZ
are_VPRT
$_$
34.4_CD
million_CD
in_PIN
aggregate_NN
._.
SUMI_NN
,_,
a_DT
wholly-owned_JJ
subsidiary_NN
of_PIN
Shire_NN
,_,
terminated_VBN
certain_JJ
operating_VBG
leases_NN
in_PIN
October_NN
2004_CD
._.
ii_FW
Restricted_VBN
cash_NN
in_PIN
respect_NN
of_PIN
leases_NN
At_PIN
December_NN
31_CD
,_,
2004_CD
the_DT
Company_NN
had_VBD
$_$
5.3_CD
million_CD
of_PIN
restricted_VBN
cash_NN
held_VBN [PRIV]
as_IN
collateral_NN
for_PIN
certain_JJ
equipment_NOMZ
leases_VPRT
2003_CD
:_:
$_$
5.3_CD
million_CD
._.
b_NN
Letters_NN
of_PIN
credit_NN
and_PHC
guarantees_NN
i_FPP1
As_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
,_,
the_DT
Company_NN
had_VBD
outstanding_JJ
an_DT
irrevocable_JJ
standby_JJ
letter_NN
of_PIN
credit_NN
with_PIN
Barclays_NN
Bank_NN
plc_NN
in_PIN
the_DT
amount_NN
of_PIN
$_$
15.0_CD
million_CD
providing_VBG
security_NOMZ
on_PIN
the_DT
recoverability_NOMZ
of_PIN
insurance_NN
claims_NN
._.
The_DT
Company_NN
had_VBD [PEAS]
restricted_VBN
cash_NN
of_PIN
$_$
16.0_CD
million_CD
in_PIN
connection_NOMZ
with_PIN
this_DEMO
letter_NN
of_PIN
credit_NN
._.
ii_FW
The_DT
Companys_NN
acquisitions_NOMZ
,_,
dispositions_NOMZ
and_CC
other_JJ
contractual_JJ
arrangements_NOMZ
contain_VPRT
representations_NOMZ
and_PHC
warranties_NN
,_,
which_WDT [SERE]
have_VPRT [PEAS]
been_VBN [PASS]
determined_VBN [SUAV] [PRIV]
to_TO
have_VB
fide_NN
minimis_NN
potential_JJ
liability_NOMZ
._.
c_NN
Commitments_NOMZ
i_FPP1
As_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
,_,
the_DT
Company_NN
had_VBD
outstanding_JJ
commitments_NOMZ
to_TO
subscribe_VB
for_PIN
interests_NN
in_PIN
companies_NN
and_PHC
partnerships_NN
for_PIN
amounts_NN
totalling_VBG [WZPRES]
$_$
22.0_CD
million_CD
2003_CD
:_:
$_$
8.0_CD
million_CD
of_PIN
which_WDT [PIRE]
$_$
4.2_CD
million_CD
is_VPRT [PASS]
committed_VBN
to_PIN
in_PIN
2005_CD
and_CC
a_DT
further_JJ
$_$
13.7_CD
million_CD
could_POMD
be_VB [BEMA]
payable_PRED
in_PIN
2005_CD
,_,
depending_VBG [PRESP]
on_PIN
the_DT
timing_NN
of_PIN
capital_NN
calls_NN
._.
ii_FW
MTS_FW
METHYPATCH_NN
In_PIN
connection_NOMZ
with_PIN
the_DT
Companys_NN
purchase_NN
of_PIN
MTS_NN
METHYPATCH_NN
in_PIN
2003_CD
,_,
the_DT
Company_NN
has_VPRT
an_DT
obligation_NOMZ
to_TO
make_VB
certain_JJ
payments_NOMZ
on_PIN
the_DT
achievement_NOMZ
of_PIN
milestones_NN
._.
This_DEMP
will_PRMD
require_VB [SUAV]
$_$
50_CD
million_CD
upon_PIN
regulatory_JJ
approval_NN
of_PIN
the_DT
product_NN
and_CC
up_RB
to_TO
$_$
75_CD
million_CD
linked_VBN
to_PIN
the_DT
future_JJ
sales_NN
performance_NN
._.
The_DT
Company_NN
expects_VPRT [PRIV]
to_TO
meet_VB
these_DEMO
payments_NOMZ
with_PIN
cash_NN
from_PIN
operations_NOMZ
._.
The_DT
Company_NN
expects_VPRT [PRIV]
to_TO
resubmit_VB
MTS_NN
METHYPATCH_NN
for_PIN
approval_NN
in_PIN
2005_CD
._.
iii_FW
FOSRENOL_NN
patent_NN
rights_NN
In_PIN
connection_NOMZ
with_PIN
the_DT
Companys_NN
purchase_NN
of_PIN
the_DT
global_JJ
patents_NN
for_PIN
FOSRENOL_NN
,_,
Shire_NN
agreed_VBD [SUAV] [PUBV]
to_TO
pay_VB
AnorMED_NN
Inc._NN
$_$
6_CD
million_CD
when_RB
it_PIT
is_VPRT [PASS]
approved_VBN
in_PIN
certain_JJ
European_JJ
countries_NN
and_CC
$_$
6_CD
million_CD
upon_PIN
receipt_NN
of_PIN
regulatory_JJ
approval_NN
in_PIN
Japan_NN
._.
The_DT
Company_NN
has_VPRT [PEAS]
committed_VBN
to_TO
spend_VB
a_DT
further_JJ
$_$
5.1_CD
million_CD
by_PIN
the_DT
end_NN
of_PIN
2005_CD
and_CC
has_VPRT
an_DT
additional_JJ
commitment_NOMZ
of_PIN
$_$
4.4_CD
million_CD
for_PIN
the_DT
design_NN
and_PHC
construction_NOMZ
of_PIN
a_DT
technology_NN
center_NN
at_PIN
Owings_NN
Mills_NN
,_,
Maryland_NN
,_,
also_RB
expected_VBN [PRIV]
to_TO
be_VB [PASS]
incurred_VBN
in_PIN
2005_CD
._.
v_FW
Wayne_NN
,_,
Pennsylvania_NN
fit-out_PIN
The_DT
Company_NN
is_VPRT [BEMA]
in_PIN
the_DT
process_NN
of_PIN
fitting_JJ
out_PIN
its_PIT
new_JJ
US_FPP1
headquarters_NN
at_PIN
Wayne_NN
,_,
Pennsylvania_NN
._.
As_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
,_,
the_DT
Company_NN
had_VBD
an_DT
outstanding_JJ
commitment_NOMZ
of_PIN
$_$
20.4_CD
million_CD
relating_VBG
to_PIN
this_DEMO
refurbishment_NOMZ
,_,
expected_VBN [PRIV]
to_TO
be_VB [PASS]
incurred_VBN
in_PIN
2005_CD
._.
82_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
83_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
20_CD
Commitments_NOMZ
and_PHC
contingencies_NN
continued_VBD
d_SYM
Legal_NN
proceedings_GER
i_FPP1
General_NN
The_NN
Company_NN
accounts_VPRT
for_PIN
litigation_NOMZ
losses_NN
in_PIN
accordance_NN
with_PIN
SFAS_NN
No._NN
._.
5_CD
,_,
Accounting_GER
for_PIN
Contingencies_NN
SFAS_NN
No._NN
._.
5_CD
,_,
loss_NN
contingency_NN
provisions_NN
are_VPRT [PASS]
recorded_VBN
for_PIN
probable_JJ
losses_NN
when_RB
management_NOMZ
is_VPRT [BEMA]
able_PRED
to_TO [SPIN]
reasonably_RB
estimate_VB [PRIV]
the_DT
loss_NN
._.
Where_RB
the_DT
estimated_JJ
loss_NN
lies_VPRT
within_PIN
a_DT
range_NN
and_CC
no_SYNE
particular_JJ
amount_NN
within_PIN
that_DEMO
range_NN
is_VPRT [BEMA]
a_DT
better_JJ
estimate_NN
than_PIN
any_QUAN
other_JJ
amount_NN
,_,
the_DT
minimum_NN
amount_NN
is_VPRT [PASS]
recorded_VBN
._.
In_PIN
other_JJ
cases_NN
managements_NOMZ
best_JJ
estimate_NN
of_PIN
the_DT
loss_NN
is_VPRT [PASS]
recorded_VBN
._.
These_DEMO
estimates_NN
are_VPRT [PASS]
developed_VBN
substantially_RB
before_IN
the_DT
ultimate_JJ
loss_NN
is_VPRT [PASS]
known_VBN [PRIV]
and_CC
the_DT
estimates_NN
are_VPRT [PASS]
refined_VBN
each_QUAN
accounting_GER
period_NN
in_PIN
light_NN
of_PIN
additional_JJ
information_NOMZ
being_VBG [WZPRES] [PASS]
known_VBN [PRIV]
._.
In_PIN
instances_NN
where_RB
the_DT
Company_NN
is_VPRT [BEMA]
unable_PRED
to_TO
develop_VB
a_DT
best_JJ
estimate_NN
of_PIN
loss_NN
,_,
no_SYNE
litigation_NOMZ
loss_NN
is_VPRT [PASS]
recorded_VBN
at_PIN
that_DEMO
time_NN
._.
As_IN
information_NOMZ
becomes_VPRT
known_VBN [PRIV]
a_DT
loss_NN
provision_NN
is_VPRT [PASS]
set_VBN
up_RP
when_RB
a_DT
best_JJ
estimate_NN
can_POMD
be_VB [PASS]
made_VBN
._.
The_DT
best_JJ
estimates_NN
are_VPRT [PASS]
reviewed_VBN
quarterly_JJ
and_CC
the_DT
estimates_NN
are_VPRT [PASS]
changed_VBN
when_RB
expectations_NOMZ
are_VPRT [PASS]
revised_VBN
._.
Any_QUAN
outcome_NN
upon_PIN
settlement_NOMZ
that_TSUB
deviates_VPRT
from_PIN
the_DT
Companys_NN
best_JJ
estimate_NN
may_POMD
result_VB
in_PIN
an_DT
additional_JJ
expense_NN
in_PIN
a_DT
future_JJ
accounting_GER
period_NN
._.
ii_FW
Phentermine_NN
Shire_NN
US_FPP1
Inc._NN
._.
SUS_NN
,_,
a_DT
wholly-owned_JJ
subsidiary_NN
of_PIN
Shire_NN
,_,
is_VPRT [BEMA]
a_DT
defendant_NN
in_PIN
260_CD
lawsuits_NN
still_RB
pending_VBG
in_PIN
both_DT
US_FPP1
federal_JJ
and_CC
state_NN
courts_NN
which_WDT [WHSUB]
seek_VPRT
damages_NN
for_PIN [STPR]
,_,
among_PIN
other_JJ
things_NN
,_,
personal_JJ
injury_NN
arising_VBG [WZPRES]
from_PIN
phentermine_NN
products_NN
supplied_VBD
for_PIN
the_DT
treatment_NOMZ
of_PIN
obesity_NOMZ
by_PIN
SUS_NN
and_CC
several_QUAN
other_JJ
pharmaceutical_JJ
companies_NN
._.
SUS_NN
denies_VPRT [PUBV]
liability_NOMZ
on_PIN
a_DT
number_NN
of_PIN
grounds_NN
including_VBG [WZPRES]
lack_NN
of_PIN
scientific_JJ
evidence_NN
that_DEMO
phentermine_NN
,_,
properly_RB
prescribed_VBN
,_,
causes_VPRT
the_DT
alleged_JJ
sideeffects_NN
and_CC
that_THVC
SUS_NN
did_VBD
not_XX0
promote_VB
phentermine_NN
for_PIN
long-term_JJ
combined_VBN
use_NN
as_IN
part_NN
of_PIN
the_DT
fen_NN
phen_NN
diet_NN
._.
Eon_NN
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
to_TO
defend_VB
and_PHC
indemnify_VB
SUS_NN
in_PIN
this_DEMO
litigation_NOMZ
pursuant_JJ
to_PIN
an_DT
agreement_NOMZ
dated_VBN
November_NN
30_CD
,_,
2000_CD
between_PIN
Eon_NN
and_PHC
SUS_NN
._.
iii_FW
ADDERALL_NN
XR_NN
a_DT
Barr_NN
Laboratories_NN
,_,
Inc._NN
._.
Shires_NN
extended-release_NN
once-daily_RB
version_NN
of_PIN
ADDERALL_NN
,_,
ADDERALL_NN
XR_NN
,_,
is_VPRT [BYPA]
covered_VBN
by_PIN
US_FPP1
patent_NN
No._NN
._.
In_PIN
January_NN
2003_CD
the_DT
Company_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Barr_NN
Laboratories_NN
,_,
Inc._NN
._.
Barr_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
Abbreviated_NN
New_NN
Drug_NN
Application_NOMZ
ANDA_NN
under_IN
the_DT
US_FPP1
Hatch-Waxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
versions_NN
of_PIN
the_DT
5mg_JJ
,_,
10mg_JJ
,_,
15mg_JJ
,_,
20mg_JJ
,_,
25mg_JJ
and_PHC
30mg_JJ
strengths_NN
of_PIN
ADDERALL_NN
XR_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
Companys_NN
819_CD
Patent_NN
._.
The_DT
notification_NOMZ
alleged_VBD [PUBV]
that_THVC
the_DT
819_CD
Patent_NN
is_VPRT [BYPA]
not_XX0
infringed_VBN
by_PIN
Barrs_NN
extended-release_NN
mixed_JJ
amphetamine_NN
salt_NN
product_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
subject_NN
of_PIN
Barrs_NN
ANDA_NN
._.
On_PIN
February_NN
24_CD
,_,
2003_CD
Shire_NN
Laboratories_NN
Inc._NN
._.
Shire_NN
Laboratories_NN
filed_VBD
suit_NN
against_PIN
Barr_NN
in_PIN
the_DT
United_NN
States_NN
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
Barrs_NN
ANDA_NN
infringes_VPRT
the_DT
819_CD
Patent_NN
._.
The_DT
Company_NN
is_VPRT [SPAU]
also_RB
seeking_VBG
an_DT
injunction_NOMZ
to_TO
prevent_VB
Barr_NN
from_PIN
commercializing_VBG
its_PIT
ANDA_NN
product_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
819_CD
Patent_NN
,_,
damages_NN
in_PIN
the_DT
event_NN
that_TOBJ
Barr_NN
should_NEMD
engage_VB
in_PIN
such_JJ
commercialization_NOMZ
,_,
as_RB
well_RB
as_IN
its_PIT
attorneys_NN
fees_NN
and_PHC
costs_NN
._.
On_PIN
August_NN
12_CD
,_,
2003_CD
,_,
Shire_NN
Laboratories_NN
was_VBD [PASS]
issued_VBN
a_DT
new_JJ
US_FPP1
patent_NN
No._NN
._.
In_PIN
August_NN
2003_CD
Shire_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Barr_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
under_IN
the_DT
US_FPP1
Hatch-Waxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
versions_NN
of_PIN
the_DT
5mg_JJ
,_,
10mg_JJ
,_,
15mg_JJ
,_,
20mg_JJ
,_,
25mg_JJ
and_PHC
30mg_JJ
strengths_NN
of_PIN
ADDERALL_NN
XR_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
300_CD
Patent_NN
and_CC
alleging_VBG [PUBV]
that_THVC
the_DT
300_CD
Patent_NN
is_VPRT [BEMA]
invalid_PRED
._.
The_DT
Company_NN
is_VPRT [SPAU]
also_RB
seeking_VBG
an_DT
injunction_NOMZ
to_TO
prevent_VB
Barr_NN
from_PIN
commercializing_VBG
its_PIT
ANDA_NN
product_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
300_CD
Patent_NN
,_,
damages_NN
in_PIN
the_DT
event_NN
that_TOBJ
Barr_NN
should_NEMD
engage_VB
in_PIN
such_JJ
commercialization_NOMZ
,_,
as_RB
well_RB
as_IN
its_PIT
attorneys_NN
fees_NN
and_PHC
costs_NN
._.
83_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
84_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
20_CD
Commitments_NOMZ
and_PHC
contingencies_NN
continued_VBD
d_SYM
Legal_NN
proceedings_GER
continued_VBD
iii_FW
ADDERALL_NN
XR_NN
continued_VBD
a_DT
Barr_NN
Laboratories_NN
,_,
Inc._NN
continued_VBD
The_DT
lawsuits_NN
against_PIN
Barr_NN
with_PIN
respect_NN
to_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
were_VBD [PASS]
consolidated_VBN
in_PIN
December_NN
2003_CD
and_CC
a_DT
trial_NN
date_NN
scheduled_VBN [WZPAST]
for_PIN
January_NN
2006_CD
._.
On_PIN
September_NN
27_CD
,_,
2004_CD
,_,
Barr_NN
filed_VBD
an_DT
amended_VBN
Answer_NN
,_,
Affirmative_NN
Defense_NN
and_PHC
Counterclaim_NN
in_PIN
which_WDT [PIRE]
Barr_NN
added_VBD [PUBV]
the_DT
following_VBG
counterclaims_NN
and_CC
affirmative_JJ
defenses_NN
:_:
invalidity_NOMZ
of_PIN
the_DT
819_CD
Patent_NN
,_,
non-infringement_NOMZ
of_PIN
the_DT
300_CD
Patent_NN
and_PHC
unenforceability_NOMZ
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
due_JJ
to_PIN
inequitable_JJ
conduct_NN
._.
Shire_NN
has_VPRT [PEAS]
asserted_VBN [PUBV]
affirmative_JJ
defenses_NN
,_,
alleging_VBG [PUBV]
,_,
among_PIN
other_JJ
things_NN
,_,
that_THVC
Barr_NN
has_VPRT [PEAS]
waived_VBN
its_PIT
right_NN
to_TO
assert_VB [PUBV] [THATD]
the_DT
counterclaims_NN
set_VBN [WZPAST]
forth_RB
in_PIN
its_PIT
September_NN
27_CD
,_,
2004_CD
amended_VBN
answers_NN
._.
Barr_NN
may_POMD
not_XX0
launch_VB
a_DT
generic_JJ
version_NN
of_PIN
ADDERALL_NN
XR_NN
before_IN
it_PIT
receives_VPRT
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
from_PIN
the_DT
FDA_NN
._.
Even_RB
if_COND
Barr_NN
receives_VPRT
a_DT
tentative_JJ
approval_NN
from_PIN
the_DT
FDA_NN
,_,
it_PIT
can_POMD
not_XX0
lawfully_RB
launch_VB
its_PIT
generic_JJ
version_NN
before_IN
the_DT
earlier_TIME
of_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
latest_JJ
stay_NN
February_NN
2006_CD
or_CC
a_DT
district_NN
court_NN
decision_NN
in_PIN
its_PIT
favor_NN
._.
In_PIN
the_DT
event_NN
that_TOBJ
Barr_NN
receives_VPRT
a_DT
favorable_JJ
decision_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
stay_NN
,_,
then_RB
Barr_NN
could_POMD
be_VB [BEMA]
in_PIN
a_DT
position_NOMZ
to_TO
market_VB
its_PIT
extended-release_NN
mixed_JJ
amphetamine_NN
salt_NN
product_NN
,_,
upon_PIN
FDA_NN
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
,_,
following_VBG [PRESP]
the_DT
expiration_NOMZ
of_PIN
the_DT
Hatch-Waxman_NN
exclusivity_NOMZ
period_NN
._.
However_CONJ
,_,
on_PIN
October_NN
28_CD
,_,
2004_CD
the_DT
FDA_NN
granted_VBD [SUAV]
an_DT
additional_JJ
six_CD
months_NN
exclusivity_NOMZ
to_PIN
ADDERALL_NN
XR_NN
based_VBN [WZPAST]
upon_PIN
pediatric_JJ
studies_NN
carried_VBD
out_PIN
on_PIN
the_DT
drug_NN
product_NN
,_,
meaning_VBG [PRIV]
that_THVC
Barr_NN
may_POMD
not_XX0
market_VB
its_PIT
ANDA_NN
products_NN
until_IN
after_IN
Hatch-Waxman_NN
exclusivity_NOMZ
expires_VPRT
on_PIN
April_NN
11_CD
,_,
2005_CD
._.
b_NN
Impax_NN
Laboratories_NN
,_,
Inc._NN
._.
In_PIN
November_NN
2003_CD
,_,
Shire_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Impax_NN
Laboratories_NN
,_,
Inc._NN
._.
Impax_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
under_IN
the_DT
US_FPP1
Hatch-Waxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
version_NN
of_PIN
the_DT
30mg_JJ
strength_NN
of_PIN
ADDERALL_NN
XR_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
dates_NN
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
and_CC
alleging_VBG [PUBV]
that_THVC
the_DT
819_CD
and_CC
300_CD
Patents_NN
are_VPRT [BYPA]
not_XX0
infringed_VBN
by_PIN
Impaxs_NN
extended-release_NN
mixed_JJ
amphetamine_NN
salt_NN
product_NN
,_,
the_DT
subject_NN
of_PIN
Impaxs_NN
ANDA_NN
._.
The_DT
Company_NN
is_VPRT [SPAU]
also_RB
seeking_VBG
an_DT
injunction_NOMZ
to_TO
prevent_VB
Impax_NN
from_PIN
commercializing_VBG
its_PIT
ANDA_NN
product_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
,_,
damages_NN
in_PIN
the_DT
event_NN
that_TOBJ
Impax_NN
should_NEMD
engage_VB
in_PIN
such_JJ
commercialization_NOMZ
,_,
as_RB
well_RB
as_IN
its_PIT
attorneys_NN
fees_NN
and_PHC
costs_NN
._.
A_DT
trial_NN
date_NN
of_PIN
October_NN
11_CD
,_,
2005_CD
has_VPRT [PEAS]
been_VBN [PASS]
set_VBN
._.
In_PIN
December_NN
2004_CD
,_,
Shire_NN
received_VBD
an_DT
additional_JJ
notification_NOMZ
from_PIN
Impax_NN
advising_VBG [WZPRES]
of_PIN
the_DT
filing_NN
of_PIN
an_DT
ANDA_NN
for_PIN
generic_JJ
versions_NN
of_PIN
the_DT
5mg_JJ
,_,
10mg_JJ
,_,
15mg_JJ
,_,
20mg_JJ
and_PHC
25mg_JJ
strengths_NN
of_PIN
ADDERALL_NN
XR_NN
in_CONJ
addition_NULL
to_PIN
the_DT
30mg_JJ
strength_NN
,_,
the_DT
subject_NN
of_PIN
Impaxs_NN
initial_JJ
ANDA_NN
._.
The_DT
Company_NN
is_VPRT [SPAU]
also_RB
seeking_VBG
an_DT
injunction_NOMZ
to_TO
prevent_VB
Impax_NN
from_PIN
commercializing_VBG
its_PIT
amended_VBN
ANDA_NN
products_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
,_,
damages_NN
in_PIN
the_DT
event_NN
that_TOBJ
Impax_NN
should_NEMD
engage_VB
in_PIN
such_JJ
commercialization_NOMZ
,_,
as_RB
well_RB
as_IN
its_PIT
attorneys_NN
fees_NN
and_PHC
costs_NN
._.
Even_RB
if_COND
Impax_NN
receives_VPRT
a_DT
tentative_JJ
approval_NN
from_PIN
the_DT
FDA_NN
,_,
it_PIT
can_POMD
not_XX0
lawfully_RB
launch_VB
its_PIT
generic_JJ
version_NN
before_IN
the_DT
earlier_TIME
of_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
stays_NN
May_POMD
2006_CD
in_PIN
the_DT
case_NN
of_PIN
the_DT
30mg_JJ
strength_NN
and_PHC
June_NN
2007_CD
in_PIN
the_DT
case_NN
of_PIN
the_DT
5mg_JJ
,_,
10mg_JJ
,_,
15mg_JJ
,_,
20mg_JJ
and_PHC
25mg_JJ
strengths_NN
or_CC
a_DT
district_NN
court_NN
decision_NN
in_PIN
its_PIT
favor_NN
._.
In_PIN
the_DT
event_NN
that_TOBJ
Impax_NN
receives_VPRT
a_DT
favorable_JJ
decision_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
stays_NN
,_,
then_RB
Impax_NN
could_POMD
be_VB [BEMA]
in_PIN
a_DT
position_NOMZ
to_TO
market_VB
its_PIT
extended-release_NN
mixed_JJ
amphetamine_NN
salt_NN
products_NN
upon_PIN
FDA_NN
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
following_VBG [WZPRES]
the_DT
expiration_NOMZ
of_PIN
the_DT
existing_VBG
Hatch-Waxman_NN
exclusivity_NOMZ
and_CC
upon_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
first_JJ
to_PIN
files_NN
exclusivity_NOMZ
rights_NN
._.
However_CONJ
,_,
on_PIN
October_NN
28_CD
,_,
2004_CD
the_DT
FDA_NN
granted_VBD [SUAV]
an_DT
additional_JJ
six_CD
months_NN
exclusivity_NOMZ
to_PIN
ADDERALL_NN
XR_NN
based_VBN [WZPAST]
upon_PIN
pediatric_JJ
studies_NN
carried_VBD
out_PIN
on_PIN
the_DT
drug_NN
product_NN
,_,
meaning_VBG [PRIV]
that_THVC
Impax_NN
may_POMD
not_XX0
market_VB
its_PIT
ANDA_NN
products_NN
until_IN
after_IN
Hatch-Waxman_NN
exclusivity_NOMZ
expires_VPRT
on_PIN
April_NN
11_CD
,_,
2005_CD
._.
c_NN
Colony_NN
Pharmaceuticals_NN
,_,
Inc._NN
._.
In_PIN
December_NN
2004_CD
,_,
Shire_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Colony_NN
Pharmaceuticals_NN
Inc._NN
._.
Colony_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
under_IN
the_DT
US_FPP1
Hatch-Waxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
version_NN
of_PIN
the_DT
5mg_JJ
,_,
10mg_JJ
,_,
15mg_JJ
,_,
20mg_JJ
,_,
25mg_JJ
and_PHC
30mg_JJ
strengths_NN
of_PIN
ADDERALL_NN
XR_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
Companys_NN
819_CD
and_CC
300_CD
Patents_NN
._.
In_CONJ
any_NULL
event_NULL
,_,
Colony_NN
may_POMD
not_XX0
market_VB
its_PIT
ANDA_NN
products_NN
until_IN
FDA_NN
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
following_VBG [WZPRES]
the_DT
expiration_NOMZ
of_PIN
Shires_NN
existing_VBG [WZPRES]
Hatch-Waxman_NN
exclusivity_NOMZ
on_PIN
April_NN
11_CD
,_,
2005_CD
and_CC
upon_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
first_JJ
to_PIN
files_NN
exclusivity_NOMZ
rights_NN
._.
84_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
85_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
20_CD
Commitments_NOMZ
and_PHC
contingencies_NN
continued_VBD
d_SYM
Legal_NN
proceedings_GER
continued_VBD
iii_FW
ADDERALL_NN
XR_NN
continued_VBD
d_SYM
Teva_NN
Pharmaceuticals_NN
USA_NN
,_,
Inc._NN
._.
In_PIN
February_NN
2005_CD
,_,
Shire_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Teva_NN
Pharmaceuticals_NN
USA_NN
,_,
Inc._NN
._.
Teva_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
under_IN
the_DT
US_FPP1
Hatch-Waxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
versions_NN
of_PIN
the_DT
10mg_JJ
and_PHC
30mg_JJ
strengths_NN
of_PIN
ADDERALL_NN
XR_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
Companys_NN
819_CD
and_CC
300_CD
Patents_NN
._.
In_CONJ
any_NULL
event_NULL
,_,
Teva_NN
may_POMD
not_XX0
market_VB
its_PIT
ANDA_NN
products_NN
until_IN
FDA_NN
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
following_VBG [WZPRES]
the_DT
expiration_NOMZ
of_PIN
the_DT
existing_VBG
Hatch-Waxman_NN
exclusivity_NOMZ
on_PIN
April_NN
11_CD
,_,
2005_CD
and_CC
upon_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
first_JJ
to_PIN
files_NN
exclusivity_NOMZ
rights_NN
._.
iv_NN
CARBATROL_NN
In_PIN
August_NN
2003_CD
the_DT
Company_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Nostrum_NN
Pharmaceuticals_NN
,_,
Inc._NN
._.
Nostrum_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
under_IN
the_DT
US_FPP1
HatchWaxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
version_NN
of_PIN
the_DT
300mg_JJ
strength_NN
of_PIN
CARBATROL_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
Companys_NN
US_FPP1
patents_NN
for_PIN
CARBATROL_NN
,_,
US_FPP1
patent_NN
No._NN
._.
The_DT
notification_NOMZ
alleges_VPRT [PUBV]
that_THVC
the_DT
013_CD
and_CC
570_CD
Patents_NN
are_VPRT [BYPA]
not_XX0
infringed_VBN
by_PIN
Nostrums_NN
300mg_CD
extended-release_NN
carbamazepine_NN
product_NN
,_,
the_DT
subject_NN
of_PIN
Nostrums_NN
ANDA_NN
._.
On_PIN
September_NN
18_CD
,_,
2003_CD
Shire_NN
Laboratories_NN
filed_VBD
suit_NN
against_PIN
Nostrum_NN
in_PIN
the_DT
United_NN
States_NN
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
for_PIN
infringement_NOMZ
of_PIN
these_DEMO
two_CD
patents_NN
._.
The_DT
Company_NN
was_VBD [SPAU]
also_RB
seeking_VBG
an_DT
injunction_NOMZ
to_TO
prevent_VB
Nostrum_NN
from_PIN
commercializing_VBG
its_PIT
ANDA_NN
product_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
013_CD
and_CC
570_CD
Patents_NN
,_,
damages_NN
in_PIN
the_DT
event_NN
that_TOBJ
Nostrum_NN
should_NEMD
engage_VB
in_PIN
such_JJ
commercialization_NOMZ
,_,
as_RB
well_RB
as_IN
its_PIT
attorneys_NN
fees_NN
and_PHC
costs_NN
._.
On_PIN
January_NN
23_CD
,_,
2004_CD
the_DT
Company_NN
amended_VBD
the_DT
Complaint_NN
to_TO
delete_VB
the_DT
allegations_NOMZ
with_PIN
respect_NN
to_PIN
the_DT
013_CD
Patent_NN
._.
On_PIN
July_NN
12_CD
,_,
2004_CD
the_DT
United_NN
States_NN
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
dismissed_VBD
Nostrums_NN
abuse_NN
of_PIN
process_NN
counterclaim_NN
for_PIN
failure_NN
to_TO
state_VB [PUBV]
a_DT
claim_NN
upon_PIN
which_WDT [PIRE]
relief_NN
can_POMD
be_VB [PASS]
granted_VBN [SUAV]
._.
On_PIN
December_NN
10_CD
,_,
2004_CD
Nostrum_NN
filed_VBD
a_DT
summary_NN
judgment_NOMZ
motion_NOMZ
seeking_VBG [WZPRES]
a_DT
declaration_NOMZ
of_PIN
non-infringement_NOMZ
of_PIN
the_DT
570_CD
Patent_NN
._.
Shires_NN
opposition_NOMZ
to_PIN
this_DEMO
motion_NOMZ
was_VBD [PASS]
filed_VBN
on_PIN
January_NN
14_CD
,_,
2005_CD
._.
Even_RB
if_COND
Nostrum_NN
receives_VPRT
tentative_JJ
approval_NN
from_PIN
the_DT
FDA_NN
for_PIN
its_PIT
ANDA_NN
,_,
it_PIT
can_POMD
not_XX0
lawfully_RB
launch_VB
its_PIT
generic_JJ
version_NN
before_IN
the_DT
earlier_TIME
of_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
stay_NN
February_NN
2006_CD
or_CC
a_DT
district_NN
court_NN
decision_NN
in_PIN
its_PIT
favor_NN
._.
In_PIN
the_DT
event_NN
that_TOBJ
the_DT
Company_NN
does_VPRT
not_XX0
prevail_VB
,_,
then_RB
Nostrum_NN
could_POMD
be_VB [BEMA]
in_PIN
a_DT
position_NOMZ
to_TO
market_VB
its_PIT
300mg_JJ
extended-release_NN
carbamazepine_NN
product_NN
upon_PIN
FDA_NN
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
._.
21_CD
Related_VBN
parties_NN
a_DT
Professional_JJ
fees_NN
The_DT
Company_NN
incurred_VBN
professional_JJ
fees_NN
with_PIN
Stikeman_NN
Elliott_NN
,_,
a_DT
law_NN
firm_NN
in_PIN
which_WDT [PIRE]
The_DT
Hon_NN
James_NN
Grant_NN
,_,
a_DT
director_NN
of_PIN
Shire_NN
,_,
is_VPRT [BEMA]
a_DT
partner_NN
,_,
totalling_VBG
$_$
2.1_CD
million_CD
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
$_$
0.8_CD
million_CD
and_CC
$_$
1.2_CD
million_CD
for_PIN
the_DT
years_NN
to_PIN
December_NN
31_CD
,_,
2003_CD
and_CC
2002_CD
._.
b_NN
NeuroChem_NN
Inc._NN
._.
In_PIN
April_NN
2004_CD
Shire_NN
BioChem_NN
Inc._NN
._.
BioChem_NN
,_,
a_DT
subsidiary_NN
of_PIN
Shire_NN
,_,
sold_VBD
a_DT
Canadian_JJ
property_NN
to_PIN
NeuroChem_NN
Inc._NN
for_PIN
$_$
7.8_CD
million_CD
CAN$_NN
10.5_CD
million_CD
._.
Dr_NN
Bellini_NN
,_,
a_DT
non-executive_JJ
Director_NN
of_PIN
BioChem_NN
and_CC
,_,
until_IN
May_POMD
10_CD
,_,
2003_CD
,_,
a_DT
non-executive_JJ
Director_NN
of_PIN
Shire_NN
,_,
and_ANDC
Mr_NN
Nordmann_NN
,_,
a_DT
non-executive_JJ
Director_NN
of_PIN
Shire_NN
,_,
are_VPRT [BEMA]
both_DT
directors_NN
of_PIN
NeuroChem_NN
Inc._NN
._.
Dr_NN
Bellini_NN
had_VBD
an_DT
indirect_JJ
substantial_JJ
interest_NN
in_PIN
the_DT
issued_VBN
share_NN
capital_NN
of_PIN
NeuroChem_NN
Inc._NN
at_PIN
the_DT
time_NN
of_PIN
the_DT
transaction_NOMZ
._.
In_PIN
April_NN
2004_CD
,_,
BioChem_NN
contributed_VBD
cash_NN
of_PIN
$_$
3.7_CD
million_CD
CAN$_NN
5.0_CD
million_CD
and_CC
equipment_NOMZ
and_CC
intellectual_JJ
property_NN
to_PIN
the_DT
start-up_NN
of_PIN
a_DT
new_JJ
Canadian-based_JJ
pharmaceutical_JJ
R&D_NN
organization_NOMZ
,_,
ViroChem_NN
Pharma_NN
Inc._NN
in_PIN
return_NN
for_PIN
an_DT
equity_NOMZ
interest_NN
and_PHC
royalties_NN
on_PIN
the_DT
sale_NN
of_PIN
certain_JJ
products_NN
subsequently_TIME
launched_VBN
by_PIN
ViroChem_NN
._.
BioChem_NN
has_VPRT [PEAS]
undertaken_VBN
to_TO
invest_VB
an_DT
additional_JJ
$_$
8.3_CD
million_CD
CAN$_NN
10.0_CD
million_CD
in_PIN
ViroChem_NN
in_PIN
two_CD
equal_JJ
tranches_NN
of_PIN
CAN$_NN
5.0_CD
million_CD
in_PIN
April_NN
2005_CD
and_CC
April_NN
2006_CD
._.
Dr_NN
Bellini_NN
,_,
a_DT
non-executive_JJ
Director_NN
of_PIN
BioChem_NN
and_CC
,_,
until_IN
May_POMD
10_CD
,_,
2003_CD
,_,
a_DT
non-executive_JJ
Director_NN
of_PIN
Shire_NN
,_,
had_VBD
,_,
at_PIN
the_DT
time_NN
of_PIN
the_DT
transaction_NOMZ
,_,
an_DT
indirect_JJ
substantial_JJ
interest_NN
in_PIN
a_DT
company_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
a_DT
co-investor_NN
in_PIN
ViroChem_NN
Pharma_NN
Inc._NN
85_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
86_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
22_CD
Earnings_GER
per_PIN
share_NN
The_DT
following_VBG
table_NN
reconciles_NN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
and_CC
the_DT
weighted_JJ
average_JJ
ordinary_JJ
shares_NN
outstanding_JJ
for_PIN
basic_JJ
and_PHC
diluted_JJ
earnings_GER
per_PIN
share_NN
for_PIN
the_DT
periods_NN
presented_VBN
:_:
Restated_VBN
Restated_VBN
2004 2003 2002_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
333,299_CD
297,937_CD
260,145_CD
Loss_NN
from_PIN
discontinued_VBN
operations_NOMZ
,_,
net_NN
of_PIN
tax_NN
20,135_CD
21,886_CD
11,659_CD
Loss_NN
gain_NN
on_PIN
disposal_NN
of_PIN
discontinued_VBN
operations_NOMZ
44,157_CD
2,083_CD
Numerator_NN
for_PIN
basic_JJ
earnings_GER
per_PIN
share_NN
269,007_CD
276,051_CD
250,569_CD
Interest_NN
charged_VBN [WZPAST]
on_PIN
convertible_JJ
debt_NN
,_,
net_NN
of_PIN
tax_NN
3,421_CD
5,218_CD
5,585_CD
Numerator_NN
for_PIN
diluted_JJ
earnings_GER
per_PIN
share_NN
272,428_CD
281,269_CD
256,154_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
2004 2003 2002_CD
Weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
outstanding_JJ
Number_NN
of_PIN
shares_NN
Number_NN
of_PIN
shares_NN
Number_NN
of_PIN
shares_NN
Basic_JJ
496,306,604_CD
498,212,826_CD
500,687,594_CD
Effect_NN
of_PIN
dilutive_JJ
shares_NN
:_:
Share_NN
options_NOMZ
3,035,620_CD
1,859,076_CD
1,883,475_CD
Convertible_JJ
debt_NN
11,858,416_CD
18,895,493_CD
19,847,177_CD
Warrants_NN
66,792_CD
14,960,828_CD
20,754,569_CD
21,730,652_CD
Diluted_NN
511,267,432_CD
518,967,395_CD
522,418,246_CD
Basic_JJ
earnings_GER
per_PIN
share_NN
:_:
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
67.2_CD
59.8_CD
51.9_CD
Loss_NN
from_PIN
discontinued_VBN
operations_NOMZ
,_,
net_NN
of_PIN
tax_NN
4.1_CD
4.4_CD
2.3_CD
Loss_NN
gain_NN
on_PIN
disposal_NN
of_PIN
discontinued_VBN
operations_NOMZ
8.9_CD
0.4_CD
54.2_CD
55.4_CD
50.0_CD
Diluted_VBN
earnings_GER
per_PIN
share_NN
:_:
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
65.9_CD
58.4_CD
50.8_CD
Loss_NN
from_PIN
discontinued_VBN
operations_NOMZ
,_,
net_NN
of_PIN
tax_NN
4.0_CD
4.2_CD
2.2_CD
Loss_NN
gain_NN
on_PIN
disposal_NN
of_PIN
discontinued_VBN
operations_NOMZ
8.6_CD
0.4_CD
53.3_CD
54.2_CD
49.0_CD
The_DT
warrants_NN
and_PHC
share_NN
options_NOMZ
not_XX0
included_VBD
within_PIN
the_DT
calculation_NOMZ
of_PIN
the_DT
diluted_VBN
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
,_,
because_CAUS
the_DT
exercise_NN
prices_NN
exceeded_VBD
the_DT
Companys_NN
average_JJ
share_NN
price_NN
during_PIN
the_DT
calculation_NOMZ
period_NN
,_,
are_VPRT [PASS]
shown_VBN [PRIV]
below_PLACE
:_:
2004 2003 2002_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
Number_NN
of_PIN
shares_NN
Number_NN
of_PIN
shares_NN
Number_NN
of_PIN
shares_NN
Share_NN
options_NOMZ
16,640,724_CD
17,006,093_CD
17,492,575_CD
Warrants_NN
1,346,407_CD
1,346,407_CD
16,640,724_CD
18,352,500_CD
18,838,982_CD
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
the_DT
Company_NN
recorded_VBD
a_DT
loss_NN
on_PIN
redemption_NOMZ
of_PIN
the_DT
convertible_JJ
loan_NN
notes_NN
of_PIN
$_$
7.4_CD
million_CD
,_,
which_WDT [SERE]
resulted_VBD
from_PIN
the_DT
write-off_PIN
of_PIN
unamortized_JJ
debt_NN
issuance_NN
costs_NN
._.
Diluted_NN
EPS_NN
would_PRMD
have_VB [PEAS]
been_VBN [BEMA]
53.9_CD
,_,
or_CC
0.6_CD
higher_JJ
,_,
without_PIN
this_DEMO
loss_NN
on_PIN
redemption_NOMZ
._.
86_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
87_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV] [THATD]
23_CD
Segment_NOMZ
reporting_VBG [PUBV] [THATD] [WZPRES]
The_DT
Company_NN
has_VPRT [PEAS]
disclosed_VBN [PUBV]
segment_NOMZ
information_NOMZ
for_PIN
the_DT
individual_JJ
reporting_GER
segments_NOMZ
of_PIN
the_DT
business_NOMZ
,_,
based_VBN [PASTP]
on_PIN
the_DT
way_NN
in_PIN
which_WDT [PIRE]
the_DT
business_NOMZ
is_VPRT [PASS]
managed_VBN
and_PHC
controlled_VBN
._.
The_DT
Companys_NN
principal_JJ
reporting_GER
segments_NOMZ
are_VPRT [BEMA]
by_PIN
operational_JJ
function_NOMZ
,_,
each_QUAN
being_VBG [PASS]
managed_VBN
and_PHC
monitored_VBN
separately_RB
and_CC
serving_VBG
different_JJ
markets_NN
._.
The_DT
Company_NN
evaluates_VPRT
performance_NN
based_VBN [WZPAST]
on_PIN
operating_VBG
income_NN
._.
The_DT
Company_NN
does_VPRT
not_XX0
have_VB
inter-segment_JJ
transactions_NOMZ
._.
The_DT
US_FPP1
segment_NOMZ
represents_VPRT
the_DT
Companys_NN
commercial_JJ
operations_NOMZ
in_PIN
the_DT
United_NN
States_NN
and_CC
the_DT
International_NN
segment_NOMZ
represents_VPRT
the_DT
commercial_JJ
operations_NOMZ
in_PIN
the_DT
Rest_VB
of_PIN
the_DT
World_NN
._.
The_DT
R&D_NN
segment_NOMZ
represents_VPRT
all_QUAN
direct_JJ
R&D_NN
costs_NN
incurred_VBN [WZPAST]
by_PIN
the_DT
Company_NN
throughout_PIN
the_DT
world_NN
._.
Corporate_JJ
represents_VPRT
the_DT
royalty_NN
business_NOMZ
that_DEMP
is_VPRT [PASS]
managed_VBN
at_PIN
the_DT
Corporate_JJ
office_NN
and_CC
certain_JJ
costs_NN
that_TSUB
are_VPRT [PASS]
managed_VBN
at_PIN
the_DT
corporate_JJ
office_NN
and_CC
not_XX0
allocated_VBN
to_PIN
the_DT
other_JJ
segments_NOMZ
._.
The_DT
results_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2003_CD
and_CC
2002_CD
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
to_TO
reflect_VB [PRIV]
the_DT
disposal_NN
of_PIN
the_DT
vaccines_NN
business_NOMZ
,_,
which_WDT [SERE]
had_VBD [SPAU] [PEAS]
previously_TIME
been_VBN [PASS]
reported_VBN [PUBV]
as_IN
the_DT
Biologics_NN
segment_NOMZ
._.
The_DT
US_FPP1
and_PHC
International_NN
reportable_JJ
segments_NOMZ
have_VPRT [SPAU] [PEAS]
also_RB
been_VBN [PASS]
restated_VBN
as_IN
certain_JJ
components_NN
of_PIN
the_DT
vaccines_NN
business_NOMZ
previously_TIME
formed_VBD
part_NN
of_PIN
these_DEMO
segments_NOMZ
._.
Depreciation_NOMZ
from_PIN
manufacturing_VBG
plants_NN
$_$
2.7_CD
million_CD
is_VPRT [PASS]
included_VBN
in_PIN
cost_NN
of_PIN
product_NN
sales_NN
._.
Depreciation_NOMZ
and_PHC
amortization_NOMZ
relating_VBG [WZPRES]
to_PIN
R&D_NN
assets_NN
are_VPRT [PASS]
included_VBN
in_PIN
US_FPP1
and_PHC
International_NN
segments_NOMZ
._.
87_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
88_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
23_CD
Segment_NOMZ
reporting_GER
continued_VBD
Restated_NN
Restated_NN
Restated_NN
Restated_NN
Restated_NN
US_FPP1
International_NN
Corporate_NN
R&D_NN
Total_NN
Year_NN
to_PIN
December_NN
31_CD
,_,
2003_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
External_NN
revenues_NN
:_:
Product_NN
sales_NN
846,438_CD
157,869_CD
1,004,307_CD
Royalties_NN
14_CD
10,314_CD
193,245_CD
203,573_CD
Licensing_GER
and_PHC
development_NOMZ
3,376_CD
301_CD
3,677_CD
Other_JJ
revenues_NN
13_CD
13_CD
Total_JJ
revenues_NN
849,841_CD
168,484_CD
193,245_CD
1,211,570_CD
Cost_NN
of_PIN
product_NN
sales_NN
94,597_CD
48,563_CD
143,160_CD
2_CD
Research_NN
and_PHC
development_NOMZ
194,902_CD
194,902_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
234,091_CD
80,968_CD
56,755_CD
371,814_CD
1_CD
,_,
2_CD
Depreciation_NOMZ
and_PHC
amortization_NOMZ
30,965_CD
24,338_CD
26,804_CD
82,107_CD
Total_JJ
operating_GER
expenses_NN
359,653_CD
153,869_CD
83,559_CD
194,902_CD
791,983_CD
Operating_GER
income_NN
loss_NN
490,188_CD
14,615_CD
109,686_CD
194,902_CD
419,587_CD
US_FPP1
International_NN
Corporate_NN
R&D_NN
Total_NN
Year_NN
to_PIN
December_NN
31_CD
,_,
2003_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Total_JJ
assets_NN
from_PIN
continuing_VBG
operations_NOMZ
697,460_CD
413,134_CD
1,269,300_CD
109,131_CD
2,489,025_CD
Long-lived_JJ
assets_NN
238,774_CD
233,313_CD
200,225_CD
46,691_CD
719,003_CD
Capital_NN
expenditure_NN
on_PIN
long-lived_JJ
assets_NN
18,324_CD
46,368_CD
15,827_CD
16,854_CD
97,373_CD
1_CD
Included_VBN
in_PIN
depreciation_NOMZ
and_PHC
amortization_NOMZ
are_VPRT [BEMA]
the_DT
write-downs_NN
of_PIN
intangible_JJ
assets_NN
of_PIN
$_$
27.5_CD
million_CD
$_$
15.8_CD
million_CD
in_PIN
the_DT
International_NN
segment_NOMZ
and_CC
$_$
11.7_CD
million_CD
in_PIN
the_DT
US_FPP1
segment_NOMZ
,_,
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
of_PIN
$_$
6.0_CD
million_CD
Corporate_JJ
segment_NOMZ
and_PHC
assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
resale_NN
of_PIN
$_$
10.7_CD
million_CD
Corporate_JJ
segment_NOMZ
._.
Depreciation_NOMZ
from_PIN
manufacturing_VBG
plants_NN
$_$
2.6_CD
million_CD
is_VPRT [PASS]
included_VBN
within_PIN
cost_NN
of_PIN
product_NN
sales_NN
._.
Depreciation_NOMZ
and_PHC
amortization_NOMZ
relating_VBG [WZPRES]
to_PIN
R&D_NN
assets_NN
are_VPRT [PASS]
included_VBN
within_PIN
US_FPP1
and_PHC
International_NN
segments_NOMZ
._.
2_CD
Costs_NN
associated_VBN [WZPAST]
with_PIN
the_DT
closure_NN
of_PIN
the_DT
Lead_JJ
Optimization_NOMZ
division_NN
and_CC
other_JJ
related_JJ
activities_NOMZ
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2003_CD
are_VPRT
:_:
Research_NN
and_PHC
development_NOMZ
$_$
7.2_CD
million_CD
and_CC
depreciation_NOMZ
and_PHC
amortization_NOMZ
$_$
16.7_CD
million_CD
._.
These_DEMO
amounts_NN
are_VPRT [PASS]
reflected_VBN [PRIV]
in_PIN
reorganization_NOMZ
costs_NN
in_PIN
the_DT
statement_NOMZ
of_PIN
operations_NOMZ
._.
Depreciation_NOMZ
from_PIN
manufacturing_VBG
plants_NN
is_VPRT [PASS]
included_VBN
within_PIN
cost_NN
of_PIN
product_NN
sales_NN
$_$
0.8_CD
million_CD
._.
88_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
89_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
23_CD
Segment_NOMZ
reporting_GER
continued_VBD
Material_NN
customers_NN
In_PIN
the_DT
periods_NN
set_VBN [WZPAST]
out_PIN
below_PLACE
,_,
certain_JJ
customers_NN
,_,
all_QUAN
within_PIN
the_DT
US_FPP1
operating_GER
segment_NOMZ
,_,
accounted_VBD
for_PIN
greater_JJ
than_PIN
10_CD
%_NN
of_PIN
the_DT
Companys_NN
total_VPRT
revenues_NN
:_:
2004 2004 2003 2003_CD
2002_CD
2002_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
%_NN
revenue_NN
$_$
000_CD
%_NN
revenue_NN
$_$
000_CD
%_NN
revenue_NN
Customer_NN
A_DT
339,136_CD
25_CD
%_NN
274,771_CD
23_CD
%_NN
231,270_CD
23_CD
%_NN
Customer_NN
B_NN
303,965_CD
22_CD
%_NN
269,364_CD
22_CD
%_NN
197,184_CD
19_CD
%_NN
Customer_NN
C_NN
167,998_CD
12_CD
%_NN
175,856_CD
15_CD
%_NN
160,210_CD
16_CD
%_NN
Customer_NN
D_NN
156,578_CD
11_CD
%_NN
158,689_CD
13_CD
%_NN
149,613_CD
15_CD
%_NN
Amounts_NN
outstanding_JJ
as_IN
of_PIN
December_NN
31_CD
,_,
in_PIN
respect_NN
of_PIN
these_DEMO
material_NN
customers_NN
were_VBD
as_IN
follows_VPRT
:_:
2004_CD
2003_CD
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
Customer_NN
A_DT
28,178_CD
23,793_CD
Customer_NN
B_NN
23,535_CD
25,676_CD
Customer_NN
C_NN
8,515_CD
45,712_CD
Customer_NN
D_NN
16,975_CD
8,212_CD
77,203_CD
103,393_CD
24_CD
Other_JJ
income_NN
expense_NN
,_,
net_JJ
2004 2003 2002_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
SERP_NN
valuation_NOMZ
adjustment_NOMZ
see_VPRT [PRIV]
Note_NN
25 264 175_CD
2,301_CD
Impairment_NOMZ
of_PIN
long-term_JJ
investments_NOMZ
see_VPRT [PRIV]
Note_NN
10_CD
15,364_CD
15,540_CD
8,680_CD
GeneChem_NN
Funds_NN
management_NOMZ
fee_NN
4,036_CD
3,755_CD
3,333_CD
Gain_NN
on_PIN
sale_NN
of_PIN
available-for-sale_JJ
security_NOMZ
see_VPRT [PRIV]
Note_NN
10_CD
14,805_CD
Foreign_JJ
exchange_NN
2,467_CD
6,716_CD
344_CD
Other_JJ
2,571_CD
2,319_CD
4,507_CD
3,845_CD
20,645_CD
12,499_CD
25_CD
Retirement_NOMZ
benefits_NN
a_DT
Personal_JJ
defined_VBN
contribution_NOMZ
pension_NN
plans_VPRT
The_DT
Company_NN
makes_VPRT
contributions_NOMZ
to_TO
defined_VBN
contribution_NOMZ
retirement_NOMZ
plans_NN
that_TSUB
together_RB
cover_VPRT
substantially_RB
all_QUAN
employees_NN
._.
For_PIN
the_DT
defined_VBN
contribution_NOMZ
retirement_NOMZ
plans_NN
,_,
the_DT
level_NN
of_PIN
the_DT
Companys_NN
contribution_NOMZ
is_VPRT [PASS]
fixed_VBN
at_PIN
a_DT
set_VBN
percentage_NN
of_PIN
employees_NN
pay_VPRT
._.
Company_NN
contributions_NOMZ
to_PIN
personal_JJ
defined_VBN
contribution_NOMZ
pension_NN
plans_NN
totaled_VBD
$_$
9.0_CD
million_CD
,_,
$_$
16.1_CD
million_CD
and_CC
$_$
6.8_CD
million_CD
for_PIN
the_DT
years_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
,_,
2003_CD
and_CC
2002_CD
respectively_RB
,_,
and_ANDC
were_VBD [PASS]
charged_VBN
to_PIN
operations_NOMZ
as_IN
they_TPP3
became_VBD
payable_JJ
._.
b_NN
Defined_VBN
benefit_NN
pension_NN
plan_NN
Roberts_NN
,_,
a_DT
company_NN
with_PIN
which_WDT [PIRE]
the_DT
Company_NN
merged_VBD
in_PIN
December_NN
1999_CD
,_,
operated_VBD
a_DT
defined_VBN
SERP_NN
for_PIN
certain_JJ
US_FPP1
employees_NN
,_,
which_WDT [SERE]
was_VBD [PASS]
established_VBN [PRIV]
in_PIN
1998_CD
._.
This_DEMO
plan_NN
was_VBD [BEMA]
available_PRED
to_PIN
former_JJ
employees_NN
of_PIN
Roberts_NN
who_WP [WHSUB]
met_VBD
certain_JJ
age_NN
and_PHC
service_NN
requirements_NOMZ
._.
As_IN
part_NN
of_PIN
the_DT
restructuring_GER
of_PIN
the_DT
Company_NN
following_VBG [WZPRES]
the_DT
Roberts_NN
merger_NN
,_,
the_DT
SERP_NN
was_VBD [PASS]
closed_VBN
to_PIN
new_JJ
members_NN
and_PHC
contributions_NOMZ
ceased_VBD
being_VBG [PASS]
paid_VBN
into_PIN
the_DT
plan_NN
for_PIN
existing_VBG
members_NN
._.
As_IN
part_NN
of_PIN
this_DEMO
arrangement_NOMZ
,_,
the_DT
Company_NN
paid_VBD
a_DT
lump_NN
sum_NN
contribution_NOMZ
into_PIN
the_DT
plan_NN
of_PIN
$_$
18.0_CD
million_CD
,_,
the_DT
result_NN
of_PIN
which_WDT [PIRE]
is_VPRT
that_DEMO
the_DT
Company_NN
has_VPRT
no_SYNE
future_JJ
contributions_NOMZ
to_TO
make_VB
under_IN
the_DT
plan_NN
._.
In_PIN
accordance_NN
with_PIN
EITF_NN
97-14_CD
,_,
the_DT
asset_NN
and_PHC
liability_NOMZ
of_PIN
$_$
7.7_CD
million_CD
and_CC
$_$
5.5_CD
million_CD
,_,
respectively_RB
,_,
are_VPRT [PASS]
shown_VBN [PRIV]
on_PIN
the_DT
balance_NN
sheet_NN
within_PIN
the_DT
categories_NN
Other_JJ
non-current_JJ
assets_NN
,_,
Other_JJ
current_JJ
liabilities_NOMZ
and_CC
Other_JJ
non-current_JJ
liabilities_NOMZ
._.
89_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
90_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
26_CD
Income_NN
taxes_NN
The_DT
components_NN
of_PIN
pre_NN
tax_NN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
are_VPRT
as_IN
follows_VPRT
:_:
2004 2003 2002_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
UK_NN
67,363_CD
76,267_CD
50,520_CD
US_FPP1
265,770_CD
285,221_CD
218,139_CD
Other_JJ
jurisdictions_NOMZ
261,487_CD
197,393_CD
179,208_CD
Sub-total_JJ
459,894_CD
406,347_CD
346,827_CD
Equity_NOMZ
investees_NN
2,508_CD
1,057_CD
1,668_CD
The_DT
provision_NN
for_PIN
income_NN
taxes_NN
by_PIN
location_NOMZ
of_PIN
the_DT
taxing_VBG
jurisdiction_NOMZ
for_PIN
the_DT
years_NN
to_PIN
December_NN
31_CD
,_,
consisted_VBN [PASTP]
of_PIN
the_DT
following_GER
:_:
2004 2003 2002_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
Current_JJ
income_NN
taxes_NN
:_:
UK_NN
corporation_NOMZ
tax_NN
746_CD
US_FPP1
federal_JJ
tax_NN
98,668_CD
101,174_CD
67,686_CD
US_FPP1
state_NN
and_CC
local_JJ
taxes_NN
5,107_CD
4,313_CD
9,561_CD
Other_JJ
jurisdictions_NOMZ
36,417_CD
18,792_CD
19,864_CD
Total_JJ
current_JJ
taxes_NN
140,938_CD
124,279_CD
97,111_CD
Deferred_JJ
taxes_NN
:_:
UK_NN
corporation_NOMZ
tax_NN
482_CD
9,696_CD
US_FPP1
federal_JJ
tax_NN
12,171_CD
3,647_CD
1,136_CD
US_FPP1
state_NN
and_CC
local_JJ
taxes_NN
104_CD
180_CD
34_CD
Other_JJ
jurisdictions_NOMZ
922_CD
30,449_CD
9,931_CD
Total_JJ
deferred_JJ
taxes_NN
11,835_CD
16,926_CD
8,761_CD
Total_JJ
income_NN
taxes_NN
attributable_JJ
to_TO
continuing_VBG
operations_NOMZ
129,103_CD
107,353_CD
88,350_CD
Total_JJ
incomes_NN
taxes_NN
attributable_JJ
to_TO
discontinued_VBN
operations_NOMZ
4,812_CD
Total_JJ
income_NN
taxes_NN
129,103_CD
107,353_CD
93,162_CD
The_DT
reconciliation_NOMZ
of_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
before_IN
income_NN
taxes_NN
and_PHC
equity_NOMZ
in_PIN
net_JJ
income_NN
losses_NN
of_PIN
associates_NN
and_CC
discontinued_VBN
operations_NOMZ
to_PIN
the_DT
provision_NN
for_PIN
income_NN
taxes_NN
is_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
table_NN
below_PLACE
:_:
2004 2003 2002_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
before_IN
income_NN
taxes_NN
and_PHC
equity_NOMZ
in_PIN
net_JJ
income_NN
losses_NN
of_PIN
associates_NN
and_CC
discontinued_VBN
operations_NOMZ
459,894_CD
406,347_CD
346,827_CD
UK_NN
corporation_NOMZ
tax_NN
rate_NN
30_CD
%_NN
30_CD
%_NN
30_CD
%_NN
Adjustments_NOMZ
to_TO
derive_VB
effective_JJ
rate_NN
:_:
Non-deductible_JJ
items_NN
:_:
Permanent_JJ
differences_NN
2.0_CD
%_NN
1.1_CD
%_NN
1.2_CD
%_NN
Other_JJ
items_NN
:_:
Change_NN
in_PIN
valuation_NOMZ
allowance_NN
3.3_CD
%_NN
7.1_CD
%_NN
4.0_CD
%_NN
Difference_NN
in_PIN
taxation_NOMZ
rates_NN
0.6_CD
%_NN
11.2_CD
%_NN
10.5_CD
%_NN
Prior_RB
year_NN
adjustment_NOMZ
4.5_CD
%_NN
2.1_CD
%_NN
0.7_CD
%_NN
Other_JJ
0.5_CD
%_NN
2.7_CD
%_NN
0.1_CD
%_NN
Provision_NN
for_PIN
income_NN
taxes_NN
on_PIN
continuing_VBG
operations_NOMZ
28.1_CD
%_NN
26.4_CD
%_NN
25.5_CD
%_NN
90_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
91_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
26_CD
Income_NN
taxes_NN
continued_VBD
The_DT
significant_JJ
components_NN
of_PIN
deferred_JJ
income_NN
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
and_CC
their_TPP3
balance_NN
sheet_NN
classifications_NOMZ
,_,
as_IN
of_PIN
December_NN
31_CD
,_,
are_VPRT
as_IN
follows_VPRT
:_:
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2004_CD
2003_CD
$_$
000_CD
$_$
000_CD
Deferred_VBN
tax_NN
assets_NN
:_:
Accrued_VBN
expenses_NN
not_XX0
currently_RB
deductible_JJ
9,708_CD
3,340_CD
Losses_NN
carried_VBD
forward_RB
194,523_CD
248,239_CD
Provisions_NN
32,086_CD
11,299_CD
Other_JJ
32,020_CD
1,876_CD
Gross_NN
deferred_VBN
tax_NN
assets_NN
268,337_CD
264,754_CD
Less_RB
:_:
valuation_NOMZ
allowance_NN
152,915_CD
168,176_CD
115,422_CD
96,578_CD
Deferred_JJ
tax_NN
liabilities_NOMZ
:_:
Excess_NN
of_PIN
tax_NN
value_NN
over_IN
book_NN
value_NN
of_PIN
assets_NN
37,311_CD
33,446_CD
Net_JJ
deferred_JJ
tax_NN
assets_NN
78,111_CD
63,132_CD
Balance_NN
sheet_NN
classifications_NOMZ
:_:
Deferred_JJ
tax_NN
assets_NN
current_JJ
70,387_CD
64,532_CD
Deferred_JJ
tax_NN
assets_NN
liabilities_NOMZ
non-current_JJ
7,724_CD
1,400_CD
78,111_CD
63,132_CD
The_DT
approximate_JJ
net_JJ
operating_GER
loss_NN
carry-forwards_NN
as_IN
of_PIN
December_NN
31_CD
,_,
are_VPRT
as_IN
follows_VPRT
:_:
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2004_CD
2003_CD
$_$
000_CD
$_$
000_CD
US_FPP1
federal_JJ
tax_NN
NOLs_NN
25,416_CD
23,468_CD
US_FPP1
state_NN
tax_NN
NOLs_NN
93,542_CD
130,755_CD
UK_NN
NOLs_NN
246,966_CD
146,164_CD
Canadian_JJ
NOLs_NN
438,523_CD
465,476_CD
Foreign_JJ
tax_NN
jurisdictions_NOMZ
100,808_CD
188,869_CD
The_DT
tax_NN
losses_NN
shown_VBN [PRIV]
above_PLACE
have_VPRT
the_DT
following_VBG
expiration_NOMZ
dates_NN
:_:
December_NN
31_CD
,_,
2004_CD
$_$
000_CD
Within_PIN
1_CD
year_NN
1,274_CD
Within_PIN
1-2_CD
years_NN
4,403_CD
Within_PIN
2-3_CD
years_NN
2,832_CD
Within_PIN
3-4_CD
years_NN
75,943_CD
Within_PIN
4-5_CD
years_NN
36,771_CD
Within_PIN
5-6_CD
years_NN
1,430_CD
Within_PIN
6-7_CD
years_NN
923_CD
After_IN
7_CD
years_NN
95,493_CD
Available_JJ
indefinitely_RB
686,186_CD
As_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
,_,
the_DT
Company_NN
had_VBD
a_DT
valuation_NOMZ
allowance_NN
of_PIN
$_$
153_CD
million_CD
to_TO
reduce_VB
its_PIT
deferred_JJ
tax_NN
assets_NN
to_TO
estimated_VBN [PRIV]
realizable_JJ
value_NN
._.
The_DT
valuation_NOMZ
allowance_NN
relates_VPRT
to_PIN
the_DT
deferred_VBN
tax_NN
assets_NN
arising_VBG [WZPRES]
from_PIN
operating_VBG
loss_NN
carry-forwards_NN
and_PHC
capital_NN
loss_NN
carry-forwards_NN
,_,
which_WDT [SERE]
have_VPRT
no_SYNE
expiration_NOMZ
date_NN
._.
The_DT
utilization_NOMZ
of_PIN
operating_VBG
loss_NN
carry-forwards_NN
is_VPRT
,_,
however_CONJ
,_,
restricted_VBN [PASTP]
to_PIN
the_DT
taxable_JJ
income_NN
of_PIN
the_DT
subsidiary_NN
generating_VBG [WZPRES]
the_DT
losses_NN
._.
In_CONJ
addition_NULL
,_,
capital_NN
loss_NN
carry-forwards_NN
can_POMD
be_VB [PASS]
offset_VBN
only_DWNT
against_PIN
capital_NN
gains_NN
._.
As_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
,_,
based_VBN [PASTP]
upon_PIN
the_DT
level_NN
of_PIN
historical_JJ
taxable_JJ
income_NN
and_PHC
projections_NOMZ
for_PIN
future_JJ
taxable_JJ
income_NN
over_IN
the_DT
periods_NN
in_PIN
which_WDT [PIRE]
the_DT
temporary_JJ
differences_NN
are_VPRT [PASS]
anticipated_VBN [PRIV]
to_TO
reverse_VB
,_,
and_ANDC
reasonable_JJ
and_PHC
feasible_JJ
tax-planning_JJ
strategies_NN
,_,
management_NOMZ
believes_VPRT [PRIV] [THATD]
it_PIT
is_VPRT [BEMA]
more_EMPH
likely_PRED
than_PIN
not_XX0
that_DEMO
the_DT
Company_NN
will_PRMD
realize_VB [PRIV]
the_DT
benefits_NN
of_PIN
these_DEMO
deductible_JJ
differences_NN
,_,
net_NN
of_PIN
the_DT
valuation_NOMZ
allowances_NN
._.
However_CONJ
,_,
the_DT
amount_NN
of_PIN
the_DT
deferred_JJ
tax_NN
asset_NN
considered_VBN [PRIV]
realizable_JJ
could_POMD
be_VB [PASS]
adjusted_VBN
in_PIN
the_DT
future_NN
if_COND
estimates_NN
of_PIN
taxable_JJ
income_NN
are_VPRT [PASS]
revised_VBN
._.
As_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
the_DT
Company_NN
has_VPRT [PEAS]
not_XX0
made_VBN
a_DT
UK_NN
tax_NN
provision_NN
on_PIN
approximately_RB
$_$
1.4_CD
billion_CD
of_PIN
unremitted_JJ
earnings_GER
of_PIN
the_DT
Companys_NN
international_JJ
subsidiaries_NN
._.
It_PIT
is_VPRT [BEMA]
not_XX0
practical_PRED
to_TO
determine_VB [SUAV] [PRIV]
the_DT
amount_NN
of_PIN
unrecognized_JJ
deferred_JJ
tax_NN
liabilities_NOMZ
for_PIN
temporary_JJ
differences_NN
relating_VBG [WZPRES]
to_PIN
these_DEMO
investments_NOMZ
._.
91_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
92_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
27_CD
Equity_NOMZ
in_PIN
earnings_GER
losses_NN
of_PIN
equity-method_JJ
investees_NN
2004 2003 2002_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
GSK_NN
4,433_CD
3,495_CD
2,592_CD
GeneChem_NN
Funds_NN
see_VPRT [PRIV]
Note_NN
10_CD
75_CD
Other_JJ
2,000_CD
4,552_CD
924_CD
2,508_CD
1,057_CD
1,668_CD
The_DT
Company_NN
has_VPRT [PEAS]
accounted_VBN
for_PIN
its_PIT
commercialization_NOMZ
partnership_NN
with_PIN
GSK_NN
through_PIN
which_WDT [PIRE]
the_DT
products_NN
3TC_NN
and_PHC
ZEFFIX_NN
are_VPRT [PASS]
marketed_VBN
in_PIN
Canada_NN
using_VBG [WZPRES]
the_DT
equity-method_NN
of_PIN
accounting_GER
._.
The_DT
Company_NN
owns_VPRT
,_,
but_CC
does_VPRT
not_XX0
exercise_VB
control_NN
over_IN
,_,
a_DT
50_CD
%_NN
share_NN
of_PIN
the_DT
partnership_NN
._.
28_CD
Stock_NN
incentive_NN
plans_VPRT
The_DT
Company_NN
has_VPRT [PEAS]
granted_VBN [SUAV]
options_NOMZ
to_PIN
directors_NN
and_PHC
employees_NN
over_IN
ordinary_JJ
shares_NN
under_IN
the_DT
following_VBG
six_CD
stock_NN
option_NOMZ
plans_NN
:_:
i_FPP1
Shire_FW
Pharmaceuticals_NN
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
Parts_NN
A_NN
and_PHC
B_NN
Executive_NN
Scheme_NN
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Executive_NN
Scheme_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
performance_NN
criteria_NN
and_CC
can_POMD
not_XX0
be_VB [PASS]
exercised_VBN
in_PIN
full_JJ
,_,
unless_COND
Shires_NN
ordinary_JJ
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
at_PIN
least_JJ
20.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
measurement_NOMZ
period_NN
._.
If_COND
Shires_NN
ordinary_JJ
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
14.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
measurement_NOMZ
period_NN
,_,
60_CD
%_NN
of_PIN
the_DT
options_NOMZ
may_POMD
be_VB [PASS]
exercised_VBN
._.
On_PIN
February_NN
28_CD
,_,
2000_CD
,_,
the_DT
Remuneration_NOMZ
Committee_NN
of_PIN
the_DT
Board_NN
exercised_VBD
its_PIT
powers_NN
to_TO
amend_VB
the_DT
terms_NN
of_PIN
the_DT
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
so_RB
as_IN
to_TO
include_VB
a_DT
cliff_NN
vesting_VBG [WZPRES]
provision_NN
._.
It_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
that_THVC
no_SYNE
further_JJ
options_NOMZ
will_PRMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Executive_NN
Scheme_NN
._.
ii_FW
Shire_FW
Pharmaceuticals_NN
Group_NN
plc_NN
2000_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
2000_CD
Executive_NN
Scheme_NN
Options_NOMZ
granted_VBN [SUAV]
under_IN
this_DEMO
scheme_NN
are_VPRT [BEMA]
exercisable_JJ
subject_NN
to_PIN
certain_JJ
performance_NN
criteria_NN
._.
In_PIN
respect_NN
of_PIN
any_QUAN
option_NOMZ
granted_VBN [SUAV] [WZPAST]
prior_RB
to_PIN
August_NN
2002_CD
,_,
if_COND
Shires_NN
ordinary_JJ
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
at_PIN
least_JJ
20.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
measurement_NOMZ
period_NN
,_,
the_DT
option_NOMZ
becomes_VPRT
exercisable_JJ
in_PIN
full_JJ
._.
If_COND
it_PIT
increases_VPRT
by_PIN
at_PIN
least_JJ
14.5_CD
%_NN
per_PIN
annum_NN
over_IN
the_DT
same_JJ
three-year_JJ
period_NN
,_,
60_CD
%_NN
of_PIN
the_DT
options_NOMZ
granted_VBN [SUAV]
become_VBN
exercisable_JJ
._.
Given_VBN
Shires_NN
development_NOMZ
,_,
it_PIT
was_VBD [PASS]
considered_VBN [PRIV]
appropriate_JJ
that_THAC
an_DT
earnings_GER
per_PIN
share_NN
based_VBN
measure_NN
should_NEMD
be_VB [PASS]
adopted_VBN
in_PIN
place_NN
of_PIN
share_NN
price_NN
growth_NN
targets_NN
._.
Therefore_CONJ
,_,
the_DT
performance_NN
criteria_NN
were_VBD [PASS]
amended_VBN
so_OSUB
that_NULL
an_DT
option_NOMZ
would_PRMD
become_VB
exercisable_JJ
in_PIN
full_JJ
if_COND
Shires_NN
fully_AMP
diluted_VBD
earnings_GER
per_PIN
share_NN
growth_NN
over_IN
a_DT
three-year_JJ
period_NN
from_PIN
the_DT
date_NN
of_PIN
award_NN
exceeds_VPRT
the_DT
UK_NN
Retail_NN
Price_NN
Index_NN
RPI_NN
on_PIN
average_NN
a_DT
year_NN
for_PIN
the_DT
following_VBG
tranches_NN
of_PIN
grants_NN
:_:
Options_NOMZ
with_PIN
a_DT
grant_NN
value_NN
of_PIN
up_RB
to_PIN
100_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
3_CD
%_NN
per_PIN
annum_NN
directors_NN
,_,
RPI_NN
plus_PIN
5_CD
%_NN
Between_PIN
101_CD
%_NN
and_CC
200_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
5_CD
%_NN
per_PIN
annum_NN
Between_PIN
201_CD
%_NN
and_CC
300_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
7_CD
%_NN
per_PIN
annum_NN
Over_IN
301_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
9_CD
%_NN
per_PIN
annum_NN
The_DT
new_JJ
earnings_GER
per_PIN
share_NN
performance_NN
criteria_NN
apply_VPRT
to_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
from_PIN
August_NN
2002_CD
._.
After_IN
consultation_NOMZ
with_PIN
certain_JJ
of_PIN
its_PIT
institutional_JJ
shareholders_NN
,_,
the_DT
Company_NN
has_VPRT [PEAS]
decided_VBN [SUAV] [PRIV]
that_THVC
for_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
scheme_NN
from_PIN
2004_CD
onwards_NN
,_,
the_DT
retest_NN
of_PIN
the_DT
performance_NN
condition_NOMZ
if_COND
Shires_NN
earnings_GER
per_PIN
share_NN
growth_NN
has_VPRT [PEAS]
fallen_VBN
short_JJ
of_PIN
the_DT
minimum_JJ
annual_JJ
average_JJ
percentage_NN
increase_NN
over_IN
the_DT
three-year_JJ
period_NN
from_PIN
grant_NN
,_,
has_VPRT [PEAS]
been_VBN [PASS]
changed_VBN
._.
The_DT
performance_NN
condition_NOMZ
will_PRMD
be_VB [PASS]
retested_VBN
once_TIME
only_DWNT
,_,
at_PIN
five_CD
years_NN
after_IN
the_DT
grant_NN
._.
Hence_CONJ
the_DT
level_NN
of_PIN
earnings_GER
per_PIN
share_NN
growth_NN
in_PIN
the_DT
next_JJ
two_CD
years_NN
needs_VPRT
to_TO
be_VB [BEMA]
consequentially_RB
higher_PRED
to_TO
meet_VB
the_DT
test_NN
._.
Six_CD
weeks_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
,_,
any_QUAN
options_NOMZ
that_TSUB
have_VPRT
not_XX0
become_VB
exercisable_JJ
at_PIN
an_DT
earlier_TIME
date_NN
,_,
automatically_RB
vest_NN
without_PIN
reference_NN
to_PIN
the_DT
performance_NN
criteria_NN
._.
92_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
93_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
28_CD
Stock_NN
incentive_NN
plans_NN
continued_VBD
iii_NN
Shire_NN
Pharmaceuticals_NN
Sharesave_NN
Scheme_NN
Sharesave_NN
Scheme_NN
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Sharesave_NN
Scheme_NN
are_VPRT [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
80_CD
%_NN
of_PIN
the_DT
mid-market_JJ
price_NN
on_PIN
the_DT
day_NN
before_IN
invitations_NOMZ
are_VPRT [PASS]
issued_VBN
to_PIN
employees_NN
._.
iv_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Employee_NN
Stock_NN
Purchase_NN
Plan_NN
Stock_NN
Purchase_NN
Plan_NN
Under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
,_,
options_NOMZ
are_VPRT [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
85_CD
%_NN
of_PIN
the_DT
fair_JJ
market_NN
value_NN
of_PIN
a_DT
share_NN
on_PIN
the_DT
enrolment_NOMZ
date_NN
the_DT
first_JJ
day_NN
of_PIN
the_DT
offering_GER
period_NN
or_CC
the_DT
exercise_NN
date_NN
the_DT
last_JJ
day_NN
of_PIN
the_DT
offering_GER
period_NN
,_,
whichever_WDT
is_VPRT [BEMA]
the_DT
lower_JJ
._.
v_NN
Pharmavene_NN
1991_CD
Stock_NN
Option_NOMZ
Plan_NN
SLI_NN
Plan_NN
Options_NOMZ
issued_VBN
under_IN
the_DT
SLI_NN
Plan_NN
were_VBD [SPAU] [PASS]
originally_TIME
granted_VBN [SUAV]
over_IN
shares_NN
in_PIN
SLI_NN
,_,
formerly_TIME
Pharmavene_NN
Inc._NN
a_DT
company_NN
acquired_VBN [WZPAST]
by_PIN
the_DT
Company_NN
on_PIN
March_NN
23_CD
,_,
1997_CD
._.
Exercise_NN
of_PIN
these_DEMO
options_NOMZ
results_NN
in_PIN
the_DT
option_NOMZ
holder_NN
receiving_VBG [WZPRES]
ordinary_JJ
shares_NN
in_PIN
Shire_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
acquisition_NOMZ
of_PIN
SLI_NN
,_,
and_ANDC
in_PIN
accordance_NN
with_PIN
the_DT
terms_NN
of_PIN
the_DT
original_JJ
share_NN
option_NOMZ
plan_NN
,_,
all_QUAN
options_NOMZ
granted_VBN [SUAV]
under_IN
that_DEMO
plan_NN
became_VBD
immediately_TIME
capable_JJ
of_PIN
exercise_NN
._.
It_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
that_THVC
no_SYNE
further_JJ
options_NOMZ
will_PRMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
SLI_NN
Plan_NN
._.
vi_FW
BioChem_NN
Stock_NN
Option_NOMZ
Plan_NN
BioChem_NN
Plan_NN
Following_VBG [WZPRES]
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
Pharma_NN
Inc._NN
on_PIN
May_POMD
11_CD
,_,
2001_CD
,_,
the_DT
BioChem_NN
Stock_NN
Option_NOMZ
Plan_NN
was_VBD [PASS]
amended_VBN
such_OSUB
that_NULL
options_NOMZ
over_IN
BioChem_NN
Pharma_NN
Inc._NN
s_VPRT [BEMA]
common_JJ
stock_NN
became_VBD
options_NOMZ
over_IN
ordinary_JJ
shares_NN
of_PIN
Shire_NN
._.
All_QUAN
BioChem_NN
Pharma_NN
Inc._NN
options_NOMZ
,_,
which_WDT [SERE]
were_VBD
not_XX0
already_RB
exercisable_PRED
,_,
vested_JJ
and_CC
became_VBD
exercisable_JJ
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
acquisition_NOMZ
._.
It_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
that_THVC
no_SYNE
further_JJ
options_NOMZ
will_PRMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
BioChem_NN
Stock_NN
Option_NOMZ
Plan_NN
._.
In_PIN
a_DT
period_NN
of_PIN
ten_CD
years_NN
,_,
not_XX0
more_EMPH
than_PIN
10_CD
%_NN
of_PIN
the_DT
issued_VBN
share_NN
capital_NN
of_PIN
Shire_NN
may_POMD
be_VB [PASS]
placed_VBN
under_IN
option_NOMZ
under_IN
any_QUAN
employee_NN
share_NN
scheme_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
following_VBG
terms_NN
apply_VB
to_PIN
options_NOMZ
that_TSUB
may_POMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
various_JJ
plans_NN
:_:
2000_CD
Executive_NN
Scheme_NN
:_:
the_DT
maximum_JJ
number_NN
of_PIN
Shire_NN
ordinary_JJ
shares_NN
over_IN
which_WDT
incentive_NN
options_NOMZ
may_POMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
Part_NN
3_CD
of_PIN
the_DT
scheme_NN
is_VPRT [BEMA]
25,000,000_CD
._.
Stock_NN
Purchase_NN
Plan_NN
:_:
up_RP
to_PIN
2,000,000_CD
Shire_NN
ordinary_JJ
shares_NN
._.
The_DT
following_JJ
stock_NN
options_NOMZ
were_VBD [BEMA]
outstanding_PRED
as_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
:_:
Expiration_NOMZ
period_NN
Scheme_NN
Number_NN
of_PIN
options_NOMZ
from_PIN
date_NN
of_PIN
issue_NN
Vesting_JJ
period_NN
Executive_NN
Scheme_NN
2,274,395_CD
10_CD
years_NN
3_CD
years_NN
,_,
subject_JJ
to_PIN
performance_NN
criteria_NN
2000_CD
Executive_NN
Scheme_NN
20,233,565_CD
10_CD
years_NN
3_CD
years_NN
,_,
subject_JJ
to_PIN
performance_NN
criteria_NN
Sharesave_NN
Scheme_NN
319,432_CD
6_CD
months_NN
after_IN
vesting_VBG
3_CD
or_CC
5_CD
years_NN
Stock_NN
Purchase_NN
Plan_NN
435,977_CD
On_PIN
vesting_VBG
date_NN
27_CD
months_NN
SLI_NN
Plan_NN
4,710_CD
10_CD
years_NN
Immediate_NN
on_PIN
acquisition_NOMZ
by_PIN
Shire_NN
BioChem_NN
Plan_NN
4,075,546_CD
10_CD
years_NN
Immediate_NN
on_PIN
acquisition_NOMZ
by_PIN
Shire_NN
27,343,625_CD
93_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
94_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
28_CD
Stock_NN
incentive_NN
plans_NN
continued_VBD
A_DT
summary_NN
of_PIN
the_DT
status_NN
of_PIN
the_DT
Companys_NN
stock_NN
option_NOMZ
plans_NN
as_IN
of_PIN
December_NN
31_CD
,_,
2004_CD
,_,
2003_CD
and_CC
2002_CD
and_CC
of_PIN
the_DT
related_JJ
transactions_NOMZ
during_PIN
the_DT
periods_NN
then_RB
ended_VBD
is_VPRT [PASS]
presented_VBN
below_PLACE
:_:
Weighted_JJ
average_JJ
exercise_NN
price_NN
Year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
$_$
Number_CD
of_PIN
shares_NN
Outstanding_JJ
as_IN
of_PIN
beginning_GER
of_PIN
period_NN
10.92_CD
25,995,543_CD
Granted_VBN [SUAV]
9.92_CD
6,966,411_CD
Exercised_VBN
7.16_CD
2,097,716_CD
Forfeited_NN
14.62_CD
3,520,613_CD
Outstanding_JJ
as_IN
of_PIN
end_NN
of_PIN
period_NN
11.30_CD
27,343,625_CD
Exercisable_JJ
as_IN
of_PIN
end_NN
of_PIN
period_NN
16.70_CD
8,728,709_CD
6,665,144_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
._.
These_DEMO
options_NOMZ
were_VBD [PASS]
issued_VBN
with_PIN
exercise_NN
prices_NN
equivalent_JJ
to_PIN
the_DT
market_NN
value_NN
on_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
94,861_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Sharesave_NN
Scheme_NN
at_PIN
a_DT
price_NN
of_PIN
3.74_CD
approximately_RB
$_$
7.22_CD
._.
These_DEMO
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
80_CD
%_NN
of_PIN
the_DT
mid-market_JJ
price_NN
on_PIN
the_DT
day_NN
before_IN
invitations_NOMZ
were_VBD [PASS]
issued_VBN
to_PIN
employees_NN
._.
173,613_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
at_PIN
a_DT
price_NN
of_PIN
3.92_CD
approximately_RB
$_$
7.57_CD
._.
These_DEMO
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
85_CD
%_NN
of_PIN
the_DT
mid-market_JJ
price_NN
on_PIN
the_DT
day_NN
before_IN
invitations_NOMZ
were_VBD [PASS]
issued_VBN
to_PIN
employees_NN
._.
In_PIN
relation_NOMZ
to_PIN
a_DT
grant_NN
under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
at_PIN
a_DT
price_NN
of_PIN
8.06_CD
in_PIN
2001_CD
,_,
an_DT
additional_JJ
32,793_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
at_PIN
a_DT
price_NN
of_PIN
4.58_CD
on_PIN
the_DT
2004_CD
maturity_NOMZ
date_NN
._.
The_DT
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
is_VPRT
$_$
9.99_CD
._.
Weighted_JJ
average_JJ
exercise_NN
price_NN
Year_NN
to_PIN
December_NN
31_CD
,_,
2003_CD
$_$
Number_CD
of_PIN
shares_NN
Outstanding_JJ
as_IN
of_PIN
beginning_GER
of_PIN
period_NN
11.55_CD
20,051,297_CD
Granted_VBN [SUAV]
6.30_CD
9,407,852_CD
Exercised_VBN
5.12_CD
1,039,439_CD
Forfeited_NN
11.28_CD
2,424,167_CD
Outstanding_JJ
as_IN
of_PIN
end_NN
of_PIN
period_NN
10.92_CD
25,995,543_CD
Exercisable_JJ
as_IN
of_PIN
end_NN
of_PIN
period_NN
12.79_CD
8,989,450_CD
8,819,199_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
._.
182,639_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Sharesave_NN
Scheme_NN
at_PIN
a_DT
price_NN
of_PIN
3.86_CD
approximately_RB
$_$
6.91_CD
._.
406,014_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
at_PIN
a_DT
price_NN
of_PIN
4.09_CD
approximately_RB
$_$
7.32_CD
._.
The_DT
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2003_CD
is_VPRT
$_$
6.39_CD
._.
94_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
95_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
28_CD
Stock_NN
incentive_NN
plans_NN
continued_VBD
Weighted_JJ
average_JJ
exercise_NN
price_NN
Year_NN
to_PIN
December_NN
31_CD
,_,
2002_CD
$_$
Number_CD
of_PIN
shares_NN
Outstanding_JJ
as_IN
of_PIN
beginning_GER
of_PIN
period_NN
10.80_CD
16,249,844_CD
Granted_VBN [SUAV]
8.49_CD
6,179,894_CD
Exercised_VBN
3.52_CD
1,940,546_CD
Forfeited_NN
11.07_CD
437,895_CD
Outstanding_JJ
as_IN
of_PIN
end_NN
of_PIN
period_NN
11.55_CD
20,051,297_CD
Exercisable_JJ
as_IN
of_PIN
end_NN
of_PIN
period_NN
9.24_CD
8,491,051_CD
4,539,529_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
._.
186,052_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Sharesave_NN
Scheme_NN
at_PIN
a_DT
price_NN
of_PIN
5.02_CD
approximately_RB
$_$
8.08_CD
._.
18,342_CD
and_CC
1,435,971_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
at_PIN
a_DT
price_NN
of_PIN
3.19_CD
and_CC
5.44_CD
approximately_RB
$_$
5.14_CD
and_CC
$_$
8.76_CD
,_,
respectively_RB
._.
The_DT
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2002_CD
is_VPRT
$_$
8.91_CD
._.
In_PIN
the_DT
rest_NN
of_PIN
the_DT
world_NN
,_,
the_DT
Company_NN
acquired_VBD
the_DT
license_NN
to_TO
develop_VB
and_PHC
commercialize_VB
NRP104_NN
._.
The_DT
Company_NN
paid_VBD
an_DT
initial_JJ
sum_NN
of_PIN
$_$
50_CD
million_CD
on_PIN
signing_GER
,_,
and_ANDC
there_EX
is_VPRT
a_DT
further_JJ
$_$
50_CD
million_CD
due_JJ
upon_PIN
acceptance_NN
of_PIN
filing_NN
of_PIN
the_DT
New_NN
Drug_NN
Application_NOMZ
by_PIN
the_DT
FDA_NN
and_CC
up_RB
to_TO
$_$
300_CD
million_CD
in_PIN
milestone_NN
payments_NOMZ
following_VBG [WZPRES]
the_DT
first_JJ
commercial_JJ
sale_NN
depending_VBG [WZPRES]
on_PIN
the_DT
characteristics_NN
of_PIN
the_DT
FDA_NN
approved_VBD
product_NN
labeling_VBG [WZPRES]
._.
A_DT
$_$
5_CD
million_CD
milestone_NN
payment_NOMZ
is_VPRT [BEMA]
payable_PRED
following_VBG
the_DT
first_JJ
commercial_JJ
sale_NN
in_PIN
specified_VBN
European_JJ
countries_NN
._.
An_DT
additional_JJ
$_$
100_CD
million_CD
milestone_NN
would_PRMD
be_VB [BEMA]
payable_PRED
as_IN
a_DT
sales_NN
bonus_NN
upon_PIN
achieving_VBG
a_DT
significant_JJ
sales_NN
target_NN
._.
The_DT
Company_NN
may_POMD
be_VB [PASS]
entitled_VBN
to_PIN
refunds_NN
of_PIN
amounts_NN
previously_TIME
paid_VBN
in_PIN
the_DT
event_NN
of_PIN
a_DT
delayed_JJ
product_NN
approval_NN
._.
95_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
96_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
thousands_NN
of_PIN
US_FPP1
dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
Quarterly_JJ
results_NN
of_PIN
operations_NOMZ
unaudited_JJ
The_DT
following_VBG
table_NN
presents_NN
summarized_VBN
unaudited_JJ
quarterly_JJ
results_NN
for_PIN
the_DT
years_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
and_CC
2003_CD
._.
The_DT
2003_CD
results_NN
for_PIN
all_QUAN
quarterly_JJ
periods_NN
and_CC
Q1_CD
,_,
2004_CD
presented_VBN
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
to_TO
reflect_VB [PRIV]
the_DT
disposal_NN
of_PIN
the_DT
vaccines_NN
business_NOMZ
which_WDT [WHSUB]
has_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
discontinued_VBN
operation_NOMZ
._.
See_VB [PRIV]
Note_NN
3_CD
for_PIN
further_JJ
details_NN
._.
During_PIN
Q3_NN
2004_CD
the_DT
Company_NN
recorded_VBD
a_DT
loss_NN
on_PIN
redemption_NOMZ
of_PIN
the_DT
convertible_JJ
loan_NN
notes_NN
of_PIN
$_$
7.4_CD
million_CD
,_,
which_WDT [SERE]
resulted_VBD
from_PIN
the_DT
write-off_PIN
of_PIN
unamortized_JJ
debt_NN
issuance_NN
costs_NN
._.
Diluted_NN
EPS_NN
would_PRMD
have_VB [PEAS]
been_VBN [BEMA]
15.4_CD
,_,
or_CC
0.1_CD
higher_JJ
,_,
without_PIN
this_DEMO
loss_NN
on_PIN
redemption_NOMZ
._.
These_DEMP
were_VBD [BEMA]
in_PIN
respect_NN
of_PIN
the_DT
implementation_NOMZ
of_PIN
the_DT
new_JJ
business_NOMZ
model_NN
in_PIN
2004_CD
and_CC
the_DT
closure_NN
of_PIN
Lead_JJ
Optimization_NOMZ
together_RB
with_PIN
the_DT
exit_NN
of_PIN
certain_JJ
properties_NN
in_PIN
2003_CD
._.
Included_VBN [PASTP]
in_PIN
2001_CD
were_VBD
$_$
29.7_CD
million_CD
of_PIN
asset_NN
impairment_NOMZ
charges_NN
,_,
$_$
83.5_CD
million_CD
of_PIN
merger_NN
transaction_NOMZ
expenses_NN
and_CC
$_$
10.2_CD
million_CD
of_PIN
costs_NN
in_PIN
relation_NOMZ
to_PIN
the_DT
disposition_NOMZ
of_PIN
certain_JJ
assets_NN
._.
All_QUAN
of_PIN
these_DEMO
costs_NN
were_VBD [BEMA]
in_PIN
relation_NOMZ
to_PIN
the_DT
merger_NN
with_PIN
BioChem_NN
in_PIN
2001_CD
._.
2_CD
Total_JJ
other_JJ
income_NN
,_,
net_JJ
includes_VPRT
$_$
14.9_CD
million_CD
on_PIN
the_DT
sale_NN
of_PIN
a_DT
portfolio_NN
investment_NOMZ
in_PIN
2004_CD
._.
In_PIN
2001_CD
there_EX
was_VBD
a_DT
$_$
55.7_CD
million_CD
writedown_NN
of_PIN
investments_NOMZ
related_VBN [WZPAST]
to_PIN
the_DT
BioChem_NN
merger_NN
._.
3_CD
As_CONJ
a_NULL
consequence_NULL
of_PIN
the_DT
adoption_NOMZ
of_PIN
SFAS_NN
No._NN
._.
142_CD
,_,
with_PIN
effect_NN
from_PIN
January_NN
1_CD
,_,
2002_CD
,_,
the_DT
amortization_NOMZ
expense_NN
shown_VBN [PRIV] [WZPAST]
for_PIN
2001_CD
and_CC
2000_CD
in_PIN
the_DT
selected_VBN
consolidated_JJ
financial_JJ
data_NN
presented_VBN [WZPAST]
is_VPRT [BEMA]
not_XX0
on_PIN
a_DT
consistent_JJ
basis_NN
of_PIN
accounting_GER
with_PIN
subsequent_JJ
periods_NN
._.
Net_JJ
income_NN
for_PIN
2001_CD
and_CC
2000_CD
would_PRMD
have_VB [PEAS]
been_VBN
$_$
49.5_CD
million_CD
and_CC
$_$
223.0_CD
million_CD
,_,
respectively_RB
._.
97_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
98_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Summary_NN
financial_JJ
statement_NOMZ
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
General_NN
Directors_NN
The_DT
summary_NN
financial_JJ
statement_NOMZ
does_VPRT
not_XX0
contain_VB
sufficient_JJ
The_DT
Directors_NN
who_WP [WHSUB]
served_VBD
during_PIN
the_DT
year_NN
were_VBD
as_IN
follows_VPRT
:_:
information_NOMZ
to_TO
allow_VB [SUAV]
for_PIN
as_RB
full_JJ
an_DT
understanding_GER
of_PIN
the_DT
results_NN
and_PHC
state_NN
of_PIN
affairs_NN
of_PIN
the_DT
Company_NN
or_CC
Group_NN
and_CC
of_PIN
the_DT
policies_NN
and_PHC
Dr_NN
James_NN
Cavanaugh_NN
arrangements_NOMZ
concerning_VBG [WZPRES]
directors_NN
remuneration_NOMZ
,_,
as_RB
would_PRMD
Chairman_NN
,_,
non-executive_JJ
Director_NN
be_VB [BYPA]
provided_VBN
by_PIN
the_DT
full_JJ
annual_JJ
financial_JJ
statements_NOMZ
and_PHC
reports_NN
._.
Chairman_NN
of_PIN
the_DT
Nomination_NOMZ
Committee_NN
The_NN
summary_NN
financial_JJ
statement_NOMZ
is_VPRT [PASS]
prepared_VBN
under_IN
UK_NN
GAAP_NN
._.
For_PIN
further_JJ
information_NOMZ
,_,
the_DT
full_JJ
UK_NN
statutory_JJ
accounts_NN
,_,
the_DT
Mr_NN
Matthew_NN
Emmens_NN
auditors_NN
report_VPRT [PUBV]
on_PIN
those_DEMO
accounts_NN
and_CC
the_DT
Directors_NN
report_VPRT [PUBV]
Chief_NN
Executive_NN
Officer_NN
should_NEMD
be_VB [PASS]
consulted_VBN
._.
Mr_NN
Angus_NN
Russell_NN
In_PIN
accordance_NN
with_PIN
Section_NOMZ
239_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
Chief_NN
Financial_NN
Officer_NN
shareholders_NN
have_VPRT
a_DT
right_NN
and_CC
can_POMD
elect_VB
to_TO
obtain_VB
the_DT
full_JJ
report_NN
and_PHC
accounts_NN
free_JJ
of_PIN
charges_NN
by_PIN
writing_VBG [PUBV]
to_TO
:_:
Dr_NN
Barry_NN
Price_NN
Senior_NN
non-executive_JJ
Director_NN
The_NN
Company_NN
Secretary_NN
Chairman_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
The_NN
Hon_NN
James_NN
Grant_NN
Chineham_NN
Non-executive_JJ
Director_NN
Basingstoke_NN
Hampshire_NN
Mr_NN
Ronald_NN
Nordmann_NN
RG24_NN
8EP_NN
Non-executive_JJ
Director_NN
Chairman_NN
of_PIN
the_DT
Audit_NN
Committee_NN
until_IN
July_NN
2004_CD
The_DT
full_JJ
UK_NN
statutory_JJ
annual_JJ
accounts_NN
are_VPRT [PASS]
signed_VBN
on_PIN
behalf_NN
of_PIN
the_DT
Board_NN
by_PIN
AC_NN
Russell_NN
,_,
Chief_NN
Financial_NN
Officer_NN
._.
Mr_NN
Robin_NN
Buchanan_NN
Non-executive_JJ
Director_NN
The_NN
Companys_NN
auditors_NN
have_VPRT [PEAS]
given_VBN
an_DT
unqualified_JJ
report_NN
on_PIN
the_DT
statutory_JJ
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
._.
The_DT
Mr_NN
David_NN
Kappler_NN
report_NN
did_VBD
not_XX0
contain_VB
any_QUAN
statement_NOMZ
under_IN
Section_NOMZ
237_CD
2_CD
or_CC
3_CD
appointed_VBN
5_CD
April_NN
2004_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
._.
Non-executive_JJ
Director_NN
Chairman_NN
of_PIN
the_DT
Audit_NN
Committee_NN
with_PIN
effect_NN
from_PIN
July_NN
2004_CD
Summary_NN
directors_NN
report_VPRT [PUBV]
Dr_NN
Wilson_NN
Totten_NN
Results_NN
and_PHC
dividends_NN
stepped_VBD
down_RB
25_CD
May_POMD
2004_CD
The_DT
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
of_PIN
the_DT
Group_NN
was_VBD
Chief_NN
Scientific_NN
Officer_NN
57.4_CD
million_CD
2003_CD
:_:
loss_NN
of_PIN
298.3_CD
million_CD
._.
The_DT
net_JJ
assets_NN
of_PIN
the_DT
Group_NN
as_IN
at_PIN
31_CD
December_NN
2004_CD
were_VBD [BEMA]
2,232.2_CD
million_CD
2003_CD
:_:
2,308.5_CD
million_CD
._.
Business_NOMZ
review_NN
A_DT
review_NN
of_PIN
the_DT
Groups_NN
business_NOMZ
and_CC
important_JJ
events_NN
during_PIN
the_DT
Mr_NN
Angus_NN
Russell_NN
year_NN
and_CC
likely_JJ
future_NN
developments_NOMZ
is_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
Chairmans_NN
Chief_NN
Financial_NN
Officer_NN
statement_NOMZ
,_,
the_DT
Chief_NN
Executive_NN
Officers_NN
review_NN
,_,
the_DT
financial_JJ
review_NN
15_CD
April_NN
2005_CD
and_CC
the_DT
Directors_NN
remuneration_NOMZ
report_NN
in_PIN
the_DT
full_JJ
UK_NN
statutory_JJ
annual_JJ
accounts_NN
,_,
which_WDT [SERE]
are_VPRT [BEMA]
similar_PRED
to_PIN
the_DT
statements_NOMZ
contained_VBN [WZPAST]
in_PIN
the_DT
annual_JJ
review_NN
at_PIN
the_DT
front_NN
of_PIN
this_DEMO
document_NOMZ
which_WDT [WHSUB]
form_VPRT
part_NN
of_PIN
this_DEMO
summary_NN
financial_JJ
statement_NOMZ
._.
98_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
99_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Summary_NN
financial_JJ
statement_NOMZ
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
Independent_NN
Auditors_NN
Statement_NOMZ
to_PIN
the_DT
Members_NN
of_PIN
Shire_NN
Basis_NN
of_PIN
opinion_NN
Pharmaceuticals_NN
Group_NN
plc_NN
:_:
We_FPP1
conducted_VBD
our_FPP1
work_NN
in_PIN
accordance_NN
with_PIN
bulletin_NN
1999_CD
6_CD
We_FPP1
have_VPRT [PEAS]
examined_VBN
the_DT
summary_NN
financial_JJ
statement_NOMZ
which_WDT [WHOBJ]
The_DT
Auditors_NN
Statement_NOMZ
on_PIN
the_DT
Summary_NN
Financial_NN
Statement_NOMZ
comprises_VPRT
the_DT
summary_NN
Directors_NN
report_NN
,_,
consolidated_JJ
profit_NN
and_CC
issued_VBN
by_PIN
the_DT
Auditing_GER
Practices_NN
Board_NN
for_PIN
use_NN
in_PIN
the_DT
United_NN
loss_NN
account_NN
,_,
consolidated_JJ
balance_NN
sheet_NN
,_,
consolidated_JJ
cash_NN
flow_NN
Kingdom_NN
._.
We_FPP1
have_VPRT [PEAS]
not_XX0
considered_VBN [PRIV]
the_DT
effects_NN
of_PIN
any_QUAN
events_NN
statement_NOMZ
,_,
the_DT
consolidated_JJ
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
between_PIN
the_DT
date_NN
on_PIN
which_WDT [PIRE]
we_FPP1
signed_VBD
our_FPP1
report_NN
on_PIN
the_DT
annual_JJ
and_CC
losses_NN
and_PHC
Notes_NN
1_CD
to_PIN
4_CD
of_PIN
the_DT
summary_NN
financial_JJ
statements_NOMZ
._.
accounts_NN
24_CD
March_NN
2005_CD
and_CC
the_DT
date_NN
of_PIN
this_DEMO
statement_NOMZ
._.
This_DEMO
report_NN
is_VPRT [PASS]
made_VBN
solely_RB
to_PIN
the_DT
Companys_NN
members_NN
,_,
as_IN
a_DT
body_NN
,_,
Opinion_NN
in_PIN
accordance_NN
with_PIN
Section_NOMZ
251_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
._.
In_PIN
our_FPP1
opinion_NN
,_,
the_DT
summary_NN
financial_JJ
statement_NOMZ
is_VPRT [BEMA]
consistent_PRED
with_PIN
Our_FPP1
work_NN
has_VPRT [PEAS]
been_VBN [PASS]
undertaken_VBN
so_OSUB
that_NULL
we_FPP1
might_POMD
state_VB [PUBV]
to_PIN
the_DT
the_DT
full_JJ
annual_JJ
accounts_NN
,_,
the_DT
Directors_NN
report_NN
and_CC
the_DT
Directors_NN
Companys_NN
members_NN
those_DEMO
matters_NN
we_FPP1
are_VPRT [PASS]
required_VBN [SUAV]
to_PIN
state_NN
remuneration_NOMZ
report_NN
of_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
for_PIN
the_DT
to_PIN
them_TPP3
in_PIN
an_DT
auditors_NN
report_NN
and_CC
for_PIN
no_SYNE
other_JJ
purpose_NN
._.
To_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
and_CC
complies_VPRT
with_PIN
the_DT
applicable_JJ
fullest_JJ
extent_NN
permitted_VBN [WZPAST]
by_PIN
law_NN
,_,
we_FPP1
do_VPRT
not_XX0
accept_VB [PRIV]
or_CC
assume_VB [PRIV]
requirements_NOMZ
of_PIN
Section_NOMZ
251_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
and_CC
the_DT
responsibility_NOMZ
to_PIN
anyone_QUPR
other_JJ
than_PIN
the_DT
Company_NN
and_CC
the_DT
regulations_NOMZ
made_VBD
thereunder_RB
._.
Companys_NN
members_NN
as_IN
a_DT
body_NN
,_,
for_PIN
our_FPP1
audit_NN
work_NN
,_,
for_PIN
this_DEMO
report_NN
,_,
for_PIN
our_FPP1
audit_NN
report_NN
,_,
or_CC
for_PIN
the_DT
opinions_NN
we_FPP1
have_VPRT [PEAS]
formed_VBN
._.
Respective_JJ
responsibilities_NOMZ
of_PIN
Directors_NN
and_PHC
auditors_NN
The_DT
Directors_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
preparing_VBG
the_DT
annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
in_PIN
accordance_NN
with_PIN
applicable_JJ
United_NN
Kingdom_NN
law_NN
._.
Our_FPP1
responsibility_NOMZ
is_VPRT
to_TO
report_VB [PUBV]
to_PIN
you_SPP2
our_FPP1
opinion_NN
on_PIN
the_DT
consistency_NN
of_PIN
the_DT
summary_NN
financial_JJ
statement_NOMZ
with_PIN
the_DT
full_JJ
annual_JJ
accounts_NN
,_,
the_DT
Directors_NN
report_NN
and_CC
the_DT
Directors_NN
remuneration_NOMZ
report_NN
,_,
and_ANDC
its_PIT
compliance_NN
with_PIN
the_DT
relevant_JJ
requirements_NOMZ
of_PIN
Section_NOMZ
251_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
and_CC
the_DT
regulations_NOMZ
made_VBD
thereunder_RB
._.
We_FPP1
also_RB
read_VBD
the_DT
other_JJ
information_NOMZ
contained_VBN [WZPAST]
in_PIN
the_DT
annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
Deloitte_NN
&_CC
Touche_NN
LLP_NN
as_IN
described_VBN
in_PIN
the_DT
contents_NN
section_NOMZ
,_,
and_ANDC
consider_VB [PRIV]
the_DT
implications_NOMZ
Chartered_NN
Accountants_NN
and_PHC
Registered_NN
Auditors_NN
for_PIN
our_FPP1
report_NN
if_COND
we_FPP1
become_VPRT
aware_JJ
of_PIN
any_QUAN
apparent_JJ
misstatements_NOMZ
Reading_VBG [WZPRES]
or_CC
material_NN
inconsistencies_NN
with_PIN
the_DT
summary_NN
financial_JJ
statement_NOMZ
._.
18_CD
April_NN
2005_CD
99_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
100_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Summary_NN
financial_JJ
statement_NOMZ
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
Consolidated_NN
profit_NN
and_PHC
loss_NN
account_NN
2004 2003 000 000_CD
Turnover_NN
:_:
Group_NN
and_PHC
share_NN
of_PIN
joint_JJ
venture_NN
752,362_CD
749,853_CD
Less_RB
:_:
share_NN
of_PIN
joint_JJ
ventures_NN
turnover_NN
3,594_CD
Continuing_VBG
operations_NOMZ
752,362_CD
746,259_CD
Discontinued_VBN
operations_NOMZ
2,169_CD
14,809_CD
Group_NN
turnover_NN
754,531_CD
761,068_CD
Cost_NN
of_PIN
sales_NN
84,477_CD
102,384_CD
Gross_NN
profit_NN
670,054_CD
658,684_CD
Net_JJ
operating_GER
expenses_NN
2004_CD
:_:
including_VBG [PRESP]
81,185,000_CD
exceptional_JJ
goodwill_NN
impairment_NOMZ
,_,
2003_CD
:_:
426,362,000_CD
604,359_CD
958,619_CD
Operating_GER
profit_NN
loss_NN
65,695_CD
299,935_CD
Continuing_VBG
operations_NOMZ
Group_NN
76,353_CD
285,303_CD
Discontinued_VBN
operations_NOMZ
10,658_CD
14,632_CD
65,695_CD
299,935_CD
Share_NN
of_PIN
joint_JJ
ventures_NN
operating_VBG [WZPRES]
loss_NN
2,806_CD
Share_NN
of_PIN
associates_NN
operating_VBG [WZPRES]
profit_NN
37_CD
Profit_NN
on_PIN
disposal_NN
of_PIN
fixed_JJ
asset_NN
investment_NOMZ
8,264_CD
698_CD
Loss_NN
on_PIN
sale_NN
of_PIN
discontinued_VBN
operations_NOMZ
23,191_CD
Finance_NN
income_NN
,_,
net_JJ
6,630_CD
3,702_CD
Profit_NN
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
57,435_CD
298,341_CD
Tax_NN
on_PIN
profit_NN
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
70,866_CD
65,014_CD
Loss_NN
for_PIN
the_DT
financial_JJ
year_NN
13,431_CD
363,355_CD
Dividends_NN
paid_VBD
1_CD
penny_NN
per_PIN
share_NN
4,967_CD
Dividends_NN
proposed_VBN [SUAV]
2_CD
pence_NN
per_PIN
share_NN
9,952_CD
Retained_VBN
loss_NN
for_PIN
the_DT
year_NN
transferred_VBN [WZPAST]
from_PIN
reserves_NN
28,350_CD
363,355_CD
Loss_NN
per_PIN
share_NN
Basic_JJ
2.7_CD
p_NN
72.9_CD
p_NN
Diluted_NN
2.7_CD
p_NN
72.9_CD
p_NN
Consolidated_NN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
Year_NN
ended_VBD
Year_NN
ended_VBD
31_CD
December_NN
31_CD
December_NN
2004 2003 000 000_CD
Loss_NN
for_PIN
the_DT
financial_JJ
year_NN
13,431_CD
363,355_CD
Translation_NOMZ
of_PIN
the_DT
financial_JJ
statements_NOMZ
of_PIN
overseas_PLACE
subsidiaries_NN
55,510_CD
47,157_CD
Total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
relating_VBG [WZPRES]
to_PIN
the_DT
year_NN
68,941_CD
410,512_CD
100_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
101_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Summary_NN
financial_JJ
statement_NOMZ
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
Consolidated_NN
balance_NN
sheet_NN
31_CD
December_NN
31_CD
December_NN
2004 2003 000 000_CD
Fixed_JJ
assets_NN
Intangible_JJ
assets_NN
intellectual_JJ
property_NN
160,033_CD
171,548_CD
Intangible_JJ
assets_NN
goodwill_NN
1,204,056_CD
1,365,583_CD
Tangible_JJ
assets_NN
68,415_CD
97,054_CD
Fixed_VBN
asset_NN
investments_NOMZ
52,721_CD
33,269_CD
1,485,225_CD
1,667,454_CD
Current_JJ
assets_NN
Stocks_NN
21,475_CD
25,282_CD
Debtors_NN
due_JJ
within_PIN
one_CD
year_NN
excluding_VBG [WZPRES]
deferred_JJ
tax_NN
157,089_CD
141,046_CD
due_JJ
within_PIN
one_CD
year_NN
deferred_VBN
tax_NN
40,097_CD
36,049_CD
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
excluding_VBG [WZPRES]
deferred_JJ
tax_NN
20,259_CD
9,224_CD
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
deferred_VBN
tax_NN
4,023_CD
Current_JJ
asset_NN
investments_NOMZ
169,199_CD
169,895_CD
Restricted_VBN
cash_NN
11,265_CD
25,962_CD
Cash_NN
at_PIN
bank_NN
and_CC
in_PIN
hand_NN
581,500_CD
595,708_CD
1,004,907_CD
1,003,166_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
within_PIN
one_CD
year_NN
237,446_CD
141,722_CD
Net_JJ
current_JJ
assets_NN
767,461_CD
861,444_CD
Total_JJ
assets_NN
less_RB
current_JJ
liabilities_NOMZ
2,252,686_CD
2,528,898_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
Convertible_JJ
debt_NN
60_CD
202,659_CD
Other_JJ
creditors_NN
20,415_CD
17,739_CD
20,475_CD
220,398_CD
Net_JJ
assets_NN
2,232,211_CD
2,308,500_CD
Capital_NN
and_PHC
reserves_NN
Called-up_JJ
share_NN
capital_NN
24,246_CD
23,895_CD
Treasury_NN
shares_NN
137_CD
Share_NN
premium_NN
3,279,593_CD
3,218,695_CD
Exchangeable_JJ
shares_NN
137,825_CD
190,425_CD
Capital_NN
reserve_NN
3,135_CD
3,135_CD
Other_JJ
reserves_NN
24,247_CD
24,247_CD
Profit_NN
and_PHC
loss_NN
account_NN
1,236,698_CD
1,151,897_CD
Equity_NOMZ
shareholders_NN
funds_NN
2,232,211_CD
2,308,500_CD
101_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
102_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Summary_NN
financial_JJ
statement_NOMZ
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
Consolidated_NN
cash_NN
flow_NN
statement_NOMZ
2004 2003 000 000_CD
Net_JJ
cash_NN
inflow_NN
from_PIN
operating_VBG
activities_NOMZ
273,732_CD
280,275_CD
Returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
:_:
Interest_NN
and_CC
other_JJ
income_NN
received_VBD
14,524_CD
13,165_CD
Interest_NN
paid_VBN
7,856_CD
9,404_CD
Interest_NN
element_NOMZ
of_PIN
finance_NN
lease_NN
rentals_NN
38_CD
59_CD
Distribution_NOMZ
from_PIN
investments_NOMZ
672_CD
Net_JJ
cash_NN
inflow_NN
from_PIN
returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
7,302_CD
3,702_CD
Taxation_NOMZ
:_:
Foreign_NN
corporation_NOMZ
tax_NN
paid_VBN
65,761_CD
66,874_CD
Capital_NN
expenditure_NN
and_CC
financial_JJ
investments_NOMZ
:_:
Purchase_NN
of_PIN
investments_NOMZ
4,818_CD
3,447_CD
Purchase_NN
of_PIN
intangible_JJ
assets_NN
16,299_CD
30,238_CD
Purchase_NN
of_PIN
tangible_JJ
fixed_JJ
assets_NN
33,445_CD
31,400_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
investments_NOMZ
15,074_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
intangible_JJ
assets_NN
1,918_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
tangible_JJ
fixed_JJ
assets_NN
9,587_CD
1,060_CD
Net_JJ
cash_NN
outflow_NN
for_PIN
capital_NN
expenditure_NN
and_CC
financial_JJ
investments_NOMZ
27,983_CD
64,025_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
:_:
Proceeds_NN
from_PIN
sale_NN
of_PIN
a_DT
business_NOMZ
17,106_CD
559_CD
Net_JJ
cash_NN
inflow_NN
from_PIN
disposals_NN
17,106_CD
559_CD
Equity_NOMZ
dividends_NN
paid_VBD
4,967_CD
Cash_NN
inflow_NN
before_IN
management_NOMZ
of_PIN
liquid_JJ
resources_NN
and_PHC
financing_GER
199,429_CD
153,637_CD
Management_NOMZ
of_PIN
liquid_JJ
resources_NN
:_:
Decrease_NN
increase_NN
in_PIN
cash_NN
placed_VBN [WZPAST]
on_PIN
short-term_JJ
deposit_NN
9,017_CD
17,848_CD
Financing_GER
:_:
Issue_NN
of_PIN
ordinary_JJ
share_NN
capital_NN
423_CD
Exercise_NN
of_PIN
share_NN
options_NOMZ
7,285_CD
3,114_CD
Repurchase_NN
of_PIN
ordinary_JJ
share_NN
capital_NN
137_CD
31,808_CD
Capital_NN
element_NOMZ
of_PIN
finance_NN
lease_NN
rentals_NN
3,364_CD
160_CD
Net_JJ
decrease_NN
in_PIN
debt_NN
during_PIN
the_DT
year_NN
199,918_CD
18,053_CD
Net_JJ
cash_NN
outflow_NN
from_PIN
financing_VBG
195,711_CD
46,907_CD
Decrease_NN
increase_NN
in_PIN
cash_NN
in_PIN
the_DT
year_NN
5,299_CD
124,578_CD
102_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
103_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
summary_NN
financial_JJ
statement_NOMZ
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
1_CD
Basis_NN
of_PIN
preparation_NOMZ
The_DT
summary_NN
financial_JJ
statement_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
the_DT
accounting_GER
policies_NN
set_VBN [WZPAST]
out_PIN
in_PIN
the_DT
full_JJ
UK_NN
statutory_JJ
annual_JJ
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
._.
2_CD
Directors_NN
remuneration_JJ
Aggregate_NN
Directors_NN
remuneration_VPRT
The_DT
total_JJ
amounts_NN
for_PIN
Directors_NN
remuneration_NOMZ
and_CC
other_JJ
benefits_NN
were_VBD
as_IN
follows_VPRT
:_:
2004 2003 000 000_CD
Emoluments_NOMZ
2,592_CD
2,256_CD
Money_NN
purchase_NN
pension_NN
contributions_NOMZ
278_CD
4,676_CD
Gains_NN
on_PIN
exercise_NN
of_PIN
share_NN
options_NOMZ
118_CD
114_CD
Amounts_NN
receivable_JJ
under_IN
long-term_JJ
incentive_NN
schemes_NN
86_CD
276_CD
Compensation_NOMZ
for_PIN
loss_NN
of_PIN
office_NN
1,335_CD
3,074_CD
8,657_CD
Directors_NN
emoluments_VPRT
Cash_NN
Non-cash_JJ
Total_JJ
Total_JJ
Salary_NN
Bonus_NN
Fees_NN
benefits_NN
in_PIN
kind_NN
benefits_NN
in_PIN
kind_NN
2004_CD
2003_CD
Director_NN
000 000 000 000_CD
000 000 000_CD
Executive_NN
i_FPP1
ii_FW
Mr_NN
Matthew_NN
Emmens_NN
545 437 437_CD
1,419_CD
699_CD
Mr_NN
Angus_NN
Russell_NN
342_CD
257_CD
11_CD
4_CD
614_CD
499_CD
iii_FW
Dr_FW
Wilson_NN
Totten_NN
142_CD
107_CD
4_CD
3_CD
256_CD
531_CD
iv_NN
Mr_NN
Rolf_NN
Stahel_NN
311_CD
1,029_CD
801_CD
452_CD
7_CD
2,289_CD
2,040_CD
Non-executive_JJ
v_NN
Dr_NN
James_NN
Cavanaugh_NN
75_CD
75_CD
54_CD
Dr_NN
Barry_NN
Price_NN
60_CD
60_CD
43_CD
The_DT
Hon_NN
James_NN
Grant_NN
40_CD
40_CD
35_CD
Mr_NN
Ronald_NN
Nordmann_NN
54_CD
54_CD
45_CD
Mr_NN
Robin_NN
Buchanan_NN
40_CD
40_CD
16_CD
vi_FW
Mr_NN
David_NN
Kappler_NN
34_CD
34_CD
vii_NN
Dr_NN
Francesco_NN
Bellini_NN
11_CD
vii_FW
Mr_NN
Gerard_NN
Veilleux_NN
12 303 303 216_CD
Total_JJ
1,029_CD
801 303 452_CD
7_CD
2,592_CD
2,256_CD
Notes_NN
i_FPP1
Paid_NN
in_PIN
US$_$
,_,
Mr_NN
Emmens_NN
annual_JJ
salary_NN
in_PIN
2004_CD
was_VBD
$_$
999,319_CD
._.
ii_FW
The_DT
Company_NN
underwent_VBD
a_DT
major_JJ
internal_JJ
reorganisation_NOMZ
in_PIN
2004_CD
which_WDT
resulted_VBD
in_PIN
the_DT
Company_NN
selecting_VBG [WZPRES]
Philadelphia_NN
as_IN
its_PIT
US_FPP1
corporate_JJ
headquarters_NN
._.
103_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
104_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
summary_NN
financial_JJ
statement_NOMZ
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
3_CD
Loss_NN
per_PIN
share_NN
Basic_JJ
EPS_NN
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
net_JJ
profit_NN
or_CC
loss_NN
attributable_JJ
to_PIN
ordinary_JJ
shareholders_NN
divided_VBN [WZPAST]
by_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
ordinary_JJ
shares_NN
outstanding_JJ
during_PIN
the_DT
year_NN
._.
Share_NN
options_NOMZ
to_TO
purchase_VB
approximately_RB
16.6_CD
million_CD
ordinary_JJ
shares_NN
for_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2004_CD
were_VBD [BEMA]
not_XX0
dilutive_PRED
and_CC
were_VBD [SPAU] [PASS]
therefore_CONJ
excluded_VBN
from_PIN
the_DT
computation_NOMZ
of_PIN
loss_NN
earnings_GER
per_PIN
share_NN
2003_CD
:_:
17.0_CD
million_CD
._.
Warrants_NN
to_TO
purchase_VB
approximately_RB
1.3_CD
million_CD
ordinary_JJ
shares_NN
for_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2003_CD
were_VBD [BEMA]
not_XX0
dilutive_PRED
and_CC
were_VBD [SPAU] [PASS]
therefore_CONJ
excluded_VBN
from_PIN
the_DT
computation_NOMZ
of_PIN
loss_NN
per_PIN
share_NN
._.
Basic_JJ
and_PHC
diluted_JJ
2004 2003 000 000_CD
Loss_NN
for_PIN
the_DT
financial_JJ
year_NN
13,431_CD
363,355_CD
The_DT
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
used_VBN [WZPAST]
in_PIN
each_QUAN
year_NN
are_VPRT
as_IN
follows_VPRT
:_:
2004_CD
2003_CD
Number_NN
Number_NN
For_PIN
basic_JJ
and_PHC
diluted_JJ
EPS_NN
496,306,604_CD
498,212,826_CD
4_CD
Operating_GER
profit_NN
loss_NN
Operating_GER
profit_NN
loss_NN
is_VPRT [PASS]
stated_VBN [PUBV]
after_IN
charging_VBG
crediting_VBG
:_:
2004 2003 000 000_CD
Depreciation_NOMZ
and_PHC
amounts_NN
written_VBN [PUBV] [WZPAST]
off_PIN
tangible_JJ
fixed_JJ
assets_NN
owned_VBN
12,409_CD
18,772_CD
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
contracts_NN
107_CD
597_CD
Amortisation_NOMZ
and_CC
amounts_VPRT
written_VBN [PUBV]
off_PIN
intellectual_JJ
property_NN
29,164_CD
30,405_CD
Amortisation_NOMZ
and_CC
amounts_VPRT
written_VBN [PUBV]
off_PIN
goodwill_NN
158,283_CD
533,115_CD
Research_NN
and_PHC
development_NOMZ
112,534_CD
131,654_CD
Reorganisation_NOMZ
costs_NN
26,529_CD
14,597_CD
Government_NOMZ
grants_NN
14_CD
2,169_CD
Operating_GER
lease_NN
rentals_NN
plant_NN
and_PHC
machinery_NN
3,580_CD
3,591_CD
other_JJ
3,541_CD
3,868_CD
Auditors_NN
remuneration_NOMZ
for_PIN
audit_NN
services_NN
1_CD
Group_NN
1,715_CD
630_CD
1_CD
Company_NN
60_CD
20_CD
Auditors_NN
remuneration_NOMZ
for_PIN
non-audit_JJ
services_NN
2_CD
Group_NN
audit_NN
related_VBN
1,172_CD
1,015_CD
3_CD
Group_NN
tax_NN
2,583_CD
1,145_CD
4_CD
Group_NN
other_JJ
100_CD
177_CD
4_CD
Company_NN
other_JJ
75_CD
1_CD
Audit_NN
fees_NN
consisted_VBD
of_PIN
audit_NN
work_NN
only_DWNT
the_DT
Companys_NN
auditors_NN
can_POMD [SPAU]
reasonably_RB
be_VB [PASS]
expected_VBN [PRIV]
to_TO
perform_VB
,_,
such_JJ
as_IN
statutory_JJ
audits_NN
,_,
and_ANDC
in_PIN
2004_CD
included_VBD
the_DT
audit_NN
in_PIN
relation_NOMZ
to_PIN
internal_JJ
control_NN
over_IN
US_FPP1
GAAP_NN
Form_NN
10-K_JJ
financial_JJ
reporting_GER
._.
104_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
105_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Shire_NN
head_NN
office_NN
and_CC
main_JJ
operating_GER
locations_NOMZ
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Shire_NN
Italia_NN
S._NN
p._NN
A._NN
Suite_NN
500_CD
Ville_NN
Saint-Laurent_NN
,_,
Qubec_NN
H4S_NN
2C9_NN
Canada_NN
Tel_NN
1_CD
514 787 2300_CD
Fax_NN
1_CD
514 787 2427 105_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
106_CD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Shareholder_NN
information_NOMZ
Registered_NN
office_NN
address_NN
US_FPP1
Shareholders_NN
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
i_FPP1
ADSs_NN
Basingstoke_NN
,_,
Hampshire_NN
RG24_NN
8EP_NN
The_NN
Companys_NN
American_NN
Depository_NN
Shares_NN
ADSs_NN
,_,
each_QUAN
United_NN
Kingdom_NN
representing_VBG [WZPRES]
three_CD
ordinary_JJ
shares_NN
,_,
are_VPRT [PASS]
listed_VBN
on_PIN
the_DT
NASDAQ_NN
Registered_NN
in_PIN
England_NN
national_JJ
market_NN
under_IN
the_DT
symbol_NN
SHPGY_NN
._.
2883758_CD
reports_NN
and_CC
other_JJ
documents_NOMZ
with_PIN
the_DT
Securities_NOMZ
and_PHC
Exchange_NN
Commission_NN
SEC_NN
which_WDT [WHSUB]
are_VPRT [BEMA]
available_PRED
for_PIN
inspection_NOMZ
and_PHC
Investor_NN
relations_NOMZ
copying_VBG [WZPRES]
at_PIN
the_DT
SECs_NN
public_JJ
reference_NN
facilities_NOMZ
or_CC
can_POMD
be_VB [PASS]
obtained_VBN
Europe_NN
and_CC
Rest_VB
of_PIN
the_DT
World_NN
:_:
Cla_NN
Rosenfeld_NN
by_PIN
writing_VBG [PUBV]
to_PIN
the_DT
Company_NN
Secretary_NN
._.
Tel_NN
44_CD
0_CD
1256 894160_CD
Fax_NN
44_CD
0_CD
1256 894708_CD
ii_FW
ADS_NN
Depositary_NN
Email_NN
investorrelations@uk_NN
._.
com_NN
Morgan_NN
Guaranty_NN
Trust_NN
Company_NN
of_PIN
New_NN
York_NN
is_VPRT [BEMA]
the_DT
depositary_NN
for_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
ADSs_NN
._.
All_QUAN
enquiries_NN
North_NN
America_NN
:_:
Brian_NN
Piper_NN
concerning_VBG [WZPRES]
ADS_NN
records_NN
,_,
certificates_NN
or_CC
transfer_NN
of_PIN
ordinary_JJ
Tel_NN
1_CD
484 595 8800_CD
shares_NN
into_PIN
ADSs_NN
should_NEMD
be_VB [PASS]
addressed_VBN
to_TO
:_:
Fax_NN
1_CD
484 595 8151_CD
Email_NN
bpiper@us_FPP1
._.
com_NN
Morgan_NN
Guaranty_NN
Trust_NN
Company_NN
of_PIN
New_NN
York_NN
PO_NN
Box_NN
8205_CD
www_NN
._.
com_NN
Boston_NN
,_,
Massachusetts_NN
02266-8205_CD
USA_NN
Registrars_NN
and_CC
transfer_VB
office_NN
Tel_NN
1_CD
781 575 4328_CD
All_QUAN
administrative_JJ
enquiries_NN
relating_VBG [WZPRES]
to_PIN
shareholdings_GER
Fax_NN
1_CD
781 575 4088_CD
should_NEMD
be_VB [PASS]
addressed_VBN
to_PIN
Lloyds_NN
TSB_NN
Registrars_NN
,_,
clearly_RB
stating_VBG [PUBV]
the_DT
registered_VBN
shareholders_NN
name_NN
and_PHC
address_NN
._.
Canadian_JJ
Shareholders_NN
i_FPP1
Exchangeable_JJ
Shares_NN
of_PIN
Shire_NN
Acquisition_NOMZ
Inc._NN
._.
Lloyds_NN
TSB_NN
Registrars_NN
Exchangeable_JJ
shares_NN
in_PIN
Shire_NN
Acquisition_NOMZ
Inc._NN
are_VPRT [BEMA]
convertible_JJ
Customer_NN
Services_NN
,_,
The_DT
Causeway_NN
into_PIN
three_CD
ordinary_JJ
shares_NN
of_PIN
Shire_NN
or_CC
one_CD
ADS_NN
representing_VBG [WZPRES]
three_CD
Worthing_JJ
,_,
West_NN
Sussex_NN
BN99_NN
6DA_NN
ordinary_JJ
shares_NN
of_PIN
Shire_NN
._.
Exchangeable_JJ
shares_NN
trade_NN
on_PIN
the_DT
United_NN
Kingdom_NN
Toronto_NN
Stock_NN
Exchange_NN
under_IN
the_DT
symbol_NN
SHQ_NN
._.
Shires_NN
ordinary_JJ
Tel_NN
44 870 600 3970_CD
shares_NN
are_VPRT [PASS]
listed_VBN
on_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
and_PHC
Shires_NN
ADSs_NN
are_VPRT [PASS]
listed_VBN
on_PIN
the_DT
NASDAQ_NN
national_JJ
market_NN
._.
ii_FW
Trustee_NN
for_PIN
Exchangeable_JJ
Shareholders_NN
Natcan_NN
Trust_NN
Company_NN
,_,
a_DT
wholly_RB
owned_VBN
subsidiary_NN
of_PIN
the_DT
National_NN
Bank_NN
of_PIN
Canada_NN
,_,
acts_VPRT
as_IN
Trustee_NN
for_PIN
Exchangeable_JJ
Shareholders_NN
._.
All_QUAN
enquiries_NN
concerning_VBG [WZPRES]
Exchangeable_JJ
Share_NN
records_NN
or_CC
conversions_NN
of_PIN
Exchangeable_JJ
Shares_NN
into_PIN
ordinary_JJ
shares_NN
of_PIN
Shire_NN
or_CC
ADSs_NN
should_NEMD
be_VB [PASS]
addressed_VBN
to_TO
:_:
Natcan_NN
Trust_NN
Company_NN
1100_CD
University_NOMZ
Street_NN
Suite_NN
900_CD
Montreal_NN
,_,
Qubec_NN
H3B_NN
2G7_NN
Canada_NN
Tel_NN
1_CD
514 871 7171_CD
1_CD
800 341 1419_CD
Fax_NN
1_CD
514 871 7442 106_CD
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
107_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Shire_NN
Trade_NN
Marks_NN
|_NN
Cautionary_NN
statements_NOMZ
Shire_NN
Trade_NN
Marks_NN
Cautionary_NN
statements_NOMZ
ADDERALL_NN
XR_NN
mixed_JJ
amphetamine_NN
salts_VPRT
Statements_NOMZ
included_VBD
herein_NN
that_TSUB
are_VPRT [BEMA]
not_XX0
historical_JJ
facts_NN
are_VPRT
ADDERALL_NN
mixed_JJ
amphetamine_NN
salts_VPRT
forward-looking_JJ
statements_NOMZ
._.
Such_JJ
forward-looking_JJ
statements_NOMZ
AGRYLIN_NN
anagrelide_NN
hydrochloride_NN
involve_VPRT
a_DT
number_NN
of_PIN
risks_NN
and_PHC
uncertainties_NN
and_CC
are_VPRT [BEMA]
subject_JJ
AMATINE_NN
midodrine_NN
hydrochloride_NN
to_TO
change_VB
at_PIN
any_QUAN
time_NN
._.
In_PIN
the_DT
event_NN
such_JJ
risks_NN
or_CC
uncertainties_NN
CALCICHEW_NN
calcium_NN
carbonate_NN
materialize_VPRT
,_,
Shires_NN
results_NN
could_POMD
be_VB [SPAU] [PASS]
materially_RB
affected_VBN
._.
The_DT
risks_NN
CALCICHEW_NN
D3_CD
FORTE_NN
calcium_NN
carbonate_NN
and_PHC
uncertainties_NN
include_VPRT
,_,
but_CC
are_VPRT [PASS]
not_XX0
limited_VBN
to_TO
,_,
risks_NN
associated_VBN
CARBATROL_NN
carbamazepine_NN
with_PIN
the_DT
inherent_JJ
uncertainty_NN
of_PIN
pharmaceutical_JJ
research_NN
,_,
product_NN
COLAZIDE_NN
balsalazide_NN
development_NOMZ
,_,
manufacturing_GER
and_PHC
commercialization_NOMZ
,_,
the_DT
impact_NN
EQUETRO_NN
carbamazepine_NN
of_PIN
competitive_JJ
products_NN
,_,
including_VBG
,_,
but_CC
not_XX0
limited_VBN
to_TO
,_,
the_DT
impact_NN
FOSRENOL_NN
lanthanum_NN
carbonate_NN
of_PIN
those_DEMO
on_PIN
Shires_NN
Attention_NOMZ
Deficit_NN
Hyperactivity_NOMZ
Disorder_NN
ADHD_NN
METHYPATCH_NN
methylphenidate_NN
franchise_NN
,_,
patents_NN
,_,
including_VBG
but_CC
not_XX0
limited_VBN
to_TO
,_,
legal_JJ
challenges_NN
MICROTROL_NN
relating_VBG [WZPRES]
to_PIN
Shires_NN
ADHD_NN
franchise_NN
,_,
government_NOMZ
regulation_NOMZ
and_PHC
PROAMATINE_NN
midodrine_NN
hydrochloride_NN
approval_NN
,_,
including_VBG
but_CC
not_XX0
limited_VBN
to_PIN
Health_NN
Canadas_NN
suspension_NN
SOLARAZE_NN
diclofenac_JJ
sodium_NN
3_CD
%_NN
of_PIN
ADDERALL_NN
XR_NN
sales_NN
in_PIN
Canada_NN
and_CC
the_DT
expected_VBN [PRIV]
product_NN
TROXATYL_NN
troxacitabine_NN
approval_NN
dates_NN
of_PIN
METHYPATCH_NN
MTS_NN
ADHD_NN
,_,
SPD503_NN
VANIQA_NN
eflornithine_NN
hydrochloride_NN
ADHD_NN
,_,
SPD465_NN
ADHD_NN
,_,
SPD476_NN
ulcerative_JJ
colitis_NN
,_,
and_ANDC
XAGRID_NN
anagrelide_NN
hydrochloride_NN
NRP104_NN
ADHD_NN
,_,
including_VBG [PRESP]
its_PIT
scheduling_GER
classification_NOMZ
by_PIN
the_DT
Drug_NN
Enforcement_NOMZ
Agency_NN
in_PIN
the_DT
United_NN
States_NN
,_,
Shires_NN
ability_NOMZ
to_TO
secure_VB
new_JJ
products_NN
for_PIN
development_NOMZ
,_,
and_ANDC
other_JJ
risks_NN
and_CC
Third-party_JJ
Trade_NN
Marks_NN
uncertainties_NN
detailed_VBN [WZPAST]
from_PIN
time_NN
to_PIN
time_NN
in_PIN
Shires_NN
filings_GER
with_PIN
3TC_NN
lamivudine_NN
trade_NN
mark_NN
of_PIN
GSK_NN
the_DT
Securities_NOMZ
and_PHC
Exchange_NN
Commission_NN
,_,
including_VBG [PRESP]
its_PIT
Annual_JJ
COMBIVIR_NN
trade_NN
mark_NN
of_PIN
GSK_NN
Report_NN
on_PIN
Form_NN
10-K_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2004_CD
._.
EPIVIR_NN
trade_NN
mark_NN
of_PIN
GSK_NN
EPIVIR-HBV_NN
trade_NN
mark_NN
of_PIN
GSK_NN
The_NN
statements_NOMZ
of_PIN
the_DT
individuals_NN
and_CC
medical_JJ
practitioners_NN
HEPTOVIR_VPRT
trade_NN
mark_NN
of_PIN
GSK_NN
appearing_VBG [SMP] [WZPRES]
in_PIN
the_DT
operating_GER
review_NN
on_PIN
pages_NN
8_CD
to_PIN
23_CD
of_PIN
this_DEMO
PENTASA_NN
mesalamine_NN
trade_NN
mark_NN
of_PIN
Ferring_GER
AS_NN
document_NOMZ
have_VPRT [PEAS]
been_VBN [BYPA]
made_VBN
by_PIN
and_CC
represent_VB
the_DT
views_NN
of_PIN
the_DT
REMINYL_NN
galantamine_NN
hydrobromide_NN
named_VBN
individuals_NN
._.
The_DT
views_NN
represented_VBN [WZPAST]
are_VPRT [BEMA]
those_DEMO
of_PIN
the_DT
trade_NN
mark_NN
of_PIN
Johnson_NN
&_CC
Johnson_NN
named_VBD
medical_JJ
practitioners_NN
and_CC
should_NEMD
not_XX0
necessarily_RB
be_VB [BEMA]
TRIZIVIR_JJ
trade_NN
mark_NN
of_PIN
GSK_NN
taken_VBN
to_TO
represent_VB
the_DT
views_NN
of_PIN
Shire_NN
._.
ZEFFIX_NN
lamivudine_NN
trade_NN
mark_NN
of_PIN
GSK_NN
107_NN
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
108_CD
Designed_VBN
and_PHC
produced_VBN
by_PIN
Bostock_NN
and_PHC
Pollitt_NN
Limited_NN
,_,
London_NN
Printed_NN
in_PIN
the_DT
UK_NN
by_PIN
Butler_NN
and_PHC
Tanner_NN
The_DT
paper_NN
used_VBN [WZPAST]
in_PIN
this_DEMO
publication_NOMZ
is_VPRT [BEMA]
Elemental_JJ
Chlorine_NN
Free_NN
ECF_NN
sourced_VBD
from_PIN
sustainably_RB
managed_VBN
forests_NN
._.
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
IBC109_NN
5977_CD
Accounts_NN
2004_CD
._.
qxd_NN
5_CD
9_CD
05_CD
5:26_CD
PM_NN
Page_NN
BC110_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
Basingstoke_NN
,_,
Hampshire_NN
RG24_NN
8EP_NN
United_NN
Kingdom_NN
Tel_NN
44_CD
0_CD
1256 894000_CD
Fax_NN
44_CD
0_CD
1256 894708_CD
www_NN
._.
